austria
centuri
rich
histori
cultur
grow
scientif
commun
fin
de
siecl
heavili
concentr
vienna
freud
boltzmann
oding
mach
might
first
name
find
whenev
one
cite
austrian
scientist
relat
transfus
nobl
prize
winner
max
perutz
karl
landstein
landstein
fate
illustr
brain
drain
begin
earli
escal
anschluss
lead
forc
emigr
mani
scientist
loss
regener
post
war
year
aggrav
dubiou
often
undisclos
relat
scandal
naziera
togeth
lead
sever
loss
credibl
product
univers
across
decad
open
univers
access
earli
intens
histor
workup
scandal
transform
austrian
univers
open
effect
scientif
institut
drive
innov
countri
austria
achiev
great
econom
deal
recent
decad
acceler
eu
membership
result
strong
longterm
econom
perform
countri
gross
domest
product
gdp
per
capita
eighth
highest
among
oecd
countri
fourth
level
poverti
incom
inequ
oecd
averag
invest
research
develop
r
increas
sinc
eu
access
austria
r
intens
aggreg
r
expenditur
percentag
gdp
well
oecd
averag
significantli
far
lower
switzerland
countri
austria
prefer
comparison
eu
target
r
intens
first
met
sixth
highest
among
oecd
countri
second
highest
austria
show
second
highest
increas
r
intens
oecd
countri
exceed
korea
rapid
expans
match
similar
increas
human
resourc
scientif
output
univers
austrian
scienc
quantum
mechan
quantum
commun
inform
world
renown
vienna
major
biotech
hub
linz
mathemat
mechatron
graz
automot
product
technolog
austria
net
resourc
recipi
horizon
preced
framework
programm
small
mediums
enterpris
show
high
propens
cooper
univers
research
organis
includ
scientif
grant
scheme
vienna
largest
student
citi
germanspeak
world
consist
rank
among
top
citi
world
qualityoflif
indic
austria
possess
global
recognis
cultur
attract
rang
fame
salzburg
festiv
vienna
new
year
concert
inhabit
awar
progress
made
r
thrive
innov
go
countri
still
love
show
cultur
heritag
event
impress
world
kind
etern
sound
music
patient
refractori
bcell
malign
nonhodgkin
lymphoma
nhl
resist
standard
therapi
dismal
prognosi
outcom
even
poorer
patient
relaps
autolog
stem
cell
transplant
patient
qualifi
allogen
hematopoiet
cell
transplant
hct
due
refractori
diseas
lack
suitabl
allogen
donor
higher
age
cumul
toxic
previou
chemotherapi
despit
patient
undergo
allogen
hct
normal
profit
graftversu
lymphoma
effect
overal
surviv
patient
nhl
hct
remain
short
similar
situat
observ
patient
acut
lymphoblast
leukemia
therefor
novel
treatment
modal
urgent
need
chimer
antigen
receptor
car
cell
new
class
cellular
immunotherapi
involv
ex
vivo
genet
modif
cell
incorpor
engin
car
use
clinic
trial
major
studi
bcell
malign
treat
target
cart
cell
analyz
austria
advantag
particip
two
intern
trial
past
current
involv
cart
studi
recent
result
direct
cart
cell
trial
increas
followup
patient
led
fda
food
drug
administr
ema
european
medicin
agenc
approv
tisagenlecleucel
axicabtagen
ciloleucel
common
advers
event
ae
includ
cytokin
releas
syndrom
neurolog
toxic
may
requir
admiss
intens
care
unit
b
cell
aplasia
hemophagocyt
lymphohistiocytosi
ae
manag
treat
appropri
train
team
follow
establish
algorithm
present
result
four
larg
phase
ii
cell
trial
patient
nhl
focu
ae
summar
preoper
anemia
known
risk
factor
increas
periop
morbid
mortal
patient
undergo
major
surgeri
previou
studi
shown
higher
inhospit
mortal
also
increas
hospit
length
stay
greater
postop
admiss
rate
intens
care
prolong
use
mechan
ventil
intens
care
resourc
patient
anemia
compar
normal
preoper
hemoglobin
concentr
patient
schedul
major
surgeri
suffer
preoper
anemia
figur
even
higher
patient
requir
orthotop
liver
transplant
patient
diagnos
anemia
prior
surgeri
transfus
pack
red
blood
cell
prbc
commonli
use
correct
anem
hemoglobin
valu
howev
transfus
prbc
associ
increas
morbid
mortal
patient
undergo
cardiac
orthoped
abdomin
surgeri
addit
transfus
prbc
associ
greater
incid
postop
acut
kidney
injuri
patient
undergo
orthotop
liver
transplant
preoper
anemia
might
increas
periop
use
prbc
neg
effect
observ
prbc
transfus
might
even
augment
data
influenc
preoper
anemia
morbid
mortal
orthotop
liver
transplant
limit
thu
retrospect
analyz
associ
preoper
anemia
mortal
adult
patient
undergo
orthotop
liver
transplant
institut
addit
examin
influenc
anemia
periop
paramet
transfus
requir
surgic
complic
earli
allograft
dysfunct
acut
kidney
injuri
need
renal
replac
therapi
base
result
obtain
retrospect
analysi
ongo
prospect
random
clinic
trial
initi
two
suspens
treatment
sickl
cell
diseas
scd
hydroxycarbamid
induc
product
function
hbf
normal
repress
birth
red
blood
cell
rbc
transfus
critic
compon
scd
manag
howev
rbc
transfus
without
risk
repeat
exposur
allogen
rbc
result
develop
rbc
alloantibodi
make
difficult
find
compat
rbc
futur
transfus
howev
main
concern
alloimmun
develop
hemolyt
transfus
reaction
sever
case
hyperhemolysi
lead
multi
organ
failur
death
case
prevent
life
threaten
condit
must
base
risk
factor
howev
although
risk
factor
alloimmun
identifi
much
mechan
underli
dhtr
remain
mysteri
particularli
sever
case
present
hyperhemolysi
describ
current
futur
develop
prevent
treat
sever
syndrom
order
decreas
exposur
transfus
scd
also
improv
red
blood
cell
qualiti
new
product
develop
oxid
damag
one
paramet
could
diminish
work
also
ongo
prevent
filter
blockag
leucodeplet
preciou
rbc
unit
afrocaribbean
donor
carri
sickl
cell
trait
final
countri
higher
risk
transmiss
infecti
diseas
treatment
red
blood
cell
unit
infecti
agent
discuss
current
cur
treatment
scd
hematopoiet
stem
cell
transplant
hc
howev
occurr
frequenc
effect
immun
hematolog
complic
hc
remain
discuss
final
gene
therapi
real
hope
definit
cur
treatment
clinic
trial
ongo
franc
discuss
well
remain
place
transfus
therapeut
context
chronic
myeloid
leukemia
cml
hypothes
quiescent
leukem
hematopoiet
stem
cell
hsc
compart
escap
current
tyrosin
kinas
inhibitor
tki
treatment
part
associ
molecular
relaps
may
target
cartcel
immunotherapi
gene
express
profil
studi
establish
cell
surfac
biomark
express
leukem
normal
talk
focu
whole
process
develop
cartcel
start
recombin
protein
mice
immun
produc
specif
monoclon
antibodi
mab
proof
concept
demonstr
move
clinic
produc
select
specif
mab
clone
diaclon
sa
besanc
franc
molecular
character
antigenbind
domain
nucleotid
sequenc
fuse
gener
cell
activ
code
sequenc
clone
singl
chain
lentivir
backbon
compris
safeti
switch
suicid
gene
induc
caspas
monitoringselect
cell
surfac
marker
demonstr
invitro
invivo
xenograft
murin
model
car
cell
activ
presenc
cell
line
primari
cml
cell
secret
proinflammatori
cytokin
degranul
specif
kill
also
demonstr
multitki
treatment
period
affect
transduct
effici
cml
patient
tcell
car
vector
autolog
cartcel
abl
target
leukem
primari
hsc
offtumoron
target
toxic
predict
studi
express
tissu
macroarray
compris
normal
human
tissu
donor
detect
variou
intens
stain
tissu
regard
healthi
hematopoiet
system
flow
cytometri
stain
detect
hematopoiet
cell
except
monocyt
express
poorli
expect
monocyt
subpopul
target
autolog
cart
cell
ratio
e
lower
level
cml
cell
line
invivo
investig
specif
toxic
autolog
cartcel
hsc
andor
immun
cell
cord
blood
cell
engraftednog
murin
model
also
invitro
coloni
form
unit
assay
nt
reveal
signific
toxic
immunocompet
cell
subpopul
suggest
healthi
hsc
affect
final
overcom
potenti
toxic
function
rimiducid
safeti
switch
demonstr
invitro
also
invivo
nsg
tumor
xenograft
model
show
activ
system
abl
elimin
cartcel
exposur
conclus
base
cml
model
demonstr
interest
target
cartcel
immunotherapi
limit
target
tumor
predict
toxic
next
step
upscal
process
order
match
use
human
regard
also
regulatori
requir
strategi
may
appli
futur
hematolog
malign
mortal
rang
trauma
victim
sever
bleed
larg
depend
transfus
therapi
benefit
natur
therapi
impact
prognosi
halv
mortal
plasmaprbc
ratio
greater
decreas
proport
platelet
transfus
close
whole
blood
speed
therapi
actual
administ
major
impact
well
increas
mortal
minut
delay
make
entir
therapi
avail
explain
mainli
fact
probabl
death
patient
greater
within
minut
admiss
hospit
median
time
death
h
admiss
allow
plasma
platelet
prbc
made
avail
time
manner
north
american
trauma
center
mandat
trauma
center
massiv
transfus
pack
patient
bedsid
within
min
simplifi
speed
logist
distribut
transfus
sever
trauma
center
use
whole
blood
store
return
old
product
larg
inspir
militari
experi
whole
blood
mainli
use
warm
immedi
collect
compel
evid
effect
return
civilian
practic
requir
abil
deleukocyt
preserv
platelet
store
maintain
hemostat
function
good
qualiti
data
show
achiev
sever
clinic
studi
plan
begin
come
month
franc
french
blood
establish
french
armi
cooper
initi
prospect
random
noninferior
storhm
trial
sang
total
pour
la
r
eanim
de
h
emorragi
massiv
compar
whole
blood
separ
blood
compon
ratio
sever
bleed
trauma
patient
primari
endpoint
thromboelastograph
paramet
maximum
amplitud
assess
hour
admiss
secondari
endpoint
includ
earli
overal
mortal
lactat
clearanc
reflect
effect
resuscit
h
organ
failur
trial
recruit
patient
french
trauma
center
plan
initi
second
half
localneighbour
day
innov
germani
mesenchym
stromal
cell
regen
therapi
bmmsc
asc
obtain
protocol
character
detail
preclin
evalu
manufactur
licens
msc
asc
plateletderiv
growth
factor
concentr
obtain
explor
sever
clinic
trial
treatment
bone
defect
eudract
number
eudract
number
eudract
number
summar
result
complet
clinic
trial
confirm
feasibl
safeti
autolog
msc
asc
treatment
provid
evid
efficaci
gjerd
et
al
stem
cell
re
introduct
vitro
produc
megakaryocyt
mk
may
serv
sourc
produc
platelet
plt
ex
vivo
vivo
establish
strategi
differenti
mk
induc
pluripot
stem
cell
ipsc
bioreactor
studi
aim
largescal
product
mk
use
microcarri
increas
mk
yield
character
phenotyp
function
irradi
method
decreas
possibl
safeti
concern
associ
ipsc
origin
method
ipsc
cultur
aggreg
form
presenc
absenc
microcarri
use
ml
stir
flask
cell
differenti
mk
use
tpo
scf
medium
period
day
nonirradi
irradi
ipscderiv
mk
analys
polyploidi
phenotyp
proplt
product
use
flow
cytometri
fluoresc
microscopi
also
pltproduct
investig
vivo
nonirradi
irradi
mk
transfus
nod
blood
analyz
human
plt
result
differenti
mk
presenc
microcarri
result
increas
mk
per
ipsc
comparison
aggreg
result
mean
total
mk
harvest
ae
microcarrierassist
bioreactor
comparison
ae
mk
collect
bioreactor
contain
aggreg
interestingli
mk
produc
microcarrierassist
bioreactor
show
higher
proplt
format
capac
mk
deriv
aggreg
bioreactor
mk
phenotyp
dna
content
compar
mk
deriv
type
bioreactor
irradi
mk
affect
phenotyp
capabl
form
proplt
plt
transfus
mice
conclus
microcarri
show
significantli
increas
yield
ipscderiv
mk
stir
bioreactor
clinic
relev
number
may
facilit
use
ipscderiv
mk
ex
vivo
product
plt
direct
transfus
innov
mkbase
regen
therapi
although
rosetta
stone
found
troop
napoleon
egypt
near
citi
rosetta
rashid
contain
small
amount
text
three
languag
key
deciph
hieroglyph
rosetta
mission
tri
achiev
someth
similar
look
tini
bodi
goal
deciph
origin
solar
system
planet
includ
earth
life
year
rosetta
spacecraft
softli
crashland
comet
churyumovgerasimenko
septemb
travel
billion
kilomet
studi
small
km
diamet
black
boulder
name
churyumovgerasimenko
result
mission
seem
fulli
justifi
time
money
spent
last
decad
endeavor
go
alon
univers
big
question
talk
show
answer
got
rosetta
comet
churi
follow
pathway
materi
make
solar
system
dark
cloud
solar
nebula
final
planet
life
show
inde
result
stardust
happen
may
happen
elsewher
univers
cell
tissu
entir
organ
collect
seen
live
drug
genet
unalt
cell
routin
use
clinic
practic
treat
diseas
divers
anemia
bleed
disord
leukemia
organ
failur
groundbreak
advanc
genet
genom
engin
technolog
propel
cell
therapi
frontlin
medic
research
practic
hematopoiet
system
particularli
amen
genet
engin
specif
cell
type
purifi
base
express
specif
surfac
protein
abil
cultur
expand
cell
ex
vivo
recent
unpreced
clinic
success
killer
cell
reprogram
chimer
antigen
receptor
car
attack
express
tumor
cell
demonstr
power
immunotherapi
genet
engin
immun
cell
howev
given
rapid
develop
novel
genom
engin
synthet
biolog
tool
like
begin
new
era
engin
cellular
therapi
present
recent
progress
immun
cell
reprogram
gene
correct
safeti
aspect
remain
challeng
manufactur
cell
free
nucleic
acid
cfna
circul
plasma
individu
thought
releas
host
foreign
cell
circul
fraction
centrifug
cfna
extract
supernat
whole
blood
sampl
manufactur
blood
product
dna
rna
sequenc
human
bacteri
viral
fungal
origin
human
doubl
strand
dna
research
cfna
increas
thank
technolog
advanc
molecular
biolog
result
alreadi
implement
clinic
practic
area
prenat
diagnosi
oncolog
infecti
diseas
latter
investig
focus
explor
nonhuman
cfna
field
metagenom
high
throughput
sequenc
associ
bioinformat
socal
new
gener
sequenc
ng
sped
investig
nonhuman
cfna
tool
provid
opportun
classifi
cfna
human
nonhuman
categori
identifi
thu
possibl
explor
simultan
whole
landscap
bacteri
viral
fungal
popul
present
ng
human
blood
alreadi
proven
feasibl
valu
identifi
emerg
virus
investig
clinic
case
fever
unknown
etiolog
ng
cfna
also
particularli
effect
analyz
differ
genotyp
viru
case
coinfect
eg
hepat
c
viru
studi
cfna
new
molecular
technolog
therefor
great
import
transfus
medicin
especi
regard
secur
clinic
transfus
reaction
first
transfus
transmit
infect
fear
advers
complic
second
febril
nonhemolyt
transfus
reaction
also
frequent
report
advers
event
hemovigil
system
physiolog
mechan
oneremain
clearli
elucid
investig
cfna
could
thu
improv
understand
strategi
aim
reduc
two
clinic
advers
event
survey
comprehens
composit
circul
infecti
agent
blood
product
ng
technolog
could
interest
investig
sever
febril
transfus
reaction
moreov
cost
analysi
reduc
might
possibl
screen
prospect
regularli
whole
metagenom
asymptomat
blood
donor
addit
classic
epidemiolog
surveil
instanc
studi
test
ng
method
manufactur
fresh
frozen
plasma
astroviru
identifi
final
respons
transfus
physician
implic
manufactur
blood
product
ensur
cfna
within
blood
product
clinic
impact
innat
immun
recipi
accord
recent
research
vitro
cfna
purifi
blood
product
induc
transcript
inflammatori
cytokin
mononuclear
cell
nonhuman
cfna
effect
tolllik
receptor
tlrlink
inflammatori
pathway
would
also
relev
insur
donor
cfna
signific
effect
immun
system
recipi
conclus
cfna
divers
molecul
contamin
blood
product
technolog
progress
make
investig
avail
besid
use
marker
infect
asymptomat
donor
impact
recipi
immun
investig
activ
life
regular
train
part
healthi
life
style
mani
includ
particip
endur
exercis
competit
differ
level
thu
highli
relev
know
blood
donat
affect
exercis
perform
close
done
endur
competit
endur
exercis
perform
determin
mani
factor
three
primari
maxim
oxygen
uptak
rel
load
individu
sustain
time
final
effici
movement
given
disciplin
year
number
studi
sampl
blood
volum
rang
ml
appli
differ
methodolog
approach
measur
maxim
oxygen
uptak
recoveri
period
rang
day
overal
gener
find
reduct
blood
haemoglobin
attenu
maxim
oxygen
uptak
well
endur
perform
blood
donat
normal
welltrain
men
maxim
oxygen
uptak
perform
normal
two
week
one
studi
normal
blood
donat
ml
remain
attenu
four
week
anoth
studi
despit
chang
blood
haemoglobin
concentr
similar
design
methodolog
also
similar
two
studi
addit
maxim
oxygen
uptak
rel
load
toler
exercis
probabl
also
attenu
decreas
arterioven
oxygen
extract
avail
data
limit
first
part
talk
highlight
major
find
discuss
methodolog
issu
complic
interpret
conclus
sex
differ
circul
blood
volum
haemoglobin
concentr
haematocrit
hormon
level
thu
entir
possibl
sex
differ
effect
blood
donat
physic
perform
recoveri
blood
donat
addit
basic
physiolog
sex
differ
also
higher
preval
iron
defici
premenopaus
women
physic
activ
women
women
donat
blood
therefor
studi
influenc
standard
ml
blood
donat
maxim
oxygen
uptak
endur
perform
subsequ
recoveri
physic
activ
women
observ
iron
suffici
women
blood
haemoglobin
concentr
maxim
oxygen
uptak
back
baselin
day
blood
donat
endur
perform
normal
alreadi
day
second
part
talk
discuss
sex
differ
effect
blood
donat
maxim
oxygen
uptak
endur
perform
overal
avail
data
suggest
care
conserv
approach
week
need
normal
blood
donat
fulli
recov
particip
endur
exercis
competit
one
ten
attempt
donat
blood
result
temporari
deferr
due
concern
impact
donat
donor
recipi
well
establish
evid
temporari
deferr
impact
neg
donor
larg
proport
defer
fail
return
end
deferr
period
present
provid
overview
deferr
donor
perspect
describ
likelihood
receiv
deferr
differ
donor
subgroup
impact
temporari
deferr
futur
donat
donor
consid
shortterm
longerterm
donat
pattern
also
review
outlin
donor
highest
risk
nonreturn
follow
deferr
known
accumul
impact
multipl
deferr
donor
sever
hypothes
propos
account
strong
neg
impact
deferr
donor
behaviour
preliminari
evid
psycholog
factor
emot
reaction
predict
intent
return
research
also
begin
emerg
effect
tailor
intervent
mitig
impact
deferr
donor
behaviour
evid
prevent
intervent
strategi
reactiv
donor
laps
postdeferr
review
recommend
blood
centr
made
well
suggest
futur
research
address
continu
gap
knowledg
influenti
studi
gift
relationship
richard
titmuss
coin
idea
voluntari
nonpaid
blood
donat
gift
life
fellow
citizen
metaphor
power
mobil
donor
busbi
convey
direct
relationship
blood
donat
patient
vital
well
differ
gain
cost
gift
life
blood
donat
seen
symbol
pure
altruism
promot
solidar
stranger
appli
metaphor
success
donat
blood
research
ask
group
finnish
blood
donor
would
think
frc
blood
servic
invit
give
blood
sampl
person
inform
research
blood
donor
usual
will
contribut
research
public
benefit
saw
great
potenti
scienc
creat
solut
help
patient
futur
howev
base
interview
data
previou
research
suggest
analog
gift
life
donat
research
work
way
metaphor
fail
address
donor
question
new
type
relationship
interest
risk
relat
use
person
data
research
left
unansw
could
discourag
donat
research
henc
argu
gift
life
metaphor
applic
donor
recruit
research
context
present
wish
look
better
metaphor
donat
research
blood
servic
collect
research
data
could
appli
academi
day
transfus
challeng
patient
sickl
cell
diseas
immunohaematolog
featur
patient
sickl
cell
diseas
lfa
consid
polymorph
antigen
african
popul
lfa
present
commerci
panel
situat
even
complic
recipi
lack
highfrequ
antigen
common
one
hr
hr
b
sec
u
neg
u
var
js
b
hy
jo
final
high
rh
divers
among
peopl
african
descent
harbor
variant
allel
andor
partial
rh
antigen
risk
develop
alloantibodi
set
screen
partial
rh
antigen
make
sens
figur
illustr
divers
vari
approach
use
one
take
consider
rhd
rhce
ce
variant
allel
sever
american
studi
preval
estim
respect
team
take
consider
c
e
partial
antigen
preval
estim
respect
alloimmun
rate
respect
result
phenotyp
discrep
scd
patient
like
alloimmun
overal
immun
rate
commonli
admit
gener
popul
depend
unit
select
polici
andor
studi
design
immun
rate
scd
patient
vari
highest
figur
establish
match
polici
implement
metaanalysi
public
overal
alloimmun
rate
around
alloimmun
thought
enhanc
inflammatori
state
often
present
scd
patient
prone
develop
new
alloantibodi
use
stochast
model
alloimmun
increas
risk
produc
addit
antibodi
versu
gener
popul
autoantibodi
identifi
risk
factor
alloimmun
result
scd
patient
often
complex
mixtur
allo
autoantibodi
rh
antibodi
consid
irregular
natur
antibodi
present
signific
proport
anoth
characterist
antibodi
scd
patient
evanesc
alloantibodi
becom
undetect
within
year
initi
develop
relatedli
third
dhtr
report
happen
patient
previou
histori
immun
addit
third
patient
develop
antibodi
dhtr
identifi
patient
risk
develop
dhtr
key
manag
properli
alloimmun
seriou
risk
red
blood
cell
transfus
patient
sickl
cell
diseas
scd
result
sever
delay
haemolyt
transfus
reaction
exacerb
clinic
symptom
lifethreaten
hyperhaemolysi
alloimmun
presenc
alloantibodi
patient
blood
complic
pretransfus
test
hamper
select
compat
blood
product
numer
studi
shown
scd
patient
rel
high
risk
alloimmun
compar
gener
popul
explain
larg
number
transfus
given
also
increas
exposur
foreign
antigen
result
differ
antigen
makeup
scd
recipi
blood
donor
popul
factor
involv
immun
respons
age
first
transfus
inflammatori
state
hla
type
investig
start
unravel
blood
transfus
still
one
main
treatment
modal
scd
patient
lifelong
transfus
depend
import
minim
alloimmun
rate
theoret
complet
match
relev
blood
group
antigen
would
prevent
alloimmun
howev
possibl
donor
comprehens
match
strategi
develop
minim
alloimmun
balanc
patient
need
donor
avail
cost
effect
develop
prevent
match
strategi
factor
need
establish
antibodi
specif
clinic
relev
antigen
immunogen
avail
specif
antigen
type
donor
popul
recipi
donor
type
phenotyp
andor
genotyp
extent
latter
especi
import
scd
patient
sinc
african
descent
preval
genet
variat
popul
rel
high
rhd
rhce
variant
common
remain
undetect
serolog
type
use
discov
high
resolut
molecular
type
patient
partial
rh
phenotyp
risk
alloimmun
apart
special
rh
phenotyp
individu
african
descent
fy
ab
phenotyp
relat
gatabox
mutat
fyb
allel
uor
u
var
phenotyp
result
genet
variat
mn
allel
also
common
sever
studi
shown
scd
patient
antibodi
direct
rhd
rhe
rhc
k
frequent
found
unmatch
transfus
given
prevent
match
antigen
proven
success
reduc
alloimmunis
extend
match
rh
antigen
fy
jk
jk
b
decreas
alloimmunis
rate
current
differ
countri
prevent
match
strategi
place
vulner
patient
group
genotyp
avail
within
reach
optim
antigen
type
approach
patient
donor
combin
serolog
genet
develop
lectur
sever
aspect
antigen
type
approach
prevent
match
strategi
benefit
scd
patient
discuss
artifici
intellig
becom
buzzword
appear
anywher
media
forget
ai
subfield
comput
scienc
field
machin
learn
around
year
improv
comput
power
abund
data
progress
comput
scienc
arriv
afford
cloud
solut
brought
daili
live
also
health
care
news
ai
becom
omnipres
landmark
paper
come
algorithm
outperform
team
physician
diagnosi
kind
skin
diseas
eye
diseas
retina
scan
detect
cancer
ct
scan
howev
littl
solut
actual
shown
clinic
practic
yet
anaesthesia
work
first
algorithm
come
anaesthesia
practic
hypotens
surgeri
associ
strongli
poor
outcom
like
myocardi
ischemia
surgic
complic
renal
failur
even
mortal
work
machinelearn
train
algorithm
predict
hypotens
event
use
arteri
blood
pressur
curv
min
actual
event
get
fda
ce
approv
howev
mere
mathemat
valid
requir
achiev
retrospect
dataset
realiti
need
use
algorithm
support
decisionmak
intern
retrospect
extern
prospect
passiv
use
valid
step
clinic
ie
rct
valid
need
moreov
need
assess
econom
impact
ultim
tool
reach
clinic
practic
start
help
us
go
reactiv
proactiv
hemodynam
manag
like
start
work
machinelearn
tool
predict
incid
specif
type
patient
come
e
predict
infect
surgeri
discuss
approach
essenti
start
machin
learn
practic
learn
also
discuss
first
project
design
use
machin
learn
manag
bleed
patient
get
best
therapi
advic
blood
product
use
like
plasma
fibrinogen
et
cetera
start
use
tool
unison
exist
tool
improv
scienc
clinic
practic
respect
bio
medic
field
thrombocytopenia
common
hematolog
abnorm
found
newborn
especi
preterm
neonat
two
subgroup
distinguish
earli
thrombocytopenia
occur
within
first
h
life
late
thrombocytopenia
occur
first
h
life
earli
thrombocytopenia
associ
intrauterin
growth
restrict
wherea
late
thrombocytopenia
caus
mainli
sepsi
necrot
enterocol
platelet
transfus
hallmark
treatment
neonat
thrombocytopenia
transfus
prophylact
mean
given
absenc
bleed
howev
efficaci
transfus
prevent
bleed
never
proven
addit
risk
platelet
transfus
seem
pronounc
preterm
neonat
lack
data
platelet
transfus
guidelin
differ
wide
countri
recent
random
control
trial
studi
among
preterm
infant
sever
thrombocytopenia
found
randomli
assign
receiv
platelet
transfus
plateletcount
threshold
l
significantli
higher
rate
death
major
bleed
within
day
random
receiv
platelet
transfus
plateletcount
threshold
l
present
summar
current
understand
etiolog
manag
neonat
thrombocytopenia
transfusionassoci
circulatori
overload
taco
sever
transfus
advers
reaction
associ
increas
mortal
morbid
incid
taco
adult
vari
probabl
underdiagnos
underreport
incid
pediatr
popul
undetermin
taco
usual
occur
patient
receiv
larg
volum
blood
product
short
period
time
common
patient
known
risk
factor
cardiovascular
diseas
renal
failur
older
younger
age
year
year
hospitalis
patient
intens
care
patient
also
risk
typic
present
taco
respiratori
distress
dyspnea
tachypnea
occur
within
h
blood
transfus
associ
sign
symptom
hypoxia
hypertens
tachycardia
posit
fluid
balanc
high
central
venou
pressur
acut
worsen
pulmonari
edema
chest
xray
echocardiographi
measur
brain
natriuret
peptid
bnp
ntermin
prohormon
ntprobnp
help
diagnosi
sever
definit
criteria
propos
taco
none
adapt
children
particularli
criticallyil
children
risk
probabl
main
reason
taco
even
underdiagnos
underreport
pediatr
popul
recent
studi
compar
incid
taco
pediatr
intens
care
unit
use
intern
societi
blood
transfus
isbt
criteria
two
differ
way
defin
abnorm
valu
use
normal
pediatr
valu
publish
nelson
textbook
pediatr
use
patient
control
compar
preand
posttransfus
valu
either
differ
threshold
monitor
taco
h
posttransfus
total
patient
includ
taco
incid
vari
depend
definit
use
wide
variabl
conclud
oper
definit
taco
need
pediatr
particularli
criticallyil
children
differenti
diagnosi
dyspneaassoci
transfus
advers
reaction
eg
transfusionassoci
lung
injuri
anaphylaxi
import
treatment
differ
guidelin
blood
bank
treatment
taco
similar
cardiogen
pulmonari
edema
oxygen
diuresi
ventilatori
support
prevent
possibl
avoid
unnecessari
transfus
transfus
necessari
amount
blood
product
avoid
rapid
transfus
use
diuret
background
risk
import
transfusiontransmit
hepat
e
viru
tthev
infect
contamin
blood
current
controversi
discuss
topic
transfus
medicin
particular
infecti
dose
final
determin
quantiti
differ
countri
chosen
differ
approach
deal
pathogen
one
central
question
need
individu
nat
screen
id
versu
minipool
nat
screen
mp
approach
identifi
relev
viremia
blood
donor
aim
comparison
evalu
avail
screen
strategi
relat
infecti
dose
minim
risk
tthev
infect
method
systemat
review
present
known
case
tthev
infect
avail
routin
natscreen
assay
furthermor
blood
donat
screen
strategi
hev
ehev
effect
european
union
compar
also
describ
experi
hev
screen
utilis
idnatbas
donor
screen
algorithm
compar
mpnat
pool
sampl
novemb
januari
total
blood
donat
screen
presenc
hev
rna
use
mpnat
hous
realstar
hev
rtpcr
kit
idnat
coba
platform
result
review
literatur
reveal
signific
variat
regard
infecti
dose
caus
hepat
e
systemat
case
review
compon
viral
load
vl
greater
iu
caus
infect
definit
infecti
dose
difd
lowest
infecti
dose
result
tthev
infect
observ
gener
iu
minim
infecti
dose
mifd
infecti
dose
differ
blood
product
mainli
influenc
remain
plasma
content
data
compar
two
differ
hev
screen
algorithm
reveal
eight
hev
rna
posit
donat
use
mpnat
incid
wherea
hev
rna
posit
donat
identifi
idnat
incid
idnat
posit
donat
vl
iuml
summaryconclus
taken
account
current
knowledg
requir
mifd
difd
analyt
sensit
screen
method
extrapol
detect
probabl
hevrna
posit
blood
donor
use
differ
test
strategi
nat
assay
id
vs
minipool
differ
pool
size
also
consid
amount
plasma
differ
blood
product
calcul
infecti
dose
need
detect
id
test
would
suffici
detect
minimum
vl
donor
avoid
tthev
infect
base
current
known
mifd
highli
sensit
mpnat
adequ
routin
screen
assay
identifi
high
virem
donor
avoid
tthev
infect
base
difd
also
determin
incid
hev
infect
approxim
higher
idnat
use
howev
vl
iuml
like
result
tthev
infect
taken
account
current
known
mifd
difd
clinic
relev
need
identif
low
level
hev
posit
donor
still
requir
investig
last
year
sever
pathogen
inactiv
pi
technolog
develop
appli
blood
compon
technolog
inactiv
pathogen
plasma
platelet
avail
european
union
other
current
develop
first
pi
technolog
introduc
market
plasma
base
addit
methylen
blue
illumin
light
theraflex
mbplasma
macopharma
gr
platelet
plasma
two
technolog
licens
one
base
addit
amotosalen
illumin
ultraviolet
light
uv
intercept
ceru
one
combin
addit
riboflavin
vitamin
b
illumin
uv
light
mirasol
terumo
bct
current
anoth
technolog
platelet
inactiv
base
illumin
uvc
light
strong
agit
develop
theraflex
macopharma
red
blood
cell
one
technolog
base
addit
one
molecul
amustalin
ceru
develop
mechan
action
spectrum
level
inactiv
pathogen
vari
among
differ
technolog
addit
number
studi
clinic
relev
endpoint
number
patient
includ
studi
homogen
publish
evid
show
treat
blood
compon
safe
efficaci
patient
although
treat
platelet
concentr
decreas
posttransfus
recoveri
surviv
transfus
platelet
occur
differ
differ
technolog
howev
cumul
experi
use
routin
technolog
almost
year
support
concept
safeti
efficaci
blood
compon
treat
pathogen
inactiv
technolog
without
signific
increas
util
use
pathogen
inactiv
blood
compon
widespread
differ
epidemiolog
countri
infecti
risk
percept
concern
potenti
advers
effect
associ
use
econom
consider
might
explain
differ
observ
implement
histori
p
k
antigen
complic
sometim
confus
sever
chang
nomenclatur
associ
antigen
genet
home
rais
mani
question
well
longstand
enigma
regard
molecular
mechan
underli
common
p
p
phenotyp
system
isbt
current
includ
three
differ
antigen
p
k
antigen
discov
alreadi
landstein
levin
p
k
describ
respect
abo
system
naturallyoccur
antibodi
igm
andor
igg
class
form
miss
k
carbohydr
structur
usual
weak
coldreact
antibodi
rare
implic
hemolyt
transfus
reaction
htr
hemolyt
diseas
fetu
newborn
hdfn
howev
antibodi
report
react
bind
complement
caus
immedi
delay
htr
p
k
antibodi
caus
htr
antinor
regard
polyagglutinin
unknown
clinic
signific
higher
frequenc
miscarriag
seen
women
rare
phenotyp
p
p
k
p
k
rbc
fetu
well
newborn
express
low
amount
p
p
k
antigen
placenta
show
high
express
consequ
possibl
target
antibodi
caus
miscarriag
p
k
antigen
wide
tissu
distribut
act
host
receptor
variou
pathogen
toxin
furthermor
alter
express
p
k
antigen
describ
sever
cancer
form
longstand
question
individu
p
phenotyp
lack
p
k
p
express
also
recent
clarifi
galactosyltransferas
synthes
p
k
antigen
addit
p
p
phenotyp
confirm
caus
transcript
regul
transcript
factor
bind
select
p
allel
region
enhanc
transcript
gene
debat
whether
p
k
antigen
exist
glycoprotein
human
rbc
membran
glycolipid
membran
compon
carri
epitop
recent
public
show
antigen
detect
human
rbc
glycoprotein
thu
glycosphingolipid
longer
consid
sole
carrier
antigen
blood
group
system
start
one
antigen
gain
two
member
name
p
k
step
step
biochem
genet
basi
underli
antigen
express
system
reveal
still
mani
question
remain
solv
neither
repres
blood
group
system
mutat
gene
encod
transcript
factor
tf
shown
result
simultan
alter
express
blood
group
antigen
certain
rare
blood
group
phenotyp
particular
mutat
gene
respons
dominantli
inherit
lu
phenotyp
commonli
refer
lu
ab
gross
reduct
lutheran
antigen
express
red
cell
lu
individu
though
also
weaken
express
blood
group
antigen
like
highincid
antigen
anwj
antigen
indian
blood
group
system
among
other
sinc
first
descript
variant
associ
lu
phenotyp
mani
variant
gene
report
impact
blood
group
antigen
express
list
tabl
blood
group
allel
mutat
gene
also
found
associ
xlink
form
lutheranmod
phenotyp
likewis
regist
allel
tabl
besid
effect
tf
variant
blood
group
antigen
express
transcript
factorbind
site
polymorph
regulatori
region
blood
group
gene
also
impact
express
encod
antigen
red
cell
first
exampl
type
polymorph
describ
disrupt
gata
motif
gene
promot
found
abolish
erythroid
gene
express
fy
ab
individu
african
descent
impact
mutat
affect
bind
site
also
describ
abo
subgroup
like
bm
phenotyp
regulatori
element
gata
bind
site
first
intron
abo
gene
found
alter
individu
phenotyp
either
delet
point
mutat
disrupt
gata
motif
recent
find
also
reveal
xga
express
red
cell
depend
bind
control
element
locat
kb
upstream
xg
gene
singl
nucleotid
polymorph
snp
within
region
shown
correl
well
expect
distribut
xga
neg
phenotyp
differ
popul
work
demonstr
g
c
snp
disrupt
bind
site
consequ
abolish
erythrocyt
xg
express
overal
investig
allow
elucid
underli
genet
basi
xga
express
made
xga
genotyp
possibl
similar
xga
antigen
known
long
time
determin
gene
molecular
basi
underli
common
phenotyp
remain
elus
till
recent
sever
cisregulatori
snp
identifi
noncod
sequenc
around
exon
show
good
correl
antigen
express
interestingli
potenti
bind
site
sever
hematopoiet
tf
identifi
region
final
recent
investig
demonstr
role
tf
express
antigen
select
bind
regulatori
site
present
allel
summar
variat
blood
group
antigen
express
may
result
mutat
polymorph
regulatori
region
blood
group
gene
recent
report
unravel
molecular
mechan
underli
express
xga
blood
group
antigen
involv
tf
bind
allelespecif
regulatori
element
similar
mechan
may
also
regul
antigen
express
blood
group
system
clinic
immunolog
copenhagen
univers
hospit
copenhagen
denmark
sinc
discoveri
cellfre
fetal
dna
cffdna
pregnant
women
blood
develop
noninvas
prenat
test
nipt
provid
new
diagnost
applic
prenat
care
transfus
medicin
clinic
immunolog
cffdna
extract
matern
plasma
predict
fetal
blood
group
purpos
guid
target
rh
prophylaxi
nonimmun
rhd
neg
women
assess
risk
hemolyt
diseas
fetu
newborn
hdfn
immun
women
give
overview
noninvas
prenat
test
fetal
blood
group
base
literatur
summar
current
experi
noninvas
prenat
test
fetal
rhd
blood
group
rhd
neg
pregnant
women
routin
clinic
test
avail
sever
countri
worldwid
assess
risk
hdfn
immun
women
routin
test
guid
rh
prophylaxi
implement
nationwid
servic
european
countri
noninvas
prenat
test
fetal
rhd
highli
accur
sensit
report
clinic
program
gener
sensit
challeng
low
quantiti
cffdna
especi
earli
pregnanc
specif
challeng
polymorph
rh
blood
group
system
care
attent
need
navig
among
mani
rhd
variant
rhd
variant
may
complic
cffdna
analysi
interpret
result
especi
popul
mix
ethnic
despit
challeng
fetal
rhd
test
feasibl
implement
care
attent
issu
blood
group
determin
snp
kel
rhc
main
challeng
interfer
matern
dna
analyz
fetal
dna
result
low
accuraci
lower
sensit
use
qpcr
applic
novel
techniqu
next
gener
sequenc
droplet
digit
pcr
accur
noninvas
predict
fetal
blood
group
demonstr
success
predict
fetal
rhd
success
clinic
implement
nation
program
encourag
widespread
use
cellfre
dna
base
analysi
futur
work
noninvas
prenat
test
fetal
blood
group
determin
snp
may
consolid
applic
cellfre
dna
test
target
includ
human
platelet
antigen
isbt
newli
form
cfdna
subgroup
red
cell
immunogenet
blood
group
terminolog
work
parti
work
facilit
clinic
applic
implement
evalu
cellfre
dna
test
blood
bank
nordic
countri
share
veintovein
approach
short
mean
collect
blood
prepar
blood
compon
testingreleas
store
serv
singl
actor
top
recipi
donor
blood
group
crossmatch
deliveri
registr
transfus
complic
usual
handl
singl
blood
bank
inform
system
bbi
mean
blood
bank
nordic
tradit
oper
singl
vendor
need
process
control
singl
vendor
bbi
present
solut
unsolv
challeng
untap
possibl
streamlin
process
scrutin
intent
describ
separ
process
acquir
best
breed
best
suit
itsystem
aim
integr
rather
build
integr
itsystem
support
need
veintovein
process
precondit
nordic
countri
multipl
itsystem
support
isol
process
intend
facilit
develop
furthermor
increas
flexibl
whole
process
set
reveal
exist
knowledg
literatur
vendor
strategi
blood
bank
nt
succeed
identifi
relev
literatur
howev
systemat
literatur
studi
vendor
strategi
choos
health
base
prisma
method
identifi
studi
elig
full
text
review
met
inclus
criteria
even
broader
literatur
studi
reveal
littl
evid
two
studi
find
singl
vendor
strategi
poor
conclud
best
suit
solut
optim
one
studi
abl
correl
vendor
strategi
investig
product
conclud
best
suit
best
breed
strategi
requir
larger
organiz
chang
singl
vendor
strategi
summari
exist
research
contradictori
paper
add
basic
knowledg
break
process
control
blood
bank
smaller
process
add
possibl
identifi
best
breed
best
suit
vendor
instead
reli
singl
vendor
solut
furthermor
call
research
field
vendor
select
strategi
studi
nt
succeed
identifi
appli
drone
suppli
blood
remot
area
rwanda
experi
biomed
servic
rwandaministri
healthnat
blood
servic
kigali
rwanda
background
rwanda
blood
transfus
servic
start
genocid
tutsi
almost
socioeconom
fabric
rwanda
destroy
well
health
infrastructur
healthcar
system
suffer
aftermath
health
inequ
urban
rural
area
includ
access
blood
transfus
govern
start
rebuild
cours
life
includ
health
system
blood
servic
particular
nation
center
blood
transfus
ncbt
mandat
provid
safe
effect
adequ
blood
blood
compon
patient
need
pivot
achiev
health
relat
mdg
today
rwanda
ambiti
vision
put
million
citizen
within
minut
essenti
medic
product
everi
second
matter
emerg
manag
use
drone
perfect
solut
mani
last
mile
challeng
tradit
difficult
overcom
imposs
forecast
accur
need
singl
patient
govern
provid
easi
solut
central
suppli
provid
ondemand
emerg
medic
deliveri
drone
doctor
empow
provid
qualiti
care
suppli
hand
patient
treat
close
home
elimin
wast
potenti
overstock
health
worker
know
quick
reliabl
sourc
suppli
descript
govern
rwanda
start
oper
world
first
nation
drone
deliveri
program
blood
lifesav
medic
product
drone
carri
two
six
unit
blood
time
deliv
minut
depend
hospit
locat
averag
durat
hour
round
trip
vehicl
system
use
drone
drone
current
deliv
blood
health
facil
throughout
countri
set
reach
transfus
health
facil
outsid
kigali
end
year
within
first
year
healthcar
worker
save
averag
hour
per
deliveri
total
hour
lost
time
road
pick
could
instead
dedic
patient
care
march
deliveri
made
emerg
deliveri
total
blood
unit
deliv
februari
ziplin
obtain
highest
rate
health
facil
serv
perform
evalu
conduct
nation
center
blood
transfus
doctor
medic
staffer
need
blood
place
order
hemovigil
order
portal
sent
confirm
messag
say
drone
way
drone
fli
health
facil
kmh
within
five
minut
destin
medic
staffer
receiv
notif
drone
drop
packag
attach
parachut
special
drop
zone
conclus
suppli
develop
countri
problem
global
issu
rwanda
first
one
recogn
potenti
technolog
decid
someth
first
fast
ensur
access
univers
access
blood
product
scottish
nation
blood
transfus
servic
edinburgh
unit
kingdom
support
provis
viabl
transfus
servic
remoterur
area
geograph
challeng
limit
qualifi
blood
bank
resourc
small
throughput
volum
increas
regul
three
addit
factor
combin
threaten
safe
sustain
transfus
servic
deliveri
inventori
manag
hour
servic
provis
identifi
essenti
area
thought
technolog
form
remot
control
blood
fridg
could
provid
key
element
overal
solut
radio
frequenc
identif
rfid
fridg
rack
system
instal
standard
blood
bank
fridg
connect
laboratori
inform
manag
system
lim
common
remot
central
blood
bank
central
blood
bank
enabl
test
patient
sampl
remot
laboratori
identifi
compon
locat
remot
fridg
suitabl
patient
allow
correct
compon
issu
even
qualifi
staff
unavail
remot
laboratori
test
conclud
instal
remot
fridg
manag
play
major
role
help
maintain
remot
inventori
permit
patient
compat
compon
issu
sustain
transfus
servic
remot
commun
avoid
transport
patient
requir
transfus
support
locat
mile
home
antibodi
fcgriiib
report
neonat
alloimmun
neutropenia
result
matern
antibodi
transfer
transplacent
fetu
caus
known
hnaantibodi
specif
ie
specif
hna
hla
antibodi
induc
mild
febril
transfus
reaction
trali
sinc
introduct
male
plasma
strategi
mani
countri
trali
incid
decreas
still
one
common
caus
sever
transfus
reaction
especi
antibodi
contain
plasma
femal
donor
respons
sever
even
fatal
reaction
also
hla
class
class
ii
antibodi
report
latter
activ
monocyt
secret
solubl
factor
act
prime
neutrophil
narrow
lung
capillari
laboratori
test
laboratori
workup
requir
knowledg
patient
clinic
condit
method
appropri
detect
relev
antibodi
classic
granulocyt
agglutin
test
gat
combin
granulocyt
indirect
immunofluoresc
test
gift
detect
nearli
relev
antibodi
hla
class
antibodi
clearli
detect
gift
antibodi
strongli
agglutin
neutrophil
gat
monoclon
antibodyspecif
immobil
granulocyt
antigen
maiga
test
detect
hnaantibodi
except
high
glycoprotein
specif
sensit
time
consum
requir
highli
skill
personnel
trali
diagnost
laboratori
test
complet
method
like
indirect
lymphocyt
immunofluoresc
test
lift
elisa
hla
class
antibodi
hla
class
ii
specif
elisa
sinc
sever
year
fluoresc
bead
base
assay
luminex
enabl
faster
autom
hna
antibodi
detect
date
specif
especi
reliabl
detect
still
classic
gift
gat
complet
methodolog
spectrum
serolog
type
today
mostli
reduc
determin
gift
molecular
reason
phenotyp
complet
understood
establish
one
pcrasp
reaction
main
polymorph
would
compris
risk
miss
molecular
caus
howev
hna
allelotyp
pcr
method
first
choic
summaryconclus
granulocyt
serolog
still
today
wide
base
varieti
manual
method
reserv
special
laboratori
requir
experienc
laboratori
staff
profound
knowledg
granulocyt
immunobiolog
norwegian
nation
unit
platelet
immunolog
laboratori
medicin
univers
hospit
north
norway
tromso
norway
matern
alloantibodi
antigen
human
platelet
caus
sever
thrombocytopenia
bleed
fetu
newborn
identifi
fetalneonat
alloimmun
thrombocytopenia
fnait
although
case
thrombocytopenia
selfresolv
within
two
first
week
life
infant
present
bleed
symptom
thu
requir
platelet
transfus
set
laboratori
analys
requir
confirm
fnait
diagnosi
addit
guid
compat
platelet
affect
newborn
correct
diagnosi
valuabl
assess
risk
fnait
subsequ
pregnanc
addit
platelet
alloantibodi
may
also
complic
platelet
transfus
immunemedi
platelet
refractori
requir
proper
identif
patient
antibodi
specif
prior
select
donor
platelet
algorithm
laboratori
investig
includ
serolog
molecular
assay
depend
object
time
whether
urgent
need
platelet
transfus
followup
pregnanc
known
risk
fullscal
laboratori
test
confirm
diagnosi
molecular
genotyp
includ
hpa
system
relev
local
popul
caucasian
prefer
option
extend
panel
system
low
frequenc
popul
due
immigrationmobl
less
frequent
seen
alloantibodi
commonli
includ
serolog
test
antibodi
bind
platelet
often
initi
test
flow
cytometri
analysi
direct
test
andor
crossmatch
howev
detect
plateletspecif
antibodi
often
complic
presenc
antihla
class
antibodi
thu
requir
sensit
platelet
glycoproteinspecif
assay
serolog
test
plateletspecif
antibodi
includ
minimum
panel
antigen
gpiibiiia
gpibix
gpiaiia
prefer
addit
target
popul
asianafrican
origin
sever
method
avail
ie
beadbas
assay
elisa
base
method
howev
refer
laboratori
perform
variant
monoclon
antibodi
immobil
platelet
antigen
assay
maipa
report
intern
platelet
immunolog
workshop
isbt
investig
also
includ
measur
quantit
maipa
present
report
potenti
predict
sever
fnait
pregnanc
known
risk
fnait
method
avail
perform
noninvas
prenat
type
matern
plasma
feasibl
far
appropri
routin
test
fetal
type
quantit
pcr
melt
curv
analysi
sophist
yet
resourcedemand
techniqu
also
recent
report
importantli
also
type
hpasystem
molecular
basi
express
justu
liebig
univers
institut
clinic
immunolog
transfus
medicin
giessen
germani
human
neutrophil
antigen
neutrophilspecif
antigen
locat
gpianchor
glycoprotein
also
known
absent
neutrophil
surfac
healthi
individu
divid
popul
posit
null
individu
exposur
null
individu
posit
neutrophil
pregnanc
transfus
transplant
induc
immun
consequ
product
isoantibodi
isoantibodi
involv
mechan
neonat
alloimmun
neutropenia
nain
transfusionrel
acut
lung
injuri
trali
graft
failur
follow
bone
marrow
transplant
presenc
neutrophil
surfac
posit
individu
follow
bimod
express
categor
circul
neutrophil
posit
neg
subset
gene
contain
exon
encod
protein
amino
acid
lack
null
individu
associ
presenc
missens
mutat
exon
gene
induc
prematur
stop
codon
codon
mutat
alon
combin
introduc
main
reason
absenc
null
individu
pseudogen
highli
homolog
exon
gene
locat
downstream
gene
convers
exon
gene
respons
gener
missens
mutat
addit
heterozygos
homozygos
account
regul
neg
posit
neutrophil
subpopul
genotyp
reveal
null
individu
heterozyg
mutat
without
indic
presenc
complementari
mechan
regul
express
newli
null
individu
individu
atyp
express
polymorph
combin
describ
altogeth
data
indic
complex
compound
mechan
regul
express
neutrophil
surfac
present
summar
recent
find
express
highlight
potenti
genotyp
method
genet
assess
express
donor
patient
blood
product
order
transfus
start
end
time
whether
patient
experienc
reaction
transfus
well
vital
measur
taken
transfus
includ
temperatur
oxygen
level
blood
pressur
heart
rate
valid
process
transfus
nurs
note
sampl
review
assess
accuraci
inform
regard
blood
product
order
whether
patient
experienc
reaction
start
end
time
transfus
field
across
sampl
note
claritynlp
tool
reproduc
data
point
percent
accuraci
addit
tool
suppli
transfus
end
time
numer
structur
record
miss
key
data
point
summaryconclus
claritynlp
effici
digest
larg
number
transfus
nurs
note
simultan
also
excel
job
extract
main
characterist
transfus
use
partnership
structur
data
produc
accur
complet
pictur
patient
transfus
immunohematolog
genom
new
york
blood
center
new
york
unit
state
antibodybas
type
posit
result
reflect
agglutin
red
cell
rbc
serv
profess
nearli
centuri
enabl
safe
effect
transfus
therapi
power
rbc
type
serolog
method
lie
avail
standard
antibodi
reagent
target
mani
specif
signific
transfus
abil
directli
detect
antigen
express
rbc
hemagglutin
histor
rel
inexpens
particularli
abo
rhd
import
blood
group
popul
serolog
rbc
type
reliabl
requir
sophist
equip
gener
straightforward
perform
fast
requir
less
h
result
henc
antibodybas
test
consid
gold
standard
blood
group
type
age
genom
dnabas
genotyp
increasingli
use
altern
antibodybas
method
antigen
associ
singl
nucleotid
chang
snp
respect
gene
genotyp
valid
comparison
antibodybas
type
shown
highli
correl
power
genotyp
rbc
lie
abil
test
antigen
serolog
reagent
type
numer
antigen
singl
assay
use
autom
dnaarray
increas
accuraci
weak
antigen
express
reveal
fresh
rbc
sampl
requir
dna
extract
interfer
transfus
rbc
igg
bound
patient
rbc
dnabas
type
econom
provid
much
inform
test
requir
special
equip
train
turn
around
best
approach
use
serolog
type
replac
dnabas
type
inde
genotyp
increasingli
use
practic
transfus
medicin
especi
growth
whole
genom
sequenc
wg
howev
serolog
type
abo
rhd
fast
accur
often
reli
sampl
identif
genotyp
sole
mean
routin
type
genom
sequenc
approach
certainli
reveal
unrecogn
chang
genet
variabl
rbc
membran
protein
variat
immunogen
genet
polymorph
must
associ
antibodi
product
consid
blood
group
antigen
import
antibodi
antibodi
reactiv
continu
central
defin
princip
transfus
two
side
coin
key
safe
effect
transfus
therapi
sinc
research
molecular
basi
structur
function
aspect
protein
carri
produc
antigen
led
upgrad
modern
understand
blood
group
variat
commonli
singl
nucleotid
polymorph
snp
base
basic
molecular
type
techniqu
util
test
new
find
smaller
subset
sampl
result
concord
seroand
genotyp
result
gener
howev
quit
commonli
small
number
sampl
deliv
discrep
result
trigger
consecut
round
analysi
resolut
final
result
better
knowledg
respect
underli
blood
group
variat
round
repetit
repres
synergist
increment
process
learn
learn
serologist
molecular
biologist
inherit
public
presenc
high
frequenc
low
frequenc
partial
antigen
notic
weakli
express
almost
undetect
antigen
mark
path
increment
learn
may
best
exemplifi
discoveri
within
blood
group
system
abo
rhd
kell
name
phenoand
genotyp
coevolv
alongsid
perman
discoveri
new
antigen
present
antigen
antithet
counterpart
test
exist
commonli
report
independ
exemplarili
shown
follow
kell
phenotyp
consist
three
antithet
antigencoupl
kk
kp
ab
js
ab
altern
phenotyp
could
state
kel
genotyp
hand
rather
mirror
actual
biolog
background
eg
display
two
parent
allel
haplotyp
present
individu
sampl
genotyp
mention
exampl
would
read
kel
italic
ideal
diagnost
environ
blood
group
system
encod
protein
everi
singl
blood
group
allel
would
defin
full
genom
sequenc
deriv
one
parent
chromosom
includ
region
therebi
everi
ideal
allel
would
fulli
declar
presenc
absenc
public
lowand
highfrequ
antigen
possess
ideal
name
trend
biallel
snp
immedi
relat
antithet
antigen
coupl
might
distract
origin
intend
mean
blood
group
allel
recent
final
genotyp
depend
ideal
allel
name
consid
mendelian
inherit
pattern
domin
recess
would
allow
fulli
comprehens
phenotyp
predict
recent
blood
group
serolog
eg
second
side
coin
seem
gain
momentum
sinc
advent
whole
genom
sequenc
access
mani
human
genom
seem
dozen
new
blood
group
allel
discov
almost
daili
basi
besid
challeng
name
multitud
allel
respect
discoveri
frequent
made
sampl
lack
phenotyp
blood
group
prevalu
clear
procedur
need
address
name
analyz
phenotyp
result
previous
unknown
allel
consequ
question
ask
year
ago
chang
today
molecular
biologist
look
hundr
newli
discov
blood
group
allel
find
ask
serologist
confirm
serolog
instead
pose
question
expert
blood
group
phenotyp
confirm
genotyp
background
screen
blood
donor
return
travel
activ
transmiss
area
highlight
import
diagnosi
acut
arbovir
infect
context
coinfect
similar
clinic
sign
endem
zone
differenti
diagnosi
arbovirus
essenti
discrimin
caus
agent
detect
viral
nucleic
acid
serum
plasma
provid
definit
diagnosi
howev
instanc
viremia
transient
within
less
two
week
onset
clinic
ill
addit
cross
reactiv
due
high
degre
structur
sequenc
homolog
zikv
flavivirus
signific
concern
combin
molecular
identif
viral
genom
immunolog
assay
detect
immun
respons
key
challeng
follow
natur
histori
infect
improv
patient
manag
epidemiolog
surveil
aim
context
develop
innov
platform
base
agglutin
superparamagnet
nanoparticl
npmag
coval
graft
either
nucleic
proteic
probe
face
continu
emerg
arbovirus
method
dengu
denv
zika
zikv
virus
select
model
studi
panflaviviru
rtpcr
use
molecular
assay
amplifi
viral
genom
biotinyl
viral
amplicon
captur
specif
complementari
origin
polythiol
probe
coat
npmag
immunolog
assay
npmag
graft
viral
protein
captur
antidenv
antizikv
antibodi
potenti
present
plasma
sampl
test
perform
dispos
cuvett
homogen
format
magnet
field
gener
electromagnet
appli
reaction
medium
align
npmag
chain
enhanc
captur
target
two
npmag
aggreg
form
detect
field
turn
optic
densiti
measur
realtim
nm
sever
cycl
magnet
relax
result
studi
molecular
analyt
perform
evalu
human
sampl
blood
donor
histori
infect
neg
control
viral
standard
clinic
sampl
use
viral
refer
standard
observ
sensit
tcid
ml
zikv
denv
serotyp
detect
phase
around
min
first
result
obtain
zikv
clinic
sampl
previous
test
commerci
realtim
pcr
ct
altona
show
correl
two
detect
method
fals
posit
result
cross
reaction
observ
concern
immunolog
assay
commerci
human
plasma
donor
test
posit
denv
zikv
antibodi
detect
posit
innov
approach
less
min
sampl
detect
instead
h
classic
elisa
assay
clinic
sampl
plan
confirm
preliminari
result
summaryconclus
innov
strategi
combin
molecular
immunoassay
analyt
platform
offer
new
opportun
rapid
blood
test
improv
surveil
prevent
arbovir
infect
background
zika
viru
zikv
caus
dramat
epidem
puerto
rico
pr
blood
donor
reactiv
zikv
rna
idnat
test
peak
june
aim
perform
serosurvey
antizikv
igg
use
six
panel
donor
specimen
collect
march
begin
peak
end
epidem
march
april
method
employ
commerci
avail
zikv
igg
elisa
antibodi
ab
assay
base
zikv
antigen
biotechn
character
zikv
seropreval
crosssect
sampl
set
anonym
select
demograph
inform
result
pr
donor
sampl
collect
april
initi
evalu
use
manufactur
suppli
cutoff
confirm
zikv
ab
result
larg
neg
posit
equivoc
despit
high
dengu
viru
seropreval
pr
could
potenti
lead
fals
posit
zikv
ab
result
use
dataset
togeth
known
posit
collect
month
postdetect
zikv
nat
yield
donor
set
populationspecif
cutoff
base
receiv
oper
characterist
roc
curv
analysi
cutoff
yield
sensit
specif
valu
area
curv
auc
demonstr
highli
accur
assay
use
new
cutoff
calcul
final
rate
seroreact
addit
sampl
set
sampl
estim
season
incid
rate
reactiv
togeth
mean
net
od
reactiv
shown
parenthes
calcul
sampl
set
background
sex
hormon
intak
blood
donor
occur
three
demograph
group
premenopaus
women
take
contracept
drug
progestin
without
estrogen
postmenopaus
women
receiv
estrogen
replac
therapi
may
combin
progestin
testosteron
therapi
men
hypothes
sex
hormon
therapi
may
modul
qualiti
red
blood
cell
rbc
product
via
alter
rbc
function
predisposit
hemolysi
cold
storag
aim
object
studi
evalu
associ
sex
hormon
intak
rbc
measur
hemolysi
examin
possibl
mechan
sex
hormon
interact
rbc
method
selfreport
sex
hormon
intak
menstrual
statu
evalu
femal
blood
donor
nation
heart
lung
blood
institut
rbcomic
studi
associ
hormon
intak
donor
score
spontan
storag
osmot
oxid
hemolysi
determin
women
menstrual
state
interact
sex
hormon
rbc
determin
sex
hormon
progesteron
testosteron
potenc
inhibit
calcium
influx
hemolysi
incub
cold
storag
calcium
fluorophor
use
defin
rbc
calcium
influx
respons
treatment
sex
hormon
drug
modul
transient
receptor
potenti
cation
trpc
channel
activ
includ
select
activ
result
sex
hormon
intak
menstrual
statu
higher
premenopaus
women
postmenopaus
women
femal
hormon
intak
significantli
p
associ
reduc
storag
hemolysi
femal
ae
versu
ae
control
enhanc
suscept
oxid
hemolysi
ae
versu
ae
control
reduc
osmot
hemolysi
postmenopaus
women
ae
versu
ae
control
vitro
supraphysiolog
level
progesteron
lmoll
testosteron
inhibit
spontan
calcium
influx
rbc
associ
lower
spontan
hemolysi
day
cold
storag
ae
versu
ae
progesteron
lmoll
versu
solvent
control
dimethyl
sulfoxid
p
coincub
h
rbc
presenc
progesteron
activ
lmoll
suggest
progesteron
protect
hemolysi
ae
ae
versu
ae
progesteron
lmoll
versu
alon
p
oneway
anova
summaryconclus
studi
reveal
sex
hormon
intak
blood
donor
capabl
modul
rbc
predisposit
hemolysi
led
us
propos
new
mechanist
pathway
progesteron
regul
calcium
influx
hemolysi
human
rbc
preand
postmenopaus
women
respond
differ
hormon
intak
effect
rbc
respons
osmot
oxid
stress
progesteron
modul
calcium
influx
rbc
via
mechan
may
involv
interact
membran
channel
activ
associ
prehemolyt
event
senesc
eryptosi
intern
cooper
swiss
red
cross
wabern
switzerland
background
red
cross
red
crescent
societi
play
import
role
set
blood
transfus
establish
mani
low
resourc
countri
red
cross
activ
nation
blood
program
approxim
countriesmostli
blood
donor
recruit
educ
today
major
organiz
develop
blood
transfus
servic
made
high
incom
set
nearli
worldwid
donat
take
place
home
popul
data
show
median
annual
blood
donat
rate
highincom
countri
popul
compar
lowincom
countri
factor
low
turnout
multilay
wellknown
resourc
poor
set
suffer
low
rate
regular
donor
challeng
setup
financi
sustain
nation
blood
donor
program
red
cross
red
crescent
rc
societi
assum
key
role
reach
retain
donor
commun
contribut
significantli
better
safeti
avail
blood
partnership
intern
collabor
swiss
red
cross
src
program
aim
strengthen
nation
structur
improv
blood
safeti
face
today
epidemiolog
demograph
technolog
challeng
aim
present
work
aim
review
role
mandat
impact
rc
societi
improv
blood
safeti
systemat
voluntari
nonremuner
regular
blood
donor
vnrbd
program
intern
partnership
method
data
evid
drawn
src
intern
cooper
project
last
year
specif
partner
three
rc
societi
data
global
advisori
panel
gap
ifrc
includ
global
map
result
promot
vnrbd
specif
object
src
support
program
engag
rc
societi
train
volunt
partner
health
author
project
significantli
increas
blood
donor
rate
recruit
retain
donor
commun
exampl
rc
societi
increas
total
donat
lebanon
vnrbd
annual
kirgizstan
practic
zero
south
sudan
import
rc
societi
also
underlin
publish
global
map
gap
show
provid
level
full
blood
servic
level
b
systemat
blood
donor
recruit
level
c
vnrbd
blood
promot
blood
servic
gap
also
commenc
new
three
year
vnrbd
support
program
aim
establish
tool
materi
nation
societi
summaryconclus
red
cross
red
crescent
movement
uniqu
mandat
posit
improv
global
blood
safeti
level
huge
network
volunt
even
blood
donor
remot
commun
reach
retain
rc
societi
low
resourc
set
level
b
level
c
role
capit
partnership
local
intern
actor
leverag
technic
assist
fund
activ
background
essenti
motiv
encourag
public
donat
blood
eager
help
save
live
order
maintain
safe
adequ
nation
blood
suppli
aim
technic
assist
recruit
futur
blood
donor
europeaid
project
aim
avoid
problem
suppli
safest
blood
contribut
improv
public
health
increas
knowledg
primari
secondari
school
student
regard
blood
donat
ii
creat
sensit
school
princip
teacher
regard
voluntari
nonremuner
blood
donat
vnrd
iii
motiv
famili
member
student
blood
donat
iv
creat
public
awar
media
method
effect
coordin
establish
ministri
health
moh
ministri
nation
educ
mone
turkish
red
crescent
trc
exist
curricula
textbook
primari
secondari
school
review
revis
correspond
materi
import
blood
donat
creat
human
resourc
capac
moh
mone
trc
support
rais
awar
blood
donat
develop
rais
public
awar
blood
donat
nationwid
educ
recruit
campaign
organ
pilot
school
addit
media
public
relat
campaign
blood
donat
organ
throughout
countri
result
exist
curricula
textbook
relev
promot
blood
donat
review
revis
report
board
educ
mone
correspond
educ
materi
student
teacher
develop
distribut
blood
donat
club
establish
pilot
school
train
conduct
personnel
moh
trc
blood
donat
regard
respons
cascad
train
conduct
personnel
transfus
center
school
princip
provinc
inform
seminar
deliv
student
teacher
famili
member
student
school
campaign
four
anim
film
blood
donat
produc
broadcast
nation
tv
channel
trt
three
differ
comput
game
target
differ
age
group
develop
upload
web
portal
project
distribut
pilot
school
media
spot
produc
broadcast
time
differ
tv
radio
channel
billboard
poster
brochur
prepar
distribut
provinc
rais
public
awar
advertis
project
import
vnrd
display
time
nation
local
newspap
time
onlin
news
broadcast
nation
tv
channel
campaign
unit
whole
blood
collect
pilot
school
visibl
kit
recruit
futur
blood
donor
prepar
distribut
throughout
project
activ
awar
knowledg
level
student
teacherspar
import
blood
donat
increas
respect
assess
pretest
posttest
voluntari
nonremuner
donat
rate
nation
demand
increas
two
year
summaryconclus
train
campaign
programm
success
increas
knowledg
blood
donat
achiev
nation
selfsuffici
safe
blood
suppli
effort
recruit
continu
background
despit
pakistan
popul
year
blood
suppli
come
voluntari
donor
remain
blood
collect
famili
replac
donor
pakistan
system
outsourc
mobil
blood
donor
patient
famili
result
mani
peopl
reach
network
includ
facebook
locat
blood
donor
thousand
post
month
pakistan
seek
blood
donor
facebook
facilit
needi
famili
global
social
media
giant
facebook
launch
special
blood
donat
featur
pakistan
collabor
sbtp
pakistan
featur
make
easier
peopl
sign
becom
blood
donor
help
connect
voluntari
donor
peopl
organ
need
blood
similar
featur
launch
facebook
india
bangladesh
brazil
address
problem
blood
shortag
countri
howev
among
four
countri
pakistan
uniqu
posit
exist
nation
counterpart
sbtp
facilit
facebook
promot
featur
provid
feedback
impact
innov
effort
continu
improv
featur
aim
promot
voluntari
blood
donat
blood
safeti
pakistan
facebook
method
facebook
sbtp
team
launch
pilot
studi
impact
effect
facebook
blood
donat
featur
tool
commun
engag
six
month
plan
chalk
measur
impact
tool
five
select
blood
centr
checklist
call
checklist
share
blood
centr
fulfil
basic
requir
offici
blood
bank
page
includ
display
pictur
cover
photo
contact
inform
direct
etc
regular
skype
meet
held
team
sbtp
facebook
san
francisco
singapor
blood
centr
monitor
progress
pilot
gener
feedback
result
facebook
blood
donat
featur
record
remark
success
one
million
signup
within
month
pakistan
blood
centr
particip
pakistan
studi
experienc
enhanc
voluntari
blood
donat
trend
walkin
donor
averag
telephon
queri
regard
voluntari
blood
donat
per
month
center
trend
gradual
surg
featur
refin
basi
feedback
receiv
pilot
end
june
statist
gener
sinc
januari
encourag
underscor
import
social
media
reach
untap
potenti
blood
donor
studi
use
plan
effect
nationwid
strategi
increas
donor
mobil
recruit
retent
background
region
increas
number
patient
african
asian
origin
sickl
cell
diseas
scd
transfus
depend
thalassemia
tdt
requir
red
blood
cell
rbc
transfus
mani
rbc
alloantibodi
select
optim
match
rbc
unit
patient
essenti
prevent
acut
hemolysi
also
alloimmunis
besid
antigenmatch
abo
rh
c
c
e
e
k
patient
scd
tdt
ideal
receiv
rbc
unit
match
also
fya
fyb
jka
jkb
extend
phenotyp
polici
center
current
provid
rbc
product
patient
hemoglobinopathi
vast
major
blood
donor
caucasian
select
match
rbc
unit
patient
differ
ethnic
origin
difficult
therefor
expand
number
avail
african
asian
blood
donor
becom
increasingli
necessari
aim
herebi
recruit
strategi
noncaucasian
blood
donor
introduc
center
describ
result
obtain
six
year
report
method
sinc
whenev
firsttim
blood
donor
noncaucasian
origin
regist
alert
enter
donor
file
trigger
determin
extend
rbc
phenotyp
along
routin
test
rbc
antigen
determin
perform
laboratori
serolog
method
select
case
ie
suspect
rhd
rhce
variant
sampl
sent
molecular
analysi
ssp
pcr
rare
rbc
phenotyp
rel
ethnic
among
other
fy
ab
ss
lu
b
uncommon
rh
phenotyp
rare
rbc
phenotyp
detect
code
comment
enter
donor
data
donor
list
nation
rare
donor
file
result
extend
determin
rbc
antigen
perform
subject
present
blood
donat
twentynin
rare
donor
identifi
includ
rare
donor
file
fy
ab
lu
ab
lu
b
fy
ab
ccddee
r
r
overal
donor
provid
rbc
unit
rang
date
donor
still
activ
reserv
dedic
donat
intern
price
rbc
antigen
test
per
donor
approxim
chf
result
total
financi
effort
around
time
sinc
project
start
summaryconclus
experi
passiv
recruit
noncaucasian
blood
donor
base
ethnic
overal
low
effici
logist
financi
point
view
moreov
african
asian
blood
donor
may
requir
investig
hemoglobin
variant
serolog
malaria
addit
routin
test
nevertheless
target
determin
extend
rbc
antigen
phenotyp
allow
identif
person
rare
phenotyp
current
measur
activ
recruit
potenti
rare
blood
donor
implement
center
pilot
phase
project
nationwid
recruit
strategi
elabor
goal
build
nation
registri
patient
hemoglobinopathi
requir
transfus
blood
transfus
essenti
treatment
transfus
safeti
consist
sever
compon
although
import
ion
richer
countri
order
prioriti
typic
avoid
transfus
transmitt
infect
qualiti
blood
product
strong
focu
compon
therapi
prevent
sever
transfus
reaction
avoid
cleric
error
suffici
avail
blood
keynot
lectur
order
prioriti
transfus
safeti
probabl
differ
resourc
limit
environ
suffici
avail
blood
proper
utilis
avoid
transfus
transmitt
infect
avoid
cleric
error
prevent
sever
transfus
reaction
qualiti
blood
product
import
region
limit
resourc
patient
suffer
undertransfus
enough
blood
avail
effort
made
reduc
wastag
avail
blood
either
inappropri
storag
handl
nonind
transfus
addit
preval
number
pathogen
transmitt
transfus
much
higher
richer
part
world
aggrav
fact
reject
blood
donor
base
histori
problemat
blood
bank
empti
aim
develop
central
nation
blood
servic
site
manufactur
cost
effect
low
personnel
cost
highqual
blood
product
distribut
region
hospit
match
realiti
infrastructur
government
support
function
healthcar
system
limit
resourc
usual
avail
personnel
hand
problem
reagent
equip
even
electr
preciou
resourc
lectur
propos
focu
staff
train
educ
establish
local
hospitalbas
transfus
servic
provid
blood
product
region
base
donor
recruit
campaign
adjust
avail
technolog
local
cultur
includ
replac
donor
program
retent
safe
donor
highest
prioriti
fraction
blood
compon
standard
transfus
medicin
recent
whole
blood
experienc
reviv
patient
acut
blood
loss
given
main
transfus
indic
postpartum
hemorrhag
sever
trauma
region
limit
infrastructur
whole
blood
might
appropri
product
patient
requir
transfus
region
younger
volum
overload
whole
blood
major
issu
addit
frequent
electr
failur
allow
prolong
storag
plasma
therefor
mostli
wast
although
issu
overcom
solar
power
freezer
ideal
whole
blood
pathogen
inactiv
two
method
current
avail
reduc
frequenc
acut
hemolyt
transfus
reaction
educ
train
minim
cleric
error
transfus
process
import
extend
test
rhesu
antigen
k
besid
abo
rhd
transfus
depend
hemoglobinopathi
patient
may
help
reduc
delay
hemolyt
transfus
reaction
current
leukodeplet
pathogeninactiv
whole
blood
product
might
mostli
serv
need
blood
transfus
region
limit
infrastructur
develop
world
invest
research
effort
develop
product
avail
afford
cost
background
modern
transfus
medicin
serolog
investig
blood
cell
antigen
complement
genotyp
array
pcr
assay
whilst
platform
inform
major
refer
investig
limit
abil
defin
nucleotid
variant
associ
rare
antigen
unabl
detect
novel
variant
potenti
affect
antigen
nextgener
sequenc
increasingli
employ
refer
set
provid
inform
obtain
method
whole
genom
whole
exom
sequenc
success
employ
mani
investig
novel
rare
antigen
howev
concern
remain
regard
collect
genom
data
unrel
refer
investig
report
clinic
signific
incident
find
concern
address
use
target
sequenc
panel
report
design
test
efficaci
panel
provid
comprehens
genotyp
profil
red
cell
platelet
neutrophil
antigen
singl
test
aim
design
customis
target
exom
sequenc
panel
red
cell
platelet
neutrophil
antigen
gene
benchmark
efficaci
commerci
medic
sequenc
panel
illumina
trusight
one
tso
test
panel
inhous
genotyp
predict
script
sequenc
output
sampl
known
red
cell
platelet
neutrophil
genotyp
phenotyp
determin
whether
predict
concord
method
panel
design
probe
cover
exon
gene
associ
red
cell
platelet
neutrophil
antigen
use
illumina
nextera
rapid
captur
technolog
sampl
test
five
sequenc
run
standard
micro
chemistri
determin
optim
sampl
plexiti
per
standard
run
efficaci
smaller
flow
cell
lower
throughput
applic
inhous
python
script
use
predict
starallel
genotyp
base
variant
list
isbt
embl
databas
predict
compar
result
serolog
snp
array
previou
tso
data
result
coverag
consist
averag
target
qualiti
optim
sampl
plexiti
standard
run
determin
sampl
allow
suffici
coverag
clinic
signific
variant
red
cell
sampl
previou
type
data
exclud
rh
structur
variant
script
correctli
predict
snp
base
red
cell
genotyp
script
predict
concord
platelet
genotyp
four
five
neutrophil
antigen
genotyp
genotyp
defin
could
reliabl
determin
increas
target
coverag
panel
allow
detect
clinic
signific
heterozyg
variant
scianna
system
previous
undetect
tso
panel
due
extrem
low
coverag
addit
variant
defin
potenti
novel
null
allel
detect
system
summaryconclus
panel
demonstr
consider
higher
coverag
qualiti
throughput
compar
tso
allow
detect
variant
previous
overlook
due
low
sequenc
coverag
sampl
reliabl
sequenc
singl
run
script
correctli
predict
snp
base
allel
howev
rh
structur
variant
requir
manual
analysi
background
ensur
safeti
transfus
critic
identifi
blood
type
donor
recipi
serolog
method
type
abo
rh
kel
use
monoclon
antibodi
howev
type
reagent
rare
blood
group
expens
unavail
unreli
dnabas
identif
human
blood
group
use
overcom
limit
applic
reduc
rate
alloimmunis
chronic
transfus
patient
howev
date
cost
per
sampl
prevent
univers
applic
dnabas
donor
type
aim
achiev
univers
adopt
dna
base
donor
type
blood
transfus
genom
consortium
bgc
set
develop
afford
dna
base
platform
capabl
type
red
cell
antigen
hla
class
ii
human
platelet
antigen
method
uk
biobank
axiom
array
previous
use
type
uk
citizen
redesign
donor
type
use
three
approach
mine
transfus
medicin
knowledg
eg
isbt
allel
tabl
ii
inclus
loci
associ
donor
health
iii
extract
code
variant
relev
gene
frequenc
identifi
largescal
sequenc
data
sampl
nhsbt
sanquin
blood
donor
n
use
perform
assess
red
cell
platelet
antigen
donor
infer
genotyp
use
bloodtyp
algorithm
concord
clinic
serolog
type
result
assess
result
concord
genotyp
serolog
type
result
comparison
discrep
serolog
neg
genotyp
posit
given
antigen
kk
fy
ab
lu
ab
case
dna
variant
known
modifi
weaken
antigen
express
detect
display
power
genotyp
detect
variant
weakantigen
express
across
antigen
serolog
avail
genotyp
provid
increas
number
type
result
avail
per
donor
vs
furthermor
genotyp
provid
data
addit
clinic
relev
antigen
allow
identif
antigenneg
donor
blood
group
identif
antibodi
commerci
avail
power
genotyp
panel
donor
support
patient
manag
demonstr
retrospect
analysi
clinic
case
refer
nhsbt
patient
referr
alloantibodi
uniqu
alloantibodi
profil
identifi
found
greater
likelihood
find
neg
compat
donor
patient
use
genotyp
data
nhsbt
donor
importantli
number
alloantibodi
combin
compat
antigenneg
donor
could
identifi
fell
repres
addit
patient
could
provid
directli
compat
blood
use
donor
summaryconclus
bgc
effort
afford
fulli
autom
genotyp
platform
includ
process
qualiti
assur
data
analysi
develop
furthermor
demonstr
realworld
benefit
extens
donor
characteris
provid
select
blood
patient
multipl
antibodi
result
intern
collabor
provid
opportun
introduc
fullyautom
genotypebas
donor
type
safe
costeffici
manner
blood
suppli
organis
biobank
perform
wholegenom
sequenc
wg
individu
nationwid
data
suitabl
allel
frequenc
analysi
demonstr
gene
express
genet
profil
popul
also
estim
signific
antigen
transfus
practic
aim
aim
provid
verifi
populationbas
blood
group
antigen
profil
use
wg
dna
sampl
taiwan
biobank
method
near
wg
demograph
data
analyz
annot
blood
group
antigen
perform
accord
variant
isbt
allel
tabl
includ
transcript
factor
variant
lewi
system
obtain
previou
studi
annot
blood
group
variant
verifi
dna
sampl
target
sequenc
illumina
miseq
specif
variant
verifi
dna
sampl
commerci
genotyp
kit
sanger
sequenc
allel
frequenc
wg
analysi
compar
popul
serolog
data
use
twoproport
z
test
result
populationwid
blood
group
antigen
analyz
reveal
indepth
antigen
express
profil
system
except
chrg
antigen
frequenc
wg
similar
compar
publish
serolog
data
except
antigen
possibl
explan
list
follow
n
insuffici
sequenc
read
c
c
ident
rhce
exon
rhd
exon
c
allel
mur
insuffici
read
lengthdepth
gypagypb
hybrid
call
individu
high
preval
mur
antigen
aborigin
tribe
enrol
blood
group
antigen
predict
variant
wg
accord
dna
verif
furthermor
system
shown
genet
variat
predict
uniform
antigen
express
popul
manag
transfus
minimum
concern
antigen
mismatch
system
moreov
found
weak
null
allel
popul
blood
group
system
previous
knowledg
lan
jr
vel
variant
help
identifi
patient
antijr
carri
homozyg
jr
null
allel
summaryconclus
taiwan
biobank
wg
suitabl
full
blood
group
antigen
profil
determin
adjust
requir
specif
antigen
popul
antigen
allel
frequenc
provid
valuabl
insight
antigen
signific
transfus
practic
match
strategi
patient
estim
likelihood
obtain
specif
antigen
neg
blood
mass
popul
also
genet
variant
reveal
studi
help
us
locat
rare
donor
integr
variat
routin
donor
blood
group
screen
provid
suitabl
blood
low
cost
effici
background
provid
adequ
amount
safe
appropri
match
blood
meet
demand
expand
age
patient
popul
present
challeng
global
problem
reason
sustain
vitro
sourc
red
cell
may
offer
desir
altern
relianc
donor
blood
first
stabl
immort
earli
adult
erythroblast
cell
line
shown
differenti
effici
matur
function
reticulocyt
trakarnsanga
et
al
nat
commun
consequ
could
provid
readili
avail
tool
diagnost
use
proof
principl
futur
therapeut
use
aim
ibgrl
next
gener
whole
exom
sequenc
we
use
previous
accur
predict
blood
group
phenotyp
number
blood
group
system
includ
abo
rh
mn
tilley
thornton
transfus
medicin
use
analys
document
blood
grouprel
genotyp
predict
blood
group
phenotyp
addit
gene
involv
cellgrowth
enucl
also
analys
order
elucid
characterist
celllin
method
cell
day
cultur
expans
medium
genom
dna
gdna
isol
cell
day
we
gdna
librari
prepar
use
nextera
rapid
captur
exom
enrich
sequenc
illumina
miseq
sequenc
align
gene
encod
known
blood
group
system
gene
encod
transcript
factor
cell
enucleationassoci
protein
visualis
use
integr
genom
viewer
whilst
illumina
variant
studio
use
identifi
observ
mutat
mutat
code
region
use
determin
genotyp
predict
phenotyp
result
good
coverag
select
gene
achiev
align
homolog
blood
group
gene
includ
rhdrhce
gypagypb
problemat
addit
analysi
coverag
gene
requir
accur
interpret
despit
number
polymorph
observ
across
test
gene
express
novel
rare
blood
group
antigen
genotyp
result
predict
common
antigen
profil
agreement
previou
serolog
genotyp
result
avail
although
number
missens
singl
nucleotid
variat
detect
analys
gene
includ
common
polymorph
variant
unlik
function
signific
summaryconclus
we
use
determin
genotyp
relat
blood
group
gene
select
gene
encod
transcript
factor
protein
associ
cell
enucl
we
allow
accur
predict
blood
group
phenotyp
show
full
concord
avail
serolog
data
trakarnsanga
et
al
small
number
mutat
identifi
unknown
signific
requir
work
determin
potenti
phenotyp
effect
complet
record
blood
grouprel
exom
enabl
reliabl
gene
edit
strategi
futur
diagnost
therapeut
purpos
addit
knowledg
full
cell
line
exom
allow
analysi
emerg
gene
interest
provid
better
insight
mechan
erythroid
differenti
enucl
background
emerg
evid
especi
neonat
shown
potenti
harm
associ
liber
platelet
transfus
strategi
littl
evid
exist
regard
optim
platelet
transfus
threshold
critic
ill
children
random
control
trial
may
difficult
due
lack
equipois
provid
region
variat
practic
exist
compar
effect
studi
may
altern
approach
aim
describ
region
variat
platelet
transfus
practic
critic
ill
children
method
secondari
analysi
prospect
observ
studi
subject
group
accord
region
north
america
europ
middl
east
asia
oceania
nation
transfus
analyz
prophylact
given
prevent
bleed
therapeut
given
treat
bleed
primari
outcom
total
platelet
count
tpc
prior
transfus
subgroup
analys
perform
children
underli
oncolog
diagnosi
support
extracorpor
life
support
ecl
dose
process
platelet
transfus
analyz
secondari
outcom
result
five
hundr
fortynin
children
countri
enrol
north
america
europ
oceania
asia
middl
east
overal
median
iqr
tpc
prior
prophylact
transfus
n
differ
significantli
region
basi
p
rang
cellsl
middl
east
cellsl
asia
median
tpc
prior
prophylact
transfus
significantli
differ
countri
p
tpc
prior
therapeut
transfus
n
differ
either
region
p
nation
p
basi
children
support
ecl
n
region
p
nation
p
differ
prophylact
transfus
howev
signific
differ
tpc
prior
therapeut
transfus
observ
region
p
nation
basi
middl
east
particular
israel
transfus
lowest
median
iqr
tpc
cellsl
children
underli
oncolog
diagnosi
n
differ
seen
tpc
prophylact
transfus
n
region
p
nation
p
basi
differ
seen
tpc
prior
therapeut
transfus
region
nation
p
basi
signific
variabl
dose
platelet
transfus
region
p
nation
basi
p
median
iqr
dose
base
volum
rang
mlkg
north
america
mlkg
europ
vast
major
transfus
leukoreduc
irradi
signific
variat
exist
storag
durat
region
p
nation
p
basi
summaryconclus
region
nation
variat
exist
platelet
transfus
practic
among
critic
ill
children
especi
given
therapeut
transfus
support
ecl
consid
variat
compar
effect
studi
may
appropri
approach
gain
evid
optim
platelet
transfus
threshold
background
optim
threshold
prophylact
platelet
plt
transfus
pediatr
patient
cancer
still
controversi
current
clinic
practic
come
studi
adult
inpati
set
intern
guidelin
icmtg
recommend
age
patient
prophylact
platelet
transfus
plt
count
l
platelet
dose
per
squar
meter
sm
bodysurfac
area
bsa
inpati
sm
outpati
set
aim
januari
start
children
hospit
prospect
protocol
order
evalu
impact
bleed
risk
current
clinic
practic
prophylact
platelet
transfus
inpati
outpati
oncohaematolog
patient
method
bsa
calcul
agestandard
weight
inpati
receiv
dose
per
transfus
sm
outpati
dose
per
transfus
sm
platelet
transfus
count
l
presenc
bleed
sign
pediatr
aliquot
obtain
buffi
coat
deriv
pool
platelet
concentr
apheresi
platelet
concentr
accord
dispon
result
januari
decemb
total
platelet
pediatr
aliquot
transfus
obtain
apheresi
platelet
concentr
buffycoatderiv
pool
platelet
concentr
major
platelet
pediatr
aliquot
transfus
oncohematolog
patient
undergo
hematopoiet
stem
cell
transplant
hsct
convent
chemotherapi
among
aliquot
transfus
inpati
set
hematolog
unit
oncolog
unit
hsct
unit
total
aliquot
transfus
outpati
set
patient
affect
hematolog
malign
patient
solid
tumor
five
major
bleed
event
grade
observ
studi
period
occur
hospit
patient
two
patient
solid
neoplasm
develop
grade
bleed
event
two
patient
hematolog
malign
patient
neuroblastoma
n
develop
intracrani
bleed
grade
platelet
count
time
event
l
l
l
respect
summaryconclus
result
show
efficaci
oncohematolog
pediatr
patient
prophylact
platelet
transfus
protocol
base
intern
guidelin
low
incid
grade
bleed
observ
inpati
set
vs
plado
trial
sj
slichter
nejm
outpati
set
doubl
platelet
dose
prevent
major
bleed
event
grade
occurr
background
problem
bloodborn
infect
remain
relev
transfus
medicin
pathogen
reduct
technolog
prt
provid
prevent
approach
wide
rang
transfusiontransmit
infecti
diseas
date
prt
wide
use
platelet
concentr
blood
plasma
howev
use
technolog
treatment
red
blood
cellcontain
blood
product
undergo
research
aim
aim
studi
evalu
safeti
efficaci
transfus
pathogenreduc
test
group
red
blood
cell
suspens
rbc
compar
data
gammairradi
rbc
control
group
method
technolog
base
combin
action
riboflavin
ultraviolet
mirasol
prt
terumo
bct
belgium
use
reduc
pathogen
whole
blood
subsequ
rbc
test
group
deriv
pathogenreduc
whole
blood
control
rbc
irradi
gammacel
elit
best
theratron
canada
dose
gray
rbc
use
transfus
day
harvest
day
pediatr
patient
variou
oncolog
hematolog
diseas
random
group
member
group
test
group
patient
receiv
transfus
pathogenreduc
rbc
control
group
receiv
transfus
gammairradi
rbc
next
day
transfus
assess
hemoglobin
hematocrit
increment
level
potassium
haptoglobin
patient
serum
frequenc
sever
transfus
reaction
day
transfus
direct
antiglobulin
test
dat
perform
day
indirect
antiglobulin
test
iat
perform
interv
next
need
transfus
also
evalu
result
increas
hemoglobin
hematocrit
p
well
concentr
potassium
p
haptoglobin
p
patient
serum
transfus
differ
group
none
patient
group
hyperkalemia
transfus
group
two
patient
febril
nonhemolyt
transfus
reaction
compar
sever
p
dat
iat
test
neg
group
interv
transfus
significantli
differ
group
p
test
group
found
correl
increas
hemoglobin
hematocrit
valu
volum
transfus
dose
adjust
dose
hemoglobin
obtain
transfus
bodi
weight
group
found
invers
correl
hemoglobin
hematocrit
increment
level
hemolysi
rbc
summaryconclus
found
clinic
efficaci
safeti
rbc
compar
group
differ
evid
immun
elimin
allosensit
caus
pathogenreduc
rbc
accord
data
spectrum
effici
safeti
indic
pathogenreduc
rbc
wors
gammairradi
rbc
provid
rbc
use
day
storag
found
correl
suggest
effici
pathogenreduc
rbc
transfus
depend
characterist
rbc
background
patient
blood
manag
pbm
program
expand
intern
level
recent
nation
repres
studi
unit
state
observ
pediatr
age
group
age
group
show
lack
object
evid
pbm
initi
goel
et
al
jama
aim
studi
aim
identifi
trend
periop
blood
util
children
undergo
elect
nonelect
surgeri
year
durat
method
use
year
data
periop
transfus
decreas
steadili
per
year
cumul
declin
children
age
ci
p
trend
cumul
chang
elect
procedur
versu
decreas
urgentemerg
procedur
p
trend
summaryconclus
larg
prospect
registri
studi
children
undergo
electivenonelect
surgeri
statist
signific
decreas
util
periop
rbc
transfus
seen
across
year
signific
decreas
urgentemerg
procedur
elect
procedur
find
need
evalu
nonsurg
indic
transfus
result
may
provid
first
evid
periop
pediatr
patient
blood
manag
strategi
implement
optim
transfus
pediatr
popul
advers
event
tti
immun
interact
risk
transfusiontransmit
infect
tti
longstand
well
recogn
concern
medicin
tackl
highest
level
guarante
safeti
transfus
procedur
stake
holder
includ
recipi
patient
donat
volunt
health
care
worker
involv
respect
contact
person
accordingli
current
nation
intern
guidelin
includ
expert
societi
provid
medic
technic
legal
framework
basi
standard
oper
procedur
nevertheless
import
challeng
render
tti
move
target
reflect
dynam
three
main
area
first
chang
type
number
recipi
patient
past
ongo
immunomodulatori
immunodefici
compon
exampl
hivaid
sot
allogen
hct
monoclon
antibodi
therapi
small
molecul
inhibitor
second
chang
exposur
known
agent
donor
due
global
travel
migrat
displac
well
environmentalclim
chang
third
discoveri
diagnost
old
new
agent
known
presum
impact
tti
aspect
requir
care
review
data
studi
judici
discuss
potenti
action
select
versu
close
monitor
keep
tti
rate
low
possibl
deliv
maxim
safeti
patient
stakehold
background
implement
nucleic
acid
test
nat
develop
sensit
specif
serolog
assay
detect
hbsag
antihbc
antibodi
significantli
reduc
risk
hbv
transfusiontransmiss
appar
redund
test
two
direct
viral
marker
prompt
debat
maintain
hbsag
screen
particularli
low
endem
countri
blood
donat
screen
antihbc
howev
frequenc
hbsagconfirm
positivenat
neg
donat
report
depend
sensit
limit
molecular
assay
use
natur
discrep
hbsag
dna
remain
larg
unknown
essenti
evalu
potenti
neg
impact
blood
safeti
consid
remov
hbsag
test
aim
preval
blood
donor
molecular
mechan
respons
persist
undetect
bare
detect
level
viral
replic
presenc
sustain
hbsag
product
investig
collabor
studi
includ
five
laboratoriesblood
center
europ
south
africa
discrep
viral
dna
hbsag
level
suggest
presenc
mutat
may
neg
affect
hbv
replic
andor
infecti
viral
particl
product
method
donor
sampl
franc
south
africa
poland
croatia
select
hbsag
level
iuml
idnat
procleixultrio
plu
tm
lod
iuml
nonreactivenonrepeat
reactiv
nrnrr
undetect
viral
load
vl
iuml
n
nat
repeat
reactiv
rr
vl
iuml
n
french
sampl
initi
test
nat
nrnrr
procleixultrio
lod
iuml
retest
ultrio
plu
prior
inclus
studi
hbv
dna
load
quantifi
coba
taqman
hbv
loq
iuml
hbv
dna
purifi
ml
plasma
ultracentrifug
whole
hbv
genom
press
precorecor
bcp
region
amplifi
sequenc
result
follow
viral
concentr
hbv
dna
presenc
confirm
sampl
undetect
vl
iuml
hbv
genotyp
b
c
e
sampl
antihbc
posit
ultrioneg
sampl
test
posit
ultrio
plu
unusu
nt
insertionsdelet
identifi
bcp
regulatori
element
tata
box
pginr
epsilon
domain
suggest
alter
viral
replic
amino
acid
substitut
n
delet
n
posit
report
involv
nucleocapsid
format
particl
envelop
virion
format
observ
core
protein
sampl
replic
properti
bcp
core
variant
current
evalu
vitro
surrog
model
direct
infect
test
preliminari
result
indic
variant
test
far
replic
capabl
similar
control
virus
analysi
pol
hbx
protein
ongo
summaryconclus
data
confirm
presenc
extrem
low
level
circul
dnacontain
viral
particl
idnat
nonreact
nonrep
reactiv
blood
donat
concomit
high
hbsag
level
antihbc
reactiv
despit
presenc
mutat
viral
genom
potenti
affect
virion
product
preliminari
data
indic
virus
plasma
retain
abil
replic
vitro
constitut
potenti
infecti
risk
background
switzerland
highli
sensit
nucleic
acid
screen
individu
donat
format
hepat
b
viru
hbv
idnat
hepat
b
surfac
antigen
hbsag
detect
mandatorili
perform
guidelin
swiss
transfus
src
switzerland
sinc
hbv
hb
vaccin
recommend
switzerland
children
adolesc
age
adult
belong
known
risk
group
aim
highlight
low
antihb
titer
sever
year
follow
hbv
vaccin
still
confer
protect
enabl
host
immun
system
clear
hbv
dna
without
develop
serolog
marker
diseas
method
retrospect
donor
interview
conduct
complet
inform
cover
question
includ
standard
donor
questionnair
routin
hbv
serolog
donor
screen
perform
quadriga
system
diasorin
former
siemen
enzygnost
hbsag
assay
diasorin
former
siemen
hbv
test
perform
abbott
architect
analys
hbsag
neutralis
hbeag
antihbc
iggigm
antihbc
igm
antihb
antihb
routin
idnat
screen
hivhcvhbv
perform
roch
coba
mpx
test
roch
coba
platform
hbv
idnat
posit
sampl
confirm
quantit
hbv
nat
assay
abbott
background
hepat
b
corerel
antigen
hbcrag
structur
antigen
hbv
consist
hbcag
hbeag
precor
protein
quantit
hbcrag
measur
sensit
marker
viral
replic
reflect
cccdna
content
persist
diseas
hbcrag
posit
found
signific
risk
factor
hbv
reactiv
hbsag
antihbc
hbv
dnapati
occult
hbv
infect
obi
undergo
immunosuppress
therapi
aim
data
hbcrag
statu
appar
healthi
subject
obi
avail
aim
studi
analys
marker
cohort
obi
blood
donor
method
hbcrag
measur
blood
donor
confirm
carrier
obi
hbsag
hbv
dna
donor
antihbc
posit
neg
donor
antihbc
antihb
reactiv
group
young
blood
donor
vaccin
hbv
infect
hbsag
hbv
dna
antihbc
patient
chronic
hbv
infect
hbsag
hbv
dna
use
neg
posit
control
group
respect
serum
hbcrag
measur
use
chemiluminesc
enzym
immunoassay
lumipuls
autom
analyz
fujirebio
tokyo
japan
lower
limit
detect
lod
quantit
assay
loguml
lower
limit
quantif
loq
loguml
due
nonlinear
result
loguml
level
hbcrag
test
three
group
analys
comparison
presenc
antihbc
antihb
statist
analysi
perform
ibm
statist
spss
result
donor
neg
control
group
undetect
hbcrag
level
wherea
patient
posit
control
group
detect
hbcrag
mean
valu
loguml
rang
confirm
individu
without
prior
exposur
hbv
would
detect
hbcrag
hbcrag
detect
obi
donor
mean
valu
loguml
rang
hbcrag
could
measur
obi
donor
loguml
loq
test
major
obi
consid
presenc
antihbc
hbcrag
detect
antihbc
antihbcobi
signific
differ
mean
level
ae
vs
ae
p
interestingli
presenc
antihb
independ
associ
higher
hbcrag
level
ae
vs
ae
p
summaryconclus
identif
donor
obi
critic
prevent
risk
hbv
transfusiontransmiss
hbcrag
associ
cccdna
content
replic
result
suggest
presenc
hbcrag
even
quantifi
could
use
marker
confirm
occult
infect
statu
even
antihbc
neg
donor
associ
hbcrag
antihbc
antihb
could
also
use
marker
identifi
obi
donor
higher
risk
hbv
reactiv
hc
group
human
peripher
blood
mononuclear
cell
pbmc
blood
donor
stimul
hbv
polypeptid
pool
vitro
cell
prolifer
assay
cfse
use
detect
cell
prolifer
enzymelink
immunospot
assay
elispot
use
detect
frequenc
hbvspecif
ifnc
secret
cell
spss
statist
analysi
softwar
use
statist
analysi
measur
data
normal
distribut
test
two
independ
sampl
test
comparison
multipl
group
analyz
oneway
anova
mannwhitney
u
test
use
comparison
nonnorm
data
set
p
consid
statist
signific
result
prolifer
characterist
cell
prolifer
lymphocyt
mainli
stimul
specif
hbv
polypeptid
pool
prolifer
rate
obi
group
chb
group
significantli
higher
hc
group
vs
signific
differ
vs
p
vs
p
frequenc
specif
ifnc
secret
cell
respons
intens
obi
group
pbmc
chb
group
pbmc
higher
hc
group
pbmc
stimul
hbv
polypeptid
pool
posit
rate
cell
respons
stimul
hbv
polypeptid
pool
highest
obi
group
summaryconclus
obi
chb
higher
rate
hbvspecif
effector
cell
prolifer
ifnc
secret
healthi
control
group
compar
chb
group
obi
group
higher
posit
rate
cell
respons
may
one
caus
host
immun
result
obi
studi
immun
factor
requir
background
western
blood
transfus
practic
current
chang
due
variou
driver
blood
manag
polici
ongo
technolog
develop
new
therapeut
option
netherland
mani
highincom
countri
result
diminish
trend
red
blood
cell
therefor
import
blood
bank
manag
anticip
futur
demand
blood
product
sake
medium
long
term
decis
make
support
decis
make
employ
scenario
develop
use
mani
sector
financ
transport
also
appli
blood
transfus
build
upon
prior
literatur
review
semistructur
interview
intern
expert
gather
expert
togeth
scenario
session
assess
opportun
threat
sanquin
mediumterm
year
strategi
use
onlin
platform
facetofac
discuss
aim
assess
opportun
threat
organiz
implic
thereof
mediumterm
futur
sanquin
dutch
nation
blood
bank
method
twentyon
multidisciplinari
expert
blood
transfus
agre
particip
separ
two
group
halfday
interact
session
use
iter
process
onlin
platform
expert
brainstorm
opportun
threat
sanquin
categor
theme
theme
rank
accord
import
certainti
consensu
expert
chose
two
theme
high
impact
high
uncertainti
chosen
theme
specif
action
blood
bank
list
mitig
andor
enhanc
threat
opportun
discuss
ampl
throughout
result
regard
opportun
threat
sanquin
medium
term
strategi
expert
brainstorm
mani
idea
categor
theme
polit
context
chang
legisl
novel
product
altern
applic
donor
intern
market
commerci
digit
chang
percept
research
demand
organiz
structur
rank
import
certainti
six
theme
chosen
chang
percept
intern
market
polit
context
opportun
demand
opportun
research
vulner
donor
vulner
theme
expert
provid
specif
action
organ
mitig
threat
stimul
opportun
accordingli
action
includ
increas
transpar
improv
commun
donor
public
lobbi
polit
sphere
increas
activ
educ
institut
larg
fund
organ
creat
collabor
novel
blood
product
intern
level
name
summaryconclus
result
show
map
assess
blood
bank
futur
use
multidisciplinari
group
expert
conduc
effect
mean
collect
divers
rang
opportun
threat
provid
opportun
blood
bank
manag
becom
proactiv
toward
potenti
opportun
threat
possibl
evolv
futur
strategi
organ
show
irondefici
femal
blood
donor
like
depress
symptom
noniron
defici
femal
blood
donor
among
particip
depress
symptom
femal
low
plasma
ferritin
level
significantli
increas
odd
report
feel
lack
energi
strength
ci
known
blood
donor
increas
risk
iron
defici
import
determin
whether
genet
predispos
lower
plasma
ferritin
level
higher
risk
experienc
tirednesslack
energi
symptom
aim
investig
whether
associ
polygen
risk
score
prss
base
plasma
ferritin
level
tirednesslack
energi
symptom
blood
donor
method
dbd
ongo
nationwid
blood
donor
cohort
genomewid
genotyp
data
avail
particip
genotyp
perform
use
infinium
global
screen
array
illumina
imput
achiev
base
scandinavian
refer
genom
ferritin
prss
base
iceland
ferritin
gwa
n
calcul
dbd
particip
femal
donor
avail
analysi
data
depress
symptom
obtain
use
valid
major
depress
inventori
scale
mdi
selfreport
mood
questionnair
assess
presenc
depress
symptom
donor
classifi
tire
respond
time
time
question
often
feel
lack
energi
strength
logist
regress
analysi
perform
adjust
age
gener
quantil
plot
particip
distribut
evenli
six
quantil
base
pr
wherebi
quantil
contain
donor
lowest
prss
genet
predispos
lower
ferritin
level
set
refer
quantil
ageadjust
regress
analysi
tirednessquantil
result
prss
femal
rang
mean
total
femal
donor
classifi
tire
classifi
tire
signific
differ
ferritin
pr
found
tire
tire
femal
donor
tire
mean
pr
tire
mean
pr
ageadjust
logist
regress
model
found
insignific
ci
p
visualis
lack
associ
quantil
plot
creat
separ
femal
donor
six
equal
quantil
base
pr
clear
trend
observ
donor
highest
prss
quantil
p
tire
compar
quantil
set
summaryconclus
signific
associ
found
ferritin
prss
femal
blood
donor
tirednesslack
energi
symptom
studi
need
understand
effect
blood
donat
versu
genet
constitut
tired
among
femal
irondefici
blood
donor
background
antiretrovir
therapi
art
critic
control
clinic
progress
human
immunodefici
viru
hiv
infect
howev
outcom
art
could
limit
drug
resistanceassoci
mutat
drm
even
lead
transmiss
drugresist
hiv
treatment
patient
blood
donor
huge
concern
art
drm
surveil
hiv
infect
group
strongli
recommend
world
health
organ
characterist
genet
divers
drm
hiv
among
blood
donor
may
provid
comprehens
data
monitor
viral
evolut
optim
art
play
import
role
blood
safeti
aim
limit
data
concern
epidem
subtyp
drm
blood
donor
avail
china
studi
investig
genet
characterist
drm
infect
blood
donor
method
blood
donat
collect
blood
center
cover
almost
whole
china
confirm
posit
nation
center
clinic
laboratori
use
abbott
realtim
assay
coba
taqman
test
version
gag
bp
pol
gene
bp
encod
whole
proteas
pr
part
revers
transcriptas
rt
sequenc
viral
rna
extract
amplif
subtyp
base
gag
prrt
region
determin
comprehens
analys
lo
alamo
hiv
blast
tool
rega
subtyp
tool
phylogenet
tree
onlin
jphmm
program
drm
analysi
perform
stanford
hiv
drug
resist
databas
result
among
donat
gag
prrt
region
sampl
sequenc
success
distribut
genotyp
follow
b
urf
isol
identifi
drm
proteas
inhibitor
pi
accessori
drm
pi
major
drm
nonnucleosid
revers
transcriptas
inhibitor
nnrti
drm
blood
donor
drm
pi
accessori
drm
pi
major
drm
includ
could
result
hlr
atazanavir
atv
nfv
llr
indinavir
idv
saquinavir
sqv
main
nnrti
drm
combin
among
two
sampl
act
synergist
reduc
efavirenz
efv
nevirapin
nvp
suscept
furthermor
two
blood
donor
mutat
revers
transcriptas
gene
high
levelresist
efv
nvp
summaryconclus
overal
preval
subtyp
among
blood
donor
studi
besid
rare
crf
sever
urf
also
found
isol
suggest
epidem
hiv
shift
high
risk
popul
gener
popul
includ
blood
donor
china
drm
observ
donor
studi
may
result
resist
pi
nnrti
especi
variant
mutat
pr
gene
mutat
rt
gene
summari
find
indic
increas
divers
blood
donor
remind
us
necess
time
genotyp
drug
resist
monitor
molecular
epidemiolog
surveil
among
blood
donor
background
label
platelet
requir
measur
recoveri
surviv
transfus
platelet
vivo
current
radioact
method
use
label
platelet
howev
applic
limit
due
safeti
issu
inabl
isol
transfus
platelet
circul
biotinlabel
platelet
attract
nonradioact
option
howev
valid
protocol
biotinyl
platelet
current
avail
clinic
purpos
aim
aim
studi
develop
simpl
standard
reproduc
method
label
platelet
biotin
nonradioact
altern
trace
transfus
platelet
vivo
method
six
pool
buffi
coat
deriv
platelet
concentr
pc
store
plasma
biotinyl
day
day
storag
distinguish
effect
process
step
effect
biotin
incub
sham
sampl
process
biotinyl
procedur
ml
pc
wash
twice
incub
mgl
biotin
dissolv
phosphat
buffer
salinepas
min
stabil
biotin
label
platelet
irradi
test
annexin
v
express
assess
measur
platelet
activ
applic
method
platelet
product
assess
three
pool
pc
store
pase
three
singl
donor
apheresi
pc
result
method
reproduc
perform
close
system
biotinyl
ae
platelet
label
platelet
count
ph
swirl
within
rang
accept
dutch
blood
bank
standard
platelet
product
number
annexin
v
posit
cell
significantli
alter
biotinyl
procedur
fresh
store
platelet
contrast
express
increas
biotinyl
platelet
iqr
compar
control
sampl
iqr
day
storag
howev
biotinyl
platelet
activ
compar
sham
sampl
iqr
thu
procedur
step
led
increas
express
biotin
label
sampl
show
maxim
respons
thrombin
receptoractiv
peptid
platelet
label
day
similar
pattern
observ
irradi
biotin
label
platelet
alter
stabil
biotin
label
cell
qualiti
furthermor
method
also
applic
pool
pc
store
pase
apheresi
pc
similar
pattern
annexin
v
express
summaryconclus
develop
standard
reproduc
protocol
accord
good
practic
guidelin
gpg
standard
biotinlabel
platelet
clinic
purpos
procedur
step
similar
step
use
product
hyperconcentr
platelet
product
led
increas
express
alter
annexin
v
express
method
appli
nonradioact
altern
trace
recov
transfus
platelet
vivo
block
activ
prototyp
insul
cell
line
substanti
reduc
genotox
cretrovir
vectormedi
carcinogenesi
mous
model
contrast
insul
smallsiz
bp
vs
kb
easili
accommod
gt
vector
without
detriment
affect
vector
titer
aim
aim
test
whether
one
newli
discov
ci
could
reduc
vectormedi
genotox
challeng
context
sinlv
insul
therapeut
globinvector
method
test
genotox
effect
cell
upon
transduct
oncogen
vector
becom
lead
transform
cell
transduc
sinlv
insul
oncogen
sffvgfpvector
transduc
cell
expand
transduct
effici
determin
vector
copi
number
vcn
transduc
cell
seed
methylcellulos
detect
potenti
transform
clone
clone
expand
infus
partial
myeloabl
mice
wbc
analysi
blood
smear
bone
marrow
bm
cytospin
perform
result
insul
neg
affect
vector
titer
sffvgfp
iuml
respect
cell
success
transduc
vector
vcn
posit
coloni
expand
decreas
number
coloni
uninsul
vector
uninsul
vectortransduc
coloni
greatli
expand
cultur
coloni
sffv
fold
chang
respect
independ
transform
event
confirm
vivo
develop
overt
leukemia
hyperleukocytosi
splenomegali
bmand
extramedullari
siteinfiltr
mice
transplant
expand
coloni
summaryconclus
forc
oncogen
condit
insul
effect
protect
therapeut
vector
vectormedi
genotox
may
serv
safeti
featur
construct
globinsinlv
background
novel
rare
nucleotid
substitut
frequent
identifi
rhd
gene
encod
immunogen
antigen
clinicallyrelev
rh
blood
group
system
result
variant
phenotyp
far
commonli
accept
substitut
amino
acid
locat
either
transmembran
intracellular
domain
rhd
protein
induc
weak
phenotyp
ie
reduc
antigen
densiti
surfac
red
blood
cell
recent
show
function
analysi
use
minigen
splice
assay
msa
decreas
antigen
express
may
due
also
alter
cellular
splice
aim
pay
attent
gener
disrupt
mechan
relat
phenotyp
consequ
novel
previous
report
singlenucleotid
variat
rhd
sought
character
function
msa
novel
candid
splice
variant
rhd
extend
project
studi
prospect
singlenucleotid
variat
report
rhd
exon
order
assess
global
correl
silico
predict
function
analysi
gain
insight
reliabl
bioinformat
tool
line
avail
phenotyp
andor
clinic
data
method
seventeen
novel
uncharacter
rhd
variat
includ
missens
synonym
intron
substitut
select
function
analysi
msa
human
cell
model
second
set
includ
missens
variant
report
rhd
exon
analyz
function
data
compar
algorithm
deriv
quepasa
method
tool
avail
alamut
suit
publish
protein
model
use
visual
locat
missens
amino
acid
substitut
assess
potenti
respect
phenotyp
consequ
result
novel
univers
minigen
valid
use
success
character
eleven
novel
splice
variant
variant
includ
six
intron
four
missens
substitut
close
consensu
dinucleotid
splice
site
well
synonym
variat
associ
weak
phenotyp
creat
de
novo
splice
site
interestingli
dneg
disrupt
total
normal
splice
c
weak
dneg
partial
alter
mechan
visual
amino
acid
chang
model
suggest
dramat
impair
rhd
protein
structurefold
subsequ
global
analysi
mutat
rhd
exon
msa
show
inclus
whole
exon
sequenc
matur
transcript
significantli
reduc
variant
correl
well
quepasalik
predict
sensibl
specif
addit
normal
exon
inclus
affect
g
weak
type
associ
substitut
seem
deleteri
protein
summaryconclus
basi
function
data
work
show
splice
disrupt
presenc
rhd
variant
common
gener
mechan
may
act
independ
synergist
alter
protein
structur
amino
acid
substitut
result
weak
phenotyp
also
illustr
potenc
combin
function
test
silico
tool
toward
phenotypicclin
interpret
rare
variant
backgroundaim
monetari
nonmonetari
incent
may
support
blood
servic
recruit
blood
donor
also
critic
violat
ethic
principl
threaten
blood
safeti
attract
donor
high
risk
infecti
diseas
although
incent
blood
donor
discuss
extens
past
decad
empir
research
topic
remain
limit
aim
studi
describ
attitud
toward
incent
blood
donor
europ
show
donor
return
rate
compens
noncompens
blood
donor
southwest
germani
method
first
present
result
secondari
analysi
eurobaromet
nation
repres
survey
member
state
european
union
particip
ask
evalu
eight
potenti
incent
blood
donat
accept
unaccept
incent
refresh
eg
coffe
physic
checkup
eg
blood
pressur
free
test
laboratori
paramet
free
medic
treatment
complimentari
item
eg
first
aid
kit
monetari
travel
reimburs
addit
cash
reimburs
releas
work
second
conduct
retrospect
analysi
donor
return
pattern
compens
noncompens
donor
start
donat
blood
mobil
fix
donat
site
compens
donor
receiv
either
eur
regular
reimburs
expens
fix
donat
site
accord
german
transfus
law
singular
free
entranc
amus
park
mobil
donat
site
compens
donor
compar
noncompens
donor
start
either
fix
mobil
donat
site
chisquar
statist
use
test
differ
regular
donor
statu
month
compens
noncompens
firsttim
donor
result
among
german
particip
eurobaromet
physic
checkup
refresh
free
test
laboratori
paramet
show
highest
accept
incent
blood
donor
travel
reimburs
free
medic
treatment
rate
accept
respect
lowest
accept
releas
work
complementari
item
addit
cash
reimburs
interestingli
accept
potenti
incent
vari
consider
across
europ
southwest
germani
donor
return
firsttim
donor
differ
significantli
type
compens
among
compens
firsttim
donor
receiv
eur
monetari
reimburs
proport
regular
donor
month
significantli
higher
among
compar
noncompens
donor
howev
nonmonetari
compens
free
entranc
increas
donor
return
rate
conclus
eurobaromet
survey
indic
european
countri
monetari
incent
accept
small
minor
refresh
checkup
free
test
laboratori
paramet
free
medic
treatment
popular
incent
blood
donor
howev
result
four
nonrandom
donor
sampl
southwest
germani
suggest
monetari
compens
may
increas
likelihood
donor
return
fix
donat
site
regular
monetari
reward
may
therefor
help
recruit
regular
donor
especi
urban
set
incident
nonmonetari
compens
free
entranc
howev
may
affect
donor
return
background
previou
research
show
whole
blood
wb
donor
temporarili
defer
onsit
higher
risk
laps
yet
littl
studi
focus
differenti
effect
differ
deferr
reason
eg
travel
hemoglobin
hb
may
donor
laps
addit
donor
experi
ie
firsttim
repeat
donor
also
previous
found
affect
donor
laps
yet
novic
prior
donat
reactiv
donor
return
year
donat
may
respond
differ
final
current
unclear
differ
deferr
reason
donor
experi
interact
influenc
donor
laps
aim
aim
understand
deferr
reason
donor
experi
jointli
affect
donor
laps
donor
may
laps
temporari
deferr
method
mix
method
approach
use
first
use
sanquin
donor
databas
quantit
analysi
return
behavior
dutch
wb
donor
n
first
wb
donat
donor
identifi
target
donat
laps
defin
nonreturn
within
followup
period
two
year
target
donat
target
donat
includ
new
donor
novic
donor
experienc
donor
reactiv
donor
deferr
reason
includ
travel
hb
medic
shortterm
day
durat
medic
longterm
day
durat
miscellan
next
interview
temporarili
defer
donor
understand
deferr
process
perspect
semistructur
interview
use
understand
donor
cognit
emot
experienc
onsit
temporari
deferr
analyz
interview
use
framework
approach
cf
hillgrov
et
al
bmc
public
health
identifi
key
topic
underli
theme
result
target
donat
defer
mostli
travel
medic
shortterm
hb
surviv
timetoev
method
show
differ
deferr
reason
donor
experi
level
differenti
impact
donor
return
laps
importantli
experi
deferr
interact
influenc
return
rate
instanc
defer
new
donor
like
laps
elig
experienc
donor
or
p
even
though
deferr
also
affect
return
experienc
donor
effect
smaller
even
nonexist
certain
deferr
reason
eg
traveland
hbrelat
deferr
qualit
result
show
almost
donor
experienc
temporari
deferr
disappoint
particularli
unexpect
eg
firsttim
deferr
donor
fulli
understood
aim
deferr
prevent
onsit
deferr
donor
belief
deferr
would
lead
laps
relat
recur
deferr
mistakenli
interpret
deferr
perman
feel
effort
pay
summaryconclus
reason
temporari
deferr
differ
impact
risk
donor
laps
differ
level
donor
experi
new
donor
reason
deferr
relat
higher
risk
laps
wherea
reason
deferr
seem
affect
laps
among
experienc
donor
unexpect
recur
deferr
may
explain
donor
laps
temporari
deferr
blood
bank
may
tackl
disappoint
deferr
explicitli
show
donor
still
valu
instanc
use
person
commun
offer
altern
good
deed
background
blood
donor
experi
temporari
reduct
hemoglobin
hb
valu
whole
blood
donat
netherland
hb
valu
measur
donat
low
hb
valu
cutoff
valu
mmoll
gl
men
mmoll
gl
women
lead
deferr
donat
order
prevent
iron
defici
anaemia
minimum
interv
two
donat
intern
set
week
time
donor
exhibit
iron
defici
blood
donor
temporarili
defer
donat
year
us
deferr
due
low
hb
especi
women
editori
transfus
due
recoveri
process
donat
unobserv
heterogen
donor
advanc
statist
method
need
model
longitudin
data
hb
valu
blood
donor
aim
estim
shape
durat
recoveri
process
hb
hb
valu
return
predon
level
assess
whether
one
distinguish
donor
fast
andor
slow
recoveri
hb
level
predict
futur
hb
valu
method
studi
base
data
donor
insight
studi
prospect
cohort
studi
perform
sanquin
netherland
employ
three
statist
model
hb
valu
mixedeffect
model
ii
latentclass
mix
effect
model
iii
latentclass
mixedeffect
transit
model
model
flexibl
function
use
model
recoveri
process
donat
latent
class
identifi
group
donor
fast
slow
recoveri
time
donor
whose
recoveri
time
increas
number
donat
transit
effect
account
possibl
state
depend
observ
data
model
estim
bayesian
way
use
data
sampl
new
entrant
donor
male
femal
prior
inform
clinic
literatur
boulton
vox
sanguini
recoveri
process
three
day
blood
donat
incorpor
analysi
sinc
valu
identifi
observ
data
result
result
show
latentclass
mixedeffect
transit
model
fit
data
best
also
found
recoveri
process
show
concav
process
initi
fast
follow
slower
recoveri
estim
recoveri
time
much
longer
current
minimum
interv
day
donat
name
depend
subgroup
donor
belong
male
show
recoveri
time
day
estim
recoveri
time
femal
vari
day
result
suggest
increas
interv
may
warrant
summaryconclus
analysi
show
use
sophist
statist
model
make
use
histor
inform
model
complex
process
time
case
hb
trajectori
time
across
repeat
donat
addit
result
suggest
much
longer
time
lag
subsequ
donat
avoid
anemia
background
complic
blood
donat
known
reduc
donor
return
futur
donat
episod
studi
experi
success
donat
show
water
drink
shortli
donat
effect
reduct
selfreport
vasovag
reaction
vvr
younger
novic
whole
blood
donor
wiersumosselton
transfus
aim
studi
analys
return
subsequ
donat
donor
particip
episod
studi
predefin
secondari
outcom
episod
studi
method
episod
studi
conduct
young
year
whole
blood
donor
make
first
second
third
fourth
donat
geograph
select
collect
centr
studi
intervent
ml
water
drink
ml
water
drink
squeez
ball
placebo
intervent
wait
screen
interview
phlebotomi
control
group
without
intervent
particip
donor
sent
onlin
questionnair
experi
within
week
follow
donat
attempt
netherland
donor
usual
invit
blood
donat
accord
hospit
need
aim
invit
elig
donor
least
year
donor
includ
return
analysi
receiv
least
one
invit
within
day
index
donat
analys
return
donat
attempt
within
day
associ
intervent
donor
donat
statu
gender
report
symptom
index
donat
analys
calcul
return
percentag
elig
donor
binomi
logist
regress
result
episod
particip
receiv
invit
return
within
studi
period
differ
donor
return
two
water
group
likelihood
return
significantli
increas
water
placebo
intervent
donor
compar
questionnair
group
ci
respect
return
slightli
lower
women
lower
firsttim
donor
nd
th
donat
staffrecord
selfreport
vvr
index
donat
reduc
donor
return
ci
respect
symptom
follow
donat
also
associ
lower
return
percentag
summaryconclus
cohort
younger
new
novic
blood
donor
return
subsequ
donat
vvr
either
staffrecord
selfreport
reduc
donor
return
donor
receiv
studi
intervent
either
water
placebo
like
return
whether
suffer
vvr
conceiv
mere
fact
studi
particip
could
also
increas
donor
return
even
de
questionnair
group
examin
total
popul
target
group
donor
background
contribut
older
blood
donor
blood
suppli
substanti
australia
donor
age
year
contribut
donat
made
howev
age
gener
health
statu
older
donor
chang
rel
faster
thu
progress
affect
abil
donat
indepth
understand
relationship
older
donor
health
statu
futur
donat
pattern
risk
irondefici
could
great
valu
inform
blood
servic
predict
number
futur
donat
manag
risk
irondefici
aim
understand
relationship
selfreport
health
blood
donat
pattern
manag
identifi
irondefici
older
blood
donor
method
link
sax
institut
studi
baselin
data
collect
blood
servic
donat
record
inpati
record
medicar
record
datalinkag
conduct
centr
health
record
linkag
use
link
data
examin
relationship
health
donat
pattern
irondefici
manag
result
follow
activ
whole
blood
donor
elig
personyear
averag
age
recruit
year
femal
averag
follow
year
perperson
adjust
effect
age
sex
bodymass
index
educ
nonenglish
languag
spoken
home
countri
birth
smoke
physic
activ
regular
use
multivitamin
alcohol
consumpt
enrol
total
number
whole
blood
donat
year
prior
enrol
particip
better
selfreport
health
recruit
show
significantli
higher
rate
donat
excel
good
good
fairpoor
health
statu
donor
made
ci
donat
per
personyear
respect
irondefici
identifi
donor
studi
n
ci
sixti
percent
iron
defici
n
ci
visit
gener
practition
gp
within
day
identif
irondefici
ci
visit
gp
underw
iron
statu
examin
monitor
adjust
sever
potenti
confound
includ
total
number
donat
made
followup
period
excel
selfreport
health
statu
independ
associ
lower
risk
irondefici
p
trend
summaryconclus
inform
selfreport
health
statu
effect
indic
estim
futur
donat
yield
older
blood
donor
panel
risk
develop
irondefici
donor
better
selfreport
health
higher
number
futur
whole
blood
donat
lower
risk
irondefici
donor
refer
gp
manag
iron
statu
utilis
health
servic
expect
howev
opportun
improv
contact
gp
medicar
record
provid
australian
govern
depart
human
servic
anaemia
major
public
health
issu
affect
popul
worldwid
accord
world
health
organ
iron
defici
respons
approxim
half
case
global
caus
includ
anaemia
chronic
diseas
nutrit
defici
haemoglobinopathi
renal
impair
malign
bone
marrow
diseas
elderli
anaemia
even
common
caus
frequent
multifactori
anaemia
associ
increas
mortal
decreas
cognit
physic
function
depress
symptom
fatigu
particularli
older
adult
poor
outcom
also
report
anaem
patient
underli
comorbid
cardiac
renal
diseas
cancer
within
hospit
set
anaemia
highli
preval
preoper
anaemia
affect
patient
associ
poor
clinic
outcom
includ
higher
inhospit
mortal
longer
length
stay
higher
icu
admiss
rate
anaemia
manag
requir
proactiv
multifacet
approach
typic
involv
multidisciplinari
team
transfus
practition
play
vital
role
includ
screen
highrisk
patient
preadmiss
clinic
identifi
manag
patient
high
risk
periop
anaemia
implement
patient
blood
manag
pbm
guidelin
recommend
shown
effect
prevent
optim
manag
anaemia
within
commun
hospit
set
transfus
practition
key
role
coordin
monitor
audit
pbm
program
activ
patient
involv
engag
member
multidisciplinari
team
includ
primari
care
clinician
also
key
enhanc
success
program
role
transfus
practition
anaemia
assess
manag
process
tip
resourc
creat
background
patient
blood
manag
pbm
evidenc
base
integr
multidisciplinari
approach
aim
improv
clinic
outcom
effect
manag
conserv
patient
blood
thu
reduc
unnecessari
exposur
transfus
pbm
patient
central
focu
aim
improv
outcom
includ
process
pbm
includ
three
pillar
optimis
patient
blood
minimis
blood
loss
optimis
patient
physiolog
toler
anaemia
delay
assessmentmanag
anaemia
contribut
increas
health
cost
unnecessari
blood
transfus
transfus
recognis
associ
increas
morbid
mortal
term
transfus
practition
tp
includ
known
transfus
nurs
transfus
safeti
offic
haemovigil
offic
patient
blood
manag
pbm
coordin
key
aspect
role
drive
influenc
clinic
blood
manag
activ
help
align
practic
intern
recognis
guidelin
standard
includ
pbm
aim
demonstr
tp
role
anaemia
assess
manag
discuss
strategi
process
tip
resourc
creat
organis
cultur
chang
implement
pbm
context
literatur
outlin
import
multidisciplinari
team
implement
pbm
relat
chang
tp
play
fundament
role
within
team
support
buy
tp
seen
enabl
pull
resourc
togeth
engag
involv
provid
educ
facilit
chang
often
one
conduct
audit
collat
data
evalu
outcom
approach
implement
pbm
tailor
suit
individu
organis
author
outlin
differ
approach
highlight
tp
support
lead
activ
one
approach
anaemia
assess
undertak
audit
exampl
avail
tool
shown
data
tp
along
pbm
team
explor
option
correct
action
could
includ
intervent
develop
pathway
specif
group
patient
assess
treat
either
preoper
clinic
local
gener
practition
complic
strategi
establish
anaemia
clinic
skill
tp
valuabl
asset
analys
clinic
specialtiespati
mix
target
achiev
best
outcom
know
organis
well
place
help
develop
processconcept
suit
provid
educ
support
promot
emb
practic
conclus
appropri
assess
manag
anaemia
requir
multidisciplinari
approach
tp
play
activ
crucial
role
team
exampl
process
tip
resourc
support
chang
emb
pbm
cultur
across
clinic
spectrum
share
depart
hematolog
central
hematolog
laboratori
inselspit
bern
bern
switzerland
immun
haemolyt
anaemia
iha
character
increas
breakdown
red
blood
cell
rbc
due
alloandor
autoantibodi
direct
rbc
antigen
without
complement
activ
clinic
laboratori
sign
haemolysi
concert
presenc
posit
direct
antiglobulin
test
character
iha
alloantibodi
form
pregnanc
andor
prior
transfus
may
caus
acut
delay
haemolyt
transfus
reaction
transfus
rbc
product
incompat
specif
alloantibodi
autoantibodi
rbc
reduc
surviv
endogen
hamper
recoveri
donor
rbc
transfus
lymphoprolif
diseas
autoimmun
diseas
infect
drug
often
caus
autoantibodi
rbc
frequent
obviou
caus
identifi
besid
antigen
specif
isotyp
critic
determin
biolog
activ
rbc
antibodi
vivo
isotyp
defin
affin
fcgamma
receptor
cell
reticuloendotheli
system
well
capac
activ
classic
pathway
complement
igm
effect
antibodymedi
complement
activ
result
opsonis
rbc
subsequ
complement
receptormedi
remov
phagocyt
extravascular
haemolysi
occasion
complement
activ
proce
via
activ
format
insert
membran
attack
complex
result
intravascular
haemolysi
grow
evid
innat
immun
system
play
import
role
pathogenesi
iha
process
complementmedi
haemolysi
result
system
inflamm
contribut
morbid
mortal
patient
suffer
iha
complement
activ
result
releas
anaphylatoxin
strongli
vasoact
mediat
chemotaxi
inflamm
format
radic
oxygen
speci
releas
cellfre
haemoglobin
cellfre
haem
upon
haemolysi
induc
endotheli
cell
activ
nodeplet
cytotox
ro
format
neutrophil
activ
natur
plasma
scaveng
haptoglobin
hemopexin
complex
target
molecul
cellfre
haemoglobin
haem
subsequ
remov
complex
via
phagocytosi
although
posit
acut
phase
protein
due
consumpt
plasma
scaveng
becom
exhaust
chronic
haemolysi
therebi
fail
prevent
advers
biolog
effect
cellfre
haemoglobin
haem
circul
induc
haem
effici
cellular
scaveng
break
haem
biliverdin
subsequ
format
bilirubin
co
ferrou
iron
subsequ
oxid
ferric
iron
storag
ferritin
h
chain
establish
role
system
protect
system
inflamm
induc
haemolyt
nonhaemolyt
diseas
lectur
emphasis
role
innat
immun
special
focu
differ
plasmaand
cellular
system
involv
pathogenesi
system
inflamm
patient
suffer
iha
understand
erythrocyt
clearanc
c
roussel
p
amireault
p
ndour
p
buffet
research
teach
institut
nation
de
la
transfus
sanguin
pari
franc
clearanc
erythrocyt
essenti
physiolog
diseas
transfus
elimin
erythrocyt
alter
senesc
patholog
process
expect
protect
microcircul
obstruct
adhes
rigid
erythrocyt
also
contribut
harm
consequ
anemia
hemolysi
hereditari
acquir
red
blood
cell
diseas
well
condit
associ
autoor
alloimmun
immunobiolog
explor
great
detail
antibodymedi
clearanc
erythrocyt
convent
approach
may
fulli
oper
explain
delay
hemolyt
transfus
reaction
import
clearanc
process
independ
recognit
molecul
antigen
erythrocyt
surfac
increas
erythrocyt
stiff
trigger
clearanc
hereditari
spherocytosi
malaria
possibl
also
context
autoimmun
anemia
known
unknown
mechan
site
erythrocyt
clearanc
present
base
critic
review
old
recent
contribut
cardiovascular
endocrinemetabol
diseas
age
istituto
superior
di
sanit
rome
itali
exist
literatur
indic
red
blood
cell
rbc
beyond
ga
transport
exert
complex
role
human
physiolog
involv
mani
function
essenti
maintain
ion
metabol
immunolog
homeostasi
rbc
display
immunomodulatori
activ
adapt
immun
cell
promot
cell
growth
surviv
inhibit
activationinduc
cell
death
balanc
cell
death
surviv
control
cell
homeostasi
anomali
balanc
account
diseas
link
excess
faulti
cell
growth
rbc
abl
modul
innat
immun
bind
endogen
molecul
chemokin
mitochondriaderiv
dna
well
extern
agent
pathogen
rbc
also
directli
modul
innat
immun
cell
activ
toler
control
matur
circul
proinflammatori
subset
dendrit
cell
dc
cell
potent
induc
primari
antigenspecif
cell
respons
produc
tnfa
stimul
lp
princip
cell
among
leukocyt
proinflammatori
capac
circul
dc
control
rbc
abl
inhibit
matur
product
diseas
character
local
inflammatori
respons
psoriasi
vulgari
rheumatoid
arthriti
proinflammatori
dc
play
role
induct
perpetu
inflamm
collect
literatur
data
indic
rbc
exert
import
modulatori
function
may
result
immun
activ
quiescenc
depend
environment
condit
rbc
encount
microenviron
character
intens
product
ro
rbc
defens
get
overwhelm
unabl
counteract
new
prooxid
statu
becom
sourc
ro
caus
gener
senesc
signal
rbc
major
featur
oxid
rbc
cluster
andor
breakdown
band
featur
complex
hb
spectrin
loss
glycophorin
extern
phosphatidylserin
reduct
marker
self
integrinassoci
protein
similar
senesc
phenotyp
document
rbc
storag
period
oxid
senesc
store
rbc
due
surfac
antigen
modif
releas
proinflammatori
molecul
fail
control
immun
cell
homeostasi
thu
contribut
perpetu
inflamm
pathogenesi
immunemedi
diseas
associ
oxid
stress
autoimmun
diseas
atherosclerosi
research
group
demonstr
rbc
patient
carotid
atherosclerosi
present
senesc
phenotyp
similar
acquir
rbc
healthi
subject
follow
vitro
oxid
oxid
erythrocyt
fail
control
lymphocyt
apoptosi
lipopolysaccharideinduc
monocytederiv
dc
matur
thu
repres
danger
signal
adapt
innat
immun
contribut
pathogenesi
atherosclerosi
conclus
crosstalk
rbc
immun
system
repres
mechan
maintain
immunolog
homeostasi
howev
high
oxid
stress
condit
take
place
prolong
storag
period
particular
diseas
rbc
acquir
prooxid
behaviour
lose
function
homeostat
featur
interf
immun
system
homeostasi
rbc
becom
potenti
tool
manipul
improv
revers
patholog
situat
character
anomali
control
adapt
innat
immun
transfus
therapi
remain
import
treatment
modal
patient
sickl
cell
diseas
scd
transfus
given
lower
percentag
circul
sickl
rbc
decreas
blood
viscos
shown
clinic
trial
reduc
risk
stroke
howev
mani
indic
transfus
scd
remain
controversi
partli
due
insuffici
random
clinic
trial
data
part
limit
understand
complex
patholog
network
lead
divers
diseas
complic
scd
despit
common
singl
mutat
similarli
incomplet
mechanist
understand
chronic
transfus
protocol
must
continu
indic
support
clinic
data
benefici
effect
transfus
therapi
scd
need
also
weigh
potenti
transfus
risk
includ
alloimmun
associ
lifethreaten
delay
transfus
reaction
increas
iron
store
associ
increas
oxid
stress
exposur
infecti
agent
believ
deeper
understand
benefit
well
harm
effect
transfus
crucial
optim
current
transfus
therapi
protocol
scd
knowledg
may
provid
highli
need
guidanc
current
lack
expans
limit
exist
indic
chronic
transfus
scd
treatment
thalassaemia
depart
pediatr
hematolog
ege
univers
faculti
medicin
bornova
izmir
turkey
thalassaemia
devast
blood
diseas
signific
worldwid
burden
annual
children
born
major
thalassemia
lifetim
rbcc
transfus
iron
chelat
remain
standard
care
treatment
thalassaemia
transfus
therapi
still
account
signific
iron
overload
relat
morbid
mortal
despit
chelat
therapi
associ
poor
adher
safeti
concern
vari
efficaci
higher
risk
transfus
transmit
infect
tti
exist
thalassemia
patient
whose
transfus
exposur
sustain
lifelong
although
risk
transmiss
tradit
virus
exceedingli
rare
modern
era
emerg
infecti
diseas
continu
recogn
potenti
threat
transfus
safeti
inadequaci
blood
safeti
point
necess
addit
layer
secur
blood
suppli
develop
world
pathogen
reduct
technolog
rbcc
may
impli
proactiv
gener
approach
new
reemerg
pathogen
develop
world
may
ultim
safeguard
transfus
safeti
develop
countri
rbc
alloimmun
may
becom
major
challeng
thalassaemia
manag
prevent
key
reduc
burden
alloimmun
recommend
transfus
thalassaem
patient
cc
ee
kell
compat
blood
univers
practic
extend
molecular
rbc
type
may
appropri
adjunct
test
addit
serolog
type
embark
transfus
therapi
complet
rbc
antigen
profil
yet
perform
alloimmun
patient
genotyp
option
accur
detect
rbc
antigen
may
guid
antibodi
identif
allogen
stem
cell
transplant
asct
avail
cur
therapi
children
hla
match
sibl
avail
approxim
patient
absenc
msd
mud
transplant
high
compat
criteria
still
limit
experi
mismatch
relat
cord
blood
haploident
donor
sct
consid
experiment
asct
carri
substanti
risk
sae
mortal
increas
recipi
age
diseas
sever
df
paediatr
adult
gene
therapi
correct
aglobin
chain
imbal
overcom
problem
donor
avail
immunolog
complic
associ
asct
multicent
clinic
studi
gene
addit
therapi
use
selfinactiv
lentivir
vector
current
underway
recent
gene
edit
either
gene
disrupt
gene
correct
emerg
potenti
altern
gene
addit
therapi
betathalassaemia
new
era
novel
therapeut
unfold
thalassemia
manag
sever
target
identifi
improv
alphabeta
chain
imbal
ineffect
erythropoiesi
iron
dysregul
number
agent
preclin
clinic
develop
hydroxyurea
may
improv
globin
chain
imbal
benefici
reduc
omit
transfus
requir
select
group
patient
ruxolitinib
shown
limit
effect
pretransfus
haemoglobin
reduct
transfus
need
allow
steadi
decreas
spleen
volum
may
serv
avoid
splenectomi
beta
thalassaemia
luspatercept
may
restor
normal
erythroid
differenti
improv
anaemia
hepcidin
mimet
inhibitor
may
modul
ineffect
erythropoiesi
iron
restrict
improv
anaemia
organ
iron
load
background
thalassaemia
major
particularli
btype
sickl
cell
diseas
scd
commonest
clinic
import
haemoglobinopathi
repres
major
sourc
morbid
recommend
therapi
regular
transfus
safe
good
qualiti
blood
monitor
relat
complic
thalassaemia
intern
feder
tif
guidelin
place
sinc
includ
strategi
precautionari
measur
use
scientif
progress
detect
inactiv
elimin
transfus
transmiss
pathogen
antigenmatch
strategi
avoid
alloimmun
rbc
antigen
measur
includ
haemovigil
key
compon
safe
blood
alongsid
voluntari
nonremuner
blood
donat
laboratori
qualiti
assur
programm
aim
present
contribut
tif
greek
experi
ensur
safeti
avail
blood
thalassaemia
patient
appli
intern
accept
standard
recommend
method
tif
nonprofit
patientdriven
organ
nation
thalassemia
associ
countri
promot
nation
control
programm
prevent
manag
contribut
achiev
final
cure
main
work
method
provis
educ
expert
support
network
commun
project
support
improv
qualiti
health
social
care
greec
technic
standard
blood
donor
select
test
appli
complianc
direct
well
haemovigil
programm
traceabl
procedur
record
advers
reaction
event
associ
transfus
rbc
direct
pretransfus
transfus
measur
recommend
council
europ
appli
particular
measur
transfus
right
blood
right
time
right
patient
leucodeplet
rbc
wash
accur
crossmatch
antigen
antibodi
screen
extend
match
polici
practis
fresh
day
old
rbc
use
molecular
test
abo
rh
perform
case
blood
group
discrep
haemovigil
greec
cover
total
blood
suppli
data
tti
patient
thalassaemia
scdthalassaemia
analys
result
tti
preval
thalassaemia
syndrom
hbv
occult
type
hcv
hiv
htlv
wnv
hev
frequent
advers
reaction
allerg
incid
nonhaemolyt
febril
reaction
alloimmunis
taco
tad
tthev
hyperhaemolysi
diagnos
two
scd
patient
delay
haemolyt
transfus
reaction
one
thalassaemia
intermedia
patient
trend
show
reduc
incid
alloimmunis
rbc
rate
allerg
pyrexi
ar
remain
stabl
major
abo
incompat
case
report
fatal
transfus
reaction
transfus
record
summaryconclus
blood
safeti
transfus
significantli
improv
high
uppermiddl
incom
unfortun
lower
low
incom
countri
blood
shortag
lack
stringent
protect
measur
thalassaemia
patient
realiti
mani
develop
countri
tif
focus
particular
attent
provis
support
promot
initi
promot
safeti
adequaci
blooda
key
compon
lifelong
manag
patient
transfusiondepend
thalassaemia
background
b
thalassemia
common
group
hereditari
hemoglobinopathi
diseas
affect
peopl
major
thalassemia
depend
regular
blood
transfus
lead
iron
overload
hepcidin
peptid
import
regul
iron
homeostasi
express
hormon
influenc
polymorph
within
hepcidin
gene
hamp
aim
studi
aim
analyz
associ
three
polymorph
promot
hamp
iron
overload
major
b
thalassemia
patient
respond
iron
chelat
therapi
materi
method
total
sampl
major
b
thalassemia
patient
collect
genom
dna
extract
sequenc
snp
statist
analysi
perform
ibm
spss
statist
use
independ
test
fisher
test
result
analysi
reveal
statist
significantli
differ
level
cardiac
iron
concentr
g
variant
p
statist
analysi
edg
signific
relationship
minor
allel
serum
ferritin
p
sampl
homozyg
allel
summaryconclus
differ
factor
affect
iron
overload
thalassemia
find
other
emphas
role
hepcidin
polymorph
key
compon
iron
homeostasi
ten
twenti
year
ago
countri
south
eastern
africa
face
peak
devast
hivaid
epidem
lead
year
drop
gener
life
expect
burden
hivaid
fall
mainli
econom
activ
popul
young
mediumag
adult
epidem
endang
social
econom
stabil
nation
heavili
affect
today
despit
aid
still
major
caus
death
south
eastern
africa
epidem
becom
exampl
public
health
gain
achiev
programmat
evidencebas
approach
endors
global
align
polici
fund
strategi
base
work
lesotho
one
four
among
adult
infect
hiv
niklau
labhardt
take
auditor
histori
hiv
program
south
eastern
africa
show
innov
pragmat
evid
base
implement
brought
region
stage
goal
end
aid
epidem
might
reach
background
franc
deferr
men
sex
men
msm
reduc
perman
month
juli
sinc
chang
impact
residu
risk
rr
undetect
hiv
among
blood
donat
ministri
health
consid
greater
access
blood
donat
msm
two
scenario
studi
deferr
msm
month
preced
donat
deferr
msm
one
sexual
partner
month
preced
donat
similarli
blood
donor
franc
aim
assess
impact
two
scenario
hiv
rr
estim
period
juli
baselin
rr
current
deferr
msm
method
baselin
hiv
rr
calcul
classic
incidencewindowperiod
method
hiv
incid
deriv
detun
assay
eiari
detect
recent
infect
day
sinc
antibodi
posit
blood
donat
test
test
assess
impact
scenario
baselin
hiv
rr
base
data
obtain
survey
among
msm
gener
popul
blood
donor
complianc
survey
estim
number
addit
msm
would
give
blood
scenario
ii
hiv
incid
estim
among
addit
donor
incid
estim
msm
blood
donor
current
deferr
polici
month
monogam
msm
gener
popul
result
juli
decemb
posit
blood
donor
test
eiari
identifi
recent
infect
allow
estim
baselin
hiv
rr
million
donat
ci
donat
number
addit
msm
donor
estim
number
addit
hiv
posit
donat
result
hiv
rr
million
donat
ci
donat
number
addit
msm
donor
estim
number
addit
hiv
posit
donat
result
hiv
rr
million
donat
ci
donat
sensit
analysi
show
number
msm
hiv
incid
multipli
risk
would
donat
summaryconclus
scenario
hiv
rr
remain
low
deferr
risk
ident
baselin
rr
robust
variat
model
paramet
one
sexual
partner
month
risk
higher
point
estim
baselin
rr
sensit
analysi
show
estim
less
robust
sinc
risk
could
time
higher
baselin
rr
scenario
modest
increas
elig
msm
donat
background
recruit
safe
blood
donor
amongst
largest
hivposit
popul
world
major
challeng
south
african
blood
transfus
servic
south
african
donor
deferr
criteria
deferr
period
perceiv
high
risk
activ
evolv
time
current
risk
factor
infect
formal
assess
addit
studi
report
risk
factor
preval
hiv
infect
wherea
risk
behaviour
incid
infect
inform
donat
infect
could
occur
window
period
avail
screen
assay
aim
identifi
demograph
behaviour
risk
factor
associ
incid
hiv
infect
among
blood
donor
south
africa
method
conduct
casecontrol
studi
incid
hivinfect
blood
donor
compar
infecti
marker
neg
control
incid
hiv
case
control
seroneg
hiv
hepat
b
c
virus
syphili
accru
donor
pool
cover
provinc
south
africa
control
frequenc
match
ratio
case
race
age
geographi
incid
hivinfect
hiv
rna
posit
individu
donat
nucleic
acid
amplif
test
idnat
procleix
grifol
antibodi
ab
neg
prism
abbott
well
rnaab
donor
recentlyacquir
hiv
base
limit
antigen
avid
lag
assay
result
normal
optic
densiti
valu
elig
case
control
complet
confidenti
audio
comput
assist
structur
interview
acasi
motiv
blood
donat
behaviour
factor
includ
behaviour
month
donat
frequenc
measur
statist
associ
risk
behaviour
compar
case
control
report
adjust
multipl
comparison
result
novemb
januari
enrol
incid
hiv
case
control
case
control
year
old
significantli
femal
case
femal
control
p
signific
hiv
risk
factor
p
report
within
donat
includ
primari
sex
partner
male
report
increas
number
male
sexual
partner
femal
male
frequenc
vagin
sex
frequenc
vagin
sex
without
condom
use
method
clean
dri
tighten
one
anu
sex
visit
tradit
healer
medic
care
lack
medic
aid
privat
health
insur
report
injuri
accid
blood
loss
also
associ
incid
hiv
infect
summaryconclus
studi
identifi
set
novel
put
risk
factor
incid
hiv
infect
among
south
african
blood
donor
confirm
number
previous
known
sexual
risk
behaviour
privat
health
insur
injur
may
marker
socioeconom
context
place
individu
higher
risk
rather
behaviour
directli
increas
hiv
transmiss
risk
detect
risk
behaviour
acasi
donor
pass
predon
questionnair
interview
suggest
acasi
potenti
improv
risk
behaviour
identif
background
franc
among
male
blood
donor
mbd
found
posit
blood
donat
screen
disclos
risk
factor
hiv
infect
postdon
interview
report
sex
men
msm
report
heterosexu
sex
ht
risk
factor
respect
aim
order
gain
new
insight
risk
factor
infect
mbd
perform
genet
network
analysi
includ
posit
mbd
patient
includ
french
primari
hiv
infect
anr
primo
cohort
pc
method
mbd
donat
blood
pc
includ
studi
epidemiolog
data
collect
french
blood
servic
ef
upon
blood
donat
postdon
interview
mbd
upon
inclus
cp
viral
strain
sequenc
genotyp
pol
gene
recent
infect
assay
perform
date
infect
mbd
recent
month
partial
transmiss
network
comput
base
tamuranei
nucleotid
distanc
threshold
st
b
nonb
assort
mix
evalu
mbd
epidemiolog
data
includ
risk
factor
hiv
infect
msm
ht
other
unknown
selfreport
data
compar
assortativityenhanc
data
result
strain
mbd
pc
link
cluster
includ
least
one
mbd
primoonli
cluster
exclud
analysi
compar
mbd
cluster
found
link
network
younger
vs
yearold
p
like
recent
infect
vs
p
assort
mix
index
show
pair
individu
like
live
area
p
risk
factor
hiv
infect
p
compar
random
distribut
imput
msm
risk
factor
nonmsm
individu
pair
msm
chang
distribut
risk
factor
follow
msm
vs
ht
vs
vs
unknown
vs
summaryconclus
valid
assort
risk
factor
pair
individu
imput
msm
risk
factor
individu
selfreport
nonmsm
includ
identifi
risk
factor
mbd
could
reclassifi
msm
worstcas
scenario
network
analysi
exclud
possibl
one
sever
person
two
pair
individu
miss
link
altogeth
result
could
help
reevalu
hiv
residu
risk
link
msm
mbd
especi
frame
evolut
blood
donor
deferr
criteria
background
although
individu
remain
asymptomat
htlv
infect
lead
adult
tcell
leukaemialymphoma
atll
associ
myelopathi
ham
seriou
natur
diseas
evid
transmiss
via
nonleucodeplet
blood
concern
high
preval
among
donor
origin
endem
area
led
uk
blood
servic
introduc
univers
blood
donat
screen
monitor
routin
surveil
commenc
htlvinfect
donor
invit
particip
htlv
nation
regist
cohort
studi
assess
diseas
progress
data
togeth
evid
lookback
previous
untest
donat
costeffect
analysi
review
expert
work
group
aim
describ
epidemiolog
htlv
among
uk
blood
donor
evid
diseas
progress
long
term
follow
asymptomat
donor
method
uk
blood
donat
screen
infect
donor
identifi
report
nation
surveil
scheme
donor
contact
result
explain
inform
clinic
histori
possibl
sourc
infect
collect
appropri
htlvinfect
donor
consent
regist
particip
complet
baselin
questionnair
health
flag
registri
cancer
death
follow
everi
year
result
uk
htlvinfect
donor
identifi
preval
among
new
donor
steadi
around
donat
preval
among
repeat
donor
peak
donat
previous
untest
preval
per
donat
averag
one
positiveyear
record
preval
among
new
donor
increas
donat
posit
increas
number
associ
asian
ethnic
coincid
increas
collect
bame
group
overal
women
ukborn
infect
mean
age
year
almost
posit
donat
previous
untest
donor
seroconvers
within
year
previou
donat
confirm
previous
test
donor
typic
infect
associ
endem
countri
includ
caribbean
region
west
africa
iran
india
japan
acquir
breast
feed
heterosexu
partner
origin
countri
interestingli
three
thought
infect
selfflagel
total
htlvposit
asymptomat
blood
donor
alreadi
recruit
htlv
nation
regist
year
followup
none
develop
atll
ham
summaryconclus
year
test
seroconvert
identifi
suggest
littl
ongo
transmiss
among
uk
blood
donor
lack
diseas
among
cohort
studi
also
reassur
although
like
earli
detect
associ
symptom
slow
progress
diseas
recruit
uniqu
dataset
continu
also
outsid
blood
donat
set
result
surveil
data
evid
lookback
costeffect
analysi
nhsbt
ceas
test
donat
previous
test
donor
unless
donat
use
manufactur
nonleucodeplet
compon
finland
lie
northern
europ
latitud
length
countri
km
width
km
surfac
area
fifth
largest
countri
eu
popul
countri
million
result
lowest
popul
densiti
eu
whole
countri
inhabit
although
popul
pack
south
climat
finland
influenc
mainli
latitud
warm
water
gulf
stream
north
atlant
drift
current
also
play
role
due
finland
northern
locat
winter
longest
season
southern
portion
countri
snowcov
three
four
month
year
northern
region
seven
month
long
distanc
low
popul
densiti
extrem
climat
give
logist
challeng
estim
logist
cost
much
gdp
finland
finnish
red
cross
blood
servic
frc
bs
nationwid
blood
servic
provid
finland
sinc
frc
bs
collect
annual
whole
blood
unit
collect
fix
site
mobil
session
around
countri
central
activ
donor
recruit
medic
support
product
test
suppli
chain
manag
digit
servic
administr
locat
helsinki
manag
transfus
highli
depend
logist
arrang
blood
donat
site
central
facil
central
inventori
hospit
logist
outsourc
three
major
partner
root
nationwid
public
transport
logist
servic
posti
ltd
state
own
compani
root
nation
postal
telecom
offic
today
lead
postal
logist
servic
compani
widest
network
coverag
finland
blood
unit
collect
differ
fix
site
mobil
session
transport
overnight
posti
ltd
frc
bs
central
facil
day
follow
blood
donat
posti
ltd
also
use
regular
deliveri
blood
product
hospit
import
partner
matkahuolto
ltd
found
maintain
bu
station
serv
common
market
compani
bu
coach
servic
finland
maintain
nationwid
packag
deliveri
system
base
schedul
bu
rout
network
matkahuolto
ltd
use
transport
donor
test
sampl
donat
site
central
laboratori
arrang
possibl
obtain
donor
sampl
laboratori
around
midnight
significantli
speed
complet
laboratori
result
third
logist
partner
jetpak
finland
ltd
oper
air
freight
nation
flight
compani
finnair
blood
transfus
servic
manag
central
larg
spars
popul
countri
manner
high
qualiti
safe
cost
effect
howev
suppli
chain
plan
care
background
elearn
divis
topic
often
criticis
inferior
form
educ
simultan
promot
mean
provid
educ
larg
number
peopl
consist
costeffect
manner
bloodsaf
elearn
australia
bea
governmentfund
blood
transfus
educ
program
commenc
provid
cours
clinic
transfus
practic
patient
blood
manag
pbm
includ
clinic
transfus
practic
cours
pbm
gener
cours
pbm
medic
cours
pbm
acut
care
surgic
cours
pbm
obstetr
matern
cours
pbm
neonat
paediatr
cours
aim
determin
engag
outcom
impact
learn
bloodsaf
elearn
australia
cours
method
retrospect
analysi
user
registr
cours
complet
record
cours
evalu
data
red
cell
usag
australia
determin
learner
demograph
impact
acquisit
knowledg
applic
clinic
practic
result
period
juli
januari
peopl
regist
learner
cours
complet
learner
came
countri
outsid
australia
analysi
profess
show
nurs
andor
midwiv
medic
laboratori
anaesthet
technician
analysi
user
evalu
data
n
april
januari
show
cours
posit
impact
respond
state
gain
addit
knowledg
abl
make
chang
clinic
practic
report
chang
improv
patient
safeti
outcom
analysi
intern
particip
show
greater
benefit
gain
knowledg
abl
chang
clinic
practic
believ
improv
patient
outcom
analysi
red
cell
usag
australia
show
sinc
reduct
red
cell
issu
achiev
number
pbm
activ
includ
develop
guidelin
research
audit
educ
wast
reduct
strategi
promot
campaign
bloodsaf
elearn
australia
cours
pbm
releas
one
part
pbm
activ
notabl
cours
widest
reach
undertaken
larg
proport
doctor
nurs
midwiv
australia
directli
involv
blood
sector
stakehold
feedback
show
program
provid
credibl
consist
educ
costeffect
reduc
duplic
bestpractic
elearn
readili
access
allow
institut
focu
develop
practic
transfus
skill
summaryconclus
analysi
show
elearn
wellaccept
wellutilis
form
educ
healthcar
worker
learn
clinic
transfus
practic
patient
blood
manag
learner
gain
knowledg
chang
clinic
practic
improv
patient
outcom
also
like
cours
contribut
better
utilis
scarc
freelydon
resourc
approach
global
reach
avail
costeffect
model
improv
transfus
practic
develop
world
provid
educ
million
healthcar
worker
prospect
platelet
audit
analysi
traine
complianc
guidelin
patholog
columbia
univers
new
york
unit
state
background
apheresi
platelet
compon
product
high
cost
limit
suppli
furthermor
potenti
sever
transfus
reaction
associ
product
transfus
relat
lung
injuri
trali
sepsi
due
bacteri
contamin
therefor
transfus
guidelin
complianc
close
monitor
mani
center
qualiti
assur
analysi
describ
experi
prospect
platelet
audit
perform
physician
patholog
resid
train
aim
studi
aim
evalu
abil
physician
train
perform
prospect
audit
compar
polici
complianc
differ
level
experi
method
qualiti
assur
analysi
prospect
platelet
audit
program
period
januari
blood
bank
page
call
physician
time
order
place
patient
platelet
count
dose
platelet
interim
repeat
count
unknown
platelet
count
audit
record
creat
physician
traine
first
post
graduat
year
compar
subsequ
year
pgi
inform
collect
includ
total
number
dose
requir
approv
number
product
approv
train
year
approv
physician
transfus
indic
cost
analys
assum
dose
platelet
descript
statist
compar
analysi
use
pearson
chisquar
use
differ
p
consid
statist
signific
result
platelet
dose
requir
approv
rout
group
pgi
group
order
dose
complianc
hospit
transfus
polici
complianc
hospit
polici
appropri
order
dose
group
declin
releas
necessit
clinic
team
insist
upon
releas
without
approv
zero
instanc
pgi
group
page
blood
bank
physician
approv
product
releas
complianc
polici
dose
pgi
physician
approv
indic
product
dose
p
product
indic
hospit
polici
held
releas
physician
dose
dose
pgi
physician
p
order
dose
complianc
hospit
polici
estim
cost
cost
calcul
save
product
releas
due
prospect
audit
addit
potenti
save
product
indic
releas
pgi
group
summaryconclus
despit
higher
number
request
rout
senior
pgi
group
disproportion
higher
number
complianc
platelet
order
releas
group
addit
withhold
need
product
sever
occas
potenti
mitig
strategi
could
includ
closer
level
oversight
physician
potenti
monetari
save
could
justifi
hire
dedic
patient
blood
manag
team
qualiti
assur
manag
monitor
complianc
provid
feedback
clinician
learn
advers
event
detect
norwegian
director
health
oslo
norway
background
primari
aim
report
system
haemovigil
system
learn
improv
identifi
risk
area
simpli
count
error
understand
learn
advers
event
descript
occur
detect
import
support
understand
use
predetermin
classif
requir
report
eu
supplement
classif
suggest
ihn
start
ask
blood
establish
step
would
take
prevent
recurr
event
ad
simpl
classif
tell
advers
event
detect
aim
studi
aim
analyz
differ
type
advers
event
report
haemovigil
system
detect
whether
current
qualiti
manag
system
use
norwegian
blood
establish
effect
barrier
whether
new
barrier
consid
method
advers
event
report
norwegian
haemovigil
system
analyz
focu
advers
event
detect
case
classif
perform
report
advers
event
confirm
reclassifi
necessari
haemovigil
team
analysi
analysi
base
classif
use
powerbi
microsoft
result
total
advers
event
report
norwegian
blood
establish
classifi
accord
advers
event
detect
twenti
advers
event
detect
alarm
warn
itsystem
equip
routin
check
blood
establish
staff
detect
event
formal
intern
extern
review
detect
one
event
seven
event
detect
donor
becam
ill
shortli
donat
ill
caus
donat
sixtyfour
percent
event
detect
way
fit
present
classif
henc
classifi
twelv
wrong
blood
tube
detect
alarm
itsystem
routin
check
six
event
relat
blood
order
two
seven
error
test
six
event
incorrect
blood
transfus
eight
event
relat
donor
select
report
human
error
list
caus
event
detect
alarm
routin
check
summaryconclus
detect
advers
event
alarm
routin
check
highli
effici
blood
establish
histor
data
check
exemplifi
wrong
blood
tube
patient
requir
irradi
blood
compon
histor
data
exist
qualiti
manag
system
requir
routin
check
event
usual
detect
chanc
analysi
need
see
qualiti
manag
system
improv
wide
varieti
advers
event
make
difficult
select
area
priorit
improv
work
result
hb
measur
finger
prick
averag
gl
higher
venou
blood
sampl
rang
differ
gl
result
use
order
add
novel
inform
determin
measur
uncertainti
hb
measur
frcb
donor
studi
venou
hemoglobin
measur
cutoff
point
donor
elig
measur
differ
finger
prick
venou
hemoglobin
measur
gl
hemoglobin
result
finger
prick
rang
gl
compar
venou
hemoglobin
result
result
finger
prick
gl
precis
devic
compar
venou
hemoglobin
result
case
differ
finger
prick
venou
measur
outsid
standard
deviat
mean
ie
bottom
n
top
n
distribut
systemat
error
seen
nurs
result
toward
low
high
hb
result
finger
prick
measur
nurs
random
error
direct
batch
cuvett
donor
age
gender
time
sampl
detect
impact
differ
finger
prick
venou
hb
measur
studi
summaryconclus
result
poc
measur
compar
cell
counter
agreement
publish
data
manufactur
inform
devic
practic
skill
test
workabl
way
develop
compet
oper
measur
hemoglobin
finger
prick
offer
opportun
give
person
feedback
nurs
concern
person
perform
use
current
hb
measur
technic
also
provid
data
accuraci
poc
method
everyday
donor
select
process
background
whole
blood
donat
frequent
relat
iron
defici
blood
donor
lose
per
donat
men
menstruat
women
iron
store
replenish
iron
lost
blood
donat
donat
interv
day
donor
need
absorb
mg
iron
per
day
amount
exce
report
maxim
amount
absorb
iron
mgday
eventu
lead
iron
defici
consequ
donor
deferr
possibl
iron
deficiencyrel
symptom
decreas
physic
endur
fatigu
pica
restless
leg
syndrom
cognit
function
sinc
hb
level
reflect
donor
true
iron
statu
measur
ferritin
better
way
detect
low
iron
store
whole
blood
donor
studi
usa
denmark
show
introduct
ferritin
measur
either
extens
donat
interv
iron
supplement
case
low
iron
store
deferr
percentag
low
hb
declin
male
femal
donor
aim
gain
insight
iron
statu
whole
blood
donor
donor
career
affect
donor
health
measur
may
prevent
low
iron
store
donor
method
netherland
sanquin
blood
bank
current
implement
polici
ferritinguid
donat
interv
brief
ferritin
level
measur
new
donor
repeat
donor
everi
donat
case
hb
deferr
threshold
donat
interv
extend
ferritin
level
lg
l
lgl
month
respect
anticip
routin
ferritin
measur
ultim
result
lower
preval
iron
defici
less
hb
deferr
improv
donor
retent
evalu
step
wedg
clusterrandom
trial
findem
may
also
identifi
subgroup
donor
prone
develop
symptom
iron
defici
addit
implement
ferritin
screen
may
lead
decreas
donor
avail
purpos
model
impact
implement
ferritin
deferr
polici
donor
avail
time
provid
insight
expect
size
impact
ferritin
deferr
polici
time
rate
impact
expect
occur
allow
blood
bank
time
plan
action
counterbal
possibl
donor
shortag
ensur
adequ
blood
suppli
lastli
iron
supplement
altern
measur
instead
donat
deferr
use
recommend
dosag
iron
supplement
vari
wide
across
blood
servic
sanquin
plan
start
new
studi
whole
blood
donor
gain
evid
dosag
frequenc
iron
supplement
effect
ferritin
hemoglobin
level
donor
health
result
beforement
studi
ongo
result
expect
onward
summaryconclus
iron
defici
frequent
side
effect
whole
blood
donat
prevent
iron
defici
consequ
like
donat
deferr
health
issu
evidencebas
insight
iron
manag
whole
blood
donor
gener
superdonor
genet
risk
profil
risk
low
hemoglobin
deferr
background
reliabl
method
exist
stratifi
new
blood
donor
maintain
suffici
hemoglobin
hb
level
defer
low
hb
mmoll
gdl
women
mmoll
gdl
men
polygen
risk
score
prss
shown
great
promis
predict
complex
diseas
risk
prss
could
also
prove
use
identif
donor
genet
predispos
low
hb
level
thu
increas
risk
deferr
aim
object
studi
evalu
associ
pr
model
predict
hb
level
quantit
trait
risk
deferr
binari
outcom
method
danish
blood
donor
studi
dbd
ongo
nationwid
blood
donor
cohort
sinc
particip
extens
genotyp
perform
approxim
dbd
particip
use
infinium
global
screen
array
illumina
extend
use
imput
base
panscandinavian
refer
genom
base
hb
genet
data
iceland
individu
independ
discoveri
cohort
construct
differ
weight
prss
individu
dbd
inform
donor
whole
blood
donat
follow
inclus
dbd
unto
end
obtain
nationwid
donat
databas
scandat
best
predictor
hb
among
nine
prss
chosen
use
subsequ
analys
perform
multilevel
mixedeffect
linear
regress
analysi
hb
outcom
pr
factor
explanatori
variabl
cutoff
th
percentil
respect
moreov
model
twolevel
cluster
donor
id
donat
site
idspecif
random
intercept
adjust
sex
binari
age
continu
year
donat
factor
time
sinc
last
donat
continu
lastli
risk
deferr
evalu
random
effect
logit
model
similar
covari
cluster
structur
result
mean
number
donat
per
donor
dbd
inclus
donat
gener
observ
statist
signific
posit
associ
pr
hb
current
hb
level
compar
donor
pr
percentil
group
donor
th
percentil
lower
hb
mmoll
ci
donor
th
percentil
higher
hb
mmoll
ci
hb
level
random
effect
logit
model
observ
mark
increas
deferr
risk
decreas
pr
percentil
strata
pr
percentil
stratum
refer
donor
th
percentil
donor
th
percentil
odd
ratio
deferr
ci
ci
respect
summaryconclus
found
statist
signific
posit
associ
pr
hb
hb
level
markedli
increas
risk
deferr
decreas
pr
hb
scientif
point
view
unsurpris
genet
score
hb
independ
cohort
associ
hb
anoth
cohort
howev
practic
perspect
prss
may
first
step
person
donat
approach
donor
risk
deferr
background
individu
calibr
interdon
interv
repeat
blood
donor
potenti
minim
risk
iron
relat
advers
outcom
eg
hemoglobin
deferr
collect
donat
donor
low
absent
iron
store
without
unduli
impact
donat
blood
suppli
machin
learn
shown
promis
person
clinic
risk
assess
aim
aim
use
machin
learn
develop
donorspecif
person
interdon
interv
minim
risk
advers
outcom
maintain
improv
adequaci
donat
blood
suppli
method
use
public
use
dataset
redsii
donor
iron
statu
evalu
rise
studi
cabl
transfus
defin
donor
profil
physiolog
measur
includ
hemoglobin
ferritin
solubl
transferrin
receptor
along
questionnair
respons
regard
diet
reproduct
health
indic
demograph
use
profil
featur
donat
repeat
donor
time
next
donat
attempt
predict
ironrel
outcom
next
donat
attempt
possibl
outcom
advers
outcom
hemoglobin
deferr
lowiron
donat
ferritin
ngml
women
ngml
men
absentiron
donat
ferritin
ngml
men
women
train
multipl
machin
learn
model
donat
select
model
best
perform
lowest
crossentropi
loss
cross
valid
assess
best
model
perform
holdout
test
set
donat
use
train
select
model
use
model
gener
risk
estim
test
donor
function
day
sinc
last
donat
vari
day
day
show
individu
variat
gener
graphic
represent
individu
donor
risk
time
result
ferritin
log
ferritin
bodi
iron
time
sinc
last
donat
use
predict
ironrel
advers
outcom
next
donat
attempt
estim
risk
advers
outcom
next
donat
attempt
vari
consider
across
donor
expect
risk
advers
outcom
day
last
donat
lower
risk
day
last
donat
donor
risk
hemoglobin
deferr
decreas
donor
risk
lowiron
donat
decreas
risk
absentiron
donat
decreas
summaryconclus
risk
ironrel
advers
outcom
function
time
sinc
last
donat
vari
consider
donor
machin
learn
model
train
relev
donor
profil
effect
estim
individu
risk
chang
time
individu
risk
estim
could
allow
blood
center
protect
highrisk
repeat
donor
continu
allow
frequent
collect
lowrisk
donor
studi
need
ensur
approach
work
well
donor
class
wellrepres
rise
dataset
assess
risk
predict
outsid
physiolog
measur
collect
rise
studi
determin
viabil
assign
optim
interdon
interv
firsttim
donor
use
approach
background
iron
deplet
common
among
repeat
blood
donor
contribut
larg
proport
blood
suppli
mani
countri
exogen
iron
multivitamin
iron
irononli
supplement
help
prevent
donationinduc
iron
deplet
whether
dietari
iron
protect
iron
deplet
repeat
donor
rigor
evalu
avail
data
redsii
rise
studi
us
cabl
transfus
danish
blood
donor
studi
riga
transfus
suggest
minor
impact
dietari
iron
consumpt
blood
donor
iron
statu
multivari
regress
model
studi
howev
analyz
food
item
singli
beef
fish
rather
aggreg
precis
limit
aim
evalu
whether
composit
measur
dietari
heme
iron
consumpt
weight
frequenc
iron
content
associ
incid
iron
deplet
among
repeat
blood
donor
method
reanalysi
rise
cohort
undertaken
test
hypothesi
report
level
anim
protein
consumpt
associ
lower
risk
incid
iron
deplet
among
repeat
blood
donor
six
blood
center
particip
rise
enrol
firsttim
frequent
donor
month
followup
donat
frequenc
iron
statu
brief
checklist
food
categori
administ
baselin
assess
frequenc
consumpt
sever
categori
anim
protein
rich
heme
iron
biochem
form
iron
readili
absorb
iron
composit
score
ic
weight
frequenc
heme
iron
content
deriv
subject
group
tertil
third
ic
iron
statu
assay
enrol
studi
complet
roughli
onethird
donat
visit
modifi
poisson
regress
gener
estim
equat
use
gener
risk
ratio
control
donat
frequenc
covari
result
enrol
donor
iron
replet
baselin
complet
food
checklist
median
valu
ic
tertil
lowest
highest
mg
heme
iron
weekli
valu
equival
approxim
serv
beef
per
week
altern
twice
mani
serv
chicken
pork
across
followup
visit
iron
outcom
assay
almost
donor
visit
associ
intermedi
iron
deplet
serum
ferritin
ngml
complet
deplet
iron
store
repres
serum
ferritin
ngml
control
demograph
factor
donat
frequenc
lowest
tertil
ic
associ
greater
higher
risk
complet
iron
deplet
followup
visit
rr
ci
compar
highest
tertil
summaryconclus
longitudin
evalu
dietari
iron
iron
statu
blood
donor
low
intak
heme
iron
elev
risk
develop
advanc
iron
deplet
result
suggest
blood
center
continu
recommend
ironrich
diet
repeat
blood
donor
background
blood
donor
lose
approxim
mg
iron
everi
blood
donat
result
frequent
blood
donor
risk
iron
defici
low
hemoglobin
hb
level
may
affect
health
elig
donat
lifestyl
behavior
dietari
iron
intak
physic
activ
may
influenc
iron
store
therebi
hb
level
gain
insight
associ
lifestyl
behavior
hb
level
valuabl
blood
suppli
organ
lifestyl
behavior
potenti
consid
prevent
hb
deferr
examin
mediat
role
ferritin
measur
reflect
iron
store
associ
help
gain
insight
whether
iron
store
could
limit
enabl
factor
link
lifestyl
behavior
hb
recoveri
donat
aim
investig
associ
lifestyl
behavior
dietari
heme
nonhem
iron
intak
physic
activ
hb
level
whether
ferritin
mediat
associ
method
donor
insightiii
disiii
dutch
cohort
studi
blood
plasma
donor
includ
donor
particip
pregnant
hemochromatosi
use
iron
supplementsmed
got
hysterectomi
bilater
oophorectomi
exclud
n
hb
level
measur
edta
whole
blood
sampl
use
hematolog
analyz
sysmex
japan
ferritin
measur
plasma
lithium
heparin
tube
architect
abbott
laboratori
usa
dietari
heme
nonhem
iron
intak
gramsday
assess
use
food
frequenc
questionnair
adapt
measur
iron
intak
moderatetovigor
physic
activ
mvpa
minutesday
assess
use
intern
physic
activ
questionnair
ipaq
short
form
result
total
femal
particip
includ
donor
higher
intak
heme
iron
significantli
higher
hb
level
regress
coeffici
b
confid
interv
ci
men
women
respect
mmoll
independ
age
smoke
menstruat
number
donat
previou
two
year
donat
interv
sedentari
behavior
lifestyl
variabl
ie
non
heme
iron
intak
mvpa
initi
hb
level
nonhem
iron
intak
neg
associ
hb
level
mmoll
men
women
respect
ferritin
mediat
associ
dietari
iron
intak
hb
level
indirect
effect
men
women
respect
lgl
heme
nonhem
mvpa
neg
associ
hb
level
men
mediat
ferritin
summaryconclus
conclus
higher
heme
lower
nonhem
iron
consumpt
associ
higher
hb
level
donor
via
higher
ferritin
level
indic
donor
high
heme
iron
consumpt
may
capabl
maintain
iron
store
recov
hb
level
blood
donat
mvpa
associ
lower
hb
level
although
effect
size
small
independ
ferritin
take
donor
lifestyl
behavior
account
may
use
prevent
low
hb
level
blood
donor
immun
thrombocytopenia
itp
still
diagnos
exclus
caus
thrombocytopenia
sensit
specif
detect
platelet
autoantibodi
may
support
clinic
diagnosi
prevent
misdiagnosi
itp
exampl
direct
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
perform
vivo
sensit
patient
platelet
offer
platelet
glycoprotein
specif
autoantibodi
detect
high
accuraci
drawback
low
platelet
count
demand
larg
blood
sampl
suffici
patient
platelet
avail
analysi
circul
platelet
autoantibodi
difficult
detect
maipa
may
demand
sensit
detect
platform
use
surfac
plasmon
reson
gener
presenc
antigpiibiiia
antigpibix
antigpv
platelet
autoantibodi
investig
antibodi
specif
found
patient
itp
itp
platelet
autoantibodymedi
destruct
via
spleen
propos
also
mechan
lead
low
platelet
count
itp
may
play
role
inhibit
megakaryocytopoiesi
autoantibodi
cell
suggest
mice
gpibdirect
antibodi
induc
loss
plateletsugar
epitop
induc
hepatocytemed
platelet
destruct
platelet
autoantibodi
caus
complement
activ
may
contribut
platelet
autoantibodymedi
destruct
interestingli
recent
found
lack
detect
platelet
autoantibodi
correl
nonrespons
rituximab
moab
treatment
itp
patient
children
newli
diagnos
often
transient
itp
platelet
autoantibodi
igg
class
often
found
igm
class
present
short
durat
conclus
test
platelet
autoantibodi
characterist
patholog
effect
may
help
establish
diagnosi
itp
choos
best
individu
therapi
itp
patient
thrombopoietin
receptor
agonist
tpora
treatment
rais
platelet
count
induc
immunomodul
immun
thrombocytopenia
itp
jw
sempl
r
aslam
e
speck
j
rebetz
r
kapur
lund
univers
lund
sweden
st
michael
hospit
toronto
canada
background
itp
autoimmun
bleed
disord
autoantibodi
autoreact
cell
target
destruct
platelet
megakaryocyt
spleen
bone
marrow
sever
therapeut
option
eg
corticosteroid
intraven
immunoglobulin
ivig
rituximab
splenectomi
avail
patient
inadequ
efficaci
side
effect
andor
expens
make
undesir
last
year
tpora
eg
romiplostim
eltrombopag
made
substanti
contribut
treatment
itp
patient
refractori
firstlin
treatment
interest
approxim
patient
taper
tpora
therapi
show
sustain
respons
eg
stabl
higher
platelet
count
treatment
mechan
tpora
induc
sustain
respons
unknown
aim
analyz
efficaci
immunomodulatori
properti
murin
tpora
amgen
wellestablish
murin
model
itp
demonstr
antibodyand
cellmedi
thrombocytopenia
chow
l
et
al
blood
method
platelet
glycoprotein
gp
iiia
knockout
ko
mice
immun
platelet
itp
initi
transfer
splenocyt
mice
sever
combin
immunodefici
scid
scid
mice
treat
either
placebo
tpora
weekli
platelet
count
serum
antiplatelet
antibodi
measur
weekli
result
initi
pilot
dose
escal
studi
control
scid
mice
treat
singl
subcutan
bolu
differ
concentr
murin
tpora
ugkg
significantli
higher
platelet
count
h
post
infus
addit
compar
untreat
mice
bone
marrow
histolog
reveal
significantli
increas
number
megakaryocyt
maxim
platelet
count
increas
observ
highest
tpora
dose
dose
chosen
treat
scid
mice
suffer
itp
scid
mice
treat
weekli
inject
tpora
platelet
count
began
increas
week
fulli
rescu
control
level
week
post
splenocyt
transfer
interest
compar
nontreat
itp
mice
serum
igg
antiplatelet
antibodi
product
tpotreat
mice
significantli
reduc
start
two
week
post
splenocyt
infus
summaryconclus
result
suggest
murin
tpora
efficaci
therapi
murin
itp
also
induc
immunomodul
indic
immunosuppress
thu
model
may
abl
elucid
mechan
tpora
induc
immunosuppress
patient
itp
background
desialyl
loss
sialic
acid
content
platelet
plt
glycoprotein
gp
recent
identifi
contribut
immun
thrombocytopenia
itp
howev
potenti
impact
autoantibodi
aab
megakaryocyt
sialyl
remain
unclear
aim
investig
effect
itp
aab
plt
megakaryocyt
mk
sialyl
subsequ
impact
plt
surviv
method
aab
wellcharacteris
itp
patient
induc
gpmodif
test
use
lectin
bind
assay
incub
mk
plt
itp
control
sera
glycan
chang
analys
flow
cytometri
fc
investig
impact
desialyl
plt
lifespan
nodscid
mous
model
use
result
itp
sera
investig
studi
sera
induc
signific
increas
rca
signal
plt
surfac
compar
control
sera
healthi
donor
rcamean
fold
increas
rcafi
rang
p
addit
sera
caus
higher
ecl
bind
test
plt
eclfi
rang
p
inject
desialyl
aab
result
acceler
clearanc
human
plt
circul
nodscid
mice
significantli
reduc
specif
neuraminidas
inhibitor
prevent
background
autoimmun
hemolyt
anemia
aiha
rare
autoimmun
diseas
characteris
hemolysi
associ
presenc
immunoglobulin
igg
igm
iga
andor
compon
complement
system
red
blood
cell
rbc
usual
demonstr
posit
direct
antiglobulin
test
dat
depend
presenc
underli
disord
aiha
subdivid
primari
secondari
temperatur
autoantibodi
bind
optim
rbc
warm
antibodi
aiha
waiha
mix
aiha
includ
warm
igg
cold
igm
antibodi
cold
agglutinin
diseas
cad
paroxysm
cold
hemoglobinuria
pch
dat
neg
aiha
frequent
find
immunohematolog
presenc
autoantibodi
rbc
without
clinic
symptom
hemolysi
may
later
develop
aim
aim
studi
analys
serolog
find
transfus
support
patient
aiha
also
analys
dat
posit
patient
without
clinic
symptom
method
includ
data
adult
patient
aiha
dat
posit
patient
without
clinic
symptom
diagnos
andor
treat
univers
hospit
centr
uhc
zagreb
croatia
period
diagnosi
aiha
defin
anemia
featur
hemolysi
elev
bilirubin
elev
lactat
dehydrogenas
andor
low
haptoglobin
level
posit
dat
result
data
patient
women
meet
inclus
criteria
analys
mean
age
time
aiha
year
rang
year
mean
hg
level
diagnosi
gl
dat
result
posit
mostli
igg
patient
warm
aiha
type
aiha
diagnos
mix
aiha
cad
pch
dat
neg
aiha
case
alloantibodi
detect
autoantibodi
patient
plasma
patient
treat
corticosteroid
line
therapi
intraven
immunoglobulin
ivig
sever
refractori
patient
rituximab
andor
splenectomi
appli
total
patient
transfus
mean
hemoglobin
level
gl
period
detect
dat
posit
patient
without
clinic
symptom
summaryconclus
patient
studi
diagnos
warm
type
aiha
follow
mix
type
aiha
cad
hand
pch
dat
neg
aiha
rare
concord
relev
literatur
patient
transfus
despit
therapi
use
desir
patient
aiha
better
control
especi
moder
case
anemia
rare
necessari
signific
number
patient
dat
posit
without
clinic
symptom
may
later
develop
aiha
close
monitor
background
autoimmun
haemolyt
anaemia
aiha
decompens
acquir
haemolysi
caus
host
immun
system
act
red
cell
antigen
aiha
rare
disord
although
british
societi
haematolog
bsh
guidelin
diagnosi
treatment
publish
februari
littl
evid
clinic
practic
unit
kingdom
aim
investig
approach
diagnosi
investig
manag
patient
aiha
english
nh
trust
method
survey
diagnost
manag
practic
design
pilot
dissemin
clinic
transfus
lead
english
acut
nh
trust
novemb
march
complet
consult
haematologist
treat
patient
aiha
respons
repres
department
consensu
encourag
result
respons
repres
english
acut
trust
median
number
adult
aiha
diagnos
annual
preced
year
recal
least
one
patient
die
due
aiha
although
undertook
bone
marrow
biopsi
patient
requir
addit
featur
mainli
neoplasia
age
treatmentrefractori
patient
suspect
druginduc
immun
haemolysi
would
organis
confirmatori
test
either
consid
unnecessari
clinician
unsur
access
test
determin
aiha
subtyp
indic
circumst
would
undertak
cold
antibodi
test
antibodi
titr
andor
thermal
amplitud
consid
unnecessari
unsur
access
test
clinic
scenario
patient
aiha
dat
posit
ae
igg
ae
cold
associ
symptom
respond
would
test
cold
antibodi
first
line
treatment
primari
warm
aiha
mean
durat
prednisolon
mgkg
given
judg
patient
refractori
reduc
dose
week
sd
rang
week
second
line
treatment
choic
rituximab
respond
splenectomi
intraven
immunoglobulin
splenectomi
cite
rescu
therapi
primari
cold
haemagglutinin
diseas
chad
first
line
treatment
rituximabbas
singl
agent
steroid
also
explor
potenti
futur
audit
research
respond
abl
identifi
patient
aiha
previous
requir
transfus
respond
would
consid
support
registri
patient
aiha
requir
transfus
key
question
respond
thought
registri
address
morbid
mortal
treatment
respons
differ
diagnosi
treatment
aiha
subtyp
uncertainti
access
cold
druginduc
antibodi
test
clinician
alway
conduct
bshrecommend
cold
antibodi
test
aiha
posit
dat
initi
treatment
primari
warm
aiha
chad
broadli
match
bsh
guidelin
although
would
continu
prednisolon
mgkg
beyond
recommend
day
start
taper
greater
toxic
risk
summaryconclus
find
support
need
rang
research
initi
includ
creation
aiha
registri
preoper
anemia
common
associ
advers
outcom
periop
period
preoper
anemia
also
increas
risk
allogen
blood
transfus
may
lead
increas
periop
mortal
increas
hospit
length
stay
infect
diagnosi
treatment
anemia
one
tenet
patient
blood
manag
pbm
along
reduct
unnecessari
transfus
diagnost
phlebotomi
well
use
hemostat
agent
reduc
bleed
among
mani
other
effect
pbm
multidisciplinari
multimod
time
individu
patientcent
earli
referr
pbm
multimod
pbm
intervent
associ
greater
improv
preoper
hemoglobin
pbm
shown
reduc
transfus
cost
systemwid
multimod
program
may
also
associ
improv
mortal
use
exampl
local
research
practic
discuss
three
aspect
pbm
iron
erythropoiesi
stimul
agent
esa
effect
safe
use
extens
manag
preoper
anemia
previou
studi
question
whether
esa
lead
increas
risk
thrombosi
howev
recent
systemat
review
support
concern
anoth
pbm
approach
reduc
bleed
surgeri
use
hemostat
agent
tranexam
acid
txa
txa
reduc
transfus
requir
knee
hip
arthroplasti
safe
wide
avail
rel
cheap
txa
effect
anem
nonanem
patient
make
attract
univers
pbm
strategi
final
recommend
evidencebas
guidelin
pbm
exist
includ
recent
intern
guidelin
develop
pbm
intern
consensu
confer
howev
knowledg
translat
pbm
problem
number
barrier
implement
identifi
includ
perceiv
actual
lack
expertis
time
resourc
well
lack
physician
patient
engag
one
way
address
patient
engag
educ
charact
driven
anim
current
tri
approach
low
vs
high
hemoglobin
trigger
transfus
vascular
surgeri
tv
random
clinic
feasibl
trial
tv
trial
background
current
guidelin
advoc
limit
redcel
transfus
surgeri
feasibl
safeti
strategi
remain
unclear
major
evid
base
postop
stabl
patient
aim
assess
effect
protocol
aim
restrict
redcel
transfus
elect
vascular
surgeri
method
fiftyeight
patient
schedul
lower
limbbypass
open
surgeri
abdomin
aortic
aneurysm
random
lowtrigg
hemoglobin
g
dl
mmoll
vs
hightrigg
hemoglobin
gdl
mmoll
redcel
transfus
throughout
hospit
intraop
chang
cerebraland
muscl
tissu
oxygen
assess
nearinfrar
spectroscopi
use
nationwid
registri
collect
data
death
major
cardiovascular
event
encompass
sever
advers
transfus
reaction
acut
myocardi
infarct
stroke
newonset
renal
replac
therapi
vascular
reoper
amput
lower
limb
result
primari
outcom
mean
hemoglobin
within
day
surgeri
significantli
lower
lowtrigg
group
gdl
vs
gdl
hightrigg
group
mean
differ
gdl
p
longitudin
analysi
unit
redcel
transfus
background
control
nonhematooncolog
studi
consist
demonstr
singleunit
red
blood
cell
rbc
transfus
polici
well
stringent
hemoglobin
hb
rbc
transfus
threshold
safe
reduc
blood
product
util
yet
unclear
whether
conclus
also
appli
hematooncolog
patient
popul
aim
quantifi
reduct
rbc
blood
product
util
introduct
restrict
singleunit
hbtrigger
rbc
transfus
polici
among
inpati
hematooncolog
popul
method
liber
transfus
protocol
appli
till
novemb
standard
doubleunit
rbc
transfus
indic
hb
threshold
gdl
andor
anemiarel
symptom
follow
date
restrict
transfus
protocol
introduc
involv
lower
threshold
gdl
singleunit
transfus
patient
asascor
iiiii
iv
hb
threshold
respect
gdl
gdl
appli
evalu
rbc
blood
product
util
month
period
start
decemb
liber
protocol
decemb
restrict
protocol
hematooncolog
patient
admit
chemotherapeut
treatment
includ
hematopoiet
stem
cell
transplant
hsct
expect
durat
neutropenia
day
analysi
categor
continu
data
perform
use
chisquar
mannwhitney
test
respect
result
observ
period
patient
admit
total
receiv
therapi
cycl
includ
acut
myeloid
leukemia
aml
induct
cycl
autolog
hsct
distribut
indic
admitt
median
age
durat
hospit
durat
neutropenia
differ
period
restrict
period
transfus
assign
hb
trigger
adher
percentag
singleunit
transfus
episod
increas
introduct
restrict
protocol
overal
rbc
blood
product
util
per
admitt
reduc
restrict
protocol
cumul
number
transfus
rbc
unit
interquartil
rang
iqr
liber
versu
iqr
restrict
period
p
howev
rbc
blood
product
util
per
neutropen
day
demonstr
trend
toward
reduct
iqr
versu
iqr
unit
per
day
liber
versu
restrict
period
respect
p
reduct
mainli
attribut
autolog
hsct
rbc
blood
product
util
decreas
iqr
iqr
unit
p
correspond
reduct
iqr
iqr
p
unit
per
neutropen
day
moreov
patient
liber
versu
restrict
period
requir
rbc
transfus
admitt
consequ
stringent
hb
threshold
compar
singleunit
transfus
seem
strongli
impact
rbc
blood
product
util
summaryconclus
hbtrigger
singleunit
transfus
polici
result
strong
reduct
rbc
blood
product
util
set
autolog
hsct
util
reduct
observ
among
hematooncolog
inpati
popul
receiv
intens
chemotherapi
improv
protocol
adher
rate
could
potenti
increas
benefit
blood
save
strategi
assess
hb
content
pack
red
cell
prbc
time
label
unit
hb
content
r
jain
n
marwaha
sachdev
transfus
medicin
aiim
new
delhi
transfus
medicin
pgimer
chandigarh
india
background
current
era
evid
base
medicin
individu
care
patient
rbc
transfus
continu
administ
basi
convent
wisdom
notion
averag
benefit
per
unit
exist
blood
transfus
practic
base
number
unit
transfus
ignor
fact
total
hb
vari
markedli
among
individu
rbc
unit
aim
present
studi
aim
estim
hb
content
pack
red
cell
unit
prepar
three
differ
protocol
ml
ml
whole
blood
collect
three
type
blood
donor
replac
blood
donor
rd
first
time
voluntari
donor
ftvd
regular
voluntari
blood
donor
rtvd
method
total
prospect
blood
donor
includ
studi
three
hundr
whole
blood
collect
perform
three
group
donor
rd
ftvd
rtvd
within
group
collect
done
doubl
ml
tripl
ml
quadrupl
ml
blood
bag
respect
predon
venou
sampl
drawn
sampl
collect
pouch
analysi
hematolog
analyz
refer
method
hb
concentr
donor
hb
content
pack
red
cell
unit
estim
collect
repres
sampl
blood
unit
volum
prbc
unit
estim
formula
weight
blood
prbc
divid
specif
graviti
hb
content
unit
estim
formula
hb
content
unit
hb
valu
prbc
unit
gdl
volum
prbc
unit
dl
result
studi
hb
concentr
gdl
compar
among
three
type
blood
donor
except
rtvd
lower
hb
valu
compar
rd
p
hemoglobin
concentr
prbc
rang
gdl
mean
hb
ae
gdl
net
hb
content
prbc
bag
lower
prbc
prepar
rd
compar
ftvd
p
rtvd
p
hb
content
prbc
unit
prepar
ml
collect
rang
g
ml
collect
rang
g
observ
wide
rang
net
hb
content
prbc
unit
correl
coeffici
show
strongest
associ
net
hb
content
prbc
unit
overal
volum
prbc
r
p
higher
volum
prbc
hb
content
volum
prbc
bag
studi
rang
ml
ml
includ
ml
collect
summaryconclus
present
studi
show
label
hb
content
prbc
unit
help
better
inventori
manag
patient
hb
content
may
help
decis
make
releas
unit
paediatriclow
weight
versu
adult
higher
weight
patient
adopt
polici
optim
dosag
rbc
transfus
could
potenti
significantli
improv
rbc
util
decreas
patient
exposur
allogen
blood
would
help
clinic
transfus
practic
base
evid
nv
p
desai
rajadhyaksha
navkudkar
n
deshpand
transfus
medicin
tata
memori
centr
homi
bhabha
nation
institut
mumbai
india
background
red
blood
cell
rbc
transfus
import
medic
therapi
benefit
patient
wide
spectrum
clinic
set
critic
ill
intens
care
unit
patient
particular
well
medic
hematooncolog
patient
among
largest
group
user
rbc
period
review
blood
compon
usag
essenti
assess
blood
util
pattern
hospit
health
care
set
institut
bed
tertiari
care
oncolog
centr
approxim
rbc
transfus
annual
transfus
requir
variou
stage
patient
treatment
like
chemotherapi
radiotherapi
surgic
palli
care
establish
guidelin
institut
follow
clinician
aim
studi
clinic
practic
rbc
transfus
base
indic
evalu
appropri
rbc
util
practic
institut
method
prospect
observ
studi
start
approv
institut
ethic
committe
total
rbc
transfus
event
adult
patient
period
four
month
includ
analyz
per
institut
guidelin
appropri
detail
transfus
event
form
pre
transfus
hemoglobin
indic
transfus
type
request
number
unit
request
issu
time
issu
site
transfus
advers
reaction
etc
obtain
depart
transfus
medicin
record
overal
statist
analysi
descript
use
spss
softwar
chisquar
test
cross
tabl
appli
see
relationship
differ
variabl
consid
signific
pvalu
result
total
rbc
transfus
event
patient
analyz
event
patient
medic
oncolog
patient
surgic
oncolog
maximum
transfus
receiv
patient
age
group
year
total
transfus
event
appropri
per
institut
guidelin
transfus
administ
oper
theatr
found
appropri
p
valu
inappropri
signific
daycar
setup
p
anemia
common
indic
rbc
transfus
observ
event
total
rbc
transfus
given
plan
urgent
transfus
common
advers
transfus
event
observ
allerg
reaction
total
transfus
reaction
summaryconclus
clinic
practic
rbc
transfus
hospit
larg
found
appropri
ration
adher
institut
guidelin
blood
util
audit
conduct
regularli
transfus
servic
result
discuss
clinician
ensur
judici
use
scarc
resourc
concept
transfus
safeti
offic
tso
introduc
better
coordin
clinician
blood
transfus
servic
improv
practic
paulehrlichinstitut
langen
germani
global
scale
blood
servic
quit
divers
regard
aspect
like
organis
structur
regulatori
background
donor
popul
donat
rate
pathogen
epidemiolog
world
health
organ
recogn
blood
blood
product
essenti
medicin
provid
guidanc
member
state
variou
aspect
like
blood
regul
best
practic
blood
collect
transfus
screen
paramet
recent
guidelin
residu
risk
transfus
associ
infect
establish
may
facilit
decisionmak
appropri
screen
algorithm
emphas
need
region
evalu
screen
assay
regulatori
control
bloodassoci
ivd
background
babesia
protozoan
parasit
infect
red
blood
cell
lead
infecti
caus
mortal
us
transfus
recipi
babesia
usual
transmit
bite
infect
tick
may
transfus
transmit
tt
transmit
mother
child
pregnanc
babesiosi
worldwid
diseas
tick
carri
babesia
global
distribut
babesiosi
report
throughout
europ
canada
korea
india
japan
prospect
test
blood
donat
endem
area
us
reveal
donor
posit
babesia
dna
antibodi
moritz
nejm
aim
report
result
ongo
babesia
clinic
trial
explain
signific
babesia
tt
infect
method
coba
babesia
use
coba
system
qualit
polymeras
chain
reaction
nucleic
acid
amplif
test
develop
detect
whole
blood
wb
donor
sampl
babesia
speci
caus
human
diseas
b
microti
b
duncani
b
divergen
b
venatorum
test
began
octob
us
fdaapprov
investig
new
drug
applic
wb
collect
proprietari
medium
lyse
red
blood
cell
stabil
babesia
rna
dna
donat
collect
state
high
low
babesia
endem
screen
individu
blood
donor
idt
sampl
reactiv
index
donat
retest
simul
minipool
plu
idt
replic
coba
babesia
reactiv
index
donat
also
test
valid
altern
babesia
nat
b
microti
igm
igg
antibodi
donor
reactiv
result
invit
enrol
followup
studi
test
addit
evid
infect
result
date
valid
donat
screen
coba
babesia
reactiv
initiallyreact
donat
confirm
posit
babesia
posit
altern
nat
serolog
result
confirmedposit
donat
collect
state
low
babesia
endem
pennsylvania
collect
state
babesia
consid
endem
iowa
confirm
posit
donat
collect
state
high
endem
confirm
babesiaposit
donat
detect
late
fall
winter
confirm
babesiaposit
donat
reactiv
serolog
result
avail
confirmedposit
donat
index
confirm
babesiaposit
donat
iggposit
none
igmposit
posit
igg
igm
confirmedbabesia
posit
donat
neg
igg
igm
antibodi
coba
babesia
show
overal
specif
exact
ci
summaryconclus
coba
babesia
test
success
identifi
babesiaposit
donat
includ
confirmedposit
donat
igm
igg
reactiv
donat
collect
state
consid
lowor
nonendem
babesia
confirmedposit
donat
collect
outsid
summer
babesia
season
clinic
case
occur
screen
coba
babesia
continu
sever
laboratori
coba
babesia
fda
licens
avail
commerci
background
babesiosi
human
caus
erythrocyt
protozoan
parasit
babesia
microti
transmit
tick
bite
also
transfus
transmit
although
frequent
asymptomat
present
flulik
symptom
normal
host
immunocompromis
infect
lead
sever
complic
death
b
microti
endem
north
easternupp
midwest
unit
state
partial
test
donat
implement
canada
studi
donor
identifi
b
microti
antibodyposit
sampl
suggest
low
risk
time
risk
monitor
aim
evalu
preval
b
microtiposit
donat
potenti
atrisk
area
canada
method
juli
novemb
blood
donor
sampl
select
site
near
us
border
minipool
test
b
microti
nucleic
acid
transcript
mediat
amplif
tma
use
procleix
babesia
assay
panther
system
individu
test
reactiv
pool
reactiv
donat
also
test
b
microtispecif
american
red
cross
arc
igg
immunofluoresc
assay
ifa
imugen
ifapcr
subset
tmaneg
sampl
primarili
provinc
manitoba
eastward
nova
scotia
test
b
microti
antibodi
use
arc
ifa
posit
imugen
ifapcr
donor
age
sex
donat
statu
residenti
locat
collect
site
locat
record
donor
test
reactiveposit
inform
defer
ask
risk
factor
possibl
tick
exposur
travel
within
canada
usa
elsewher
histori
symptom
followup
sampl
request
supplement
test
tma
arc
ifa
reactiv
donat
remov
inventori
result
donor
sampl
proport
collect
target
geograph
region
age
group
sex
donat
statu
also
similar
donor
base
collect
area
one
sampl
winnipeg
manitoba
tma
reactiv
antibodi
posit
supplementari
test
donor
rememb
symptom
spend
time
wood
area
visit
citi
fargo
north
dakota
usa
subset
sampl
test
antibodi
also
proport
collect
target
area
four
antibodyposit
sampl
identifi
midseptemb
octob
south
western
ontario
near
lake
eri
none
tma
reactiv
three
interview
none
rememb
symptom
like
tick
exposur
relev
travel
within
canada
usa
summaryconclus
largest
b
microti
preval
studi
canada
result
indic
low
preval
tmaconfirmedposit
donat
test
donor
region
canada
one
autochthon
human
case
report
activ
tick
surveil
identifi
b
microti
posit
tick
popul
seroposit
donat
south
western
ontario
may
suggest
low
preval
region
interpret
less
certain
due
lack
corrobor
supplementari
result
case
histori
given
close
proxim
us
border
forgotten
us
travel
rule
background
protozoan
parasit
toxoplasma
gondii
preval
anim
human
worldwid
wild
domest
felid
definit
host
homoeotherm
anim
serv
intermedi
one
primari
infect
parasit
persist
lifelong
within
latent
tissu
cyst
transmiss
ingest
undercook
raw
meat
infect
cyst
ingest
food
water
contamin
oocyst
transplacent
howev
also
acquir
blood
transfus
organ
transplant
toxoplasmosi
sever
diseas
immunosuppress
peopl
neonat
whose
mother
acquir
primari
infect
pregnanc
aim
inform
specif
epidemiolog
gondii
infect
blood
donor
portug
therefor
sought
determin
seropreval
gondii
associ
risk
factor
popul
blood
donor
portug
method
septemb
juli
blood
donor
attend
portugues
blood
transplant
institut
blood
bank
locat
oporto
coimbra
lisbon
also
region
blood
collect
meet
invit
particip
studi
written
inform
consent
obtain
questionnair
sociodemograph
behaviour
variabl
answer
sera
assess
igg
antibodi
gondii
modifi
agglutin
test
mat
commerci
kit
toxoscreen
da
biom
erieux
lyon
franc
result
blood
donor
mean
age
ae
rang
year
old
posit
antibodi
gondii
question
toxoplasmosi
almost
half
blood
donor
knowledg
diseas
centr
portug
highest
seropreval
follow
north
south
blood
donor
live
rural
area
significantli
higher
seropreval
p
live
urban
area
seropreval
increas
age
highest
seropreval
found
age
group
year
old
multipl
logist
regress
mlr
ci
p
decreas
educ
level
p
engag
soilrel
activ
garden
agricultur
significantli
relat
gondii
seroposit
p
regard
water
consumpt
untreat
sourc
even
though
includ
miner
tap
water
confirm
risk
factor
mlr
ci
p
behaviour
eat
characterist
includ
cat
household
eat
raw
undercook
meat
process
pork
product
wash
raw
fruit
veget
eat
associ
gondii
infect
summaryconclus
risk
gondii
transmiss
blood
transfus
low
serolog
test
antibodi
exclus
blood
donor
appear
feasibl
immunosuppress
individu
organ
transplant
patient
pregnant
women
receiv
gondii
antibodyneg
blood
compon
transfus
studi
explor
epidemiolog
gondii
portug
thu
provid
use
inform
seropreval
potenti
risk
factor
gondii
transmiss
inform
regard
toxoplasmosi
prevent
could
promot
medic
public
health
author
among
blood
donor
also
gener
popul
address
polici
design
screen
program
monitor
control
infect
diseas
portug
syphili
test
exclud
c
reynold
c
pearson
k
davison
brailsford
nhsbtphe
epidemiolog
unit
nh
blood
transplant
nhsbtphe
epidemiolog
unit
public
health
england
london
unit
kingdom
background
screen
treponem
antibodi
detect
syphili
blood
donor
place
england
sinc
report
syphili
transfus
transmiss
england
sinc
record
began
part
due
sensit
organ
cold
storag
sinc
specif
test
place
sexual
transmit
infect
hiv
hepat
b
viru
hbv
util
syphili
screen
often
question
howev
may
use
proxi
higher
risk
behaviour
particularli
follow
shorten
deferr
higher
risk
sexual
behaviour
month
novemb
background
increas
infecti
syphili
gener
popul
aim
describ
epidemiolog
recentlyacquir
syphili
blood
donor
england
compar
hiv
acut
hbv
infect
method
monthli
donat
test
result
collect
nh
blood
transplant
nhsbt
screen
centr
refer
laboratori
demograph
possibl
sourc
infect
complianc
donor
select
confirm
posit
donor
collect
proforma
posttest
discuss
nhsbt
clinic
team
recent
syphili
classifi
igm
posit
andor
recent
histori
includ
neg
donat
within
month
regular
donor
result
recent
syphili
case
hiv
acut
hbv
infect
identifi
donat
screen
recent
syphili
rate
per
donat
increas
wherea
hiv
decreas
less
posit
donat
acut
hbv
rate
rose
slightli
male
outweigh
femal
account
case
recent
syphili
hiv
acut
hbv
respect
nearli
quarter
case
recent
syphili
hiv
seen
donor
year
old
male
donor
recent
syphili
report
sex
men
women
sbmw
sex
men
sbm
report
risk
contrast
hiv
male
donor
report
sbm
report
risk
overal
male
recent
syphili
hiv
acut
hbv
respect
noncompli
sbm
deferr
place
time
donat
donor
recent
syphili
age
year
median
year
exclud
donor
pool
includ
noncompli
sbm
deferr
fewer
hiv
case
identifi
year
old
compliant
report
sbmw
hbv
acut
case
male
one
agegroup
summaryconclus
year
period
demograph
recent
syphili
case
appear
similar
hiv
highest
rate
young
male
albeit
lower
proport
report
sbm
follow
switch
month
deferr
hiv
case
detect
continu
low
level
syphili
screen
continu
exclud
higher
number
span
agegroup
potenti
risk
sexual
transmit
infect
includ
noncompli
donor
background
global
estim
million
blood
donat
given
annual
blood
servic
oblig
monitor
donor
health
ensur
blood
donat
safe
recent
year
largescal
blood
donor
cohort
studi
sever
countri
increas
knowledg
health
effect
blood
donat
health
concern
relat
immedi
side
effect
like
faint
possibl
longterm
health
issu
relat
repeat
blood
plasma
donat
studi
provid
us
data
help
us
introduc
evidencebas
individualis
donor
care
parallel
personalis
medicin
individualis
donor
care
manag
iron
deplet
studi
shown
larg
percentag
frequent
whole
blood
donor
especi
young
women
iron
deplet
iron
deplet
strong
predictor
deferr
low
haemoglobin
also
associ
eg
restless
leg
syndrom
lower
birth
weight
children
frequent
donor
risk
iron
defici
mitig
ferritinguid
prolong
interdon
interv
iron
supplement
prolong
interdon
interv
challeng
inventori
iron
supplement
hand
may
give
gastrointestin
side
effect
effect
propos
well
eg
mask
malign
diseas
increas
iron
avail
subsequ
risk
infect
larg
studi
found
iron
supplement
associ
increas
risk
infect
optim
balanc
iron
supplement
prolong
interdon
interv
grow
number
blood
servic
implement
variou
flavour
iron
manag
regimen
gener
result
moreov
genet
studi
eg
uk
us
holland
denmark
help
us
find
donor
high
risk
iron
deplet
low
haemoglobin
use
data
big
data
approach
pursuit
individualis
risk
assess
model
risk
blood
donor
present
also
cover
risk
associ
donat
new
studi
identifi
predictor
faint
blood
donat
also
new
intervent
prevent
faint
global
demand
plasma
deriv
medicin
product
increas
severalfold
last
year
plasma
donor
bled
time
per
year
us
littl
known
health
effect
frequent
plasma
donat
know
immunoglobulin
level
decreas
frequent
donat
affect
health
summaryconclus
precautionari
principl
mitig
risk
earli
intervent
prior
evid
toler
next
risk
transfusiontransmit
infecti
diseas
health
blood
donor
howev
protect
similarli
owe
whole
blood
plasma
donor
investig
health
effect
blood
donat
ensur
safeti
first
attempt
may
perfect
tool
construct
model
individualis
donor
care
background
isbt
aabb
ihn
eba
jointli
issu
standard
surveil
complic
relat
blood
donat
categor
donor
advers
event
dae
categori
subcategori
defin
specif
criteria
sever
imput
briefli
describ
option
subsequ
valid
categori
demonstr
consist
categor
reaction
wide
variat
assign
sever
intern
input
aabb
donor
biovigil
committe
develop
sever
grade
tool
sgt
use
recogn
medic
advers
event
grade
system
neutral
grade
replac
subject
term
mild
moder
sever
aim
larg
us
blood
collect
establish
bce
appli
draft
sgt
assess
use
real
case
dae
method
perform
retrospect
analysi
allogen
apheresi
needlein
donat
sever
grade
assign
base
criteria
defin
sgt
databas
review
dae
perform
event
assign
grade
base
type
outsid
medic
care
omc
specif
key
search
term
search
term
omc
includ
emerg
room
emerg
medic
respons
urgent
care
healthcar
profession
hospit
admiss
addit
specif
key
search
term
includ
fractur
concuss
lacer
dental
injuri
surgeri
hospit
sinc
durat
activ
daili
live
adl
limit
captur
dae
databas
case
dae
claim
databas
review
case
file
event
classifi
grade
higher
individu
evalu
physician
grade
accuraci
result
needlein
collect
dae
grade
sever
major
vasovag
reaction
vvr
follow
apheresisrel
needlerel
allerg
event
major
dae
grade
account
dae
follow
grade
grade
grade
grade
dae
among
vvr
grade
respect
grade
vvr
includ
concuss
fractur
dental
injuri
prefaint
faint
event
requir
hospit
workup
two
grade
vvr
involv
fall
result
intracrani
hemorrhag
requir
immedi
medic
intervent
allerg
apheresi
dae
grade
reaction
respect
grade
event
needlerel
dae
includ
grade
grade
grade
grade
event
six
grade
needlerel
dae
nerv
irrit
last
month
dvt
requir
hospit
summaryconclus
sgt
provid
consist
assign
sever
major
dae
base
outsid
medic
care
specif
key
search
term
assign
sever
base
impact
activ
daili
live
durat
injurycondit
requir
track
time
make
assign
difficult
modif
dae
track
databas
claim
databas
captur
adl
durat
improv
sever
assign
case
background
intern
haemovigil
network
ihn
collect
aggreg
data
complic
whole
blood
apheresi
donat
member
nation
haemovigil
system
hv
sinc
aim
analys
data
collect
order
learn
data
consid
futur
improv
data
collect
method
nation
hv
enter
annual
data
donor
complic
passwordprotect
istar
intern
surveil
transfus
advers
reaction
event
onlin
databas
donor
complic
spreadsheet
allow
entri
separ
data
whole
blood
donat
wbd
apheresi
also
provid
option
enter
data
donat
type
annual
number
whole
blood
apheresi
donat
also
collect
harmonis
intern
standard
definit
implement
reaction
captur
accord
sever
level
mild
moder
sever
without
distinct
donor
sex
first
time
vs
repeat
donat
extract
data
use
calcul
nation
aggreg
donor
complic
rate
gener
per
donat
result
twentyfour
hv
provid
figur
donat
donor
complic
one
year
median
year
per
countri
iqr
total
number
countri
year
cy
cover
million
donat
overal
complic
rate
donat
median
countri
rate
donat
iqr
rate
gener
consist
within
hv
year
year
show
consider
variat
hv
also
case
reaction
class
sever
countri
differenti
mild
moder
reaction
report
reaction
singl
sever
level
vasovag
reaction
commonli
report
complic
overal
donat
median
countri
rate
donat
iqr
rare
apheresisrel
type
complic
gener
allerg
reaction
per
cy
major
blood
vessel
injuri
categori
avail
sinc
overal
per
cy
report
occasion
eighteen
hv
provid
separ
data
complic
whole
blood
apheresi
donat
one
year
total
cy
million
wbd
million
apheres
total
million
donat
hv
median
rate
vasovag
reaction
wbd
iqr
apheresi
procedur
report
haematoma
rate
higher
apheresi
wbd
median
per
hv
wbd
iqr
vs
apheres
rate
arm
pain
andor
nerv
injuri
separ
also
tend
higher
median
wbd
iqr
vs
apheresi
summaryconclus
intern
report
allow
hv
studi
rate
blood
donat
complic
distinguish
wbd
apheresi
complic
rate
captur
inform
rare
event
variabl
report
sever
assess
countri
impair
feasibl
comparison
hv
work
need
improv
harmonis
classif
donat
complic
sever
assess
data
comparison
research
background
prevent
iron
relat
hb
loss
screen
ferritin
test
implement
stockholm
counti
approx
regist
blood
donor
twoyear
rollout
iron
supplement
offer
blood
donor
prevent
hb
deferr
result
control
visit
per
year
ferritin
test
hypothes
increas
iron
complianc
aim
implement
ferritin
test
surveil
iron
level
entir
blood
donor
popul
specif
attent
new
donor
women
return
pregnanc
donor
low
hb
return
visit
low
hb
yearli
test
plasma
platelet
donor
method
ferritin
test
follow
staff
educ
program
implement
applic
donor
donor
low
hb
women
pregnanc
apheresi
donor
follow
screen
regist
blood
donor
per
donat
site
initi
screen
donor
test
th
women
th
men
donat
yearli
test
young
adult
blood
donor
year
six
nurs
educ
process
ferritin
blood
count
result
donor
aberr
ferritin
contact
letter
result
establish
cutoff
level
algorithm
ferritin
test
iron
treatment
evid
base
met
practic
limit
number
analys
result
could
process
per
week
limit
liss
setup
blood
demand
contra
prefer
cutoff
iron
supplement
complianc
applic
donor
hb
test
show
femal
male
applic
regist
low
hb
mgl
respect
ad
ferritin
test
prefer
cutoff
level
lgml
male
refer
level
would
result
addit
femal
male
applic
donor
loss
would
threat
blood
demand
cutoff
set
lgml
women
femal
refer
lgml
accept
loss
femal
applic
donor
regist
blood
donor
mg
extra
iron
tablet
offer
low
ferritin
lgml
sometim
combin
prolong
interv
often
repeat
ferritin
restor
lgml
donor
ferritin
lgml
applic
donor
regist
donor
lgml
applic
donor
regist
donor
defer
recommend
see
physician
hb
deferr
interv
prolong
month
irrespect
ferritin
level
togeth
iron
supplement
result
increas
approv
hb
return
team
nurs
process
ferritin
blood
count
result
nurs
fulltim
weekday
react
approxim
donor
result
daili
repres
test
result
summaryconclus
mani
femal
donor
applic
suboptim
ferritin
level
although
meet
requir
hb
donat
iron
treatment
ad
retain
donor
low
ferritin
prolong
interv
may
danger
blood
suppli
implement
ferritin
test
necessari
wellfunct
agil
organ
creat
appli
algorithm
test
extens
interv
iron
treatment
background
sinc
novemb
new
donor
screen
regim
introduc
netherland
serum
ferritin
level
whole
blood
donor
measur
period
control
potenti
iron
defici
donor
donor
deferr
threshold
set
ngml
donor
defer
six
twelv
month
respect
ferritin
level
valu
limit
inform
avail
ferritin
recoveri
wholeblood
donor
polici
introduc
part
adapt
implement
may
consid
base
intermedi
result
impact
measur
donor
wellb
evalu
aim
assess
effect
donor
deferr
donor
ferritin
level
method
ferritin
level
measur
new
donor
everi
fifth
donat
repeat
donor
donor
ferritin
level
indic
threshold
defer
ferritin
reevalu
return
donat
six
twelv
month
polici
allow
estim
long
term
trend
ferritin
level
post
donat
repeat
donor
ferritin
level
measur
new
donor
refer
distribut
ferritin
level
healthi
individu
obtain
well
result
among
repeat
donor
male
donor
femal
donor
ferritin
level
ngml
defer
next
donat
furthermor
distribut
ferritin
level
repeat
male
femal
donor
similar
averag
ferritin
level
ngml
contrast
found
new
femal
donor
n
new
male
donor
n
ferritin
level
ngml
averag
ferritin
level
new
donor
ngml
male
ngml
femal
compar
ferritin
level
new
repeat
donor
reduct
averag
ferritin
level
observ
femal
donor
male
donor
ratio
increas
donor
age
end
decemb
donor
low
ferritin
level
return
donat
six
twelv
month
deferr
repeat
ferritin
measur
show
averag
ferritin
level
femal
donor
increas
ngml
per
year
wherea
averag
ferritin
level
male
donor
increas
ngml
per
year
summaryconclus
line
earlier
find
literatur
result
show
repeat
donat
substanti
reduc
ferritin
level
repeat
donor
rang
femal
male
donor
gener
higher
ferritin
level
deferr
donor
low
ferritin
level
seem
effect
increas
ferritin
level
donor
howev
monitor
followup
repeat
donor
warrant
see
whether
propos
scheme
allow
suffici
donor
recoveri
time
differ
rare
diseas
gene
half
identifi
approxim
million
uk
citizen
experi
prematur
illhealth
rare
diseas
conclus
diagnosi
gener
reach
averag
diagnost
odyssey
last
year
main
aim
genom
project
reduc
diagnost
delay
embed
whole
genom
sequenc
wg
accredit
standard
care
path
patient
undiagnos
rare
diseas
project
start
dna
sampl
nh
patient
close
rel
analys
wg
review
result
nihr
bioresourc
pilot
studi
genom
project
compris
phenotyp
genotyp
data
individu
recruit
hospit
use
approv
elig
criteria
rare
diseas
domain
determin
popul
structur
includ
ethnic
related
estim
high
level
phenotyp
collect
use
human
phenotyp
ontolog
hpo
term
qualiti
control
summari
metric
sampl
variant
sequenc
resourc
contain
million
uniqu
variant
genet
independ
sampl
variant
previous
unobserv
larg
scale
publicli
avail
genom
dataset
summaris
curat
gene
list
pertin
find
uniqu
diagnosticgrad
gene
domain
report
assign
pathogen
like
pathogen
causal
variant
issu
diagnost
yield
vari
domain
proport
novel
causal
variant
rang
show
power
bayesian
associ
test
bevim
recapitul
decad
clinic
genet
discoveri
identifi
novel
gene
novel
diseasecaus
variant
noncod
space
genom
show
type
data
red
cell
hpa
hla
class
antigen
extract
wg
data
mine
data
genom
project
similar
sequenc
resourc
revers
probe
content
uk
biobank
axiom
array
genotyp
donor
england
netherland
new
array
observ
concord
compar
blood
centredetermin
antigen
type
result
genotypedetermin
one
red
cell
hpa
antigen
avail
donor
array
type
provid
increas
type
result
per
donor
vs
rare
donor
identifi
use
genotyp
data
identifi
time
compat
unit
among
cohort
donor
blood
demand
model
use
referr
data
english
patient
three
red
cell
alloantibodi
conclus
genom
project
shown
feasibl
use
wg
across
univers
healthcar
system
deliv
diagnosi
patient
rare
diseas
base
result
nh
commiss
analysi
anoth
dna
sampl
patient
cancer
rare
diseas
analysi
dna
wg
array
becom
part
routin
clinic
care
blood
servic
must
develop
compet
extract
transfus
transplant
relev
inform
clinicalgrad
genotyp
data
nextgener
sequenc
ng
enabl
sequenc
thousand
gene
exom
even
entir
genom
singl
experi
reason
price
also
advanc
cytometri
use
antibodi
differ
fluoresc
tag
enabl
simultan
monitor
express
dozen
antigen
howev
immunolog
method
detect
everi
variant
discov
ng
genom
sequenc
reveal
exom
also
regulatori
element
transcriptiontransl
promot
enhanc
rna
sequenc
determin
gene
splice
transcript
express
amaz
realiz
much
novel
technolog
contribut
better
understand
variou
biolog
phenomena
sinc
initi
clone
human
blood
group
transferas
cdna
earli
studi
abo
gene
b
glycosyltransferas
b
oligosaccharid
antigen
variou
scientif
disciplin
includ
genet
immunohematolog
biochemistri
enzymolog
glycobiolog
appli
studi
made
sever
import
scientif
contribut
demonstr
central
dogma
abo
b
allel
abo
genet
locu
encod
b
transferas
synthes
b
antigen
respect
elucid
allel
basi
abo
system
found
amino
acid
substitut
b
transferas
inactiv
mutat
allel
becam
first
succeed
abo
genotyp
discrimin
aa
ao
genotyp
well
bb
bo
imposs
immunolog
approach
taken
simpl
experiment
strategi
prepar
eukaryot
express
construct
ab
transferas
deriv
dna
transfect
human
hela
cell
sublin
immunolog
detect
ab
antigen
andor
biochem
examin
enzymat
activ
use
show
codon
crucial
determin
sugar
specif
galnacgalactos
ab
transferas
also
identifi
mutat
sever
subgroup
allel
caus
restrict
substrat
use
diminish
transferas
activ
also
show
cisab
b
allel
specifi
express
b
antigen
singl
allel
encod
ab
transferas
chimera
sinc
scientist
character
abo
allel
recent
human
genom
sequenc
identifi
mani
singl
nucleotid
polymorph
variat
genom
sequenc
mani
speci
also
avail
take
advantag
sequenc
associ
inform
expand
research
includ
evolutionarili
relat
nac
transferas
gene
scale
genet
genom
level
talk
would
like
present
follow
elucid
molecular
genet
basi
abo
blood
group
system
request
organ
identif
novel
abo
allel
other
snp
data
genom
sequenc
potenti
problem
abo
genotyp
find
obtain
analysi
abo
gene
speci
bacteria
vertebr
primat
nac
transferas
gene
crosstalk
transferas
forssman
glycolipid
synthas
fs
potenti
caus
gener
abo
polymorph
speci
variat
gene
specifi
for
polymorph
recent
year
concert
effort
improv
understand
qualiti
effect
transfus
blood
compon
expand
use
larg
dataset
built
electron
health
record
allow
investig
potenti
benefit
advers
outcom
associ
transfus
therapi
togeth
data
collect
blood
donor
compon
dataset
permit
evalu
effect
donor
blood
compon
factor
transfus
recipi
outcom
larg
link
donorcompon
recipi
dataset
provid
power
studi
exposur
relev
transfus
efficaci
safeti
mani
may
otherwis
amen
studi
practic
sampl
size
reason
analysi
larg
blood
bankingtransfus
medicin
dataset
allow
character
popul
studi
provid
evid
base
futur
clinic
studi
knowledg
gener
link
analys
potenti
chang
way
donor
select
compon
process
store
alloc
howev
unrecogn
confound
bias
statist
method
continu
limit
studi
transfus
exposur
patient
outcom
result
observ
studi
blood
donor
demograph
storag
age
transfus
practic
conflict
review
summar
statist
methodolog
challeng
analysi
link
blood
donor
compon
transfus
recipi
outcom
larg
delet
span
xg
xg
constitut
genet
basi
xg
null
phenotyp
underli
antixg
product
background
xg
blood
group
system
compris
homolog
antigen
xg
gene
resid
within
pseudoautosom
region
short
arm
sex
chromosom
thu
mimic
autosom
inherit
xg
hand
xlink
straddl
pseudoautosom
boundari
truncat
pseudogen
compos
first
exon
remain
chromosom
therefor
male
carri
sole
fulllength
copi
xg
phenomenon
manifest
asymmetr
frequenc
xg
phenotyp
sex
roughli
women
men
xg
also
whilst
xg
immun
rare
vast
major
antixg
maker
report
men
recent
report
variant
disrupt
gata
motif
xg
abolish
erythroid
xg
express
caus
common
xg
red
cell
phenotyp
howev
rare
individu
produc
antixg
account
find
hypothes
structur
defect
xg
code
region
caus
true
xg
null
phenotyp
underli
antixg
product
aim
undertook
determin
genet
explan
antixg
product
method
genom
dna
gdna
extract
two
whole
blood
sampl
cellfre
dna
cfdna
archiv
plasma
sampl
donor
produc
antixg
one
cfdna
sampl
femal
donor
rest
male
polymeras
chain
reaction
pcr
experi
sanger
sequenc
databas
search
perform
identifi
confirm
delet
aliquot
gdna
four
male
report
carri
similar
delet
genom
project
also
test
result
one
gdna
sampl
exonspecif
pcr
identifi
delet
involv
part
xg
downstream
gene
databas
search
indic
like
delet
infrequ
genom
structur
variant
report
genom
project
analys
short
bp
long
bp
pcr
amplicon
across
suspect
breakpoint
determin
delet
approxim
kb
correspond
well
find
confirm
second
gdna
sampl
given
rariti
antixg
produc
decid
test
delet
cfdna
extract
old
archiv
plasma
sampl
cfdna
sampl
poor
qualiti
four
sampl
prevent
amplif
even
control
reaction
one
contamin
bacteri
dna
remain
nine
sampl
eight
could
amplifi
deletionspecif
short
amplicon
one
neg
delet
sanger
sequenc
amplicon
reveal
heterogen
repetit
dna
element
hint
previouslyreport
recombin
event
delet
detect
sampl
genom
project
reiter
previous
identifi
defici
data
interpret
report
delet
summaryconclus
larg
delet
disrupt
xg
gene
account
xg
null
phenotyp
underli
major
antixg
maker
one
sampl
remain
unexplain
indic
heterogen
explor
data
help
explain
antixg
product
rare
primarili
report
men
background
antigen
encod
gypb
differ
one
nucleotid
nt
two
differ
genet
background
associ
silenc
antigen
u
w
phenotyp
includ
nt
chang
caus
partial
exon
skip
design
gybp
gypb
ny
intron
chang
caus
complet
skip
exon
design
gypb
gypb
aim
sampl
three
individu
previous
transfus
african
american
sickl
cell
patient
blood
donor
unknown
ethnic
african
american
patient
lapadat
r
aabb
abstract
investig
discrep
serolog
molecular
result
determin
phenotyp
method
standard
method
use
rbc
type
licens
reagent
rbc
donor
also
test
monoclon
polyclon
anti
anti
dna
isol
wbc
hea
precisetyp
perform
also
test
gypb
ss
aspcr
exon
pcrrflp
aspcr
test
gypb
ss
c
chang
realtim
pcrfluorogen
nucleas
taqman
chemistri
gypb
exon
amplifi
sanger
sequenc
align
consensu
use
clustal
x
result
rbc
three
proband
type
sand
strongli
dna
test
indic
gypb
ss
assay
two
common
gypb
silenc
allel
indic
three
sampl
silenc
mutat
previous
report
independ
associ
w
phenotyp
hea
precisetyp
could
interpret
novel
allel
combin
indic
gypb
pv
possibl
variant
sampl
confirm
heterozyg
exon
specif
sequenc
aspcr
pcrrflp
realtim
pcr
long
rang
sequenc
gypb
three
heterozyg
ss
sampl
also
heterozyg
sever
previous
recogn
silent
chang
exon
summaryconclus
report
novel
silenc
gypb
allel
confound
gypb
genotyp
interpret
allel
found
three
proband
associ
phenotyp
sampl
two
chang
previous
report
inherit
independ
associ
silenc
antigen
carri
allel
dnabas
test
could
rule
separ
gypb
also
silenc
robust
rbc
type
indic
chang
gypb
gene
sequenc
confirm
chang
gypb
gyp
ny
background
frequenc
respect
african
popul
exac
although
identifi
sampl
frequenc
novel
allel
unknown
background
lutheran
blood
group
system
current
consist
antigen
antigen
low
immunogen
may
caus
mildtomoder
transfus
reaction
hemolyt
diseas
fetu
newborn
activ
luglycoproteinbcam
red
blood
cell
rbc
interact
thought
play
role
vasoocclus
sickl
cell
diseas
hematolog
disord
two
glycoprotein
isoform
luglycoprotein
bcam
encod
bcam
gene
consist
exon
locat
chromosom
number
rare
lutheran
phenotyp
previous
record
israel
includ
lu
observ
among
iranian
jew
lu
one
thalassemia
patient
one
case
lu
report
previous
transfus
pregnant
arab
patient
bthalassemia
intermedia
investig
present
antibodi
unknown
high
frequenc
antigen
hfa
potenti
relat
lutheran
system
aim
character
novel
lutheran
antigen
serolog
molecular
investig
patient
lutheran
relat
antibodi
method
initi
red
cell
phenotyp
presenc
lutheran
relat
antibodi
serum
patient
detect
standard
serolog
techniqu
util
enzym
treat
chemic
modifi
cell
rare
cell
sera
nbgrl
collect
serolog
investig
carri
use
standard
iat
liss
tube
biorad
gel
techniqu
plasma
inhibit
studi
perform
use
solubl
recombin
lu
protein
srlu
eluat
prepar
use
acid
elut
method
gamma
elukit
ii
genom
dna
isol
whole
blood
exon
bcam
gene
amplifi
pcr
directli
sequenc
sanger
sequenc
impact
identifi
mutat
lutheran
glycoprotein
structur
studi
molecular
dynam
calcul
result
patient
plasma
react
cell
test
except
three
exampl
lu
cell
cell
treat
bromid
trypsin
achymotrypsin
inhibit
studi
srlu
protein
show
complet
inhibit
antibodi
therebi
confirm
antibodi
direct
toward
epitop
luglycoprotein
addit
test
inhibit
plasma
reveal
presenc
underli
anti
antifi
eluat
prepar
isol
patient
lurel
antibodi
eluat
found
incompat
exampl
lu
lu
lu
lu
lu
lu
lu
cell
wherea
lu
compat
result
serolog
type
patient
cell
lu
system
hfa
could
conclus
determin
due
patient
recent
transfus
howev
result
suggest
absenc
mix
field
reactiv
patient
cell
lu
bcam
sequenc
analysi
confirm
patient
lu
lu
reveal
novel
homozyg
mutat
c
exon
encod
lutheran
glycoprotein
summaryconclus
novel
homozyg
mutat
c
exon
bcam
identifi
patient
antibodi
lutheran
hfa
serolog
genet
evid
present
indic
discoveri
novel
antigen
lutheran
blood
group
system
propos
name
lura
background
lutheran
glycoprotein
basal
cell
adhes
molecul
antigen
bcam
two
isoform
type
membran
glycoprotein
resid
red
cell
surfac
isoform
adhes
molecul
main
function
laminin
bind
carri
antigen
lutheran
blood
group
system
lu
system
current
compris
antigen
encod
mutat
altern
splice
singl
gene
bcam
locat
chromosom
current
isbt
list
high
incid
antigen
system
aim
report
case
studi
individu
unidentifi
alloantibodi
high
incid
antigen
present
plasma
sampl
patient
famili
investig
provid
serolog
molecular
evid
novel
high
incid
antigen
lutheran
blood
group
system
method
serolog
investig
perform
standard
iat
liss
tube
biorad
gel
techniqu
plasma
inhibit
studi
complet
solubl
recombin
lu
srlu
protein
genom
dna
isol
whole
blood
patient
famili
member
exon
bcam
gene
amplifi
pcr
analys
direct
sanger
sequenc
impact
identifi
mutat
lutheran
glycoprotein
structur
studi
molecular
dynam
calcul
result
presenc
lurel
antibodi
patient
plasma
confirm
react
moder
strength
liss
iat
untreat
papain
treat
cell
cell
patient
mother
father
two
sibl
incompat
plasma
though
weaker
panel
cell
reflect
dosag
lu
cell
compat
patient
plasma
antibodi
success
inhibit
srlu
protein
therebi
confirm
epitop
recognis
antibodi
resid
lutheran
glycoprotein
patient
cell
found
lu
bcam
sequenc
reveal
novel
homozyg
mutat
exon
encod
lu
glycoprotein
chang
appear
extrem
rare
mutat
list
gnomad
databas
frequenc
known
homozyg
exampl
homolog
model
novel
lutheran
glycoprotein
subject
allatom
molecular
dynam
calcul
analys
potenti
conform
chang
summaryconclus
report
serolog
genet
evid
novel
antigen
lutheran
system
propos
name
lunu
evid
submit
isbt
red
cell
immunogenet
blood
group
terminolog
work
parti
consider
alloc
antigen
statu
absenc
high
incid
antigen
aris
rare
singl
amino
acid
chang
lutheran
glycoprotein
presenc
antilunu
patient
plasma
presum
made
respons
previou
pregnanc
nativ
papaintr
diagast
trypsintr
sigma
rbc
genom
dna
extract
peripher
blood
cell
autom
method
amplifi
exonspecif
primer
sequenc
result
proband
femal
patient
moroccan
origin
group
dcece
k
without
transfus
histori
hospit
week
gestat
blight
ovum
requir
manual
vacuum
aspir
signific
hemorrhag
risk
rbc
antibodi
screen
perform
first
laboratori
antibodi
react
iat
nativ
reagent
rbc
neg
autocontrol
nonreact
papainand
trypsintr
cell
initi
suspect
due
pattern
reactiv
ethnic
background
new
blood
sampl
refer
nation
immunohematolog
refer
laboratori
antibodi
show
profil
could
rule
serum
nonreact
two
jmh
posit
two
jmh
sampl
patient
found
posit
addit
solubl
recombin
jmh
protein
jmh
imusyninnotrain
fulli
abolish
reactiv
panagglutin
antibodi
antibodi
overal
result
consist
probabl
jmh
variant
prompt
us
perform
sequenc
three
nucleotid
chang
found
homozyg
state
rare
nonsynonym
chang
exon
maf
sift
score
common
synonym
chang
exon
g
maf
rare
nonsynonym
chang
exon
maf
sift
score
analysi
surfac
access
asp
arg
use
structur
rcsb
http
show
arg
predict
exposedepitop
interestingli
report
jmh
variant
phenotyp
correspond
arginin
substitut
note
retrospect
found
anoth
individu
algerian
ancestri
pregnant
woman
panagglutin
antibodi
show
similar
pattern
reactiv
three
chang
unfortun
could
perform
crosscompat
test
proband
materi
left
unsuccess
contact
summaryconclus
serolog
molecular
studi
allow
us
provid
evid
novel
highpreval
antigen
jmh
blood
group
system
like
encod
substitut
propos
provision
assign
name
antigen
interestingli
two
unrel
jmh
individu
north
african
ancestri
background
abo
system
discov
almost
year
ago
underli
structur
later
elucid
carbohydr
carri
glycoprotein
glycolipid
termin
trisaccharid
gal
gal
constitut
clinic
import
b
epitop
respect
clausen
et
al
pna
show
antigen
could
extend
repetit
glycolipid
epitop
howev
extend
form
b
antigen
describ
encount
two
relat
situat
unexplain
serolog
reactiv
firstli
enzymeconvers
group
treatment
group
b
beco
red
blood
cell
rbc
famili
exogalactosidas
bzyme
abolish
b
antigen
detect
hemagglutin
flow
cytometri
monoclon
antib
test
despit
group
plasma
report
give
posit
crossmatch
result
beco
rbc
secondli
plasma
ab
b
individu
globosidedefici
p
k
phenotyp
contain
antip
react
stronger
bpprbc
appopprbc
base
find
hypothes
presenc
bzymeresist
brelat
glycolipid
aim
identifi
molecular
basi
enigmat
serolog
observ
outlin
method
plasma
eluat
b
individu
k
phenotyp
investig
hemagglutin
flow
cytometri
eluat
b
p
k
plasma
rbc
membran
glycolipid
extract
two
batch
pool
expir
group
brbc
unit
frozen
refer
prepar
confirmatori
prepar
freshli
collect
unit
nativ
enzymetr
glycolipid
fraction
analys
liquid
chromatographi
electrospray
ionizationmass
spectrometri
lcesim
immunostain
thin
layer
chromatographi
tlc
plate
antigen
express
human
erythroleukemia
hel
cell
line
analys
flow
cytometri
follow
overexpress
select
glycosyltransferas
result
antipdeplet
eluat
made
b
p
k
plasma
contain
antibodi
unknown
specif
react
stronger
nativ
papaintr
bpprbc
compar
appopprbc
remov
adsorpt
onto
opprbc
reactiv
design
antiextb
remain
bbppbeco
rbc
lcesim
glycolipid
fraction
group
b
unit
reveal
unknown
hexnachex
fuc
heptasaccharid
upon
bnacetylhexosaminidas
treatment
candid
structur
group
b
type
hexasaccharid
produc
demonstr
termin
hexnac
heptasaccharid
blink
sinc
discoveri
antiplatelet
effect
aspirin
platelet
major
therapeut
target
pharmaceut
compani
also
profit
target
howev
effect
aspirin
also
challeng
inexpens
drug
new
agent
need
show
clear
benefit
aspirin
furthermor
risk
bleed
antiplatelet
agent
especi
cerebr
bleed
also
present
challeng
oral
activ
gpiibiiia
antagonist
consid
super
aspirin
clinic
trial
show
increas
mortal
ultim
class
drug
releg
iv
use
highrisk
patient
gpibixv
antagonist
also
promis
drug
target
agent
made
market
real
breakthrough
discoveri
antagonist
clopidogrel
conjunct
aspirin
prove
effect
prevent
thrombot
event
result
becam
biggest
sell
drug
world
time
clopidogrel
offpat
combin
aspirin
clopidogrel
formid
challeng
new
agent
efficaci
term
pharmacoeonom
term
futur
new
antiplatelet
agent
grow
awar
role
platelet
inflamm
understand
immun
activ
platelet
differ
classic
haemostat
activ
platelet
possibl
develop
novel
antiplatelet
agent
target
inflamm
without
compromis
haemostasi
look
next
gener
antiplatelet
agent
univers
hospit
geneva
geneva
switzerland
platelet
function
defect
either
congenit
acquir
associ
increas
bleed
risk
particularli
periop
set
use
platelet
function
assay
therefor
tempt
order
tailor
transfus
limit
platelet
transfus
bleed
patient
impair
platelet
function
assess
assay
howev
current
guidelin
provid
weak
recommend
support
routin
use
assay
inde
numer
platelet
function
assay
market
differ
method
evalu
platelet
function
agreement
result
best
moder
threshold
valu
beyond
procedureassoci
bleed
risk
becom
worrisom
standard
moreov
observ
studi
address
predict
valu
platelet
function
test
periop
spontan
bleed
consist
final
manag
trial
random
patient
assess
benefit
platelet
function
test
scarc
recent
data
identifi
select
situat
platelet
function
test
may
use
though
review
differ
platelet
function
assay
well
select
clinic
studi
address
impact
platelet
function
test
improv
bleed
transfusionrel
outcom
latest
recommend
address
background
platelet
refractori
complic
provis
platelet
transfus
manag
thrombocytopenia
oncolog
patient
platelet
refractori
pose
challeng
due
alloimmun
hla
human
platelet
antigen
associ
advers
clinic
outcom
aim
prospect
studi
undertaken
analys
result
platelet
compat
posttransfus
platelet
count
increment
ascertain
presenc
platelet
antibodi
caus
factor
platelet
refractori
oncolog
patient
pulmonari
complic
blood
transfus
lead
caus
transfusionrel
morbid
mortal
incid
report
transfus
patient
import
transfus
relat
pulmonari
complic
transfus
associ
circulatori
overload
taco
transfus
relat
acut
lung
injuri
trali
transfus
associ
dyspnea
tad
present
recent
chang
intern
definit
present
discuss
furthermor
insight
differ
underli
pathophysiolog
mechan
highlight
past
decad
trali
prevent
strategi
success
design
implement
current
evidencebas
treatment
strategi
avail
lifethreaten
syndrom
insight
pathogenesi
pulmonari
complic
transfus
pave
way
futur
prevent
treatment
studi
issu
impact
iron
overload
toxic
hematopoiet
stem
transplant
hct
outcom
firstli
address
field
transfus
depend
thalassemia
today
concept
extend
diseas
character
period
variabl
durat
transfus
depend
myelodysplast
syndrom
md
myeloprolif
diseas
patient
requir
regular
blood
transfus
certainli
develop
iron
overload
lead
tissu
organ
damag
iron
burden
transplant
significantli
impact
outcom
longlif
posttranspl
well
known
iron
overload
deleteri
organ
liver
heart
endocrin
gland
postul
could
also
increas
risk
infect
sever
graft
versu
host
diseas
earli
hct
recent
preclin
data
shown
increas
product
reactiv
oxygen
speci
ro
result
iron
overload
condit
could
impair
stem
cell
clonal
capac
prolifer
matur
also
microenviron
cell
could
affect
mechan
reason
iron
overload
becom
import
issu
also
engraft
period
earli
posttranspl
high
baselin
ferritin
level
hct
shown
neg
influenc
clinic
outcom
nowaday
ferritin
consid
steadi
biolog
activ
form
iron
free
iron
form
non
transferrin
bound
iron
ntbi
labil
plasma
iron
lpi
consid
main
trigger
cell
damag
repres
dynam
tissu
damag
scientif
commun
move
iron
diseas
bulki
diseas
classic
thalassemia
base
quantit
iron
paramet
ferritin
red
blood
cell
transfus
number
mri
toxic
diseas
base
activ
dynam
biolog
marker
ntbilpi
time
studi
publish
hct
set
correl
direct
indirect
estim
iron
overload
mainli
serum
ferritin
outcom
paramet
explor
durat
exposur
toxic
iron
speci
taken
account
first
studi
explor
lpi
role
relationship
outcom
publish
wermk
colleagu
malign
investig
predict
valu
store
mrideriv
liver
iron
content
nontransferrinboundiron
defin
enhanc
labil
plasma
iron
elpi
posttransplant
outcom
patient
acut
myeloid
leukemia
md
prospect
observ
alliv
studi
show
patient
rais
elpi
concentr
baselin
also
significantli
increas
incid
nonrelaps
mortal
day
compar
normal
elpi
baselin
p
reinterpret
transplant
predict
factor
light
current
advanc
understand
iron
homeostasi
support
concept
key
success
transplant
regular
lifelong
chelat
therapi
consist
suppress
tissu
reactiv
iron
speci
prevent
tissu
damag
year
hct
transfus
medicin
role
donor
sex
long
consid
limit
increas
risk
trali
observ
transfus
femal
donor
risk
shown
limit
femal
donor
histori
pregnanc
plasma
rich
product
ie
exclud
red
blood
cell
product
typic
contain
ml
plasma
found
sexmismatch
red
blood
cell
transfus
associ
increas
recipi
mortal
sinc
sever
studi
confirm
find
studi
also
find
associ
studi
reli
analys
routin
collect
health
care
data
primarili
intend
use
research
result
analys
complex
often
difficult
properli
apprais
base
publish
descript
therefor
discuss
possibl
reason
discord
find
larg
focus
methodolog
approach
differ
studi
potenti
explan
includ
differ
donor
patient
popul
product
method
storag
time
blood
product
differ
potenti
explan
expect
associ
differ
underli
biolog
mechan
therefor
delin
donor
patient
product
characterist
modifi
observ
associ
could
provid
insight
underli
mechan
observ
transfus
femal
donor
previou
pregnanc
associ
increas
mortal
male
recipi
year
lead
us
postul
pregnanc
induc
long
term
chang
femal
immun
system
transfer
red
cell
transfus
neg
consequ
young
male
recipi
low
amount
plasma
present
red
cell
product
lead
us
assum
cellular
compon
like
passeng
leukocyt
involv
shown
microchimer
passeng
leukocyt
persist
decad
transfus
even
leukoreduc
blood
product
suggest
long
term
immunemodul
could
play
role
hypothes
passeng
leukocyt
would
die
storag
blood
product
neg
effect
everpregn
femal
donor
surviv
young
male
red
cell
recipi
would
therefor
attenu
increas
storag
time
howev
data
seem
indic
opposit
risk
death
increas
threefold
young
male
recipi
old
day
storag
red
cell
everpregn
donor
compar
young
male
recipi
fresh
day
storag
red
cell
everpregn
donor
cumul
incid
death
versu
neg
control
group
ie
young
male
recipi
red
cell
male
donor
show
much
weaker
associ
mortal
storag
time
ie
versu
find
seem
falsifi
hypothesi
mortal
could
caus
passeng
leukocyt
establish
long
term
immunemodulatori
effect
anoth
potenti
mechan
suggest
could
presenc
cellfre
dna
transfus
blood
product
cellfre
dna
increas
storag
howev
research
need
establish
cellfre
dna
also
link
previous
pregnant
blood
donor
mechan
could
neg
affect
young
male
transfus
recipi
clinic
trial
ct
gem
clinic
research
gener
robust
evid
medicin
public
health
costli
complic
undertak
resourc
limit
set
like
subsaharan
africa
ssa
health
system
suboptim
capac
research
limit
conduct
ct
daunt
challeng
challeng
undertak
ct
rl
may
categor
base
occurr
bottleneck
relat
ethic
regulatori
approv
process
preapprov
protocol
develop
order
develop
contextspecif
protocol
subsequ
subject
ethic
regulatori
approv
process
investig
need
review
ensur
protocol
pragmat
feasibl
respect
implement
result
timeconsum
reiter
process
realitycheck
protocol
site
select
light
limit
research
infrastructur
investig
rl
develop
world
partner
spend
consider
time
review
select
suitabl
site
particip
anticip
protocol
ct
suitabl
site
usual
compet
ongo
studi
approv
institut
review
board
irb
approv
irb
approv
process
quit
lengthi
month
consider
unpredict
period
initi
subsequ
irb
review
nation
regulatori
approv
requir
nation
regul
unusu
innumer
limit
flexibl
accommod
specif
ct
postapprov
key
postapprov
challeng
ct
implement
rl
attain
appropri
particip
enrol
maintain
high
retent
rate
specif
particip
enrol
challeng
may
unforeseen
compet
ct
target
particip
pool
commun
perspect
may
discourag
particip
get
screen
ct
retent
may
also
challeng
particularli
particip
view
enrol
chanc
access
healthcar
servic
may
therefor
incent
keep
studi
initi
studi
visit
conclus
ct
complex
undertak
wherev
conduct
doubli
challeng
rl
like
subsaharan
africa
bottleneck
preapprov
approv
postapprov
stage
consider
nevertheless
reward
perform
ctu
rl
given
data
gener
therein
highli
valu
nation
regul
may
hasten
registr
process
medic
product
background
interest
appropri
effect
whole
blood
wb
pathogen
reduct
technolog
prt
grow
especi
subsaharan
africa
residu
risk
transfusiontransmit
infect
tti
remain
unaccept
high
wb
still
frequent
use
ceru
corpor
manufactur
intercept
tm
blood
system
swiss
transfus
src
collabor
clinic
develop
program
adapt
intercept
prt
use
amustalin
glutathion
gsh
red
blood
cell
rbc
appropri
prt
wb
resourcelimit
set
africa
treatment
amustalinegsh
shown
inactiv
broad
spectrum
transfusiontransmiss
pathogen
rbc
studi
amustalinegsh
wb
shown
effect
duck
hepat
b
viru
log
reduct
plasmodium
falciparum
log
reduct
futur
studi
plan
wb
prt
system
amustalinegsh
also
potenti
benefit
minim
electr
requir
aim
describ
safeti
clinic
object
phase
clinic
trial
use
amustalinegsh
prt
system
wb
africa
describ
research
develop
effort
adapt
intercept
prt
system
rbc
robust
appropri
wb
system
set
high
burden
tti
limit
resourc
method
protocol
phase
clinic
trial
use
pathogenreduc
wb
treat
amustalinegsh
african
countri
present
current
research
develop
activ
relat
develop
prt
system
wb
result
plan
phase
clinic
trial
africa
clinic
stabl
patient
anemia
requir
wb
transfus
random
two
studi
arm
larg
medic
center
subsaharan
african
countri
enrol
patient
receiv
one
unit
nonleucocytereduc
wb
treat
amustalinegsh
unit
untreat
control
wb
rbc
primari
safeti
endpoint
incid
highimput
transfus
reaction
swissmed
within
first
hour
transfus
data
also
collect
advers
event
transfus
reaction
grade
develop
treatmentemerg
antibodi
pathogenreduc
wb
autoantibodi
within
day
studi
transfus
clinic
efficaci
character
hemoglobin
increment
hour
transfus
adjust
hemoglobin
dose
bodi
weight
summaryconclus
prt
system
wb
develop
base
intercept
prt
rbc
advanc
develop
europ
unit
state
intercepttr
rbc
met
efficaci
safeti
endpoint
phase
clinic
trial
amustalinegsh
prt
system
use
treat
intercept
rbc
demonstr
effect
inactiv
broad
spectrum
agent
may
result
tti
phase
clinic
trial
use
adapt
prt
system
wb
africa
first
step
clinic
develop
program
includ
addit
pathogen
inactiv
efficaci
studi
improv
wb
prt
implement
process
togeth
develop
evalu
repres
progress
toward
realist
appropri
prt
wb
africa
resourcelimit
set
background
australia
demand
plasmaderiv
product
increas
dramat
need
increas
plasma
collect
firsttim
donor
retent
includ
rate
firsttim
donor
return
press
issu
quick
return
optim
increas
overal
plasma
yield
associ
longterm
retent
howev
lack
evid
effect
intervent
encourag
firsttim
donor
particularli
donat
plasma
return
establish
higher
frequenc
donat
routin
work
schultz
framework
intervent
studi
base
upon
insight
interview
firsttim
plasmapheresi
donor
particip
identifi
barrier
time
lack
knowledg
plasmapheresi
facilit
includ
abl
help
peopl
donat
frequent
allow
whole
blood
particip
gener
favour
donat
frequenc
everi
week
aim
aim
studi
test
effect
three
intervent
condit
compar
businessasusu
bau
procedur
proport
donor
return
donat
plasma
number
plasma
donat
report
data
month
postdon
method
donor
randomli
assign
one
four
studi
condit
condit
donor
receiv
email
one
day
initi
donat
first
condit
donor
receiv
bau
thankyou
email
donor
second
condit
receiv
altern
email
content
deriv
interview
studi
donor
remain
condit
receiv
either
bau
email
condit
revis
email
condit
coupl
telephon
call
phone
call
script
provid
addit
inform
plasma
includ
often
plasma
donat
suggest
donat
everi
week
prompt
forwardbook
appoint
result
final
sampl
n
compris
women
men
age
mean
two
month
donor
return
donat
plasma
least
control
gender
age
blood
group
donor
intervent
condit
like
return
donat
plasma
donor
bau
condit
greatest
effect
found
donor
random
condit
revis
email
phone
call
ci
bau
donor
assign
two
telephon
condit
condit
donat
plasma
higher
frequenc
bau
summaryconclus
studi
test
effect
intervent
design
encourag
firsttim
plasma
donor
return
donat
plasma
establish
routin
donat
earli
indic
suggest
evidencebas
email
phone
call
element
effect
bau
bring
donor
back
donat
plasma
revis
email
combin
phone
call
greatest
posit
effect
shortterm
plasma
yield
background
healthi
individu
hereditari
hemochromatosi
hh
defin
hyperferritinemia
homozyg
mutat
also
carrier
hfe
mutat
homozyg
elev
serum
ferritin
sf
accept
blood
donor
allow
local
regul
elig
fulfil
gener
blood
compon
releas
transfus
normal
sf
level
ngml
femal
ngml
male
aim
prospect
twocent
random
studi
compar
efficaci
toler
doubleerythrocyt
apheresi
whole
blood
phlebotomi
wbph
iron
deplet
asymptomat
subject
hh
hyperferritinemia
hfe
mutat
set
routin
blood
donat
method
elig
criteria
includ
age
year
total
blood
volum
l
bmi
kgm
hb
gl
elev
sf
level
end
organ
damag
due
iron
overload
ml
rbc
schedul
everi
day
wbph
ml
everi
day
sf
ngml
complet
blood
count
sf
measur
baselin
everi
visit
follow
week
complet
studi
advers
event
systemat
record
treatment
effect
test
poisson
regress
gender
hfe
mutat
bmi
baselin
sf
covari
result
subject
femal
mean
age
year
random
wbph
n
femal
n
femal
hfe
mutat
subject
baselin
mean
hb
gl
sd
median
sf
ngml
iqr
ngml
procedur
wbph
n
n
complet
interrupt
local
hematoma
insuffici
flow
wbph
postpon
low
hb
non
medic
reason
dropout
wbph
arm
due
depress
poor
complianc
respect
anemia
hb
gl
male
gl
femal
occur
visit
wbph
subject
visit
subject
fatigu
report
phlebotomi
apheres
particip
complet
studi
per
protocol
blood
compon
rbc
concentr
plasma
unit
transfus
obtain
overal
median
wbph
iqr
need
reach
sf
ngml
correspond
time
median
iqr
p
analyz
separ
carrier
relat
wbph
respect
treatment
arm
hfe
mutat
covari
signific
effect
primari
endpoint
p
respect
summaryconclus
effici
wbph
iron
deplet
healthi
subject
hh
hfe
mutat
moder
hyperferritinemia
intens
treatment
schedul
gener
recommend
hh
difficult
keep
hb
drop
complianc
less
intens
treatment
asymptomat
individu
hh
inclus
blood
donat
would
avoid
neg
effect
qualiti
life
benefit
blood
collect
center
long
term
background
serum
ferritin
sf
measur
whole
blood
wb
donor
demonstr
femal
sex
intens
donat
major
risk
factor
iron
defici
approxim
ml
red
blood
cell
rbc
mg
iron
lost
wb
donat
doubl
unit
rbc
collect
ml
ca
ml
less
rbc
amount
two
wb
donat
lead
loss
mg
iron
switzerland
maxim
allow
donat
frequenc
male
donor
everi
month
everi
month
wb
donat
aim
describ
compar
cours
hemoglobin
hb
sf
male
subject
donat
wb
institut
method
includ
wb
donor
n
donat
maxim
allow
donat
frequenc
month
yield
wb
donat
exclud
subject
hyperferritinemia
known
hfe
mutat
hb
limit
gl
wb
gl
donat
apheresi
ml
rbc
collect
sf
measur
predon
serum
sampl
hb
determin
finger
prick
sampl
donor
receiv
iron
substitut
use
gener
estim
equat
model
hb
sf
trajectori
result
mean
age
first
blood
donat
wb
year
respect
first
donat
mean
hb
gl
sd
wb
gl
sd
donor
mean
sf
sd
lgl
sd
respect
averag
hb
sf
higher
donor
gl
lgl
respect
p
subject
sf
lgl
wb
group
sf
lgl
lgl
respect
donor
first
last
donat
mean
hb
declin
gl
gl
p
mean
sf
lgl
lgl
ns
wb
donor
mean
hb
drop
gl
gl
p
sf
lgl
lgl
p
similar
result
found
adjust
age
season
hb
valu
drop
baselin
th
donat
wb
donor
th
donat
donor
upward
trend
thereaft
group
hb
valu
limit
blood
donat
anemia
observ
sf
reach
nadir
th
donat
wb
donor
lgl
lgl
increas
thereaft
donor
wb
donor
sf
follow
parabol
trend
peak
th
donat
declin
last
donat
summaryconclus
maxim
allow
blood
donat
frequenc
wb
male
donor
switzerland
protect
develop
anemia
also
deferr
blood
donor
low
hb
observ
even
subject
low
sf
baselin
background
granulocyt
concentr
transfus
potenti
lifesav
option
patient
without
function
neutrophil
howev
recent
studi
fail
demonstr
anticip
clinic
effect
procedur
granulocyt
concentr
manufactur
use
sediment
agent
separ
granulocyt
red
blood
cell
enhanc
granulocyt
collect
effici
highmolecularweight
hydroxyethyl
starch
he
commonli
use
howev
author
recent
restrict
use
he
due
unfavor
riskbenefitprofil
modifi
fluid
gelatin
mfg
alreadi
use
altern
sediment
agent
granulocyt
product
contain
substanc
impact
sediment
agent
granulocyt
function
may
affect
clinic
effect
granulocyt
transfus
aim
test
hypothesi
mfg
inferior
he
term
function
viabil
granulocyt
method
granulocyt
ten
healthi
donor
isol
aliquot
incub
parallel
hour
either
control
mfg
gelafundin
b
braun
melsungen
ag
he
hespan
b
braun
medic
inc
respect
granulocyt
migrat
chemotaxi
reactiv
oxygen
speci
ro
product
neutrophil
extracellular
trap
format
netosi
antigen
express
viabil
subsequ
investig
vitro
test
perform
use
live
cell
imag
cell
embed
collagen
matrix
parallel
test
migrat
ro
product
netosi
addit
flow
cytometr
fac
analysi
util
surfac
marker
express
viabil
respiratori
burst
measur
result
granulocyt
migrat
decreas
dosedepend
manner
respons
he
mfg
rel
control
three
concentr
he
lower
migrat
distanc
p
respect
wherea
higher
concentr
mfg
show
lower
rel
migrat
distanc
p
respect
track
straight
reduc
sediment
agent
extent
p
respect
he
result
lower
express
p
higher
express
p
compar
control
wherea
differ
reach
statist
signific
mfg
affect
express
investig
surfac
antigen
mediat
endotheli
adhes
transmigr
comparison
control
signific
differ
time
ro
product
netosi
neutrophil
viabil
respiratori
burst
observ
summaryconclus
result
indic
mfg
inferior
he
term
granulocyt
phenotyp
function
vitro
use
equal
concentr
potenti
impair
granulocyt
function
occur
he
background
plateletpheresi
donat
lead
wellknown
transient
decreas
donor
platelet
question
longterm
effect
rais
develop
regular
donat
donor
order
satisfi
grow
demand
semin
work
lazaru
transfus
state
sustain
thrombopenia
frequent
plateletpheresi
donor
correl
total
number
donat
aim
french
regul
author
plateletpheresi
donat
per
year
minimum
week
interv
tri
evalu
risk
sustain
thrombopenia
condit
method
retriev
plateletpheresi
donat
occur
french
civilian
blood
donor
base
select
cohort
donor
least
donat
period
order
minim
measur
error
platelet
count
analys
mean
three
consecut
donat
ie
measur
donor
result
cohort
includ
donor
women
men
mean
platelet
count
fluctuat
plateletsml
analysi
varianc
show
statist
signific
differ
f
even
take
donor
sex
age
consider
differ
consid
total
durat
donat
either
donor
lowest
first
count
show
signific
rise
subsequ
measur
donor
highest
count
show
decreas
trend
exhibit
classic
regress
toward
mean
summaryconclus
plateletpheresi
french
regul
seem
risk
sustain
donor
thrombopenia
conclus
agreement
recent
literatur
data
primari
biolog
role
human
leukocyt
antigen
hla
system
regul
immun
respons
foreign
antigen
role
hla
gene
molecul
import
role
transplant
etiolog
mani
autoimmun
nonautoimmun
infect
diseas
also
transfus
medicin
increas
probabl
hla
noncompat
blood
product
tissu
organ
exist
due
extrem
high
polymorph
hla
gene
describ
allel
date
differ
frequenc
distribut
variou
worldwid
popul
hla
system
origin
discov
result
transfus
reaction
caus
detriment
immun
reaction
transfus
therapi
hla
antibodi
present
patient
respons
reaction
case
hla
antibodi
hla
reactiv
cell
present
transfus
product
account
immunoreact
hla
antibodi
form
result
exposur
foreign
hla
antigen
pregnanc
transplant
blood
transfus
caus
platelet
immun
refractori
febril
transfus
reaction
transfusionrel
acut
lung
injuri
transfus
associ
graft
versu
host
diseas
order
avoid
reduc
develop
transfusionrel
event
hla
antibodi
neg
compat
product
use
almost
exist
method
present
use
molecular
type
hla
polymorph
base
polymeras
chain
reaction
differ
resolut
level
low
resolut
two
digit
high
resolut
four
digit
addit
provid
precis
detect
polymorph
hla
classic
loci
eg
hlaa
b
c
molecular
method
also
determin
polymorph
hla
loci
previous
could
type
serolog
eg
commonli
use
method
detect
hla
antibodi
recent
complementdepend
cytotox
cdc
techniqu
increasingli
replac
sensit
solid
phase
base
method
luminex
technolog
conclus
accur
precis
determin
hla
gene
polymorph
hla
antibodi
presenc
essenti
safe
effici
administr
transfus
product
background
minor
pregnanc
complic
antibodi
seriou
fetalneonat
diseas
develop
difficulti
predict
mother
treat
ivig
hamper
implement
fnait
screen
found
fccore
fucosyl
galactosyl
highli
variabl
igg
glycan
featur
strongli
affect
bind
fccriiia
receptor
level
fccore
fucosyl
antihpa
alloantibodi
found
correl
platelet
count
outcom
newborn
suggest
antibodyspecif
fucosyl
might
serv
biomark
fnait
screen
howev
present
fcglycosyl
pattern
determin
complic
method
involv
purif
antigenspecif
igg
analyz
trypticli
releas
iggderivedglycopeptid
tandem
liquid
chromatographymassspectrometri
ms
techniqu
method
although
power
yet
suit
high
throughput
clinic
screen
aim
aim
provid
simplifi
method
quantifi
biolog
activ
antibodi
possibl
alloantibodi
blood
cell
method
explor
cellular
surfac
plasmon
reson
spr
imag
replac
ms
result
less
complic
handl
patient
sera
donorantigenbear
cell
strength
bind
platelet
fccr
spr
sensor
monitor
flow
spr
sensor
equip
wt
fccriiia
sensit
fcglycosyl
statu
mutant
insensit
fcglycosyl
statu
addit
biosensor
prepar
antiplatelet
antiigg
calibr
number
inject
platelet
well
quantifi
iggopson
qualiti
antihpa
glycosyl
monitor
ratio
bind
opson
platelet
wt
mutant
platelet
opson
recombin
glycoengin
antiplatelet
antibodi
differ
level
fcfucosyl
use
standard
valid
plasma
sampl
antibodi
alreadi
analyz
mass
spectrometri
known
clinic
outcom
test
sonneveld
bjh
result
found
ratio
bind
wt
fccriiia
mutant
correl
level
fucosyl
antibodi
measur
massspectrometri
r
p
overal
similar
predict
valu
diseas
sever
obtain
previous
report
retrospect
cohort
addit
quantit
inform
antibodi
concentr
also
extract
use
receptor
sensor
chip
antiigg
gave
aspecif
signal
presum
recogn
cytophil
plateletfccriiabound
antibodi
well
summaryconclus
conclus
combin
use
wt
mutant
fccriiia
label
free
spr
assay
provid
quantit
qualit
inform
platelet
bound
antihpa
antibodi
circumv
need
purif
specif
antibodi
labori
mass
spectrometr
analysi
approach
might
gener
applic
determin
biolog
activ
cell
bound
antibodi
fnait
also
antirhd
alloantibodi
hdfn
antiplatelet
antibodi
itp
background
immun
human
platelet
alloantigen
common
caus
sever
fetal
neonat
alloimmun
thrombocytopenia
fnait
otherwis
healthi
term
newborn
screen
antigen
pregnant
women
import
tool
identif
pregnant
women
risk
fetusneon
fnait
target
intervent
depend
effici
screen
method
well
sensit
specif
method
detect
within
framework
polishnorwegian
project
prevfnait
perform
screen
program
poland
aim
aim
assess
frequenc
antibodi
detect
clinic
outcom
newborn
identifi
studi
women
join
program
due
fnait
previou
child
current
newborn
analyz
studi
method
screen
pregnant
women
gestat
week
perform
fac
phenotyp
rqpcr
genotyp
ihtm
warsaw
women
test
hla
antibodi
maipa
follow
week
week
deliveri
detect
quantit
maipa
perform
neg
women
contact
inform
concern
newborn
babi
thrombocytopenia
detect
maipa
look
back
sampl
test
retrospect
paklx
test
immucor
result
neg
women
identifi
antibodi
detect
maipa
women
two
deliv
tween
addit
antibodi
later
detect
paklx
women
deliv
babi
sever
thrombocytopenia
andor
ich
total
number
immun
mother
deliv
babi
boy
three
women
treat
ivig
two
inject
sinc
th
th
gw
respect
concentr
st
one
iuml
gw
respect
nd
iuml
examin
sampl
decis
treatment
base
low
plt
gl
fetu
cordocentesi
newborn
one
deliv
tween
healthi
rd
treat
woman
enter
program
gw
concentr
high
iuml
obtain
one
inject
ivig
babi
born
mild
thrombocytopenia
ich
sever
fnait
occur
newborn
detect
paklx
antibodi
concentr
maipa
st
th
gw
respect
nd
th
gw
respect
ich
observ
plt
count
four
one
summaryconclus
sever
thrombocytopenia
due
alloimmunis
prospect
studi
occur
pregnanc
paklx
could
improv
antihpa
detect
screen
program
consid
addit
diagnost
test
maipa
result
neg
alloimmunis
frequenc
higher
pregnanc
male
femal
fetu
background
foetomatern
platelet
alloimmun
fmpai
mainli
character
foetal
neonat
thrombocytopenia
fnait
sometim
reveal
intracrani
hemorrhag
ich
even
foetal
death
utero
fdiu
experi
pnil
milwauke
usa
report
diagnosi
alloimmun
carri
neonat
thrombocytopenia
case
clinic
symptomatolog
highli
suggest
alloimmun
etiolog
aim
aim
twoyear
studi
determin
frequenc
platelet
incompat
fnait
ich
fdiu
ii
evalu
frequenc
detect
platelet
alloantibodi
alloab
specif
case
incompat
method
platelet
genotyp
perform
hpa
beadchip
genotyp
kit
bioarray
solut
immucor
warren
nj
serolog
investig
carri
differ
method
complet
maipa
kit
apdia
bvba
turnhout
belgium
pack
lxtm
assay
immucor
gti
diagnost
waukesha
wi
hous
maipa
data
collect
use
laboratori
inform
manag
system
result
patient
file
analyz
incompat
demonstr
system
n
incompat
found
case
case
platelet
alloimmun
global
confirm
case
platelet
alloab
identifi
regardless
clinic
manifest
respect
respect
alloab
found
context
neonat
thrombocytopenia
ich
fdiu
followup
pregnanc
even
alloab
could
identifi
incompat
system
highli
associ
fnait
ich
fdiu
n
n
n
case
summaryconclus
studi
strongli
confirm
known
immunogen
hpa
system
highlight
overal
sever
incompat
definit
diagnosi
fmpai
difficult
make
due
present
technic
difficulti
detect
antibodi
system
howev
result
suggest
special
attent
paid
manag
pregnanc
incompat
due
frequenc
sever
foetalneonat
advers
event
background
fetal
neonat
alloimmun
thrombocytopenia
fnait
potenti
life
threaten
diseas
caus
matern
alloantibodi
format
fetal
human
platelet
antigen
hpa
account
fast
major
case
populationbas
screen
fnait
topic
debat
decad
logist
well
financi
major
challeng
screen
type
pregnant
women
recogn
neg
women
present
type
mostli
done
genotyp
costeffect
implement
screen
need
highthroughput
quick
lowcost
phenotyp
assay
aim
aim
develop
highthroughput
quick
lowcost
phenotyp
assay
order
identifi
neg
pregnant
women
method
autom
sandwich
elisa
develop
perform
phenotyp
use
murin
monoclon
antigpiiia
coat
antibodi
horseradishperoxidaseconjug
recombin
detect
antibodi
ensur
applic
highthroughput
test
potenti
screen
set
uppermost
plasma
daysold
store
edta
anticoagul
blood
tube
use
without
first
swirl
spin
two
phase
sampl
pregnant
women
test
compar
allel
discrimin
polymeras
chain
reaction
assay
golden
standard
first
phase
sampl
unselect
consecut
pregnant
women
test
second
phase
part
prospect
screen
studi
pregnanc
confirmatori
genotyp
restrict
sampl
arbitrari
set
od
elisa
develop
elisa
optim
requir
addit
handl
swirl
spin
store
tube
phase
consecut
sampl
test
phase
ii
elisa
perform
anoth
consecut
sampl
confirmatori
qpcr
two
phase
combin
sampl
total
neg
posit
pregnant
women
genotyp
assay
reach
sensit
cutoff
od
lead
specif
summaryconclus
quick
lowcost
reliabl
assay
phenotyp
develop
use
populationbas
screen
set
select
sampl
test
presenc
antibodi
plasma
nonmix
spin
tube
three
six
dayold
sampl
use
assay
applic
set
suboptim
condit
background
cytomegaloviru
cmv
seropreval
ireland
lower
report
mani
european
countri
studi
pregnant
women
found
irish
women
cmv
seroposit
comparison
western
europ
eastern
europ
africa
intern
studi
carri
irish
blood
transfus
servic
ibt
indic
rate
cmv
seroposit
irish
blood
donor
therefor
signific
proport
irish
donor
recipi
popul
suscept
primari
cmv
particular
concern
patient
certain
atrisk
group
verylow
birthweight
cmv
seroneg
neonat
cmv
seroneg
patient
undergo
transplant
cmv
seroneg
immunocompromis
patient
result
demand
provis
cmv
seroneg
blood
compon
ibt
evalu
abbott
alin
cmv
igg
assay
replac
cmv
mastazym
eia
total
ab
eia
aim
assess
perform
abbott
alin
cmv
igg
screen
assay
comparison
cmv
mastazym
eia
total
ab
eia
method
diagnost
sensit
determin
test
confirm
cmv
igg
posit
donor
extern
laboratori
sensit
assess
use
three
seroconvers
panel
n
analyt
sensit
calcul
use
linear
regress
analysi
first
intern
standard
anticmv
igg
diagnost
specif
determin
test
donor
evalu
discord
result
carri
use
architect
anticmv
igg
igm
assay
vida
anticmv
igg
igm
assay
result
diagnost
sensit
alin
anticmv
igg
assay
determin
seroconvers
sensit
report
sampl
reactiv
analyt
sensit
alin
cmv
igg
assay
determin
iuml
valid
report
discord
result
donor
sampl
test
alin
cmv
igg
assay
current
mastazym
total
assay
discord
result
observ
alin
anticmv
igg
positivemastazym
total
neg
test
sampl
classifi
discord
result
posit
neg
indetermin
discord
result
observ
alin
anticmv
igg
negativemastazym
total
posit
test
classifi
sampl
neg
overal
diagnost
specif
determin
summaryconclus
seroconvers
analyt
sensit
compar
alin
cmv
igg
assay
cmv
mastazym
total
ab
assay
architect
cmv
igg
assay
vida
igg
assay
slight
variat
attribut
individu
assay
cutoff
definit
vari
greatli
cmv
assay
must
note
determin
diagnost
specif
includ
indetermin
discord
result
test
carri
tri
character
discord
sampl
collabor
abbott
evalu
identifi
donor
isol
confirm
cmv
igm
antibodi
pool
donor
base
evalu
abbott
alin
cmv
igg
assay
suitabl
replac
mastazym
total
ab
assay
blood
donor
screen
background
africa
uniqu
set
challeng
regard
safe
blood
transfus
two
largest
contribut
factor
common
diseas
state
subsaharan
africa
ssa
requir
larg
amount
blood
lifesav
intervent
eg
malaria
highest
burden
infecti
diseas
transmiss
transfus
tapko
tour
sambo
found
ssa
often
led
binari
donor
base
exist
ssa
consist
voluntari
nonremuner
blood
donor
vnbd
famili
replac
donor
frd
transfus
centr
unabl
suppli
demand
reli
vnbd
voluntari
nonremuner
donor
safest
blood
donor
incent
altruist
motiv
social
pressur
donat
factor
may
induc
individu
know
suspect
infect
bloodborn
agent
donat
blood
nucleic
acid
test
nat
conjunct
serolog
test
gold
standard
test
howev
vast
distanc
high
temperatur
africa
make
transport
tradit
plasma
sampl
logist
challeng
mani
public
evalu
stabil
suitabl
eas
use
dri
blood
spot
db
nat
publish
gener
result
shown
compar
tradit
plasma
sampl
db
use
success
earli
infant
diagnosi
eid
program
hiv
mean
pcr
test
especi
africa
aim
demonstr
db
andor
dri
plasma
spot
dp
test
suitabl
blood
donor
screen
make
nat
test
wide
avail
africa
determin
diagnost
sensit
specif
test
dp
db
sampl
comparison
test
plasma
sampl
method
neg
new
donor
sampl
confirm
posit
donor
sampl
defin
routin
blood
safeti
screen
done
western
cape
blood
servic
screen
use
dri
blood
spot
kit
routin
test
complet
one
db
sampl
one
dp
sampl
blood
donor
prepar
analys
ultrio
elit
assay
panther
analys
summaryconclus
dbsdp
use
sampl
screen
blood
donor
invalid
rate
found
db
sampl
logist
dbsdp
well
suit
resourcepoor
countri
sampl
easi
obtain
fingerpick
sampl
could
use
transport
simplifi
sampl
leak
haemolys
due
high
temperatur
sampl
store
room
temperatur
dbsdp
demonstr
accept
specif
ultrio
elit
perform
well
regard
hiv
hcv
sensit
sensit
regard
hbv
high
could
due
low
errat
viral
load
background
sanquin
blood
suppli
respons
blood
transfus
servic
netherland
nation
screen
laboratori
sanquin
nss
annual
blood
plasma
donat
test
averag
sampl
per
day
year
infect
serolog
test
perform
use
prism
abbott
diagnost
sinc
mid
juli
serolog
test
hbsag
hiv
agab
antihcv
antihbc
done
abbott
alin
system
aim
compar
number
initi
repeatedli
reactiv
result
whole
blood
plasma
donat
sampl
rate
nonspecif
result
lead
deferr
donat
donor
prism
alin
assay
use
data
month
month
implement
alin
system
nss
method
initi
repeat
reactiv
rate
assay
run
either
prism
hbsag
hiv
plu
hcv
alin
hbsag
hiv
agab
combo
antihcv
calcul
januari
june
prism
august
decemb
alin
due
lack
true
confirmatori
method
antihbc
compar
rate
repeatedli
reactiv
result
prism
hbc
alin
antihbc
result
rate
repeat
reactiv
result
prism
p
alin
assay
follow
hbsag
p
versu
hiv
p
versu
antihcv
p
versu
rate
antihbc
reactiv
sampl
significantli
differ
prism
alin
studi
period
rate
initi
reactiv
sampl
three
main
screen
assay
hbsag
hiv
hcv
also
compar
alin
prism
assay
mainli
attribut
rather
high
number
initi
reactiv
alin
hiv
agab
result
due
initi
issu
blood
collect
tube
resolv
result
decemb
rate
initi
reactiv
sampl
decreas
significantli
lower
three
prism
assay
summaryconclus
introduct
alin
assay
lead
decreas
averag
repeat
reactiv
test
result
hbsag
hiv
hcv
compar
prism
mainli
due
lower
fals
reactiv
rate
alin
antihcv
assay
investig
first
time
multipl
time
donor
implement
alin
sanquin
aim
improv
oper
effici
also
minim
unjustifi
disapprov
donor
first
data
show
low
initi
repeat
reactiv
rate
alin
assay
inde
posit
impact
unnecessari
deferr
donat
donor
background
blood
bank
test
blood
donat
marker
infecti
diseas
play
import
role
maintain
safeti
blood
transfus
mandatori
serolog
test
switzerland
perform
antihcv
hiv
agab
hbsag
syphili
highli
specif
sensit
test
correspond
autom
essenti
purpos
aim
compar
studi
carri
evalu
usabl
newli
launch
alin
system
abbott
specif
infecti
diseas
paramet
hbsag
antihcv
hiv
combo
syphili
abbott
current
use
elisa
method
quadriga
befre
system
diasorin
formerli
siemen
healthcar
diagnost
method
studi
took
place
interregion
blood
transfus
servic
bern
switzerland
specif
paramet
studi
blood
donor
sera
first
time
repeat
donor
sampl
test
first
quadriga
free
system
enzygnost
hbsag
enzygnost
antihcv
enzygnost
hiv
integr
assay
newbiopk
tpha
assay
newmarket
biomed
sampl
retest
day
hbsag
antihcv
hiv
combo
syphili
alin
initi
reactiv
sampl
repeat
duplic
discriminatori
test
carri
repeatedli
reactiv
sampl
use
altern
screen
test
neutralis
hbsag
abbott
architect
system
immunoblot
hiv
hcv
syphilisinnolia
fujirebio
sampl
result
routin
individu
donat
nucleic
acid
test
hcv
hiv
hbv
roch
coba
system
avail
result
base
result
test
blood
donat
observ
specif
alin
assay
enzygnost
assay
summaryconclus
alin
system
easi
use
oper
short
introductori
train
provid
good
oper
effici
high
throughput
even
select
test
sampl
need
observ
specif
abbott
alin
versu
siemen
enzygnost
assay
compar
blood
donor
screen
set
unfortun
abl
analys
statist
specif
data
due
insuffici
number
donor
sampl
test
parallel
worth
mention
around
sampl
includ
studi
deriv
repeat
donor
previous
test
enzygnost
assay
first
time
donor
alin
assay
four
assay
system
exhibit
good
specif
highli
suitabl
practic
routin
blood
donor
screen
background
effect
screen
transfusiontransmiss
infect
essenti
ensur
safe
blood
transfus
world
health
organ
recommend
mandatori
serolog
test
blood
donat
human
immunodefici
viru
hiv
hepat
b
hbv
c
hcv
syphili
due
increas
demand
clinic
laboratori
need
reliabl
accur
autom
blood
screen
test
fulli
autom
coba
e
analys
use
elecsi
infecti
diseas
paramet
screen
donor
blood
sampl
aim
compar
perform
elecsi
infecti
diseas
paramet
coba
e
analys
roch
diagnost
commerci
avail
assay
routin
firsttim
blood
donor
screen
method
provid
result
etabliss
franc
du
sang
montpelli
blood
bank
particip
larg
multicentr
studi
coba
e
analys
follow
infecti
diseas
marker
assay
compar
hiv
elecsi
hiv
duo
versu
prism
hiv
plu
hcv
elecsi
antihcv
ii
versu
prism
hcv
hbv
surfac
antigen
hbsag
elecsi
hbsag
ii
versu
prism
hbsag
hbv
core
antigen
antibodi
antihbc
elecsi
antihbc
ii
versu
prism
hbcore
syphili
elecsi
syphili
versu
newbio
pk
tpha
assay
specif
test
use
residu
fresh
serum
sampl
unselect
firsttim
blood
donor
calcul
accord
assay
packag
insert
sitespecif
cutoff
sampl
test
use
compar
assay
retest
day
use
elecsi
assay
initi
reactiv
sampl
repeat
duplic
confirmatori
test
conduct
repeatedli
reactiv
sampl
confirmatori
test
hiv
nucleic
acid
test
nat
architect
hiv
agab
innolia
hiv
iii
score
assay
hcv
nat
architect
hcv
innolia
hcv
score
assay
hbsag
nat
architect
hbsag
elecsi
prism
hbsag
confirmatori
assay
antihbc
nat
hbsag
antihb
architect
antihbc
assay
syphili
architect
syphili
tp
innolia
syphili
score
assay
sensit
test
use
preselect
anonymis
posit
citratephosphatedextroseplasma
sampl
plasmatec
laboratori
product
compar
archiv
data
compar
assay
sensit
calcul
accord
final
nat
result
result
across
infecti
diseas
marker
specif
detect
repeatedli
reactiv
sampl
use
elecsi
versu
compar
assay
similar
versu
n
specif
analys
discrep
result
hiv
test
hcv
two
hbsag
eight
antihbc
five
syphili
sensit
elecsi
hiv
duo
assay
ci
higher
prism
hiv
plu
assay
ci
differ
statist
signific
sensit
elecsi
compar
assay
hcv
ci
hbsag
ci
antihbc
ci
syphili
ci
three
hcv
six
antihbc
sampl
classifi
neg
indetermin
exclud
analys
sensit
analys
two
discrep
result
hiv
test
three
hcv
five
antihbc
summaryconclus
elecsi
infecti
diseas
paramet
coba
e
analys
demonstr
high
specificitysensit
screen
firsttim
blood
donor
sampl
similar
clinic
perform
commerci
avail
assay
background
individu
plasma
serum
specimen
whole
blood
plasmapheresi
donor
test
absenc
infecti
agent
serolog
assay
prior
use
transfus
product
blood
deriv
therapeut
depart
plasma
analyt
pa
takeda
austria
haema
ag
grifol
germani
lab
high
throughput
high
level
autom
seek
altern
replac
current
serolog
test
system
abbott
prism
next
aim
allow
direct
comparison
two
final
candid
analyz
alin
abbott
coba
roch
diagnost
gmbh
side
side
evalu
carri
pa
haema
support
abbott
roch
provis
instrument
reagent
aim
compar
assay
specif
well
handl
perform
instrument
outcom
use
better
understand
potenti
specif
differ
practic
handl
aspect
throughput
etc
next
gener
serolog
analyz
method
two
candid
instrument
instal
pa
march
june
close
aliquot
routin
preselect
repeat
donor
provid
haema
run
studi
instrument
parallel
plasma
sampl
test
hb
antigen
ag
hcv
antibodi
ab
hiv
agab
partial
syphili
ab
serum
sampl
addit
test
hbc
ab
sampl
repeat
reactiv
result
rr
two
reactiv
result
three
test
confirm
confirmatori
test
count
fals
reactiv
necessari
sampl
size
calcul
base
onesid
comparison
proport
aim
detect
potenti
specif
differ
size
specifi
manufactur
instruct
two
differ
lot
test
three
main
assay
result
plasma
serum
sampl
test
result
repres
individu
donat
found
rr
one
instrument
two
sampl
confirm
posit
hbsag
hcv
two
other
indetermin
sampl
contain
low
level
antibodi
hcv
pcr
neg
detect
roch
system
percentag
fals
reactiv
result
five
assay
two
system
alin
hb
ag
total
sampl
test
hcv
ab
p
hiv
agab
p
syphili
ab
hbc
signific
differ
found
calcul
specif
studi
manufactur
data
potenti
influenc
sampl
matrix
kit
lot
assess
trend
toward
fals
reactiv
result
serum
vs
plasma
found
nearli
assay
clearcut
statist
differ
seen
lot
summaryconclus
studi
result
line
manufactur
specif
data
show
alin
hcv
ab
hiv
agab
assay
show
slightli
higher
specif
popul
plasma
serum
sampl
repeat
donor
prescreen
prism
possibl
influenc
test
specif
sampl
matrix
detect
need
investig
possibl
edit
complex
genom
target
fashion
revolution
basic
research
biotechnolog
therapeut
applic
well
rapid
develop
genom
edit
tool
particular
zincfing
nucleas
zfn
transcript
activatorlik
effector
nucleas
talen
crisprca
system
wide
rang
therapeut
option
beenand
bedevelop
unpreced
speed
therapeut
genom
edit
hematopoiet
cell
enabl
new
intervent
blood
immun
system
includ
novel
approach
treat
immunolog
disord
infecti
diseas
cancer
develop
gmpcompliant
protocol
manufactur
gene
edit
hematopoiet
stem
precursor
cell
hspc
well
chimer
antigen
receptor
car
cell
final
goal
provid
novel
cell
therapi
patient
suffer
primari
immunodefici
chronic
infect
human
immunodefici
viru
type
tumor
entiti
despit
great
success
improv
specif
engin
design
nucleas
induc
genotox
side
effect
introduc
mutat
chromosom
aberr
establish
novel
genomewid
assay
enabl
us
detect
chromosom
aberr
induc
offtarget
activ
also
ontarget
activ
microaberr
transloc
unparallel
sensit
toto
develop
protocol
allow
us
achiev
genom
edit
hematopoiet
cell
high
effici
assess
genotox
risk
associ
express
crisprca
nucleas
talen
clinic
relev
human
cell
form
basi
plan
phase
iii
clinic
studi
adopt
cell
therapi
act
proven
potent
mean
treat
bloodborn
tumor
solid
tumor
adopt
cell
therapi
includ
cell
genet
engin
tumor
specif
cell
receptor
tcr
chimer
antigen
receptor
car
addit
tumor
infiltr
cell
til
isol
tumor
lesion
expand
reprogram
vitro
prior
transfus
patient
antitumor
efficaci
act
product
depend
sever
paramet
includ
capac
cell
produc
cytokin
chemokin
granzym
featur
critic
effect
antitumor
respons
discuss
effort
develop
improv
act
product
futur
clinic
use
present
preclin
work
develop
til
therapi
nonsmal
cell
lung
cancer
addit
show
human
cell
divid
differ
subset
one
subset
highli
cytotox
find
may
help
improv
qualiti
genet
engin
cell
product
like
tcr
car
cell
product
background
baltic
state
estonia
latvia
lithuania
lot
common
locat
side
side
share
baltic
sea
gate
west
importantli
common
histori
member
ussr
suffer
year
soviet
occup
held
hand
km
long
human
chain
across
three
state
express
mutual
support
later
even
join
european
union
day
june
st
three
differ
bit
size
popul
languag
spoken
one
explain
path
toward
voluntari
unpaid
donat
vari
aim
aim
describ
journey
toward
voluntari
nonremuner
blood
donat
baltic
state
regain
independ
soviet
union
method
inform
collect
publish
unpublish
memori
annual
report
written
interview
latvian
lithuanian
colleagu
result
soviet
time
order
came
moscow
qualiti
control
conduct
capit
citi
latvia
riga
donor
mostli
paid
given
extra
vacat
day
big
factori
best
place
collect
blood
peopl
queu
donat
soviet
union
fell
apart
baltic
state
suddenli
got
freedom
respons
decid
estonia
first
edit
guidelin
prepar
use
qualiti
assur
blood
compon
taken
guidanc
lot
advic
came
finnish
colleagu
decid
move
toward
nonpaid
voluntari
donat
process
took
year
first
coupl
year
econom
difficult
reborn
state
money
less
valu
food
instead
cash
donor
given
rapese
oil
sugar
pasta
exampl
situat
improv
food
item
replac
small
symbol
gift
carri
sentiment
valu
way
year
lithuania
process
start
later
first
program
develop
framework
voluntari
nonremuner
donat
carri
result
donat
unpaid
second
program
initi
still
ongo
aim
toward
nonremuner
donat
end
reach
begin
main
obstacl
privat
blood
center
creat
unfair
market
condit
latvia
monetari
compens
blood
donat
still
exist
younger
gener
encourag
donat
blood
free
result
alreadi
seen
summaryconclus
common
start
point
guarante
result
least
exact
time
examin
circumst
lead
differ
outcom
could
benefit
countri
yet
start
move
toward
nonremuner
donat
well
consid
opposit
haemoglobin
hb
expect
significantli
differ
women
men
meanaesem
ae
vs
ae
gdl
p
percentag
femal
low
hb
gdl
percentag
male
hb
gdl
age
group
respect
ferritin
valu
higher
male
compar
femal
median
th
th
tile
vs
lgl
p
older
age
group
compar
younger
age
group
median
rang
age
group
femal
male
respect
percentag
femal
ferritin
lgl
percentag
male
ferritin
lgl
age
group
respect
white
blood
cell
count
wbc
slightli
higher
femal
compar
male
meanaesem
ae
vs
ae
p
percentag
femal
wbc
l
percentag
male
wbc
l
age
group
respect
none
wbc
l
platelet
count
plt
higher
femal
compar
male
meanaesem
ae
vs
ae
p
percentag
femal
plt
l
percentag
male
plt
l
age
group
respect
among
low
plt
count
caus
edtadepend
pseudothrombocytopenia
extrem
deviat
normal
seldom
refer
gp
investig
summaryconclus
first
time
donor
young
younger
year
age
femalemal
ratio
first
time
donor
data
ferritin
avail
low
ferritin
lgl
typic
male
first
time
donor
neither
low
hb
low
ferritin
even
significantli
lower
ferritin
younger
donor
femal
first
time
donor
preval
low
hb
gdl
low
iron
store
lgl
high
first
time
donor
highli
appreci
campaign
could
target
male
popul
even
gender
imbal
blood
center
must
awar
higher
preval
low
iron
store
youngest
donor
background
aim
assess
suitabl
prospect
blood
donor
protect
health
safeti
transfus
patient
select
process
alway
effect
obtain
relev
inform
blood
donor
time
manner
sever
reason
risk
remain
undetect
disclos
futur
donat
therefor
record
manag
postdon
inform
pdi
great
import
improv
transfus
safeti
donor
counsel
educ
well
overal
improv
select
process
aim
aim
studi
present
result
pdi
manag
croatian
institut
transfus
medicin
citm
effect
educ
activ
trend
method
analyz
report
pdi
record
twoyear
period
accord
type
inform
obtain
age
sex
blood
donor
total
number
donat
preced
pdi
time
receiv
inform
effect
inform
leaflet
pdi
launch
novemb
assess
compar
result
two
studi
year
result
total
pdi
record
donat
donat
follow
distribut
nonsexu
risk
tattoo
pierc
surgic
procedur
travel
histori
infect
contact
medic
reason
endoscopyinvas
diagnost
procedur
malign
autoimmun
diseas
sexual
risk
major
late
pdi
reveal
futur
donat
first
next
donat
second
subsequ
donat
mean
age
blood
donor
associ
pdi
ae
year
median
year
mean
age
donor
year
median
year
pdi
relat
male
donor
total
pool
citm
donor
use
chisquar
test
signific
differ
femal
male
donor
total
pdi
frequenc
distribut
earli
late
pdi
p
median
number
donat
preced
pdi
femal
donor
male
donor
implement
educ
leaflet
blood
donor
result
reduct
pdi
compar
p
effect
pronounc
p
compar
second
first
half
reduct
observ
type
pdi
except
infectionscontact
mostli
earli
pdi
malign
diseas
share
earli
pdi
increas
may
suggest
better
awar
blood
donor
import
inform
blood
bank
chang
health
statu
summaryconclus
studi
point
import
systemat
record
manag
pdi
includ
educ
blood
donor
need
provid
relev
fact
relat
health
safeti
donat
blood
time
manner
plan
improv
provid
inform
topic
poster
screen
donat
site
background
current
transfer
data
organ
andor
comput
system
limit
present
typic
proprietari
absenc
standard
refer
format
individu
organ
vendor
attempt
integr
dispar
databas
must
develop
uniqu
solut
aggreg
inform
multipl
sourc
complex
costli
constitut
signific
barrier
effect
analysi
data
improv
practic
inform
polici
aim
standard
definit
facilit
integr
key
data
item
use
blood
donat
transfus
report
initi
effort
map
intern
harmon
critic
step
blood
collectiondon
process
order
test
approach
method
collabor
process
serial
confer
call
correspond
inform
multin
consortium
expert
across
transfus
industri
attempt
creat
vocabulari
suffici
precis
definit
usabl
autom
system
foundat
blood
collectiontransfus
medicin
common
data
model
cdm
use
follow
step
defin
scope
activ
address
segment
key
process
identifi
set
data
element
segment
common
system
review
consid
exist
standard
definit
data
element
develop
draft
definit
data
element
releas
draft
public
domain
critic
review
refin
longterm
goal
gain
widespread
endors
result
standard
approach
blood
donat
map
identif
common
pathway
core
mappabl
data
element
denomin
data
associ
donor
characterist
blood
collect
select
first
segment
address
dictionari
vocabulari
common
term
creat
present
intern
comment
summaryconclus
develop
intern
consensu
core
element
definit
across
transfus
chain
critic
data
integr
autom
effort
expect
benefit
endeavor
includ
allow
establish
algorithm
autom
report
thu
reduc
handson
staff
time
reduc
time
resourc
need
integr
new
databas
allow
system
continu
use
exist
concept
definit
intern
also
provid
data
output
standard
format
support
abil
consist
analys
interpret
present
inform
regardless
data
sourc
establish
data
definit
new
system
develop
help
improv
compar
result
provid
common
data
model
research
polici
maker
improv
confid
data
integr
reliabl
deriv
inform
author
vox
sanguini
intern
societi
blood
transfus
vox
sanguini
suppl
basi
ration
decis
make
reduc
data
gather
effort
cost
thu
improv
opportun
efficientcomplex
data
analysi
standard
transfus
medicin
dataset
first
step
achiev
autom
data
transfer
analysi
need
global
drive
patient
safeti
research
innov
best
busi
practic
step
must
address
precis
method
data
exchang
identif
respons
entiti
mainten
develop
engag
comput
system
develop
red
blood
cell
rbc
alloantibodi
develop
subset
individu
follow
exposur
nonself
rbc
transfus
pregnanc
activ
antibodi
lead
difficulti
locat
compat
rbc
acut
delay
hemolyt
transfus
reaction
hemolyt
diseas
newborn
alloimmun
underestim
due
part
antibodi
evanesc
random
natur
posttransfus
antibodi
screen
fragment
medic
care
lack
widespread
antibodi
registri
factor
influenc
develop
detect
alloantibodi
well
understood
transfus
burden
one
risk
factor
alloimmun
though
mani
highli
transfus
individu
never
form
alloantibodi
despit
exposur
mani
rbc
unit
mani
nonself
abo
blood
group
antigen
individu
sickl
cell
diseas
scd
myelodysplast
syndrom
md
like
form
rbc
alloantibodi
patient
popul
individu
rheumatolog
form
autoimmun
though
chronic
transfus
also
higher
averag
risk
form
rbc
alloantibodi
inflamm
broad
sens
one
common
thread
among
diagnos
associ
high
preval
rate
rbc
alloimmun
reductionist
murin
model
support
type
inflamm
includ
virallik
stimuli
around
time
rbc
exposur
associ
increas
likelihood
alloantibodi
format
strategi
transfus
avoid
extend
antigen
match
beyond
abo
rh
would
benefici
prevent
new
rbc
alloantibodi
format
especi
patient
highest
risk
background
uniqu
genet
makeup
omani
popul
make
rich
genet
blood
disord
omani
popul
gene
carrier
popul
aaaa
around
omani
nation
carri
gene
hb
carri
gene
bthalassaemia
recent
statist
show
around
patient
thalassaemia
major
scd
oman
rbc
abnorm
common
oman
defici
found
male
femal
omani
known
highest
frequenc
thalassaemia
report
far
race
although
blood
transfus
one
support
treatment
scd
caus
seriou
complic
patient
alloimmun
red
blood
cell
one
consequ
blood
transfus
alloimmunis
rbc
caus
haemolyt
transfus
reaction
may
trigger
hyperhaemolysi
transfus
patient
rbc
destroy
alloantibodi
caus
delay
process
transfus
costli
time
consum
high
number
patient
develop
alloantibodi
may
indic
major
differ
patient
donor
popul
may
also
indic
lack
control
generalis
sickl
patient
manag
polici
oman
decis
transfus
scd
patient
left
physician
attend
patient
aim
studi
aim
highlight
increas
number
alloimmunis
sickl
cell
patient
royal
hospit
get
new
case
sickl
patient
alloantibodi
year
acknowledg
case
may
help
assess
current
practic
transfus
scd
patient
help
defin
donor
patient
popul
differ
method
patient
recruit
royal
hospit
studi
edta
blood
sampl
taken
antibodi
screen
test
posit
case
antibodi
identifi
test
done
captur
techniqu
use
immucor
neo
machin
result
scd
patient
patient
male
femal
mean
age
year
rang
year
scd
case
posit
alloantibodi
femal
male
age
rang
year
posit
scd
trait
bthal
patient
develop
one
antibodi
howev
case
multipl
antibodi
also
detect
patient
singl
alloantibodi
two
antibodi
three
antibodi
four
antibodi
five
antibodi
major
case
igg
rh
antigen
anti
major
follow
antid
antik
antic
antic
antijk
antijk
b
antifi
anti
anti
anti
antikp
antifi
b
igm
summaryconclus
rbc
alloimmunis
rate
high
oman
major
patient
affect
femal
interestingli
sickl
trait
patient
also
transfus
develop
alloantibodi
practic
transfus
rh
kell
match
blood
unit
implement
four
year
ago
still
high
alloimmun
percentag
achiev
background
ghana
routin
pretransfus
investig
patient
sickl
cell
diseas
scd
involv
abod
type
immedi
spin
crossmatch
without
screen
irregular
rbc
antibodi
aim
determin
preval
specif
risk
factor
rbc
alloantibodi
multitransfus
patient
scd
method
crosssect
studi
multitransfus
patient
scd
two
tertiari
hospit
ghana
perform
particip
data
demographi
transfus
medic
histori
record
antibodi
screen
identif
test
done
sanquin
netherland
standard
serolog
use
liss
enhanc
papain
treat
rbc
panel
cell
enzym
character
rhd
gene
done
multiplex
ligas
amplif
assay
logist
regress
use
determin
associ
patient
characterist
ie
sex
age
enrol
continu
age
first
transfus
categor
previou
pregnanc
number
transfus
unit
year
last
transfus
presenc
alloantibodi
result
patient
male
femal
median
age
year
rang
includ
median
number
transfus
rang
median
year
last
transfus
rang
year
patient
antirbc
antibodi
detect
antibodi
weakli
reactiv
enzym
treat
cell
panreact
possibl
repres
autoantibodi
antibodi
high
frequenc
antigen
seven
patient
enzymeonli
antil
demonstr
like
natur
occur
antibodi
thu
least
patient
alloimmun
demonstr
suspect
patient
alloantibodi
enzym
besid
alloantibodi
known
specif
antid
antidc
anti
antic
anti
antik
anti
antil
antigo
three
antibodi
reactiv
fy
ab
cell
two
antibodi
yet
unidentifi
specif
detect
six
dpatient
pregnant
antid
togeth
antic
two
patient
found
three
four
patient
antid
rhd
variant
gene
demonstr
dauallel
diii
type
logist
regress
reveal
none
risk
factor
analys
associ
presenc
antibodi
patient
immunobiolog
red
cell
alloimmun
fiftyeight
patient
experienc
advers
reaction
shortli
transfus
patient
dark
urin
advers
reaction
associ
number
unit
receiv
ci
p
presenc
antibodi
p
summaryconclus
least
multitransfus
patient
scd
alloimmun
could
demonstr
mainli
direct
rh
antigen
enzym
reactiv
coupl
absenc
antibodi
seven
patient
probabl
haemolyt
reaction
known
evanesc
especi
non
rh
antibodi
suggest
possibl
low
titr
disappear
clinic
relev
antibodi
given
high
immun
rate
togeth
high
frequenc
advers
transfus
reaction
pretransfus
screen
rbc
antibodi
consid
patient
scd
background
rh
blood
group
system
mainli
antigen
one
immunogen
divers
clinic
import
proteinbas
blood
group
antibodi
antid
may
induc
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
antid
prophylax
becom
ineffect
antid
immun
occur
approxim
popul
carri
rhd
allel
associ
reduc
antigen
express
qualit
variant
epitop
lack
produc
antid
antibodi
usual
term
partial
contrast
weak
commonli
defin
quantit
variant
epitop
make
antid
del
weak
form
antigen
detect
routin
serolog
test
del
individu
alreadi
develop
antid
antibodi
wherea
other
group
contain
qualit
quantit
chang
aim
investig
prompt
find
discrep
result
type
antigen
pregnant
woman
rd
pregnanc
st
deliveri
abort
st
trimest
routin
serolog
techniqu
detect
neg
presenc
antibodi
alloantid
clinic
signific
titr
noninvas
test
statu
foetu
matern
peripher
blood
indic
applic
due
presenc
rhd
gene
woman
dna
sampl
isol
buccal
swab
aim
investig
discrep
determin
underli
rhd
genotyp
method
blood
sampl
dna
peripher
blood
buccal
swab
pregnant
woman
investig
routin
blood
group
antibodi
test
perform
column
agglutin
two
antid
sera
iddiaclon
antid
igg
cell
line
biorad
antid
duo
igmigg
clone
immucor
use
adsorptionelut
test
identif
del
phenotyp
initi
rhd
genotyp
perform
rtpcr
exon
dna
buccal
swab
resolut
perform
use
pcrssp
fluogen
innotrain
diagnostik
gmbh
sequenc
perform
sanger
analysi
innotrain
diagnostik
gmbh
result
genotyp
identifi
rhd
posit
cecertifi
pcrssp
kit
fluogen
sanger
sequenc
rhd
exon
reveal
presenc
nucleotid
delet
posit
specif
allel
rhd
nucleotid
chang
result
amino
acid
chang
caus
del
phenotyp
presenc
antigen
prove
adsorptionelut
techniqu
titr
antid
rise
pregnanc
level
two
week
deliveri
newborn
deliv
sc
without
sign
hemolyt
diseas
blood
group
newborn
reveal
blood
group
neg
dat
neg
test
del
perform
summaryconclus
case
report
show
femal
rhd
allel
abl
develop
strong
antid
immun
type
del
phenotyp
belong
partial
del
subgroup
presenc
variant
rhd
gene
mother
disabl
antenat
fetal
genotyp
matern
blood
current
method
requir
attent
approach
care
pregnanc
support
mh
czdro
uhkt
rvovfn
ea
scharberg
rothenberg
urtzel
n
gillhub
seyboth
e
richter
g
rink
p
bugert
institut
transfus
medicin
immunohematolog
drkbsd
uhe
badenbaden
institut
transfus
medicin
immunolog
heidelberg
univers
medic
faculti
mannheim
mannheim
germani
background
rb
low
preval
antigen
diego
blood
group
system
found
famili
clinic
signific
antirb
unknown
far
isbt
allel
name
di
allel
molecular
basi
rb
antigen
gnomad
databas
gene
variant
found
one
sequenc
genom
allel
frequenc
aim
prove
frequenc
allel
popul
gain
rb
posit
donor
perform
molecular
screen
blood
donor
antibodi
screen
test
accident
contain
rb
posit
test
cell
found
antirb
common
antibodi
specif
frequenc
antibodi
patient
blood
donor
prove
method
molecular
screen
blood
donor
develop
pcrssp
method
antibodi
screen
test
patient
blood
donor
perform
gel
techniqu
biorad
ahg
idcard
use
cell
screen
panel
drkbsd
src
includ
rb
posit
test
cell
posit
reaction
rb
posit
cell
confirm
addit
rb
posit
test
cell
differ
sourc
addit
antibodi
exclud
identifi
method
use
antibodi
identif
panel
drkbsd
irc
result
molecular
screen
di
allel
blood
donor
reveal
singl
posit
individu
within
first
week
usag
antibodi
screen
test
accident
contain
rb
posit
test
cell
patient
antirb
found
patient
test
laboratori
differ
part
germani
laboratori
stop
use
rb
posit
lot
avoid
expens
time
consum
identif
conform
test
randomli
test
blood
donor
antiantirb
also
present
summaryconclus
despit
low
frequenc
di
allel
antirb
frequent
unexpect
antibodi
patient
blood
donor
germani
obvious
natur
occur
even
frequent
antiwr
antivw
found
previou
studi
around
patient
donor
nation
blood
center
ministri
health
sport
yangon
myanmar
hemovigil
detect
everi
event
patient
reaction
donor
complic
also
incid
near
miss
definit
improv
qualiti
blood
transfus
servic
especi
situat
implement
standard
one
time
possibl
healthcar
system
myanmar
still
stage
requir
prioriti
clinic
profess
limit
resourc
support
role
support
servic
includ
transfus
servic
still
center
interest
priorit
health
care
system
blood
transfus
servic
practic
myanmar
sinc
real
essenc
transfus
servic
hidden
behind
laboratori
practic
transfus
regard
part
laboratori
investig
hospit
laboratori
take
care
test
blood
donat
replac
donor
kind
transfus
servic
laboratori
umbrella
still
practic
myanmar
except
nation
blood
center
nbc
establish
accord
blood
blood
product
law
law
formul
cohes
strategi
blood
safeti
global
databas
studi
sent
questionnair
assess
safeti
statu
transfus
servic
nbc
notic
data
support
correct
action
safeti
time
onward
activ
retrospect
review
exist
data
introduct
record
prospect
find
process
error
event
hospit
blood
bank
record
take
action
local
level
cost
everi
unit
blood
support
govern
nation
blood
blood
product
committe
establish
steer
committe
work
hard
get
cooper
everi
servic
aim
prevent
undesir
event
establish
nation
level
polici
standard
guidelin
sustain
servic
qualiti
conclus
use
essenc
hemovigil
tool
qualiti
transfus
servic
improv
step
step
fulfil
gap
spite
limit
resourc
system
start
local
extend
region
level
get
agreement
import
hemovigil
result
final
approach
nation
level
endors
background
erron
transfus
aboincompat
aboi
blood
almost
alway
reflect
prevent
breakdown
transfus
protocol
standard
oper
procedur
disastr
consequ
signific
morbid
mortal
incid
need
investig
systemat
manner
identifi
system
vulner
mitig
risk
improv
patient
safeti
sinc
report
shot
ask
score
extent
caus
incid
attribut
key
factor
staff
environment
organis
governmentregulatori
help
recognis
key
factor
identifi
whilst
investig
incid
aim
understand
unintent
transfus
aboi
blood
compon
continu
happen
despit
standard
procedur
nation
guidanc
avail
method
retrospect
analysi
unintent
transfus
aboi
blood
compon
report
shot
inclus
done
identifi
common
theme
recognis
area
improv
inform
provid
use
shot
human
factor
investig
tool
hfit
review
understand
error
occur
result
sixtyseven
unintent
aboi
transfus
report
major
red
cell
transfus
aboi
plasma
platelet
transfus
also
seen
error
occur
clinic
area
could
detect
point
administr
case
error
could
detect
point
administr
primari
laboratori
error
incid
review
data
hfit
case
aboi
case
total
score
staff
culpabl
compar
total
score
three
organis
system
factor
dispar
obviou
aboi
red
cell
case
score
maximum
staff
culpabl
ie
compar
combin
total
score
given
factor
preced
year
hf
score
avail
howev
emphasi
staffrel
culpabl
demonstr
case
includ
outcom
local
case
review
mention
staffrel
retrain
disciplinari
procedur
risk
haemolysi
seriou
harm
like
aboi
red
cell
compon
result
death
major
morbid
minor
advers
reaction
case
one
result
convict
manslaught
least
two
staff
dismiss
summaryconclus
transfus
never
event
continu
occur
evid
investig
incid
focu
mainli
staff
fail
consist
identifi
system
wide
chang
need
incorpor
address
preval
issu
nation
recommend
safeti
alert
use
bedsid
checklist
immedi
prior
administr
issu
support
prevent
error
never
event
continu
persist
current
approach
ineffect
often
lead
apport
blame
rather
understand
oftencompl
multidimension
factor
contribut
error
must
replac
holist
approach
address
local
work
pressur
embrac
advanc
autom
technolog
like
electron
prescrib
barcod
scan
confirm
trar
n
possibl
relat
treatment
n
trar
probabl
n
definit
relat
treatment
n
trar
grade
n
grade
none
grade
recipi
convent
wb
n
ar
n
fnhtr
n
taco
n
trali
n
unclassifi
transfus
reaction
confirm
trar
n
possibl
relat
treatment
n
trar
probabl
n
definit
relat
treatment
n
trar
grade
n
grade
n
grade
mirasoltr
wb
transfus
pregnant
women
trar
grade
probabl
relat
transfus
mirasoltr
wb
transfus
convent
wb
patient
year
old
result
n
trar
recipi
mirasoltr
wb
n
recipi
convent
wb
summaryconclus
time
data
report
trar
expand
hv
infrastructur
help
improv
hv
system
ghana
wb
transfus
routin
use
ghana
trar
recipi
mirasoltr
wb
recipi
convent
wb
addit
mirasoltr
wb
safe
transfus
pregnant
women
pediatr
patient
haematolog
monash
health
melbourn
australia
background
transfusionassoci
graftversushost
diseas
tagvhd
rare
usual
fatal
prevent
provis
irradi
blood
product
atrisk
individu
receiv
nucleosid
analogu
alemtuzumab
bendamustin
hodgkin
lymphoma
hl
durat
risk
uncertain
ensur
individu
correctli
receiv
lifelong
irradi
blood
compon
current
recommend
anzsbt
bsh
guidelin
challeng
australia
platelet
routin
irradi
red
blood
cell
rbc
aim
determin
whether
patient
receiv
fludarabin
cladribin
bendamustin
alemtuzumab
dacarbazin
hl
appropri
receiv
irradi
rbc
secondari
outcom
includ
rate
tagvhd
unintend
exposur
nonirradi
compon
factor
influenc
correct
issu
irradi
rbc
transfus
manag
plan
provis
adequ
clinic
inform
blood
request
method
perform
retrospect
audit
identifi
patient
receiv
therapi
indic
risk
tagvhd
use
pharmaci
dispens
record
januari
octob
monash
health
multicampu
univers
hospit
melbourn
australia
diagnosi
treatment
date
group
hold
g
h
request
rbc
transfus
followup
inform
sourc
laboratori
medic
record
result
identifi
patient
receiv
fludarabin
n
bendamustin
n
cladribin
n
dacarbazin
hl
n
alemtuzumab
n
median
age
patient
year
rang
male
median
followup
month
rang
postexposur
patient
receiv
transfus
correctli
receiv
irradi
rbc
remain
haematologyoncolog
receiv
total
unirradi
rbc
patient
rectifi
subsequ
transfus
case
tagvhd
median
followup
month
rang
first
rbc
transfus
medic
administr
patient
g
h
request
median
month
rang
request
suffici
clinic
inform
prompt
irradi
hl
medic
detail
ask
irradi
compon
prevent
strategi
employ
transfus
manag
plan
haematolog
patient
implement
march
audit
patient
written
day
prior
day
medic
exposur
two
written
follow
inadvert
unirradi
rbc
transfus
patient
identifi
audit
laboratori
flag
gener
prospect
pharmaci
dispens
record
sent
blood
bank
identifi
atrisk
patient
hospit
transit
electron
medic
record
emr
alert
gener
emr
order
transfus
exposur
medic
howev
clinic
awar
document
remain
vital
addit
measur
includ
patient
educ
alert
card
ongo
collabor
medic
staff
encourag
transfus
plan
summaryconclus
recognit
patient
risk
tagvhd
remain
low
even
among
haematolog
unit
make
progress
ensur
provis
lifelong
irradi
blood
compon
patient
expos
nucleosid
analogu
alemtuzumab
well
hl
patient
implement
emr
addit
strategi
domain
import
prevent
tagvhd
background
blood
transfus
consid
essenti
element
manag
patient
global
might
riski
transfus
relat
advers
reaction
may
occur
less
adher
transfus
polici
standard
guidelin
regard
screen
blood
infecti
diseas
genuin
need
transfus
abo
compat
follow
monitor
drastic
howev
patient
assess
transfus
especi
patient
bedsid
post
transfus
also
equal
import
aim
newli
establish
hospit
work
toward
best
possibl
manag
patient
regard
minim
transfus
error
highlight
lack
practic
transfus
conduct
studi
observ
complianc
rate
document
transfus
form
healthcar
staff
also
observ
complianc
line
action
taken
case
occurr
transfus
reaction
method
observ
studi
conduct
nibd
bmt
pech
campu
februari
februari
ethic
approv
obtain
prior
studi
transfus
form
transfus
fill
form
provid
inform
document
blood
product
receiv
name
employe
ident
number
date
time
receiv
blood
product
patient
name
medic
record
number
unit
patient
wrist
band
transfus
form
abo
compat
unit
form
medic
record
number
wrist
band
name
employe
ident
number
two
healthcar
staff
start
transfus
transfus
start
complet
time
time
temperatur
blood
pressur
puls
initi
staff
time
order
onset
minut
complet
transfus
also
includ
transfus
reaction
form
also
fill
healthcar
staff
data
analyz
use
spss
version
result
total
transfus
form
analyz
complianc
rate
form
avail
sourc
note
partial
complet
fill
higher
complianc
seen
initi
month
hospit
establish
later
month
pvalu
highest
non
complianc
seen
document
initi
duti
doctor
transfus
form
complet
transfus
highest
complianc
seen
document
name
healthcar
nurs
staff
start
transfus
total
advers
event
report
red
blood
cell
platelet
mean
time
start
symptom
hour
minut
red
blood
cell
platelet
hour
minut
transfus
instantli
stop
symptom
appear
delay
time
action
taken
resolv
reaction
time
appear
symptom
time
start
medic
document
error
free
blood
bag
return
blood
bank
discard
hour
per
polici
hospit
summaryconclus
studi
conduct
highlight
scarc
practic
implement
healthcar
staff
context
document
report
transfus
reaction
hospit
stringent
action
taken
adher
complianc
healthcar
staff
avoid
morbid
mortal
believ
also
help
provid
baselin
inform
process
prepar
nation
guidelin
protocol
blood
transfus
procedur
buser
holbro
l
infanti
region
blood
transfus
servic
swiss
red
cross
basel
basel
switzerland
make
blood
suppli
safer
pathogen
inactiv
pi
technolog
develop
base
photochem
amotosalenuva
riboflavin
uv
uvc
light
treatment
reduc
potenti
pathogen
blood
compon
gain
safeti
might
howev
offset
target
effect
technolog
virtual
clinic
platelet
transfus
trial
demonstr
post
transfus
increment
pi
platelet
plt
compon
lower
compar
convent
compon
indic
differ
biolog
behaviour
surviv
clearanc
nontreat
treat
plt
publish
studi
also
suggest
shorter
surviv
platelet
vivo
anim
studi
addit
data
rate
alloimmun
refractori
transfus
pi
platelet
show
discrep
result
anim
studi
suggest
reduct
rate
alloimmun
transfus
leukoreduc
pi
plt
compar
convent
plt
clinic
set
publish
data
includ
recent
report
show
differ
rate
hla
class
ii
alloimmun
two
current
avail
photochem
base
pi
technolog
pi
plt
compon
sure
benefit
patient
regard
pathogen
safeti
impact
potenti
target
effect
possibl
impair
efficaci
pi
plt
transfus
need
investig
background
brucellosi
endem
diseas
still
major
health
problem
saudi
arabia
ministri
health
saudi
arabia
list
brucellosi
notifi
diseas
due
endem
last
ten
year
incid
decreas
significantli
approxim
case
per
still
higher
develop
countri
humanto
human
transmiss
extrem
rare
includ
breast
feed
transplacent
sexual
blood
transfus
five
case
brucellosi
blood
transfus
report
literatur
brucella
transmiss
blood
transfus
like
underreport
due
long
incub
time
week
rang
day
month
vagu
clinic
present
lack
hemovigil
system
endem
area
allohsct
autolog
autohsct
hsct
patient
mean
correct
count
increment
cci
respect
mean
cci
decreas
linear
fashion
day
day
pc
day
day
respect
although
number
pc
transfus
day
autohsct
patient
small
n
background
nipah
viru
niv
paramyxoviru
genu
henipaviru
emerg
late
malaysia
sinc
identifi
caus
sporad
outbreak
sever
febril
diseas
bangladesh
india
niv
infect
frequent
associ
sever
respiratori
neurolog
diseas
infect
human
transmiss
human
inhal
contact
consumpt
niv
contamin
food
nipah
viru
niv
belong
list
pathogen
identifi
potenti
global
pandem
aim
studi
aim
investig
efficaci
theraflex
uvplatelet
system
inactiv
niv
platelet
concentr
pc
theraflex
uvplatelet
system
macopharma
use
uvc
light
without
need
addit
photoact
compound
method
plasma
reduc
pc
bc
plasma
addit
solut
ssp
spike
viru
suspens
vv
pc
n
ml
uvcirradi
macotron
uv
machin
macopharma
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
standard
jcm
titr
niv
malaysia
determin
tissu
cultur
infect
dose
tcid
endpoint
titrat
microtitr
plate
assay
vero
cell
atcc
tm
result
infect
assay
demonstr
uvc
irradi
dosedepend
inactiv
niv
spike
niv
titer
bag
bag
log
tcid
ml
receiv
pc
uvc
dose
jcm
higher
niv
inactiv
detect
limit
system
log
tcid
ml
result
log
reduct
factor
bag
bag
summaryconclus
result
demonstr
theraflex
uvplatelet
procedur
effect
technolog
inactiv
niv
contamin
pc
vs
ae
plateletsunit
p
wherea
platelet
content
apheresi
pc
chang
ae
vs
p
summaryconclus
pathogen
reduct
result
transfus
older
pc
averag
without
alter
number
pc
order
use
pc
per
patient
pathogen
reduct
improv
pc
stock
manag
without
increas
platelet
demand
despit
lower
platelet
content
buffi
coat
pc
pr
implement
donor
donat
donor
adher
right
thing
transfus
procedur
last
step
multiprocess
suppli
chain
task
match
suppli
demand
requir
donor
manag
consid
averag
consumpt
rate
weekli
monthli
basi
also
insight
variabl
order
distribut
possibl
attribut
blood
group
requir
sinc
hospit
blood
bank
usual
deepli
interwoven
often
expost
data
avail
forecast
method
implement
thorough
analysi
order
pattern
set
weekli
target
inventori
safeti
level
requir
close
inform
gap
collect
plan
need
identifi
possibl
bottleneck
prevent
plan
intership
chang
messag
urgenc
build
reserv
donor
pool
constant
analysi
collect
mobil
kpi
allow
donor
manag
implement
rollingwav
plan
approach
continu
adapt
chang
requir
unexpect
event
overal
systemat
variabl
variabl
happen
demand
side
order
quantiti
attribut
blood
group
distribut
subject
chang
howev
also
suppli
subject
signific
variat
donor
respons
rate
attrit
deferr
overal
avail
donor
constant
data
collect
facetofac
interview
method
right
donat
firsttim
donor
attend
studi
region
blood
centr
citi
turkey
survey
includ
item
accord
standard
tpb
predictor
attitud
selfefficaci
intent
selfident
anticip
regret
donat
anxieti
paraphernalia
anxieti
person
moral
norm
descript
norm
satisfact
motiv
also
assess
firsttim
donor
relat
predictor
intent
confirm
correl
analys
predictor
distribut
analys
multipl
linear
regress
number
goodnessoffit
indic
calcul
examin
test
model
ibm
amo
spss
result
goodnessoffit
test
propos
model
provid
better
fit
data
model
cmindf
moreov
result
indic
fit
propos
model
data
could
improv
modif
inclus
path
motiv
attitud
selfident
intent
moreov
inclus
path
donat
anxieti
intent
selfefficaci
attitud
contrari
recent
analys
suggest
opposit
path
evalu
goodnessoffit
test
show
good
result
revis
model
valu
cmindf
close
perfect
fit
revis
model
reveal
attitud
strongest
posit
direct
predictor
intent
follow
person
moral
norm
selfident
motiv
anticip
regret
path
coeffici
respect
donat
anxieti
neg
direct
predictor
intent
satisfact
strongest
posit
indirect
predictor
intent
via
attitud
follow
selfefficaci
paraphernalia
anxieti
neg
indirect
predictor
intent
descript
norm
show
signific
model
account
varianc
intent
summaryconclus
find
suggest
sever
potenti
avenu
enhanc
donor
retent
result
obtain
studi
provid
import
data
standpoint
donor
retent
implement
futur
strategi
turkish
red
crescent
background
transposetransfus
transplant
protect
select
donor
european
consortium
project
includ
partner
countri
review
donor
select
protect
polici
substanc
human
origin
soho
one
main
issu
current
donor
select
system
transpos
aim
tackl
mani
criteria
evid
base
transpos
consortium
therefor
tri
reassess
select
criteria
revis
need
provid
recommend
evidencebas
possibl
transpos
addit
add
current
european
director
qualiti
medicin
healthcar
edqm
guidelin
emphas
donor
safeti
aim
aim
compar
exist
donor
elig
criteria
throughout
europ
compil
list
risk
consid
evidenceor
consensusbas
deferr
criteria
provid
uniform
donor
screen
criteria
method
three
horizont
workpackag
wp
coordin
dissemin
evalu
project
four
technic
one
specif
deliver
mileston
regularli
produc
inventori
donor
select
protect
practic
develop
riskbas
guidelin
donor
select
protect
develop
standard
donor
health
questionnair
dhq
train
courseworkshop
use
guid
principl
guidelin
dhq
transpos
project
launch
septemb
complet
spring
complet
work
octob
complet
work
june
recent
commenc
result
use
deliver
creat
creat
indepth
inventori
current
practic
donor
select
protect
includ
overview
similar
differ
across
european
countri
across
soho
type
agreement
amongst
expert
exist
guidelin
often
base
precautionari
principl
rather
risk
assess
consequ
develop
guidelin
donor
select
protect
make
effort
also
emphas
donor
safeti
evidencebas
way
via
use
riskbas
assess
result
standard
dhq
common
trunk
depth
question
per
soho
summaryconclus
impact
outcom
transpos
threefold
first
outcom
expect
help
revis
donor
select
protect
relat
eu
direct
second
set
guid
principl
donor
select
protect
guidelin
facilit
eu
member
state
take
next
step
implement
donor
select
protect
polici
consist
clearcut
way
benefit
donor
recipi
soho
third
standard
donor
health
questionnair
care
guid
localregionaln
adjust
becom
avail
per
soho
use
wide
consequ
enabl
comparison
preval
certain
risk
riski
behaviour
throughout
europ
background
transposetransfus
transplant
protect
select
donor
european
consortium
project
includ
partner
countri
review
donor
select
protect
polici
blood
plasma
tissu
assist
reproduct
technolog
art
stem
cell
togeth
soho
donor
select
criteria
dsc
europ
base
eudirect
guidelin
countri
addit
criteria
literatur
show
particular
criteria
outdat
riskbas
often
lead
unnecessari
donor
deferr
underestim
risk
donor
aim
provid
comprehens
inventori
current
system
select
protect
donor
donat
critic
review
recommend
overarch
donor
health
questionnair
dhq
includ
necessari
criteria
current
use
differ
eumemb
state
eum
method
indepth
semistructur
interview
key
stakehold
blood
collect
conduct
identifi
main
topic
improv
current
dsc
form
basi
survey
sent
profession
collect
institut
soho
get
feedback
current
system
mani
eum
organis
possibl
questionnair
sent
total
expert
blood
plasma
tissu
stem
cell
art
complet
questionnair
receiv
inform
lack
addit
expert
ask
recommend
upon
dsc
result
blood
plasma
donat
four
main
area
concern
dsc
identifi
riskbas
select
adapt
flexibl
consist
stakehold
agre
dsc
often
outdat
lack
evid
henc
lead
unnecessari
deferr
donor
underestim
risk
donor
suggest
base
dsc
group
riskassess
riskbas
select
conduct
research
achiev
standard
risk
percept
evidencebas
deferr
either
safeti
recipi
donor
criteria
could
made
detail
fit
specif
group
defer
less
donor
adapt
furthermor
implement
criteria
consid
easi
abolish
criteria
regard
risk
anymor
seem
almost
imposs
flexibl
addit
deferr
period
perceiv
long
seen
neg
ie
jeopard
donor
return
intent
posit
ie
risk
safeti
consist
chang
legisl
guidanc
oftenment
suggest
improv
dsc
specif
feedback
plasma
donat
reveal
mani
whole
blood
topic
applic
plasmaonli
donor
eg
parasit
infect
malaria
deferr
need
travel
histori
deferr
need
recent
bacteri
viral
infect
deferr
period
current
long
clear
need
research
plasma
collectionrel
issu
identifi
summaryconclus
dsc
perceiv
redund
substanti
number
aspect
stakehold
besid
achiev
goal
save
suffici
soho
patient
mani
regul
could
improv
diminish
deferr
decreas
donor
risk
transpos
add
review
improv
harmonis
regul
criteria
furthermor
transpos
provid
suggest
improv
direct
guidelin
dhq
focus
donor
health
protect
safeti
donat
also
remov
deferr
criteria
relev
anymor
offer
futur
research
agenda
make
dsc
evidencebas
background
transpos
transfus
transplant
protect
select
donor
european
commiss
cofund
project
particip
stakehold
notforprofit
privat
blood
collect
organ
well
research
offici
project
aim
creat
new
evidencebas
donor
select
criteria
well
guid
principl
risk
assess
threat
safeti
substanc
human
origin
soho
except
solid
organ
part
inventori
current
donationrel
risk
perform
includ
investig
type
number
advers
event
report
aim
aim
present
overview
report
advers
event
plasma
whole
blood
donat
europ
compar
anticip
risk
rate
transpos
stakehold
method
nation
local
data
advers
reaction
year
seriou
mild
whole
blood
plasma
donor
collect
relev
stakehold
eighteen
nineteen
respect
stakehold
also
ask
grade
import
anticip
donor
risk
accord
sever
level
evid
preval
compar
relev
risk
categori
evalu
stakehold
categori
provid
data
well
heterogen
categori
number
result
thirteen
stakehold
provid
data
advers
event
whole
blood
donat
given
year
includ
total
thirtythre
differ
categori
advers
event
rang
one
unspecifi
reaction
seventeen
differ
categori
averag
nine
categori
per
stakehold
frequent
use
categori
hematoma
includ
arteri
punctur
nerv
damag
vasovag
reaction
also
frequent
includ
howev
done
variabl
vasovag
reaction
unspecifi
acut
andor
delay
vasovag
reaction
one
stakehold
report
iron
defici
plasma
donat
seven
stakehold
provid
data
advers
event
total
twentyseven
differ
categori
report
rang
one
seventeen
per
stakehold
averag
nine
frequent
report
advers
event
hematoma
citrat
reaction
arm
pain
nerv
damag
respect
anticip
risk
blood
donat
rate
nine
stakehold
rate
iron
defici
vasovag
reaction
hematoma
greatest
risk
donor
plasmapheresi
six
stakehold
rate
vasovag
reaction
hematoma
citrat
reaction
highest
risk
summaryconclus
shown
categori
use
describ
advers
event
blood
donat
vari
tremend
across
europ
countri
abl
provid
total
number
advers
event
without
specif
furthermor
gap
perceiv
high
donor
risk
report
advers
reaction
categori
donor
vigil
whole
blood
report
iron
defici
virtual
absent
despit
consid
signific
risk
find
show
need
intern
collabor
creat
intern
standard
donor
vigil
system
gather
insight
donor
risk
protect
health
donor
plenari
session
glimps
futur
modern
transplant
medicin
made
signific
progress
within
last
decad
due
better
immunolog
understand
reject
advanc
immunosuppress
howev
sever
side
effect
longterm
typic
lifelong
immunosuppress
shortag
donor
organ
remain
major
restrict
transplant
idea
behind
research
improv
transplant
outcom
alway
modif
recipi
immun
system
ideal
induc
specif
toler
toward
donor
graft
fact
immunolog
blind
recipi
toward
donor
graft
achiev
gener
reduct
immun
system
compet
repres
major
burden
transplant
patient
idea
invis
organ
entir
differ
approach
solv
problem
instead
induc
immunolog
blind
recipi
immun
system
immunolog
invis
donor
organ
creat
achiev
genet
engin
transplant
elimin
organ
immunogen
defin
gene
product
major
histocompat
complex
mhc
minor
histocompat
antigen
addit
manipul
express
mhc
gene
requir
immun
recognit
immun
cloak
strategi
use
evad
immun
reject
approach
take
advantag
creat
immunosuppress
environ
express
immun
suppress
molecul
immunomodulatori
transgen
mhc
engin
immun
cloak
entir
organ
achiev
ex
vivo
perfus
lentivir
transduct
gene
express
modifi
transgen
induc
perman
immunolog
invis
organ
importantli
mhc
engin
also
prevent
present
minor
histocompat
antigen
usual
possibl
match
donor
recipi
trigger
potent
immun
respons
graft
reject
elimin
target
cellular
humor
reject
well
creat
allograftspecif
immun
environ
immun
cloak
camouflag
organ
equip
power
set
defens
weaponri
immuneengin
transplant
achiev
inevit
ex
vivo
period
allograft
explant
without
need
accept
offtarget
effect
allow
keep
recipi
immun
system
fulli
function
capabl
combat
infect
cancer
preclin
vivo
studi
rodent
minipig
clear
surviv
advantag
ex
vivo
engin
transplant
could
demonstr
approach
potenti
elimin
burden
organ
reject
immunosuppress
therebi
sustain
increas
transplant
surviv
organ
avail
qualiti
life
gene
edit
sickl
cell
diseas
reexpress
fetal
cglobin
gene
could
univers
strategi
amelior
sever
bglobin
disord
sickl
cell
diseas
scd
bthalassemia
induct
fetal
hemoglobin
hbf
c
previous
identifi
erythroid
enhanc
sequenc
mark
hbfassoci
common
genet
variant
requir
repress
hbf
adultstag
erythroid
cell
dispens
nonerythroid
cell
recent
optim
condit
selectionfre
ontarget
edit
human
hsc
nearli
complet
reaction
without
detect
genotox
deleteri
impact
stem
cell
function
demonstr
sgrna
ribonucleoprotein
rnp
mediat
cleavag
core
sequenc
erythroid
enhanc
result
highli
penetr
disrupt
bind
motif
reduct
express
induct
fetal
cglobin
erythroid
progeni
edit
engraft
scd
hsc
express
therapeut
level
hbf
resist
sickl
bthalassemia
patient
show
restor
globin
chain
balanc
moreov
find
hsc
preferenti
undergo
nonhomolog
compar
microhomolog
mediat
endjoin
repair
nhejbas
enhanc
edit
approach
complet
allel
disrupt
hsc
appear
feasibl
therapeut
strategi
produc
durabl
hbf
induct
present
compar
contrast
enhanc
edit
autolog
cur
gene
therapi
gene
edit
approach
variou
stage
clinic
preclin
evalu
oxygen
vital
life
without
oxygen
death
assur
aerob
organ
although
everybodi
know
fact
lot
medic
act
forget
take
care
lead
lot
potenti
troubl
inde
cell
respir
glucos
oxid
oxygen
give
carbon
dioxid
water
energi
energi
also
call
atp
necessari
cellular
metabol
consequ
life
identifi
extracellular
hemoglobin
come
marin
worm
call
arenicola
marina
abl
deliv
oxygen
anim
live
intertid
area
atlant
coast
franc
north
sea
biarritz
molecul
call
develop
medic
devic
name
hemo
life
show
product
effici
protect
organ
transplant
multi
center
clinic
trial
perform
supervis
pr
le
meur
chu
brest
patient
wait
kidney
graft
show
delay
graft
function
reduc
roughli
three
two
kidney
harvest
donor
without
hemo
life
graft
recipi
world
first
realiz
franc
pr
lantieri
georg
pompid
hospit
pari
franc
inde
first
time
patient
receiv
second
graft
face
surgeri
realiz
hemo
life
show
nice
result
accord
pr
lantieri
anastomosi
easi
edema
observ
furthermor
develop
dress
incorpor
make
product
call
hemheal
preclin
data
diabet
mice
show
increas
heal
process
hemoxycarri
therapeut
oxygen
carrier
also
progress
develop
order
address
ischem
diseas
sickl
cell
diseas
myocardiac
infract
stroke
univers
oxygen
carrier
without
blood
type
ancestor
red
blood
cell
contain
hemoglobin
show
abl
deliv
oxygen
differ
biolog
level
cellular
tissu
organ
could
address
multitud
medic
applic
background
main
goal
transfus
save
life
andor
improv
health
statu
human
safe
blood
need
regular
voluntari
unpaid
blood
donor
donor
recruit
sensit
challeng
part
blood
suppli
system
actual
global
socioeconom
condit
achiev
enough
voluntari
nonremuner
blood
donat
vnrbd
establish
effici
donor
recruit
effici
donor
recruit
still
close
relat
blood
donor
recruit
although
mani
new
tool
occup
specif
right
respons
blood
donor
recruit
wide
rang
differ
countri
explain
complet
specif
condit
countri
also
concret
document
intern
consensu
exist
subject
turkish
blood
foundat
tbf
organ
intern
workshop
sinc
anatolian
blood
day
abd
blood
donor
recruit
topic
abdvii
march
aim
main
aim
workshop
check
evalu
exist
system
particip
countri
creat
model
clearli
defin
occup
specif
respons
right
blood
donor
recruit
method
expert
countri
particip
workshop
countri
albania
algeria
bosniaherzegovina
estonia
franc
germani
hungari
india
kazakhstan
lithuania
macedonia
montenegro
oman
portug
qatar
romania
russia
saudi
arabia
serbia
slovenia
sri
lanka
tajikistan
turkey
uganda
uzbekistan
countri
reflect
almost
religi
ethnic
social
cultur
econom
situat
world
questionnair
analyz
exist
system
particip
countri
sent
workshop
countri
present
differ
discuss
group
organ
list
topic
announc
final
declar
result
donor
recruit
univers
degre
prefer
market
busi
administr
field
certif
andor
profession
experi
public
relat
effici
skill
convers
sociabl
independ
selfconfid
reliabl
resili
conscienti
well
work
team
get
special
train
includ
social
topic
public
relat
market
etc
medic
topic
relat
bb
tm
practic
alon
donor
recruit
perman
staff
basic
salari
perform
bonu
might
given
elig
monitor
modifi
mobil
team
work
period
blood
drive
particip
mobil
blood
drive
hesh
organ
particip
group
creat
promot
materi
nation
blood
servic
number
blood
establish
defin
base
annual
blood
collect
staff
whole
blood
collect
annual
germani
summaryconclus
conclus
donor
recruit
retent
easi
task
undergo
public
age
birth
rate
decreas
around
world
dedic
blood
donor
recruit
whose
occup
specif
right
respons
clearli
defin
corner
stone
success
provid
enough
safe
blood
transfus
ct
smit
sibinga
j
emmanuel
background
africa
larg
contin
independ
state
total
popul
februari
healthcar
polici
strategi
develop
advocaci
guidanc
support
hq
geneva
region
offic
eastern
mediterranean
region
offic
emro
support
arab
speak
countri
african
region
offic
afro
respons
subsaharan
countri
popul
distribut
approxim
urban
larg
number
differ
local
dialect
languag
spoken
main
languag
spoken
english
french
portugues
spanish
arab
countri
mainli
classifi
undp
low
medium
human
develop
index
africa
societi
blood
transfus
afsbt
member
countri
advoc
develop
sustain
effect
blood
servic
develop
stepwis
level
accredit
program
emro
held
consensu
meet
develop
strateg
framework
blood
safeti
avail
set
prioriti
intervent
focus
leadership
govern
cooper
collabor
provis
safe
blood
blood
product
appropri
clinic
use
blood
qualiti
system
manag
member
state
african
union
au
countri
abuja
nigeria
pledg
nation
budget
health
least
nation
fiscal
budget
minist
health
member
state
endors
blood
blood
product
includ
essenti
medicin
list
endors
univers
health
coverag
uhc
yet
fulli
implement
aim
analyz
gapanalysi
extend
countri
africa
implement
world
health
assembl
resolut
avail
safeti
qualiti
blood
product
urg
govern
ensur
safe
access
afford
avail
suppli
blood
compon
voluntari
nonremuner
blood
donor
meet
clinic
transfus
requir
achiev
nation
selfsuffici
follow
guidelin
recommend
method
provid
overview
current
statu
blood
suppli
africa
strength
weak
data
global
statu
report
blood
safeti
avail
analyz
use
studi
descript
explor
result
report
identifi
number
area
requir
attent
principl
amongst
inadequ
fund
lack
govern
leadership
ineffect
public
educ
blood
donat
absenc
capac
build
clinician
ration
use
blood
lack
haemovigil
implement
qualiti
manag
system
need
regulatori
oversight
mechan
summaryconclus
nation
author
address
area
requir
attent
progress
toward
ensur
sustain
safe
suffici
suppli
blood
product
achiev
key
commit
support
nation
govern
implement
resolut
recommend
agre
minist
health
wha
african
union
background
core
function
blood
donat
test
bdt
laboratori
screen
everi
unit
blood
collect
donor
blood
group
type
infecti
diseas
marker
ensur
safeti
nation
blood
suppli
prior
transfus
lab
oper
daili
two
work
shift
compris
staff
morn
shift
staff
afternoon
pm
shift
weekday
staff
shift
staff
pm
shift
weekend
bdt
lab
staff
strength
roster
work
shift
staff
fiveday
work
week
work
pm
shift
shift
per
month
averag
higher
number
pm
shift
lead
staff
feedback
get
suffici
time
even
famili
social
leisur
activ
lean
six
sigma
project
initi
review
work
roster
improv
worklif
balanc
staff
aim
project
aim
reduc
number
staff
work
pm
shift
without
affect
downstream
process
continu
meet
time
releas
blood
suppli
hospit
method
lean
six
sigma
tool
use
studi
bdt
lab
workflow
process
identifi
factor
contribut
higher
number
pm
shift
staff
take
data
turnaround
time
maneffort
requir
screen
test
perform
analyz
survey
also
conduct
understand
prefer
staff
accept
number
pm
shift
per
month
result
main
contribut
factor
staff
requir
perform
pm
shift
due
major
daili
donat
sampl
receiv
even
factor
beyond
control
bdt
lab
redeploy
work
pm
shift
shift
eventu
select
solut
reduc
number
staff
need
pm
shift
screen
test
shift
determin
base
test
system
shortest
turnaroundtim
abl
allow
continu
releas
result
time
staff
must
train
test
system
trial
new
roster
involv
staff
shift
staff
pm
shift
conduct
total
number
pm
shift
per
month
reduc
use
redefin
process
reduct
translat
fewer
number
pm
shift
staff
undertak
abl
meet
staff
expect
summaryconclus
adopt
new
process
workflow
bdt
lab
abl
reduc
number
pm
shift
staff
need
roster
use
evid
base
process
improv
method
importantli
lab
satisfi
team
staff
better
worklif
balanc
background
prepared
blood
transfus
servic
emerg
crisi
situat
import
issu
concern
patient
transfus
safeti
aim
experi
delay
blood
compon
suppli
emerg
situat
due
partial
interrupt
hospit
inform
system
aim
creat
crisi
kit
constitut
altern
work
flow
emerg
crisi
situat
method
stipul
failur
normal
conduct
process
transfus
would
disabl
disast
crisi
situat
brain
storm
made
possibl
challeng
associ
disabl
transfus
emerg
accord
scenario
kit
develop
process
manag
transfus
emerg
result
flow
chart
design
proper
transfus
emerg
definit
instruct
written
explain
flow
chart
form
categor
differ
colour
code
design
fill
handwrit
kit
consist
flow
chart
instruct
analysi
request
form
blue
colour
blood
compon
request
form
pink
colour
proceed
form
green
colour
pen
blood
sampl
tube
edta
put
plastic
folder
label
transfus
emerg
disast
crisi
tedc
kit
addit
kit
place
seal
clear
plastic
bag
deliv
inpati
intens
care
unit
pediatr
pediatr
surgeri
train
programm
concern
transfus
emerg
situat
usag
tedc
kit
develop
health
care
worker
involv
blood
transfus
process
pre
postassess
test
develop
evalu
effect
train
programm
summaryconclus
challeng
improv
respons
capac
blood
transfus
servic
emerg
crisi
situat
abstract
withdrawn
background
india
develop
countri
licens
blood
bank
major
manual
document
caus
inaccuraci
error
blood
bank
activ
monitor
herculean
task
computeris
need
hour
goal
involv
mani
hurdl
challeng
aim
aim
studi
discuss
challeng
face
computeris
blood
bank
activ
remedi
solut
method
depart
transfus
medicin
king
georg
medic
univers
lucknow
one
biggest
blood
bank
countri
annual
collect
blood
unit
two
year
ago
blood
bank
work
total
manual
system
computeris
involv
challeng
associ
hardwar
softwar
instal
personnel
train
hardwar
instal
two
phase
initi
hp
system
later
shift
appl
imac
due
frequent
breakdown
hp
server
softwar
instal
easi
softwar
involv
errat
internet
connect
henc
chang
lan
customis
involv
radic
chang
accord
need
time
chang
way
work
suit
softwar
biometr
link
medic
registr
cash
id
gener
donat
serolog
crossmatch
autom
blood
group
label
chemiluminesc
nat
test
blood
compon
prepar
camp
includ
challeng
everi
level
remedi
action
taken
small
big
train
staff
essenti
part
implement
computeris
initi
show
consider
resist
time
fake
ignor
due
apprehens
mistak
highlight
penalis
herculean
task
creat
password
protect
ident
enforc
use
gradual
staff
realis
computeris
made
task
easier
cut
paper
work
repetit
also
prevent
seriou
mistak
happen
hard
copi
certain
essenti
area
still
maintain
continu
work
event
major
breakdown
comput
result
computeris
aid
us
regul
movement
donor
time
repetit
due
manual
entri
transfer
data
ensur
safe
suppli
mistak
could
retrac
easili
implement
includ
instal
train
enforc
took
period
month
overcom
challeng
minimis
hard
copi
regist
start
take
printout
necessari
detail
turnov
time
employe
due
computeris
decreas
wait
time
attend
decreas
traceabl
unit
becam
supervis
activ
carri
accur
identif
donor
easi
due
biometr
includ
thumb
impress
iri
scan
decis
make
time
donor
decreas
thu
make
system
effici
summaryconclus
manual
computeris
involv
involv
sourc
suppli
essenti
anticip
challeng
prepar
solut
order
make
implement
success
ct
smit
sibinga
abdella
f
kone
iqm
consult
zuidhorn
netherland
eastern
mediterranean
offic
cairo
egypt
background
defin
essenti
medicin
em
medicin
product
satisfi
healthcar
need
major
popul
avail
time
adequ
amount
appropri
dosag
form
assur
qualiti
afford
blood
blood
product
whole
blood
red
cell
platelet
plasma
plasmaderiv
product
ad
model
list
em
appropri
effect
regulatori
framework
legisl
regul
etc
function
regulatori
author
ra
crucial
manag
blood
product
em
howev
particularli
less
develop
world
prerequisit
bare
implement
aim
analyz
advis
exist
legisl
regul
exist
legisl
instrument
member
state
eastern
mediterranean
region
emr
collect
analys
relev
appropri
prepar
use
blood
blood
product
well
use
associ
substanc
relev
medic
devic
literatur
search
done
match
combin
regulatori
system
regulatori
framework
legisl
regul
product
use
blood
blood
product
result
almost
exclus
refer
respect
nation
intern
legisl
benchmark
recommend
aid
emoir
eu
direct
method
exist
legisl
instrument
member
state
eastern
mediterranean
region
emr
collect
analys
relev
appropri
prepar
use
blood
blood
product
well
use
associ
substanc
relev
medic
devic
literatur
search
done
match
combin
regulatori
system
regulatori
framework
legisl
regul
product
use
blood
blood
product
result
almost
exclus
refer
respect
nation
intern
legisl
benchmark
recommend
aid
emoir
eu
direct
result
variou
formal
legisl
document
countri
put
forc
govern
egypt
till
pakistan
sindh
detail
descript
ra
oper
establish
specif
requir
howev
none
legisl
compli
eu
recommend
format
content
support
effect
regulatori
oversight
promot
enhanc
qualiti
safeti
avail
em
summaryconclus
govern
provid
effect
leadership
govern
develop
nation
blood
system
nb
fulli
integr
nation
healthcar
system
essenti
function
nb
includ
appropri
regulatori
framework
legisl
regul
nonlegisl
instrument
administ
ra
document
spell
principl
cadr
standard
set
organ
blood
system
ensur
adequ
suppli
blood
blood
product
safe
clinic
transfus
model
design
structur
nb
depend
organ
level
develop
healthcar
system
howev
critic
activ
within
nb
coordin
nation
promot
uniform
standard
economiesofscal
consist
staff
compet
qualiti
safeti
em
best
transfus
practic
key
formul
appropri
regulatori
framework
administ
ra
respons
regul
veintovein
chain
prepar
use
em
background
capac
blood
transfus
servic
provid
adequ
suppli
blood
compon
issu
concern
health
provid
worldwid
longer
term
observ
trend
respect
therefor
crucial
valu
aim
studi
aim
analysi
basic
activ
polish
blood
transfus
servic
includ
organiz
chang
number
donor
donat
blood
compon
well
activ
direct
increas
safeti
method
retrospect
analysi
data
suppli
region
blood
transfus
center
btc
result
discuss
period
blood
blood
compon
collect
region
btc
local
collect
site
well
mobil
collect
although
number
local
collect
site
decreas
favor
mobil
collect
increas
former
still
number
one
locat
donat
blood
averag
donat
perform
local
collect
site
total
number
blood
donor
begin
end
discuss
period
similar
donor
nonremuner
howev
number
firsttim
donor
drop
significantli
total
number
donat
increas
frequent
whole
blood
collect
blood
compon
mostli
plasma
platelet
concentr
also
collect
apheresi
frequent
prepar
blood
compon
red
blood
cell
concentr
rbc
unit
per
year
fresh
frozen
plasma
ffp
unit
platelet
concentr
pc
unit
signific
increas
tendenc
addit
process
method
leukocyt
deplet
irradi
frequent
appli
pc
respect
year
irradi
leukocytedeplet
rbc
irradi
leukocytedeplet
pathogen
reduct
technolog
plasma
pc
implement
date
howev
use
technolog
limit
btc
approxim
pc
ffp
unit
issu
transfus
subject
pathogen
reduct
technolog
summaryconclus
studi
data
may
contribut
assess
longterm
tendenc
observ
polish
blood
transfus
servic
may
serv
practicalbenchmark
turn
may
prove
benefici
transfus
commun
whole
background
poland
hospit
depend
blood
treatment
patient
mln
unit
blood
compon
annual
transfus
therefor
purpos
expand
knowledg
factor
impact
blood
transfus
servic
bt
institut
hematolog
transfus
medicin
ihtm
compet
author
respons
collect
data
relat
activ
polish
blood
transfus
center
bct
data
exploit
much
lesser
degre
recent
avail
statist
method
data
process
tool
would
allow
moreov
survey
research
field
public
health
indic
neglig
share
issu
relat
bt
seem
therefor
necessari
fill
gap
true
assess
perform
polish
bct
improv
bt
activ
st
stage
investig
refer
collect
merg
data
differ
sourc
unif
prepar
big
data
analysi
perform
use
multidimension
statist
analysi
data
mine
method
aim
assess
activ
polish
btc
yearperiod
two
stage
goal
st
stage
data
digit
scan
paper
document
develop
uniform
templat
collect
digit
data
variou
sourc
standard
unif
qualiti
improv
avail
data
fill
miss
data
elimin
error
duplic
record
etc
may
distort
outcom
analyz
select
data
analysi
method
digit
big
data
method
process
variou
type
data
store
paper
form
b
digit
store
two
file
type
doc
xl
year
respect
datatyp
separ
excel
file
model
creat
model
merg
one
analyt
tabl
data
process
method
result
page
paper
document
scan
model
develop
data
differ
sourc
paperdata
rewritten
ascrib
model
outcom
tabl
column
row
b
doc
xl
filesdata
ascrib
model
outcom
tabl
column
row
model
merg
analyt
tabl
creat
mb
databas
compar
approx
min
music
data
subject
standard
unif
qualiti
improv
fill
miss
data
elimin
error
duplic
record
may
distort
result
analyz
select
data
analysi
nd
stage
summaryconclus
st
stage
provid
set
select
data
analysi
nd
stage
reli
multidimension
statist
analysi
data
mine
method
outcom
analysi
contribut
optim
realiz
object
gain
indepth
knowledg
fundament
phenomena
shape
polish
bt
b
identif
potenti
chang
bct
c
develop
overal
guidelin
chang
manag
aim
touch
untouch
less
touch
topic
bb
tm
far
workshop
organ
year
around
countri
particip
almost
religi
ethnic
social
cultur
econom
situat
world
support
realiz
major
chang
bb
tm
turkey
convinc
medic
individu
agenc
mainli
moh
give
deserv
consider
bb
tm
b
encourag
recognit
establish
nation
blood
program
c
issu
new
blood
act
numer
necessari
bylaw
etc
creat
appropri
standard
donor
questionnair
form
e
chang
blood
transfus
practic
whole
blood
f
chang
donat
blood
screen
criteria
antihcv
screen
becam
obligatori
malaria
screen
cancel
g
prepar
nation
guidelin
h
promot
haemovigil
nurs
post
promot
patient
blood
manag
around
blood
banker
attend
nation
cours
attend
nation
congress
attend
nationwid
symposium
summaryconclus
bbtst
accept
sampl
scientif
nongovernment
organ
may
give
posit
impact
develop
progress
bb
tm
activ
close
collabor
moh
relat
organ
abstract
withdrawn
background
global
grow
invest
inform
technolog
busi
similar
trend
observ
blood
establish
computer
system
bec
invest
high
henc
decis
need
properli
inform
africa
societi
blood
transfus
afsbt
encourag
use
african
blood
servic
optim
qualiti
blood
servic
therebi
improv
patient
outcom
afsbt
establish
work
group
afsbt
itwg
support
swiss
red
cross
src
spearhead
standard
among
member
blood
servic
number
prioriti
themat
area
identifi
includ
govern
focus
creation
strateg
align
preserv
risk
manag
busi
valu
absenc
publish
literatur
structur
govern
framework
implement
resourc
constrain
set
review
nation
blood
servic
zimbabw
nbsz
govern
done
base
publish
govern
framework
aim
explor
structur
govern
develop
implement
monitor
resourc
constrain
set
method
publish
mitcisr
framework
six
compon
use
assess
strength
gap
opportun
govern
result
nbsz
implement
evolv
structur
govern
system
term
servic
strategi
organ
wellestablish
function
reflect
nbsz
strateg
plan
ensur
annual
budgetari
support
averag
total
budget
govern
arrang
decis
right
assign
differ
staff
execut
specialist
user
rang
solut
embed
within
nbsz
oper
bec
financi
donor
mobil
applic
social
media
temperatur
monitor
human
resourc
busi
perform
goal
defin
congruent
across
variou
busi
unit
organ
desir
behavior
document
ict
polici
procedur
need
remedi
action
avail
code
conduct
metric
includ
within
nbsz
monitor
evalu
system
use
four
color
traffic
light
report
system
note
account
undesir
tilt
specialist
henc
ict
project
tend
delay
deliver
govern
mechan
support
tool
servic
level
agreement
establish
commun
approach
simpl
excel
base
solut
use
track
critic
perform
metric
interact
blood
suppli
manag
statu
averag
base
project
stock
suppli
level
nbsz
need
properli
document
return
invest
ict
initi
estim
annual
save
summaryconclus
blood
servic
resourc
constrain
set
implement
properli
structur
govern
ensur
maximum
return
invest
nbsz
approach
share
develop
afsbt
itwg
support
blood
servic
improv
govern
haematologyblood
transfus
alfr
health
melbourn
australia
background
octob
integr
electron
medic
record
emr
implement
australian
metropolitan
multicampu
heath
servic
use
cerner
millennium
tm
aim
achiev
himss
healthcar
inform
manag
system
societi
level
prior
implement
larg
number
blood
specimen
collect
patient
unnecessarili
sent
patholog
without
test
request
attach
blood
test
request
ntr
specimen
requir
addit
process
laboratori
electron
specimen
collect
use
cerner
specimen
collect
tm
allow
streamlin
specimen
process
elimin
paper
request
part
new
workflow
individu
specimen
label
print
specifi
blood
test
correct
tube
type
help
prevent
practic
collect
addit
specimen
due
uncertainti
collect
requir
aim
quantifi
expect
reduct
ntr
specimen
follow
introduct
electron
specimen
collect
outlin
benefit
determin
impact
collect
error
wrong
blood
tube
wbit
event
method
data
obtain
directli
cerner
millennium
tm
use
ccl
cerner
command
languag
queri
run
monthli
patholog
staff
data
includ
specimen
regist
month
indic
reject
specimen
wbit
ntr
sampl
reject
specimen
includ
incomplet
specimen
andor
request
certif
unlabel
specimensrequest
mismatch
specimen
inform
wbit
event
collat
riskman
report
staff
interview
result
data
month
prior
emr
implement
compar
month
post
ntr
number
reduc
reduct
free
storag
space
fridg
reject
specimen
due
inadequ
patient
request
label
reduc
mean
wbit
number
increas
slightli
median
rang
median
rang
although
hope
wbit
incid
may
reduc
new
emr
post
implement
wbit
involv
electron
specimen
collect
departur
plan
protocol
involv
lack
work
printer
caus
staff
print
patient
label
away
patient
bedsid
well
multipl
patient
label
print
individu
printer
appear
main
caus
emr
wbit
summaryconclus
emr
implement
led
reduct
ntr
reject
specimen
due
inadequ
request
label
well
increas
storag
space
laboratori
refriger
associ
benefit
includ
decreas
financi
cost
wast
equip
decreas
staff
time
collect
process
unus
specimen
decreas
environment
impact
manufactur
dispos
unus
specimen
decreas
potenti
iatrogen
anaemia
work
prevent
occurr
wbit
ongo
ensur
label
printer
work
order
plenti
suppli
easili
access
staff
also
ensur
posit
patient
identif
blood
collect
patient
bedsid
remain
prioriti
jm
mustaffa
k
teo
tsai
p
heng
r
sagun
wong
laboratori
medicin
khoo
teck
puat
hospit
singapor
singapor
background
khoo
teck
puat
hospit
ktph
gener
acut
care
hospit
open
serv
peopl
live
northern
sector
singapor
blood
bank
ktph
depart
laboratori
medicin
provid
specimen
test
blood
transfus
servic
ktph
well
neighbour
yishun
commun
hospit
ych
one
largest
commun
hospit
singapor
provid
intermedi
care
recuper
patient
includ
rehabilit
servic
process
order
transfusionrel
test
request
hospit
print
form
aim
line
hospit
direct
move
toward
electron
patient
manag
ktph
blood
bank
intend
implement
electron
type
screen
et
system
goal
project
ensur
zero
patient
identif
error
maintain
full
traceabl
account
blood
collect
process
transfusionrel
test
anoth
aim
system
reduc
repeat
venepunctur
specimen
reject
due
miss
essenti
patient
inform
print
form
implement
mandatori
field
et
form
method
et
implement
phase
phase
onlin
version
print
form
sign
electron
order
doctor
wit
within
electron
medic
record
system
sunris
clinic
manag
scm
system
doctor
countercheck
sign
specimen
label
ensur
correct
patient
identif
phase
order
doctor
requir
sign
specimen
label
sinc
fingerprint
biometr
requir
electron
signin
phase
elimin
wit
step
blood
collect
specimen
collect
reject
data
analys
specimen
reject
rate
present
percentag
reject
specimen
mislabel
unlabel
cleric
error
total
specimen
count
month
result
januari
march
implement
et
phase
averag
reject
rate
blood
bank
specimen
identif
cleric
error
respect
phase
implement
reject
rate
increas
due
unfamiliar
new
work
process
februari
implement
final
phase
et
system
specimen
reject
rate
identif
cleric
error
respect
reject
specimen
mostli
locat
use
paper
requisit
due
workflow
infrastructur
limit
summaryconclus
et
system
implement
success
ktph
full
traceabl
account
blood
collect
process
maintain
fulli
electron
system
adopt
electron
document
also
reduc
number
prevent
repeat
venepunctur
due
incomplet
order
inform
print
form
futur
develop
technolog
full
implement
et
system
hospit
locat
may
make
zero
patient
identif
error
achiev
ensur
transfus
safeti
patient
near
futur
background
blood
compon
administr
repres
critic
phase
due
possibl
occurr
error
differ
step
identif
patient
infus
product
error
occurr
reduc
implement
valid
inform
system
test
scweb
system
bedsid
transfus
outpati
clinic
aim
aim
studi
valid
system
design
assist
control
blood
administr
step
step
use
electron
devic
ensur
traceabl
document
process
method
scweb
system
base
monitor
checklist
guid
personnel
follow
procedur
accord
best
practic
system
must
initi
activ
oper
recogn
autosign
system
base
bluetooth
low
energi
avoid
oper
identifi
himselfherself
beforehand
appropri
privaci
protect
provid
thereaft
system
take
task
give
instruct
verifi
adher
ask
activ
confirm
proper
fulfil
activ
continu
registr
document
made
system
standard
specif
step
procedur
configur
scweb
system
track
detail
oper
patient
identif
presenc
inform
consent
transfus
blood
pressur
puls
temperatur
record
vein
access
verif
blood
unit
alarm
set
min
ensur
control
patient
condit
step
activ
confirm
action
requir
nurs
doctor
direct
involv
must
activ
confirm
devic
oper
system
test
bedsid
patient
admit
outpati
clinic
red
cell
concentr
transfus
complianc
personnel
organiz
impact
record
result
system
requir
short
train
eas
scweb
system
allow
implement
without
neg
impact
organ
transfus
outpati
clinic
without
difficulti
oper
nurs
doctor
appreci
help
given
check
system
registr
electron
check
list
offer
reliabl
tool
traceabl
transfus
procedur
also
grant
paperless
time
avail
document
entir
process
registr
electron
format
oper
action
everi
singl
phase
transfus
process
prescrib
confirm
checklist
possibl
presenc
activ
confirm
two
oper
doctor
nurs
summaryconclus
scweb
system
use
barrier
mismatch
transfus
prevent
measur
traceabl
document
measur
tool
train
personnel
blood
transfus
administr
avoid
paper
registr
transfus
process
due
time
registr
activ
perform
oper
recogn
system
thank
bluetooth
low
energi
autosign
devic
scweb
system
connect
transfus
data
manag
system
monitor
process
arriv
unit
blood
bank
background
blood
bank
aim
reduc
cost
increas
custom
satisfact
provid
qualiti
servic
qualiti
servic
attain
streamlin
process
restructur
suppli
chain
organ
implement
tool
aim
aim
understand
complex
flow
inform
process
within
suppli
chain
blood
bank
requir
studi
part
integr
erp
model
integr
function
blood
bank
method
approach
use
understand
map
sequenc
process
work
respons
process
oper
decis
involv
step
process
map
data
flow
diagram
front
end
system
model
analysi
process
map
repres
schemat
diagram
dfd
data
flow
diagram
construct
repres
system
context
diagram
also
construct
understand
entiti
interact
system
emr
system
aim
replac
support
paper
base
medic
record
whole
model
system
divid
two
partsfront
end
back
end
front
end
design
analysi
done
use
epc
eventdriven
process
chain
resourc
view
data
flow
diagram
data
view
report
donor
select
financ
collect
blood
bag
blood
collect
process
compon
prepar
blood
test
blood
distribut
result
process
map
use
event
driven
process
chain
gener
whole
view
process
involv
resourc
view
gave
organiz
structur
personnel
involv
data
view
use
context
diagram
data
flow
diagram
give
flow
data
amount
data
involv
framework
use
busi
process
reengin
blood
bank
conduct
time
studi
remov
non
valu
ad
activ
data
view
help
analyz
redund
data
process
also
help
staff
train
orient
within
depart
summaryconclus
systemat
overview
present
paper
facilit
remov
non
valu
ad
process
duplic
data
bottleneck
reduct
cycl
time
therebi
improv
servic
qualiti
blood
bank
background
transfus
blood
compon
one
preval
intervent
clinic
practic
major
expenditur
item
healthcar
servic
tend
increas
recent
year
aim
intend
investig
impact
transfus
associ
cost
hospit
cost
pediatr
intens
care
unit
picu
patient
method
year
period
januari
patient
femal
male
receiv
transfus
blood
compon
along
stay
picu
includ
studi
transfus
associ
cost
total
cost
healthcar
servic
children
treat
picu
collect
use
hospit
inform
system
statist
analysi
data
perform
spss
softwar
version
spss
inc
chicago
il
usa
mannwhitney
u
test
kruskalw
test
perform
comparison
independ
categor
variabl
numer
data
chisquar
analysi
perform
comparison
two
numer
variabl
spearman
correl
analysi
perform
associ
result
median
age
patient
month
interquantil
rangeiqr
median
length
stay
day
iqr
total
blood
compon
transfus
red
blood
cell
concentr
apheresi
platelet
concentr
granulocyt
concentr
fresh
frozen
plasma
cryoprecipit
whole
blood
ratio
transfus
associ
expenditur
hospit
cost
categor
interv
percentag
patient
rank
lowest
interv
median
hospit
cost
transfus
associ
cost
euro
iqr
euro
iqr
respect
signific
strong
posit
correl
number
transfus
hospit
cost
picu
detect
r
p
found
signific
weak
posit
correl
transfus
associ
cost
hospit
cost
r
p
also
signific
weak
posit
correl
age
transfus
associ
cost
p
r
signific
differ
found
patient
without
hematolog
malign
p
transfus
associ
cost
reason
pediatr
dosag
mostli
prefer
hospit
provid
healthcar
children
split
blood
compon
common
hospit
unexpectedli
signific
increas
transfus
associ
cost
relat
split
blood
compon
detect
p
summaryconclus
studi
econom
blood
transfus
conduct
mostli
patient
requir
chronic
multipl
transfus
picu
special
facil
provid
care
patient
sever
lifethreaten
diseas
major
depart
often
necessit
multipl
transfus
mani
variabl
evalu
impact
transfus
associ
cost
hospit
cost
picu
patient
major
factor
underli
condit
admit
diagnos
transfus
strategi
although
unexpect
data
studi
demonstr
increas
impact
transfus
associ
cost
origin
blood
compon
split
pediatr
usag
signific
relationship
determin
explain
situat
studi
econom
blood
transfus
carri
clarifi
variabl
transfus
associ
cost
background
approxim
transfus
blood
compon
pack
red
cell
prc
order
prc
unit
common
practic
excess
pretransfus
test
wast
resourc
advers
consequ
cost
high
crossmatch
transfus
ct
ratio
qualiti
indic
blood
bank
impli
crossmatch
perform
unnecessarili
aim
aim
studi
evalu
cost
effect
strategi
limit
number
pretransfus
test
order
prc
method
prc
unit
order
dr
hasan
sadikin
hospit
januari
decemb
collect
retrospect
studi
number
order
prc
unit
complet
pretransfus
test
order
prc
unit
prc
unit
transfus
record
restrict
pretransfus
test
strategi
done
base
hemoglobin
level
diagnosi
transfus
indic
criteria
cost
effect
measur
multipli
unit
cost
pretransfus
test
number
prc
unit
result
total
order
prc
unit
subject
pretransfus
test
order
prc
unit
pretransfus
test
transfus
mean
order
prc
unit
subject
pretransfus
test
show
save
rupiah
ct
ratio
demonstr
good
order
pattern
howev
complet
pretransfus
test
order
prc
unit
transfus
lead
blood
bank
loss
rupiah
summaryconclus
strategi
limit
number
pretransfus
test
good
ct
ratio
still
associ
save
cost
effect
background
blood
preciou
resourc
save
patient
live
purpos
blood
blood
compon
therapi
provid
suitabl
safe
blood
product
achiev
best
clinic
outcom
nurs
import
role
ensur
safe
blood
transfus
crucial
nurs
suffici
knowledg
blood
donat
collect
storag
compon
prepar
possibl
advers
effect
blood
transfus
necessari
manag
care
aim
aim
studi
assess
impact
educ
intervent
knowledg
awar
nurs
regard
blood
transfus
servic
practic
method
baselin
studi
assess
knowledg
awar
regard
blood
transfus
servic
practic
nurs
post
variou
area
hospit
includ
ward
oper
theatr
critic
care
area
carri
institut
hospit
tertiari
care
teach
centr
nurs
sensit
educ
regard
blood
transfus
servic
practic
day
day
activ
refer
blood
transfus
guidelin
institut
subsequ
selfdevelop
questionnair
use
baselin
assess
knowledg
awar
nurs
use
reassess
total
question
includ
questionnair
pertain
gener
awar
two
question
blood
donat
two
question
test
blood
compon
prepar
relat
two
question
storag
bloodblood
compon
two
question
pretransfus
check
bed
side
transfus
practic
eleven
question
fifti
nurs
includ
baselin
well
postsensit
assess
differ
categori
question
correct
respons
rate
compar
obtain
baselin
studi
use
mannwhitney
test
entir
studi
durat
spread
period
three
month
decemb
februari
result
overal
mean
percentag
correct
respons
question
baselin
studi
wherea
post
sensit
mean
percentag
increas
gener
awar
relat
question
storag
bloodblood
compon
relat
question
pretransfus
check
bedsid
transfus
practic
relat
question
test
blood
compon
prepar
relat
question
blood
donat
relat
question
percentag
increas
correct
respons
found
static
signific
five
categori
question
overal
mean
percentag
increas
correct
respons
rate
also
statist
signific
p
summaryconclus
studi
reveal
sensit
educ
intervent
signific
improv
knowledg
awar
nurs
regard
blood
transfus
servic
practic
abstract
withdrawn
background
tact
introduc
uk
support
manag
provid
resourcesav
continu
realtim
monitor
knowledgebas
compet
staff
transfus
laboratori
tact
avail
onlin
complement
exist
practic
compet
scheme
extern
qualiti
assess
multipl
variat
standard
pretransfus
test
scenario
gener
use
constrain
randomis
logic
rule
automat
assess
sampl
accept
abod
antibodi
screen
identif
asid
compon
issu
base
bsh
guidanc
tact
offer
intern
transfus
laboratori
manag
trial
saw
uptak
five
countri
core
tact
programm
base
upon
uk
guidelin
review
program
convers
customis
intern
commun
aim
assess
feasibl
tact
program
convers
meet
requir
countryspecif
pretransfus
test
guidelin
direct
futur
program
line
feedback
intern
user
method
guidelin
intern
user
obtain
translat
necessari
compar
core
assess
element
current
tact
program
intern
user
approach
feedback
current
version
tact
compar
local
polici
practic
result
follow
criteria
crossreferenc
specif
transfus
request
form
sampl
label
accept
criteria
reagent
use
abod
asid
resolut
group
anomali
alloantibodi
confirmationexclus
select
criteria
blood
compon
transfusiondepend
patient
women
childbear
potenti
appar
differ
includ
australia
select
red
cell
patient
immun
antid
greec
inclus
name
patient
father
transfus
request
itali
test
new
patient
antia
b
reagent
two
differ
monoclon
antid
reagent
intern
user
three
countri
suppli
feedback
includ
suggest
greater
complex
case
present
provis
patient
histori
inclus
followon
test
eg
phenotyp
cell
antibodi
confirmationexclus
broader
rang
reaction
strength
grade
offici
profession
cpd
credit
follow
differ
note
nomenclatur
use
format
content
request
form
use
english
abbrevi
patient
clinic
detail
avail
provis
specif
blood
compon
summaryconclus
analysi
shown
instanc
current
tact
iter
differ
guidelin
review
feasibl
expand
use
tact
intern
basi
current
iter
tact
develop
repres
abbrevi
scope
pretransfus
test
practic
appli
laboratori
practic
outsid
uk
without
difficulti
work
requir
enabl
intern
user
configur
tact
system
repres
laboratori
practic
intern
basi
aim
cours
provid
educ
clinician
patient
blood
manag
safe
transfus
neonat
paediatr
set
order
improv
patient
outcom
increas
awar
nation
patient
blood
manag
guidelin
analysi
aim
investig
uptak
practic
use
perceiv
valu
cours
learner
method
retrospect
analysi
cours
complet
statist
cours
evalu
data
result
paediatr
neonat
cours
complet
march
februari
learner
nurs
andor
midwiv
analysi
cours
evalu
data
n
show
cours
provid
knowledg
improv
patient
safeti
outcom
result
chang
clinic
practic
relev
clinic
practic
easi
use
readili
access
exampl
learner
provid
appli
learn
clinic
practic
includ
awar
special
requir
neonat
blood
transfus
feel
confid
especi
talk
parent
check
patient
blood
result
speak
unnecessari
blood
sampl
good
ambigu
clinic
practic
well
shown
explan
expert
field
nt
lot
transfus
remind
transfus
alway
first
answer
babi
clinic
pictur
summaryconclus
analysi
cours
user
evalu
data
demonstr
cours
use
nurs
doctor
work
neonat
paediatr
set
provid
knowledg
pbm
appli
clinic
practic
therebi
contribut
improv
patient
care
background
blood
transfus
highrisk
clinic
activ
must
master
theoret
practic
order
guarante
requir
result
without
incid
complic
masteri
transfus
knowledg
among
nurs
repres
import
link
transfus
chain
object
work
compar
theoret
practic
knowledg
transfus
among
two
group
nurs
divid
accord
senior
aim
crosssect
descript
studi
conduct
period
month
st
th
april
select
two
group
care
staff
st
group
consist
student
end
train
higher
institut
nurs
scienc
nd
made
nurs
work
univers
hospit
tuni
current
practic
blood
transfus
evalu
tool
use
questionnair
simpl
multipl
choic
question
relat
theoret
knowledg
labil
blood
product
transfus
practic
ten
question
consid
lifethreaten
answer
fals
compar
studi
made
two
group
method
crosssect
descript
studi
conduct
period
month
st
th
april
select
two
group
care
staff
st
group
consist
student
end
train
higher
institut
nurs
scienc
nd
made
nurs
work
univers
hospit
tuni
current
practic
blood
transfus
evalu
tool
use
questionnair
simpl
multipl
choic
question
relat
theoret
knowledg
labil
blood
product
transfus
practic
ten
question
consid
lifethreaten
answer
fals
compar
studi
made
two
group
result
particip
rate
survey
nd
group
particip
averag
senior
year
half
senior
less
year
year
experi
rate
correct
answer
item
combin
student
versu
practic
nurs
theoret
knowledg
part
master
st
group
practic
nurs
vs
correct
answer
hand
control
transfus
act
better
nd
group
vs
overal
danger
respons
rate
student
practic
nurs
fals
practic
knowledg
common
group
vs
summaryconclus
theoret
well
practic
knowledg
remain
well
master
care
staff
studi
highlight
best
theoret
masteri
young
student
practic
practic
nurs
could
explain
fresh
knowledg
first
group
daili
practic
second
group
background
european
commiss
ec
direct
blood
donor
select
criteria
year
old
meantim
knowledg
risk
relat
blood
donor
select
progress
challeng
sever
obligatori
rule
transpos
transfus
transplant
protect
select
donor
european
commiss
cofund
project
particip
stakehold
notforprofit
privat
organ
provid
substanc
human
origin
soho
project
aim
provid
evidencebas
donor
select
criteria
guid
principl
risk
assess
threat
safeti
soho
part
work
inventori
current
blood
donor
select
criteria
europ
evalu
evid
behind
current
practic
perform
expert
work
project
aim
identifi
gap
ec
direct
whole
blood
donor
select
criteria
current
evalu
clinic
relev
criteria
base
scientif
literatur
panel
european
expert
within
transpos
project
method
perform
inventori
blood
donor
transfus
recipi
risk
particip
european
countri
project
member
ask
provid
exist
donor
select
criteria
relat
risk
carri
riskbas
evalu
evalu
base
avail
scientif
literatur
risk
assess
templat
base
abo
riskbas
decisionmak
framework
develop
transpos
risk
diverg
assess
within
panel
resolv
discuss
case
expert
consensu
establish
subsequ
compar
result
content
ec
direct
everi
risk
therebi
identifi
discrep
miss
item
direct
result
panel
identifi
risk
consid
signific
distribut
donor
recipi
expert
evalu
deviat
content
ec
direct
ec
direct
provid
inform
decis
make
particular
discrep
observ
criteria
concern
gener
health
medic
transfus
transmiss
infect
highrisk
behaviour
travel
diseas
summaryconclus
result
highlight
signific
gap
whole
blood
donor
select
criteria
state
ec
direct
scientif
evalu
perform
panel
transpos
particip
expert
gap
includ
new
risk
address
ec
direct
address
risk
howev
evalu
differ
involv
blood
donor
transfus
recipi
safeti
variou
medic
epidemiolog
topic
cover
sever
aspect
blood
donat
criteria
strongli
recommend
chang
european
legisl
allow
procedur
guarante
blood
donor
select
criteria
updat
regularli
within
framework
european
institut
keep
align
scientif
progress
epidemiolog
chang
medic
practic
order
enabl
updat
riskand
evidencebas
framework
donor
select
criteria
riskassess
method
elabor
transpos
project
valuabl
instrument
purpos
background
brazilian
health
regulatori
agenc
anvisa
develop
method
assess
potenti
risk
hemotherapi
servic
marpsh
base
data
collect
inspect
blood
servic
carri
regulatori
author
use
marpsh
blood
servic
classifi
one
possibl
potenti
risk
categori
high
mediumhigh
medium
mediumlow
low
risk
categori
repres
differ
potenti
risk
level
accord
proport
complianc
establish
regulatori
requir
marpsh
use
sinc
show
trend
risk
reduct
blood
servic
evalu
countri
aim
work
aim
describ
util
marpsh
tool
integr
risk
manag
model
also
show
main
result
obtain
year
data
monitor
coordin
regulatori
action
polici
anvisa
target
qualiti
safeti
blood
product
method
util
marpsh
follow
network
risk
manag
model
sinc
inspect
carri
decentr
organ
state
municip
inspector
fulfil
standard
inspect
guid
contain
regulatori
requir
item
associ
level
risk
vari
iii
risk
increas
end
inspect
statist
calcul
servic
categor
classif
give
estim
qualiti
profil
guid
adopt
suitabl
measur
risk
manag
local
author
servic
data
send
state
realiz
municip
anvisa
perform
consolid
nation
level
either
state
anvisa
use
data
coordin
risk
manag
measur
broader
spectrum
data
continu
monitor
anvisa
part
strateg
panel
indic
anvisa
follow
special
blood
servic
high
mediumhigh
risk
aim
help
complement
local
author
action
addit
anvisa
period
send
inform
brazilian
ministri
health
local
government
organ
brazilian
nation
blood
system
also
support
action
improv
qualiti
blood
servic
network
result
sinc
assess
cover
blood
servic
marpsh
reach
blood
servic
blood
servic
regist
correspond
almost
inspect
cover
year
period
possibl
notic
dramat
decreas
trend
proport
blood
servic
classifi
high
mediumhigh
risk
vari
summaryconclus
marpsh
gener
data
necessari
categor
blood
servic
five
level
potenti
risk
result
regulatori
action
appli
local
organ
purpos
reduc
elimin
risk
involv
product
use
blood
compon
data
shown
signific
risk
reduct
year
marpsh
util
addit
monitor
data
nation
level
permit
appropri
plan
priorit
integr
strategi
direct
risk
manag
strengthen
blood
servic
brazil
background
subsaharan
africa
highest
need
blood
transfus
world
mainli
childbear
women
children
suffer
malaria
meet
basic
qualiti
oper
requir
provid
patient
safe
blood
remain
challeng
set
aim
aim
identifi
priorit
potenti
hazard
patient
blood
bank
practic
democrat
republ
congo
drc
focus
two
subset
sensibilis
select
donor
ii
qualif
product
blood
product
use
failur
mode
effect
analysi
fmea
method
two
risk
analysi
workshop
organ
nation
blood
transfus
centr
kinshasa
democrat
republ
congo
workshop
multidisciplinari
team
invit
repres
differ
hospit
profil
transfus
manag
drc
qualiti
coordin
n
train
coordin
n
medic
doctor
donor
select
n
hemovigil
offic
n
laboratori
technician
perform
donor
sampl
blood
qualif
product
n
biomed
scientist
n
microbiologist
n
clinic
biologist
n
nurs
n
principl
fmea
appli
impli
identif
possibl
hazard
failur
process
flow
follow
score
hazard
accord
impact
probabl
detect
feasibl
workshop
particip
guid
extern
facilit
guarante
common
understand
methodolog
main
focu
risk
analysi
potenti
harm
transfus
patient
process
sensibilis
select
donor
ii
qualif
product
blood
product
idea
written
colour
card
map
chart
accord
impact
probabl
detect
feasibl
score
hazard
rank
accord
final
risk
score
multipli
four
score
result
process
sensibilis
select
donor
three
hazard
highest
final
score
impact
probabl
detect
feasibl
paid
donor
recruit
sensibilis
famili
member
patient
ii
donor
select
staff
approv
nonelig
donor
blood
donat
personalfinanci
motiv
iii
blood
donor
correctli
inform
blood
donat
sensibilis
famili
member
patient
flow
qualif
blood
product
highest
score
made
doubl
check
valid
sort
qualifi
blood
product
ii
stockout
reagent
iii
check
match
regist
test
result
test
blood
tube
regard
product
blood
product
top
three
consist
transport
time
blood
collect
process
h
ii
storag
qualifi
quarantin
blood
product
fridg
site
iii
power
cut
summaryconclus
risk
analysi
result
three
priorit
hazard
process
donor
selectionsensibilis
blood
product
qualificationproduct
specif
subsaharan
african
set
describ
power
cut
famili
paid
donor
stock
ruptur
action
plan
need
put
place
reduc
final
risk
score
risk
analysi
need
continu
remain
blood
transfus
flow
background
million
germani
popul
quarter
resid
migrat
background
major
root
region
popul
distribut
pattern
blood
group
hlaantigen
differ
consider
predomin
one
german
popul
suffici
suppli
individu
red
blood
cell
rbc
platelet
concentr
tc
continu
major
challeng
futur
blood
donor
compat
blood
group
antigen
dramat
underrepres
local
donor
pool
mani
migrant
suffer
sever
hematolog
disord
bthalassemia
sickl
cell
diseas
need
compat
blood
transfus
allogen
stem
cell
transplant
forese
futur
healthi
famili
donor
often
avail
present
suitabl
stem
cell
donor
similar
genet
background
found
intern
donor
registri
aim
project
initi
recruit
new
donor
migrat
background
blood
donat
increas
number
blood
stem
cell
donor
among
group
method
serolog
extend
blood
group
phenotyp
perform
autom
gel
card
techniqu
fa
grifol
erytra
includ
rh
ccdee
kk
fy
ab
jk
ab
lu
ab
n
hla
type
hlaa
b
c
dr
dq
dp
perform
next
gener
sequenc
allel
frequenc
analys
use
genepop
version
rare
rare
allel
defin
accord
allel
frequenc
databas
wwwallelefrequenciesnet
rbc
genotyp
use
next
gener
sequenc
current
establish
includ
addit
antigen
frequent
distribut
pattern
differ
migrant
resid
popul
accord
literatur
result
far
blood
donor
migrat
background
recruit
blood
donat
project
amongst
group
blood
donor
noneuropean
countri
enrol
potenti
stem
cell
donor
initi
evalu
data
reveal
similar
distribut
blood
group
compar
current
blood
donor
popul
north
rhinewestphalia
migrant
donor
ten
fy
ab
donor
identifi
correspond
percentag
amongst
hlatyp
potenti
stem
cell
donor
found
rare
rare
allel
summaryconclus
blood
donor
rare
blood
group
hla
phenotyp
eg
null
type
fy
ab
demand
adequ
medic
care
peopl
migrat
background
technolog
develop
blood
group
determin
next
gener
sequenc
significantli
improv
suppli
blood
transfus
recipi
germani
project
fund
european
develop
fund
erdf
european
union
background
mortal
due
uncontrol
haemorrhag
follow
trauma
import
caus
potenti
prevent
death
trauma
care
system
low
middl
incom
countri
like
india
still
develop
phase
also
role
blood
compon
therapi
improv
patient
outcom
mostli
deriv
combat
set
applic
protocol
urban
setup
well
establish
mark
variat
practic
exist
henc
studi
aim
identifi
key
compon
transfus
practic
optim
transfus
protocol
trauma
set
aim
studi
current
transfus
practic
sever
injur
trauma
patient
admit
red
arearesuscit
bay
initi
triag
ed
method
prospect
observ
studi
conduct
period
year
start
june
may
depart
transfus
medicin
collabor
emerg
depart
jpnatc
aiim
new
delhi
studi
includ
sever
injur
patient
iss
admit
within
h
red
arearesuscit
bay
triag
data
collect
includ
demograph
injuri
laboratori
transfus
detail
patient
result
studi
period
patient
male
enrol
mean
iss
score
mean
time
hospit
admiss
injuri
iqr
hour
mean
time
first
rbc
transfus
follow
admiss
iqr
hour
approxim
patient
shock
sbp
mm
hg
puls
rate
wherea
patient
coagulopath
pt
time
normal
initi
h
admiss
patient
transfus
rbc
ffp
rdp
cryoprecipit
total
blood
compon
util
patient
massiv
transfus
defin
transfus
h
given
patient
summaryconclus
signific
quantiti
blood
compon
requir
initi
resuscit
sever
injur
patient
prehospit
transfus
significantli
reduc
time
transfus
studi
need
assess
util
pre
hospit
transfus
sever
injur
patient
background
allogen
stem
cell
transplant
recipi
known
main
consum
platelet
concentr
pc
geneva
univers
hospit
one
three
allogen
hematopoiet
stem
cell
transplant
hsct
center
switzerland
sinc
blood
center
also
part
hospit
data
pc
consumpt
easili
avail
need
rose
steadili
sinc
sever
year
averag
increas
per
year
pc
suppli
seriou
concern
center
aim
studi
tri
evalu
pretranspl
indic
could
help
forecast
number
pc
need
allogen
hematopoiet
stem
cell
transplant
method
observ
retrospect
studi
conduct
geneva
hospit
patient
suffer
variou
inherit
acquir
disord
hematopoiet
system
treat
hsct
pc
consumpt
examin
januari
decemb
five
indic
gender
stem
cell
sourc
bone
marrow
bm
vs
peripher
blood
stem
cell
pbsc
donor
type
hla
match
vs
haploident
condit
regimen
standard
vs
reduc
intens
cmv
serolog
recipi
result
data
total
patient
age
year
analyz
male
femal
cmvneg
cmvposit
total
transplant
haploident
hlamatch
accord
stem
cell
sourc
bm
transplant
case
pbsc
case
two
patient
also
receiv
stem
cell
boost
analysi
show
mean
followup
day
number
pc
transfus
patient
treat
hsct
rang
unit
averag
median
illustr
high
variabl
result
indic
gender
stem
cell
sourc
bm
vs
pbsc
condit
regimen
standard
vs
reduc
intens
cmv
serolog
recipi
statist
impact
platelet
consumpt
howev
observ
tendenc
increas
need
platelet
transfus
patient
cmv
posit
result
also
show
statist
signific
p
higher
number
pc
transfus
patient
treat
haploident
versu
hlamatch
transplant
summaryconclus
studi
point
high
variabl
platelet
consumpt
hsct
limit
forecast
platelet
product
need
support
allogen
hsct
recipi
larger
cohort
would
requir
confirm
potenti
higher
platelet
consumpt
cmv
posit
patient
consolid
result
show
higher
pc
consumpt
patient
treat
haploident
transplant
abstract
withdrawn
background
histor
institut
minimum
four
red
blood
cell
rbc
unit
crossmatch
cardiac
surgeri
case
regardless
surgic
casetyp
patient
characterist
two
rbc
unit
pack
valid
blood
product
cooler
brought
oper
room
balanc
crossmatch
unit
remain
blood
bank
retrospect
review
reveal
rbc
transfus
moreov
approxim
product
wast
month
direct
result
practic
thu
recogn
opportun
improv
inventori
manag
term
personnel
activ
blood
compon
util
aim
goal
studi
reduc
advanc
prepar
cooler
cardiac
surgeri
case
without
compromis
patient
care
safeti
limit
intervent
patient
elig
electron
crossmatch
maintain
aforement
histor
practic
patient
histori
current
demonstr
clinic
signific
red
blood
cell
alloantibodi
method
multidisciplinari
group
consist
repres
blood
bank
cardiac
surgeri
cardiac
nurs
cardiac
anesthesia
surgeri
qualiti
depart
assembl
octob
determin
whether
modif
practic
reason
safe
group
member
evalu
site
specif
societi
thorac
surgeri
st
cardiac
surgic
data
juli
decemb
establish
intraop
red
cell
transfus
rate
classifi
type
urgenc
surgeri
group
main
goal
discontinu
prepar
default
cooler
patient
elig
electron
crossmatch
schedul
type
nonemerg
cardiac
surgeri
case
histor
case
requir
least
one
red
cell
transfus
addit
team
member
simul
multipl
protocol
red
blood
cell
could
prepar
deliv
estim
time
scenario
result
review
st
data
show
follow
case
met
criteria
elect
primari
coronari
arteri
bypass
graft
cabg
urgent
primari
cabg
elect
mitral
valv
repair
elect
aortic
valv
replac
simul
show
patient
elig
electron
crossmatch
prepar
receipt
order
complet
unit
pack
deliveri
took
min
use
pneumat
tube
system
maximum
unit
per
tube
min
use
deliveri
cooler
use
human
courier
summaryconclus
base
simul
result
consensu
agreement
multidisciplinari
group
default
cooler
prepar
elect
primari
cabg
urgent
primari
cabg
elect
mvr
elect
avr
discontinu
decemb
one
year
follow
implement
chang
polici
rbc
unit
issu
reduct
transfus
compar
wastag
rate
decreas
product
month
per
month
averag
summaryconclus
obviou
drawback
pabd
higher
cost
run
program
comparison
collect
allogen
blood
area
addit
patient
attent
cleric
input
label
separ
storag
audit
autolog
blood
compon
transfus
intend
recipi
wast
context
pabd
program
could
consid
costeffect
approach
protect
blood
safeti
background
nation
blood
servic
zimbabw
nbsz
blood
suppli
manag
statu
bsm
integr
process
ensur
avail
safe
suffici
blood
suppli
provis
nbsz
introduc
new
daili
blood
bank
statement
improv
metric
may
new
analyt
approach
focus
three
interact
compon
blood
bank
statement
avail
stock
quarantin
stock
per
desir
stock
level
demand
versu
suppli
imper
close
monitor
blood
suppli
chain
blood
limit
shelf
life
uncertainti
suppli
demand
bloodforfre
proclam
govern
zimbabw
juli
set
pressur
blood
demand
metricbas
analyt
seek
assess
nbsz
improv
blood
bank
statement
realist
model
bsm
aim
assess
use
interact
metric
monitor
blood
suppli
manag
statu
method
prospect
crosssect
studi
conduct
total
daili
blood
bank
statement
submit
may
decemb
five
branch
analyz
bsm
calcul
averag
three
interact
measur
quarantin
stock
avail
stock
demand
versu
suppli
determin
subanalysi
branch
done
determin
individu
branch
perform
analysi
month
done
assess
season
variat
find
recommend
share
among
key
stakehold
valid
bsm
methodolog
result
overal
quarantin
stock
averag
sd
avail
stock
sd
demand
versu
suppli
sd
overal
bsm
sd
studi
period
gweru
masvingo
nearli
suppli
demand
blood
overal
bsm
overal
bsm
respect
bulawayo
suppli
blood
demand
overal
bsm
mutar
suppli
bsm
harar
bsm
monthli
variat
servic
could
suppli
blood
demand
month
may
servic
met
demand
bsm
novemb
decemb
suppli
bsm
bsm
respect
august
also
averag
suppli
bsm
june
octob
septemb
record
averag
valu
bsm
bsm
respect
summaryconclus
overal
bsm
perform
satisfactori
note
branch
capacit
accord
demand
new
interact
analyt
approach
appropri
show
blood
bank
statu
assess
perform
branch
new
approach
optim
decisionmak
process
blood
suppli
manag
metric
track
use
excel
base
model
henc
approach
suitabl
resourc
constrain
set
limit
ict
infrastructur
st
vincent
hospit
melbourn
svhm
tertiari
hospit
support
medicin
surgeri
nonmajor
trauma
emerg
itu
servic
implement
mtp
subsequ
mtp
reassess
led
implement
regular
multidisciplinari
review
mt
identifi
area
improv
transfus
aspect
support
critic
bleed
patient
aim
implement
systemat
servicewid
stakehold
review
mt
event
svhm
aim
identifi
defici
implement
improv
mt
manag
method
multidisciplinari
mt
review
team
establish
subcommitte
hospit
transfus
committe
tc
updat
organis
mtp
subsequ
continu
meet
quarterli
mt
review
subcommitte
mtr
tc
systemat
review
aspect
mt
svhm
instanc
red
cell
unit
transfus
h
identifi
laboratori
inform
system
review
mtr
includ
repres
accid
emerg
intens
care
oper
suit
os
transfus
laboratori
staff
head
patient
treat
unit
also
invit
contribut
review
includ
demograph
clinic
detail
comorbid
time
patient
arriv
pretransfus
specimen
collectionreceipt
time
blood
request
releasetransfus
regular
full
blood
examin
fbe
coagul
coag
test
time
blood
compon
transfus
total
compon
provisionratio
compon
wast
patient
outcom
commun
variou
clinic
area
also
laboratori
discuss
summari
action
recommend
provid
tc
case
refer
hospit
mortalityclin
review
committe
result
case
review
treat
unit
includ
cardiothorac
surgeri
hepatobiliarygastrointestinalcolorect
surgeri
vascular
surgeri
neurosurgeri
orthopaed
surgeri
endocrin
encompass
gener
surgeri
urolog
gener
medicin
oncolog
area
monitoringimprov
identifi
transfus
document
regular
fbecoag
specimen
submiss
reduc
time
patient
arriv
specimen
collect
reduc
specimen
transport
time
interfac
point
care
bloodga
analys
central
patholog
result
manag
system
well
compon
managementwast
reduct
introduct
viscoelastometri
assess
os
review
case
involv
transfus
emerg
uncrossmatch
rhd
neg
red
cell
unit
appropri
use
preciou
resourc
also
review
mtr
summaryconclus
svhm
mtr
meet
regularli
review
mt
event
formalis
multidisciplinari
collabor
identifi
possibl
improv
support
often
critic
ill
patient
matter
highlight
includ
commun
issu
delay
specimen
deliveri
blood
compon
wast
minimis
area
work
includ
minimis
delay
mt
event
review
formalis
key
perform
indic
mt
background
use
radio
frequenc
identif
rfid
technolog
manag
blood
suppli
chain
recogn
major
enhanc
oper
blood
bank
hospit
transfus
servic
facilit
optim
blood
suppli
manag
crucial
guarante
integr
rfid
tag
throughout
transfus
chain
sinc
rfid
tag
affix
blood
product
earli
process
tag
undergo
processstep
blood
product
eg
centrifug
label
print
shockfreez
irradi
aim
goal
studi
valid
mechan
function
resist
biologid
rfid
tag
differ
blood
relat
process
centrifug
label
print
shockfreez
intens
read
irradi
biologid
tag
passiv
hf
mhz
tag
compliant
iso
follow
guidelin
use
rfid
technolog
transfus
medicin
vox
sanguini
method
biologid
tag
evalu
use
seri
rfid
encod
read
test
process
step
tag
encod
donat
number
site
id
product
code
blood
group
expiri
date
data
encod
use
isbt
format
differ
process
step
condit
test
centrifug
quintupl
whole
blood
bag
fill
ml
water
centrifug
rpm
min
tag
process
tag
per
kit
affix
differ
posit
shockfreez
shockfreez
angelantoni
unit
process
read
immedi
remov
shock
freezer
water
tag
irradi
gy
tag
gy
result
biologid
tag
encod
read
success
rate
seri
test
summaryconclus
biologid
rfid
tag
encod
read
common
process
use
throughout
blood
transfus
chain
mechan
function
integr
affect
centrifug
shockfreez
intens
read
print
eto
steril
irradi
background
provis
compat
red
blood
cell
intern
cooper
present
unit
meant
old
femal
homozyg
sickl
cell
diseas
scd
multipl
complic
patient
blood
group
posit
antic
e
wr
antibodi
high
preval
antigen
rh
system
antihr
b
possibl
combin
antihr
b
antibodi
reactiv
rh
null
dor
hr
b
neg
cell
donor
center
put
intern
request
group
rh
null
dunit
lack
wr
possibl
k
fy
jk
wr
latter
antigen
prophylact
match
patient
sampl
genotyp
rhd
rhce
use
mlpa
sanger
sequenc
patient
found
carri
rhd
rhce
rhce
aim
request
sent
american
rare
donor
program
ardp
ardp
work
american
red
cross
nation
molecular
laboratori
use
rh
genotyp
inform
identifi
donor
carri
similar
rh
variant
allel
use
rh
allel
match
approach
describ
previous
keller
et
al
transfus
method
recent
blood
sampl
use
confirm
antihr
b
antihr
b
detect
patient
rhd
rhce
allel
use
build
punnett
squar
gene
donor
carri
similar
allel
would
predict
compat
tier
donor
predict
carri
combin
rhd
rhce
allel
patient
tier
donor
predict
homozyg
one
allel
combin
carri
patient
tier
donor
predict
carri
allel
similar
ident
carri
patient
similar
predict
phenotyp
databas
donor
ardp
carri
rh
variant
allel
queri
allel
patientspecif
punnett
squar
result
donor
group
match
rh
allel
identifi
follow
tier
tier
tier
donor
clinic
team
agre
drop
one
prophylact
antigen
match
one
tier
unit
lack
jk
identifi
american
red
cross
request
process
patient
experienc
sickl
cell
crisi
red
cell
aplasia
recurr
aiha
hemoglobin
level
drop
gdl
time
transfus
compat
unit
avail
rare
dphenotyp
hb
increas
gdl
eventu
gdl
tier
rh
allel
match
unit
ship
amsterdam
frozen
reserv
transfus
care
patient
summaryconclus
case
illustr
rh
allel
match
blood
found
highli
rh
alloimmun
patient
avoid
use
exquisit
rare
dor
rh
null
blood
background
blood
transfus
complic
highriski
clinic
procedur
error
could
caus
seriou
injuri
patient
better
assur
procedur
safeti
aim
enhanc
built
blood
transfus
databas
platform
develop
inventori
manag
strategi
better
guarante
patient
transfus
safeti
method
design
six
new
featur
platform
assur
patient
identif
barcod
techniqu
design
structur
order
entri
proactiv
remind
physician
patient
previou
blood
transfus
reaction
relat
precaut
includ
use
leukoreduct
filter
automat
remind
physician
happen
reaction
suggest
relev
test
build
complet
traceabl
log
system
support
data
analysi
blood
transfus
safeti
team
includ
medic
technologist
nurs
physician
system
analyst
blood
transport
whole
process
electron
manag
new
blood
transfus
platform
integr
workflow
reduc
incid
abnorm
blood
sampl
collect
implement
p
reduc
time
call
medic
technologist
blood
compon
prepar
improv
achiev
rate
emerg
blood
crossmatch
implement
p
barcod
correctli
identifi
patient
monitor
entir
transfus
process
reduc
error
rate
blood
compon
suppli
implement
p
summaryconclus
transdisciplinari
team
approach
emonitor
better
design
clinic
decis
support
modul
barcod
technolog
blood
transfus
databas
platform
improv
blood
suppli
effici
assur
blood
transfus
safeti
background
modern
world
terrorist
act
character
multipl
combin
injuri
larg
number
victim
qualifi
medic
care
urgent
requir
larg
number
patient
one
local
time
lead
increas
emerg
demand
blood
compon
mostli
red
blood
cell
desir
donat
blood
victim
natur
manifest
societi
solidar
respons
tragic
event
howev
donor
activ
patient
need
alway
correl
aim
analyz
donor
activ
terrorist
attack
method
retrospect
analysi
donat
activ
period
terrorist
attack
moscow
moscow
averag
daili
blood
donat
number
dbdn
ta
compar
number
donat
day
ta
dbdn
day
ta
also
number
deliv
rbc
unit
drbcu
daili
ta
daili
day
compar
result
terribl
ta
occur
moscow
peopl
die
injur
explos
subway
peopl
die
injur
number
drbcu
increas
taday
next
day
dbdn
day
ta
increas
time
next
day
time
second
explos
subway
result
die
injur
number
drbcu
increas
taday
day
dbdn
day
ta
increas
time
next
day
time
explos
market
result
die
injur
drbcu
deliveri
increas
taday
day
dbdn
day
increas
time
decreas
time
next
week
subway
explos
peopl
die
injur
number
drbcu
increas
taday
day
dbdn
day
ta
increas
time
next
day
time
explos
airport
peopl
die
injur
rbcu
deliveri
increas
taday
next
day
dbdn
day
ta
increas
time
next
day
time
summaryconclus
increas
donor
activ
observ
alreadi
next
day
ta
usual
last
day
correl
number
victim
rbc
deliveri
blood
bank
increas
case
day
ta
therefor
guarante
patient
mainten
rbc
stock
includ
cryopreserv
one
also
necessari
promptli
send
excess
red
blood
cell
harvest
peak
activ
cryobank
background
rh
system
major
blood
group
system
besid
abo
system
even
proper
blood
group
cross
match
possibl
alloimmunis
recipi
rh
minor
blood
group
antigen
like
kell
mnss
duffi
etc
medic
colleg
bear
financi
burden
complet
phenotyp
patient
donor
implement
rh
kell
phenotyp
match
blood
transfus
play
major
role
prevent
alloimmunis
advers
event
multitransfus
patient
aim
evalu
efficaci
rh
kell
phenotyp
cost
effect
measur
instead
extend
phenotyp
multitransfus
patient
method
studi
carri
depart
transfus
medicin
one
biggest
blood
bank
countri
annual
collect
blood
unit
patient
thalassemia
aplast
anemia
leukemia
taken
requir
multipl
transfus
complet
phenotyp
done
initi
patient
transfus
patient
taken
control
taken
case
blood
unit
healthi
donor
chosen
male
femal
donor
unit
identif
rh
kell
phenotyp
done
antigen
antibodi
agglutin
test
erythrocyt
magnet
technolog
fulli
autom
immunohaematolog
analyz
qwali
blood
unit
transfus
patient
select
case
control
group
patient
transfus
blood
unit
phenotyp
rh
kell
gel
crossmatch
done
followup
done
patient
transfus
reaction
end
six
month
evalu
alloimmunis
result
end
month
reaction
report
case
receiv
rh
kell
phenotyp
blood
alloimmunis
seen
repeat
phenotyp
control
group
hand
report
reaction
case
phenotyp
end
three
month
show
alloimmunis
e
antibodi
phenotyp
frequenc
rh
kell
blood
group
popul
compar
publish
studi
amongst
rh
antigen
e
common
follow
c
c
e
thu
e
common
e
least
common
rh
type
background
preval
particular
blood
group
uneven
distribut
differ
geograph
area
larg
determin
nation
composit
popul
moscow
one
largest
citi
europ
popul
million
understand
preval
red
blood
cell
antigen
rbcag
among
popul
great
import
blood
bank
plan
aim
determin
frequenc
distribut
pattern
transfusionsignific
rbcag
among
donor
moscow
region
method
result
immunohematolog
studi
rhesu
kell
system
analyz
retrospect
blood
donor
year
moscow
data
collect
process
carri
use
region
inform
system
transfusiolog
rbcag
detect
rh
kell
system
perform
use
micropl
method
automat
immunohematolog
analyz
galileo
neo
immucor
inc
usa
biorad
laboratori
usa
diagnost
card
result
frequent
blood
group
ii
blood
group
b
iii
ab
iv
n
rh
establish
posit
presenc
antigen
rh
neg
absenc
donor
weak
variant
antigen
du
determin
rh
posit
ratio
rh
rh
respect
donor
phenotyp
detect
routin
conduct
year
therefor
number
donor
common
phenotyp
among
donor
ccdee
second
frequenc
ccdee
third
frequenc
rhesu
neg
phenotyp
ccddee
studi
popul
ccdee
ccdee
phenotyp
respect
rare
ccdee
ccdee
ccddee
option
ccddee
ccdee
ccdee
ccddee
ccddee
ccdee
ccddee
detect
singl
case
amount
total
n
cw
antigen
test
donor
detect
cw
commonli
found
donor
ccddee
phenotyp
ccdee
ccdee
variant
data
phenotyp
antigen
detect
examin
n
antigen
k
detect
donor
antigen
absent
n
summaryconclus
studi
transfusionrelev
antigen
distribut
popul
necessari
build
effect
flexibl
model
blood
servic
manag
differenti
approach
choos
strategi
form
longterm
bank
store
blood
compon
take
account
frequenc
variou
antigen
variant
contribut
improv
qualiti
access
safeti
medic
care
disloc
divis
blood
establish
orthopaed
hospit
valdoltra
obv
number
outdat
unit
hospit
side
drop
consider
result
sinc
issu
number
red
blood
cell
unit
rbc
amount
issu
unit
rose
drop
less
steadili
period
hospit
programm
rose
area
number
donat
unit
declin
reorgan
number
outdat
unit
fell
stock
unit
set
disloc
unit
ctdiz
obv
locat
number
discard
rbc
fell
transfus
specialist
constantli
contact
clinician
hospit
import
day
routin
stock
avail
display
happen
time
day
preview
day
collect
releas
anoth
three
time
day
updat
occur
central
base
led
ljubljana
capit
centr
abl
control
order
stock
blood
bank
blood
wastag
remain
low
traceabl
blood
usag
southwestern
region
remain
high
though
support
inform
system
traceabl
form
blood
bank
patient
done
paper
issu
demand
big
effort
staff
blood
bank
hospit
summaryconclus
reorgan
enabl
better
stock
util
traceabl
issu
unit
sometim
imposs
predict
peak
demand
rbc
especi
summer
season
popul
area
doubl
car
accid
well
transfus
specialist
effort
assur
optim
blood
stock
repres
crucial
daili
routin
blood
bank
grand
intern
hospit
kathmandu
nepal
background
voluntari
nonremuner
blood
donor
consist
blood
donor
popul
nepal
therefor
demograph
distribut
blood
donor
accord
age
group
import
achiev
voluntari
nonremuner
blood
donor
nepal
aim
explor
demograph
distribut
blood
donor
differ
age
group
kathmandu
nepal
method
retrospect
studi
conduct
nepal
red
cross
societi
central
blood
transfus
servic
data
januari
januari
collect
donor
manag
softwar
data
includ
socio
demograph
data
data
process
spss
version
result
year
studi
period
total
blood
donat
happen
mobil
blood
collect
inhous
blood
collect
collect
age
group
age
group
age
group
group
age
group
age
group
age
group
respect
summaryconclus
distribut
abo
blood
group
vari
region
one
popul
anoth
kathmandu
nepal
year
age
group
common
age
group
encount
donat
blood
data
gener
present
studi
sever
studi
differ
geograph
region
india
use
health
planner
futur
health
challeng
region
background
inform
system
hemovigil
coordin
nation
health
institut
avail
blood
bank
countri
softwar
allow
central
record
identif
data
donor
infecti
immunohematolog
test
well
fraction
final
destin
blood
compon
obtain
donor
aim
describ
abo
rhd
type
discrep
blood
donor
found
blood
group
variabl
regist
blood
bank
method
retrospect
analysi
inform
regist
blood
bank
author
nationwid
januari
decemb
result
receiv
inform
accept
donor
one
donat
blood
bank
period
month
total
abo
rhd
discrep
identifi
peopl
made
donat
blood
bank
estim
risk
one
discrep
per
accept
donor
five
blood
bank
implic
discrep
hospitalbas
annual
averag
collect
ae
unit
repres
nation
collect
remain
blood
bank
distributor
averag
collect
ae
unit
per
year
repres
nation
collect
blood
group
type
discrep
n
relat
abo
group
common
discrep
type
group
ab
type
group
case
blood
bank
initi
regist
donor
blood
type
donat
later
blood
type
n
b
type
n
rhd
type
discrep
account
n
total
addit
three
donor
simultan
discrep
abo
rhd
type
detect
blood
bank
result
could
due
failur
warn
mechan
releas
blood
compon
b
error
type
inform
donor
regist
system
c
failur
identif
donor
time
select
show
risk
process
control
blood
compon
releas
impact
patient
safeti
unless
abo
rhd
type
blood
group
systemat
verifi
transfus
summaryconclus
despit
blood
bank
verif
valid
process
softwar
releas
blood
compon
flaw
detect
although
softwar
valid
inform
releas
blood
compon
program
abo
rhd
type
discrep
identifi
donor
attend
blood
bank
multipl
time
find
impli
increas
control
use
blood
bank
avoid
lose
traceabl
process
put
risk
life
recipi
blood
donor
test
depart
blood
transfus
institut
ni
ni
serbia
background
abil
autom
blood
group
antibodi
detect
procedur
requir
blood
donor
test
laboratori
mistak
sampl
identif
test
procedur
could
prevent
test
autom
immunohematolog
system
irregular
antibodi
screen
aborhd
group
blood
donor
test
perform
routin
blood
transfus
institut
ni
neo
iri
immucor
usa
fulli
autom
instrument
abo
rh
group
use
micropl
hemagglutin
techniqu
antibodi
screen
identif
use
solid
phase
red
cell
adher
sprca
aim
evalu
autom
neo
iri
system
abo
group
irregular
antibodi
screen
blood
donor
blood
transfus
institut
ni
method
evalu
period
total
edtaanticoagul
sampl
abo
forward
revers
group
use
micropl
anti
anti
antijka
antik
one
case
fail
identifi
antic
antibodi
low
titer
sampl
anti
cd
antibodi
presenc
two
sampl
falseposit
result
observ
system
neo
iri
two
case
neo
iri
due
nonspecif
reason
summaryconclus
aborhd
group
result
obtain
neo
iri
system
use
micropl
method
good
correl
result
system
routin
column
agglutin
method
antibodi
screen
identif
neo
iri
show
high
sensit
detect
clinic
signific
antibodi
import
step
increas
blood
transfus
safeti
background
continu
improv
laboratori
qualiti
provid
accuraci
test
result
precis
diagnosi
treatment
mission
advanc
laboratori
immunogenet
test
histocompat
includ
human
leukocyt
antigen
hla
type
hla
antibodi
detect
cytotox
test
critic
diagnosi
evalu
transplant
prognosi
monitor
order
improv
qualiti
experi
compet
extern
qualiti
assur
scheme
review
educ
per
year
program
establish
perform
period
taiwan
aim
profici
test
pt
held
semiannu
review
investig
outcom
compet
improv
laboratori
particip
program
method
test
item
exercis
classifi
group
hla
genotyp
includ
pharmacogenet
hla
type
cytotox
test
hla
platelet
antibodi
method
hla
genotyp
includ
ssp
sequenc
specif
primer
sso
sequenc
specif
oligonucleotid
sbt
sequenc
base
type
either
sspsso
sspsbt
use
method
hla
antibodi
includ
elisa
flow
cytometri
luminex
use
method
platelet
antibodi
includ
sprca
elisa
use
four
shipment
exercis
materi
two
year
shipment
includ
two
posit
one
neg
sampl
antibodi
detect
two
whole
blood
serum
cytotox
b
cell
three
whole
blood
hla
genotyp
aim
studi
aim
survey
transfus
relat
laboratori
test
qualiti
improv
hospit
blood
bank
manag
method
analyz
survey
result
kind
routin
work
categori
blood
bank
regist
korean
associ
extern
qualiti
assess
servic
blood
bank
worker
voluntarili
repli
electron
survey
categori
follow
characterist
institut
equip
blood
bank
kind
tube
blood
bank
present
kind
blood
bank
test
abo
rh
type
test
crossmatch
test
irregular
antibodi
test
hemovigil
system
blood
bank
test
massiv
transfus
protocol
qualiti
control
issu
analyz
compar
categori
data
accord
consid
characterist
hospit
result
consensu
differ
current
blood
bank
test
present
result
pilot
survey
especi
crossmatch
test
divid
salin
phase
method
ad
irregular
antibodi
test
complet
step
antihuman
globulin
phase
accord
institut
environ
autom
type
machin
autom
irregular
antibodi
test
devic
increas
largescal
hospit
smallscal
hospit
differ
kind
tube
use
edta
tube
abo
rh
type
plain
tube
crossmatch
test
retent
segment
rbc
reserv
minimum
day
blood
bank
regist
regularli
list
transfus
event
korean
hemovigil
system
safeti
transfus
also
lot
institut
none
underdevelop
massiv
transfus
protocol
specif
survey
result
analyz
poster
present
summaryconclus
survey
show
current
statu
transfus
relat
blood
bank
test
institut
blood
bank
comparison
help
assess
currenc
individu
blood
bank
environ
abstract
withdrawn
background
know
qualiti
manag
continu
process
involv
implement
mainten
improv
aim
purpos
show
experi
implement
qualiti
manag
system
whole
institut
first
step
achiev
jaci
accredit
stem
cell
collect
facil
order
provid
patient
donor
best
possibl
care
method
institut
transfus
medicin
republ
macedonia
itm
main
institut
charg
blood
transfus
servic
bt
whole
countri
nation
unifi
system
stem
cell
collect
facil
part
itm
facil
oper
sinc
year
collect
stem
cell
patient
collect
sibl
donor
till
obtain
implement
mainten
qm
establish
iso
standard
whole
institut
itm
well
implement
jaci
standard
stem
cell
collect
facil
two
colleagu
becam
jaci
inspector
standard
oper
procedur
sop
develop
follow
regular
meet
train
selfevalu
personnel
ask
orient
visit
independ
jaci
inspector
order
come
one
step
closer
jaci
accredit
improv
overal
qm
result
institut
transfus
medicin
rm
part
ipa
project
strengthen
blood
suppli
system
project
aim
ultim
bring
blood
transfus
servic
european
union
standard
allow
exchang
blood
compon
type
collabor
european
union
countri
futur
project
put
basi
unif
blood
transfus
standard
oper
procedur
whole
countri
well
set
essenti
educ
blood
transfus
personnel
although
lot
strength
found
orient
visit
jaci
inspector
still
lot
area
improv
strength
motiv
team
support
institut
leadership
includ
macedonian
ministri
health
area
improv
label
cellular
therapi
product
lack
laboratori
qualiti
control
nation
regulatori
framework
place
world
bank
initi
macedonia
support
qualiti
health
care
accredit
summaryconclus
institut
plan
implement
isbt
standard
label
cellular
therapi
product
establish
laboratori
qualiti
control
cellular
therapi
well
meet
requir
becom
jaci
accredit
facil
work
standard
follow
rule
regular
selfevalu
help
us
maintain
strong
qualiti
manag
system
everi
institut
benefit
qualiti
manag
system
bring
line
intern
standard
ensur
qualiti
servic
product
essenti
keep
safe
strong
blood
transfus
servic
background
implement
robust
qualiti
assur
program
key
high
perform
blood
establish
qualiti
control
qualiti
assur
system
togeth
constitut
key
qualiti
system
part
qualiti
manag
effect
effici
qualiti
control
polici
provid
guidanc
help
increas
reliabl
result
also
maintain
laboratori
consist
perform
overtim
aim
therefor
establish
set
qc
limit
use
histor
data
time
identifi
unexpect
variat
test
system
trigger
review
test
process
blood
screen
laboratori
part
qualiti
assur
system
method
last
two
consecut
year
jan
dec
qc
data
architect
abbott
laboratori
chicago
extract
use
abbottlink
philippin
red
cross
tower
nation
blood
center
total
data
point
data
point
data
point
obtain
differ
qc
level
four
serolog
blood
screen
assay
hiv
combo
hbsag
antihcv
syphili
data
sort
assaylot
qc
level
combin
year
qc
limit
calcul
use
simpl
mean
standard
deviat
sd
coeffici
variat
cv
valid
compar
manufactur
recommend
result
six
posit
qualiti
control
level
cv
within
manufactur
precis
recommend
within
lab
precis
hbsag
antihcv
syphili
hiv
five
six
posit
qualiti
control
level
cv
show
within
manufactur
precis
recommend
within
lab
precis
hbsag
antihcv
syphili
hiv
except
syphili
tp
posit
control
four
neg
qualiti
control
level
show
sd
valu
within
respect
summaryconclus
excel
qc
perform
observ
philippin
red
cross
tower
nation
blood
center
blood
screen
laboratori
base
histor
data
evidencebas
laboratori
qc
limit
blood
screen
assay
establish
use
histor
data
take
account
total
variat
expect
test
system
offer
robust
meaning
mechan
set
control
limit
first
time
background
qualiti
indic
qi
transfus
medicin
tm
critic
import
aspect
transfus
medicin
practic
measur
util
gain
insight
continu
qualiti
improv
degre
tm
capabl
provid
qualiti
tm
care
product
servic
aspect
practic
measur
follow
comparison
measur
accept
local
intern
refer
threshold
benchmark
standard
practic
guidelin
critic
control
point
ccp
select
studi
administr
techniqu
monitor
key
element
select
sinc
clinic
fratern
play
larger
role
ensur
qualiti
servic
administr
blood
compon
need
follow
complianc
standard
protocol
bedsid
transfus
practic
henc
decid
studi
four
select
qualiti
indic
introduc
correct
measur
necessari
aim
assess
exist
transfus
practic
institut
specif
qualiti
indic
introduc
correct
reform
improv
exist
practic
assess
transfus
practic
intervent
use
qualiti
indic
method
assess
exist
transfus
practic
centr
transfus
prospect
follow
structur
checklist
qualiti
indic
use
verif
blood
compon
prior
transfus
ii
initi
transfus
within
min
releas
blood
bank
iii
close
observ
transfus
first
min
iv
complet
transfus
within
right
time
frame
compon
correct
measur
transfus
monitor
format
design
distribut
everi
ward
nurs
offic
inform
monitor
document
transfus
use
addit
blood
bank
staff
made
call
ward
ensur
transfus
everi
compon
initi
within
min
issu
transfus
practic
monitor
follow
transfus
use
qualiti
indic
result
signific
differ
four
variabl
two
phase
transfus
verifi
phase
verifi
phase
ii
p
transfus
start
within
half
hour
issu
second
phase
rose
p
transfus
observ
first
min
phase
observ
second
phase
p
phase
transfus
complet
within
right
time
phase
ii
p
summaryconclus
recommend
follow
qualiti
indic
bedsid
transfus
practic
background
antibodi
titrat
consist
perform
antibodi
detect
select
red
cell
differ
sampl
dilut
titer
report
reciproc
highest
dilut
induc
macroscop
agglutin
usual
applic
titrat
prenat
studi
complex
antibodi
identif
public
demonstr
variat
antibodi
titer
titrat
score
note
upon
repeat
test
sampl
test
perform
tube
compar
repeat
test
gel
aim
evalu
efficaci
autom
antibodi
titrat
versu
manual
method
use
gel
microcolumn
technolog
method
edtaanticoagul
whole
blood
donor
plasma
frozen
sampl
contain
known
irregular
rh
kidd
duffi
mn
etc
regular
b
antibodi
select
titer
sampl
determin
parallel
use
grifol
analyz
erytra
erytra
eflexi
compar
versu
grifol
gel
manual
method
use
grifol
gel
microcolumn
technolog
grifol
red
blood
cell
reagent
sixti
also
process
parallel
erytra
erytra
eflexi
analyz
comparison
precis
studi
sampl
test
autom
system
time
datapoint
analyz
differ
test
day
handson
manual
intervent
averag
time
requir
complet
titrat
measur
expert
technician
differ
sampl
workload
sampl
test
result
compar
number
independ
titrat
perform
grifol
analyz
walkaway
time
differ
sampl
workload
sampl
test
assess
manual
method
expert
technician
compar
time
obtain
reproduc
grifol
analyz
result
provid
analyz
review
compar
manual
method
result
titer
obtain
erytra
erytra
eflexi
equival
titer
obtain
manual
differ
titer
titer
result
prove
instrument
equival
perform
titrat
differ
titer
titer
precis
result
show
differ
titer
obtain
run
perform
grifol
analyz
differ
titer
titer
manual
handson
autom
system
reduc
compar
manual
method
sampl
number
sampl
increas
sampl
differ
handson
even
reduc
addit
walkaway
higher
autom
system
compar
manual
method
furthermor
number
sampl
increas
sampl
walkaway
differ
increas
even
final
autom
system
softwar
demonstr
increas
standard
test
sampl
result
reagent
traceabl
automat
manag
summaryconclus
grifol
gel
system
includ
erytra
erytra
eflexi
analyz
provid
scalabl
effici
solut
perform
standard
titrat
immunohematolog
lab
studi
prove
use
grifol
gel
system
titrat
run
autom
reliabl
way
less
onefold
differ
versu
manual
gel
thu
reduc
least
handson
increas
least
walkaway
rise
standard
autom
test
traceabl
fourth
case
use
result
scenario
task
consid
easi
user
easi
user
user
consid
suffici
design
eas
interact
user
never
found
situat
know
proceed
fifth
case
use
user
role
user
consid
task
easi
easi
user
consid
suffici
design
eas
interact
user
never
found
situat
know
proceed
sixth
case
use
mainten
plan
user
consid
task
consid
easi
easi
user
never
found
situat
know
proceed
user
consid
mainten
plan
similar
better
instrument
reliabl
analysi
background
qualiti
control
procedur
blood
group
serolog
reagent
techniqu
personnel
work
autom
equip
essenti
accuraci
laboratori
result
observ
high
number
uninterpret
result
blood
donor
group
motiv
investig
possibl
target
problem
aim
identifi
blood
group
interpret
problem
analyz
test
result
obtain
commerci
qualiti
control
sampl
routin
use
blood
group
method
micropl
mp
system
perform
abo
rhd
well
rh
phenotyp
kell
blood
group
determin
two
autom
analyz
techno
correspond
two
mpreader
lyra
use
maestro
softwar
diam
current
use
blood
donor
type
three
type
mp
use
b
ab
dvi
dvi
b
profil
first
time
donor
b
ctl
repeat
donor
final
c
c
e
e
k
ctl
profil
accuraci
safeti
blood
group
result
ensur
use
diam
qc
system
consist
tube
whole
blood
tube
contain
serum
known
specif
antibodi
analyz
compar
interpret
qc
whole
blood
sampl
result
analyz
new
optic
camera
instal
techno
system
ward
ward
method
prospect
observ
pilot
studi
done
around
prbc
unit
issu
follow
real
time
understand
tat
within
blood
bank
ward
ward
per
definit
area
time
document
perfectli
understood
consid
calcul
base
conclus
pilot
studi
monitor
form
design
utilis
monitor
tat
within
bb
wtw
data
analys
monthli
avg
tat
bb
wtw
calcul
common
caus
delay
provid
blood
compon
analys
strengthen
reduc
control
tat
result
pilot
studi
total
wtw
tat
averag
min
highest
time
taken
min
addit
process
like
leukodeplet
irradi
salin
wash
red
cell
hold
transfus
lowest
wtw
tat
found
min
prior
inform
crossmatch
surveil
form
start
averag
time
taken
wtw
tat
came
min
maximum
min
jan
area
delay
happen
identifi
intern
courier
delay
technician
delay
bill
logist
delay
concern
staff
put
regular
train
maintain
tat
summaryconclus
although
ethic
staff
work
provid
better
care
patient
area
delay
life
support
blood
transfus
monitor
use
tat
surveil
form
help
avoid
delay
henc
provid
better
time
transfus
support
blood
donat
blood
donor
recruit
hematolog
physiolog
characterist
regular
blood
donor
betathalassemia
trait
background
accord
recent
evid
physiolog
variabl
observ
hematolog
characterist
regular
blood
donor
link
certain
caseswith
genet
factor
donor
lifestyl
may
affect
red
blood
cell
rbc
storag
lesion
betathalassemia
heterozyg
bthalhet
blood
donor
repres
group
particular
interest
high
frequenc
thalassemia
mutat
specif
geograph
area
b
physiolog
bthalhet
rbc
predispos
toward
effect
manag
storageassoci
stress
aim
goal
present
studi
compar
examin
hematolog
rbc
physiolog
featur
regular
blood
donor
without
betathalassemia
trait
blood
process
transfus
purpos
method
healthi
blood
donor
greek
origin
year
old
met
blood
donat
criteria
recruit
studi
plasmaserum
uric
acid
electrolyt
extracellular
hemoglobin
antioxid
capac
cellular
rbc
indic
biolog
paramet
corpuscular
fragil
proteasom
activ
etc
measur
result
statist
analyz
topolog
repres
biolog
network
donor
group
bthalhet
signific
accept
p
result
bthalhet
repres
donor
cohort
differ
lifestyl
smoke
alcohol
consumpt
physic
exercis
observ
two
group
nevertheless
regardless
sex
sexdepend
paramet
eg
hct
hb
concentr
bthalhet
demonstr
reduc
hct
mcv
mch
p
p
p
respect
b
increas
rbc
count
p
compar
averag
donor
moreov
mpv
platelet
index
found
slightli
elev
p
serum
total
protein
concentr
slightli
reduc
p
group
trend
higher
plasma
antioxid
capac
p
evid
group
bthalhet
addit
statist
signific
lower
level
osmot
fragil
p
hemolysi
p
compar
control
final
analysi
three
proteasomeassoci
enzymat
activ
n
per
group
rbc
cytosol
membran
reveal
similar
level
two
group
p
bthalhet
control
biolog
network
show
insignific
variat
respect
amount
connect
hub
profil
howev
differ
observ
regard
number
type
connect
even
topolog
network
cluster
lipid
triglycerid
ldl
etc
nitric
oxid
clusterin
carbonyl
plasma
protein
rbc
osmot
fragil
correl
concentr
electrolyt
select
bthalhet
donor
two
group
summaryconclus
bthalhet
meet
criteria
blood
donat
nonneglig
subgroup
total
donor
popul
greec
exhibit
sever
similar
gener
cohort
differ
fine
characterist
rbc
physiolog
includ
resist
hemolysi
extracellular
antioxid
capac
differenti
network
profil
hematolog
redox
paramet
may
import
respect
subsequ
blood
process
storag
bthalhet
erythrocyt
transfus
purpos
background
blood
servic
poland
base
voluntari
nonremuner
donat
region
blood
donor
centr
poznan
well
region
centr
total
entiti
author
collect
process
store
distribut
blood
compon
hospit
region
activ
also
respons
provid
suffici
amount
blood
compon
region
blood
donor
centr
poznan
one
largest
blood
center
poland
total
number
donat
exceed
per
year
recent
year
observ
grow
popular
tattoo
among
variou
age
group
well
among
peopl
regist
donat
blood
first
time
repeat
donor
henc
critic
introduc
suitabl
measur
ensur
safeti
blood
compon
aim
aim
analys
correl
increas
number
donor
defer
donat
blood
due
tattoo
made
number
record
confirm
hcv
infect
effect
may
safeti
blood
compon
method
analysi
made
use
data
year
obtain
comput
system
blood
bank
oper
region
blood
centr
poznan
poland
analys
total
number
deferr
donor
due
recent
acquir
tattoo
total
number
record
confirm
hepat
c
infect
must
note
categori
temporari
deferr
due
tattoo
broad
one
includ
call
regular
artist
tattoo
perman
makeup
procedur
well
medic
tattoo
result
record
signific
increas
number
deferr
due
tattoo
group
male
donor
trend
remain
rather
stabl
slight
decreas
group
femal
donor
growth
promin
term
record
confirm
hcv
infect
downward
trend
observ
group
male
donor
group
femal
donor
summaryconclus
conclud
analysi
appli
polici
temporari
deferr
donor
recent
acquir
tattoo
last
month
prove
reliabl
method
increas
safeti
blood
compon
nevertheless
current
conduct
qualif
donor
requir
month
deferr
follow
new
tattoo
must
complement
variou
numer
educ
activ
regard
mean
hcv
transmiss
bloodborn
virus
hbv
hiv
way
protect
possibl
infect
special
emphasi
must
put
group
femal
donor
growth
deferr
promin
among
time
vital
ensur
constant
avail
donor
well
design
concis
educ
materi
hard
copi
premis
articl
infograph
download
etc
websit
background
temporari
deferr
neg
impact
donor
retent
mani
donor
fail
return
end
deferr
period
anecdot
evid
collect
australian
red
cross
blood
servic
suggest
mani
donor
know
elig
return
donat
suggest
remind
messag
may
effect
promot
donor
return
deferr
end
aim
aim
studi
evalu
effect
remind
messag
return
rate
defer
donor
end
deferr
period
remind
messag
notifi
donor
deferr
period
end
encourag
make
appoint
donat
studi
also
aim
determin
effect
time
send
messag
messag
content
mode
commun
sm
vs
email
optimis
donor
retent
post
deferr
method
three
separ
randomis
control
trial
conduct
answer
question
data
donor
attempt
return
behaviour
subsequ
deferr
appoint
donat
made
one
month
deferr
end
date
collect
analys
result
overal
donor
receiv
remind
messag
attempt
return
compar
donor
control
group
p
look
time
point
donor
receiv
messag
week
deferr
end
like
attempt
return
compar
control
group
p
week
prior
remind
messag
particularli
effect
male
attempt
return
donat
compar
femal
p
signific
differ
return
rate
donor
receiv
recipi
versu
nonrecipi
focus
messag
donor
receiv
messag
via
email
sm
summaryconclus
remind
messag
sent
defer
donor
end
deferr
period
simpl
costeffect
way
promot
donor
retent
provid
clear
inform
regard
date
donor
return
donat
well
prompt
make
appoint
background
challeng
provid
voluntari
donat
safe
blood
thu
take
account
current
histori
famili
donat
promot
blood
donat
level
awar
voluntari
donat
variou
institut
opinion
interviewe
give
us
clearer
idea
want
achiev
need
improv
futur
aim
provid
voluntari
donat
safe
blood
establish
special
depart
within
nation
blood
transfus
center
respons
market
promot
voluntari
blood
donat
method
studi
conduct
combin
qualit
quantit
method
studi
combin
identif
exist
data
direct
interview
person
differ
age
group
prepar
dissemin
questionnair
analyt
process
collect
inform
studi
questionnair
question
total
divid
section
question
blood
practic
answer
interviewe
peopl
answer
question
blood
transfus
servic
question
blood
knowledg
answer
peopl
question
knowledg
blood
transfus
answer
peopl
question
blood
donat
answer
peopl
question
commun
channel
answer
peopl
result
interviewe
never
donat
intend
donat
due
fact
afraid
needl
infect
smallest
part
nt
donat
blood
allow
religion
donat
express
readi
donat
futur
donat
voluntarili
famili
donor
regular
volunt
donor
donat
voluntarili
sever
time
want
donat
anymor
donat
donat
one
rel
donat
thalassem
children
donat
benefit
free
checkup
donat
valuabl
health
question
whether
would
voluntarili
donat
answer
ye
still
sure
mean
donat
donat
leav
posit
impress
increas
desir
repeat
donat
rather
restrain
made
unsaf
repeat
donat
among
caus
mention
interviewe
bad
condit
donat
facil
staff
behavior
inadequ
treatment
feel
good
donat
hematoma
venipunctur
summaryconclus
base
result
obtain
studi
nation
blood
transfus
center
need
establish
genuin
promot
depart
need
transfus
doctor
activ
part
nation
blood
transfus
center
build
implement
rigor
retent
polici
voluntari
blood
donor
studi
found
around
donor
donat
would
like
donat
attract
donor
retent
polici
sure
lead
selfsuffici
safe
blood
safe
blood
public
good
reason
duti
state
instanc
media
nongovernment
organ
give
support
promot
voluntari
blood
donat
background
smoke
unhealthi
diet
sedentari
behavior
inabl
maintain
adequ
exercis
signific
consequ
sever
chronic
disord
includ
obes
balanc
equilibr
nutrit
may
prevent
neg
consequ
associ
statu
obes
itali
overweight
obes
increas
adult
overweight
obes
higher
frequenc
south
blood
center
play
public
health
role
obes
surveil
intervent
aim
sinc
qualiti
life
selfreport
patient
relat
health
adequ
qualiquantit
nutrit
becom
necessari
relev
field
nutrit
conduct
demograph
studi
evalu
health
statu
blood
donor
monitor
nutrit
habit
lifestyl
method
descript
crosssect
facetofac
questionnair
develop
includ
item
dietari
assess
report
semiquantit
food
frequenc
dietari
behavior
question
selfrat
health
statu
normal
weight
establish
bmi
kgm
overweight
bmi
kgm
obes
bmi
kgm
obes
preval
standard
sex
donor
repeat
blood
donor
made
least
donat
last
year
elig
donat
result
blood
donor
enrol
juli
januari
regular
repeat
donor
wish
chose
respond
survey
sever
reason
ie
lack
time
privaci
accept
defer
blood
donat
exclud
analysi
among
includ
particip
n
male
age
rang
year
mean
age
ae
sd
n
femal
age
rang
year
mean
age
ae
sd
data
show
donor
follow
mainli
mediterranean
diet
awar
lifestyl
women
men
comparison
gener
popul
preval
overweight
found
men
women
survey
show
particip
evalu
health
good
without
gender
differ
men
vs
women
besid
report
health
good
summaryconclus
overweight
obes
common
among
regular
blood
donor
frequent
men
women
preliminari
data
show
women
better
knowledg
nutrit
properti
food
consequ
adopt
balanc
proper
diet
furthermor
clear
awar
relationship
lifestyl
health
put
practic
inform
unfortun
survey
structur
observ
natur
make
possibl
establish
whether
women
alert
health
particip
donat
program
contrari
statu
regular
donor
could
help
improv
knowledg
healthi
lifestyl
background
donor
recruit
pose
ongo
challeng
blood
bank
worldwid
one
approach
improv
effect
donor
recruit
target
influenc
factor
yearli
leagu
conduct
sultan
qaboo
univers
squ
encourag
univers
student
faculti
donat
blood
colleg
evalu
base
differ
measur
includ
number
donor
recruit
colleg
effort
made
student
increas
awar
blood
donat
colleg
societi
via
differ
mean
includ
util
social
media
whole
competit
organ
ran
independ
group
student
aim
studi
aim
studi
impact
yearli
squ
colleg
competit
percept
blood
donat
among
squ
student
method
comprehens
anonym
voluntari
survey
develop
use
assess
percept
student
age
attend
squ
univers
nonsqu
two
year
period
analysi
perform
use
ibm
spss
statist
categor
variabl
present
number
percentag
associ
group
analyz
use
chisquar
test
pvalu
consid
statist
signific
result
total
student
survey
squ
nonsqu
statist
differ
squ
nonsqu
student
regard
past
histori
blood
donat
number
donat
made
compar
cohort
squ
nonsqu
student
report
univers
main
sourc
inform
p
squ
nonsqu
student
report
social
media
main
sourc
respect
p
statist
differ
male
femal
donor
percept
level
selfknowledg
blood
donat
p
youth
agre
blood
donat
one
duti
toward
commun
squ
student
report
higher
rate
respond
specif
request
blood
donat
vs
p
squ
student
report
greater
influenc
peer
vs
p
person
knowledg
vs
p
person
experi
vs
p
compar
nonsqu
student
also
report
feel
commit
societi
vs
p
squ
student
report
lower
influenc
parent
vs
p
lower
rate
fear
needl
vs
p
lower
rate
fear
blood
vs
p
differ
male
femal
gender
discourag
factor
summaryconclus
result
highlight
posit
impact
import
rule
youth
promot
blood
donat
among
yearli
colleg
competit
recruit
blood
donor
dissemin
knowledg
blood
donat
distinct
promot
strategi
adopt
increas
first
time
repeat
blood
donat
among
youth
advoc
similar
initi
encourag
blood
donat
dissemin
knowledg
among
individu
commun
dubai
blood
donat
center
dubai
health
author
dubai
unit
arab
emir
background
dubai
multicultur
citi
unit
arab
emir
popul
consist
uae
nation
rest
compris
expatri
variou
countri
world
approxim
expatri
popul
emir
total
popul
asian
chiefli
indian
pakistani
dubai
blood
donat
centr
centr
provid
blood
donat
servic
dubai
arab
nation
offici
languag
english
use
second
languag
order
good
qualiti
screen
import
blood
donor
understand
educ
materi
questionnair
properli
aim
dubai
blood
donat
centr
receiv
donor
nation
resid
gcc
card
holder
variou
countri
aim
studi
analyz
multin
profil
donor
find
need
add
third
languag
meet
custom
need
expect
method
crosssect
studi
blood
donor
conduct
dubai
blood
donat
centr
donor
ask
countri
origin
languag
read
understand
prefer
mode
commun
result
total
donor
survey
ask
languag
read
understand
respons
obtain
common
languag
read
understood
blood
donor
dbdc
english
n
arab
n
hindi
n
malayalam
n
donor
come
differ
countri
common
donor
indian
uae
found
donor
read
understand
one
languag
major
donor
read
understand
either
offici
languag
arab
english
howev
donor
ca
nt
read
understand
two
offici
languag
common
languag
hindi
malayalam
donor
ask
prefer
mode
commun
respons
obtain
common
mode
commun
sm
telephon
togeth
summaryconclus
base
find
conclud
blood
donor
profil
centr
multin
uniqu
almost
similar
popul
profil
dubai
donor
ca
nt
read
understand
arab
english
decid
educ
materi
questionnair
need
prepar
one
languag
hindi
decid
third
languag
centr
donor
questionnair
educ
materi
hindi
also
made
avail
donor
donor
commun
sm
routin
messag
diseas
notif
telephon
call
done
blood
urgent
requir
background
metabol
disord
metd
includ
hypertens
dyslipidemia
hyperglycemia
central
obes
tightli
associ
cardiovascular
diseas
type
diabet
mellitu
due
sedentari
lifestyl
increas
consumpt
highcalori
diet
modern
societi
metd
becom
seriou
health
problem
worldwid
better
understand
possibl
improv
blood
donor
health
condit
conduct
survey
preval
metd
among
blood
donor
blood
donat
station
locat
hsinchu
scienc
park
taiwan
particip
metd
provid
health
educ
materi
metabol
risk
reduct
order
prevent
develop
futur
complic
aim
aim
studi
determin
preval
metabol
disord
among
blood
donor
calcul
much
money
would
paid
identifi
case
hyperglycemia
hyperlipidemia
undiagnos
diabet
method
studi
approv
institut
review
board
taiwan
blood
servic
foundat
tbsf
bodi
weight
bodi
height
waist
circumfer
wc
blood
pressur
bp
particip
measur
blood
sampl
obtain
determin
valu
hemoglobin
background
law
blood
donat
support
develop
blood
servic
guarante
protect
donor
right
mainten
health
blood
donat
russian
feder
nation
criteria
donor
select
blood
donat
use
activ
blood
servic
establish
aim
ensur
blood
product
safeti
studi
characterist
blood
donor
allow
predict
develop
blood
servic
plan
volum
blood
product
transfus
plasma
fraction
aim
aim
work
studi
characterist
whole
blood
apheresi
donor
blood
servic
russian
feder
method
indic
activ
blood
servic
establish
russian
feder
sector
statist
observ
period
calcul
indic
character
whole
blood
apheresi
donor
analyz
data
present
accord
administr
divis
russian
feder
feder
district
fd
result
proport
whole
blood
donor
plasmapheresi
donor
blood
cell
apheresi
includ
plateletapheresi
donor
period
percentag
repeat
regular
whole
blood
apheresi
donor
increas
percentag
firsttim
donor
rang
largest
proport
plasmapheresi
donor
observ
volga
fd
total
plasma
collect
apheresi
donor
percentag
plateletapheresi
donor
increas
largest
percentag
plateletapheresi
donor
observ
central
fd
signific
part
medic
center
cardiac
surgeri
hematolog
bone
marrow
transplant
locat
proport
platelet
concentr
collect
apheresi
increas
action
recruit
young
donor
blood
donat
compon
regularli
carri
feder
district
summaryconclus
russian
feder
structur
donat
character
increas
proport
plateletapheresi
donor
stabil
percentag
plasmapheresi
donor
increas
proport
repeat
regular
whole
blood
apheresi
donor
signific
region
variat
donor
characterist
feder
district
background
shortag
blood
suppli
despit
continu
blood
donat
campaign
especi
local
festiv
season
major
issu
countri
thu
faculti
initi
blood
donat
drive
collabor
nation
blood
centr
order
meet
demand
blood
requir
howev
predon
deferr
rate
rel
high
among
young
blood
donor
lead
loss
valuabl
blood
unit
understand
caus
donor
deferr
provid
direct
strategi
young
donor
recruit
retent
futur
blood
donat
aim
aim
studi
evalu
young
donor
deferr
pattern
identifi
factor
could
help
minim
prevent
deferr
method
retrospect
studi
voluntari
young
blood
donor
age
year
old
recruit
mobil
blood
donat
faculti
medicin
univers
teknolog
mara
malaysia
studi
conduct
januari
decemb
data
retriev
offici
report
mobil
blood
donat
result
total
young
blood
donor
attend
mobil
blood
donat
studi
period
overal
predon
deferr
rate
main
caus
deferr
low
haemoglobin
hb
level
follow
low
blood
pressur
upper
respiratori
tract
infect
sleep
less
h
summaryconclus
low
haemoglobin
low
blood
pressur
two
common
reason
blood
donat
deferr
among
young
blood
donor
studi
signific
proport
deferr
due
sleep
less
h
wherebi
could
prevent
donor
awar
donor
select
criteria
strategi
mitig
prevent
deferr
improv
blood
donor
retent
particularli
young
blood
donor
sourc
motiv
futur
blood
donat
urg
avoid
addit
stress
blood
suppli
background
modern
world
donat
blood
becom
human
manner
save
patient
life
barrier
blood
donat
design
ensur
donor
blood
recipi
safeti
anemia
one
common
health
problem
world
base
estim
nearli
quarter
world
popul
suffer
anemia
preval
vari
among
popul
age
group
preval
anemia
among
men
nonpregn
women
aim
aim
studi
determin
statu
hemoglobin
volunt
blood
donor
refer
far
provinc
blood
transfus
servic
determin
demograph
statu
last
two
year
studi
includ
blood
donor
blood
donor
last
two
year
method
studi
descript
crosssect
sampl
nonrandom
simpl
sampl
method
paramet
relat
donor
includ
age
sex
type
donat
investig
analyz
spss
softwar
result
total
number
referr
blood
donat
repeat
blood
donor
total
popul
highest
number
referr
follow
first
laps
donor
respect
term
gender
distribut
femal
male
highest
rate
hemoglobin
level
less
gdl
found
firsttim
donor
lowest
preval
observ
laps
donor
follow
repeat
donor
repeat
blood
donor
hemoglobin
higher
signific
differ
blood
donat
type
hemoglobin
level
summaryconclus
accord
find
low
hemoglobin
level
common
among
firsttim
femal
donor
requir
special
train
among
group
high
share
first
time
donor
blood
suppli
posit
impact
femal
donor
blood
safeti
correct
action
group
recommend
finnish
blood
donor
biobank
j
partanen
wahlfor
arva
j
clanci
k
aki
e
palokanga
n
nikiforow
background
increas
need
larg
wellcharacter
cohort
healthi
individu
modern
biomed
research
genom
phenom
studi
typic
includ
ten
even
hundr
thousand
subject
pose
possibl
use
blood
servic
option
collect
sampl
relat
data
possibl
recontact
blood
donor
repeat
sampl
ask
addit
data
increas
interest
collect
larg
biobank
blood
donor
also
need
studi
thoroughli
effect
blood
donat
donor
health
aim
firstphas
goal
recruit
blood
donor
broad
biobank
consent
finngen
http
wwwfinngenfi
project
larg
publicpriv
effort
aim
collect
genom
healthrel
registri
data
finnish
popul
dental
examin
medic
histori
perman
deferr
name
risk
factor
involv
transfus
transmit
infect
chronic
diseas
respect
prime
caus
perman
deferr
risk
factor
involv
transfus
transmit
infect
temporari
deferr
bed
side
hypertens
gender
wise
lead
caus
donor
deferr
male
bed
side
hypertens
anaemia
major
caus
femal
summaryconclus
find
survey
aid
evalu
signific
caus
blood
donor
deferr
studi
suggest
restrict
criteria
use
blood
donor
select
turn
increas
blood
suppli
tertiari
care
hospit
background
donor
select
first
step
toward
safe
blood
retain
blood
donor
also
import
blood
suppli
donor
questionnair
medic
interview
provid
optim
doctor
deferr
aim
evalu
deferr
rate
blood
donor
order
identifi
main
reason
target
eventu
correct
activ
method
analys
data
concern
blood
donor
regist
period
three
year
use
data
inform
system
edelphyn
background
iron
defici
id
blood
donor
underestim
issu
mani
countri
may
caus
symptom
blood
donor
even
without
anemia
id
prevent
mainli
base
prevent
anemia
whole
blood
donor
done
defer
donor
whose
haemoglobin
level
defin
threshold
gl
women
gl
men
franc
ef
french
blood
establish
studi
observ
rate
deferr
anemia
significantli
higher
women
men
either
french
west
indi
versu
continent
franc
assess
preval
id
great
interest
sinc
strategi
counteract
must
deal
donor
health
selfsuppli
howev
data
id
miss
franc
aim
estim
preval
id
french
whole
blood
donor
identifi
risk
factor
associ
id
method
nonintervent
crosssect
multicent
studi
perform
blood
donor
ef
ctsa
blood
center
french
militari
health
servic
whole
blood
donor
met
select
criteria
potenti
includ
donor
come
bloodlet
donor
refus
particip
studi
exclud
addit
sampl
taken
studi
ferritin
test
blood
qualif
surplu
amount
sampl
select
random
within
geograph
area
mobil
blood
drive
blood
center
march
march
result
studi
ferridon
approv
ethic
research
committe
nine
thousand
whole
blood
donor
includ
ef
center
continent
franc
inform
donor
afrocaribbean
origin
comoro
origin
donat
includ
french
west
indi
reunion
island
addit
whole
blood
donor
includ
ctsa
center
studi
id
defin
ferritin
lower
ngml
iron
overload
defin
ferritin
higher
ngml
donor
iron
defici
overload
receiv
letter
advis
consult
gener
practition
weight
calibr
age
sex
geograph
area
sampl
repres
french
whole
blood
donor
estim
id
preval
take
account
weight
logist
regress
model
use
analyz
risk
factor
associ
id
data
analyz
april
may
get
result
end
may
summaryconclus
ferridon
first
studi
id
french
blood
donor
consid
french
health
care
system
diet
interest
compar
result
result
countri
mostli
studi
allow
consid
variou
strategi
deal
donor
safeti
selfsuppli
background
portug
age
popul
around
million
peopl
blood
donor
countri
nation
center
blood
suppli
central
hospit
blood
donat
center
despit
grow
practic
excel
concept
patient
blood
manag
imperi
attract
new
donor
need
inspir
use
new
approach
toward
peopl
constant
work
promot
aim
reach
major
local
popul
use
radio
telecommun
well
social
network
attempt
rais
number
new
blood
donor
central
hospit
north
portug
method
activ
commun
popul
refer
area
via
social
network
facebook
tm
instagram
tm
educ
digit
poster
messeng
servic
answer
kind
question
establish
contact
radio
televis
station
well
mayor
citi
journalist
school
town
hall
deputi
celebr
email
telephon
call
design
poster
flyer
public
advertis
distribut
citi
result
social
network
possibl
reach
popul
dozen
thousand
citi
daili
basi
nation
world
donor
day
celebr
success
health
facil
citi
mayor
journalist
also
three
televis
station
nation
broadcast
reach
million
peopl
celebr
sport
televis
music
standup
comedi
journalist
magician
accept
challeng
video
donat
blood
appeal
blood
donat
sponsor
caus
project
continu
avail
innov
given
hospit
selfsuffici
instead
impli
receiv
less
blood
uniti
nation
center
blood
suppli
recent
project
involv
high
school
attempt
educ
next
gener
donor
meet
town
hall
deputi
district
school
deleg
summaryconclus
age
popul
low
percentag
blood
donor
import
issu
concern
public
health
nevertheless
good
continu
advertis
educ
work
toward
popul
appeal
ethic
civil
respons
sinc
young
age
shown
improv
capac
respons
central
hospit
increas
autosuffici
blood
uniti
interest
younger
donor
utmost
import
understand
continu
hard
work
profession
team
hospit
involv
countless
call
email
hour
obtain
posit
respons
endless
job
mean
interv
donat
shorter
former
regular
donor
month
p
wherea
donor
interv
month
like
regular
aor
ci
summaryconclus
provinci
blood
transfus
centr
bukavu
percentag
regular
donor
low
substanti
loss
former
regular
donor
factor
identifi
link
fidel
uniqu
studi
femal
gender
longer
interdon
interv
factor
similar
found
elsewher
particular
signific
donor
popul
consist
mainli
young
peopl
peopl
without
incom
effort
must
undertaken
ensur
suppli
voluntari
donat
recruit
strategi
target
group
must
refin
futur
qualit
studi
need
explain
variou
associ
factor
better
understand
motiv
regular
nonregular
donor
improv
donor
retent
result
kazakhstan
proport
donor
higher
especi
primari
number
blood
especi
plasma
donat
higher
explain
presenc
sever
albumin
immunoglobulin
product
site
increas
evid
blood
transfus
rule
develop
patient
blood
manag
combin
increas
qualiti
blood
compon
caus
reduct
clinic
need
red
blood
cell
plasma
transfus
time
need
platelet
grow
difficult
assess
correct
compar
amount
bank
whole
blood
equal
difficult
compar
number
receiv
distribut
donor
red
blood
cell
plasma
russia
measur
liter
kazakhstan
dose
certain
degre
condition
platelet
extract
compar
russia
count
equival
dose
isol
dose
whole
blood
least
cell
per
dose
kazakhstanin
therapeut
dose
least
cell
per
dose
estim
consumpt
platelet
kazakhstan
exceed
russian
indic
platelet
kazakhstan
russia
harvest
apheresi
method
inactiv
pathogen
perform
platelet
kazakhstan
russia
pathogen
inactiv
amotosalen
allow
us
abandon
examin
donor
cytomegaloviru
irradi
platelet
concentr
main
modern
trend
use
cryoprecipit
use
sourc
fibrinogen
blood
coagul
factor
first
deplet
coagulopathi
associ
injuri
massiv
bleed
product
grow
countri
endow
kazakhstan
exceed
russian
indic
signific
plasma
percentag
countri
pass
quarantin
due
repeat
nonappear
donor
subject
destruct
inactiv
pathogen
perform
plasma
kazakhstan
russia
despit
instruct
select
donor
laboratori
screen
infect
marker
remain
effect
russia
often
identifi
hiv
viral
hepat
c
potenti
donor
viral
hepat
b
syphili
detect
kazakhstan
donor
kazakhstan
exempt
due
result
multiplex
screen
nucleic
acid
three
hemotransmiss
virus
summaryconclus
blood
servic
russia
kazakhstan
perform
task
provid
medic
organ
effect
blood
compon
condit
decreas
demand
red
blood
cell
plasma
advis
focu
effici
resourc
use
improv
qualiti
blood
compon
produc
blood
collect
includ
apheresi
finnish
red
cross
blood
servic
helsinki
finland
background
skin
disinfect
must
effect
reduc
microb
arm
donor
result
poor
disinfect
microb
may
transfer
skin
via
venepunctur
collect
blood
contamin
blood
compon
aim
ensur
effici
skin
disinfect
use
donor
arm
disinfect
valid
valid
two
criteria
postdisinfect
sampl
must
achiev
bacteria
growth
near
punctur
spot
result
cfu
sampl
total
amount
bacteria
averag
cm
sampl
allow
cm
method
microbiolog
sampl
taken
contact
plate
voluntari
person
elbow
fold
skin
disinfect
disinfect
perform
accord
normal
procedur
five
nurs
altogeth
ethanol
base
disinfect
use
blood
donat
sampl
plate
x
mark
direct
punctur
spot
point
nurs
postdisinfect
sampl
taken
moment
skin
would
punctur
needl
result
amount
bacteria
vari
cm
predisinfect
sampl
disinfect
reduc
bacteria
well
critic
punctur
spot
total
clean
cm
sampl
sampl
cm
averag
number
bacteria
disinfect
cm
maximum
number
cm
remain
bacteria
singl
coloni
edg
plate
summaryconclus
main
criteria
fulfil
sub
criteria
second
main
criteria
also
full
fill
critic
coloni
edg
plate
taken
account
skin
disinfect
question
shown
effect
still
use
blood
donat
pay
attent
thorough
procedur
perform
accord
instruct
suffici
dri
time
disinfect
background
research
question
involv
blood
donat
recipi
data
often
requir
advanc
statist
methodolog
methodolog
may
appear
medic
research
area
specif
tailormad
statist
tool
approach
requir
analysi
bloodrel
data
toolkit
often
requir
collabor
alway
readili
avail
blood
servic
especi
resourcelimit
set
intern
network
statistician
epidemiologist
clinic
research
establish
purpos
start
invit
session
meet
intern
biometr
societi
aim
exchang
idea
experi
knowledg
improv
qualiti
blood
sector
research
method
current
network
cover
four
major
blood
servic
member
five
differ
countri
network
monthli
confer
call
past
current
research
topic
wish
extend
network
establish
subcommitte
statist
epidemiolog
methodolog
regular
facetofac
meet
intern
organ
isbt
result
monthli
meet
alreadi
demonstr
member
share
common
problem
interest
exampl
discuss
techniqu
analyz
data
repeat
measur
eg
elig
haemoglobin
test
way
assess
healthi
donor
effect
eg
determin
appropri
control
group
predict
model
blood
suppli
demand
eg
stochast
process
queu
model
network
also
aim
organ
train
session
methodolog
either
site
andor
develop
web
lectur
summaryconclus
intern
network
statist
methodolog
analysi
blood
donat
recipi
data
improv
qualiti
research
field
transfus
medicin
research
expand
network
includ
countri
blood
servic
research
limit
set
need
activ
pursu
background
blood
donor
hemoglobin
concentr
hb
commonli
measur
skinprick
sampl
donat
site
low
hb
common
reason
temporari
donor
deferr
proport
deferr
reflect
true
low
hb
skinprick
sampl
prone
preanalyt
error
variat
result
fals
deferr
aim
assess
applic
venou
blood
sampl
secondlin
hb
screen
blood
donor
fail
initi
skinprick
test
method
initi
hb
measur
skinprick
sampl
hemocu
hemocu
ab
pointofcar
poc
devic
donor
hb
gl
femal
gl
male
decreas
gl
latest
donat
includ
studi
studi
group
venou
blood
sampl
collect
hb
measur
poc
devic
donat
site
donat
elig
base
hb
result
venou
hb
also
determin
hematolog
analyz
sysmex
xn
sysmex
co
blood
servic
current
workflow
serv
control
group
two
skinprick
sampl
collect
donor
final
hb
donat
elig
assess
algorithm
base
three
skinprick
hb
result
result
studi
n
control
n
group
proport
male
donor
mean
initi
skinprick
hb
gl
gl
similar
significantli
less
donor
defer
donat
studi
group
control
group
chisquar
test
p
mean
differ
venou
hb
poc
devic
versu
hematolog
analyz
gl
rang
gl
two
donor
incorrectli
accept
base
venou
sampl
poc
result
howev
hb
measur
hematolog
analyz
gl
limit
donat
elig
gl
femal
gl
male
interestingli
donor
defer
studi
group
would
elig
donat
base
hematolog
analyz
result
summaryconclus
util
venou
blood
sampl
secondlin
screen
donor
fail
initi
skinprick
hb
test
significantli
decreas
low
hb
deferr
without
compromis
donor
health
blood
donor
blood
servic
nurs
reaction
new
workflow
favor
conclud
valuabl
donat
recov
donor
satisfact
increas
implement
secondlin
hb
screen
model
util
venou
sampl
analysi
donat
site
background
pauciti
literatur
haemoglobin
hb
refer
valu
adult
year
age
age
group
report
use
blood
suppli
studi
report
declin
mean
hb
age
other
found
chang
age
conflict
find
hb
level
healthi
elderli
popul
may
associ
challeng
access
data
healthi
older
adult
small
sampl
size
select
bia
recent
health
popul
data
donat
blood
individu
assess
healthi
must
meet
minimum
hb
criteria
howev
hb
criteria
across
countri
vari
mani
blood
collect
servic
upper
age
limit
donor
mani
popul
around
world
age
restrict
upper
age
limit
blood
donat
may
potenti
affect
size
donor
pool
consequ
nation
blood
suppli
aim
explor
hb
level
healthi
older
adult
multicentr
retrospect
observ
studi
blood
donor
age
year
older
method
oneyear
period
hb
valu
collect
blood
donor
age
year
blood
centr
four
countri
estim
proport
blood
donor
age
year
old
countri
south
korea
sk
hong
kong
hk
indonesia
indo
japan
jap
minimum
hb
criteria
vari
countri
rang
gdl
women
gdl
men
hb
level
determin
use
point
care
test
hemocu
compolab
hemcontrol
sysmex
depend
countri
origin
statist
analysi
mean
standard
deviat
cumul
distribut
hb
determin
gender
age
background
medic
usag
assess
determin
donor
elig
perspect
recipi
donor
safeti
differ
time
frame
sinc
last
taken
appli
differ
medic
assess
medic
use
vari
jurisdict
european
centr
use
multipl
question
often
includ
gener
question
recent
medic
use
wherea
usa
canadian
blood
servic
medic
question
donor
histori
questionnair
dhq
includ
medic
use
last
day
vaccin
specif
medic
differ
time
frame
high
teratogen
medic
name
medic
taken
reason
use
document
staff
donat
attempt
assess
frequenc
process
occur
first
step
improv
effici
aspect
donor
screen
aim
determin
percentag
donor
answer
ye
medic
question
demograph
variabl
method
whole
blood
donor
complet
dhq
full
length
abbrevi
includ
analysi
donor
answer
medic
question
extract
nation
epidemiolog
donor
databas
well
sex
age
number
percentag
donat
attempt
donor
answer
ye
medic
question
calcul
donor
answer
ye
medic
question
sort
sex
age
group
total
percentag
calcul
result
donat
attempt
complet
dhq
overal
donor
answer
ye
medic
last
day
vaccin
less
other
slightli
femal
vs
answer
ye
medic
question
well
individu
question
percentag
donor
answer
ye
medic
question
increas
progress
age
group
year
old
age
p
trend
summaryconclus
one
third
donat
attempt
answer
ye
medic
question
requir
question
document
common
older
donor
follow
similar
trend
gener
popul
medic
use
comparison
way
assess
medic
use
differ
countri
may
help
identifi
effect
effici
approach
addit
contribut
donor
recipi
safeti
assess
medic
assess
blood
center
experi
trima
accel
tome
softwar
j
schreier
davison
j
gambart
l
opez
c
calong
e
herranz
terumo
bct
lakewood
unit
state
centro
de
transfusi
de
la
comunidad
de
madrid
madrid
spain
background
madrid
commun
apheresi
platelet
collect
complet
almost
complet
blood
transfus
center
remaind
sever
hospit
region
trima
accel
implement
meet
product
need
blood
transfus
center
improv
donat
experi
tome
terumo
oper
medic
equip
softwar
enabl
bidirect
commun
trima
accel
devic
use
connect
central
manag
trima
accel
devic
autom
data
captur
report
aim
aim
studi
evalu
oper
improv
use
trima
accel
tome
compar
trima
accel
version
method
retrospect
studi
analyz
apheresi
procedur
trima
accel
version
control
period
januari
septemb
compar
apheresi
procedur
trima
accel
test
period
septemb
decemb
pair
studi
oper
intervent
complet
procedur
rate
comparison
analyz
use
test
wherea
donor
demograph
data
analyz
use
ttest
result
trima
accel
use
collect
singl
doubl
platelet
product
store
platelet
addit
solut
oper
select
either
singl
target
platelet
yield
doubl
target
platelet
yield
platelet
donat
base
desir
procedur
time
maximum
number
product
could
collect
per
donor
statist
signific
differ
observ
donor
test
arm
compar
donor
control
arm
total
blood
volum
control
ml
test
ml
p
hematocrit
control
test
p
platelet
precount
control
test
p
femal
repres
donor
control
arm
compar
donor
test
arm
platelet
split
rate
platelet
product
per
procedur
increas
trima
accel
version
trima
accel
procedur
time
decreas
min
min
singl
collect
min
min
doubl
collect
trima
accel
differ
statist
signific
percentag
procedur
complet
oper
intervent
due
access
alert
increas
p
rate
complet
apheresi
procedur
increas
p
trima
accel
manual
transcript
data
procedur
discontinu
implement
trima
accel
tome
tome
captur
procedur
data
oper
step
barcod
scan
track
configur
event
inform
transfer
tome
post
procedur
print
final
report
summaryconclus
trima
accel
significantli
decreas
oper
intervent
autom
data
captur
tome
elimin
manual
transcript
data
outcom
freed
oper
complet
task
focu
donor
wellb
background
european
committe
partial
agreement
blood
transfus
cdpt
council
europ
coe
appoint
work
group
wg
focu
issu
plasma
suppli
manag
psm
task
wg
among
other
collect
analyz
data
order
fill
knowledg
gap
concern
donor
safeti
plasmapheresi
work
group
gather
evid
base
data
support
upcom
revis
th
edit
coe
guid
prepar
use
qualiti
assur
blood
compon
blood
guid
intern
survey
conduct
septdec
distribut
blood
establish
be
cdpt
repres
coe
member
observ
state
questionnair
includ
section
cover
collect
practic
volum
frequenc
manag
red
cell
loss
donor
panel
demograph
data
donor
advers
event
aim
aim
studi
investig
whether
collect
practic
follow
recommend
publish
blood
guid
maxim
collect
volum
number
donat
per
year
inde
associ
higher
level
donor
safeti
improv
donor
base
sustain
method
total
respond
be
collect
plasma
fraction
pff
apheresi
studi
dataset
cover
plasma
donat
latest
fiscal
year
lfi
paramet
use
marker
donor
safeti
rate
immedi
vasovag
reaction
loss
conscious
vvr
loc
per
plasma
collect
paramet
use
marker
donor
base
sustain
retent
rate
donor
ie
donor
activ
previou
year
return
make
donat
lfi
result
blood
guid
collect
volum
per
apheresi
limit
estim
total
blood
volum
maxim
ml
includ
anticoagul
respond
differ
practic
scale
collect
program
align
lower
higher
collect
volum
altogeth
report
immedi
vvr
loc
rate
mainli
lower
collect
small
trend
toward
reduc
rate
larger
collect
volum
allow
current
blood
guid
salin
compens
collect
affect
rate
vvr
loc
correl
observ
annual
donor
retent
rate
rate
vvr
loc
salin
compens
practic
report
respond
retent
rate
band
rang
mean
min
interquartil
rang
max
associ
maximum
allow
yearli
plasma
collect
l
appear
reason
constant
show
clear
associ
donor
retent
rate
summaryconclus
restrict
maximum
collect
limit
accord
current
blood
guid
associ
either
lower
vvr
loc
higher
donor
retent
rate
studi
support
reassess
current
blood
guid
limit
collect
volum
maximum
ml
per
donat
l
per
year
per
donor
method
serum
ferritin
concentr
establish
sera
store
repetit
platelet
donor
use
architect
ferritin
assay
chemiluminesc
microparticl
immunoassay
cmia
hematimetr
paramet
evalu
total
blood
sampl
use
celldyn
sixteen
sampl
obtain
women
age
ae
year
rang
sampl
men
age
ae
year
rang
correspond
total
femal
male
repetit
donor
platelet
apheresi
use
trima
accel
terumobct
amicu
tm
freseniuskabi
differ
concentr
serum
ferritin
last
first
donat
establish
well
chang
predon
platelet
count
last
first
event
result
studi
popul
women
men
perform
repetit
donat
platelet
apheresi
interv
less
three
month
chang
ferritin
concentr
evalu
accord
interv
donat
women
ferritin
delta
ae
ngml
donat
interv
less
three
month
vs
ae
ngml
time
donat
higher
p
men
chang
ferritin
level
ae
ngml
donat
time
less
three
month
vs
author
vox
sanguini
intern
societi
blood
transfus
vox
sanguini
suppl
ae
ngml
prolong
donat
time
p
women
chang
platelet
count
ae
ul
donat
interv
less
three
month
vs
ae
ul
time
donat
greater
p
men
delta
platelet
count
ae
ul
donat
time
less
three
month
vs
ae
higher
donat
time
p
correl
found
concentr
serum
ferritin
platelet
count
r
q
male
r
q
femal
summaryconclus
data
obtain
suggest
repetit
donat
platelet
apheresi
interv
donat
less
three
month
significantli
reduc
serum
ferritin
concentr
women
men
although
normal
level
maintain
group
correl
platelet
count
therefor
propos
develop
prospect
studi
establish
minimum
time
interv
safeti
platelet
apheresi
donor
procedur
background
demand
platelet
concentr
increas
continu
becom
challeng
blood
establish
apheresi
platelet
collect
may
solut
challeng
improv
apheresi
collect
effici
maintain
blood
donor
safeti
import
goal
servic
du
sang
belgian
red
cross
aim
establish
evalu
improv
trima
accel
autom
blood
collect
system
version
compar
routin
perform
previou
softwar
version
method
prospect
multisit
control
nonrandom
trial
apheresi
collect
perform
three
sf
site
lieg
mon
namur
use
two
trima
softwar
version
sequenti
data
collect
decemb
april
june
juli
simpl
doubl
dose
platelet
respect
collect
platelet
addit
solut
ssp
macopharma
concurr
plasma
cohort
donor
accord
donor
elig
prefer
order
maintain
final
platelet
content
platelet
concentr
trima
accel
tool
yield
scale
factor
ysf
subsequ
adjust
platelet
yield
durat
procedur
number
alarm
requir
oper
intervent
record
evalu
donor
hypocalcemia
avoid
give
prevent
oral
intraven
calcium
document
oper
result
five
hundr
nineti
collect
record
complet
procedur
respect
mean
durat
procedur
min
min
p
mean
alert
number
per
procedur
p
wherea
maximum
alert
number
per
procedur
respect
procedur
requir
oper
intervent
inlet
flowrat
automat
adjust
procedur
inlet
flowrat
increas
respons
access
pressur
procedur
procedur
inlet
flowrat
decreas
procedur
inlet
flowrat
increas
decreas
procedur
autoflow
system
summaryconclus
autoflow
function
improv
apheresi
donor
experi
decreas
oper
intervent
signific
reduct
access
draw
alert
expect
trima
accel
platform
postdon
safeti
remain
high
weak
increas
procedur
durat
observ
platelet
yield
may
resolv
adjust
background
trima
accel
system
apheresi
platform
reli
continu
flow
centrifug
collect
donor
platelet
plasma
rbc
base
donor
qualif
latest
softwar
version
trima
accel
introduc
autoflow
featur
allow
autom
flow
rate
adjust
moreov
leverag
mobil
capac
spleen
increas
potenti
platelet
product
maintain
high
postdon
safeti
standard
characterist
trima
accel
aim
object
evalu
assess
impact
softwar
retrospect
comparison
procedur
data
potenti
increas
product
trima
accel
version
cohort
platelet
donor
method
eight
hundr
twenti
one
procedur
start
januari
octob
compar
procedur
start
octob
st
decemb
procedur
data
trima
devic
captur
use
cadenc
system
terumo
bct
lakewood
co
paramet
investig
number
machin
access
pressur
alert
per
procedur
potenti
higher
platelet
yield
collect
actual
collect
yield
within
cohort
platelet
donor
result
donor
popul
vs
respect
compar
character
tbv
vs
ml
platelet
count
preprocedur
vs
hematocrit
preprocedur
vs
gender
distribut
femal
vs
venou
access
pressur
alert
significantli
improv
averag
alert
per
procedur
compar
ie
decreas
decreas
went
male
procedur
analyz
maximum
number
pressur
alert
went
alert
one
particular
run
cohort
alert
one
procedur
procedur
time
singl
platelet
product
reduc
min
doubl
platelet
product
min
respect
donor
qualif
possibl
procedur
yield
singl
product
procedur
yield
doubl
product
percentag
procedur
qualifi
doubl
increas
term
split
rate
ie
mani
platelet
dose
could
produc
per
apheresi
collect
potenti
split
rate
increas
respect
fact
observ
split
rate
rose
modestli
shorter
procedur
gener
select
accord
donor
prefer
summaryconclus
compar
donor
popul
implement
decreas
number
access
pressur
alert
significantli
compar
previou
trima
version
averag
procedur
durat
also
found
slightli
reduc
implement
potenti
increas
product
significantli
observ
modest
actual
rise
split
rate
suggest
factor
relat
donor
inventori
manag
determin
extent
potenti
new
softwar
use
donor
compar
experi
trima
accel
trima
accel
version
august
octob
trima
accel
test
period
novemb
januari
pair
studi
donor
complet
survey
recov
apheresi
procedur
cantina
result
paper
survey
transcrib
excel
analysi
result
donor
complet
survey
control
period
wherea
donor
complet
survey
test
period
mean
number
previou
donat
control
period
min
max
test
period
min
max
first
time
donor
control
period
first
time
donor
test
period
donor
rate
overal
donat
experi
good
trima
accel
compar
trima
accel
version
zero
donor
rate
experi
either
trima
accel
devic
poor
donor
respond
question
said
would
donat
trima
accel
summaryconclus
signific
differ
observ
donor
experi
trima
accel
version
trima
accel
version
receiv
high
mark
background
trend
growth
queri
donor
platelet
concentr
observ
russia
past
year
report
edqm
higher
number
platelet
consum
compar
patient
hematolog
malign
treatment
requir
platelet
concentr
transfus
chemotherapi
immunotherapi
hematopoiet
stem
cell
transplant
accord
data
collect
nation
research
center
hematolog
nrch
patient
treat
within
facil
receiv
platelet
transfus
transfus
therapi
total
number
transfus
unit
higher
compar
platelet
concentr
product
perform
either
apheresi
process
pool
individu
unit
recov
whole
blood
take
account
nrch
produc
blood
unit
need
pool
suitabl
method
product
implement
nt
cover
requir
platelet
overproduc
rbc
platelet
concentr
nrch
obtain
apheresi
summari
growth
requir
platelet
concentr
safe
explain
need
compar
studi
effect
platelet
product
use
variou
apheresi
system
aim
aim
studi
compar
effect
platelet
concentr
product
use
mc
haemonet
upp
trima
accel
terumo
bct
version
protocol
method
data
protocol
platelet
donat
perform
analyz
trima
accel
msc
donor
voluntari
nonpaid
donor
previou
experi
blood
donat
choic
platelet
collect
devic
random
analysi
main
characterist
donor
reveal
signific
differ
group
median
age
donor
year
old
height
cm
weight
kg
platelet
count
donat
l
hematocrit
detail
data
present
tabl
student
ttest
unrel
set
use
statist
analysi
data
valu
p
less
consid
signific
result
data
obtain
show
signific
differ
p
averag
number
platelet
collect
trima
accel
ae
l
mc
ae
l
cost
consum
compar
trima
accel
demonstr
higher
effici
procedur
durat
also
compar
averag
within
min
devic
detail
data
present
tabl
crucial
mention
proport
trima
accel
donat
significantli
increas
nrch
reach
total
flexibl
usag
trima
accel
consum
differ
procedur
regular
platelet
collect
collect
pa
allow
chang
pasregular
platelet
collect
ratio
summaryconclus
obtain
result
prove
effect
trima
accel
use
platelet
concentr
product
allow
increas
averag
count
platelet
obtain
one
procedur
compar
mc
cost
consum
procedur
durat
compar
donor
comfort
procedur
affect
either
long
term
increas
number
platelet
collect
reduc
cost
platelet
concentr
product
abstract
withdrawn
background
apheresi
collect
platelet
concentr
prefer
term
reduc
risk
advers
reaction
platelet
transfus
compar
random
donor
platelet
concentr
aim
aim
studi
present
experi
collect
donat
singl
donor
platelet
apheresi
method
retrospect
studi
perform
institut
transfus
medicin
till
donor
fulli
inform
donat
procedur
sign
inform
consent
donat
optim
platelet
count
want
achiev
equal
random
donor
platelet
dose
minimum
preapheresi
platelet
count
donor
request
start
apheresi
collect
platelet
collect
perform
use
flow
cell
separ
haemonet
mc
trima
accel
acid
citrat
dextros
formula
use
anticoagul
median
precollect
platelet
count
donor
rang
male
donor
femal
singl
procedur
usual
took
min
median
platelet
count
collect
rang
median
process
blood
volum
ml
median
use
acda
ml
mean
total
volum
collect
product
ml
advers
effect
includ
vein
perfor
numb
extrem
reaction
acda
hypocalcemia
occur
rare
mild
summaryconclus
collect
platelet
count
want
optimum
platelet
count
number
apheresi
donor
increas
work
expand
voluntari
platelet
donor
registri
increas
number
type
donor
registri
background
determin
valu
hemoglobin
blood
donor
tool
method
use
cyanmethemoglobin
method
detect
hemoglobin
quantit
method
cupric
sulfat
solut
detect
hemoglobin
qualit
accord
world
health
organ
determin
level
hemoglobin
blood
donor
enough
use
solut
specif
weight
detect
valu
hemoglobin
grdl
solut
specif
weight
detect
elimin
valu
hemoglobin
grdl
polycythemia
sick
central
blood
transfus
unit
utdp
central
blood
servic
indonesia
manufactur
cupric
sulfat
solut
specif
weight
detect
valu
hemoglobin
dl
determin
valu
hemoglobin
grdl
test
accuraci
solut
cupric
sulfat
detect
elimin
donor
valu
hemoglobin
test
sampl
aim
determin
accuraci
effect
blood
donor
unit
indonesia
red
cross
use
solut
specif
weight
detect
elimin
valu
hemoglobin
donor
grdl
method
use
method
cyanmethemoglobin
determin
valu
hemoglobin
donor
test
result
analyz
spss
softwar
version
use
nonparametr
analysi
wilcoxon
test
result
research
test
accuraci
effect
use
solut
specif
weight
detect
elimin
hemoglobin
valu
donor
data
process
use
spss
wilcoxon
test
p
valu
summaryconclus
found
solut
detect
hemoglobin
valu
effect
check
hemoglobin
blood
donor
seen
data
process
spss
version
wilcoxon
test
p
valu
import
monitor
precis
cours
repeat
blood
donat
affect
hb
probabl
low
hb
deferr
zinc
protoporphyrin
zpp
function
indic
bodi
iron
level
hypothes
predict
hb
level
among
blood
donor
advanc
statist
method
necessari
properli
analyz
longitudin
associ
zpp
hb
data
repeat
donat
per
donor
aim
determin
whether
predict
futur
hb
level
use
current
hb
level
improv
take
zpp
level
account
illustr
use
statist
model
repeat
measur
blood
donor
method
use
data
zpp
iron
netherland
cohort
zinc
studi
identifi
previou
zpp
level
logtransform
main
predictor
adjust
previou
hb
level
age
day
time
donat
donat
histori
bmi
blood
volum
blood
pressur
use
linear
mix
model
take
account
miss
data
outcom
associ
repeat
measur
investig
longitudin
associ
previou
zpp
current
hb
level
longitudin
analysi
linear
mix
model
contrast
simpler
analysi
base
area
receiveroperatingcharacterist
roc
curv
probabl
low
hb
deferr
result
total
whole
blood
donor
wholeblood
donat
includ
zinc
studi
femal
donor
previou
zpp
show
statist
signific
associ
p
hb
level
femal
size
associ
quit
small
regress
coeffici
b
confid
interv
true
male
size
associ
even
smaller
blood
volum
age
women
signific
secondari
predictor
variabl
blood
volum
age
donat
interv
men
comparison
roc
analys
show
rel
larger
less
statist
signific
predict
effect
zpp
hb
summaryconclus
zpp
statist
signific
predictor
hb
level
size
effect
adjust
previou
hb
variabl
small
result
cast
doubt
whether
zpp
effect
predict
marker
hb
level
low
hb
deferr
suggest
zpp
includ
predict
model
hb
level
properli
adjust
associ
repeat
measur
use
avail
data
longitudin
model
provid
less
bias
precis
estim
simpler
crosssect
analys
background
finnish
red
cross
blood
servic
frcb
nation
blood
servic
respons
blood
collect
compon
product
finland
highest
age
blood
donor
year
end
year
sinc
begin
donor
year
abl
donat
blood
blood
donat
age
possibl
donor
donat
within
last
month
upper
age
limit
rais
base
advers
event
data
frcb
donor
year
publish
data
blood
establish
aim
aim
studi
find
new
polici
upper
age
limit
year
safe
therefor
donor
advers
event
data
analyz
order
evalu
blood
donor
older
year
advers
event
compar
donor
common
donor
advers
event
donor
year
haematoma
regist
time
age
group
haematoma
regist
time
differ
oldest
age
group
compar
donor
statist
signific
p
vvr
loc
regist
time
vvr
without
loc
time
total
number
dae
age
group
year
older
respect
number
age
group
number
vvr
without
loc
total
number
dae
age
group
year
older
smaller
group
differ
group
statist
signific
p
summaryconclus
donor
age
year
less
donor
advers
event
age
group
decis
rais
age
limit
seem
proven
right
older
age
group
even
less
donor
advers
event
donor
background
deep
vein
thrombosi
dvt
donor
phlebotomi
arm
rare
seriou
complic
blood
donat
need
recognis
manag
appropri
time
manner
post
donat
dvt
class
seriou
advers
event
donat
sa
event
either
result
donor
death
hospitalis
intervent
signific
symptom
persist
oneyear
post
donat
aim
review
case
dvt
post
donat
report
uk
year
identifi
common
theme
improv
practic
method
data
relat
sa
four
uk
blood
servic
report
shot
last
year
inclus
review
look
report
dvt
post
donat
result
total
sa
report
uk
approxim
million
donat
whole
blood
apheresi
collect
period
three
case
upper
limb
dvt
report
time
account
sa
report
rate
dvt
million
donat
collect
case
regular
male
whole
blood
donor
earli
report
worsen
arm
pain
day
follow
blood
donat
pain
venepunctur
small
bruis
site
donat
diagnos
upper
limb
dvt
extend
subclavian
brachiocephal
vein
start
oral
anticoagul
contributori
factor
obviou
case
femal
donor
gave
sixth
whole
blood
donat
without
event
day
donat
develop
worsen
arm
pain
donat
arm
diagnos
upper
limb
dvt
commenc
oral
anticoagul
identifi
risk
factor
thrombosi
case
femal
donor
develop
pain
swell
red
itchi
donat
arm
chest
wall
two
day
donat
also
describ
promin
vein
affect
side
compar
arm
contact
transfus
servic
one
week
donat
time
also
breathless
minim
exert
admit
hospit
commenc
anticoagul
therapi
diagnosi
dvt
associ
pulmonari
embolu
confirm
donor
risk
factor
thrombosi
use
oral
contracept
pill
summaryconclus
rare
complic
blood
donat
like
dvt
occur
superfici
venou
thrombosi
may
occasion
progress
deeper
vein
donor
arm
dvt
also
occur
without
sign
symptom
superfici
thrombosi
none
patient
overt
evid
superfici
thrombosi
one
patient
seri
report
use
oral
contracept
pill
risk
factor
thrombosi
forthcom
transfus
servic
encourag
donor
make
earli
contact
blood
servic
experi
arm
complic
investig
manag
time
manner
staff
deal
donor
must
recognis
possibl
rare
complic
explor
addit
contributori
factor
initi
prompt
appropri
manag
background
voluntari
blood
donat
wide
consid
safe
minimum
chanc
advers
reaction
may
occur
end
phlebotomi
procedur
aim
find
advers
blood
donor
reaction
among
voluntari
blood
donor
tertiari
care
hospit
kathmandu
method
prospect
studi
done
among
voluntari
blood
donor
grand
intern
hospit
kathmandu
nepal
februari
march
outlin
report
commun
advers
donor
reaction
also
collect
blood
donat
voluntari
blood
donor
differ
locat
includ
outdoor
inhous
blood
donat
drive
result
present
studi
whole
blood
donor
includ
period
year
advers
donor
reaction
report
major
advers
donor
reaction
mild
natur
sweat
light
headed
nausea
vomit
allergi
bruis
sore
arm
hematoma
sever
advers
reaction
similarli
anaphylaxi
loss
conscious
convuls
syncop
marker
advers
donor
reaction
age
sex
puls
weight
blood
pressur
donat
statu
age
first
time
statu
relat
significantli
higher
risk
advers
reaction
year
old
higher
risk
compar
year
old
first
time
donor
higher
risk
compar
repeat
volunt
donor
summaryconclus
result
studi
help
identifi
understand
complic
advers
donor
reaction
though
incid
reaction
blood
donor
lower
studi
donor
age
donat
statu
strong
possibl
complic
background
blood
donor
polleninduc
allergi
asthma
must
often
refrain
donat
pollen
season
despit
medic
symptom
sever
similar
airway
infect
extract
medicin
mushroom
agaricu
blazei
muril
abm
given
oral
found
reduc
ige
antiovalbumin
level
amelior
skew
cytokin
balanc
mice
sensit
ovalbumin
takimoto
immunopharm
immunotox
ellertsen
hetland
clin
mol
allergi
aim
object
examin
whether
supplement
abmbas
extract
use
mous
model
allergi
could
allevi
allergi
asthma
blood
donor
reduc
specif
ige
level
basophil
sensit
method
sixti
donor
oslo
blood
bank
selfreport
birch
pollen
allergi
andor
asthma
recruit
random
doubleblind
placebocontrol
studi
oral
supplement
week
birch
pollen
season
abmbas
extract
andosan
tm
immunopharma
oslo
norway
water
extract
bacidomycet
mushroom
abm
hericeum
erinaceu
grifola
frondosa
particip
fill
questionnair
allerg
conjunct
rhiniti
asthma
medic
serum
ige
immunocap
immunodiagnost
sweden
bet
v
basophil
activ
whole
blood
determin
express
flow
cytomet
flow
cast
uhlmann
lab
ag
switzerland
analyz
pollen
season
trial
record
clinicaltrialsgov
result
signific
reduct
allov
allergyrel
ailment
type
allergi
medic
use
abm
extract
compar
placebo
group
pollen
season
side
effect
also
abm
treat
asthmat
fewer
symptom
use
less
medic
control
abm
group
serum
level
specif
ige
antibet
v
significantli
reduc
pollen
season
compar
level
placebo
group
wherea
maxim
allergen
concentr
need
elicit
basophil
activ
season
chang
significantli
lower
concentr
ie
enhanc
sensit
season
placebo
group
concentr
remain
similar
group
given
mushroom
extract
summaryconclus
oral
preseason
supplement
abmbas
extract
month
reduc
gener
allergi
ailment
asthma
symptom
medic
blood
donor
birch
polleninduc
allergi
asthma
pollen
season
due
reduc
specif
ige
level
basophil
render
less
sensit
allergen
activ
studi
suggest
supplement
abm
mushroom
extract
prophylact
effect
aeroallergeninduc
allergi
asthma
blood
donor
may
therefor
reduc
ailment
affect
blood
donor
impact
blood
donat
pollen
season
result
dhv
start
data
present
abstract
till
data
collect
total
blood
donor
male
donor
femal
donor
repeat
donor
account
first
time
donor
total
number
donor
advers
event
record
report
male
donor
femal
donor
donor
advers
event
stratifi
agewis
highest
incid
report
age
group
year
male
femal
among
age
group
year
male
femal
wherea
age
group
year
male
femal
data
analysi
total
report
regist
donor
advers
event
categor
hyperventil
sweat
dizzi
presyncop
loss
conscious
vomit
convuls
hematoma
reble
nerv
irrit
offsit
reaction
mani
donor
show
multipl
form
reaction
summaryconclus
evalu
donor
side
effect
help
improv
donat
process
donor
complianc
frequent
record
reaction
remain
dizzi
presyncop
donor
vigil
data
show
reaction
occur
frequent
younger
age
femal
first
time
donor
repeat
donat
age
predictor
low
rate
advers
event
particip
dhv
impli
effort
improv
donor
care
safeti
infrastructur
desir
nation
intern
comparison
determin
best
practic
also
look
effect
risk
reduct
strategi
followup
trend
predon
hydrat
implement
intervent
tool
test
effect
hydrat
presyncop
reaction
blood
donat
specif
target
highest
risk
femal
firsttim
high
school
donor
result
await
background
descript
deferr
categori
knowledg
percentag
deferr
categori
valu
formul
recruit
retent
strategi
also
help
plan
effici
recruit
strategi
therebi
assist
reduc
shortag
blood
suppli
aim
aim
studi
categor
donor
defer
medic
checkup
find
donor
deferr
rate
dubai
blood
donat
center
januari
st
decemb
st
also
find
whether
yearli
season
trend
categori
deferr
criteria
aid
forecast
manag
donor
pool
method
retrospect
studi
donor
defer
last
three
year
januari
st
decemb
st
done
dubai
blood
donat
centr
donor
defer
predon
medic
checkup
categor
categori
includ
low
hemoglobin
high
low
bp
intak
antibiot
fever
flu
take
medic
travel
histori
etc
deferr
analyz
monthli
yearli
compil
find
yearli
trend
season
trend
donor
deferr
rate
categori
data
analyz
use
spss
softwar
p
valu
consid
signific
assess
donor
suitabl
accord
aabb
standard
consist
appli
everi
blood
donat
set
occas
donat
blood
donor
result
studi
donor
regist
januari
st
decemb
st
donor
defer
common
reason
deferr
low
hb
high
bp
travel
histori
intak
antibiot
coughflu
symptom
signific
decreas
deferr
rate
p
specif
deferr
rate
due
low
hb
also
significantli
p
decreas
three
year
though
chang
seen
deferr
due
reason
reduct
rate
deferr
due
low
hemoglobin
mayb
link
chang
staff
perform
hemoglobin
test
dbdc
nurs
instead
phlebotomist
assign
perform
hb
estim
donor
season
variat
deferr
rate
three
yearslowest
june
increas
peak
octob
plateau
till
januari
pattern
deferr
corrobor
rate
deferr
due
flufev
cough
antibiot
averag
june
increas
octob
p
summaryconclus
staff
compet
pertin
accur
defer
donor
also
signific
season
pattern
flufev
intak
antibiot
deferr
rate
reflect
total
donor
deferr
pattern
season
variat
specif
categori
donor
deferr
taken
account
donor
recruit
retent
effort
background
west
nile
viru
wnv
mosquito
transmiss
flaviviru
shown
vogel
thesi
common
mosquito
netherland
transmit
wnv
laboratori
circumst
present
lead
effect
transmiss
howev
number
outbreak
wnv
increas
move
eastern
southern
european
border
toward
tradit
colder
western
northern
part
europ
order
prevent
wnv
transmiss
blood
transfus
recipi
dutch
donor
travel
region
wnv
risk
defer
period
day
whole
blood
platelet
donat
quarantin
plasma
order
exclud
potenti
infect
asymptomat
donor
aim
assess
number
dutch
donor
defer
travel
wnv
risk
area
within
europ
return
onsit
offsit
deferr
donor
method
data
donat
attempt
deferr
retriev
eprogesa
blood
bank
inform
system
onsit
deferr
defin
donat
attempt
deferr
period
day
prior
deferr
deferr
consid
offsit
gener
estim
equat
model
use
assess
associ
onsit
versu
offsit
wnv
risk
deferr
subsequ
return
rate
within
two
year
donor
inact
accord
domain
result
donat
attempt
led
onsit
deferr
wnv
risk
whole
blood
donat
attempt
new
donor
examin
total
offsit
deferr
could
trace
directli
donat
base
next
donat
probabl
whole
blood
donor
number
deferr
peak
year
august
major
holiday
period
netherland
increas
august
august
increas
probabl
caus
expans
wnv
risk
region
return
rate
wnv
defer
whole
blood
donor
slightli
lower
donor
defer
versu
wnv
defer
new
donor
return
rate
versu
deferr
thu
wnv
deferr
result
approxim
extra
laps
donor
year
howev
wnv
defer
donor
older
odd
ratio
confid
interv
ci
male
sex
ci
whole
blood
donor
oppos
new
donor
ci
like
return
donat
differ
return
rate
offsit
onsit
deferr
summaryconclus
travelrel
wnv
deferr
increas
expand
risk
region
especi
holiday
season
avail
donor
alreadi
low
although
number
donor
perman
lost
wnv
deferr
limit
increas
number
lost
donat
make
import
consid
altern
donor
deferr
wnv
nat
test
background
low
haemoglobin
due
iron
defici
increasingli
recogn
seriou
problem
mani
blood
center
donor
educ
iron
supplement
ferritin
monitor
lengthen
interdon
interv
current
main
mitig
measur
howev
number
factor
particular
donor
knowledg
could
impact
success
local
iron
supplement
programm
implement
sinc
target
group
donor
given
blood
within
last
six
month
aim
look
onlin
donor
survey
gain
insight
view
programm
knowledg
method
donor
success
blood
donat
past
six
month
would
given
day
one
tablet
iron
supplement
mg
element
iron
sinc
electron
questionnair
sent
blood
donor
assess
view
programm
knowledg
focus
iron
store
absorpt
complianc
side
effect
occur
result
donor
male
femal
repli
questionnair
receiv
iron
supplement
male
femal
respond
one
donat
preced
month
donor
receiv
iron
tablet
took
took
took
less
take
gastrointestin
upset
report
donor
constip
seen
among
took
least
iron
supplement
respond
answer
correctli
question
knowledg
iron
store
absorpt
compar
better
complianc
took
took
less
significantli
donor
former
knew
vitamin
c
could
enhanc
iron
absorpt
p
hand
differ
seen
ask
iron
absorb
meat
tea
coffe
consum
meal
enhanc
iron
absorpt
everyon
take
iron
supplement
iron
store
male
alway
femal
summaryconclus
result
suggest
definit
room
enhanc
blood
donor
knowledg
iron
store
absorpt
order
improv
effect
iron
supplement
programm
besid
side
effect
report
donor
could
import
limit
factor
better
altern
explor
consid
background
vasovag
reaction
vvr
wellestablish
deterr
donor
return
howev
correspond
vvr
experi
donor
laps
perfect
australia
exampl
vvr
reduc
twoyear
return
rate
whole
blood
donor
plasma
donor
element
vvr
donor
interpret
event
protect
encourag
laps
yet
identifi
aim
studi
explor
view
donor
donat
follow
vvr
particular
interest
emot
reaction
vvr
understand
caus
reaction
intent
return
method
semistructur
telephon
interview
conduct
whole
blood
plasma
donor
recent
vvr
experi
data
analys
use
framework
approach
result
donor
gener
motiv
give
blood
help
other
posit
impact
commun
anticip
feel
good
donat
contrast
mani
vvr
leav
feel
anxiou
embarrass
disappoint
donor
experi
vvr
neg
influenc
perceiv
abil
donat
success
mani
fear
happen
howev
effect
appear
minimis
among
donor
least
partial
attribut
reaction
behaviour
poor
hydrat
donor
alreadi
juggl
multipl
demand
vvr
may
tip
balanc
donat
becom
much
effort
perceiv
risk
howev
donor
appear
confid
return
felt
support
staff
could
donat
famili
friend
summaryconclus
studi
provid
valuabl
insight
vvr
experi
aid
improv
donor
safeti
retent
find
highlight
need
improv
commun
time
follow
vvr
educ
donor
reduc
vvr
risk
interven
help
donor
maintain
perceiv
abil
give
blood
order
maximis
retent
follow
vvr
background
frequent
blood
donat
deplet
iron
store
blood
donor
iron
deplet
might
neg
effect
health
gener
popul
effect
blood
donor
popul
well
known
aim
investig
iron
statu
finnish
blood
donor
popul
relat
donor
health
finnish
red
cross
blood
servic
set
findonor
studi
investig
whether
chang
donor
selfrat
health
possibl
chang
could
associ
differ
iron
biomark
ferritin
solubl
transferrin
receptor
stfr
hemoglobin
level
first
studi
visit
method
particip
recruit
three
donat
site
capit
region
finland
may
decemb
particip
fill
electron
questionnair
health
lifestyl
donat
site
enrol
visit
particip
ask
letter
fill
questionnair
electron
summer
includ
particip
men
premenopaus
postmenopaus
women
complet
health
questionnair
evalu
selfrat
health
use
wellvalid
singl
question
would
rate
health
gener
particip
abl
evalu
health
statu
fivepoint
scale
excel
good
good
moder
poor
iron
biomark
venou
hemoglobin
measur
blood
sampl
collect
first
studi
visit
first
comput
oddsratio
report
poorer
health
depend
demograph
group
compar
iron
biomark
hemoglobin
level
donor
report
improv
similar
poorer
health
rate
result
donor
rate
health
first
questionnair
moder
n
good
n
good
n
excel
n
health
tend
report
improv
similar
similar
poorer
health
rate
respect
second
questionnair
premenopaus
women
report
health
poorer
second
questionnair
compar
first
questionnair
often
postmenopaus
women
premenopaus
postmenopaus
women
ci
differ
group
signific
differ
iron
biomark
level
ferritin
stfr
hemoglobin
level
donor
whose
health
rate
improv
similar
poorer
summaryconclus
cohort
premenopaus
women
rate
health
poorer
end
begin
studi
often
postmenopaus
women
associ
found
chang
selfrat
health
iron
level
ferritin
stfr
hemoglobin
level
studi
factor
relat
blood
donor
selfrat
health
need
carri
background
recent
year
blood
donat
busi
made
great
achiev
still
avoid
occurr
advers
reaction
blood
donat
bring
certain
obstacl
blood
donat
work
also
affect
enthusiasm
blood
donor
aim
understood
caus
relev
factor
advers
reaction
among
blood
donor
inform
blood
donor
dai
autonom
prefectur
xishuangbanna
analyz
method
data
volunt
januari
decemb
analyz
caus
advers
reaction
classifi
incid
advers
reaction
compar
term
gender
frequenc
age
blood
type
blood
donor
result
blood
donor
advers
reaction
caus
induc
among
mental
stress
common
factor
account
case
signific
differ
incid
advers
reaction
men
femal
p
frequenc
blood
donat
incid
first
donor
significantli
higher
second
donor
p
come
age
incid
differ
age
group
highest
among
differ
blood
group
donat
signific
differ
p
summaryconclus
advers
reaction
blood
donat
close
relat
psycholog
state
age
blood
donor
staff
blood
center
optim
servic
strengthen
commun
public
knowledg
blood
donat
ultim
goal
increas
blood
donat
rate
basi
reduc
advers
reaction
background
blood
loss
due
repeat
blood
donat
lead
iron
defici
anemia
current
manag
plan
prevent
iron
defici
korean
blood
donor
femal
male
donor
requir
wait
least
week
blood
donat
korea
shortest
period
among
northeast
asian
countri
femal
male
donor
allow
donat
whole
blood
five
time
per
year
platelet
time
per
year
space
day
apart
latter
due
chronic
blood
suppli
shortag
fact
induc
concern
impact
blood
donat
donor
iron
statu
aim
studi
aim
evalu
effect
oral
iron
supplement
repeat
donor
base
sole
donat
histori
method
highrisk
group
includ
male
donor
whole
blood
donat
plasmapheresi
plateletpheresi
donat
femal
donor
whole
blood
donat
compon
donat
within
previou
year
control
group
consist
firsttim
reactiv
ftra
donor
histori
blood
donat
past
year
hemoglobin
hb
level
ferritin
level
total
iron
bind
capac
tibc
transferrin
satur
solubl
transferrin
receptor
stfr
repeat
donor
high
risk
iron
defici
compar
ftra
donor
iron
defici
erythropoiesi
ide
defin
present
log
ratio
solubl
transferrin
receptor
ferritin
repeat
donor
took
iron
supplement
week
test
repeat
week
evalu
effect
side
effect
complianc
assess
result
total
male
femal
repeat
donor
recruit
male
femal
ftra
donor
recruit
control
group
iron
supplement
among
male
donor
preval
low
hb
level
gdl
decreas
low
ferritin
level
ngml
decreas
high
tibc
level
lgdl
decreas
low
transferrin
satur
decreas
ide
stfrferritin
decreas
among
femal
donor
percentag
low
hb
level
gdl
decreas
low
ferritin
level
ngml
decreas
high
tibc
level
lgdl
decreas
low
transferrin
satur
level
decreas
ide
stfrferritin
decreas
total
male
femal
blood
donor
report
undesir
side
effect
relat
iron
supplement
total
male
femal
blood
donor
administ
iron
supplement
day
particip
answer
will
take
complimentari
iron
supplement
summaryconclus
ferritin
level
consid
reliabl
indic
iron
statu
increas
ide
decreas
significantli
iron
supplement
femal
donor
group
male
donor
group
compar
ferritin
level
ide
control
donor
iron
supplement
repeat
donor
high
risk
iron
defici
shown
reduc
risk
iron
defici
anemia
irrespect
gender
howev
oral
iron
supplement
enough
restor
iron
storag
level
male
donor
group
background
creactiv
protein
crp
acutephas
protein
nonspecif
maker
inflamm
tissu
damag
produc
liver
sever
prospect
epidemiolog
studi
demonstr
highsensit
creactiv
protein
hscrp
predictor
futur
coronari
event
among
appar
healthi
men
women
hscrp
level
greater
mgl
independ
associ
excess
risk
incid
coronari
heart
diseas
chd
compar
level
less
mgl
frequent
blood
donat
associ
lower
incid
coronari
arteri
diseas
cad
howev
dearth
inform
serum
level
crp
nigerian
donor
popul
aim
investig
whether
regular
blood
donat
associ
lower
serum
hscrp
level
nigerian
blood
donor
method
descript
crosssect
studi
carri
measur
serum
level
high
sensit
creactiv
protein
hscrp
ferritin
among
blood
donor
attend
donor
clinic
lago
univers
teach
hospit
luth
subject
meet
criteria
blood
donat
exclud
addit
data
sociodemograph
characterist
collect
use
intervieweradminist
questionnair
serum
ferritin
analys
use
chemiluminesc
microparticl
immunoassay
perform
abbott
architect
abbott
laboratori
abbott
park
il
usa
serum
concentr
hscrp
estim
immunoturbidimetri
method
use
analyt
kit
erba
diagnost
mannheim
gmbh
semiautoanalyz
xl
erba
mannheim
data
analys
use
stata
version
stata
corp
statist
softwar
result
total
blood
donor
male
femal
mean
age
ae
year
two
hundr
thirti
four
first
time
donor
regular
donor
serum
level
hscrp
slightli
higher
regular
donor
compar
first
time
donor
ae
vs
ae
mgl
p
though
differ
signific
serum
level
ferritin
significantli
higher
first
time
donor
compar
regular
donor
ae
vs
ae
ngml
p
interestingli
level
serum
hscrp
significantli
higher
male
femal
popul
ae
vs
ae
mgl
p
smoker
nonsmok
ae
mgl
vs
ae
mgl
p
correl
analysi
show
correl
serum
hscrp
serum
ferritin
level
categori
donor
weak
posit
correl
hscrp
level
white
blood
cell
among
first
time
donor
summaryconclus
present
studi
reveal
decreas
baselin
level
serum
hscrp
regular
blood
donat
smoke
statu
gender
howev
associ
increas
baselin
hscrp
find
suggest
hscrp
level
might
use
marker
futur
coronari
event
healthi
blood
donor
nigeria
background
blood
donat
remov
mg
iron
donor
iron
defici
frequent
occur
regular
blood
donor
lead
long
term
anemia
aim
determin
effect
blood
donat
ferritin
level
regular
blood
donor
method
prospect
donor
submit
physic
examin
health
histori
assess
intend
ensur
prospect
donor
good
gener
health
elig
donat
blood
accept
criteria
hemoglobin
gdl
male
gdl
femal
inter
donat
interv
day
donationsyear
male
femal
elig
donor
defer
donor
reason
except
low
hemoglobin
accept
enrol
studi
sign
consent
addit
medic
exam
two
sampl
collect
one
cbc
anoth
ferritin
donat
histori
sex
age
weight
document
result
first
time
regular
donor
accept
enrol
studi
femal
donor
particip
studi
particip
first
time
donor
male
femal
frequent
donor
iron
defici
male
blood
donor
iron
defici
serum
ferritin
ngml
repeat
donor
femal
donor
iron
defici
serum
ferritin
ng
ml
repeat
donor
repeat
donor
iron
defici
deplet
donor
first
time
donor
summaryconclus
frequent
blood
donor
higher
preval
iron
defici
first
time
donor
femal
donor
slightli
higher
preval
iron
defici
male
donor
preval
iron
defici
abu
dhabi
donor
popul
lower
publish
data
chang
need
done
increas
inter
donat
interv
restrict
total
number
allow
donat
period
whole
blood
red
cell
modifi
donor
hemoglobin
requir
test
serum
ferritin
iron
supplement
donor
educ
abstract
withdrawn
background
haemovigil
procedur
aim
guarante
safeti
recipi
blood
compon
safeti
donor
well
everi
advers
reaction
occur
donat
blood
compon
potenti
threat
health
donor
subsequ
lead
decis
donor
resign
donat
blood
aim
aim
analys
type
frequenc
occurr
advers
reaction
among
donor
donat
blood
compon
independ
method
donat
method
analys
number
collect
donat
number
advers
reaction
year
group
donor
age
specifi
follow
advers
reaction
vasovag
respons
without
faint
vasovag
respons
faint
vascular
reaction
bruis
eg
allerg
reaction
anticoagul
loss
blood
pressur
due
hypovolemia
analysi
made
use
data
obtain
comput
system
blood
bank
oper
blood
center
pozna
n
poland
result
year
total
number
advers
reaction
among
donor
record
total
number
collect
donat
advers
reaction
occur
group
donor
age
vasovag
respons
without
faint
common
advers
reaction
total
number
reaction
total
advers
reaction
group
donor
age
total
advers
reaction
second
common
type
advers
reaction
vasovag
syncop
total
analys
group
donor
vascular
reaction
bruis
total
advers
reaction
analys
group
remain
advers
reaction
total
summaryconclus
vasovag
reaction
without
faint
prove
common
advers
reaction
group
donor
age
ie
group
donor
start
donat
blood
seem
reason
continu
research
reason
occurr
psychosomat
reaction
seem
benefici
provid
constant
educ
activ
young
donor
regard
prepar
process
donat
blood
compon
proper
nourish
hydrat
well
plan
time
schedul
donat
long
enough
safe
pleasant
procedur
seem
benefici
provid
constant
train
medic
staff
involv
process
donat
regard
activ
observ
donor
proper
conduct
situat
advers
reaction
occur
blood
donat
way
minim
fear
donor
effect
commun
donor
explain
process
blood
donat
proper
behaviour
donat
eg
avoid
physic
exercis
strain
arm
blood
product
blood
process
storag
releas
background
accumul
microvesicl
mv
rbc
concentr
storag
may
respons
clinic
symptom
inflamm
coagul
immun
aim
aim
determin
whether
cd
molecul
respons
import
function
present
microvesicl
express
level
depend
storag
period
rbc
unit
addit
use
cytometr
analysi
phagocytosi
visual
confoc
microscop
examin
interact
donor
monocyt
erythrocyt
microvesicl
depend
time
storag
method
erythrocyt
microvesicl
isol
fresh
nd
day
old
nd
day
store
rbc
unit
qualit
quantit
cytometr
analysi
membran
structur
perform
use
annexin
vfitc
antibodi
calibr
bead
microvesicl
also
visual
confoc
microscop
express
molecul
phosphatidylserin
analys
use
flow
cytometri
measur
microvesicl
phagocytosi
human
monocyt
carri
use
flow
cytomet
confoc
microscop
result
analysi
microvesicl
calibr
bead
allow
us
identifi
structur
diamet
lm
fresh
old
blood
sampl
observ
statist
signific
increas
number
microvesicl
old
unit
ae
mv
per
compar
microvesicl
fresh
ae
mv
per
day
microvesicl
elev
express
level
reduc
express
level
phosphatidylserin
signific
chang
also
observ
case
molecul
express
molecul
vesicl
isol
fresh
rbc
lower
case
vesicl
phagocytosi
index
significantli
higher
microvesicl
isol
store
rbc
microvesicl
background
platelet
concentr
pc
convent
store
room
temperatur
limit
shelflif
day
altern
storag
method
cold
storag
cryopreserv
attract
option
due
potenti
extend
storag
reduc
bacteri
growth
improv
hemostat
function
cryopreserv
human
pc
associ
format
microparticl
elev
procoagul
activ
compar
liquidstor
room
temperatureand
coldstor
pc
microparticl
submicron
plasma
membran
particl
postul
potenti
mediat
advers
transfus
outcom
similar
size
storagerel
chang
day
suggest
sheep
may
suitabl
model
investig
effect
pc
transfus
previou
research
establish
room
temperatur
store
sheep
pc
contain
fewer
microparticl
human
pc
howev
noth
known
effect
storag
condit
aim
studi
aim
determin
whether
cold
storag
cryopreserv
contribut
variat
concentr
size
sheep
platelet
deriv
microparticl
compar
convent
store
sheep
pc
method
sheep
buffi
coat
deriv
pc
ssp
prepar
minor
modif
standard
procedur
prepar
human
pc
sheep
pc
split
unit
n
day
store
either
room
temperatur
rt
agit
day
cold
store
day
agit
cryopreserv
addit
dimethyl
sulfoxid
day
sampl
postthaw
platelet
supernat
prepar
doubl
centrifug
store
mean
size
concentr
microparticl
measur
use
nanosight
nanoparticl
track
analysi
system
malvern
instrument
result
mean
ae
standard
deviat
storag
associ
chang
overtim
determin
use
oneway
analysi
varianc
bonferroni
posttest
pair
ttest
appli
determin
effect
cryopreserv
pvalu
consid
signific
result
day
sheep
pc
microparticl
concentr
microparticlesml
mean
size
nm
storag
durat
rt
sheep
pc
associ
signific
chang
microparticl
concentr
size
cryopreserv
sheep
pc
significantli
increas
concentr
microparticl
ml
p
mean
size
nm
p
microparticl
postthaw
mean
size
concentr
microparticl
coldstor
pc
day
compar
room
temperatur
pc
store
day
nm
vs
nm
p
ae
microparticlesml
vs
microparticlesml
p
respect
summaryconclus
cold
storag
sheep
pc
impact
format
microparticl
day
storag
period
howev
cryopreserv
increas
microparticl
concentr
size
postthaw
investig
requir
determin
whether
find
influenc
hemostat
function
preclin
sheep
model
coldstor
cryopreserv
pc
transfus
facilit
mechanist
studi
complement
clinic
trial
background
storag
properti
rbc
storag
solut
chang
storag
lesion
instanc
ph
atp
concentr
decreas
upon
prolong
storag
chang
affect
oxygen
deliveri
cell
capac
deliv
oxygen
defin
oxygen
tension
hemoglobin
satur
oxygen
dissoci
curv
odc
repres
nonlinear
relationship
satur
hemoglobin
relationship
depend
temperatur
ph
due
chang
factor
curv
shift
along
xaxi
whole
blood
mm
hg
much
known
rbc
storag
solut
chang
storag
aim
determin
oxygen
dissoci
rbc
store
standard
red
cell
addit
solut
sagm
pagggm
experiment
red
cell
addit
solut
transfus
method
rbc
prepar
sagm
n
pagggm
n
pagggm
design
better
maintain
atp
storag
rbc
store
sampl
day
intern
ph
atp
determin
hemox
analyz
tc
scientif
corp
principl
hemox
base
measur
spectrophotometr
properti
hemoglobin
differ
oxygen
pressur
rbc
sampl
brought
oxygenrich
environ
oxygenpoor
environ
use
ga
determin
obtain
odc
result
whole
storag
period
ph
pagggmrbc
higher
compar
sagmrbc
content
sagmrbc
decreas
storag
detect
limit
day
content
pagggmrbc
increas
first
day
storag
slowli
decreas
day
day
pagggmrbc
still
contain
lmolg
hb
valu
decreas
storag
mmhg
day
mmhg
day
sagmrbc
mmhg
mmhg
pagggmrbc
valu
pagggmrbc
higher
entir
storag
period
summaryconclus
storag
decreas
rbc
higher
pagggmrbc
whole
storag
period
higher
pagggmrbc
seem
correl
higher
content
cell
background
belgium
platelet
pathogen
inactiv
pi
legisl
requir
minimum
platelet
content
per
platelet
concentr
pc
therefor
routin
pool
produc
buffycoat
bc
face
increas
demand
pc
stabl
slightli
declin
red
blood
cell
rbc
demand
product
whole
blood
wb
deriv
platelet
must
adapt
switch
flexibl
bc
per
pool
dual
pool
strategi
allow
align
wb
collect
forecast
pc
inventori
pc
demand
pc
product
aim
first
develop
pool
procedur
bc
ml
platelet
addit
solut
pa
instead
ml
bc
without
chang
set
wb
separ
platelet
separ
maintain
content
platelet
ratio
plasmapa
requir
pi
valid
deploy
dual
pool
strategi
bcpool
method
wb
collect
top
bottom
kit
composelect
freseniu
kabi
separ
macopress
macopharma
produc
ml
bc
haematocrit
htc
platelet
recoveri
averag
platelet
content
random
bc
pool
ml
bc
pool
ml
pase
platelet
extract
tacsi
pl
terumo
bct
pc
treat
pi
intercept
blood
system
ceru
pc
sampl
platelet
content
determin
abx
pentra
xl
horiba
result
studi
bc
process
pool
bc
bc
tacsi
separ
bc
mixtur
pase
volum
ae
ml
bc
ae
ml
bc
respect
htc
ae
ae
plasma
pa
ratio
ae
case
tacsi
separ
perform
one
program
type
pool
pi
platelet
content
pool
ae
bc
ae
bc
averag
ae
standard
deviat
pool
limit
bc
bc
platelet
concentr
ae
bc
ae
bc
platelet
recoveri
bc
ae
bc
summaryconclus
bc
could
theoret
produc
pool
bc
pool
bc
mean
maximum
potenti
gain
pc
practic
shortag
period
switch
bc
dictat
actual
inventori
level
hospit
need
advantag
dual
pool
strategi
gain
product
capac
cover
shortag
period
pc
disadvantag
pool
randomli
bc
pool
contain
less
platelet
per
pool
potenti
limit
usag
low
weight
paediatr
patient
preselect
bc
base
platelet
count
could
optim
bc
pool
procedur
background
apheresisderiv
platelet
concentr
apc
standard
medic
therapi
indispens
contrast
bleed
hemorrhag
howev
bacteri
infect
caus
storag
room
temperatur
rt
still
remain
major
drawback
recent
show
coldstor
apc
associ
better
plt
function
acceler
clearanc
haematologica
pmid
coldinduc
apoptosi
identifi
potenti
mechan
shorter
plt
surviv
aim
investig
protect
effect
apoptot
inhibitor
cold
storag
apc
method
apc
collect
store
rt
presenc
absenc
inhibitor
phosphatidylserin
exposur
mitochondri
membran
potenti
mmp
tetramethylrhodamin
ethyl
ester
perchlor
tmre
stain
measur
use
flow
cytometri
protein
express
quantifi
western
blot
result
higher
express
apoptot
marker
phosphatidylserin
detect
coldstor
apc
compar
rt
apoptot
event
meanaesem
ae
vs
ae
p
verifi
apoptot
signal
observ
phosphatidylserin
specif
involv
intrins
pathway
mmp
analyz
marker
aliv
cell
interestingli
cold
storag
decreas
mmp
observ
compar
rt
indic
activ
intrins
pathway
mean
fluoresc
intens
tmre
meanaesem
ae
vs
ae
p
accordingli
decreas
level
cold
storag
detect
western
blot
analysi
howev
plt
store
presenc
inhibitor
signific
rescu
coldstor
cell
viabil
observ
tmre
stain
aliv
cell
meanaesem
ae
vs
ae
caspas
inhibitor
vs
ionomycin
p
indic
activ
apoptot
pathway
induc
cold
storag
prevent
use
caspas
inhibitor
summaryconclus
result
show
reduct
coldstor
plt
viabil
prevent
specif
caspas
inhibitor
consequ
cold
storag
associ
better
plt
function
may
becom
effici
strategi
apc
storag
combin
apoptot
inhibitor
background
gammairradi
use
treat
red
blood
cell
rbc
concentr
rcc
patient
immunosuppress
treatment
known
damag
rbc
increas
storag
lesion
one
caus
storag
lesion
presenc
oxygen
sever
studi
shown
base
differ
strategi
reduc
reduct
storag
lesion
relat
metabol
protein
modif
cell
morpholog
aim
present
research
work
investig
effect
gammairradi
rcc
store
normal
condit
hypoxiahypocapnia
method
satur
abomatch
rcc
whole
blood
donat
leukoreduc
prepar
paggsm
macopharma
franc
pool
split
two
ident
rcc
within
h
postdon
one
bag
treat
submit
oxygen
carbon
dioxid
adsorpt
oxygen
reduct
bag
hemanext
usa
h
orbit
shaker
rpm
transfer
storag
bag
imperm
ga
one
control
left
two
bag
store
girradi
treatment
gy
gammacel
elan
theratron
appli
day
rcc
expiri
date
day
day
respect
store
day
hematolog
paramet
glycolyt
metabolit
extracellular
potassium
level
antioxid
power
morpholog
deform
measur
result
start
valu
n
control
n
treat
bag
reach
day
respect
expect
increas
glycolysi
rate
observ
deoxygen
without
influenc
irradi
potassium
level
ident
treat
control
reach
around
mm
expiri
irradiationdepend
kinet
releas
antioxid
power
deform
ident
condit
differ
hemolysi
observ
irradi
day
valu
stay
equival
end
storag
day
hemolysi
control
hemolysi
treat
ae
pvalu
irradi
day
hemolysi
lower
pvalu
treat
rcc
end
storag
day
compar
control
seven
day
postirradi
twothird
control
rcc
limit
wherea
treat
rcc
remain
limit
quantif
microvesicl
morpholog
analysi
confirm
data
summaryconclus
storag
hypoxia
benefici
effect
rbc
storag
thank
decreas
content
improv
metabol
benefit
provid
equival
storag
rcc
irradi
day
advantag
irradi
day
importantli
result
show
combin
irradi
hypoxiahypocapnia
retain
improv
hemolysi
profil
deplet
rbc
summari
reduct
level
rcc
enabl
better
storag
rcc
late
irradi
appli
background
vitro
blood
circuit
machin
requir
constant
monitor
blood
flow
rate
maintain
constant
valu
also
measur
hematocrit
flow
blood
machin
essenti
perform
realtim
diagnost
recent
acoustophoresi
emerg
promis
blood
separ
technolog
capabl
replac
centrifug
prepar
platelet
concentr
avoid
damag
blood
cell
techniqu
use
without
infus
pump
thu
increas
need
flow
monitor
howev
acoustophoresi
chip
perform
low
flow
rate
outsid
rang
avail
commerci
flow
meter
addit
hematocrit
measur
particular
interest
acoustophoresi
sinc
direct
indic
separ
effici
aim
studi
present
straightforward
doppler
ultrasound
system
design
measur
blood
flow
rate
hematocrit
acoustophoresi
chip
bohec
et
al
platelet
show
stabil
vitro
environ
use
obtain
high
level
accuraci
doppler
method
use
basic
lowcost
experiment
setup
improv
allow
precis
measur
flow
rate
low
mlmin
submillimet
tube
furthermor
evalu
capabl
system
measur
hematocrit
human
blood
sampl
come
differ
donor
method
experiment
setup
constitut
ultrason
continu
wave
doppler
probe
mount
print
support
accuraci
flow
rate
measur
mlmin
mlmin
evalu
well
optim
measur
time
differ
blood
bag
relationship
link
total
energi
doppler
signal
hematocrit
deriv
hematocrit
rang
estim
doppler
signal
blood
bag
result
system
abl
acquir
exploit
doppler
signal
whole
flow
rate
hematocrit
rang
flow
rate
estim
signal
show
high
accuraci
mean
measur
error
measur
time
mean
error
still
measur
time
hematocrit
estim
doppler
signal
show
good
linear
correl
refer
measur
bag
hematocrit
estim
bag
diverg
refer
valu
summaryconclus
propos
doppler
ultrasound
system
capabl
measur
low
blood
flow
rate
narrow
medic
tube
high
accuraci
particularli
suit
acoustophoresi
devic
versatil
system
make
easili
applic
vitro
blood
circuit
furthermor
demonstr
system
use
measur
hematocrit
without
addit
develop
find
interest
applic
blood
sort
technolog
also
demonstr
doppler
ultrasound
potenti
simpl
low
cost
method
measur
hematocrit
flow
blood
vitro
background
hereditari
hemochromatosi
hh
common
genet
disord
popul
northern
european
descent
manifest
high
level
storag
iron
ferritin
blood
tissu
standard
treatment
serial
therapeut
phlebotomi
decreas
iron
overload
collect
blood
frequent
discard
blood
bank
allow
healthi
hh
patient
donat
blood
patient
use
red
cell
concentr
hh
donor
report
safe
transfus
littl
data
avail
platelet
concentr
hh
donor
includ
potenti
contribut
surplu
iron
platelet
storag
lesion
aim
aim
studi
compar
platelet
qualiti
activ
aggreg
sevenday
storag
plateletrich
plasma
patient
newli
diagnos
hh
healthi
control
method
whole
blood
ml
drawn
compoflow
blood
bag
contain
cpd
sagm
healthi
control
newli
diagnos
hh
patient
plateletrich
plasma
prp
prepar
whole
blood
split
four
compoflex
bag
contain
ml
prp
rang
plateletsl
platelet
qualiti
test
perform
day
storag
platelet
aggreg
test
use
chronolog
aggregomet
four
agonist
adp
arachidon
acid
collagen
epinephrin
platelet
express
measur
flow
cytometri
ph
metabolit
measur
blood
ga
analyz
supernat
quantifi
use
enzymelink
immunosorb
assay
result
hh
control
group
includ
male
femal
mean
age
significantli
lower
control
group
year
year
hh
group
year
year
p
ferritin
level
significantli
higher
hh
patient
median
rang
control
median
ngml
rang
ngml
p
hh
group
genotyp
result
prp
qualiti
control
test
compar
two
studi
group
seven
day
storag
p
except
glucos
higher
hh
patient
time
point
p
platelet
aggreg
express
activ
marker
platelet
supernat
compar
hh
control
prp
unit
seven
day
storag
analysi
reveal
compar
expect
alter
metabol
platelet
activ
marker
sevenday
storag
group
ph
increas
glucos
decreas
lactat
increas
time
express
decreas
increas
platelet
aggreg
respons
decreas
storag
vari
degre
depend
agonist
howev
decreas
compar
case
control
summaryconclus
result
suggest
high
iron
store
hh
advers
affect
qualiti
platelet
unit
produc
hh
patient
furthermor
data
also
suggest
blood
hh
patient
includ
platelet
donat
patient
use
background
platelet
often
ship
long
distanc
collect
centr
blood
process
centr
subsequ
hospit
platelet
agit
facilit
oxygen
transfer
thu
promot
aerob
metabol
maintain
platelet
ph
shipment
platelet
agit
continu
may
promot
anaerob
metabol
previou
studi
examin
effect
prolong
period
without
agit
apheresi
platelet
collect
plasma
platelet
platelet
addit
solut
pa
therefor
import
determin
whether
platelet
qualiti
function
maintain
prolong
transport
hold
time
shipper
aim
aim
studi
evalu
effect
prolong
storag
without
agit
vitro
qualiti
apheresi
platelet
pa
method
tripl
dose
apheresi
platelet
n
collect
use
trima
accel
platform
pa
ssp
rest
h
platelet
split
equal
three
compon
pack
shipper
transport
immedi
blood
centr
upon
arriv
one
platelet
compon
remov
h
other
remain
within
shipper
without
agit
second
compon
remov
h
postcollect
third
remov
h
postcollect
round
h
platelet
test
day
postcollect
vitro
qualiti
function
monitor
data
analys
use
twoway
repeat
measur
anova
pvalu
consid
signific
result
platelet
held
without
agit
h
consum
significantli
glucos
remov
h
immedi
upon
arriv
p
even
day
postcollect
accompani
increas
lactat
product
p
indic
increas
anaerob
glycolysi
consequ
ph
significantli
lower
platelet
p
averag
ph
unit
lower
platelet
held
shipper
h
less
howev
ph
remain
compon
mean
platelet
volum
also
reduc
platelet
p
suggest
acceler
platelet
storag
lesion
phosphatidylserin
exposur
surfac
express
microparticl
gener
significantli
higher
platelet
throughout
storag
period
p
suggest
platelet
activ
releas
also
increas
platelet
p
wherea
extend
storag
shipper
affect
releas
rant
p
adpinduc
activ
glycoprotein
iibiiia
measur
bind
decreas
platelet
p
indic
reduc
platelet
respons
agonist
stimul
addit
aggreg
respons
collagen
p
adp
p
significantli
lower
platelet
suggest
decrement
platelet
function
prolong
storag
without
agit
summaryconclus
signific
vitro
chang
observ
platelet
held
without
agit
h
result
suggest
length
time
platelet
held
shipper
minimis
possibl
background
shelflif
platelet
product
restrict
day
limit
window
time
intend
sustain
qualiti
platelet
reduc
risk
bacteri
growth
recent
demonstr
suitabl
platelet
bag
platelet
product
qualiti
remain
high
day
storag
prove
examin
vitro
qualiti
paramet
platelet
platelet
concentr
glucos
ldh
ph
alexopoulo
k
et
al
haema
new
target
extend
research
extra
day
storag
also
want
determin
bacteri
develop
period
aim
goal
investig
capabl
storag
period
platelet
unit
day
method
studi
platelet
collect
normal
blood
donor
blood
bank
depart
gener
hospit
patra
agio
andrea
total
ae
ml
whole
blood
drawn
tripl
cpdsagm
toptop
bag
blood
contain
system
lmb
technologi
gmbh
platelet
concentr
prepar
platelet
rich
plasma
prp
method
place
platelet
incub
agit
helmer
pc
sampl
drawn
asept
needless
access
coupler
cairlgl
day
platelet
count
done
ceeldyn
rubi
abbott
data
shown
report
mean
ae
standard
deviat
sd
swirl
effect
remain
posit
seven
day
storag
period
bacteri
screen
found
neg
summaryconclus
platelet
concentr
bag
remain
constant
day
day
maintain
platelet
yield
decreas
glucos
increas
lactat
along
decreas
ph
show
platelet
remain
metabol
activ
day
storag
ph
remain
well
within
accept
rang
bacteri
contamin
report
thu
conclud
platelet
concentr
specif
bag
may
use
extend
shelf
life
day
studi
need
platelet
bag
confirm
hypothesi
abstract
withdrawn
aim
introduc
rtdc
fast
robust
unbias
qualiti
control
tool
pc
rcc
hpsc
util
interdepend
cell
deform
molecular
state
cytoskeleton
demonstr
rtdc
capabl
assess
qualiti
blood
product
method
rtdc
assess
platelet
storag
room
temperatur
rt
day
apheresi
pc
addit
standard
vitro
platelet
function
assay
ii
red
blood
cell
gamma
irradi
addit
hemolysi
iii
hpsc
cryopreserv
dmso
addit
cell
count
vitro
viabil
addit
compar
regener
time
patient
platelet
leukocyt
transplant
hpsc
product
contain
either
dmso
result
pc
standard
qualiti
assur
test
show
major
differ
room
temperatur
storag
rtdc
show
highli
signific
differ
start
condit
day
p
day
p
red
cell
found
rtdc
impact
gamma
irradi
gy
entir
storag
period
day
assess
differ
rcc
hpsc
rtdc
show
cryopreserv
liquid
nitrogen
result
signific
increas
deform
dmso
versu
control
without
dmso
p
howev
differ
high
extent
whether
dmso
use
cryopreserv
respect
p
hpsc
viabil
lower
cryopreserv
use
dmso
comparison
use
dmso
overal
blood
cell
regener
compar
dmso
summaryconclus
studi
platelet
red
blood
cell
concentr
well
hematopoiet
stem
cell
differ
clinic
relev
storag
condit
result
demonstr
intrins
materi
properti
reveal
insight
cell
function
allow
predict
cellular
state
robust
way
use
small
sampl
volum
order
offer
flexibl
product
process
storag
bc
overnight
h
valid
blood
center
aim
aim
studi
assess
platelet
qualiti
platelet
concentr
deriv
overnight
store
buffi
coat
method
whole
blood
collect
day
separ
plasma
bc
red
cell
concentr
either
day
day
bc
store
pool
step
without
agit
pc
prepar
day
pool
isogroup
bc
seven
hpc
prepar
bc
store
h
whole
blood
separ
day
six
minpc
bc
store
min
whole
blood
separ
day
standard
qualiti
control
measur
perform
process
storag
addit
qualiti
platelet
prepar
pc
assess
throughout
period
storag
measur
hypoton
shock
respons
hsr
measur
flow
cytometri
proport
platelet
apoptosi
mark
annexin
v
function
platelet
mark
activ
platelet
mark
chang
observ
storag
period
appear
limit
compat
pr
process
use
photochem
treatment
amotosalen
uva
intercept
summaryconclus
leukocytedeplet
doubl
dose
buffi
coat
platelet
high
platelet
content
readi
pathogen
reduct
obtain
ipp
pool
leukodeplet
set
develop
kansuk
storag
period
h
appli
photochem
treatment
feasibl
without
significantli
alter
biolog
qualiti
platelet
method
ddbcpc
prepar
bc
ml
pa
intersol
freseniu
kabi
germani
steril
dock
octopu
har
combin
ml
pool
bag
pool
centrifug
pc
supernat
express
bioflex
cs
leukodeplet
filter
temporari
platelet
storag
contain
obtain
ddbcpc
test
within
h
prepar
storag
h
platelet
storag
contain
volum
platelet
content
residu
leukocyt
wbc
plasma
ratio
biolog
paramet
ph
po
pco
glucos
lactat
mpv
ldh
pselectin
swirl
result
platelet
content
ddbcpc
n
averag
ae
volum
ae
ml
mean
plasma
ratio
min
pc
contain
wbc
min
lq
max
po
decreas
ae
mmhg
separ
h
ae
mmhg
h
ph
pco
stabl
time
period
glucos
decreas
ae
mmoll
h
ae
mmoll
h
lactat
increas
ae
mmoll
h
ae
mmoll
h
vpm
stabl
ae
h
h
ldh
increas
ae
ul
h
ae
ul
h
pselectin
ae
ngml
h
ae
ng
ml
unit
maintain
swirl
chang
observ
storag
period
appear
limit
compat
pr
process
use
photochem
treatment
intercept
summaryconclus
leukocytedeplet
doubl
dose
buffi
coat
platelet
high
platelet
content
readi
pathogen
reduct
obtain
platelet
pool
leukodeplet
set
develop
freseniu
storag
period
h
appli
photochem
treatment
feasibl
without
significantli
alter
biolog
qualiti
platelet
background
irish
blood
transfus
servic
ibt
statutori
bodi
respons
ireland
nation
blood
suppli
ibt
collect
whole
blood
unit
perform
platelet
apheresi
procedur
blood
collect
three
fix
six
mobil
site
return
overnight
temperatur
control
van
singl
process
site
septemb
ibt
implement
tacsi
autom
system
prepar
buffycoat
deriv
platelet
altern
orbisac
system
aim
aim
studi
compar
oper
aspect
qualiti
data
buffycoat
deriv
platelet
prepar
tacsi
tpc
orbisac
opc
autom
system
method
qc
data
tpc
opc
year
analyz
ibt
prepar
orbisac
platelet
pool
qc
test
orbisac
tacsi
platelet
pool
prepar
test
tacsi
platelet
pool
prepar
qc
test
qc
data
compris
pc
volum
platelet
content
unit
residu
leucocyt
content
unit
ph
expiri
feedback
process
laboratori
oper
collect
compar
oper
aspect
prepar
tpc
opc
result
opc
test
mean
pc
volum
ae
ml
initi
tpc
mean
volum
ae
ml
recent
volum
increas
addit
larger
volum
addit
solut
ae
ml
platelet
content
unit
significantli
improv
tpc
ae
compar
opc
ae
p
well
residu
leucocyt
content
unit
lower
tpc
ae
compar
opc
ae
p
ph
expiri
lower
tpc
ae
compar
ae
remain
within
qualiti
requir
oper
perspect
two
tacsi
devic
five
oper
produc
approxim
tpc
per
hour
compar
lower
throughput
opc
per
hour
five
orbisac
devic
tacsi
system
compat
batch
process
align
staf
arrang
routin
product
result
greater
product
sinc
introduct
tacsi
implement
revert
manual
pool
buffi
coat
new
staff
undergo
train
achiev
optim
platelet
recoveri
staff
train
valid
observ
increas
platelet
recoveri
process
laboratori
staff
indic
tacsi
devic
easier
simpler
maintain
comparison
orbisac
highlight
improv
tacsi
system
box
could
made
make
system
robust
summaryconclus
pc
prepar
tacsi
orbisac
autom
system
met
nation
european
qualiti
requir
howev
observ
signific
improv
qualiti
marker
pc
prepar
tacsi
process
staff
report
easier
mainten
process
tacsi
compar
orbisac
throughput
higher
tacsi
greater
addit
capac
increas
product
futur
requir
perez
aliaga
f
puent
aranda
j
domingo
l
call
en
bah
banco
de
sangr
tejido
de
arag
aragon
spain
terumo
bct
europ
nv
zaventem
belgium
background
blood
bank
tissu
arag
bsta
respons
collect
process
distribut
blood
region
aragon
spain
five
fix
five
mobil
site
bsta
collect
process
whole
blood
unit
per
year
improv
qualiti
process
unit
work
condit
personnel
bsta
decid
implement
reveo
autom
system
valid
studi
carri
novemb
routin
use
start
juli
parallel
bsta
initi
pathogen
inactiv
platelet
concentr
pc
novemb
improv
transfus
safeti
novemb
mirasol
prt
system
implement
due
simplic
platform
aim
aim
abstract
describ
result
valid
studi
carri
reveo
implement
ii
present
routin
use
data
product
process
reveo
iii
provid
inform
mirasol
implement
method
whole
blood
unit
process
use
reveo
qualiti
paramet
red
cell
concentr
rcc
hemoglobin
hb
hematocrit
hct
volum
plasma
volum
residu
platelet
content
pc
volum
yield
analyz
control
group
consist
unit
process
semiautom
platform
use
comparison
survey
sent
collect
process
staff
feedback
oper
aspect
use
reveo
qc
data
rcc
n
plasma
n
pc
n
process
reveo
collect
number
mirasol
treat
pc
hemovigil
data
collect
result
volum
hb
hct
rcc
process
reveo
significantli
higher
compar
control
rcc
volum
ae
ml
vs
ae
ml
hb
ae
g
unit
vs
ae
gunit
hct
ae
vs
ae
control
plasma
unit
higher
volum
ae
ml
lower
residu
platelet
content
ae
l
compar
reveo
plasma
unit
volum
ae
ml
residu
platelet
content
ae
l
pc
volum
higher
unit
process
reveo
compar
control
ae
ml
vs
ae
statist
differ
observ
platelet
content
reveo
ae
unit
control
ae
unit
observ
either
increas
stabil
qc
paramet
rcc
plasma
pc
year
routin
use
reveo
exampl
percentag
rcc
unit
hemolyz
drop
platelet
content
pc
increas
unit
first
six
month
routin
unit
plasma
volum
increas
ml
valid
ml
survey
result
staff
highlight
user
friendli
reveo
devic
number
mirasol
treat
pc
increas
pathogen
transmiss
seriou
advers
event
report
follow
transfus
product
summaryconclus
implement
two
userfriendli
system
reveo
whole
blood
autom
system
mirasol
prt
system
observ
increas
standard
process
enabl
us
provid
higher
qualiti
safer
blood
product
hospit
patient
serv
background
white
blood
cell
wbc
may
regard
contamin
blood
compon
potenti
reduc
transfus
safeti
current
enough
evid
show
wbc
reduct
prestorag
filtrat
reduc
incid
three
major
complic
allogen
blood
transfus
febril
nonhemolyt
transfus
reaction
fnhtr
refractori
randomdonor
platelet
transfus
transmiss
cmv
leukodeplet
mandatori
canada
sever
european
countri
aim
aim
studi
evalu
leukoreduct
perform
qualiti
result
red
blood
cell
concentr
rbc
produc
new
quadrupl
system
top
bottom
imuflex
crc
integr
red
blood
cell
filter
use
whole
blood
fraction
routin
condit
san
paolo
asl
blood
bank
method
twentyseven
whole
blood
donat
ml
collect
use
quadrupl
blood
bag
top
bottom
system
integr
rbc
filter
imuflex
crc
terumo
bct
centrifug
process
use
tace
ii
terumo
bct
whole
blood
unit
follow
blood
bank
sop
obtain
rbc
plasma
buffi
coat
rbc
dilut
sagm
ml
filter
graviti
averag
h
blood
collect
obtain
leukoreduc
rbc
averag
temperatur
filtrat
sampl
collect
leukoreduct
calcul
hemoglobin
loss
filtrat
process
filtrat
time
record
final
hb
hematocrit
hct
residu
platelet
white
blood
cell
determin
filtrat
use
standard
laboratori
method
blood
cell
counter
result
wb
donat
n
perform
rbc
characterist
postfiltr
separ
follow
volum
ae
ml
hematocrit
ae
hemoglobin
ae
gdl
hemoglobin
per
unit
ae
g
residu
platelet
ae
residu
wbc
mean
filtrat
time
ae
min
filter
block
observ
summaryconclus
usabl
perform
new
quadrupl
system
top
bottom
imuflex
crc
integr
rbc
filter
evalu
qualiti
paramet
compli
italian
european
guidelin
requir
conclus
set
found
reliabl
effici
collect
separ
system
perform
consist
background
novel
devic
autom
whole
blood
process
reveo
tm
terumo
bct
instal
region
center
blood
donat
blood
treatment
katowic
modern
autom
product
blood
compon
system
allow
separ
four
whole
blood
unit
four
buffi
coat
deplet
red
blood
cell
concentr
rbc
four
unit
plasma
four
interim
platelet
concentr
ipu
unit
one
automat
cycl
ipu
start
blood
compon
product
pool
leucoreduc
platelet
concentr
lpc
residu
leukocyt
wbc
obtain
byproduct
discard
use
system
shorten
product
time
combin
otherwis
two
separ
step
centrifug
blood
separ
press
aim
evalu
qualiti
blood
compon
obtain
newli
develop
reveo
nlr
kit
whole
blood
collect
kit
contain
leucocyt
reduct
filter
rbc
method
blood
wb
collect
nlr
reveo
set
terumo
bct
process
h
collect
use
protocol
qualiti
control
perform
rbc
plasma
ipu
rbc
test
hemoglobin
hb
content
hematocrit
ht
residu
white
blood
cell
wbc
volum
hemolysi
level
last
day
nd
day
storag
content
wbc
platelet
count
plt
protein
factor
viii
day
product
one
month
storag
determin
plasma
ipu
platelet
leucocyt
count
volum
averag
platelet
yield
index
pyi
display
devic
process
record
furthermor
comparison
fulli
autom
semiautom
whole
blood
process
done
compar
amount
time
necessari
fraction
whole
blood
unit
use
two
differ
process
background
direct
singl
step
automat
blood
separ
devic
reveo
tm
terumo
bct
instal
region
center
katowic
system
allow
full
autom
whole
blood
fraction
one
produc
blood
compon
interim
platelet
unit
ipu
contain
platelet
limit
white
blood
cell
wbc
pool
filter
form
therapeut
unit
leucoreduc
platelet
concentr
lpc
rough
estim
platelet
yield
ipu
socal
platelet
yield
index
pyi
calcul
display
devic
end
separ
phase
use
tool
optim
select
ipu
pool
produc
lpc
aim
determin
qualiti
poll
lpc
obtain
basi
ipu
whole
blood
process
h
collect
use
method
daili
practic
method
ipu
use
product
lpc
obtain
use
fulli
autom
whole
blood
process
singl
step
system
reveo
tm
terumo
bct
begin
applic
method
therapeut
unit
lpc
produc
overnight
hold
pool
ipu
ipu
made
use
platelet
pool
set
terumo
bct
use
ml
ssp
solut
macopharma
result
therapeut
unit
lpc
analyz
mean
volum
lpc
ae
ml
platelet
content
ae
white
blood
cell
wbc
count
ae
lpc
wbc
ph
measur
made
fifth
day
storag
ph
determin
unit
lpc
ae
summaryconclus
use
interim
platelet
unit
daili
practic
increas
possibl
produc
high
qualiti
blood
compon
patient
great
altern
laborintens
manual
method
lpc
product
background
develop
coldstor
platelet
hamper
rapid
remov
blood
transfus
apoptosi
desialyl
due
platelet
storag
lesion
caus
refriger
previou
studi
shown
antioxid
inhibit
activ
desialyl
coldstor
platelet
day
also
inhibit
rapid
elimin
transfus
anim
model
aim
tri
whether
longterm
day
longer
storag
condit
antioxid
show
similar
effect
inhibit
activ
desialyl
coldstor
platelet
method
plateletrich
plasma
ml
obtain
healthi
blood
donor
type
blood
group
divid
ml
platelet
storag
bag
manufactur
manufactur
condit
includ
room
temperatur
refriger
condit
variou
kind
antioxid
prepar
ph
glucos
lactic
acid
activ
index
gpiba
annexin
v
degre
reactiv
oxygen
speci
sialidas
activ
day
phagocytosi
use
cell
line
platelet
recoveri
vivo
transfus
use
scid
mice
compar
compar
result
coldstor
platelet
show
autoaggreg
day
storag
appar
aggreg
fifth
day
visual
observ
antioxidanttr
group
expect
ph
glucos
lactat
level
cold
platelet
maintain
platelet
room
temperatur
chang
significantli
nac
nacetylcystein
treat
platelet
less
activ
day
sialidas
activ
maintain
lower
control
group
day
degre
phagocytosi
cell
line
remain
level
storag
period
vivo
recoveri
rate
anim
model
superior
antioxidanttr
cold
platelet
h
h
transfus
summaryconclus
cold
platelet
could
develop
clinic
effect
agent
two
week
appropri
preserv
ad
antioxid
especi
nacetylcystein
effect
background
reveo
procedur
produc
follow
three
blood
compon
transfus
plasma
rbc
singl
interim
platelet
unit
ipu
whole
blood
collect
reveo
blood
bag
set
held
room
temperatur
minimum
h
process
devic
process
reveo
devic
plasma
product
readi
freez
rbc
product
readi
combin
sagm
addit
solut
leukoreduc
use
integr
leukoreduct
filter
ipu
rest
agit
recommend
time
exampl
whole
blood
process
within
h
collect
ipu
agit
overnight
pool
ipu
made
one
unit
whole
blood
approxim
ipu
pool
togeth
leukoreduc
filtrat
prior
storag
platelet
storag
bag
leukoreduc
platelet
pool
unit
suppli
demand
hospit
like
platelet
apheresi
product
aim
assess
usabl
reveo
autom
blood
process
system
collect
unit
whole
blood
process
unit
reveo
devic
produc
blood
compon
meet
product
qualiti
specif
method
studi
evalu
approxim
unit
whole
blood
use
reveo
system
approxim
unit
pool
platelet
product
total
unit
whole
blood
wb
collect
reveo
blood
bag
set
held
room
temperatur
without
use
activ
cool
system
temperatur
control
system
cool
plate
case
ice
pack
unit
unit
process
reveo
devic
use
fresh
procedur
within
h
collect
nine
unit
process
use
overnight
wbhold
procedur
unit
process
success
without
alarm
result
three
compon
rbc
plasma
platelet
also
evalu
four
platelet
pool
creat
eighteen
interim
platelet
unit
ipu
one
ipu
discard
due
whole
blood
collect
time
leukocyt
count
compon
use
automat
sysmexxn
cell
blood
counter
result
red
blood
cell
meet
criteria
hematocrit
hemoglobin
residu
wbc
count
less
million
per
unit
plasma
unit
meet
criteria
display
volum
accuraci
compar
measur
volum
also
factor
viii
level
averag
residu
platelet
plasma
level
meet
criteria
platelet
pool
meet
accept
criteria
platelet
yield
volum
limit
data
n
suggest
criteria
easili
met
provid
wb
hold
condit
suitabl
platelet
summaryconclus
final
result
indic
product
produc
reveo
system
meet
exceed
product
qualiti
expect
staff
report
reveo
system
easi
use
abstract
withdrawn
background
thorough
manual
mix
overnightheld
whole
blood
wb
unit
prior
centrifug
separ
red
cell
rc
plateletrichplasma
prp
current
practis
hong
kong
red
cross
blood
transfus
servic
hkrcbt
mix
step
crucial
maximis
platelet
yield
labori
may
caus
elbow
wrist
injuri
oper
laboratori
shaker
reax
heidolph
instrument
schwabach
germani
origin
design
mix
solvent
modifi
allow
mix
sourc
wb
unit
supplier
enhanc
wellb
oper
context
occup
health
safeti
oh
manag
feasibl
applic
blood
mixer
replac
manual
mix
step
blood
compon
prepar
explor
aim
evalu
vitro
qualiti
control
qc
paramet
blood
compon
prepar
use
modifi
mixer
method
fiftyeight
wb
collect
includ
unit
ml
quadrupl
bag
withwithout
integr
leucofilt
unit
ml
quadrupl
bag
process
accord
hkrcbt
prevail
compon
process
protocol
except
use
motordriven
mixer
lieu
manual
mix
wb
collect
divid
group
mix
revolut
per
minut
rpm
min
n
min
n
process
rc
prp
platelet
plasma
compon
vitro
qc
assess
includ
haematocrit
hct
haemoglobulin
hb
haemolysi
expiri
rc
absolut
platelet
count
ph
platelet
concentr
plt
volum
residu
platelet
count
plasma
unit
evalu
compar
result
compon
deriv
process
blood
mixer
fulfil
qc
requir
stipul
aabb
standard
council
europ
coe
guidelin
signific
differ
qc
paramet
rc
plasma
compon
produc
mix
min
summaryconclus
overal
perform
blood
compon
process
motordriven
mixer
met
accept
criteria
hkrcbt
accord
aabb
coe
standard
higher
platelet
yield
observ
prolong
mix
min
howev
prolong
mix
much
delay
routin
compon
process
evalu
intermedi
mix
time
min
may
help
determin
optim
mix
durat
maximis
platelet
yield
without
compromis
process
workflow
conclud
use
modifi
blood
mixer
replac
labori
manual
mix
compon
prepar
promis
improv
oh
blood
compon
prepar
oper
background
leukocyt
reduct
wide
use
reduc
risk
nonhemolyt
febril
transfus
reaction
alloimmun
multipl
blood
transfus
around
year
univers
leukocyt
reduct
adopt
mani
develop
countri
mainli
two
type
filter
one
filter
whole
blood
filter
red
cell
concentr
rcc
use
prestorag
blood
process
aim
studi
conduct
filtrat
test
sepacel
tm
rcc
comparison
sepacel
tm
sepacel
tm
pure
rc
wide
use
world
background
cardarelli
hospit
blood
bank
process
whole
blood
unit
yearli
order
constantli
cope
huge
demand
platelet
oncohematolog
intens
care
depart
progress
review
process
protocol
platelet
concentr
pc
buffycoat
bc
pool
recent
implement
reduc
number
unit
assembl
routin
itali
pc
unit
slightli
lower
volum
plasma
content
factor
limit
transfus
risk
addit
assembl
allow
facilit
product
pc
unit
obtain
blood
type
order
minim
advers
reaction
relat
aborh
incompat
amount
bc
use
final
describ
innov
also
impact
workload
reduct
assembl
centrifug
separ
time
aim
aim
work
defin
optim
protocol
prepar
pc
unit
pool
platelet
yield
alway
higher
minimum
valu
requir
current
regulatori
cellsunit
background
blood
basic
compon
human
life
henc
blood
transfus
integr
intervent
treatment
patient
need
blood
transfus
increas
decreas
blood
suppli
due
limit
blood
donat
convers
wastag
blood
product
also
topic
discuss
ensur
avail
blood
product
need
wastag
blood
product
control
minim
aim
studi
design
investig
quantiti
reason
wastag
blood
product
hospit
method
observ
studi
base
statist
data
avail
blood
bank
depart
nibd
bmt
pech
campu
karachi
pakistan
studi
period
februari
februari
studi
approv
institut
review
board
blood
product
wastag
reason
wastag
evalu
frequenc
calcul
use
spss
version
result
total
blood
product
avail
institut
includ
platelet
pack
red
cell
fresh
frozen
plasma
ffp
overal
wastag
rate
pack
red
cell
platelet
fulli
consum
yet
shortag
suppli
observ
howev
highest
wastag
observ
ffp
blood
bank
ie
result
investig
common
caus
blood
product
wastag
hospit
reveal
highli
associ
common
caus
includ
expiri
unus
product
follow
broken
bag
summaryconclus
studi
show
diminut
wastag
rate
ffp
wastag
highest
among
blood
product
wastag
blood
product
genuin
issu
hospit
setup
strategi
plan
action
discuss
implement
includ
enhanc
collabor
centr
outsourc
blood
product
even
donat
time
educ
train
staff
better
clinic
use
blood
product
ensur
avail
need
background
earli
blood
servic
republ
kazakhstan
function
along
line
soviet
period
donat
blood
approach
place
use
carri
hospit
screen
donor
blood
carri
one
stage
enzym
immunoassay
analyz
semiautomat
type
mechan
calcul
cost
blood
compon
activ
blood
center
fund
rate
liter
whole
blood
donat
popular
societi
household
fear
infect
common
donat
aim
research
object
studi
main
stage
reform
blood
servic
republ
kazakhstan
rok
research
method
base
system
analysi
condit
rok
blood
servic
base
indic
product
activ
period
result
order
effect
reform
blood
servic
follow
step
taken
blood
suppli
central
optim
blood
collect
hospit
termin
blood
collect
subject
close
result
effici
use
technic
human
financi
resourc
well
ensur
high
qualiti
blood
compon
produc
today
blood
center
republicon
administr
territori
unit
republ
screen
donor
blood
transfus
infect
marker
transfer
twostep
principleimmunolog
analysi
nat
test
fulli
autom
analyt
equip
close
type
use
screen
unifi
blood
center
republ
unif
equip
choic
allow
provid
central
servic
mainten
complex
equip
uninterrupt
oper
sinc
nation
refer
laboratori
oper
blood
servic
conduct
extern
assess
qualiti
laboratori
research
blood
center
well
research
controversi
complex
case
introduc
pathogen
inactiv
platelet
concentr
case
platelet
erythrocyt
use
weigh
solut
leukoreduct
use
resourcesav
blood
harvest
technolog
well
method
enhanc
infecti
immunolog
safeti
compon
expand
annual
foundat
develop
appli
scientif
research
field
transfus
medicin
laid
school
transfusiologist
creat
result
reform
blood
servic
mechan
reimburs
blood
servic
cost
budget
republ
chang
uniform
tariff
defin
type
blood
compon
blood
compon
supplier
countri
summaryconclus
transform
made
possibl
creat
blood
servic
kazakhstan
correspond
best
intern
practic
ensur
qualiti
efficaci
safeti
transfus
therapi
develop
blood
servic
aim
deepen
reform
studi
develop
cellular
technolog
new
properti
plasma
blood
compon
improv
clinic
practic
use
donor
blood
compon
background
reconstitut
platelet
concentr
rpc
compon
contain
platelet
thrombocyt
resuspend
plasma
blood
group
compat
recipi
use
transfus
platelet
concentr
necessari
fresh
platelet
concentr
specif
blood
group
avail
group
rh
neg
platelet
resuspend
ab
group
plasma
univers
use
compon
use
recipi
independ
blood
group
area
activ
region
blood
center
poznan
rpc
use
often
patient
stem
cell
transplant
incompat
blood
group
aim
aim
analysi
evalu
loss
number
platelet
reconstitut
platelet
concentr
order
determin
qualiti
usag
method
use
analysi
unit
pool
platelet
concentr
deriv
buffi
coat
unit
pool
platelet
concentr
deriv
apheresi
reconstitut
group
ab
plasma
use
investig
number
platelet
prior
reconstitut
follow
measur
calcul
number
platelet
pool
platelet
concentr
deriv
buffi
coat
number
platelet
pool
platelet
concentr
deriv
apheresi
averag
valu
standard
deviat
well
loss
number
platelet
due
reconstitut
number
platelet
calcul
imped
method
use
horiba
pentra
xl
analys
pool
platelet
concentr
deriv
buffi
coat
number
platelet
reconstitut
unit
ae
number
platelet
reconstitut
unit
ae
loss
number
platelet
platelet
concentr
deriv
apheresi
number
platelet
reconstitut
unit
ae
number
platelet
reconstitut
unit
ae
loss
number
platelet
summaryconclus
reconstitut
result
loss
platelet
comparison
initi
valu
pool
platelet
concentr
deriv
buffi
coat
averag
number
platelet
reconstitut
unit
fulfil
qualiti
requir
reconstitut
result
loss
platelet
comparison
initi
valu
pool
platelet
concentr
deriv
apheresi
averag
number
platelet
reconstitut
unit
slightli
deviat
qualiti
requir
result
obtain
show
process
reconstitut
alway
result
loss
number
platelet
qualiti
platelet
concentr
reprocess
alway
higher
recommend
reconstitut
perform
special
case
patient
stem
cell
transplant
incompat
blood
group
hospit
suppli
platelet
concentr
deriv
buffi
coat
apheresi
method
extract
human
pc
use
immunoaffin
chromatographi
specif
antibodi
column
hereaft
purifi
concentr
tube
kda
molecular
weight
cutoff
dialyz
via
dialysi
tube
kda
cutoff
concentr
measur
bradford
method
specif
enzymelink
immunosorb
assay
elisa
dot
blot
analysi
use
determin
specif
molecular
weight
obtain
determin
polyacrylamid
gel
electrophoresi
page
result
data
confirm
clearli
separ
kda
molecular
weight
correspond
tetram
addit
elisa
show
qualifi
true
antigen
dot
blot
analysi
help
us
assur
specif
summaryconclus
use
optim
homemad
protocol
isol
purifi
nevertheless
scientif
report
among
databas
util
similar
purif
method
recombin
feasibl
readytous
price
may
discourag
research
studi
biolog
unus
human
pc
specif
antibodi
consid
altern
separ
particularli
lab
shortag
resourc
background
whole
blood
increasingli
use
civilian
hospit
altern
blood
compon
trauma
resuscit
massiv
bleed
howev
hemostat
effect
whole
blood
depend
initi
platelet
content
decreas
rapidli
within
first
week
storag
consequ
problem
aris
provid
wb
trauma
center
without
lose
valuabl
low
titer
group
unit
unit
use
within
expiri
date
use
aim
assess
invitro
qualiti
red
cell
concentr
rcc
produc
day
cold
store
leucodeplet
whole
blood
unit
filter
plateletspar
whole
blood
filtrat
filter
order
save
rcc
wb
unit
reach
expiri
date
method
unit
whole
blood
leucodeplet
within
h
use
platelet
spare
filter
imuflex
wbspterumo
bct
store
day
ae
th
day
storag
unit
centrifug
rcc
supplement
sagm
addit
solut
addit
storag
day
ae
vitro
paramet
hemoglobin
hematocrit
residu
leucocyt
platelet
content
hemolysi
glucos
lactat
atp
dpg
test
storag
result
imuflex
wbsp
provid
satisfi
leucodeplet
wb
unit
ae
maintain
initi
platelet
content
ae
mean
volum
ae
ml
hemoglobin
content
ae
gu
hematocrit
ae
within
conform
rang
day
storag
initi
platelet
content
collect
maintain
mean
hemolysi
ae
rcc
process
day
unev
without
loss
hemoglobin
notic
hemolysi
mean
volum
ae
ml
hematocrit
ae
hemolysi
ae
conform
mandatori
standard
day
day
storag
ie
day
collect
rcc
qualiti
paramet
maintain
howev
increas
hemolysi
ae
usual
valu
routin
observ
rcc
produc
day
process
unit
rcc
maximum
limit
day
collect
increas
hemolysi
pronounc
day
collect
ae
proport
rcc
nonconform
hemolysi
ratio
accept
threshold
test
unit
summaryconclus
rcc
unit
readili
obtain
leucodeplet
wb
unit
spare
platelet
content
day
cold
storag
vitro
qualiti
attribut
rcc
within
conform
rang
hemoglobin
hematocrit
volum
hemolysi
hemolysi
increas
rapidli
standard
rcc
thu
limit
possibl
use
within
day
collect
addit
studi
initi
reduc
hemolysi
storag
g
hetland
f
mahmood
l
nissenmey
nentwich
immunolog
transfus
medicin
oslo
univers
hospit
immunolog
univers
oslo
oslo
immunolog
transfus
medicin
akershu
univers
hospit
norway
background
allergenspecif
ige
donor
plasma
transfer
blood
donor
recipi
via
plasmacontain
product
consequ
sensit
recipi
effector
cell
bear
receptor
ige
mast
cell
basophil
thrombocyt
etc
cell
degranul
exposur
allergen
caus
allergi
symptom
variou
degre
johansson
allergi
food
allergenspecif
ige
antibodi
although
caus
mild
symptom
blood
donor
clinic
import
plasma
recipi
due
vari
sensit
activ
grade
recipi
effector
cell
aim
aim
studi
assess
sensit
profil
array
allergen
randomli
select
blood
donor
identifi
donor
high
concentr
foodspecif
ige
antibodi
could
bear
risk
clinic
import
sensit
plasma
product
recipi
method
test
serum
sampl
blood
donor
randomli
select
one
donat
day
outsid
pollen
season
use
serum
per
sampl
multiplex
ige
lineblot
enzymoimmunoassay
analyt
eurolin
atopi
screen
euroimmun
germani
compris
food
allergen
extract
singl
allergen
inhal
allergen
extract
insect
venom
extract
one
carbohydr
allergen
ccd
highthroughput
method
enabl
scan
serum
sampl
ige
allergen
less
h
result
express
east
enzymoimmunoassay
class
class
sensit
weak
sensit
moder
sensit
strong
strong
sensit
result
east
class
allergen
number
sampl
food
allergen
class
detect
class
sesam
seed
class
appl
hazelnut
class
appl
almond
hazelnut
sesam
seed
soybean
cow
milk
alphalactalbumin
class
donor
weakli
sensit
one
allergen
kiwi
appl
almond
hazelnut
sesam
soybean
wheat
mutton
beef
cow
milk
betalactoglobulin
alphalactalbumin
find
donor
sensit
apricot
peanut
rice
rye
yeast
cow
milk
casein
carbohydr
allergen
ccd
insect
venom
class
none
class
wasp
venom
honey
bee
lower
class
report
abstract
summaryconclus
found
consider
sensit
inhal
allergen
sensit
probabl
repres
low
risk
clinic
allergi
due
passiv
transfer
antibodi
sensit
insect
venom
neglig
disclos
one
blood
donor
high
ige
sesam
seed
potenti
transfer
clinic
relev
ige
antibodi
via
plasma
product
need
broad
screen
donor
ige
sensit
remain
still
question
background
platelet
storag
lesion
psl
one
key
factor
limit
platelet
shelflif
day
mechan
mediat
psl
well
understood
becom
increasingli
evid
platelet
donor
store
well
other
similarli
assess
mani
vitro
qualiti
paramet
use
predict
transfus
outcom
vari
degre
success
donor
attribut
age
bodi
mass
index
bmi
may
contribut
differ
aim
characteris
variabl
qualiti
function
apheresi
platelet
donat
examin
associ
donor
attribut
platelet
characterist
method
apheresi
platelet
n
collect
store
agit
test
day
day
postcollect
vwf
fibrinogen
bind
indic
platelet
adhes
ae
ristocetin
stimul
phosphatidylserin
ps
exposur
annexin
v
bind
microparticl
annexinv
measur
flow
cytometri
platelet
aggreg
initi
collagen
thrombin
arachidon
acid
thromboxan
txa
measur
elisa
proport
procoagul
platelet
coat
platelet
assess
fibrinogen
bind
follow
collagenthrombin
stimul
plateletattach
glycan
measur
use
flow
cytometri
lectin
ricinu
communi
detect
galactoseresidu
wheat
germ
agglutinin
wga
detect
sialic
acid
nacetyldglucosamin
glcnacresidu
ae
stimul
ristocetin
donat
time
donor
age
blood
pressur
bp
bmi
record
linear
regress
perform
use
graphpad
prism
softwar
result
mani
paramet
measur
high
interdonor
variabl
platelet
subset
donor
show
higher
vwf
fibrinogen
bind
format
coat
platelet
microparticl
number
bind
lectin
also
highli
variabl
donor
indic
variabl
sugar
cleavag
follow
ristocetin
stimul
bind
lectin
increas
high
variabl
respons
higher
bind
platelet
subset
donor
particular
interest
aggreg
respons
arachidon
acid
observ
platelet
donat
test
although
platelet
nonrespond
aggreg
respons
collagen
thrombin
txa
also
higher
arachidon
acid
respond
p
associ
platelet
paramet
donor
attribut
associ
typic
weak
ph
day
weakli
associ
donor
age
p
r
bmi
p
r
trend
toward
lower
ph
younger
donor
summaryconclus
data
indic
apheresi
platelet
product
highli
variabl
whilst
donor
characterist
may
influenc
qualiti
donat
platelet
product
high
level
inher
interdonor
biolog
variabl
much
larger
sampl
size
requir
confirm
find
determin
whether
clinic
implic
background
frequenc
beta
thalassemia
mutat
thu
beta
thalassemia
heterozygot
bthalhet
particularli
high
certain
geograph
region
report
signific
proport
donor
occasion
bthalhet
meet
criteria
blood
donat
hb
g
dl
red
blood
cell
rbc
bthalhet
donor
character
vivo
particular
geometri
redox
statu
despit
sporad
indic
rbc
storag
lesion
may
milder
bthalhet
target
research
donor
group
still
miss
aim
aim
studi
investig
whether
bthalhet
rbc
storag
blood
bank
lead
distinct
hemolyt
physiolog
redox
profil
thu
make
bthalhet
uniqu
blood
donor
group
method
blood
sampl
healthi
nonsmok
donor
bthalhet
carrier
control
analyz
prepar
storag
leukoreduc
pack
rbc
unit
cpdsagm
variou
time
interv
suscept
hemolysi
presenceabs
oxid
mechan
osmot
stimuli
redox
statu
lipid
peroxid
reactiv
oxygen
speci
ro
accumul
antioxid
capac
intracellular
ca
proteasom
activ
determin
statist
analysi
signific
accept
p
sampl
red
cell
unit
collect
asept
process
dual
centrifug
g
min
store
process
sampl
thaw
analys
use
nanosight
nanoparticl
track
analysi
system
malvern
instrument
sampl
timepoint
unit
analys
day
data
analys
oneway
anova
bonferroni
multipl
comparison
test
result
red
cell
unit
contain
averag
ae
mv
ml
mean
size
mv
ae
nm
mode
size
ae
nm
concentr
mv
increas
gradual
throughout
storag
p
reach
maximum
ae
mvsml
mean
p
mode
p
size
mv
increas
storag
howev
size
increas
primarili
occur
first
week
storag
vs
p
mean
mode
mean
mode
size
mv
ae
nm
ae
nm
summaryconclus
nanoparticl
track
analysi
demonstr
presenc
mv
smaller
nm
red
cell
unit
concentr
size
mv
present
red
cell
unit
increas
day
routin
storag
concentr
mv
approxim
higher
previous
detect
use
flow
cytometri
aung
patholog
indic
advantag
sensit
techniqu
characteris
mv
background
lack
avail
steril
salin
format
suitabl
use
blood
center
manual
wash
led
urgent
need
blood
servic
consid
altern
method
oper
flexibl
would
desir
abl
produc
wash
rbc
unit
shelf
life
longer
h
aim
aim
studi
valid
manual
method
wash
rbc
use
sagm
solut
wash
storag
solut
ascertain
whether
extend
storag
period
wash
rbc
may
feasibl
method
six
day
old
leukocyt
deplet
red
blood
cell
ldrbc
six
day
old
ldrbc
manual
wash
store
sagm
half
unit
prestor
irradi
gy
volum
ml
wash
solut
sagm
ad
ldrbss
steril
connect
mix
unit
centrifug
min
g
hettich
roto
silenta
rs
remov
supernat
use
compomat
extractor
wash
procedur
repeat
twice
use
ml
sagm
solut
remov
last
supernat
ml
sagm
solut
ad
unit
immedi
measur
volum
haematocrit
albumin
iga
potassium
haemolysi
haemoglobin
ph
glucos
lactat
test
h
day
day
storag
ae
result
wash
ldrbc
met
european
specif
haematocrit
one
hb
content
gunit
hemolysi
increas
storag
rate
hemolysi
irradi
ldrbc
greater
time
nonirradi
unit
unit
irradi
nonirradi
met
european
specif
hemolysi
less
day
wash
wash
potassium
level
low
increas
storag
increas
greater
irradi
nonirradi
unit
potassium
concentr
day
wash
irradi
exceed
level
found
end
shelf
life
day
standard
ldrbc
ph
decreas
storag
due
metabol
activ
red
blood
cell
convert
glucos
lactat
ph
level
supernat
depend
age
unit
irradi
glucos
concentr
supernat
wash
high
due
sagm
solut
concentr
glucos
decreas
lactat
increas
due
metabol
activ
red
blood
cell
current
specif
europ
finland
iga
wash
rbc
aabb
american
red
cross
rare
donor
program
stipul
level
iga
less
mgdl
mgl
iga
method
lower
limit
detect
mgl
result
level
total
albumin
well
finnish
specif
mgunit
background
room
temperatur
standard
storag
condit
platelet
sinc
shown
improv
vivo
surviv
compar
store
howev
storag
room
temperatur
sever
disadvantag
includ
risk
bacteri
contamin
short
outdat
recent
interest
coldstor
platelet
increas
especi
patient
hemostat
need
use
extens
analysi
techniqu
evalu
vitro
qualiti
cold
store
platelet
addit
solut
aim
investig
vitro
qualiti
platelet
store
pase
method
three
experi
perform
two
platelet
concentr
prepar
buffi
coat
ml
pase
pc
pool
split
equal
pc
pc
store
day
one
pair
agit
flatb
shaker
without
agit
variou
paramet
analyz
studi
vitro
qualiti
storag
compar
routin
room
temperatur
storag
result
cold
storag
swirl
phenomenon
disappear
within
one
day
due
lower
temperatur
metabol
platelet
lower
compar
room
temperatur
storag
metabol
condit
accept
ph
platelet
count
u
glucos
still
mm
least
day
storag
platelet
activ
maintain
accept
level
express
ps
exposur
increas
rapidli
day
storag
aggreg
test
show
function
platelet
day
storag
agit
storag
effect
test
paramet
summaryconclus
storag
platelet
hematolog
paramet
ph
met
routin
requir
swirl
phenomenon
disappear
alreadi
first
day
function
platelet
decreas
cold
storag
indic
swirl
phenomenon
good
surrog
marker
condit
strong
increas
ps
exposur
might
involv
observ
short
surviv
coldstor
platelet
platelet
concentr
store
potenti
suitabl
hemostat
agent
patient
bleed
need
platelet
studi
need
aim
goal
studi
reinforc
platelet
reserv
case
emerg
event
increas
avail
treatment
preferenti
patient
massiv
bleed
method
perform
compar
studi
cpp
fp
vitro
buffi
coatderiv
pool
leukoreduc
platelet
rhd
neg
frozen
dmso
store
month
cpp
thaw
reconstitut
platelet
addit
solut
ssp
compar
fp
measur
paramet
platelet
content
platelet
concentr
platelet
loss
prepar
process
coagul
properti
volum
ph
dmso
concentr
titr
antia
antib
antibodi
result
averag
platelet
loss
process
freez
reconstitut
amount
platelet
platelet
concentr
unit
lower
cpp
compar
fp
high
enough
amount
unit
concentr
unit
type
plt
either
pcc
fp
maintain
accept
ph
storag
swirl
valu
fp
valu
cpp
averag
plasma
content
fp
compar
cpp
reconstitut
measur
titr
igm
antia
antib
antibodi
low
cpp
faster
clot
initi
rotem
clot
time
ct
cpp
fp
cpp
contribut
suffici
clot
rotem
maximum
clot
firm
mcf
cpp
mm
fp
mm
summaryconclus
result
show
cpp
higher
procoagul
activ
simultan
lower
clot
firm
thaw
reconstitut
platelet
easi
fast
process
platelet
addit
solut
use
method
help
increas
avail
platelet
emerg
medicin
low
plasma
content
cpp
enabl
use
wash
platelet
product
specif
group
patient
method
donat
whole
blood
store
room
temperatur
overnight
separ
next
morn
reveo
system
seven
abo
compat
ipu
target
volum
ml
select
connect
pool
set
provid
terumo
bct
prior
pool
ipu
ml
addit
solut
tpa
provid
terumo
bct
ad
distribut
evenli
ipu
bag
pool
set
kept
h
bench
room
temperatur
follow
h
agit
ae
filtrat
pool
might
manual
adjust
volum
exceed
maximum
ml
meet
requir
intercept
tm
blood
system
final
product
two
pathogenreduc
platelet
unit
shelf
life
day
result
valid
method
pathogenreduc
platelet
unit
control
addit
platelet
count
ph
glucos
lactat
day
storag
platelet
count
ae
per
unit
day
ph
valu
day
day
day
glucos
concentr
decreas
mmoll
day
respect
mean
level
kpa
mean
kpa
lactat
concentr
mmoll
day
respect
sinc
routin
implement
method
april
regular
qualiti
control
show
averag
platelet
count
ae
n
volum
ae
ml
per
unit
summaryconclus
valid
method
follow
two
year
experi
routin
show
pool
ipu
process
reveo
system
meet
requir
need
intercept
tm
ds
process
set
pathogen
reduct
platelet
result
qualiti
control
final
platelet
unit
accord
local
eu
guidelin
method
data
analyz
publish
unpublish
clinic
studi
perform
primari
secondari
test
platelet
use
bta
system
studi
includ
apheresi
whole
blood
deriv
buffi
coat
platelet
test
ml
sampl
volum
per
cultur
bottl
studi
classifi
result
base
aabb
bulletin
definit
modif
follow
assumpt
made
includ
data
summar
total
number
posit
test
observ
total
number
test
perform
day
post
collect
assum
one
test
perform
per
platelet
unit
unit
elig
secondari
test
neg
primari
test
data
need
demonstr
benefit
use
bta
system
detect
contamin
reveal
previou
bacteri
test
well
clinic
specif
result
total
platelet
unit
studi
secondari
test
platelet
perform
analyz
platelet
test
day
repres
unit
test
respect
true
posit
detect
platelet
unit
repres
total
platelet
test
major
report
platelet
test
day
total
data
show
bta
system
use
secondari
test
detect
preval
contamin
report
staphylococcu
spp
h
major
detect
h
incub
allow
interdict
unit
prior
transfus
instrument
specif
report
studi
platelet
test
day
day
total
fals
posit
rate
rang
instrument
sensit
use
secondari
test
could
determin
sinc
subcultur
neg
bottl
perform
routin
use
previou
valid
test
lrap
lrwbpc
cultur
bottl
confirm
true
neg
subcultur
summaryconclus
data
studi
test
platelet
day
post
collect
provid
evid
bta
bpa
bpn
detect
contamin
miss
previous
test
platelet
unit
data
support
bactalert
system
effect
safeti
measur
secondari
test
platelet
product
extend
platelet
date
beyond
day
day
test
perform
use
test
paramet
describ
bpa
bpn
bottl
ifu
accord
fda
draft
guidanc
background
magnet
nanoparticl
recent
shown
great
potenti
nonradioact
label
platelet
platelet
label
effici
enhanc
particl
conjug
protein
like
human
serum
albumin
hsa
howev
optim
hsa
densiti
coat
particl
uptak
mechan
singl
particl
platelet
remain
unclear
aim
character
interact
singl
particl
platelet
determin
optim
hsa
amount
requir
coat
particl
method
ferucarbotran
iron
oxid
nanoparticl
coat
hsa
differ
amount
mgml
confirm
success
hsa
coat
addit
crosslink
hsa
antibodi
dynam
light
scatter
label
platelet
pool
platelet
concentr
mm
ferucarbotran
coat
nanoparticl
analyz
label
platelet
iron
content
atom
absorpt
spectroscopi
particl
local
transmiss
electron
microscopi
singlemolecul
forc
spectroscopi
use
determin
bind
forc
nanoparticl
platelet
compart
appli
hsaparticl
via
linker
differ
length
ie
nm
medium
nm
nm
cantilev
tip
let
interact
platelet
provid
collagen
surfac
interact
determin
ruptur
forc
requir
platelet
retriev
result
iron
content
per
platelet
reach
maximum
mgml
hsa
coat
particl
ae
ae
pgplatelet
respect
howev
mgml
hsa
coat
result
higher
bind
affin
platelet
particl
coat
mgml
hsa
depend
peg
length
tip
particl
particl
interact
differ
platelet
shown
one
two
three
forc
distribut
pn
correspond
three
differ
bind
pathway
respect
result
indic
particl
interact
three
target
includ
platelet
membran
open
canalicular
system
platelet
granul
summaryconclus
result
reveal
mechan
plateletparticl
interact
singl
particl
level
provid
optim
hsa
concentr
coat
particl
gain
maxim
platelet
label
effici
label
platelet
magnet
nanoparticl
may
substitut
radioact
label
result
activationles
total
platelet
small
mediums
platelet
platelet
popul
detect
storag
day
increas
express
percentag
cell
among
popul
larg
platelet
chang
storag
day
increas
express
detect
larg
platelet
small
mediums
platelet
increas
express
day
express
total
platelet
increas
significantli
day
stay
unchang
day
pattern
express
detect
small
mediums
platelet
wherea
larg
platelet
express
continu
increas
end
storag
decreas
percentag
cell
detect
among
total
platelet
popul
mediums
larg
platelet
storag
induc
extern
phosphatidylserin
total
platelet
platelet
popul
detect
level
tgfb
pselectin
pcbc
supernat
unchang
storag
period
increas
annexin
concentr
detect
day
concentr
btg
increas
day
storag
continu
rise
end
storag
summaryconclus
evalu
express
activ
marker
differ
platelet
popul
could
use
addit
analysi
qualiti
control
platelet
concentr
assess
novel
approach
platelet
concentr
manipul
ie
test
new
addit
solut
cryoconserv
protocol
cryoprotect
background
primari
goal
autolog
blood
transfus
reduc
risk
relat
allogen
blood
transfus
includ
transfusionassoci
graftversushost
diseas
tagvhd
although
downward
trend
rate
autolog
blood
transfus
report
europ
america
still
play
role
elimin
risk
relat
allogen
blood
transfus
japan
especi
tagvhd
sinc
februari
transfus
servic
hospit
manag
autolog
blood
conserv
techniqu
help
prevent
mistransfus
employ
bar
codebas
electron
identif
system
aim
object
studi
determin
use
type
autolog
blood
compon
singl
institut
approxim
period
method
februari
decemb
retrospect
analyz
autolog
blood
transfus
includ
periop
autolog
cell
salvag
pac
preoper
autolog
blood
donat
pad
acut
normovolem
hemodilut
anh
investig
use
autolog
blood
compon
rate
compli
electron
pretransfus
check
bedsid
oper
room
also
determin
advers
reaction
autolog
blood
transfus
categor
accord
definit
propos
intern
societi
blood
transfus
isbt
work
parti
haemovigil
result
total
patient
receiv
oper
receiv
blood
transfus
receiv
autolog
blood
transfus
alon
autolog
allogen
blood
transfus
allogen
blood
transfus
alon
rate
autolog
blood
transfus
among
patient
receiv
blood
transfus
pac
unit
transfus
patient
pad
unit
patient
anh
unit
patient
multipl
blood
conserv
techniqu
use
one
patient
overal
complianc
rate
electron
pretransfus
check
bedsid
autolog
blood
compon
advers
reaction
observ
pad
transfus
pac
anh
number
rate
advers
reaction
pad
transfus
respect
common
febril
nonhemolyt
transfus
reaction
follow
allerg
reaction
hypotens
transfus
reaction
sever
advers
reaction
pad
transfus
grade
nonsever
case
seriou
advers
reaction
observ
among
pad
unit
rate
advers
reaction
whole
blood
pad
unit
frozen
pad
unit
autolog
ffp
unit
summaryconclus
observ
indic
rate
autolog
blood
transfus
among
patient
receiv
blood
transfus
type
autolog
blood
conserv
techniqu
includ
accur
determin
rate
autolog
blood
transfus
hospit
may
better
transfus
servic
manag
type
autolog
blood
conserv
techniqu
clinic
avail
blood
product
residu
plasma
level
product
prepar
use
autom
cell
processor
haemonet
corp
approxim
recent
retrospect
multicent
studi
report
product
effect
safeti
prevent
recurr
sever
transfus
reaction
plt
product
gener
store
continu
agit
maintain
qualiti
interrupt
agit
plt
suspend
addit
solut
plasma
carryov
h
previous
found
slight
impact
vitro
plt
properti
howev
small
hospit
agit
initi
transfus
delay
emerg
chang
patient
condit
interrupt
agit
may
prolong
aim
aim
studi
evalu
effect
interrupt
agit
h
shelf
life
wpc
japan
vitro
qualiti
plt
method
leukoreduc
apheresi
platelet
concentr
plasma
wash
day
one
blood
collect
use
autom
closedsystem
cell
processor
n
wpc
rest
h
prepar
divid
equal
control
test
unit
use
polyolefin
contain
day
one
control
unit
agit
day
one
seven
test
unit
store
without
agit
day
one
three
agit
subsequ
perform
day
seven
unit
store
vitro
plt
qualiti
examin
day
one
three
four
seven
result
plt
concentr
prepar
wpc
ae
l
volum
control
test
unit
divis
ae
ae
ml
ph
valu
test
unit
day
three
lower
control
unit
howev
ph
unit
maintain
higher
sevenday
storag
period
swirl
well
maintain
clump
visibl
unit
storag
period
signific
differ
observ
plt
concentr
mpv
hsr
aggreg
respons
pco
po
bicarbon
glucos
lactat
mean
valu
test
unit
slightli
lower
higher
control
unit
day
three
four
level
express
significantli
higher
test
unit
control
unit
day
three
ae
vs
ae
p
howev
differ
decreas
timedepend
manner
agit
resum
level
express
test
unit
rel
lower
control
unit
day
seven
signific
differ
two
unit
background
monitor
residu
white
blood
cell
rwbc
requir
qualiti
monitor
qm
product
leucocyt
deplet
blood
compon
although
flow
cytometri
wide
use
monitor
rwbc
wide
accept
method
accur
consist
measur
rrbc
blood
compon
sysmex
develop
novel
algorithm
term
blood
bank
bb
mode
xnseri
haematolog
analys
specif
design
quantit
level
rwbc
rrbc
blood
compon
aim
previous
assess
linear
accuraci
reproduc
bb
mode
spike
sampl
rd
lab
sought
assess
perform
bb
softwar
routin
high
throughput
blood
compon
manufactur
depart
method
unit
plasma
platelet
pc
red
cell
concentr
rcc
produc
accord
standard
uk
specif
within
nh
blood
transplant
nhsbt
qm
residu
cell
test
use
bb
mode
whilst
rwbc
addit
analys
flow
cytometri
use
bd
leucocount
kit
result
field
trial
data
point
collect
repres
type
manufactur
compon
pc
bb
mode
result
sampl
tube
contain
edta
gave
high
rwbc
valu
indic
potenti
larg
number
ld
failur
result
significantli
differ
obtain
pc
use
edta
sampl
p
show
high
valu
rcc
plasma
rang
result
plain
edta
tube
significantli
differ
p
analys
ld
platelet
plasma
concentr
either
bb
mode
flow
cytometri
show
ld
compon
less
rwbcunit
ld
failur
n
good
correl
r
flow
cytometri
bb
mode
measur
spike
studi
suggest
limit
detect
quantit
rrbc
around
rrbcll
respect
residu
red
cell
count
manufactur
compon
show
wide
variat
number
unit
expect
platelet
product
method
also
show
signific
differ
p
rrbc
contamin
lower
level
apheresi
platelet
median
rbcll
n
compar
produc
buffi
coat
median
rbcll
n
hand
although
time
taken
analys
sampl
similar
flow
cytometri
bb
mode
consider
time
save
manual
handl
process
sampl
flow
cytometri
approxim
h
sampl
summaryconclus
abl
emb
sysmex
bb
mode
routin
product
environ
confirm
perform
spike
sampl
mirror
routin
use
platelet
sampl
collect
edta
essenti
bb
mode
offer
opportun
reduc
oper
time
compar
flow
cytometri
whilst
gain
addit
inform
rrbc
abstract
withdrawn
result
experi
typic
size
spectrin
matrix
section
l
nm
without
oxid
height
h
dip
nm
due
oxid
junction
complex
spectrin
membran
protein
ruptur
spectrin
surfac
structur
control
group
valu
l
h
vari
significantli
depend
intens
time
exposur
observ
signific
chang
spectrin
matrix
exposur
uv
radiat
model
experi
local
topolog
defect
membran
aris
action
oxid
agent
red
blood
cell
mechan
appear
connect
mainli
distort
spectrin
matrix
result
oxid
process
spectrin
molecul
damag
transform
tetram
dimer
addit
easili
seen
afm
spectrin
network
structur
essenti
destroy
part
spectrin
matrix
damag
structur
mesh
break
dip
uv
irradi
also
result
network
distort
respons
temperatur
chang
obtain
present
preliminari
result
spectrin
matrix
chang
longterm
storag
prbc
summaryconclus
atom
forc
microscopi
direct
biophys
experi
allow
observ
quantit
measur
disturb
spectrin
matrix
nanostructur
respons
oxid
process
rbc
studi
import
fundament
research
interact
rbc
molecular
level
redox
process
consequ
structur
function
cellular
level
import
advanc
transfus
medicin
intens
care
medicin
molecular
radiat
biolog
method
blood
sampl
taken
donor
prophylact
examin
collect
edtafil
microvett
sarstedt
ag
co
germani
experi
carri
accord
institut
guidelin
regul
polylysineco
glass
use
perform
sediment
method
format
nativ
rbc
smear
import
fix
nt
use
stiff
rbc
membran
studi
nativ
rbc
control
nativ
cell
applic
modifi
glutaraldehyd
hemin
zn
heavi
metal
ion
local
stiff
studi
atom
forc
spectroscopi
af
ntegra
prima
ntmdt
russian
feder
result
experiment
kinet
curv
z
measur
nonlinear
fit
method
use
determin
young
modulu
experiment
depend
membran
bend
approxim
hertz
model
depth
nm
young
modulu
e
ae
kpa
control
rbc
shown
natur
oxid
hemin
membran
fix
glutaraldehyd
modifi
heavi
metal
ion
zn
significantli
increas
absolut
valu
young
modulu
rbc
membran
time
biophys
paramet
hertz
depth
h
hz
determin
curv
influenc
modifi
hertz
depth
h
hz
chang
nm
nm
present
preliminari
result
longterm
storag
blood
summaryconclus
blood
rheolog
determin
rbc
deform
associ
membran
stiff
young
modulu
use
quantit
criterion
estim
membran
state
nativ
cell
result
work
use
clinic
practic
assess
qualiti
donor
blood
storag
transfus
biophys
studi
rbc
state
abstract
withdrawn
immunohemotherapi
centro
hospitalar
universit
ario
epe
porto
portug
background
transfus
blood
blood
compon
essenti
resourc
modern
medicin
proper
use
human
blood
irreplac
resourc
necessari
order
achiev
minim
wastag
blood
wastag
may
occur
number
reason
like
expiri
date
haemolysi
seroreact
low
volum
monitor
wastag
blood
product
collect
test
process
blood
use
qualiti
indic
aim
determin
annual
rate
discard
blood
compon
due
expiri
date
portugues
univers
hospit
blood
bank
bb
januari
decemb
order
implement
appropri
measur
minim
number
discard
blood
reason
rate
method
retrospect
analys
rate
blood
compon
discard
meet
expiri
date
portugues
univers
hospit
blood
bank
januari
decemb
result
total
whole
blood
unit
apheresi
platelet
collect
studi
period
blood
compon
pack
red
cell
whole
blood
pool
platelet
apheresi
platelet
prepar
studi
period
total
blood
compon
discard
due
expiri
date
rate
discard
pack
red
cell
accord
compon
product
decreas
consider
year
similar
tendenc
shown
pool
platelet
consecut
year
increas
rate
apheresi
platelet
variabl
behaviour
rate
respect
summaryconclus
blood
transfus
essenti
part
patient
care
reason
implement
qualiti
system
continu
evalu
activ
bb
help
achiev
maximum
quantiti
qualiti
safe
blood
identifi
date
expiri
main
reason
discard
blood
compon
although
signific
decreas
rate
discard
pack
red
cell
three
year
properli
implement
blood
transfus
polici
donor
screen
train
staff
well
implement
autom
also
help
improv
process
reduc
discard
rate
blood
blood
compon
background
storag
perform
platelet
plt
associ
age
donor
risk
plt
poor
storag
perform
character
high
lactat
product
rapid
acidif
plt
concentr
pc
show
posit
correl
age
wish
explor
whether
high
lactat
product
associ
donor
health
issu
aim
investig
high
lactat
product
store
platelet
relationship
donor
health
method
singledonor
pc
collect
apheresi
prepar
buffi
coat
donor
evalu
could
mark
rapid
acidifi
total
apheresi
pc
pc
whole
blood
includ
four
studi
inform
donor
health
obtain
either
blood
bank
inform
system
use
questionnair
donor
lipid
profil
measur
plasma
diabet
marker
red
cell
triglycerid
level
mmoll
level
mmolmol
defin
high
result
twenti
two
percent
donor
mark
rapid
acidifi
donor
health
issu
rapid
acidifi
age
median
rang
year
three
group
donor
distinguish
donor
affect
metabol
syndrom
prediabet
type
diabet
indic
high
cholesterol
andor
triglycerid
high
andor
use
medic
treat
diabet
b
donor
affect
vascular
diseas
report
use
medic
treat
high
blood
pressur
c
donor
use
medic
treat
variou
condit
remain
rapid
acidifi
high
triglycerid
level
report
health
issu
summaryconclus
pc
rapid
acidif
high
lactat
product
mainli
collect
older
donor
health
issu
postul
high
lactat
product
store
plt
associ
health
issu
combin
detail
donor
inform
health
behavior
vitro
qualiti
signific
number
donat
background
develop
appli
biotechnolog
requir
search
creation
new
method
cell
function
complet
analysi
instrument
assess
platelet
qualiti
select
effect
donor
qualiti
assess
platelet
concentr
short
longterm
storag
select
platelet
cryopreserv
demand
blood
servic
assess
platelet
morphofunct
statu
possibl
use
morpholog
studi
variou
platelet
granul
fraction
makarov
med
alfavit
among
biolog
complet
platelet
special
popul
cell
socal
granulerich
platelet
grp
cell
contain
largest
number
cytoplasm
granul
visual
distinct
granul
establish
grp
increas
viabil
function
activ
earlier
found
correl
grp
level
blood
plasma
shift
redox
potenti
valu
blood
plasma
cryodestruct
platelet
tsivadz
et
al
dokladi
physic
chemistri
suggest
shift
redox
potenti
may
partli
due
releas
low
molecular
weight
antioxid
contain
function
complet
platelet
outsid
cell
turn
concentr
low
molecular
weight
antioxid
estim
use
cyclic
voltammetri
aim
aim
studi
estim
cyclic
voltammetri
method
possibl
qualiti
assess
platelet
method
function
platelet
examin
platelet
concentr
pc
obtain
apheresi
ae
voltammetr
analysi
pc
platelet
cryodestruct
carri
platinum
electrod
potenti
rang
mv
mv
use
potentiostat
ipc
pro
l
satur
agagcl
electrod
refer
morphofunct
analysi
platelet
vital
stain
fluorochrom
stain
trypaflavin
acridin
orang
microscop
examin
platelet
carri
use
confoc
microscop
nikon
eclips
follow
paramet
evalu
concentr
percentag
platelet
granul
concentr
percentag
grp
result
voltammetr
studi
pc
show
two
oxid
peak
low
molecular
weight
antioxid
voltammogram
potenti
mv
mv
analysi
pc
cell
cryodestruct
show
chang
height
oxid
peak
occur
indic
increas
antioxid
content
blood
plasma
time
correl
chang
height
oxid
peak
grp
content
sampl
found
sampl
reduc
initi
grp
content
less
cell
cryodestruct
signific
chang
height
oxid
peak
observ
regardless
total
number
cell
pc
summaryconclus
conclus
voltammetr
analysi
allow
indirectli
estim
popul
function
activ
platelet
combin
method
analysi
serv
assess
qualiti
platelet
product
background
determin
hemoglobin
deriv
blood
one
import
studi
clinic
laboratori
diagnost
especi
storag
donor
blood
transfus
concentr
hemoglobin
deriv
chang
redox
process
aim
show
possibl
use
nonlinear
fit
method
calcul
concentr
hemoglobin
deriv
reductionoxid
process
method
perform
model
biophys
experi
vitro
blood
sampl
collect
edta
microvett
healthi
donor
sarstedt
ag
co
germani
prophylact
examin
donor
gave
consent
particip
studi
suspens
erythrocyt
prepar
pb
buffer
ph
use
ultraviolet
uv
irradi
blood
nano
oxid
agent
drug
cytoflavin
stpf
polisan
russian
feder
use
antioxid
studi
use
digit
spectrophotomet
unico
usa
measur
absorpt
scatter
light
nm
step
method
nonlinear
fit
use
find
concentr
hemoglobin
deriv
empir
spectrum
l
k
exp
approxim
theoret
curv
l
k
l
theor
fit
experiment
curv
best
way
approxim
light
absorpt
differ
hemoglobin
deriv
consid
model
simultan
effect
rayleigh
light
scatter
structur
size
k
coeffici
light
scatter
particl
size
k
coeffici
k
taken
account
l
k
l
theor
e
l
c
l
e
hb
l
c
hb
l
e
methb
l
c
methb
l
e
hbno
l
c
hbno
l
e
l
c
l
e
methbno
l
c
methbno
lksk
l
e
h
l
molar
absorpt
coeffici
hb
h
deriv
given
wavelength
k
l
c
h
concentr
deriv
hb
h
l
thick
solut
layer
l
k
l
optic
densiti
substanc
k
paramet
model
result
determin
concentr
hemoglobin
deriv
without
addit
chemic
blood
measur
experiment
spectra
differ
agent
action
blood
shown
concentr
methb
increas
uv
irradi
nano
action
calcul
c
h
hb
h
deriv
establish
theoret
curv
coincid
experiment
data
good
accuraci
r
incub
rbc
cytoflavin
lead
reduct
methb
hbo
summaryconclus
determin
hemoglobin
deriv
concentr
method
nonlinear
fit
without
ad
special
chemic
agent
blood
use
measur
carboxyhemoglobin
blood
toxic
state
organ
also
import
assess
rbc
qualiti
blood
transfus
background
use
line
leukoreduct
filter
highli
expand
iranian
blood
transfus
center
within
last
decad
order
provid
suffici
leukoreduc
blood
fraction
healthi
safe
frequent
blood
donat
suppli
leukocyt
sensit
patient
leukoflex
domin
brand
filter
procur
iranian
blood
transfus
organ
updat
gener
filter
use
around
world
aim
studi
tri
recov
trap
leukocyt
novel
filter
differ
buffer
system
optim
elut
mode
cell
differenti
viabl
recov
white
blood
cell
determin
flow
cytometri
method
pass
routin
virolog
test
eight
leukoflex
leukoreduct
filter
freshli
use
tehran
blood
transfus
center
daili
collect
back
flush
selfdesign
mechan
system
peristalt
pump
tripl
junction
regul
part
air
pump
use
variou
condit
addit
pb
buffer
differ
ph
order
find
highest
recoveri
yield
leukocyt
optim
elut
character
flow
cytometri
subcellular
profil
determin
result
illustr
system
consist
pb
without
ph
contain
mm
edta
ww
dextran
without
addit
amount
triton
optim
buffer
system
filter
back
flush
total
cell
content
also
determin
granulocyt
lymphocyt
monocyt
use
auto
hemoanalysi
flow
cytometr
method
summaryconclus
addit
partli
compens
overhead
expens
inflict
applic
leukoreduct
filter
healthcar
system
result
assist
blood
organ
system
classifi
ration
profil
design
futur
cell
therapi
strategi
except
blood
manag
also
recov
cell
could
signific
stem
cell
scienc
cellular
interact
studi
well
novel
molecular
develop
drug
discoveri
vox
sanguini
result
three
line
strategi
place
pursu
selfsuffici
largest
number
pdmp
first
strategi
line
maxim
yield
drive
protein
repres
immunoglobulin
ig
albumin
assur
csl
behr
yield
g
ig
intraven
privigenand
subcutan
hizentra
g
albumin
alburex
per
kg
plasma
fraction
correspond
g
ig
g
albumin
base
present
demand
repres
selfsuffici
respect
naip
region
second
strategi
line
ensur
product
plasma
fraction
fraction
grant
g
fibrinogen
riastap
iu
vwffviii
haemat
p
per
year
correspond
present
demand
naip
region
product
full
potenti
plasma
thu
provid
high
margin
safeti
case
increas
demand
case
fibrinogen
third
strategi
line
exchang
cryoprecipit
fibrinogen
vwf
italian
region
whose
plasma
fraction
compani
obtain
prothrombin
complex
concentr
pcc
kedcom
antithrombin
atk
satisfi
naip
region
demand
strategi
allow
suppli
iu
iu
pcc
capabl
ensur
selfsuffici
naip
region
summaryconclus
itali
differenti
plasma
contract
manufactur
among
compani
differ
portfolio
allow
naip
region
obtain
signific
contribut
selfsuffici
vnrd
plasma
varieti
pdmp
differ
complementari
strategi
consist
maxim
yield
portfolio
protein
fraction
exchang
product
among
region
pdmp
high
demand
includ
portfolio
singl
fraction
plasma
check
system
valuabl
tool
plasma
freez
valid
monitor
background
valid
plasma
freez
process
may
result
problemat
monitoringcontrol
critic
process
paramet
cpp
itali
litr
plasma
produc
frozen
aim
order
assist
plasma
freez
valid
cpp
monitor
italian
be
perform
plasma
freez
util
plasma
check
system
pc
system
abl
record
store
certifi
temperatur
detect
core
surrog
bag
entir
freez
session
consist
gmp
requir
pc
patent
commerci
expertm
srl
verona
itali
http
wwwexpertmedit
method
pc
consist
part
surrog
bag
checkbag
ml
correspond
averag
standard
volum
real
product
contain
fluid
valid
simul
thermal
behaviour
plasma
b
mobil
probe
cryom
position
core
checkbag
c
dedic
softwar
memotrack
plasma
freez
session
data
track
via
barcoderfid
consult
pc
associ
blast
freezer
code
oper
code
cryom
checkbag
data
plasma
freez
store
share
folder
transfer
inform
system
pc
also
use
check
monitor
outofstorag
variat
core
frozen
plasma
unit
ie
label
packag
procedur
thu
allow
establish
optim
timefram
oper
suitabl
valid
procedur
period
pievesestina
emilia
romagna
region
plasma
unit
frozen
allow
complet
freez
within
temperatur
freez
session
use
pc
process
valid
chang
control
systemat
monitor
core
freez
session
furthermor
bologna
test
outofstorag
condit
plasma
unit
carri
revalid
procedur
label
packag
result
freez
session
carri
pievesestina
detect
fail
reach
core
checkbag
within
latter
case
technic
error
activ
cryom
identifi
addit
pc
systemat
util
period
revalid
freez
procedur
test
perform
bologna
valid
outofstorag
procedur
frozen
plasma
label
packag
allow
modifi
oper
procedur
place
establish
optim
timefram
oper
prompt
correct
action
regard
number
unit
taken
storag
site
label
session
unit
ii
label
time
iii
optim
storag
vs
iv
optim
time
two
open
storag
site
summaryconclus
pc
valuabl
system
plasma
freez
valid
monitor
well
perform
monitor
control
whole
pathway
frozen
plasma
technolog
advanc
easytous
costeffect
tool
effici
replac
tradit
method
commonli
use
abovement
purpos
assess
blood
group
match
qualiti
use
six
sigma
metric
background
sixsigma
metric
provid
gener
methodolog
evalu
process
perform
sigma
scale
implement
sixsigma
qualiti
assur
benefit
health
care
sector
one
import
health
care
sector
blood
transfus
servic
reason
maintain
high
qualiti
blood
transfus
servic
requir
pathogen
activ
plasma
one
main
product
provid
blood
transfus
servic
process
produc
pathogen
inactiv
plasma
involv
blood
group
match
step
qualiti
blood
group
match
extrem
signific
deliveri
plasma
satisfi
recipi
need
aim
aim
studi
assess
qualiti
blood
group
match
pool
plasma
unit
use
six
sigma
metric
clarifi
potenti
implement
six
sigma
metric
qualiti
manag
tool
method
retrospect
studi
conduct
compon
prepar
lab
kuwait
central
blood
bank
twelv
month
januari
decemb
data
pool
fresh
frozen
plasma
unit
recruit
examin
data
separ
data
without
doubl
check
month
data
doubl
check
month
data
statist
analysi
conduct
use
six
sigma
metric
result
sampl
size
first
six
month
mismatch
found
equal
dpmo
sigma
metric
sampl
size
second
six
month
mismatch
found
equal
dpmo
sigma
metric
whole
pool
unit
found
mismatch
found
discard
abo
discrep
broken
expir
still
avail
system
rest
mismatch
unit
issu
summaryconclus
use
six
sigma
principl
studi
present
success
assess
blood
group
match
qualiti
sigma
metric
obtain
first
month
shift
sigma
metric
second
month
addit
doublecheck
step
blood
group
match
pool
plasma
process
implement
metric
laboratori
qualiti
manag
shown
benefici
sixsigma
metric
abl
clarifi
reduct
blood
group
match
error
although
sixsigma
benefit
major
qualiti
improv
help
reach
error
free
laboratori
servic
yet
present
new
challeng
laboratori
practition
current
hemophilia
patient
treat
factor
viii
concentr
first
line
therapi
expens
suppli
suffici
use
factor
viii
concentr
prophylaxi
therapi
case
hemophilia
patient
indonesia
depend
subsidi
world
feder
hemophilia
first
handicap
concentr
case
therapi
prophylaxi
big
blood
center
indonesia
produc
routin
fresh
frozen
plasma
ffp
cryoprecipitateanti
hemophil
factor
ahf
replac
therapi
hemophilia
content
safeti
factor
viii
ml
ffp
need
improv
nowaday
avail
kit
produc
minipool
cryoprecipit
mc
better
safeti
qualiti
avail
liquid
product
store
strict
specif
temperatur
prophylaxi
therapi
hemophilia
patient
need
stabl
product
easi
use
conveni
treatment
patient
aim
analyz
content
safeti
f
viii
minipool
cryoprecipit
mc
lyophil
mc
home
therapi
method
produc
mc
mc
control
mc
lyophil
excipi
mc
without
excipi
analyz
number
factor
viii
safeti
stabil
count
erythrocyt
leukocyt
platelet
residu
mc
use
flow
cytometri
also
measur
ph
osmol
solubl
learn
stabil
storag
day
room
temperatur
blood
bank
refriger
temperatur
central
blood
transfus
servic
cbt
result
found
content
f
viii
excipi
higher
iuml
without
excipi
iuml
storag
blood
bank
refriger
better
room
temperatur
group
residu
cell
bacteri
found
mc
signific
differ
ph
osmol
solubl
group
summaryconclus
lyophil
mc
excipi
store
blood
bank
temperatur
better
room
temperatur
experi
continu
know
stabil
extend
storag
time
background
peptic
ulcer
diseas
pud
multifactori
complex
diseas
affect
wide
rang
peopl
world
howev
perfect
therapi
pud
yet
avail
present
therefor
provid
novel
therapeut
approach
pud
patient
observ
effect
studi
aim
provid
novel
therapeut
approach
pud
patient
observ
effect
studi
method
random
control
trial
pud
patient
resid
chongq
enrol
randomli
assign
two
group
control
group
use
rabeprazol
b
plateletrich
plasma
prp
group
receiv
combin
therapi
autolog
plateletrich
plasma
aprp
rabeprazol
aggreg
rate
aprp
measur
via
aggreg
remot
analyz
modul
therapeut
effect
assess
via
ulcer
size
symptom
score
data
record
analyz
statist
use
spss
result
total
patient
includ
patient
control
group
patient
prp
group
analysi
found
aggreg
rate
aprp
affect
ph
treatment
pepsin
result
show
signific
differ
prp
group
control
group
treatment
also
signific
differ
heal
time
two
group
differ
variabl
howev
regress
analysi
reveal
heal
time
less
prp
group
control
group
patient
higher
symptom
score
initi
examin
need
time
heal
treatment
summaryconclus
studi
show
encourag
preliminari
result
aprp
posit
result
peptic
ulcer
patient
seem
better
choic
refractori
pud
patient
despit
followup
studi
need
determin
durat
efficaci
aprp
approach
help
improv
pud
treatment
clinic
background
croatian
institut
transfus
medicin
citm
collect
produc
distribut
blood
compon
area
million
habit
annual
collect
whole
blood
apheresi
donat
platelet
concentr
pc
inclin
bacteri
contamin
due
storag
condit
favor
bacteri
replic
citm
decid
evalu
mirasol
pathogen
reduct
technolog
prt
system
offer
possibl
work
nontox
nonmutagen
compound
upon
uv
illumin
induc
nucleic
acid
damag
reduc
risk
septic
transfus
aim
studi
object
evalu
qualiti
pc
treat
mirasol
prt
system
platelet
store
tpa
day
platelet
shaker
method
pc
produc
accord
citm
sop
either
pool
bc
tpa
wbd
apheresi
collect
use
two
devic
freseniu
amicu
ad
haemonet
mc
system
mcd
pc
store
plasma
pa
mcd
subsequ
evalu
also
plasma
pa
ident
pc
produc
poolsplit
protocol
prttreat
serv
untreat
control
pc
treat
mirasol
system
accord
manufactur
instruct
qc
paramet
yield
ph
swirl
measur
day
bacteria
steril
test
perform
day
sampl
treat
platelet
protein
content
pc
produc
routin
citm
determin
assess
accuraci
plasma
carryov
calcul
process
pc
result
mirasoltr
wbd
n
ad
pc
n
store
plasma
show
day
averag
ph
swirl
yield
untreat
counterpart
show
averag
valu
ph
swirl
yield
mcd
store
plasma
n
underw
prt
show
day
averag
valu
ph
swirl
yield
control
mcd
show
averag
valu
ph
swirl
yield
mcd
store
plasma
n
underw
prt
show
averag
valu
ph
swirl
yield
untreat
counterpart
averag
ph
swirl
yield
total
protein
content
pc
deriv
wbd
n
ad
n
mcd
n
gl
gl
gl
respect
coeffici
variat
wbd
ad
rang
plasma
product
respect
one
mcd
reach
prtpc
neg
bacteri
growth
day
summaryconclus
mirasol
treat
wbd
ad
produc
accord
citm
current
sop
quit
similar
untreat
control
expiri
day
pass
requir
eu
guidelin
th
edit
qualiti
mcd
unit
met
eu
criteria
day
swirl
decreas
significantli
day
might
explain
variabl
plasma
content
mc
deriv
platelet
challeng
accur
calcul
illumin
index
mirasol
treatment
mirasol
treat
pc
show
minim
platelet
loss
end
storag
implement
pr
costneutr
could
implement
annual
produc
buffi
coat
platelet
concentr
bcp
bcpyear
requir
chang
bcp
product
method
primari
aim
implement
offer
increas
blood
safeti
vulner
patient
secondari
aim
ensur
builtup
enough
routin
experi
pr
enabl
us
quickli
rampup
product
prbcp
outbreak
emerg
pathogen
madrid
region
aim
verifi
could
prbcp
without
increas
overal
product
cost
opc
bcp
also
evalu
impact
pr
overal
scrap
rate
bcp
outdat
rate
usag
safeti
measur
method
compar
opc
bcp
prepr
period
cost
offset
substitut
semiautom
product
method
bcp
use
produc
bcpunit
manual
doubl
dose
buffi
coat
product
method
ddbcp
combin
pr
enabl
us
reduc
bcpdispos
cost
despit
move
semiautom
manual
product
method
overal
scrap
rate
product
decreas
extens
max
storag
time
day
bcpunit
pr
result
decreas
overal
outdat
rate
versu
reduct
outdat
rate
reduc
opc
gammairradi
fewer
bcpunit
minim
impact
opc
summaryconclus
result
studi
confirm
reach
initi
object
prbcp
without
increas
overal
product
cost
opc
bcp
enabl
us
offer
increas
blood
safeti
vulner
patient
builtup
enough
routin
experi
pr
could
quickli
rampup
product
prbcp
outbreak
emerg
pathogen
madrid
region
background
irradi
red
cell
unit
undertaken
prevent
transfusionassociatedgraftversushostdiseas
tagvhd
immunocompromis
patient
irradi
use
radioact
cray
sourc
primarili
found
blood
establish
requir
regular
recalibr
supplementari
safeti
measur
xirradi
shown
similar
biolog
effect
cirradi
requir
radioact
sourc
intern
interest
move
away
gamma
sourc
reduc
vulner
terror
although
damag
impact
irradi
red
cell
well
recognis
limit
number
studi
compar
red
cell
compon
qualiti
follow
cand
xirradi
standard
volum
red
cell
concentr
rcc
neonat
red
cell
split
rc
aim
compar
vitro
qualiti
rcc
rc
subject
cor
xirradi
day
storag
store
day
rc
also
irradi
day
storag
common
practic
nh
blood
transplant
nhsbt
method
four
rcc
pool
split
arm
day
storag
unit
arm
unit
receiv
irradi
dose
gy
two
arm
remain
standard
volum
rcc
either
cor
xirradi
day
storag
two
arm
split
rc
day
storag
irradi
day
earli
arm
day
late
arm
storag
replic
arm
split
cirradi
split
xirradi
arm
test
day
prior
irradi
day
postirradi
red
cell
qualiti
paramet
haemolysi
intracellular
atp
dpg
supernat
potassium
glucos
lactat
ph
red
cell
microvesicl
releas
rcc
arm
sampl
storag
rc
arm
split
test
test
day
postirradi
anova
use
detect
statist
differ
storag
cand
xirradi
compon
result
compon
produc
within
nhsbt
specif
volum
haemoglobin
haematocrit
signific
differ
red
cell
vitro
qualiti
paramet
studi
storag
cand
xirradi
unit
standard
volum
arm
neonat
arm
whether
rc
irradi
earli
late
storag
moreov
arm
within
haemolysi
specif
end
storag
unit
haemolysi
unit
atp
level
recommend
minimum
accept
posttransfus
surviv
lmolghb
haemolysi
potassium
level
end
storag
standard
cirradi
rcc
compar
laboratori
histor
data
compon
summaryconclus
summari
storag
qualiti
rcc
rc
postxirradi
differ
cirradi
studi
provid
reassur
either
method
could
use
routin
manufactur
pajar
herraiz
c
coello
de
portug
moral
f
solano
c
perez
parrilla
rodriguez
hidalgo
diaz
rueda
flore
direccion
region
transfus
center
toledoguadalajara
transfus
servic
toledo
hospit
complex
toledo
transfus
servic
gener
univers
hospit
guadalajara
guadalajara
transfus
servic
hospit
nuestra
del
prado
de
talavera
de
la
reina
talavera
region
transfus
center
region
transfus
center
toledoguadalajara
toledo
spain
background
region
transfus
center
toledoguadalajara
rtc
manag
collect
process
distribut
blood
compon
hemotherapi
area
castilla
la
mancha
spain
serv
gener
hospit
hospit
complex
toledo
hct
univers
gener
hospit
guadalajara
ughg
hospit
nuestra
del
prado
de
talavera
nspt
need
inhabit
also
manag
hct
transfus
servic
facilit
handl
stock
sinc
rtc
initi
pathogen
inactiv
pi
part
platelet
compon
pc
intercept
blood
system
ceru
use
photochem
treatment
amotosalen
ultravioleta
system
allow
inactiv
broad
panel
pathogen
leukocyt
extend
shelflif
cp
day
affect
expiri
discard
blood
compon
allow
better
manag
inventori
influenc
product
cost
aim
object
evalu
influenc
pi
product
cp
rtc
expiri
hemotherapi
area
last
year
divid
four
period
result
pc
predominantli
obtain
whole
blood
collect
bc
apheresi
platelet
avail
bc
use
product
period
period
b
c
wast
approxim
distribut
pc
stabl
period
studi
pc
distribut
period
pc
b
pc
c
pc
pi
platelet
shelf
life
avail
hospit
limit
period
increas
period
b
c
respect
percentag
wast
stabl
discard
due
expiri
went
period
stabil
period
b
c
period
gener
hospit
expiri
went
hct
ughg
nspt
respect
summaryconclus
greater
control
pc
stock
histor
analysi
consumpt
project
togeth
tool
use
pi
pc
shelf
life
allow
reduc
discard
expiri
last
period
analyz
rtc
major
hospit
hemotherapi
area
great
valu
costreduct
improv
inventori
manag
effici
process
background
blood
center
face
mani
challeng
includ
avail
concentr
platelet
well
ensur
highest
qualiti
product
overcom
shortag
platelet
apheresi
use
pool
platelet
deriv
whole
blood
unit
separ
use
autom
standard
system
assist
blood
bank
meet
increas
demand
platelet
pathogen
inactiv
pi
technolog
improv
qualiti
product
mitig
risk
transfusiontransmit
diseas
ttd
residu
white
cell
result
minim
non
hemolyt
transfus
reaction
howev
pathogen
inactiv
treatment
must
impact
platelet
qualiti
function
significantli
well
patient
safeti
aim
evalu
qualiti
pool
platelet
deriv
whole
blood
five
interim
platelet
unit
separ
use
reveo
autom
blood
process
system
terumo
bct
pool
donor
plasma
pathogen
inactiv
amotosalenuva
technolog
method
five
interim
platelet
unit
ipu
produc
reveo
devic
terumo
bct
singl
whole
blood
donat
pool
platelet
pool
set
terumo
bct
leucodeplet
lrfxl
filter
haemonet
thirti
pool
includ
studi
unit
treat
use
larg
volum
ceru
intercept
process
set
platelet
accord
manufactur
instruct
store
day
swirl
determin
visual
inspect
volum
yield
content
assess
preinactiv
treatment
pathogen
inactiv
cell
counter
beckman
coulter
rbc
contamin
also
measur
preinactiv
cell
counter
beckman
coulter
bacteri
contamin
assess
autom
blood
cultur
bact
alert
system
biomerieux
ph
platelet
unit
assess
phmeter
jenway
residu
amotosalen
level
assess
hplc
assay
result
impact
amotosalenuva
pathogeninactiv
pool
platelet
product
qualiti
assess
pre
postinactiv
unit
show
swirl
score
averag
volum
per
unit
preinactiv
ml
ml
post
inactiv
ml
ml
averag
volum
loss
inactiv
ml
ml
correspond
averag
platelet
yield
per
unit
preinactiv
post
inactiv
averag
platelet
loss
averag
rbc
contamin
per
unit
rbcml
cultur
test
neg
averag
ph
day
averag
ph
day
averag
residu
amotosalen
concentr
post
treatment
lm
lm
summaryconclus
qualiti
pathogeninactiv
pool
platelet
test
met
criteria
set
aabb
guidelin
volum
platelet
loss
accept
rang
align
previous
publish
data
residu
amotosalen
concentr
lm
consid
safe
accept
french
german
author
evalu
data
support
reason
assur
qualiti
effect
devic
use
accord
indic
use
background
implement
pathogen
inactiv
process
pi
allow
redesign
process
obtain
safe
blood
compon
reduc
need
addit
test
pathogen
detect
minim
residu
risk
infecti
window
period
pathogen
detect
usual
elimin
need
select
test
eg
cytomegaloviru
serolog
test
complement
gamma
irradi
given
abil
inactiv
white
blood
cell
addit
routin
implement
pi
reduc
incid
bacteri
infect
recipi
blood
compon
allow
blood
servic
proactiv
protect
blood
suppli
futur
emerg
infect
aim
verifi
function
integr
viabil
platelet
concentr
inactiv
pathogen
agent
use
safe
function
compon
transfus
method
total
independ
platelet
concentr
studi
platelet
donat
process
call
plateletpheresi
accord
establish
norm
process
platelet
concentr
submit
pi
intercept
blood
system
tm
platform
uva
illumin
immedi
sampl
donat
platelet
concentr
carri
take
sampl
ml
preinactiv
anoth
sampl
postinactiv
h
pi
platelet
viabil
sampl
evalu
demonstr
express
marker
flow
cytometri
process
platelet
concentr
releas
safe
compon
donat
compil
experiment
data
platelet
count
platelet
activ
marker
respect
total
platelet
compar
nonparametr
test
wilcoxon
carri
two
measur
pre
vs
post
platelet
viabil
pi
determin
result
total
independ
platelet
concentr
studi
averag
percentag
preinactiv
platelet
express
marker
percentag
function
platelet
post
inactiv
result
show
function
platelet
alter
inactiv
process
wilcoxon
test
confirm
signific
differ
platelet
activ
preand
postinactiv
confid
level
summaryconclus
process
photochem
treatment
amotosalen
hydrochlorid
longwavelength
ultraviolet
light
uva
appli
platelet
concentr
provid
function
product
without
alter
platelet
function
transfus
background
treatment
platelet
concentr
pc
pathogen
reduct
technolog
wide
implement
blood
establish
reduc
risk
bacteri
contamin
face
presenc
new
emerg
agent
blood
compon
aim
reduct
antioxid
power
aop
could
qualiti
control
test
prove
complet
viroinactiv
treatment
evalu
goal
studi
feasibl
method
abonnenc
et
al
transfus
anoth
blood
servic
assess
aop
platelet
unit
treat
intercept
technolog
method
aop
express
edel
valu
one
edel
equival
lmoll
ascorb
acid
repeat
intermedi
precis
accuraci
determin
linear
evalu
use
linear
regress
calcul
pearson
coeffici
limit
quantif
loq
determin
measur
aop
use
nacl
sampl
defin
background
roc
curv
use
determin
threshold
discrimin
pc
treatment
distinct
realiz
men
women
apheresi
pc
buffi
coat
bc
pc
oneyear
evalu
assess
pc
treatment
routin
product
result
coeffici
variat
repeat
less
intermedi
precis
coeffici
variat
less
pc
treatment
result
rose
valu
linear
detect
limit
correspond
result
edel
loq
equal
edel
concern
roc
curv
men
apc
threshold
edel
compar
women
apc
edel
threshold
bcpc
edel
result
specif
threshold
intercept
treatment
consid
execut
oneyear
experi
routin
pc
product
apc
women
men
bcpc
test
bcpc
women
apc
threshold
treatment
concern
men
apc
pc
treatment
threshold
summaryconclus
devic
valid
satisfi
oneyear
evalu
concern
men
group
apc
threshold
found
abonnenc
et
al
edel
studi
show
threshold
specif
sensit
edel
much
lower
specif
favor
compar
sensit
analysi
revis
adapt
threshold
get
higher
sensit
lead
reduc
nonconform
allow
measur
aop
treatment
women
threshold
found
edel
compar
edel
abonnenc
et
al
concern
sex
apc
result
statist
lower
women
group
men
group
treatment
bcpc
two
popul
treatment
distinguish
threshold
edel
lower
abonnenc
threshold
edel
conclus
edel
threshold
enabl
segreg
depend
prepar
process
adapt
blood
servic
aim
studi
goal
measur
antioxid
power
aop
level
plasma
unit
treat
mb
technolog
aim
use
test
qualiti
control
assay
document
execut
pathogen
inactiv
treatment
prepar
plasma
unit
method
aop
measur
perform
use
potentiostat
electrochem
analyz
volum
sampl
deposit
electrod
singleus
microship
aop
express
edel
valu
one
edel
equival
lmoll
ascorb
acid
reflect
redox
statu
plasma
unit
differ
protocol
establish
understand
role
mb
illumin
filtrat
aop
variat
measur
complet
treatment
plasma
mb
without
illumin
plasma
without
mb
illumin
plasma
without
mb
without
illumin
ten
dosag
men
donor
sampl
except
protocol
n
realiz
viroinactiv
process
correspond
dosag
plasma
treatment
plasma
mb
dri
tablet
passag
time
illumin
correspond
final
product
filtrat
result
protocol
mb
increas
observ
addit
mb
illumin
illumin
edel
valu
decreas
less
expect
degrad
mb
photoproduct
illumin
seri
illumin
seem
effect
without
mb
aop
increas
final
filtrat
goal
elimin
residu
mb
photoproduct
step
aop
valu
fell
seri
confirm
efficaci
filter
remov
mb
shown
decreas
aop
ae
edel
ae
edel
howev
absenc
mb
seri
result
statist
differ
summaryconclus
filtrat
decreas
aop
rate
except
mb
result
noncomplet
viroinactiv
treatment
allow
conclud
measur
aop
rate
may
indic
treatment
complet
sinc
signific
differ
treatment
found
noncomplet
treatment
seri
vox
sanguini
background
intercept
blood
system
ib
photochem
treatment
amotosalen
uva
use
inactiv
pathogen
leukocyt
plasma
intercept
tm
plasma
process
set
ceru
bv
netherland
modifi
incorpor
plastic
contain
nonpvc
materi
sourc
altern
supplier
connect
part
accessori
nondehp
pvc
formul
make
system
dehpfre
final
storag
contain
modifi
higher
contact
surfac
plasma
limit
thaw
time
proport
unit
fibrinogen
concentr
gl
requir
mean
recoveri
fviii
fibrinogen
ib
treatment
frozen
storag
respect
residu
platelet
l
leucocyt
l
red
blood
cell
l
unit
protein
content
gl
residu
amotosalen
lm
postcad
sampl
concentr
tat
complex
slightli
reduc
treatment
frozen
storag
concentr
significantli
reduc
cad
treatment
plasma
thaw
time
water
bath
consist
short
min
summaryconclus
pathogen
inactiv
plasma
unit
ffpaib
ffpwbib
prepar
dehp
free
intercept
process
set
retain
vitro
characterist
meet
qualiti
standard
therapeut
plasma
process
activ
coagul
complement
reduc
ffp
thaw
time
routin
min
import
benefit
emerg
use
background
plasma
coagul
factor
concentr
usual
differ
individu
donor
therefor
pool
wholeblood
deriv
plasma
unit
moder
high
low
coagul
factor
concentr
ensur
transfus
standard
blood
compon
moreov
pool
contribut
dilut
reactiv
antibodi
may
reduc
risk
nonhemolyt
transfus
reaction
trali
addit
pathogen
inactiv
reduc
risk
transfusiontransmit
infect
nonhemolyt
transfus
reaction
well
gvhd
inactiv
residu
lymphocyt
aim
assess
impact
plasma
pool
pathogen
inactiv
standard
blood
compon
plasma
qualiti
method
studi
includ
experi
experi
maledonor
abocompat
wholeblood
deriv
plasma
unit
ml
collect
differ
donor
pool
use
donopack
optipool
plasma
pool
set
ceru
europ
bv
pool
split
equal
minipool
subsequ
treat
intercept
blood
system
ceru
europ
bv
minipool
split
ml
therapeut
unit
sampl
collect
pool
well
inactiv
assess
coagul
factor
content
fviii
fix
fibrinogen
vwf
antigen
use
elisa
coagul
time
aptt
pt
studyanalysi
includ
sampl
five
pool
singl
plasma
unit
respect
background
biotin
bio
altern
radioact
red
blood
cell
rbc
tracer
allow
one
concurr
track
vivo
multipl
cell
popul
label
differ
bio
densiti
american
clinic
trial
multilabel
biorbc
transfus
man
assess
surviv
mock
et
al
transfus
studi
differ
biorbc
popul
monitor
ex
vivo
flow
cytometri
analysi
use
streptavidin
far
biotinyl
reagent
biosulfonh
compli
good
manufactur
practic
gmp
moreov
biorbc
bio
lgml
induc
immun
recipi
rare
case
schmidt
et
al
transfus
repres
obstacl
regard
regulatori
european
author
aim
aim
studi
describ
procedur
biotinyl
rbc
intend
clinic
trial
refin
level
bio
lgml
method
steril
statu
met
throughout
process
rbc
taken
standard
rbc
concentr
treat
biosulfonh
gmpgrade
lgml
recent
commerci
wash
buffer
injectablegrad
biotinyl
efficaci
control
flow
cytometri
streptavidin
conjug
differ
fluorochrom
phycoerythrin
pe
brilliant
violet
result
label
biosulfonh
gmpgrade
non
gmpgrade
compar
popul
rbc
could
easili
distinguish
unlabel
blood
cell
biosulfonh
lgml
mfi
gmp
mfi
non
gmp
mfi
gmp
mfi
non
gmp
mfi
gmp
mfi
non
gmp
mfi
brighter
streptavidinp
promis
tool
amplifi
signal
fluoresc
allow
good
differenti
popul
rbc
treat
lgml
biosulfonh
summaryconclus
preliminari
studi
explor
feasibl
multilabel
biorbc
product
clinic
trial
benefit
approach
overcom
need
nonradioact
tracer
follow
simultan
variou
popul
rbc
consequ
limit
number
volunt
reduc
risk
immun
use
bio
lgml
background
rejuven
aim
revert
ageingrel
diseas
develop
heterochron
parabiosi
studi
reveal
eotaxin
young
old
murin
blood
regul
brain
age
neurogenesi
umbil
cord
blood
ucb
born
factor
includ
tissu
inhibitor
metalloproteinas
neonat
immun
cell
also
contribut
rejuven
anim
model
human
platelet
lysat
hpl
commonli
use
us
other
highli
effici
cell
propag
vitro
burnouf
et
al
biomateri
publish
data
indic
limit
differ
adult
ucbderiv
hpl
partli
question
enigmat
rejuven
effect
aim
verifi
candid
regen
factor
neonat
blood
product
compar
protein
content
neonat
adult
plasma
platelet
respect
method
heparin
ucb
sampl
n
centrifug
within
h
collect
neonat
platelet
rich
plasma
aliquot
apheresi
platelet
concentr
n
use
adult
counterpart
platelet
concentr
adjust
l
plasma
supernat
platelet
obtain
centrifug
platelet
pellet
resuspend
salin
two
freezethaw
cycl
platelet
lysi
npl
apl
platelet
fragment
remov
centrifug
protein
content
analyz
proteom
profil
tm
array
nine
sampl
group
pool
avoid
individu
donor
variat
threshold
au
spot
densiti
defin
cutoff
data
analyz
graphpad
prism
use
twoway
anova
result
semiquantit
evalu
analyt
per
array
reveal
signific
differ
plasma
sampl
platelet
analyt
detect
cutoff
respect
neonat
plasma
found
highli
preval
protein
au
spot
densiti
compar
adult
plasma
vs
thirteen
protein
significantli
elev
neonat
plasma
includ
growthdifferenti
factor
gdf
platelet
deriv
growth
factor
aa
pdgfaa
serpin
p
highli
preval
protein
detect
npl
compar
apl
protein
significantli
elev
includ
vascular
cell
adhes
platelet
factor
epiderm
growth
factor
p
adult
sampl
protein
significantli
higher
plasma
three
protein
apl
compar
neonat
group
p
p
summaryconclus
detect
signific
differ
regen
growth
factor
cytokin
content
neonat
adult
plasma
platelet
sampl
respect
addit
experi
underway
character
impact
distinct
function
readout
background
product
storag
condit
platelet
pl
product
intend
transfus
constantli
evolv
need
sometim
vivo
evalu
clinic
trial
ascertain
whether
platelet
retain
abil
surviv
circul
requir
transfus
platelet
distinguish
recipi
circul
platelet
label
platelet
biotin
bio
afford
track
vivo
concurr
multipl
cell
popul
cover
variou
biotin
densiti
alreadi
describ
red
blood
cell
mock
transfus
surprisingli
one
studi
describ
transfus
human
biopl
stohlawetz
transfus
far
biotinyl
reagent
biosulfonh
compli
good
manufactur
practic
gmp
repres
obstacl
regard
regulatori
author
aim
aim
studi
describ
procedur
label
inject
human
platelet
densiti
biotin
evalu
impact
biotinyl
platelet
function
track
human
biopl
circul
mous
method
platelet
taken
standard
platelet
concentr
treat
lgml
biosulfonh
gmpgrade
recent
commerci
main
platelet
function
assess
vitro
human
biopl
surviv
evalu
immunodefici
nsgmice
treat
liposomeclodron
elimin
macrophag
prevent
reject
circul
human
biopl
detect
ex
vivo
flow
cytometri
streptavidin
phycoerythrin
result
use
trap
lm
pselectin
extern
reveal
normal
capac
secret
biopl
gpiba
gpiibiiia
express
affect
biotinyl
process
biopl
abil
aggreg
use
arachidon
acid
mm
amplitud
aggreg
ae
bio
ae
bio
lg
ml
ae
bio
lgml
use
collagen
lgml
amplitud
aggreg
ae
bio
ae
bio
lgml
ae
bio
lgml
biopl
popul
could
easili
distinguish
unlabel
blood
cell
mous
circul
h
h
mean
fluoresc
intens
ae
unlabel
circul
mous
platelet
ae
ae
circul
human
biopl
cover
respect
lgml
biotin
summaryconclus
label
approach
help
evalu
new
platelet
product
vivo
repres
altern
radioact
tracer
allow
follow
simultan
differ
platelet
popul
consequ
limit
number
volunt
clinic
trial
background
sever
ocular
surfac
diseas
dri
eye
syndrom
persist
recurr
corneal
epitheli
defect
diabet
neurotroph
keratopathi
mainli
success
cure
standard
treatment
protocol
howev
rare
refractori
usual
treatment
appear
especi
seriou
form
diseas
militari
medic
academi
autolog
serum
eye
drop
auto
sed
autolog
platelet
lysat
apl
eye
drop
appli
treatment
ophthalmolog
patient
categori
previous
resist
standard
therapi
aim
show
achiev
result
therapeut
use
autolog
blood
product
auto
sed
apl
treatment
ophthalmolog
patient
previous
respond
convent
therapysingl
center
experi
method
auto
sed
prepar
take
autolog
blood
tube
bd
vacutain
cat
ml
apl
tube
anticoagul
greiner
bioon
acda
ml
control
tti
everi
patient
steril
everi
seri
conduct
treatment
subject
ocular
discomfort
ocular
surfac
diseas
index
osdi
object
paramet
tear
film
schirmer
test
rose
bengal
tear
breakup
time
tbut
measur
epitheli
zone
analyz
apl
obtain
plateletrich
plasma
frozen
unfrozen
dilut
nacl
solut
auto
sed
administ
form
eye
drop
result
auto
sed
appli
ophthalmolog
patient
men
women
previous
resist
standard
therapi
total
treatment
perform
last
day
success
cure
one
two
treatment
per
patient
averag
appli
apl
use
multipl
time
one
patient
ogren
syndrom
sever
multipl
tropic
corneal
chang
ophthalmolog
patient
subject
improv
averag
pre
post
treatment
osdi
score
respect
also
object
progress
present
patient
p
summaryconclus
use
auto
sed
apl
treatment
ophthalmolog
patient
previous
resist
standard
therapi
constant
increas
simplic
low
expens
apl
turn
better
auto
sed
patient
sever
trophic
chang
apl
contain
larger
amount
nerv
growth
factor
tgfb
vegf
platelet
deriv
growth
factor
howev
larger
number
clinic
case
need
futur
conclus
background
whole
blood
wb
recent
regain
favor
treatment
massiv
bleed
patient
militari
civilian
set
platelet
plt
vital
compon
clot
format
compon
wb
critic
maintain
function
throughout
storag
red
blood
cell
rbc
store
hypox
hypocapn
condit
preserv
high
level
reduc
storag
lesion
stem
oxid
stress
hand
effect
steadi
hypoxia
mmhg
plt
contain
leukoreduc
wb
poorli
character
aim
examin
effect
hypox
condit
plt
function
microvesicl
mv
format
wb
store
hypox
h
convent
c
storag
method
unit
wb
collect
mayo
clinic
rochest
blood
donor
center
normal
healthi
volunt
ml
wb
leukoreduc
use
pltspare
filter
terumo
wb
split
control
c
hypox
h
hwb
process
oxygenreduct
bag
hemanext
lexington
unit
store
bag
ml
wb
collect
unit
day
week
plt
count
agonist
thrombin
receptor
agonist
peptid
trap
adenosin
diphosph
adp
collagen
stimul
platelet
aggreg
nonactiv
agonist
activ
plt
surfac
express
phosphatidylserin
ps
annexinv
bind
pselectin
fibrinogen
receptor
bind
microvesicl
mv
measur
coulter
counter
digit
flow
cytomet
pair
student
ttest
use
analyz
differ
degrad
rate
signific
p
result
hplt
count
declin
process
similar
declin
observ
week
c
thereaft
remain
steadi
plt
activ
ps
increas
time
h
c
process
c
increas
rapidli
storag
pselectin
increas
time
h
c
show
larg
increas
week
remain
steadi
h
c
plt
activ
trap
adp
declin
modestli
week
hplt
show
reduct
time
point
collagen
activ
cplt
increas
week
gradual
increas
week
reduct
h
compar
c
pltderiv
mv
v
storag
time
day
mv
lever
significantli
higher
h
subsequ
increas
rate
similar
lower
total
number
pltderiv
mv
wb
supernat
increas
week
c
h
suppress
increas
major
trend
describ
show
signific
differ
h
c
summaryconclus
plt
activ
period
store
leukoreduc
wb
accompani
modest
loss
agonistinduc
activ
oxygen
reduct
treatment
initi
activ
hplt
subsequ
increas
activ
rate
suppress
compar
cplt
wb
plt
retain
activat
hypox
condit
show
modest
reduct
activat
hypox
wb
may
provid
higher
qualiti
wb
trauma
patient
level
initi
plt
activ
improv
oxygen
reduct
procedur
method
inform
consent
elig
patient
random
either
first
receiv
autolog
follow
allogen
sed
first
receiv
allogen
follow
autolog
sed
sed
treatment
phase
one
month
separ
one
month
patient
standard
treatment
wash
period
sed
treatment
phase
patient
donat
ml
whole
blood
autolog
sed
prepar
allogen
sed
prepar
blood
nevertransfus
male
donor
blood
group
ab
serum
dilut
ad
salin
aliquot
eye
drop
dispens
system
meis
uhl
germani
visit
osdi
determin
use
valid
questionnair
higher
score
reflect
poorer
outcom
result
analyz
intentiontotreat
random
effect
linear
mix
model
crossov
design
use
result
total
patient
enrol
exclud
fail
autolog
blood
donat
background
follow
blood
compon
nontransfusion
use
bcntu
produc
transfusion
center
tc
allogen
platelet
gel
pg
deriv
buffycoat
bc
human
cord
blood
platelet
gel
cbpg
autolog
serum
eye
drop
sed
creation
type
platelet
gel
start
confirm
process
daili
product
blood
compon
use
treat
pediatr
patient
epidermolysi
bullosa
sed
produc
dedic
treat
patient
dri
eye
syndrom
aim
product
storag
bcntu
method
whole
process
product
bcntu
trace
transfusion
informat
system
emonetinsielmercato
condit
anoth
blood
transfusion
compon
process
take
place
close
circuit
use
laminar
flow
hood
pg
product
start
bc
resuspend
plasma
use
daili
platelet
concentr
instead
cbpg
produc
use
cord
blood
unit
use
hematopoiet
transplant
platelet
concentr
neg
blood
cultur
requir
italian
law
unit
frozen
last
pg
cbpg
must
activ
calcium
glucon
batroxobin
use
ophthalmologist
patient
dri
eye
syndrom
donat
ml
autolog
blood
serum
separ
dilut
balanc
salin
solut
divid
box
contain
singledos
vial
store
last
one
year
neg
blood
cultur
evalu
result
background
candida
albican
common
pathogen
detect
fungal
infect
aim
studi
aim
evalu
vitro
antifung
activ
volunteerderiv
platelet
rich
plasma
prp
c
albican
atcc
strain
possibl
effect
certain
chemokin
kinocidin
might
play
role
activ
method
prp
nine
volunt
deriv
use
magellan
prp
kit
calcium
glucon
use
obtain
autolog
thrombin
c
albican
isol
final
yeast
concentr
cfuml
cfuml
inocul
sabouraud
dextros
agar
st
nd
th
th
th
hour
incub
reveal
antifung
activ
autolog
thrombinactiv
prp
coloni
count
h
incub
chemokin
kinocidin
platelet
also
measur
simultan
elisa
method
result
compar
pbscontrol
group
group
show
antifung
activ
still
go
th
hour
differ
coloni
product
two
group
th
hour
statist
signific
p
observ
antifung
activ
continu
th
hour
decreas
th
hour
group
group
although
amount
prp
use
amount
chemokin
kinocidin
releas
group
concentr
c
albican
consid
import
detect
effect
group
although
increas
level
hour
two
prp
group
elisa
method
antifung
effect
detect
c
albican
observ
decreas
valu
result
antifung
activ
advanc
hour
prp
group
wherea
act
antifung
activ
summaryconclus
even
studi
group
highest
platelet
count
obtain
lowest
concentr
c
albican
reproduct
could
complet
elimin
mention
literatur
repeat
dose
prp
applic
drug
use
patient
may
longer
durat
action
even
complet
repress
reproduct
outcom
background
gener
blood
avail
develop
countri
transfus
sometim
transfus
previous
pregnant
patient
form
alloantibodi
red
cell
antigen
rare
antigen
high
preval
case
focus
twoyearold
girl
pakistani
descent
diagnos
neuroblastoma
stage
iv
antiin
b
e
although
public
indic
pakistani
indian
iranian
popul
b
discov
blood
type
exceedingli
rare
intern
search
requir
ensur
blood
product
avail
chemotherapi
autolog
hematopoiet
progenitor
cell
transplant
aim
illustr
respons
public
power
stori
child
need
rare
blood
treatment
intern
collabor
provis
rare
unit
method
case
report
twoyearold
patient
sampl
refer
antibodi
identif
patient
receiv
four
transfus
ml
red
cell
preced
period
hgb
level
fluctuat
consist
decreas
transfus
red
cell
surviv
follow
last
transfus
ml
hemoglobin
decreas
antiin
b
ficinonli
reactiv
anti
identifi
serum
antiin
b
eluat
monocyt
monolay
assay
predict
antiin
b
clinic
signific
reactiv
transfus
antigen
neg
unit
obtain
result
stabl
transfus
respons
although
expect
b
blood
would
easili
sourc
two
donor
usa
b
e
unit
blood
request
posttranspl
period
nation
intern
search
initi
robust
media
appeal
donor
result
mani
donor
intens
domest
screen
effort
usa
search
intern
rare
donor
panel
intern
blood
group
refer
laboratori
reveal
three
known
b
edonor
two
british
one
australian
contact
recruit
collect
ship
usa
work
american
rare
donor
program
ardp
staff
isbt
work
parti
rare
donor
isbt
wprd
member
countri
result
intens
media
coverag
oneblood
florida
blood
center
collabor
treatment
hospit
includ
onlin
news
outlet
youtub
facebook
result
respons
nation
intern
potenti
donor
test
b
isbt
wprd
member
sent
web
inform
potenti
donor
identifi
countri
ardp
sampl
blood
center
associ
laboratori
test
antiin
b
oneblood
two
new
b
donor
discov
type
e
thu
match
child
summaryconclus
intens
media
coverag
overwhelm
donor
respons
unpreced
experi
coordin
cooper
among
numer
blood
center
reflect
deep
dedic
blood
bank
commun
wellb
special
patient
need
case
illustr
respons
potenti
power
stori
medic
appeal
exquisit
rare
blood
util
social
media
onlin
news
outlet
gener
background
blood
platelet
unit
gener
store
blood
bank
day
afterward
discard
prepar
infus
platelet
membran
ipm
fresh
outdat
human
platelet
correct
prolong
bleed
time
thrombocytopen
anim
rabbit
infus
platelet
membran
ipm
platelet
substitut
may
feasibl
approach
reach
target
market
previou
experi
shown
ipm
hemostat
efficaci
shorten
bleed
time
without
advers
effect
rabbit
aim
abnorm
toxic
european
pharmacopoeia
standard
assess
biolog
product
test
materi
administ
mice
studi
abnorm
toxic
ipm
evalu
experiment
anim
model
mice
assur
safeti
ipm
without
evid
seriou
toxic
method
experiment
studi
infus
platelet
membran
ipm
prepar
outdat
platelet
concentr
platelet
concentr
pool
disrupt
freezethaw
procedur
pasteur
h
inactiv
possibl
viral
bacteri
contamin
sodium
capryl
stabil
formul
sucros
human
serum
albumin
final
lyophil
first
test
steril
carri
asept
condit
ipm
vial
inject
ml
ipm
mgkg
intraven
second
health
mice
weigh
gram
test
perform
accord
eu
pharmacopeia
monograph
result
steril
test
evid
microbi
growth
product
found
abnorm
toxic
test
pass
none
anim
die
h
inject
one
anim
die
prepar
fail
test
one
anim
die
test
repeat
experi
five
mice
aliv
h
ipm
inject
summaryconclus
research
result
show
ipm
platelet
substitut
free
abnorm
toxic
adequ
safeti
may
use
human
clinic
trial
studi
feasibl
approach
develop
platelet
substitut
futur
howev
studi
requir
confirm
differ
aspect
safeti
well
success
investig
may
affect
patient
care
transfus
medicin
futur
substanti
number
infant
especi
prematur
infant
unabl
receiv
adequ
amount
mother
milk
varieti
reason
world
health
organ
recommend
infant
especi
preterm
ill
infant
fed
qualitycontrol
donor
milk
fed
mother
milk
due
possibl
transmiss
human
immunodefici
viru
mani
human
milk
bank
close
therefor
avail
donor
milk
decreas
aim
analyz
process
donor
milk
requir
laboratori
test
establish
human
milk
bank
within
blood
donat
servic
cooper
depart
neonatolog
frankfurt
univers
hospit
method
base
recommend
promot
human
milk
bank
germani
austria
switzerland
efcni
evalu
manufactur
step
qualiti
control
requir
establish
human
milk
bank
background
patient
suffer
sever
ocular
surfac
disord
treatment
blood
deriv
serum
eye
drop
sed
highli
effect
therapi
autolog
sed
prepar
patient
blood
use
prefer
approach
year
experi
autos
manufactur
due
medic
reason
allogen
sed
present
altern
sinc
year
allogen
approach
well
establish
center
aim
retrospect
evalu
experi
allos
method
germani
manufactur
allos
possibl
individu
heal
attempt
patient
experienc
regular
male
donor
without
blood
born
diseas
never
receiv
blood
product
take
kind
medic
select
addit
donor
must
pass
questionnair
exclud
form
dri
eye
syndrom
allos
manufactur
direct
individu
patient
accord
process
autos
close
system
patient
file
serum
eye
drop
donor
screen
patient
receiv
allogen
treatment
data
concern
indic
allos
contraind
phlebotomi
problem
donor
select
manufactur
well
serolog
microbiolog
test
result
obtain
clinic
result
evalu
author
vox
sanguini
intern
societi
blood
transfus
vox
sanguini
suppl
ocular
surfac
diseas
index
osdi
patient
questionnair
ask
subject
benefit
symptom
reduct
possibl
side
effect
consumpt
comparison
artifici
eye
drop
applic
autos
furthermor
patient
undergo
regular
ophthalmolog
examin
within
special
consult
dri
eye
syndrom
hospit
result
patient
identifi
receiv
allogen
sed
patient
treat
autolog
previous
total
allogen
sed
produc
time
sinc
june
indic
ocular
gvhd
n
neurotroph
keratopathi
n
mucou
membran
pemphigoid
n
ogren
syndrom
n
secondari
keratoconjunct
sicca
virtu
chemotherapi
meig
syndrom
rosacea
morbu
bruton
n
contraind
autolog
donat
underli
diseas
n
poor
venou
access
n
low
haemoglobin
n
low
bodi
weight
n
young
age
n
circulatori
disturb
n
lack
respons
autos
n
patient
present
one
contraind
manufactur
problem
lipem
donor
plasma
n
high
donor
haemoglobin
n
unspecif
posit
serolog
find
antihb
n
microbiolog
test
steril
everi
time
side
effect
one
case
allerg
reaction
suspect
serum
protein
allergi
appear
clinic
outcom
consid
equival
ase
subject
patient
benefit
therapi
report
allevi
symptom
indic
highli
activ
gvhd
allos
might
even
better
option
summaryconclus
consid
previou
experi
allos
seem
safe
equal
effect
altern
autos
patient
unabl
donat
blood
case
urgent
indic
time
suppli
sometim
difficult
overcom
disadvantag
licens
allos
new
blood
product
possibl
product
storag
advanc
would
desir
goal
addit
suppli
would
becom
even
safer
prepar
allos
accord
quarantin
principl
like
ffp
abstract
withdrawn
background
vernal
keratoconjunct
chronic
recurr
bilater
inflamm
outer
ocular
layer
mostli
affect
children
young
peopl
condit
common
boy
diseas
present
eye
pruritu
itch
eye
photophobia
sensit
bright
light
excess
tear
foreign
eye
syndrom
sever
case
manifest
diffus
overgrown
papilla
usual
upper
eyelid
burst
connect
tissu
barrier
appear
giant
papilla
press
cornea
corneal
ulcer
sever
complic
vernal
keratoconjunct
may
induc
scar
corneal
neovascular
occasion
perfor
treatment
keratoconjunct
mainli
reli
steroid
mast
cell
stabil
antihistamin
immunosuppress
drug
cyclosporin
artifici
tear
contact
lensdress
cryotherapi
surgic
papilla
remov
present
case
yearold
girl
corneal
ulcer
appli
artifici
tear
tradit
method
treatment
prove
unsuccess
aim
aim
share
experi
artifici
tear
therapi
appli
ophthalm
disord
method
autolog
blood
ml
collect
dispos
steril
transfer
bag
use
routin
blood
compon
prepar
anticoagul
incub
h
clot
remov
centrifug
serum
contain
erythrocyt
press
extract
centrifug
appli
obtain
serum
free
cellular
compon
serum
divid
ml
segment
capsul
artifici
tear
appli
left
eye
daili
result
ulcer
heal
report
week
therapi
artifici
tear
dosag
reduc
daili
recurr
corneal
ulcer
observ
subsequ
week
summaryconclus
artifici
tear
safe
effect
therapi
ophthalm
disord
children
background
arv
nondisclosur
among
hivposit
donor
test
hiv
antibodi
ab
posit
rna
neg
abrna
socal
fals
elit
control
previous
describ
group
south
africa
abrnadon
sinc
test
arv
posit
extent
undisclos
arv
use
time
donat
repres
signific
risk
blood
safeti
countri
grow
treat
hiv
popul
aim
establish
preval
arv
nondisclosur
among
four
subgroup
hivposit
donor
south
africa
along
demograph
correl
nondisclosur
method
south
african
blood
donor
screen
selfadminist
questionnair
includ
question
current
hiv
statu
arv
use
follow
semistructur
person
interview
specimen
hiv
hepat
b
c
test
collect
time
donat
base
idnat
procleix
grifol
antibodi
prism
abbott
western
blot
test
hivposit
blood
donat
classifi
acut
abrna
recent
abrna
limit
antigen
avid
lag
odn
longstand
abrna
lag
odn
potenti
elit
control
abrna
case
store
plasma
donat
test
four
arv
drug
use
qualit
liquid
chromatographytandem
mass
spectrometri
detect
limit
lgml
chisquar
test
use
assess
associ
hiv
case
type
gender
ethnic
age
donor
type
donor
clinic
fix
mobil
type
arv
nondisclosur
result
donor
test
hivposit
sampl
avail
test
arv
overal
preval
undisclos
arv
use
n
efavirenz
frequent
detect
follow
lopinavir
nevirapin
potenti
elit
control
case
highest
proport
detect
arv
p
follow
longstand
recent
infect
none
acut
hiv
case
test
posit
arv
associ
arv
use
gender
ethnic
howev
older
year
hivposit
donor
significantli
like
test
posit
arv
younger
year
donor
p
arv
use
frequent
among
first
time
laps
repeat
donor
p
donor
mobil
clinic
significantli
higher
arv
nondisclosur
donor
fix
site
vs
p
summaryconclus
preval
undisclos
infect
arv
use
among
hivposit
south
african
blood
donor
alarm
higher
rate
nondisclosur
among
firsttim
donor
expect
nondisclosur
among
repeat
laps
donor
suggest
failur
donor
educ
assess
preval
among
concord
abrna
case
may
suggest
suboptim
viral
suppress
lack
detect
arv
acut
case
qualifi
sampl
test
tenofovir
common
drug
use
preexposur
prophylaxi
donor
motiv
nondisclosur
known
hiv
infect
arv
use
need
investig
sinc
earli
arv
initi
infect
prep
could
lead
low
ab
rna
level
failur
detect
hivinfect
donat
transfusiontransmiss
hiv
blood
bank
rotari
blood
bank
new
delhi
india
background
voluntari
blood
donat
ensur
safe
blood
transfus
care
blood
donor
select
import
provid
safe
blood
patient
although
new
methodolog
also
adopt
blood
center
blood
safeti
minim
risk
transmit
infect
blood
transfus
qualiti
avail
blood
compon
depend
willing
donat
reliabl
inform
given
donor
health
includ
risk
behaviour
blood
donor
histori
questionnair
design
evalu
donor
histori
accord
guidelin
laid
fda
donor
defer
blood
bank
less
motiv
return
donat
counsel
effect
import
reduc
number
deferr
good
donor
comprehens
centr
mechan
recal
temporarili
defer
donor
aim
aim
studi
analys
donor
histori
test
result
donat
blood
past
histori
jaundic
base
histori
suggest
type
viral
infect
donor
accept
defer
data
collect
voluntari
blood
donor
screen
blood
donat
year
method
studi
donor
histori
analys
refer
histori
jaundic
jaundic
donor
age
yr
histori
surgeri
blood
transfus
bodi
tattoo
acupunctur
treatment
within
past
one
year
donat
histori
multipl
sex
partner
relat
histori
intraven
drug
abus
histori
taken
consider
donor
reveal
past
histori
jaundic
ask
detail
ill
recoveri
blood
donat
donor
histori
jaundic
elicit
understood
type
viru
caus
jaundic
hepat
b
c
could
give
correct
histori
sure
caus
hepat
individu
defer
aim
assess
perform
followup
program
term
donor
particip
success
confirm
posit
rate
potenti
reentri
rate
method
elig
donor
test
hbsag
hcvab
hivabag
tpab
two
eia
marker
sampl
reactiv
least
one
assay
test
electrochemiluminesc
assay
eca
reactiv
sampl
consid
repeat
reactiv
rr
tpab
reactiv
donat
retest
particl
agglutin
assay
tppa
sampl
eca
tppa
nonreact
consid
nonrepeat
reactiv
nrr
background
blood
donat
servic
suhl
process
sampl
annual
whole
blood
apheresi
donat
test
averag
around
sampl
per
day
last
year
serolog
screen
perform
architect
instrument
abbott
arc
chang
alin
system
ali
middl
although
design
ali
assay
base
arc
assay
undertook
thorough
evalu
four
mandatori
screen
assay
detect
hbsag
hiv
agab
antihcv
antihbc
aim
valid
mandatori
screen
assay
new
ali
system
lab
term
sensit
specif
also
includ
sampl
known
falsereact
result
determin
rate
fals
reactiv
result
hbsag
antihcv
antihiv
may
lead
deferr
donat
donor
method
sensit
use
known
posit
sampl
confirm
immunoblot
nat
known
unspecif
posit
sampl
arc
confirm
immunoblot
nat
test
ali
also
close
unselect
sampl
edta
plasma
routin
blood
apheresi
donor
test
parallel
system
arc
ali
determin
rate
initi
repeat
reactiv
result
result
known
confirm
posit
sampl
ident
detect
ali
sampl
known
unspecif
reactiv
result
retest
ali
follow
result
antihcv
hiv
agab
hbsag
found
reactiv
ali
one
donat
acut
hiv
infect
earli
seroconvers
period
detect
method
routin
test
reactiv
result
ali
alreadi
known
arc
specif
screen
assay
ali
versu
arc
assay
follow
hbsag
ali
vs
arc
hiv
ali
arc
antihcv
ali
vs
arc
number
antihbc
reactiv
sampl
differ
ali
arc
summaryconclus
switch
new
system
mainli
driven
oper
effici
obvious
high
specif
alin
assay
reduc
unnecessari
deferr
donat
donor
abstract
withdrawn
background
blood
donor
select
cornerston
blood
transfus
safeti
design
safeguard
health
donor
recipi
donor
safeti
target
reduc
risk
complic
associ
blood
donat
transfus
safeti
reduc
risk
transfusiontransmit
infect
tti
prevent
transfus
reaction
alway
compromis
blood
donor
safeti
well
blood
safeti
outdoor
mega
blood
donat
drive
due
variou
reason
mainli
due
number
donat
within
stipul
time
aim
compar
blood
donor
select
pattern
hous
blood
donat
donat
mega
blood
donat
drive
influenc
donor
safeti
blood
safeti
tertiari
care
hospit
india
method
retro
prospect
studi
done
audit
compar
blood
donor
safeti
blood
safeti
period
year
januari
decemb
blood
donor
safeti
analyz
two
indic
donor
health
questionnair
dhq
monitor
blood
donor
reaction
rate
blood
safeti
tti
posit
rate
mega
blood
donat
drive
summaryconclus
good
donor
select
lengthi
process
involv
predon
inform
advic
usual
provid
leaflet
especi
transfusiontransmit
infect
associ
risk
factor
potenti
risk
donat
fill
dhq
donor
donor
interview
conduct
qualifi
medic
specialist
train
donor
select
process
health
assess
end
interview
declar
donor
elig
give
blood
defer
temporarili
perman
observ
seropreval
rate
number
donor
reaction
incomplet
fill
dhq
among
blood
donat
mega
blood
donat
drive
compar
blood
donat
hous
collect
mainli
due
huge
number
blood
donat
stipul
time
limit
time
spent
proper
donor
select
stringent
implement
strategi
safe
donor
safe
blood
way
blood
donor
transfus
safeti
background
safeti
blood
transfus
great
concern
especi
crisi
countri
humanitarian
emerg
transfus
transmit
infect
tti
one
major
health
problem
yemen
associ
blood
transfus
complic
aim
aim
studi
determin
preval
tti
among
blood
donor
nation
blood
transfus
research
center
nbtrc
contribut
addit
reactiv
therebi
total
reactiv
hcv
reactiv
hbv
nat
yield
viral
load
nat
reactiv
rang
iuml
hcv
hbv
yield
extrem
viral
load
iuml
nat
reactiv
show
seroconvers
month
followup
eclia
screen
hcv
reactiv
hbv
reactiv
summaryconclus
incid
rate
indic
current
risk
transfus
transmit
viral
infect
attribut
blood
donat
rel
high
countri
parallel
use
serolog
nat
screen
donat
blood
countri
high
seropreval
improv
blood
safeti
centr
use
best
class
serolog
nat
technolog
would
add
extra
layer
safeti
blood
suppli
interdict
sampl
donor
recent
infect
abstract
withdrawn
abstract
withdrawn
hivrna
hcvrna
detect
donor
nat
identifi
window
period
summaryconclus
studi
found
nat
could
detect
infect
case
hbvdna
hivrna
hcvrna
forgotten
serolog
method
therefor
nat
sensit
screen
method
detect
low
viral
load
shorten
window
period
viru
infect
ensur
safeti
blood
transfus
servic
du
sang
croix
roug
de
belgiqu
namur
belgium
background
due
enhanc
kit
specif
machin
throughput
roch
elecsi
technolog
potenti
partner
blood
donat
screen
laboratori
aim
aim
studi
assess
perform
elecsi
serolog
assay
coba
equip
clinic
specif
analyt
sensit
reproduc
background
deceas
donor
primari
sourc
organ
tissu
transplant
risk
infecti
complic
recipi
high
main
caus
morbid
mortal
transplant
minim
risk
infect
organ
tissu
transplant
donor
test
hbsag
antihbc
antihcv
syphili
laboratori
test
may
requir
depend
histori
donor
tissu
properti
certain
graft
donat
circulatori
death
donor
howev
absenc
heartbeat
may
chang
dramat
blood
composit
eg
haemolysi
proteolysi
may
impact
test
perform
lead
fals
result
therefor
assay
valid
need
test
cadaver
sampl
aim
valid
studi
perform
demonstr
suitabl
elecsi
hbsag
ii
antihbc
ii
antihcv
ii
hiv
combi
pt
hiv
duo
syphili
htlviii
chaga
use
cadaver
sampl
nonheart
beat
donor
method
basi
valid
follow
recommend
paulehrlichinstitut
pei
propos
valid
hiv
ag
ab
combin
assay
antihcv
assay
hbsag
antihbc
assay
use
cadaver
sampl
comparison
spike
sampl
live
donor
cadaver
donor
use
demonstr
accuraci
determin
precis
two
cadaver
specimen
test
sever
replic
accept
criteria
implement
accord
pei
recommend
result
result
found
within
specif
request
pei
recommend
test
assay
summaryconclus
evalu
result
support
extens
use
assay
cadaver
specimen
background
develop
countri
blood
donor
routin
screen
rang
blood
born
virus
hiv
hbv
hcv
htlv
use
highli
sensit
screen
test
dramat
improv
safeti
blood
suppli
howev
transmiss
transfus
unknown
unsuspect
virus
remain
continu
threat
particularli
relev
consid
signific
proport
transfus
patient
immunocompromis
frequent
subject
fatal
outcom
develop
countri
blood
donor
routin
screen
rang
blood
born
virus
hiv
hbv
hcv
htlv
use
highli
sensit
screen
test
dramat
improv
safeti
blood
suppli
howev
transmiss
transfus
unknown
unsuspect
virus
remain
continu
threat
particularli
relev
consid
signific
proport
transfus
patient
immunocompromis
frequent
subject
fatal
outcom
aim
context
metagenom
analys
viral
content
blood
donat
collect
geograph
zone
recogn
hotspot
viral
emerg
repres
suitabl
approach
without
priori
identif
potenti
emerg
viral
risk
may
compromis
blood
safeti
method
framework
viral
discoveri
program
found
french
nation
agenc
medicin
secur
ansm
french
plasma
sampl
collect
subsaharan
africa
countri
amazon
region
brazil
alreadi
analys
metagenom
result
although
viral
sequenc
could
describ
novel
ie
new
speci
even
new
genu
unexpectedli
identifi
felin
bocaviru
two
donor
mauritania
larg
divers
known
virus
part
regularli
monitor
agent
also
observ
among
anellovirus
formerli
known
gbvc
papillomavirus
herp
virus
parvoviru
chikungunya
viru
enteroviru
variou
small
circular
virus
circo
cycloand
gemycircularvirus
signif
differ
observ
higher
classif
detect
viru
familiesgenera
africa
brazil
observ
variat
sequenc
level
allow
better
resolut
genet
divers
sever
virus
exampl
character
genotyp
summaryconclus
overal
absenc
novel
virus
blood
sampl
collect
across
countri
two
distant
contin
reassur
regard
threat
emerg
howev
continu
monitor
prospect
blood
bank
continu
summaryconclus
high
peak
observ
first
period
studi
show
decreas
seropreval
viral
marker
continu
next
five
year
second
period
mark
irregular
evolut
seropreval
lower
level
first
period
recruit
new
donor
allow
quantit
increas
donat
howev
improv
qualiti
blood
product
essenti
condit
transfus
safeti
achiev
retent
recruit
blood
donor
background
blood
screen
laboratori
sampl
may
transfer
autom
serolog
molecular
instrument
potenti
sampl
contamin
seriou
risk
integr
nucleic
acid
test
nat
result
sensit
limit
detect
lod
hiv
hcv
nat
assay
combin
high
viral
titer
encount
specimen
patient
acut
infect
present
challeng
maintain
sampl
integr
neg
specimen
addit
cost
per
test
risk
reduc
singleus
filter
pipett
tip
aim
evalu
efficaci
appli
induct
heat
wash
nondispos
pipettor
serolog
instrumentsalin
alin
architect
abbott
diagnost
preserv
integr
sampl
transfer
downstream
molecular
instrument
realtim
abbott
molecular
diagnost
amplifi
viral
nucleic
acid
target
exponenti
method
applic
induct
heat
metal
pipettor
warm
resist
coilinduc
electr
current
sweep
pipettor
induct
coil
temperatur
pipettor
elev
throughout
length
singl
donor
high
viral
titer
hiv
genotyp
log
iuml
b
log
iuml
c
log
iuml
log
iuml
log
iuml
urf
log
iuml
well
singl
donor
high
viral
titer
hcv
genotyp
log
iuml
log
iuml
log
iuml
log
iuml
log
iu
ml
log
iuml
use
potenti
sourc
contamin
genotyp
account
major
hiv
hcv
infect
worldwid
serolog
instrument
one
high
viral
titer
hiv
hcv
specimen
three
consecut
suscept
neg
sampl
hivhcv
rna
neg
human
plasma
abbott
molecular
diagnost
test
hiv
agab
combo
antihcv
immunoassay
abbott
diagnost
schema
repeat
four
time
per
posit
specimen
induct
heat
wash
occur
sampl
process
serolog
instrument
first
suscept
neg
test
block
approxim
ml
residu
sampl
volum
test
use
ml
abbott
realtim
hiv
assay
lod
copiesml
ml
abbott
realtim
hcv
assay
lod
iuml
hcv
ag
immunoassay
lod
fmoll
abbott
diagnost
studi
accept
criteria
requir
suscept
neg
sampl
detect
level
hiv
hcv
rna
result
first
suscept
neg
sampl
n
per
platform
per
viru
schema
run
alin
alin
architect
use
induct
heat
wash
high
viral
titer
hiv
specimen
hcv
specimen
hiv
agab
combo
nonreact
sco
report
detect
level
hiv
rna
target
antihcv
nonreact
sco
report
detect
level
hcv
rna
core
antigen
target
summaryconclus
precaut
continu
taken
sampl
run
molecular
instrument
integr
sampl
origin
test
alin
alin
architect
preserv
downstream
molecular
test
use
induct
heat
wash
aim
increas
safeti
blood
blood
product
motiv
blood
donor
regular
donor
method
nation
report
system
show
high
preval
tti
among
first
blood
donor
compar
regular
donor
per
donat
confirm
posit
hiv
hcv
hbv
case
report
among
first
blood
donor
end
nation
program
name
predon
screen
test
develop
implement
high
preval
provinc
whole
countri
base
program
first
blood
donor
accept
donat
site
donor
select
process
elig
donat
blood
refer
give
blood
sampl
screen
tti
test
month
invit
letter
smss
send
donor
neg
result
screen
tti
test
elig
donat
blood
anoth
donor
select
process
donat
reject
least
one
hiv
hcv
hbv
confirm
posit
result
reject
rate
show
signific
decreas
tti
preval
among
blood
donat
preval
hiv
hcv
hbv
among
donat
decreas
significantli
compar
preval
hiv
among
donat
reduc
hcv
hbv
result
experienc
respect
reduc
seem
appli
studi
could
effect
scale
safeti
nation
blood
suppli
addit
intervent
could
support
iranian
blood
transfus
servic
increas
proport
regular
blood
donor
mean
increas
regular
blood
donor
popul
size
safeti
iranian
blood
blood
product
scale
summaryconclus
evid
base
report
show
high
rate
preval
transfus
transmit
infect
tti
among
first
blood
donor
effect
intervent
reduc
risk
unsaf
first
blood
donat
effect
increas
safeti
blood
blood
product
pre
donat
screen
test
program
iran
support
nation
program
decreas
rate
tti
among
blood
donat
abstract
withdrawn
abstract
withdrawn
background
despit
univers
applic
viral
inactiv
elimin
technolog
prepar
plasmaderiv
product
exclus
infecti
donat
procedur
remain
first
essenti
step
well
major
determin
safeti
untreat
labil
blood
product
current
select
screen
techniqu
reduc
risk
viral
transmiss
low
level
still
low
quantifi
risk
transmiss
donat
beyond
routin
detect
particularli
seroconvers
window
infect
blood
donor
say
period
recent
infect
donor
yet
develop
serolog
respons
level
residu
risk
must
low
possibl
mainli
condit
rate
infect
concern
hiv
hepat
b
viru
hbv
c
hcv
blood
donor
summaryconclus
evolut
serolog
marker
gener
satisfactori
continu
regress
improv
particularli
hiv
hand
hepat
b
still
concern
still
high
rate
among
new
donor
desir
initi
regular
donor
vaccin
program
protect
hepat
b
background
blood
centr
requir
high
throughput
assay
high
level
reproduc
assur
consist
result
minim
unnecessari
retest
sampl
deferr
donor
addit
continu
econom
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
aim
evalu
reproduc
hcvab
havab
igm
havab
igg
essay
use
abbott
alin
compar
architect
determin
repeat
test
alin
essay
method
month
studi
conduct
sever
sampl
minimum
sampl
per
test
randomli
sort
test
use
alin
architect
result
compar
use
ibm
spss
statist
order
evalu
repeat
least
sampl
differ
reactiv
degre
high
intermedi
low
per
test
repeat
use
alin
averag
time
per
sampl
determin
percentag
coeffici
variat
cv
result
total
sampl
test
hcvab
havab
igm
havab
igg
use
alin
architect
ensur
statist
signific
differ
result
p
use
sampl
total
essay
found
cv
hcvab
rang
sampl
test
havab
igm
total
essay
cv
rang
havab
igg
test
sampl
essay
cv
rang
summaryconclus
new
autom
equip
alin
system
demonstr
statist
differ
compar
architect
repeat
ensur
demonstr
precis
result
gener
fulli
autom
blood
screen
analyz
help
assur
consist
result
test
retest
blood
specimen
hcvab
havab
igm
havab
igg
background
blood
centr
requir
high
throughput
assay
high
level
reproduc
assur
consist
result
minim
unnecessari
retest
sampl
deferr
donor
addit
continu
econom
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
aim
evalu
reproduc
hbsag
hbsab
hbcab
hbeag
hbeab
essay
use
abbott
alin
compar
architect
determin
repeat
test
alin
essay
method
month
studi
conduct
sever
sampl
minimum
sampl
per
test
randomli
sort
test
use
alin
architect
result
compar
use
ibm
spss
statist
order
evalu
repeat
least
sampl
differ
reactiv
degre
high
intermedi
low
per
test
repeat
use
alin
averag
time
per
sampl
determin
percentag
coeffici
variat
cv
result
total
sampl
test
hbsag
hbsab
hbcab
hbeag
hbeab
use
alin
architect
ensur
statist
signific
differ
result
p
use
sampl
total
essay
found
cv
hbsag
rang
sampl
test
hbsab
total
essay
cv
rang
hbcab
test
sampl
essay
cv
rang
use
sampl
total
essay
found
cv
hbeag
rang
sampl
test
hbeab
total
essay
cv
rang
summaryconclus
new
autom
equip
alin
system
demonstr
statist
differ
compar
architect
repeat
ensur
demonstr
precis
result
gener
fulli
autom
blood
screen
analyz
help
assur
consist
result
test
retest
blood
specimen
hbsag
hbsab
hbcab
hbeag
hbeab
background
blood
centr
requir
high
throughput
assay
high
level
reproduc
assur
consist
result
minim
unnecessari
retest
sampl
deferr
donor
addit
continu
econom
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
aim
evalu
reproduc
hivagab
syphili
htlv
iii
essay
use
abbott
alin
compar
architect
determin
repeat
test
alin
essay
method
month
studi
conduct
sever
sampl
minimum
sampl
per
test
randomli
sort
test
use
alin
architect
result
compar
use
ibm
spss
statist
order
evalu
repeat
least
sampl
differ
reactiv
degre
high
intermedi
low
per
test
repeat
use
alin
averag
time
per
sampl
determin
percentag
coeffici
variat
cv
result
total
sampl
test
hivagab
syphili
htlv
iii
use
alin
architect
ensur
statist
signific
differ
result
p
use
sampl
total
essay
found
cv
hivagab
rang
sampl
test
syphili
total
essay
cv
rang
htlv
iii
test
sampl
essay
cv
rang
summaryconclus
new
autom
equip
alin
system
demonstr
statist
differ
compar
architect
repeat
ensur
demonstr
precis
result
gener
fulli
autom
blood
screen
analyz
help
assur
consist
result
test
retest
blood
specimen
hivagab
syphili
htlv
iii
human
immunodefici
hiv
hepat
c
hcv
virus
infect
blood
donor
respect
consecut
posit
result
hbv
hcv
nil
hiv
sampl
carri
consecut
reactiv
donor
donat
patient
relat
infect
patient
statist
signific
p
summaryconclus
among
tti
reactiv
donor
consecut
reactiv
reason
may
process
relat
like
sampl
carri
reagent
carri
donor
relat
donor
relat
reason
may
one
close
rel
reactiv
viru
transmit
famili
member
studi
reactiv
donor
either
close
contact
person
histori
infect
diseas
first
degre
famili
rel
find
found
statist
signific
p
studi
recommend
analysi
consecut
posit
result
elisa
along
look
proceduresampl
error
also
need
take
retrospect
histori
donor
close
contact
infect
patient
background
screen
transfusiontransmit
infect
tti
critic
ensur
safeti
blood
product
transmiss
infect
transfus
remain
major
sourc
viral
hepat
especi
hbv
hcv
effect
rapid
immunochromatograph
test
ict
devic
screen
blood
concern
need
valid
advanc
method
like
chemiluminesc
immunoassay
clia
polymeras
chain
reaction
pcr
aim
current
studi
conduct
evalu
perform
screen
effect
commerci
avail
rapid
screen
kit
comparison
clia
pcr
method
singl
centr
cross
section
studi
conduct
depart
blood
transfus
servic
shahe
zulfiqar
ali
bhutto
medic
univers
islamabad
januari
june
total
ten
commerci
avail
ict
devic
one
clia
kit
liaisonr
xl
test
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
accuraci
use
posit
neg
sampl
hbv
hcv
respect
comparison
valu
determin
pcr
ict
kit
includ
hightop
rightsign
wondfo
accuchek
fastep
abon
immum
instaansw
biocheck
ctk
result
sensit
specif
ict
kit
hbsag
hightop
rightsign
wondfo
accuchek
fastep
abon
immum
instaansw
biocheck
ctk
respect
similarli
sensit
specif
differ
ict
kit
hcv
hightop
rightsign
wondfo
accu
check
fastep
abon
immum
insta
answer
biochek
ctk
respect
sensit
specif
diasorin
liaison
murex
assay
hbv
hcv
found
compar
pcr
ppv
npv
accuraci
determin
accordingli
summaryconclus
rapid
test
ict
devic
hbv
hcv
avail
pakistan
found
variabl
degre
sensit
specif
compar
pcr
compar
expens
qualiti
method
reliabl
compar
rapid
devic
data
gener
help
polici
maker
prepar
futur
plan
action
introduc
concept
qualiti
control
blood
centr
analysi
shown
popul
blood
donor
also
includ
peopl
infect
syphili
refer
number
test
sampl
number
quit
signific
analysi
prove
increas
number
syphili
infect
among
blood
donor
consist
gener
trend
popul
summaryconclus
prove
test
blood
donor
treponema
pallidum
infect
increas
safeti
recipi
blood
compon
obligatori
test
donor
fulli
justifi
use
third
fourth
gener
serolog
assay
mandatori
screen
blood
donor
unit
hbv
hcv
infect
transfus
routin
blood
bank
india
screen
unit
elisa
test
nat
common
due
cost
constraint
aim
aim
studi
determin
frequenc
load
hbv
dna
hcv
rna
hb
hcv
reactiv
blood
donor
respect
henc
intend
contribut
determin
whether
routin
hb
hcv
screen
blood
donor
use
elisa
method
alon
provid
concret
benefit
regard
hbv
hcv
risk
reduct
whether
implement
nat
great
benefit
lowresourc
countri
like
india
high
preval
hbv
hcv
abstract
withdrawn
donor
routin
test
hbv
dna
use
cobastaqscreen
roch
procleix
ultrio
ultrio
plu
id
grifol
assay
obi
confirm
repeat
dna
test
perform
addit
serolog
molecular
investig
index
followup
sampl
antihb
concentr
determin
antihbc
antibodi
test
three
distinct
commerci
clia
assay
antihbc
elecsi
roch
architect
antihbc
ii
abbott
hiscl
antihbc
assay
sysmex
hbv
press
precorecor
bcp
region
pcramplifi
viral
particl
concentr
viral
amplicon
sequenc
result
hbsagdna
donor
includ
confirm
obi
identifi
preval
among
obi
donor
test
antihbcantihb
antihbcantihb
antihbcantihb
antihbcantihbsprimari
obi
antihbcantihb
obi
donor
significantli
younger
mean
year
rang
year
antihbcantihb
mean
year
rang
year
antihbcantihb
median
year
rang
year
profil
p
hbv
vaccin
document
donor
report
one
donor
without
definit
evid
extrem
low
hbv
dna
load
rang
iuml
transient
detect
seven
donor
follow
genotyp
identifi
genotyp
b
n
genotyp
c
n
preliminari
analysi
core
protein
n
bcp
n
sequenc
show
particular
genet
featur
could
associ
alter
antigen
core
gene
express
followup
avail
antihbcantihb
donor
samplesdonor
rang
month
antihbc
remain
undetect
clia
assay
donor
except
one
low
transient
detect
level
hbv
dna
observ
overtim
antihb
level
fluctuat
iul
signific
differ
hlaa
b
except
hlab
frequent
detect
antihbc
neg
obi
summaryconclus
overal
preval
antihbsonli
hbv
dna
posit
obi
carrier
total
donor
dalian
blood
donor
confirm
previou
report
south
east
asia
phenomenon
relat
core
antigen
variat
significantli
associ
younger
age
carrier
particular
rout
natur
histori
infect
may
consid
hypothesi
acutephas
vaccin
breakthrough
rule
donor
month
stabil
serolog
profil
breakthrough
immun
donor
may
still
suspect
studi
need
evalu
potenti
infect
antihbsonlyhbv
dna
obi
carrier
character
potenti
viral
immunolog
mechan
respons
unusu
hbv
infect
profil
confirmatori
laboratori
hungarian
nation
blood
transfus
servic
hnbt
budapest
hungari
background
vaccin
hepat
b
viru
hbv
effect
tool
avoid
infect
hungari
popul
born
consid
immun
inocul
mandatori
children
campaign
vaccin
sinc
hbv
vaccin
strongli
recommend
healthcar
worker
moreov
trip
endem
countri
awar
individu
could
also
reason
vaccin
immunolog
agegroup
sinc
hbv
vaccin
contain
surfac
antigen
recent
inocul
caus
reactiv
hbsag
screen
assay
posit
confirmatori
test
sever
day
result
deferr
donor
blood
donat
former
regul
hnbt
valid
decemb
allow
reentri
donor
whose
immun
record
neg
hbv
confirm
second
blood
sampl
prove
previou
vaccin
result
hbsag
confirm
posit
aim
aim
studi
strengthen
vaccin
hbv
blood
donat
result
reactiv
hbsag
screen
confirmatori
assay
background
brazil
introduct
nucleic
acid
test
nat
hbvdna
detect
routin
screen
public
blood
bank
rel
recent
fundac
pr
osanguehemocentro
de
paulo
fpssp
blood
donor
submit
serolog
screen
test
hbv
hcv
chaga
diseas
syphili
nat
hiv
hcv
hbv
per
year
approxim
blood
donat
discard
due
reactiv
result
hbv
discard
rate
aim
studi
aim
determin
potenti
infecti
case
among
sampl
one
hbvreactiv
screen
result
antihbc
hbsag
mpnathbv
verifi
differ
categori
hbv
infect
acut
chronic
occult
hepat
b
infect
obi
immunolog
window
furthermor
character
distribut
hbv
genotyp
drug
resist
escap
mutat
analyz
risk
factor
method
carri
crosssect
studi
roughli
donat
may
decemb
hbv
antibodi
antigen
screen
perform
use
cmia
kit
architect
abbotthbsag
architect
abbottantihbc
nat
screen
perform
minipool
mp
six
sampl
use
kit
nat
hivhcv
hbv
biomanguinho
sensit
lod
iuml
hbv
reagent
sampl
n
present
one
hbvreactiv
screen
result
antihbc
hbsag
andor
mpnathbv
submit
individu
nucleic
acid
extract
hous
quantit
realtim
pcrhbv
idpcrhbv
target
hbsag
region
sensit
uiml
hbv
genotyp
mutat
analys
determin
direct
sequenc
hbv
polgenesurfacegen
use
onlin
analysi
tool
hbv
sociodemograph
epidemiolog
data
also
analyz
financi
support
fapesp
result
among
hbv
reactiv
sampl
reactiv
antihbc
hbsag
reactiv
marker
hbv
dna
routin
test
idpcrhbv
identifi
sampl
activ
infect
hbv
reactiveposit
test
result
hbv
dnayield
sampl
hbsagyield
obi
observ
viral
load
activ
infect
sampl
rang
copml
median
hbv
subgenotyp
found
donor
respect
revers
transcriptas
inhibitorresist
variant
detect
escap
mutat
small
hbsag
protein
shb
region
detect
follow
main
substitut
mean
age
donor
activ
hbv
infect
year
mostli
donor
male
mix
white
conclud
high
school
summaryconclus
discard
rate
due
isol
antihbc
high
obi
found
blood
donor
popul
studi
addit
case
immunolog
window
hbv
hbsagyield
detect
predomin
subgenotyp
mutat
associ
escap
found
hbvdnaposit
sampl
continu
research
surveil
hbv
preval
among
blood
donor
need
maintain
evenli
increas
blood
safeti
brazil
background
screen
antihbcor
antibodi
blood
donor
consid
contribut
significantli
blood
safeti
sinc
reveal
donor
occult
probabl
occult
hepat
b
variabl
result
molecular
screen
due
low
viral
load
howev
univers
antihbcor
test
blood
donor
might
exclud
consider
number
blood
donor
countri
high
hbv
preval
even
countri
low
moder
preval
like
greec
aim
aim
investig
percentag
blood
donor
natur
hbv
infect
confirm
posit
antihbcor
hbv
immun
due
vaccin
antihb
due
vaccin
predict
impact
gener
antihbcor
test
method
period
novemb
blood
donor
ask
give
consensu
addit
screen
hepat
b
antihbcor
antihb
antibodi
besid
obligatori
serolog
molecular
screen
sampl
donor
disagre
examin
sampl
repeat
posit
antihbcor
result
examin
antihbcor
igm
antihb
antibodi
furthermor
new
donor
sampl
request
confirm
reactiv
serolog
result
record
excel
spreadsheet
addit
data
includ
age
sex
nation
number
previou
blood
donat
abo
blood
group
famili
histori
hbv
infect
hbv
vaccin
also
record
statist
evalu
donor
inform
posit
result
result
total
edta
sampl
test
use
architect
antihbcor
antihb
ntihbcorem
antihb
assay
chemiluminesc
microparticl
immunoassay
cmia
repeat
antihbcor
occur
sampl
among
also
antihb
antihb
found
iuml
miuml
miuml
among
antihbcor
posit
donor
foreign
greek
foreign
consist
donor
examin
antihbcor
found
posit
foreign
countri
high
preval
hepat
b
infect
greek
total
sampl
antihb
miuml
consid
seroprotect
donor
summaryconclus
almost
half
blood
donor
immun
vaccin
natur
infect
incid
natur
infect
significantli
higher
foreign
versu
antihbcor
donor
antihb
iuml
might
potenti
infecti
especi
immunocompromis
patient
choos
screen
blood
donor
antihbcor
reject
posit
result
regardless
antihb
level
would
probabl
lose
signific
number
donor
jeopard
blood
suffici
altern
could
reject
antihb
choos
select
screen
predon
blood
donor
countri
high
preval
hbv
infect
follow
pilot
studi
preval
immun
hbv
larg
number
blood
donor
variou
part
greec
must
investig
order
decid
whether
introduc
screen
aim
aim
studi
perform
phylogenet
analysi
donor
sampl
hcv
found
neighbour
villag
determin
natur
transmiss
method
altogeth
approxim
million
blood
donor
sampl
screen
antihcv
immunoassay
architect
antihcv
abbott
gmbh
wiesbaden
germani
reactiv
result
confirm
antihcv
lineimmunoassay
innolia
hcv
score
fujirebio
europ
gent
belgium
base
lia
posit
sampl
associ
hcv
infect
suppos
resid
place
donor
three
neighbour
villag
situat
less
km
pcr
posit
sampl
sampl
hcv
sequenc
phylogenet
analysi
perform
fourteen
hcv
infect
sampl
gener
popul
ivd
user
also
includ
studi
result
phylogenet
analysi
detect
genet
relationship
among
hcv
viru
sequenc
donor
sampl
abund
subtyp
form
two
differ
group
phylogenet
tree
accord
genet
distanc
distant
mutual
ancestor
could
suppos
two
sampl
subtyp
origin
villag
differ
nucleotid
three
hcv
ivd
user
control
group
show
close
genet
relationship
virus
detect
donor
sampl
summaryconclus
base
phylogenet
analysi
hcv
transmiss
blood
donor
could
consequ
ivd
use
origin
might
relat
primari
human
sourc
signific
increas
hcv
seropreval
among
ivd
user
observ
approxim
threefold
rural
area
hungari
recent
find
highlight
import
proper
donor
select
identifi
typic
sign
ivd
use
moreov
enhanc
awar
blood
donor
educ
signific
issu
order
reduc
risk
transfus
transmit
infect
abstract
withdrawn
background
china
residu
risk
transfusiontransmit
hcv
declin
sinc
screen
blood
donor
antihcv
andor
hcv
nat
howev
mani
high
sensit
reagent
use
test
blood
donor
sampl
lead
falseposit
result
donor
loss
aim
studi
intend
establish
donor
reentri
procedur
hcv
screen
reactiv
donor
china
method
march
decemb
blood
donor
sampl
screen
reactiv
belong
grey
zone
elisa
andor
reactiv
nucleic
acid
test
nat
local
blood
center
collect
chines
blood
center
sampl
sent
institut
blood
transfus
ibt
nation
refer
laboratori
antihcv
hcv
individu
nucleic
acid
test
idnat
conduct
result
reactiv
antihcv
sampl
test
recombin
immunoblot
assay
riba
result
base
studi
donor
studi
could
classifi
two
categori
hcv
statu
true
posit
fals
posit
total
donor
lost
followup
hcv
statu
determin
certainti
base
data
reentri
procedur
hcv
screen
reactiv
donor
propos
summaryconclus
base
propos
donor
reentri
procedur
hcv
screen
reactiv
donor
major
screen
falseposit
donor
reentri
safe
abstract
withdrawn
background
provid
safe
blood
transfus
subsaharan
africa
ssa
particular
challeng
due
combin
factor
limit
resourc
infrastructur
suboptim
diagnost
high
preval
major
transfusiontransmiss
infect
tti
averag
seropreval
data
estim
ugandan
kenyan
blood
transfus
servic
bt
hepat
c
hcv
current
stand
respect
januari
decemb
mbale
eastern
uganda
hcv
preval
amongst
blood
donor
alarm
provis
fund
confirmatori
test
bt
unabl
confirm
refut
diagnosi
activ
hcv
result
larg
quantiti
blood
wastag
unnecessari
anxieti
potenti
donor
high
donor
deferr
rate
limit
donor
pool
aim
aim
determin
true
preval
activ
hcv
infect
amongst
seroposit
donor
bt
uganda
kenya
addit
aim
compar
perform
local
use
serodiagnost
best
avail
altern
test
examin
feasibl
costeffect
addit
altern
test
help
provid
accur
result
infecti
statu
blood
method
hcv
seroposit
blood
sampl
bt
studi
site
kampala
mbale
mombasa
retest
use
local
serolog
screen
test
abbott
architect
antihcv
altern
prequalifi
rapid
antibodi
test
sd
biolin
confirmatori
test
hcv
core
antigen
test
discrep
result
need
clarif
sampl
test
cepheid
xpert
platform
reversetranscriptas
pcr
obtain
quantit
rna
result
sco
specimen
cutoff
valu
fals
posit
sampl
screen
serolog
analys
present
preanalyt
factor
centrifug
speed
haemolysi
check
time
delay
collect
test
control
document
result
pilot
data
retest
quarantin
hcv
seroposit
donor
blood
mbale
bt
uganda
demonstr
seroposit
blood
rna
pcr
neg
decemb
seroposit
sampl
screen
antihcv
serolog
kampala
bt
sco
valu
cutoff
indic
posit
sampl
data
retest
seroposit
sampl
true
represent
activ
hcv
demonstr
sco
valu
studi
period
concomitantli
retrospect
analysi
januari
decemb
preanalyt
factor
cost
analysi
comparison
diagnost
platform
coupl
cost
donor
deferr
process
fals
posit
case
present
summaryconclus
bt
ssa
signific
resourc
financi
implic
repeat
test
donor
deferr
counsel
requir
evalu
introduc
new
appropri
diagnost
algorithm
screen
hcv
crucial
improv
suppli
safe
blood
transfus
servic
east
africa
background
novemb
blood
servic
england
scotland
wale
reduc
donor
deferr
threemonth
commerci
sex
worker
individu
higher
risk
sexual
partner
includ
sex
men
chang
recommend
detail
review
extern
expert
committe
sabto
recommend
shorten
deferr
month
would
allow
detect
recent
acquir
infect
maintain
residu
risk
rr
toler
level
recommend
accept
govern
govern
commit
explor
individualis
approach
aim
assess
impact
deferr
blood
safeti
term
epidemiolog
infect
blood
donor
complianc
donor
select
criteria
explor
evid
requir
develop
individualis
approach
donor
select
polici
method
routin
uk
blood
donat
surveil
data
preliminari
review
annual
preval
incid
hbv
hiv
infect
estim
poisson
regress
model
test
trend
incid
calcul
donor
seroconvert
within
andor
microbiolog
clinic
evid
recent
infect
donor
posit
complianc
deferr
determin
uk
hemovigil
data
scrutinis
evid
transfus
transmit
infect
tti
associ
newli
elig
donor
result
among
new
donor
annual
hiv
preval
decreas
significantli
averag
year
p
donat
signific
trend
observ
hbv
annual
hiv
incid
among
repeat
donor
also
decreas
significantli
averag
year
p
year
pyr
base
seroconvert
signific
trend
hbv
incid
studi
period
howev
incid
increas
pyr
base
seroconvert
respect
inform
avail
date
none
seroconvert
donor
noncompli
report
confirm
tti
associ
polici
chang
summaryconclus
hiv
preval
incid
continu
declin
hbv
incid
repeat
donor
increas
although
initi
analysi
suggest
associ
polici
chang
monitor
continu
residu
risk
reestim
data
postchang
accumul
data
reassur
therefor
appropri
scope
evid
feasibl
individualis
approach
select
polici
multidisciplinari
steer
group
conven
includ
represent
patient
stakehold
group
gap
knowledg
defin
packag
work
develop
project
fair
assess
individualis
risk
use
abo
rdf
guidanc
background
perman
deferr
men
sex
men
msm
establish
primarili
minimis
risk
hiv
transfusiontransmit
infect
increasingli
challeng
accordingli
blood
servic
mani
countri
chang
timebas
deferr
canada
deferr
implement
reduc
deferr
consid
aim
estim
risk
undetect
hiv
among
screen
blood
donat
deferr
sinc
last
sex
men
method
appli
model
combin
featur
previous
publish
english
canadian
model
estim
hiv
risk
deferr
three
scenario
vari
hiv
incid
preval
noncompli
deferr
model
assum
constant
hiv
nucleic
acid
window
period
test
procedur
error
rate
assay
sensit
model
input
incid
current
deferr
calcul
hiv
posit
donor
previou
neg
within
month
divid
number
person
year
number
hiv
posit
donat
hiv
posit
msm
hiv
msm
incid
case
newli
elig
msm
donor
donor
surveil
complianc
survey
risk
deferr
estim
three
scenario
one
determin
like
msm
donor
noncompli
hiv
incid
hiv
posit
donat
chang
msm
newli
elig
donat
estim
complianc
survey
scenario
base
data
two
sequenti
polici
chang
canada
optimist
scenario
noncompli
halv
pessimist
scenario
msm
hiv
incid
hiv
posit
donat
noncompli
new
msm
donor
doubl
also
use
median
hiv
residu
risk
use
final
estim
uncertainti
estim
assess
percentil
simul
ci
result
incid
per
donat
estim
like
optimist
pessimist
scenario
respect
deferr
like
scenario
hiv
residu
risk
predict
million
donat
ci
million
million
optimist
scenario
hiv
residu
risk
estim
million
donat
ci
million
million
final
pessimist
scenario
hiv
residu
risk
estim
million
donat
ci
million
million
residu
risk
estim
base
number
donat
canada
one
hiv
infecti
donat
would
inventori
everi
year
like
scenario
everi
year
optimist
scenario
everi
year
pessimist
scenario
summaryconclus
risk
hiv
enter
blood
suppli
canada
msm
deferr
predict
low
model
scenario
includ
pessimist
doubl
hiv
incid
post
chang
background
safeti
blood
blood
product
major
concern
pakistan
preval
transfus
transmit
infect
among
multitransfus
thalassaemia
patient
high
hiv
epidem
pakistan
follow
asian
epidem
model
establish
among
high
risk
group
transmiss
gener
public
rapid
fear
stigma
ignor
contribut
heavili
hiv
transmiss
pakistan
hiv
detect
among
blood
donor
rise
report
occur
media
repeatedli
aim
investig
possibl
transmiss
hiv
blood
transfus
punjab
pakistan
highlight
step
taken
reduc
transmiss
infect
method
septemb
report
hiv
transmiss
blood
transfus
report
media
mother
newborn
acquir
hiv
blood
transfus
hiv
posit
donor
confirm
later
case
refer
investig
punjab
blood
transfus
author
pbta
pbta
team
took
blood
sampl
recipi
mother
newborn
blood
donor
famili
rel
sampl
test
highli
sensit
chemiluminesc
immunoassay
clia
clia
result
confirm
presenc
hiv
recipi
blood
donor
due
matern
hiv
antibodi
transfer
placenta
infect
statu
newborn
reconfirm
die
within
two
week
donor
inform
donat
time
past
year
pbta
abl
trace
one
earlier
donat
three
month
ago
recipi
femal
found
test
clia
found
hiv
posit
case
occur
unlicens
privat
blood
bank
screen
hiv
rapid
manual
devic
blood
bank
seal
author
infect
case
regist
provinci
aid
control
programm
treat
summaryconclus
main
reason
hiv
spread
blood
transfus
use
substandard
rapid
screen
devic
evalu
valid
nation
level
addit
exist
system
reli
familyreplac
donor
nation
safe
blood
transfus
programm
implement
blood
safeti
system
reform
recommend
reform
agenda
blood
transfus
author
made
function
grant
licens
blood
bank
proper
system
ensur
qualiti
safeti
blood
product
programm
develop
nation
system
evalu
select
valid
assay
use
screen
blood
close
coordin
drug
regulatori
author
pakistan
promot
cultur
voluntari
blood
donat
programm
taken
concret
step
initi
formul
nation
blood
donor
polici
interact
celebr
celebr
world
blood
donor
day
recent
launch
blood
donat
featur
facebook
promot
voluntari
blood
donat
concept
along
regul
blood
sector
reduc
risk
hiv
transmiss
blood
transfus
pakistan
mianyang
blood
center
mianyang
urumqi
blood
center
urumqi
china
rti
intern
rockvil
nation
heart
lung
blood
institut
bethesda
stanford
univers
stanford
unit
state
background
incid
hiv
infect
increas
substanti
past
decad
china
especi
among
young
peopl
repres
nearli
half
chines
blood
donor
popul
upward
trend
hiv
infect
underscor
import
monitor
hiv
preval
incid
chines
blood
donor
aim
estim
hiv
preval
incid
rate
ir
among
chines
blood
donor
use
blood
donat
data
five
geographicallydispers
blood
center
particip
recipi
epidemiolog
donor
evalu
studyiii
redsiii
china
program
method
western
blot
confirmatori
test
done
sampl
blood
donat
reactiv
one
round
routin
elisa
test
posit
nucleic
acid
amplif
test
nat
multipl
imput
use
sampl
miss
confirmatori
test
result
hiv
preval
calcul
among
firsttim
donor
estim
hiv
ir
firsttim
donor
singlewel
lagavid
eia
test
conduct
firsttim
hiv
recent
incid
infect
defin
infect
within
approxim
day
base
avid
hiv
antibodi
novel
model
deriv
estim
hiv
ir
among
infrequ
repeat
donor
provid
one
donat
estim
interv
deriv
overal
hiv
ir
repeat
donor
estim
combin
classicalmodel
ir
estim
repeat
donor
given
least
donat
estim
interv
multivari
logist
regress
model
use
examin
factor
associ
hiv
infect
result
total
whole
blood
apheresi
platelet
donat
postdon
screen
result
collect
five
blood
center
includ
donat
firsttim
donor
donat
repeat
donor
hiv
preval
among
firsttim
donor
per
donor
ci
hiv
ir
estim
per
personyear
ci
among
firsttim
donor
per
personyear
ci
among
repeat
donor
hiv
preval
ir
vari
across
region
increas
trend
observ
blood
center
among
firsttim
donor
male
older
year
minor
ethnic
less
colleg
educ
certain
occup
commerci
servic
factori
worker
retir
unemploy
selfemploy
associ
posit
hiv
confirmatori
test
result
summaryconclus
although
hiv
preval
incid
remain
low
among
chines
blood
donor
import
monitor
hiv
epidemiolog
blood
donor
continu
basi
especi
among
popul
region
higher
risk
donor
screen
educ
strategi
need
develop
evalu
reduc
risk
ir
method
use
studi
first
time
donor
well
repeat
donor
donat
infrequ
readili
applic
countri
similar
donat
pattern
background
thailand
nation
blood
centr
respons
blood
donat
servic
includ
followup
blood
donor
counsel
order
indic
infect
statu
especi
hivposit
blood
donor
current
although
epidem
hiv
infect
thailand
declin
hivposit
case
still
found
blood
donor
screen
thu
monitor
hiv
infect
statu
blood
donor
postblood
donor
counsel
import
provid
hivposit
infect
donor
lead
access
hiv
treatment
immedi
aim
studi
hiv
followup
case
serolog
test
year
assess
hiv
infect
thai
blood
donor
retrospect
analysi
hiv
followup
case
serolog
test
cmia
ic
western
blot
conduct
thai
nation
blood
centr
result
total
voluntari
blood
donat
year
repeat
reactiv
result
hiv
serolog
screen
case
half
hiv
reactiv
donor
return
followup
test
ascertain
hiv
statu
hiv
followup
process
hiv
reactiv
screen
donor
must
follow
month
test
use
differ
three
principl
hiv
serolog
test
total
hiv
reactiv
result
separ
three
pattern
includ
hiv
posit
result
inconclus
result
neg
result
number
group
case
case
case
respect
hiv
posit
result
found
case
posit
hiv
serolog
test
firsttim
followup
case
test
becom
posit
result
followup
one
time
case
inconclus
result
case
reactiv
test
donor
return
confirm
lead
temporarili
defer
donor
blood
donor
system
addit
case
inconclus
result
could
conclud
hiv
result
although
repeat
sever
time
last
pattern
neg
result
case
show
case
neg
result
followup
month
case
inconclus
result
chang
neg
result
almost
case
group
reentri
blood
donor
deferr
period
summaryconclus
number
repeat
reactiv
result
hiv
screen
constant
year
return
followup
half
hiv
reactiv
donor
lead
accumul
temporarili
defer
donor
blood
donat
system
hiv
followup
posit
case
inform
counsel
immedi
refer
anonym
clinic
treatment
problem
challeng
hiv
followup
inconclus
result
unclear
return
retest
lead
loss
reentri
donor
might
chang
neg
result
afterward
henc
effect
counsel
followup
system
need
taken
urgent
encourag
temporarili
deferr
donor
return
retest
reduc
stigma
defer
donor
hiv
followup
case
analyz
inform
nonreact
result
infecti
marker
report
blood
bank
repres
risk
blood
recipi
result
load
inform
sivigila
donor
found
men
peopl
donat
obtain
whole
blood
donor
reactiv
result
hiv
subsequ
report
sivigila
addit
five
reactiv
simultan
hbv
blood
bank
took
averag
ae
day
report
sivigila
donor
hiv
reactiv
result
notifi
sivigila
subsequ
reactiv
blood
bank
behavior
may
suggest
attempt
spread
diseas
donor
men
despit
initi
report
sivigila
databas
present
nonreact
result
blood
bank
hiv
one
reactiv
syphili
hbv
one
hbv
pattern
may
suggest
fals
posit
neg
result
one
two
databas
analyz
fourteen
donor
neg
test
blood
bank
hiv
rang
month
reactiv
sivigila
donat
whole
blood
conduct
may
suggest
accept
donat
window
period
therefor
warrant
investig
consid
two
blood
compon
could
obtain
averag
donor
potenti
risk
estim
recipi
summaryconclus
donor
report
first
blood
bank
later
sivigila
allow
estim
adequ
orient
health
servic
inform
gener
epidemiolog
surveil
program
could
improv
select
donor
transfus
safeti
background
assum
bacteri
contamin
blood
product
often
take
place
donat
process
number
bacteria
time
point
estim
around
cfu
per
bag
littl
known
growth
behavior
differ
bacteria
speci
whole
blood
wb
unit
storag
distribut
bacteria
differ
blood
product
aim
aim
current
studi
determin
growth
differ
bacteria
speci
contamin
wb
unit
studi
distribut
bacteria
differ
blood
compon
method
whole
blood
n
per
speci
inocul
approxim
cfu
differ
bacteria
speci
escherichia
coli
klebsiella
pneumonia
pseudomona
fluorescen
staphylococcu
aureu
staphylococcu
epidermidi
streptococcu
dysgalactia
streptococcu
pyogen
store
h
room
temperatur
centrifug
separ
red
blood
cell
rbc
buffi
coat
bc
plasma
bc
spike
wb
pool
random
bc
prepar
plasmareduc
platelet
concentr
pc
sampl
taken
wb
storag
blood
product
rbc
bc
plasma
pc
right
prepar
bacteri
titer
determin
steril
pc
test
bactalert
seven
day
storag
result
bacteri
growth
wb
vari
remark
donat
bacteria
speci
highest
titer
wb
detect
streptococcu
speci
wherea
staphylococcu
aureu
staphylococcu
epidermidi
escherichia
coli
pseudomona
fluorescen
multipli
bacteria
prefer
accumul
bc
separ
reach
titer
cfuml
bc
cfuml
correspond
pc
right
prepar
total
pc
test
posit
bacteria
end
storag
result
depend
speci
use
eg
pc
test
posit
spike
streptococcu
pyogen
pc
test
posit
spike
escherichia
coli
bacteri
contamin
rbc
plasma
unit
much
less
frequent
associ
higher
bacteri
titer
parent
wb
unit
summaryconclus
growth
distribut
bacteria
process
wb
differ
blood
product
speciesdepend
remark
vari
donat
result
patient
male
yo
yo
histori
acut
myelogen
leukemia
statuspost
haploident
stem
cell
transplant
patient
thrombocytopen
underw
simultan
transfus
irradi
nonpr
day
platelet
store
platelet
addit
solut
singl
apheresi
collect
blood
supplier
primari
prereleas
bacteri
cultur
neg
onsit
point
releas
secondari
safeti
measur
pan
genera
detect
pgd
test
neg
gram
posit
gp
gram
neg
gn
organ
apheresi
unit
also
pass
visual
inspect
prior
releas
blood
bank
transfus
patient
display
sign
septic
transfus
reaction
includ
rigor
fever
hypoxemia
tachypnea
tachycardia
hypotens
transfus
reaction
evalu
initi
patient
admit
medic
intens
care
unit
start
broadspectrum
antibiot
gram
stain
one
platelet
unit
demonstr
gram
neg
rod
gnr
gram
posit
cocci
gpc
cluster
second
platelet
unit
demonstr
gnr
repeat
secondari
safeti
measur
pgd
test
unit
neg
gp
gn
organ
direct
bacteri
cultur
platelet
unit
grew
gnr
gpc
identifi
baumanii
saprophyticu
h
incub
coloni
initi
bacteri
plate
numer
count
tntc
subsequ
replat
platelet
unit
show
unit
baumanii
tntc
saprophyticu
cfuml
unit
baumanii
cfuml
saprophyticu
cfuml
blood
cultur
collect
patient
becam
posit
within
h
gnr
gram
stain
blood
cultur
ultim
grew
baumanii
saprophyticu
primari
prereleas
cultur
blood
supplier
remain
neg
day
antibiot
pressor
patient
stabil
discharg
home
blood
donor
interview
well
cultur
collect
summaryconclus
case
document
failur
primari
prereleas
bacteri
test
secondari
onsit
point
releas
pgd
test
identifi
two
pathogen
organ
baumanii
saprophyticu
unusu
caus
septic
transfus
reaction
possibl
organ
differ
limit
detect
pgd
assay
compar
organ
rapid
attent
clinic
sign
transfus
prompt
initi
antibiot
critic
manag
septic
transfus
reaction
current
evalu
way
reduc
septic
transfus
reaction
includ
increas
util
pathogen
reduc
platelet
background
transfusionassoci
infect
due
transmiss
bacteria
still
repres
major
risk
develop
countri
nowaday
despit
refriger
storag
red
blood
cell
rbc
fatal
reaction
patient
receiv
contamin
rbc
unit
repeatedli
report
order
increas
safeti
blood
transfus
new
strategi
measur
develop
context
transfusionrelev
bacteria
refer
strain
serv
valuabl
tool
valid
comparison
interpret
new
develop
aim
conduct
collabor
studi
establish
first
repositori
red
blood
cell
transfusionrelev
bacteria
refer
strain
method
six
bacteri
strain
serratia
liquefacien
serratia
marcescen
pseudomona
fluorescen
listeria
monocytogen
yersinia
enterocolitica
yersinia
enterocolitica
distribut
paulehrlichinstitut
laboratori
countri
enumer
identif
growth
measur
interv
total
day
lowcount
spike
rbc
bag
colonyform
unit
cfu
rbc
bag
result
except
marcescen
strain
show
goodtoexcel
growth
rbc
liquefacien
p
fluorescen
enterocolitica
enterocolitica
achiev
cfuml
day
cfuml
day
growth
l
monocytogen
lower
reach
maximum
concentr
cfuml
day
laboratori
marcescen
show
growth
summaryconclus
five
six
test
strain
show
robust
growth
rbc
independ
donor
variabl
promis
candid
adopt
offici
rbc
transfusionrelev
refer
strain
world
health
organ
background
samplok
sampl
kit
ssk
itl
biomed
use
nh
blood
transplant
nhsbt
sampl
platelet
compon
pc
bacteri
screen
use
bactalert
system
inocul
bactalert
bottl
perform
immedi
sampl
valid
delay
inocul
retent
sampl
within
ssk
devic
would
allow
conting
transport
screen
site
event
incid
prevent
test
sampl
site
ssk
maintain
close
system
sampl
pc
compat
standard
blood
collect
bag
graduat
chamber
ml
ensur
requir
sampl
volum
collect
integr
needl
allow
inocul
bactalert
bottl
aim
nation
bacteriolog
laboratori
nhsbt
evalu
impact
prolong
storag
pc
sampl
ssk
devic
regard
bacteri
viabil
detect
method
four
refer
speci
assess
staphylococcu
aureu
atcc
streptococcu
agalactia
atcc
escherichia
coli
atcc
clostridium
perfringen
atcc
pool
split
method
use
apheresi
pc
suspend
plasma
unit
screen
use
bactalert
prior
spike
prove
absenc
contamin
pc
spike
singl
speci
rang
cfuml
test
bactalert
ml
inocul
anaerob
aerob
bottl
posit
control
enumer
perform
confirm
bacteri
concentr
unit
sampl
use
two
ml
ssk
held
period
h
process
repeat
period
elaps
ml
ssk
inocul
aerob
anaerob
bactalert
bottl
one
ssk
per
atmospher
per
speci
remain
sampl
enumer
bottl
incub
bact
alert
system
maximum
day
subcultur
posit
result
posit
control
detect
growth
bactalert
exclud
aerob
bottl
c
perfringen
expect
anaerob
organ
storag
period
bottl
detect
growth
bactalert
aureu
show
increas
h
cfuml
h
cfuml
cfuml
agalactia
increas
h
cfuml
cfuml
h
cfuml
cfuml
c
perfringen
increas
h
cfuml
cfuml
h
cfuml
cfuml
e
coli
concentr
h
reduc
cfuml
cfuml
howev
possibl
result
inher
count
error
h
increas
growth
cfuml
obtain
summaryconclus
storag
pc
sampl
ssk
devic
h
neg
effect
bacteri
viabil
detect
use
bactalert
system
background
intercept
tm
blood
system
platelet
effici
inactiv
pathogen
leukocyt
platelet
concentr
pc
system
util
amotosalen
uva
light
avail
treatment
apheresi
whole
blood
wb
deriv
platelet
mostli
buffi
coat
pool
europ
plasma
platelet
addit
solut
pa
treatment
apheresi
platelet
us
trima
tm
plasma
amicu
tm
intersol
plasma
acinetobact
baumanii
staphylococcu
saprophyticu
strain
isol
salin
flush
taken
h
success
complet
transfus
apheresi
intercepttr
pc
plasma
patient
suspect
septic
reaction
occur
h
post
transfus
bacteri
isol
sampl
gram
stainneg
cultureneg
sister
split
pc
submit
evalu
report
vitro
inactiv
fast
grow
gram
neg
bacterium
baumanii
slower
grow
gram
posit
saprophyticu
sister
unit
assess
amotosalen
break
product
indic
success
intercept
treatment
aim
object
studi
evalu
bacteri
inactiv
baumanii
saprophyticu
apheresi
platelet
assess
immedi
treatment
recultur
end
day
shelflif
method
doubl
apheresi
pc
collect
plasma
split
three
equal
compon
yield
approxim
ml
plateletspc
baumanii
saprophyticu
grown
lb
broth
pc
unit
inocul
either
bacteri
strain
combin
strain
log
coloni
form
unitsml
cfuml
inocul
contamin
unit
treat
small
volum
sv
intercept
kit
sampl
taken
pre
postinactiv
treatment
day
storag
sampl
analyz
plate
lb
plate
ml
residu
amotosalen
level
assess
hplc
result
initi
bacteri
titer
cfuml
follow
inactiv
treatment
viabl
bacteria
detect
plate
cultur
bacteria
detect
day
storag
correspond
log
inactiv
bacteri
strain
perform
intercept
treatment
process
confirm
sister
pc
unit
evidenc
level
amotosalen
byproduct
characterist
intercept
treatment
well
review
process
document
summaryconclus
amotosalenuva
effect
inactiv
baumanii
saprophyticu
individu
togeth
limit
detect
day
storag
bacteria
sister
pc
gram
stain
cultur
presenc
amotosalen
byproduct
suggest
pc
collect
involv
septic
reaction
steril
time
intercept
treatment
success
illumin
possibl
oneoftwo
split
pc
contamin
due
biofilm
format
minim
intercept
system
decant
platelet
virgin
storag
bag
end
treatment
contamin
sourc
pc
contain
like
occur
intercept
treatment
possibl
time
spike
transfus
background
studi
subsaharan
africa
document
bacteri
contamin
blood
product
transfus
vari
time
higher
north
publish
data
central
africa
lack
aim
aim
studi
determin
proport
blood
product
contamin
bacteria
three
hospit
democrat
republ
congo
drc
assur
asept
sampl
use
close
system
sampl
bag
addit
presenc
contamin
assess
semiquantit
coloni
count
method
juli
decemb
total
blood
product
sampl
provinci
g
en
eral
de
r
ef
erenc
kinshasa
hpgrk
p
ediatriqu
kalemb
lemb
kinshasa
hpkll
saintluc
kisantu
hslk
compatibil
blood
product
ml
blood
transfer
primari
blood
bag
attach
sampl
bag
sampl
bag
seal
store
fridg
transport
daili
bacteriolog
laboratori
use
adapt
connect
sampl
bag
ml
blood
inocul
blood
cultur
bactalertpf
biom
erieux
incub
day
cultur
check
daili
sign
growth
addit
ml
blood
equal
distribut
cled
macconkey
agarco
side
dipslid
meu
srl
dipslid
incub
h
semiquantit
cultur
express
colonyformingunit
cfu
per
ml
case
blood
cultur
growth
bacteria
identifi
second
blood
cultur
inocul
exclud
contamin
process
bacteria
grown
semiquantit
cultur
also
identifi
result
total
whole
blood
red
cell
concentr
contamin
bacteria
hpgrk
blood
product
contamin
hpkll
hslk
proport
contamin
blood
product
significantli
higher
hpgrk
compar
hslk
p
signific
differ
site
p
p
major
isol
bacteri
speci
coagulaseneg
staphylococcu
sppmicrococcu
spp
bacillu
spp
remain
bacteri
isol
identifi
nonfer
gramneg
rod
klebsiella
pneumonia
staphylococcu
aureu
mould
listeria
spp
corynebacterium
sppcoryneform
bacteria
concentr
isol
bacteria
lower
cfuml
except
one
coagulaseneg
staphylococcu
spp
found
hpgrk
cfuml
summaryconclus
knowledg
first
reach
sampl
size
blood
product
bacteri
cultur
first
use
close
system
sampl
bag
subsaharan
africa
guarante
asept
sampl
blood
cultur
might
explain
low
bacteri
contamin
rate
blood
product
three
hospit
drc
compar
previou
studi
subsaharan
african
countri
moreov
bacteri
concentr
contamin
blood
product
low
cfuml
differ
proport
contamin
studi
site
suggest
differ
environ
practic
play
role
risk
bacteri
contamin
background
although
screen
treponema
pallidum
tp
mandatori
blood
donat
necess
controversi
transmiss
blood
product
document
develop
countri
last
decad
aim
base
laboratori
marker
activ
earli
tp
infect
donor
aeid
determin
demograph
aeid
frequenc
measur
case
compar
earli
infect
syphili
case
syc
notifi
gener
popul
regist
nphc
method
altogeth
donor
screen
antitp
immunoassay
architect
syphili
tp
abbott
wiesbaden
germani
reactiv
result
confirm
immunoblot
viram
biotech
ag
planegg
germani
discrimin
specif
antitp
igg
igm
nonspecif
vdrl
antibodi
five
dilut
meet
criteria
antitp
igg
posit
vdrl
titer
antitp
igm
posit
donor
consid
aeid
stratifi
age
gender
resid
region
proport
aeid
paeid
syc
psyc
calcul
first
time
ft
repeat
test
rt
donor
gener
popul
respect
year
studi
period
preval
pp
aeid
syc
estim
popul
risk
across
statist
weight
proport
oneway
anova
tukey
posthoc
test
z
score
test
appli
statist
signific
defin
p
result
antitp
reactiv
confirm
blood
donor
aeid
prove
case
ft
rt
donor
period
syc
notifi
aeid
syc
age
group
year
approxim
individu
domin
proport
men
p
aeid
syc
respect
paeid
estim
ft
donor
significantli
higher
p
rt
donor
proport
syc
gener
popul
pp
aeid
show
roughli
homogen
distribut
region
howev
pp
syc
signific
p
central
hungari
domin
relat
region
compar
pp
aeid
syc
central
hungari
indic
signific
differ
vs
p
howev
region
show
substanti
differ
summaryconclus
donor
antitp
confirm
posit
refer
healthcar
system
base
laboratori
marker
test
aeid
could
separ
demograph
characterist
pretti
similar
syc
notifi
gener
hungarian
popul
proport
earli
activ
infect
ft
donor
significantli
higher
rt
donor
proport
syc
gener
popul
given
consider
number
tp
infect
background
qualiti
assur
safeti
hematopoiet
stem
cell
hsc
emphasi
prevent
bacteri
fungal
contamin
prerequisit
transplant
procedur
bacteri
contamin
particular
signific
occur
rel
frequent
bacteria
gradual
gain
antimicrobi
resist
aim
aim
determin
incid
rate
bacteri
fungal
contamin
process
transplant
materi
institut
hematolog
transfus
medicin
ihtm
take
account
hsc
sourceperipher
blood
pbsc
bone
marrow
bm
cord
blood
cb
method
analysi
involv
autolog
allogen
compon
collect
ihtm
hospit
dedic
ihtm
patient
analysi
compris
donat
includ
bm
pbsc
cb
donat
process
laboratori
year
bm
collect
oper
theatrecondit
pbsc
cell
separ
baxter
cobe
spectra
gambro
trima
accel
terumo
bct
cb
acquir
umbil
vein
obstetr
gynaecolog
ward
aerob
anaerob
bacteria
contamin
determin
variou
incub
temperatur
room
temperatur
use
varieti
cultur
media
pbsc
bm
test
use
sampl
trypcasesoy
broth
tsbt
schaedler
vit
biomerieux
cb
test
use
bactec
ped
plusf
bactec
bectondickinson
result
period
contamin
product
found
pbsc
test
pbsc
unit
cb
test
cb
unit
infect
bm
product
determin
overal
percentag
contamin
product
estim
three
product
found
contamin
staphylococcu
epidermidi
came
one
patient
central
venou
cathet
collect
consecut
day
product
contamin
mostli
staphylococcu
epidermidi
detail
result
present
poster
summaryconclus
accord
ihtm
polici
contamin
product
admit
clinic
use
outcom
studi
identifi
process
experi
staff
main
indic
product
qualiti
import
also
proper
assess
donor
health
condit
inject
site
product
usual
collect
central
venou
cathet
close
system
addit
safeguard
contamin
process
sampl
collect
procedur
help
avoid
fals
posit
result
background
syphili
consid
global
public
health
problem
world
health
organ
estim
annual
around
million
new
case
syphili
world
occur
develop
countri
despit
signific
decreas
syphili
transfus
transmiss
recent
increas
worldwid
incid
associ
risk
transmiss
platelet
concentr
cp
store
room
temperatur
call
attent
potenti
residu
risk
syphili
transmiss
transfus
observ
institut
signific
increas
posit
syphili
among
blood
donor
p
aim
determin
preval
activ
syphili
blood
donor
character
serolog
profil
syphili
posit
donor
method
posit
sampl
treponem
chemiluminesc
assay
cmia
abbott
architect
perform
blood
donor
screen
submit
treponem
elisa
antitreponema
pallidum
igm
euroimmun
nontreponem
test
antigenomega
diagnost
sampl
posit
result
one
two
test
indic
recent
syphili
submit
realtim
pcr
syphili
innolia
syphilisfujirebio
immunoblot
test
also
perform
sampl
present
posit
result
elisaigm
alon
financi
support
fapesp
result
among
sampl
screen
present
posit
result
cmia
syphili
includ
studi
total
sampl
show
vdrligm
vdrligmand
vdrl
elisa
igm
innolia
syphili
test
perform
confirmatori
test
sampl
present
posit
result
elisa
igm
vdrl
neg
posit
result
undetermin
neg
none
sampl
show
presenc
treponema
dna
realtim
pcr
preval
incid
year
incid
relat
total
posit
preval
incid
higher
men
white
marri
age
year
high
school
educ
level
observ
ahbc
seropreval
elisa
igmsyphili
posit
sampl
preval
htlv
coinfect
summaryconclus
observ
signific
increas
preval
syphili
incid
total
case
initi
posit
cmia
test
accord
data
could
identifi
risk
syphili
transfus
transmiss
blood
bank
exclus
use
vdrl
donor
screen
found
case
neg
vdrl
elisa
igm
innolia
posit
continu
monitor
profil
donor
infect
syphili
time
reemerg
diseas
use
import
blood
bank
reflect
epidemiolog
situat
diseas
commun
contribut
definit
health
polici
background
transfus
relat
sepsi
seriou
concern
limit
platelet
storag
time
day
room
temperatur
unit
screen
bacteri
contamin
collect
bacteri
monitor
method
take
day
detect
contamin
thu
cold
storag
platelet
repres
attract
altern
improv
platelet
safeti
studi
assess
bacteri
growth
platelet
store
either
roomtemperatur
rt
refriger
cs
aim
aim
studi
assess
effect
storag
temperatur
platelet
function
bacteri
growth
contamin
platelet
unit
identifi
factor
contribut
bacteri
growth
rt
storag
method
apheresi
platelet
plasma
plt
obtain
healthi
donor
use
terumo
trima
accel
autom
blood
collect
system
terumo
bct
fresh
plasma
fp
collect
similarli
aliquot
plt
fp
transfer
ph
safe
minibag
blood
cell
storag
inc
contamin
acinetobact
baumannii
escherichia
coli
pseudomona
aeruginosa
staphylococcu
aureu
staphylococcu
epidermidi
pb
uninfect
control
minibag
store
rt
agit
use
orbit
shaker
set
rpm
cs
aliquot
store
static
condit
bacteri
growth
monitor
daili
dilut
plate
lactat
level
assess
istat
abbott
test
cartridg
plasma
glucos
level
assess
use
blood
glucos
test
strip
germain
laboratori
platelet
activ
aggreg
assess
day
flow
cytometri
multipl
platelet
aggregometri
respect
result
bacteri
growth
progress
rapidli
first
day
postcollect
plt
aliquot
store
rt
except
challeng
epidermidi
signific
growth
epidermidi
detect
day
bacteri
number
remain
unchang
refriger
aliquot
day
rt
storag
result
significantli
p
decreas
platelet
aggreg
time
exacerb
bacteri
challeng
plt
function
larg
preserv
refriger
regardless
challeng
bacteri
growth
significantli
reduc
least
delay
fp
fp
challeng
gramneg
pathogen
exhibit
signific
p
delay
bacteri
growth
day
growth
e
coli
p
aeruginosa
recov
day
growth
baumannii
significantli
p
inhibit
throughout
fp
challeng
gramposit
pathogen
exhibit
signific
p
reduct
bacteri
growth
rel
plt
aliquot
bacteri
growth
correl
plt
lactat
product
lactat
level
plt
challeng
e
coli
show
diminish
significantli
day
indic
lactat
util
except
fp
challeng
aureu
bacteri
growth
restor
fp
supplement
lactic
acid
challeng
group
summaryconclus
refriger
preserv
platelet
function
inhibit
bacteri
growth
lactat
product
convers
opposit
observ
rt
storag
data
demonstr
bacteri
growth
control
refriger
without
loss
function
rt
storag
may
potenti
growth
certain
bacteri
strain
acceler
plt
metabol
background
bacteri
contamin
peripher
blood
progenitor
cell
pbpc
transfus
caus
seriou
sepsi
lifethreaten
infect
howev
standard
procedur
choic
test
sampl
establish
screen
pbpc
product
microbi
contamin
product
larg
enough
facilit
inocul
recommend
volum
autom
blood
cultur
system
sampl
taken
byproduct
plasma
low
volum
pbpc
product
cultur
routin
steril
test
aim
evalu
residu
risk
microbi
contamin
pbpc
product
transplant
cultur
suffici
postthaw
inocul
volum
pbpc
product
discard
variou
reason
blood
center
method
routin
steril
test
sampl
byproduct
plasma
collect
pbpc
product
inocul
bactalert
bpa
bpn
cultur
bottl
ml
within
h
collect
bottl
place
bact
alert
system
incub
least
day
posit
reaction
indic
autom
liquidmedia
cultur
system
moreov
postthaw
sampl
would
cultur
transplant
perform
residu
risk
investig
discard
pbpc
product
thaw
aliquot
taken
cultur
method
posit
bottl
subcultur
bacteri
isol
identif
result
septemb
march
maintain
liquid
nitrogen
year
pbpc
product
collect
patient
preserv
volum
ml
discard
product
cultur
neg
routin
steril
test
plasma
sampl
final
product
thaw
cultur
aliquot
one
pbpc
product
posit
cultur
result
retest
sampl
nevertheless
pbpc
product
neg
result
postthaw
pbpc
sampl
byproduct
plasma
sampl
propionibacterium
acn
isol
bpn
posit
bottl
summaryconclus
residu
risk
microbi
contamin
pbpc
postthaw
product
still
exist
routin
steril
test
plasma
sampl
volum
pbpc
sampl
bacterium
isol
pbpc
product
normal
skin
flora
bacterium
optim
screen
method
pbpc
product
merit
studi
increas
safeti
blood
suppli
background
hospit
hygien
tool
serv
proxi
assess
microbi
contamin
increasingli
use
includ
adenosin
triphosph
atp
bioluminesc
air
particl
count
howev
use
microbi
monitor
blood
bank
remain
underexplor
could
particular
interest
subsaharan
african
set
temperatur
dust
circumv
bacteri
cultur
provid
direct
result
usabl
monitor
time
aim
aim
studi
quantifi
environment
bacteria
air
surfac
regularli
contact
blood
product
ii
evalu
atp
bioluminesc
techniqu
particl
count
predictor
bacteri
contamin
three
blood
bank
democrat
republ
congo
drc
method
sampl
taken
three
blood
bank
democrat
republ
congo
p
ediatriqu
de
kalembelemb
hpkll
surfac
air
provinci
g
en
eral
de
r
ef
erenc
hpgrk
surfac
air
nation
blood
transfus
centr
cnt
surfac
air
surfac
regularli
contact
blood
product
select
sealer
fridg
donor
chair
regular
surfac
sampl
use
rodac
contact
plate
contain
cled
macconkey
agar
irregular
surfac
use
swab
nrsii
medicalwir
atp
measur
surfac
kikkoman
express
rel
light
unit
rlu
per
air
sampl
activ
sampl
liter
spinair
iul
cled
macconkey
medium
parallel
particl
lm
lm
count
use
particl
counter
liter
meton
cultur
media
incub
h
count
coloni
form
unit
cfu
result
regular
surfac
median
rang
viabl
bacteri
count
cfurodac
cfurodac
cfurodac
hpkll
cnt
hpgrk
respect
hpkll
highest
viabl
count
found
sink
plain
growth
cool
box
cfurodac
cnt
blood
process
bench
donor
chair
arm
support
wash
basin
show
highest
count
plain
growth
wherea
hpgrk
bacteria
found
fridg
plain
growth
blood
bag
trolley
plain
growth
manual
separ
cfu
rodac
gramneg
bacilli
isol
water
basin
sink
cnt
hpkll
also
surfac
close
donor
chair
hpgrk
median
rang
atp
per
rlu
hpkll
rlu
cnt
hpgrk
atp
result
total
viabl
count
correl
n
p
median
rang
bacteri
count
air
site
togeth
correl
found
total
bacteri
count
particl
lm
lm
r
r
respect
p
n
summaryconclus
total
viabl
bacteri
count
surfac
vari
blood
bank
site
accord
result
atp
particl
count
correl
bacteri
count
surfac
air
respect
bacteri
isol
blood
bank
environ
drc
need
identifi
season
variat
need
evalu
background
risk
transfusiontransmit
hepat
e
viru
tthev
infect
line
question
necess
hevnat
screen
blood
product
current
subject
ongo
debat
import
time
introduct
hev
screen
blood
donor
impact
blood
safeti
differ
countri
chosen
differ
regulatori
approach
recent
german
feder
author
introduc
mandatori
test
therapeut
blood
product
begin
januari
howev
alreadi
decid
voluntarili
test
blood
product
sinc
januari
aim
studi
present
result
screen
therapeut
blood
product
hev
rna
includ
four
year
activ
surveil
hepat
e
infect
among
blood
donor
germani
method
januari
decemb
total
allogen
blood
donat
individu
german
blood
donor
screen
minipool
format
sampl
presenc
hev
rna
realstar
hev
rtpcr
kit
altona
diagnost
technolog
adt
hamburg
germani
nucleic
acid
extract
ml
plasma
use
chemagen
msmi
extractor
viral
perkin
elmer
chemagen
gmbh
lod
assay
determin
iuml
iuml
per
singl
donat
presenc
hevspecif
igm
igg
antibodi
determin
use
antihev
igmigg
elisa
euroimmun
luebeck
hev
rna
concentr
quantifi
use
first
intern
standard
hepat
e
viru
rna
natbas
assay
hev
rna
posit
donor
defer
donat
month
followup
sampl
test
presenc
hev
rna
hevspecif
antibodi
genotyp
perform
sequenc
hypervari
region
hvr
result
total
hev
rna
posit
donor
identifi
hev
rnaposit
donor
natonli
posit
donat
neg
antihev
igm
antihev
igg
three
donor
posit
igm
titer
donor
show
reactiv
igm
igg
titer
donor
alreadi
isol
igg
titer
median
valu
viral
load
approxim
twice
high
index
donat
antibodi
neg
mere
donor
show
elev
alt
level
mostli
within
doubl
increas
within
refer
rang
donor
even
elev
alt
level
significantli
higher
alt
valu
found
donor
viral
load
iuml
compar
group
viral
load
iuml
avail
followup
sampl
confirm
igg
seroconvers
donor
howev
also
observ
longterm
igm
posit
donor
genotyp
reveal
genotyp
case
monthdepend
incid
rang
blood
donat
peak
june
juli
summaryconclus
high
number
identifi
hev
rna
posit
donor
emphas
need
hevnat
screen
increas
safeti
blood
product
studi
confirm
hev
infect
common
german
blood
donor
background
zika
viru
zikv
mosquitoborn
viru
caus
outbreak
central
south
america
februari
threaten
safeti
blood
transfus
global
high
risk
zikv
transmiss
whole
blood
blood
compon
transfus
report
zikv
rna
infect
patient
plasma
detect
within
week
howev
whole
blood
zikv
rna
might
present
posit
day
symptom
appear
patient
even
clinic
symptom
disappear
zikv
rna
neg
plasma
phenomenon
suggest
presenc
zika
associ
red
blood
cell
rbc
moreov
anoth
report
show
viral
load
whole
blood
type
west
nile
viru
wnv
patient
higher
type
impli
bind
viru
rbc
may
relat
blood
group
glycoprotein
zikv
wnv
member
flaviviru
genu
studi
intend
explor
whether
zikv
adher
mechan
rbc
wnv
aim
investig
distribut
zikv
blood
compon
adher
zikv
differ
blood
type
rbc
whole
blood
method
five
unit
blood
type
b
ab
whole
blood
randomli
select
unit
ml
whole
blood
divid
two
halfunit
zikv
ad
one
halfunit
certain
proport
incub
day
compon
whole
blood
collect
viral
load
detect
halfunit
rbc
suspend
type
pool
plasma
equal
volum
plasma
remov
whole
blood
centrifug
zikv
ad
certain
proport
incub
day
whole
blood
sampl
upper
plasma
centrifug
collect
detect
zikv
rna
meanwhil
rbc
wash
resuspend
normal
salin
follow
viral
load
detect
result
zika
rna
sampl
extract
whole
blood
rbc
plasma
determin
quantit
revers
transcript
pcr
viral
rna
compon
copiesml
although
zikv
rna
load
show
signific
differ
distribut
rbc
correspond
plasma
compon
zikv
rna
quantif
significantli
higher
plasma
p
type
rbc
lower
plasma
p
type
ab
rbc
summaryconclus
studi
detect
high
viral
rna
load
rbc
demonstr
zikv
adher
erythrocyt
whole
blood
blood
type
may
influenc
adher
background
hong
kong
endem
dengu
viru
denv
document
case
import
presenc
suffici
number
mosquito
vector
aed
albopictu
territori
led
two
selflimit
indigen
outbreak
affect
resid
august
septemb
anoth
outbreak
confirm
case
autochthon
dengu
fever
report
depart
health
link
two
epidemiolog
cluster
one
lion
rock
park
near
wong
tai
sin
wt
district
case
cheung
chau
outli
island
case
aim
assess
risk
dengu
transmiss
blood
donor
outbreak
use
simplifi
version
probabilist
model
develop
biggerstaff
petersen
bp
european
upfront
risk
assess
tool
eufrat
model
oei
transfus
method
patient
demograph
gener
popul
data
obtain
centr
health
protect
depart
censu
statist
hong
kong
govern
number
patient
outbreak
resid
age
rang
hong
kong
wt
district
respect
year
old
elig
age
rang
first
time
donat
appli
bp
model
estim
denv
incid
among
donor
hong
kong
territori
wt
confirm
denv
infect
august
septemb
correct
clinic
subclin
infect
ratio
mean
length
asymptomat
viraemia
probabl
collect
blood
asymptomat
donor
describ
previous
seed
transfus
estim
risk
use
eufrat
model
outbreak
blood
donat
variabl
enter
eufrat
webbas
interfac
http
eufrattoolecdceuropaeu
provid
automat
calcul
riskrel
output
paramet
result
use
bp
model
estim
risk
collect
denv
viraem
donat
one
territorywid
studi
period
increas
one
wt
similarli
appli
eufrat
model
risk
encount
viraem
donor
territorywid
wt
period
eufrat
also
predict
territorywid
issu
unit
denvcontamin
labil
blood
compon
outbreak
period
summaryconclus
like
mani
mosquitoborn
infect
denv
risk
characterist
localis
vari
geograph
season
outbreak
averag
predict
risk
collect
denvviraem
donat
territorywid
low
outbreak
base
bp
model
gener
consid
toler
howev
risk
increas
fold
blood
donat
collect
wt
resid
higher
chanc
pay
visit
lion
rock
park
close
proxim
justifi
institut
risk
mitig
polici
geographicallybas
deferr
andor
fresh
compon
restrict
enhanc
postdon
report
etc
protect
blood
safeti
background
hev
develop
threat
blood
safeti
follow
report
sever
case
transfus
transmiss
hev
tthev
transfusionrel
hev
infect
report
sever
countri
true
frequenc
probabl
underestim
often
asymptomat
test
blood
donor
infrequ
pakistan
classifi
highli
endem
region
sporad
case
hev
occur
throughout
year
mainli
affect
adult
popul
best
knowledg
studi
report
pakistan
epidemiolog
hev
blood
donor
aim
assess
epidemiolog
hev
specif
antibodi
serum
alt
level
blood
donor
capit
twin
citi
pakistan
method
cross
section
studi
conduct
juli
decemb
three
blood
bank
capit
twin
citi
rawalpindi
islamabad
pakistan
blood
donor
equal
distribut
across
three
blood
bank
donor
test
neg
hiv
hbv
hcv
includ
studi
serum
alt
level
analyz
use
autom
clinic
chemistri
analyz
selctra
pro
use
merck
kit
sampl
test
hevspecif
antibodi
igm
igg
use
enzym
link
immunosorb
assay
elisa
kit
adalti
itali
statist
analys
perform
use
spss
softwar
version
ibm
result
studi
popul
male
femal
mean
age
recruit
blood
donor
sd
ae
rang
younger
donor
common
frequenc
year
old
found
overal
hev
igg
preval
hev
igm
preval
blood
donor
posit
igg
igm
antibodi
result
reveal
hev
specif
antibodi
igg
igm
preval
increas
age
mean
valu
serum
alt
sd
ae
rang
iul
serum
alt
level
elev
iul
blood
donor
signific
correl
p
serum
alt
level
hev
specif
antibodi
igg
igm
summaryconclus
studi
show
signific
proport
blood
donor
blood
center
infect
hev
may
abl
caus
tthev
yet
measur
hev
rna
use
igm
antibodi
proxi
donor
activ
infect
hev
gener
asymptomat
debat
whether
mandatori
hev
screen
blood
donor
requir
result
pilot
studi
show
need
conduct
larger
studi
nation
level
highli
sensit
assay
make
screen
hev
mandatori
pakistan
background
hepat
e
viru
hev
zoonot
viru
estim
million
hev
infect
million
acut
hev
case
thousand
hevrel
death
worldwid
year
recent
year
preval
hev
european
american
countri
increas
significantli
survey
result
show
posit
rate
hev
igg
blood
donor
respect
new
zealand
britain
denmark
unit
state
netherland
hev
becom
global
public
health
concern
addit
food
rout
infect
sever
case
report
hev
transmit
via
blood
product
aim
investig
preval
hepat
e
viru
hev
infect
among
voluntari
blood
donor
potenti
impact
blood
safeti
guangzhou
china
method
blood
sampl
blood
donor
collect
april
april
guangzhou
blood
center
test
antihev
igg
antibodi
hev
igg
antihev
igm
antibodi
hev
igm
hev
antigen
hev
ag
enzym
link
immunosorb
assay
elisa
hev
rna
detect
perform
hev
antigen
posit
sampl
rtpcr
associ
age
gender
ethnic
occup
alt
hev
igg
igm
analyz
chisquar
test
multivari
logist
regress
analysi
appli
identifi
independ
risk
factor
hev
infect
result
posit
rate
hev
igg
igm
hev
ag
respect
posit
hev
rna
detect
age
ethnic
independ
risk
factor
hev
igg
hev
igm
rate
hev
antibodi
increas
significantli
age
igg
p
igm
p
donor
zhuang
minor
show
higher
antihev
han
ethnic
differ
statist
signific
igg
p
igm
p
addit
found
occup
independ
risk
factor
hev
infect
student
show
lowest
antihev
rate
summaryconclus
result
indic
posit
rate
hev
antibodi
among
blood
donor
guangzhou
high
infect
statu
differ
differ
popul
studi
provid
basic
data
estim
risk
transfusiontransmit
hev
background
human
cytomegaloviru
hcmv
belong
viral
famili
herpesvirida
envelop
doublestrand
dna
viru
wide
distribut
human
popul
seroposit
subject
worldwid
caus
sever
diseas
immunocompromis
patient
upon
infect
foetu
normal
healthi
subject
hcmv
persist
lifelong
without
clinic
manifest
undergo
altern
phase
activ
viral
replic
latenc
sinc
hcmv
readili
detect
blood
free
viru
well
associ
neutrophil
monocyt
hcmv
transmiss
complic
blood
transfus
even
though
leukoreduct
blood
product
shown
significantli
reduc
risk
hcmv
transmiss
higher
inactiv
standard
may
requir
highrisk
immunocompromis
group
patient
aim
studi
murin
macrophag
infect
murin
cytomegaloviru
mcmv
use
model
studi
inactiv
cellassoci
cmv
human
plasma
use
theraflex
mbplasma
system
macopharma
method
mcmv
express
green
fluoresc
protein
use
infect
murin
macrophag
infect
macrophag
harvest
h
infect
wash
use
spike
plasma
plasma
unit
n
ml
spike
infect
cell
suspens
vv
treat
theraflex
mbplasma
system
accord
manufactur
protocol
use
illumin
devic
macopharma
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
addit
mb
standard
jcm
blueflex
filtrat
mcmv
titer
determin
endpoint
titrat
larg
volum
plate
murin
fibroblast
infecti
viru
express
gfp
infect
cell
detect
use
fluoresc
microscop
result
result
infect
assay
show
treatment
human
plasma
theraflex
mbplasma
system
inactiv
cellassoci
mcmv
dosedepend
manner
spike
mcmv
infect
macrophag
mcmv
titer
bag
bag
log
tcid
ml
achiev
plasma
unit
hold
sampl
mcmv
titer
bag
bag
log
tcid
ml
determin
illumin
step
theraflex
mbplasma
treatment
procedur
effici
inactiv
mcmv
alreadi
threefourth
standard
light
dose
decreas
infect
cell
associ
remain
cellfre
mcmv
infect
level
limit
detect
log
investig
would
need
evalu
log
reduct
capac
blueflex
filtrat
step
cellassoci
mcmv
summaryconclus
result
murin
model
viru
suggest
theraflex
mbplasma
system
effect
technolog
inactiv
cellassoci
cmv
human
plasma
unit
background
use
pathogen
inactiv
pi
technolog
platelet
concentr
plasma
slowli
steadili
increas
method
treatment
red
blood
cell
rbc
commonli
use
blood
compon
still
develop
aim
novel
approach
pi
rbc
unit
employ
uvc
light
develop
method
pi
treatment
appli
fullscal
rbc
unit
leukodeplet
pi
capac
uvcbas
method
evalu
bacteria
viru
infect
assay
panel
vitro
assay
measur
qualiti
metabol
function
morpholog
blood
group
serolog
variabl
appli
poolandsplit
approach
pathogenreduc
rbc
investig
comparison
untreat
rbc
result
uvc
treatment
caus
dosedepend
inactiv
bacteria
envelop
nonenvelop
virus
rbc
unit
full
dose
mean
log
reduct
factor
rang
bacillu
cereu
serratia
liquefacien
test
bacteria
emcv
vsv
test
virus
uvc
treatment
alter
rbc
blood
group
antigen
express
qualiti
uvctreat
rbc
maintain
storag
eg
hemolysi
uvctreat
untreat
rbc
well
day
storag
summaryconclus
data
obtain
show
uvc
irradi
potenti
new
method
pi
rbc
justifi
develop
process
background
histoblood
abh
antigen
mayor
allogen
antigen
human
wide
distribut
almost
tissu
express
encod
gene
determin
secretor
statu
individu
caucasian
popul
function
copi
secretor
gene
express
abh
blood
group
solubl
antigen
organ
fluid
saliva
semin
plasma
individu
known
secretor
solubl
abh
blood
group
antigen
associ
sever
metabol
infecti
diseas
well
reproduct
failur
incid
infertil
relat
male
femal
factor
continu
rise
despit
mani
advanc
reproduct
technolog
well
known
abo
antigen
express
sperm
membran
semin
fluid
secretor
well
abo
antibodi
present
cervic
mucu
previou
studi
observ
signific
loss
progress
motil
spermatozoa
nonsecretor
compar
secretor
one
caus
specif
cervic
mucu
antibodi
aboincompat
coupl
addit
sperm
cell
haploid
cell
heterozyg
individu
two
sperm
subpopul
express
correspond
allel
specif
antibodi
cervic
mucu
attack
complementari
sperm
aim
evalu
preval
secretor
charact
men
belong
fertil
infertil
coupl
order
investig
possibl
associ
reproduct
success
method
sampl
semen
infertil
men
fertil
control
studi
comprehens
infertil
evalu
perform
patient
accord
criteria
secretor
phenotyp
evalu
semin
plasma
inhibit
hemagglutin
assay
use
salin
erythrocyt
suspens
monoclon
antibodi
antia
antib
lectin
ulex
europaeu
antih
distinguish
abo
gene
genom
dna
extract
enzymat
digest
method
pcr
design
two
set
oligonucleotid
allow
amplif
two
differ
region
transferas
without
use
restrict
enzym
comparison
band
pcr
product
individu
genotyp
determin
cervic
mucu
antibodi
femal
partner
titrat
correspond
red
blood
cell
result
result
analys
group
infertil
coupl
abo
incompat
frequenc
nonsecretor
phenotyp
male
partner
significantli
higher
fertil
coupl
p
result
obtain
pcr
sperm
cell
correl
red
cell
phenotyp
summaryconclus
incid
infertil
continu
increas
sever
factor
neg
impact
men
reproduct
health
immunolog
implic
studi
consid
caus
failur
spermegg
interact
even
among
normal
gamet
secretor
phenotyp
male
partner
could
help
reproduct
success
block
cervic
abo
antibodi
furthermor
male
heterozyg
cervic
mucu
antibodi
affect
correspond
sperm
propos
evalu
abh
antigen
express
sperm
membran
semin
plasma
well
abo
antibodi
cervic
mucu
contribut
diagnosi
treatment
human
infertil
background
h
blood
group
contain
one
antigen
h
antigen
present
virtual
red
blood
cell
rbc
acceptor
substrat
b
genespecifi
glycosyltransferas
blood
group
h
antigen
remain
unmodifi
therefor
rbc
show
highest
rbc
blood
type
ab
least
amount
h
antigen
individu
call
bombay
phenotyp
carri
homozyg
h
null
allel
h
h
produc
h
antigen
parabombay
phenotyp
retain
h
antigen
rbc
either
induc
weakli
activ
h
w
h
w
complet
silenc
gene
h
h
mandatori
link
activ
gene
aim
studi
aim
develop
adapt
flow
cytometr
method
quantifi
rel
amount
h
substanc
present
rbc
order
distinguish
differ
abo
phenotyp
routin
diagnost
well
captur
rare
hdefici
phenotyp
method
analys
perform
flow
cytomet
fac
canto
ii
bd
bioscienc
ch
measur
ident
instrument
set
list
mode
data
evalu
visualis
use
bd
facsdiva
softwar
rbc
incub
increas
concentr
monoclon
antih
antibodi
mixtur
ibgrl
uk
rins
cell
pb
microaggreg
mechan
dissolv
rbc
blood
donor
differ
abo
phenotyp
b
b
b
patient
genet
confirm
bombay
parabombay
phenotyp
assess
result
satur
h
antigen
bind
site
type
rbc
achiev
upon
use
antibodi
mixtur
cover
approx
half
hbind
site
unconjug
contrast
nono
type
rbc
reach
satur
hbind
site
use
pure
rbc
coat
satur
reveal
distinct
pattern
mfi
mean
fluoresc
intens
depend
abo
phenotyp
addit
mfi
rbc
upon
stain
discrimin
bombayand
parabombay
type
rbc
respect
summaryconclus
adapt
flow
cytometri
abl
distinguish
variant
express
rbc
h
antigen
thu
flow
cytometr
method
may
complement
tradit
serolog
genet
analys
routin
abo
phenotyp
case
intrigu
bombay
parabombay
phenotyp
suspect
interest
prove
method
investig
addit
rare
hdefici
phenotyp
case
chen
x
xu
x
hong
k
j
j
chen
f
zhu
blood
centr
zhejiang
provinc
zhejiang
provinci
key
laboratori
blood
safeti
research
hangzhou
china
background
weaken
b
antigen
express
result
abo
type
discrep
h
gene
control
develop
h
substanc
b
antigen
develop
depress
b
antigen
express
strengthen
h
antigen
express
alway
simultan
observ
abo
subgroup
possibl
weak
antigen
express
abo
system
leukem
chang
pregnanc
undiscov
whether
abnorm
express
b
h
antigen
stand
abo
subgroup
hemopath
patient
aim
aim
studi
explor
role
enhanc
reaction
antih
direct
abo
subgroup
hemopath
patient
method
sampl
blood
donor
hemopath
patient
nonconcord
abo
type
serolog
test
collect
consent
inform
agglutin
strength
rbc
antih
reagent
record
enhanc
reaction
determin
comparison
result
normal
abo
group
genom
dna
sampl
extract
genotyp
abo
system
work
sponsor
medic
scienc
research
foundat
zhejiang
provinc
result
sampl
blood
donor
show
increas
express
h
antigen
identifi
abo
subgroup
enhanc
reaction
hemopath
patient
howev
final
confirm
normal
abo
genotyp
statist
signific
vs
p
frequenc
strengthen
h
antigen
express
observ
donor
hemopath
patient
total
number
subgroup
respect
blood
donor
hemopath
patient
extrem
signific
statist
differ
vs
p
exist
frequenc
subgroup
enhanc
h
antigen
meant
possibl
subgroup
hemopath
patient
sampl
less
summaryconclus
express
h
antigen
compar
enhanc
subgroup
hemopathi
hemopath
patient
strengthen
h
antigen
express
present
normal
abo
genotyp
result
enhanc
reaction
antih
necessari
suffici
serolog
identif
abo
subgroup
hemopath
patient
background
although
use
autom
blood
bank
analyz
advantag
speed
effici
recent
increas
abo
discrep
autom
blood
bank
analyz
caus
report
delay
result
increas
task
aim
analyz
caus
abo
discrep
autom
blood
bank
analyz
suggest
solut
strategi
base
caus
method
novemb
januari
case
abo
discrep
among
abo
blood
type
test
perform
use
reaction
mode
chonbuk
nation
univers
hospit
blood
bank
identifi
compar
test
result
mode
result
immedi
mode
use
differ
red
cell
reagent
analyz
caus
discrep
perform
addit
test
microscopi
autocontrol
antibodi
screen
identif
abo
genotyp
result
immedi
reaction
use
differ
red
cell
reagent
case
discrep
disappear
case
remain
discrep
abo
discrep
observ
reaction
due
serum
side
caus
one
case
due
serum
red
cell
side
caus
nonspecif
respons
case
cold
antibodi
case
rouleaux
format
case
cisab
case
abo
subtyp
case
analyz
caus
discrep
one
discrep
due
cisab
disappear
immedi
reaction
use
differ
red
cell
reagent
abo
subtyp
chang
total
differ
blood
group
hand
case
discrep
correct
immedi
reaction
use
differ
red
cell
reagent
intens
posit
result
still
observ
immedi
reaction
differ
reaction
summaryconclus
autom
blood
bank
analyz
consid
use
autom
abo
blood
type
observ
abo
discrep
expect
mostli
address
reexamin
immedi
reaction
mode
use
differ
red
cell
reagent
abstract
withdrawn
background
abo
blood
group
antigen
mainli
express
red
blood
cell
along
also
present
mani
organ
tissu
like
epithelia
platelet
vascular
endothelia
neuron
etc
import
abo
antigen
extend
beyond
transfus
medicin
associ
variou
system
diseas
like
cardiovascular
diseas
gastric
diseas
cancer
infecti
diseas
etc
proven
previous
previou
research
also
tri
find
involv
abo
antigen
neurolog
diseas
like
alzheim
diseas
parkinson
diseas
etc
associ
neurolog
tumour
less
explor
aim
studi
aim
analys
associ
abo
blood
group
antigen
neurolog
tumour
method
retrospect
studi
tertiari
care
institut
india
analys
year
data
jan
dec
carcinoma
patient
admit
neurosurg
depart
studi
period
includ
studi
diagnosi
abo
blood
group
collect
hospit
inform
system
data
analys
microsoft
excel
spss
version
result
studi
period
total
patient
neurolog
tumour
admit
hospit
blood
group
frequenc
patient
b
ab
respect
common
neurolog
tumour
found
studi
glioma
follow
pituitari
adenoma
meningioma
schwannoma
cavernoma
neuroma
space
occupi
lesion
preval
abo
antigen
almost
similar
neurolog
tumour
except
neuroma
neuroma
found
group
patient
compar
blood
group
found
statist
signific
p
summaryconclus
studi
tri
analys
associ
neurolog
tumour
abo
blood
group
antigen
found
associ
neurolog
tumour
abo
blood
group
preval
abo
group
gener
popul
almost
similar
patient
neurolog
tumour
except
neuroma
neuroma
group
tumour
like
neurofibroma
neuroblastoma
nerv
tumour
etc
common
group
patient
popul
frequenc
b
blood
group
antigen
common
compar
blood
group
background
rhd
rhce
repres
homolog
gene
headtohead
posit
chromosom
encod
protein
rhd
resp
rhce
compos
togeth
rhesu
associ
glycoprotein
rhag
band
ankyrin
ankyrin
complex
ac
link
red
blood
cell
rbc
membran
aspectrin
rbc
cytoskeleton
se
lux
blood
cooper
protein
ac
import
matur
physiolog
properti
rbc
mani
protein
rbc
membran
express
blood
group
antigen
extracellular
surfac
therefor
concern
transfus
medicin
cepellini
et
al
describ
weaken
hemagglutin
reaction
rhd
rbc
presenc
rhc
antigen
cepellini
et
al
pna
attempt
elucid
express
rhdrhag
protein
variou
rhcerhc
phenogenotyp
use
sophist
flow
cytometri
approach
aim
studi
investig
flow
cytometr
method
measur
antigendens
variou
rhcephenotyp
method
analysi
perform
flow
cytomet
facscanto
ii
becton
dickinson
bd
use
bd
facsdiva
softwar
ident
instrument
set
sampl
optim
number
rbc
incub
satur
concentr
peconjug
antirhd
antibodi
ibgrl
bristol
uk
debri
exclud
rbc
gate
fscssc
plot
quantibritep
beat
bd
appli
accord
manufactur
instruct
quantifi
rel
express
rhd
epitop
addit
repres
number
sampl
common
phenotyp
assess
express
rhag
use
ibgrl
result
total
sampl
healthi
blood
donor
serolog
defin
rhcde
phenotyp
includ
studi
rr
variant
express
rhd
differ
rhce
phenotyp
use
shown
rhd
weakli
express
presenc
rhc
antigen
cepellini
effect
effect
rhd
gene
dose
rhd
protein
express
mitig
rhcc
genotyp
sampl
molecularli
confirm
phenotyp
assess
rhdce
genotyp
predict
consist
strength
rhd
protein
express
outlier
sampl
retrospect
genotyp
reveal
rhdce
genotyp
expect
strength
rhd
express
falsifi
serolog
rhcde
phenotyp
contrast
rhee
polymorph
site
correl
rhd
express
addit
rhag
protein
equal
present
across
rhcde
phenotyp
similar
result
obtain
use
altern
antid
antibodi
although
differ
antibodi
avid
preclud
quantit
comparison
antigen
express
rbc
summaryconclus
sophist
fac
method
reveal
differ
express
rhd
rbc
accord
rhcerhc
phenotypegenotyp
rhcc
polymorph
site
c
g
g
exon
exon
resp
intron
linkag
rhd
express
confirm
observ
cepellini
et
al
contrast
rhee
g
exon
linkag
rhd
express
base
epigenom
signatur
conceiv
alter
transcript
factor
bind
site
tb
rhd
mirror
homolog
rhcc
may
caus
variant
rhd
express
rhee
snp
mirror
homolog
sequenc
rhd
exon
recognis
tb
addit
although
ac
compris
three
rh
protein
rhd
rhce
rhag
transcript
regul
seem
distinct
red
cell
refer
laboratori
australian
red
cross
blood
servic
perth
australia
background
antigen
first
describ
antisera
thought
contain
potent
antic
react
c
cell
nonreact
c
cell
classifi
c
rh
antibodi
specif
polyclon
antic
contain
antic
previou
studi
shown
monoclon
antic
reagent
actual
reagent
detect
c
antigen
red
cell
rh
aim
australian
red
cross
blood
servic
investig
phenotyp
discrep
blood
donor
donor
histor
phenotyp
c
r
r
inconsist
current
donat
phenotyp
c
r
r
aim
investig
caus
discrep
donor
could
assign
correct
phenotyp
identifi
root
caus
discrep
implement
correct
action
method
donor
red
cell
phenotyp
avail
antic
reagent
per
manufactur
product
insert
across
manual
autom
test
platform
follow
variabl
result
weaker
reaction
reagent
dna
extract
edta
sampl
genotyp
use
immucor
bioarray
tm
hea
precis
rhce
beadchip
tm
target
dna
sequenc
rhd
rhce
also
perform
use
trusight
tm
one
sequenc
panel
review
histor
phenotyp
result
includ
test
platform
reagent
use
time
also
perform
result
current
sampl
donor
red
cell
gave
reaction
tube
biorad
seraclon
clone
immulab
epiclon
tm
clone
antic
reagent
sampl
test
neg
beckman
coulter
use
beckman
coulter
antic
clone
blood
group
reagent
test
posit
reaction
immucor
neo
use
immuclon
antic
clone
immucor
bioarray
tm
hea
precis
beadchip
tm
predict
c
phenotyp
variant
detect
bioarray
tm
rhce
beadchip
tm
trusight
tm
one
sequenc
panel
genotyp
donor
rhd
rhce
predict
phenotyp
c
c
w
e
e
locr
rh
review
donor
histor
record
indic
donor
test
c
time
use
inhous
bromelain
prepar
sigmaaldrich
diagast
olymp
pheno
antic
reagent
clone
summaryconclus
result
indic
phenotyp
discrep
caus
c
rh
variant
associ
rhce
allel
reagent
contain
clone
correctli
phenotyp
donor
c
manual
tube
reagent
show
weaker
reaction
may
alert
oper
possibl
variant
import
patient
set
beckman
coulter
associ
antic
clone
fail
detect
c
antigen
reagent
appear
detect
c
antigen
associ
rh
phenotyp
contrast
previou
report
faa
et
al
transfus
demonstr
clone
react
c
rh
bromelain
treat
red
cell
abstract
withdrawn
background
although
serolog
rhd
type
alway
challeng
due
variat
techniqu
variabl
sensit
antid
reagent
individu
unequivoc
type
either
rhd
posit
rhd
neg
howev
variant
weak
partial
phenotyp
may
present
type
difficulti
individu
partial
miss
epitop
antigen
must
type
rhd
neg
blood
receiv
rhd
posit
blood
donor
aim
aim
studi
evalu
algorithm
use
sinc
ahepa
univers
blood
center
resolv
rhd
type
problem
among
first
time
donor
method
sinc
automat
analyz
may
type
variant
rhd
rhd
practic
routin
perform
two
differ
type
method
first
time
donor
autom
micropl
method
neo
analyz
immucor
slide
test
use
potent
reagent
antid
blendimmunodiagnostika
case
neg
weak
slow
mixedfield
reaction
test
autom
micropl
weak
method
immucormodifi
indirect
antiglobulin
antiigg
test
follow
next
step
protocol
consist
test
commerci
idparti
rhd
type
kit
biorad
compris
panel
monoclon
antid
reagent
indirect
coomb
gel
test
assay
pattern
obtain
kit
distinguish
weak
partial
also
differenti
categori
ii
iv
v
vi
vii
dfr
dbt
dhar
last
step
algorithm
consist
molecular
test
immucor
bioarray
rhce
rhd
beadchip
assay
hellen
nation
blood
transfus
center
case
remain
uncertainti
result
appli
algorithm
sampl
use
partial
kit
sampl
type
four
sampl
character
partial
dfr
weak
four
weak
sampl
women
reproduct
age
confirm
molecular
type
weak
type
three
sampl
weak
type
one
sampl
b
nine
remain
sampl
show
atyp
serolog
pattern
sent
molecular
test
character
sampl
weak
type
one
sampl
weak
type
anoth
weak
type
result
pend
sampl
summaryconclus
experi
partial
rhd
may
mistyp
rhd
technologist
inspect
pattern
reaction
take
account
assign
automat
analyz
use
algorithm
serolog
character
suffici
distinguish
weak
partial
case
molecular
type
necessari
rest
integr
molecular
techniqu
improv
qualiti
accuraci
type
blood
donor
appli
patient
also
allow
administr
posit
blood
without
compromis
safeti
carri
preval
weak
type
report
produc
antid
furthermor
permit
withhold
rhig
case
pregnant
women
carri
weak
type
background
rhd
antigen
one
clinic
signific
blood
group
antigen
except
posit
neg
phenotyp
rhd
variant
repres
serolog
weak
phenotyp
swd
patient
certain
swd
make
antid
alloantibodi
serolog
test
possibl
clearli
distinguish
among
differ
swd
croatian
institut
transfus
medicin
citm
patient
pregnant
femal
swd
mostli
report
rhd
neg
gener
refer
confirm
molecular
test
part
algorithm
remain
risk
shortag
rhd
neg
blood
overus
antid
immunoprophylaxi
pregnant
femal
accord
uk
guidelin
patient
swd
like
requir
chronic
transfus
support
femal
year
treat
neg
refer
confirm
type
peopl
rhd
genotyp
weak
type
suscept
rhd
alloimmunis
one
studi
show
croatian
popul
frequent
variant
weak
type
aim
aim
studi
estim
preval
swd
patient
pregnant
femal
find
serolog
molecular
characterist
swd
refer
confirm
method
analys
sampl
patient
pregnant
femal
rhd
type
perform
antid
igm
monoclon
reagent
direct
agglutin
micromethod
tango
biorad
dreieich
germani
swing
maestro
lmh
lmh
idcard
biorad
cressier
switzerland
cutoff
valu
tango
determin
gel
microtyp
sampl
result
cutoff
report
treat
rhd
neg
except
gave
discrep
result
current
test
histor
data
sent
rhd
genotyp
confirm
dna
extract
done
qiaamp
blood
mini
kit
qiagen
hilden
germani
rhd
genotyp
pcrssp
kit
readi
geneweak
readi
genecd
innotrain
kronberg
im
taunu
germani
result
sampl
swd
refer
rhd
genotyp
sampl
weak
type
weak
type
partial
variant
vii
va
serolog
reaction
monoclon
igm
antid
reagent
show
differ
pattern
weak
type
clearli
neg
serolog
reaction
given
sampl
bs
bs
sampl
lmh
sampl
summaryconclus
preval
swd
studi
rather
low
rhd
genotyp
refer
sampl
final
report
posit
serolog
determin
variant
inconsist
rhd
genotyp
resolv
rhd
statu
swd
defin
perman
rhd
statu
swd
femal
childbear
potenti
patient
like
chronic
transfus
introduc
rhd
genotyp
new
algorithm
background
among
blood
group
system
antigen
abo
system
far
clinic
signific
come
second
import
antigen
rh
system
compris
c
e
c
e
antigen
anoth
clinic
relev
antigen
k
kell
blood
group
system
known
involv
htr
hdfn
distribut
major
blood
group
antigen
rh
kell
wellstudi
among
popul
develop
countri
contrari
rel
studi
address
frequenc
saudi
arabian
popul
also
case
jazan
provinc
two
publish
studi
analys
preval
abo
antigen
frequenc
clinic
import
antigen
rh
kell
antigen
yet
explor
aim
determin
frequenc
follow
clinic
relev
blood
group
antigen
rh
c
e
c
e
k
among
saudi
blood
donor
king
fahd
central
hospit
jazan
provinc
method
retrospect
crosssect
studi
carri
blood
bank
king
fahd
central
hospit
jazan
provinc
red
cell
phenotyp
record
blood
donat
randomli
select
saudi
donor
donat
blood
januari
june
review
identifi
preval
follow
antigen
c
e
c
e
k
hospit
blood
bank
routin
perform
phenotyp
blood
donat
use
either
biorad
ortho
diagnost
column
agglutin
technolog
cat
platform
phenotyp
frequenc
express
percentag
result
studi
includ
total
saudi
voluntari
well
famili
replac
blood
donor
antigen
found
posit
k
antigen
posit
among
studi
rh
antigen
e
common
follow
c
c
e
dcedc
dcedc
common
phenotyp
amongst
dposit
dneg
donor
respect
surprisingli
dcedc
phenotyp
significantli
preval
almost
time
higher
frequenc
compar
report
caucasian
rare
phenotyp
dcedc
found
donor
dcedc
dcedc
phenotyp
found
one
donor
summaryconclus
studi
first
determin
frequenc
rh
k
antigen
saudi
blood
donor
jazan
provinc
determin
frequenc
clinic
signific
antigen
geograph
area
facilit
select
antigenmatch
red
cell
unit
transfus
recipi
multipl
alloantibodi
also
help
manag
blood
donat
process
plan
estim
need
blood
stock
differ
blood
group
phenotyp
meet
patient
need
abstract
withdrawn
background
gerbich
ge
blood
group
system
includ
sever
highfrequ
antigen
locat
glycophorin
c
report
publish
clinic
signific
antibodi
direct
antigen
unclear
whether
blood
transfus
antigen
neg
presenc
antig
antibodi
monocyt
monolay
assay
mma
invitro
method
use
estim
clinic
signific
alloantibodi
aim
illustr
role
monocyt
monolay
assay
mma
transfus
manag
patient
antig
alloantibodi
method
clinic
transfus
histori
retrospect
retriev
patient
medic
record
serolog
investig
perform
indirect
antihuman
globulin
test
papain
trypsin
treat
cell
also
use
clinic
signific
antibodi
assess
mma
genom
dna
isol
whole
blood
sampl
character
pcr
result
male
patient
lung
cancer
without
previou
transfus
admit
surgeri
hemoglobin
gl
antig
antibodi
detect
decid
transfus
geposit
pack
red
blood
cell
prbc
howev
blood
transfus
need
juli
patient
admit
colon
cancer
surgeri
hemoglobin
gdl
antig
alloantibodi
still
detect
ssppcr
reveal
genotyp
ge
mma
perform
pretransfus
sampl
reveal
monocyt
index
mi
antibodi
consid
clinic
relev
mi
interpret
follow
signific
inconclus
clinic
signific
howev
due
clinic
background
patient
decid
transfus
geneg
prbc
obtain
etabliss
francai
du
sang
ef
pari
franc
two
day
surgeri
patient
receiv
unit
ge
prbc
without
transfus
reaction
one
half
year
later
periton
carcinomatosi
complic
colon
cancer
diagnos
patient
hemoglobin
gl
passag
disord
symptom
deterior
adynamia
base
mma
result
juli
indic
clinic
signific
antibodi
decid
transfus
geposit
prbc
follow
day
patient
receiv
total
unit
geposit
prbc
immedi
delay
transfus
reaction
observ
follow
transfus
two
mma
perform
sampl
drawn
decemb
th
th
day
transfus
total
three
two
day
two
prbc
respect
show
mi
und
respect
antig
antibodi
consid
still
clinic
signific
summaryconclus
report
case
patient
antig
antibodi
transfus
geposit
prbc
geneg
prbc
avail
switzerland
easi
obtain
intern
mma
help
decis
transfus
case
clinic
cours
confirm
mmabas
predict
transfus
geposit
prbc
toler
without
sign
symptom
immedi
delay
transfus
reaction
background
abo
group
discrep
occur
result
forward
group
corrobor
revers
group
may
due
weak
subgroup
b
miss
weak
abo
antibodi
red
cell
alloantibodi
determin
correct
abo
blood
group
donor
essenti
prevent
abo
incompat
transfus
avoid
hemolyt
transfus
reaction
recipi
aim
determin
frequenc
abo
discrep
resolut
correctli
identifi
blood
group
donor
also
determin
frequenc
weak
posit
rhd
neg
donor
method
retrospect
studi
donor
sampl
collect
st
april
th
septemb
two
half
year
discrep
sampl
abo
rhd
group
repeat
use
tube
techniqu
use
commerci
antisera
antia
antib
antiab
antid
igm
antid
blend
igmigg
antih
lectin
adsorptionelut
test
done
detect
weak
subgroup
b
antibodi
screen
identif
done
gel
techniqu
biorad
switzerland
weak
test
rhd
neg
donor
also
perform
gel
techniqu
antibodi
titrat
done
use
tube
techniqu
donor
detail
includ
name
age
registrationunit
number
donat
also
check
discrep
avoid
repetit
data
analysi
result
detect
abo
discrep
total
donor
sampl
test
studi
period
rhd
posit
common
caus
abo
discrep
weak
antib
antibodi
follow
weak
antia
antibodi
weak
subgroup
weak
subgroup
b
remain
discrep
due
agglutin
cell
revers
group
overal
frequenc
weak
subgroup
b
collect
background
detect
unexpect
red
blood
cell
rbc
antibodi
transfus
critic
prevent
hemolyt
transfus
reaction
ideal
unexpect
rbc
antibodi
detect
carri
within
day
receiv
patient
sampl
howev
case
retest
could
perform
day
evalu
transfus
reaction
qualiti
control
research
therefor
necessari
determin
stabil
antibodi
refriger
freez
certain
period
time
aim
carri
antibodi
identif
test
fresh
refriger
frozen
sampl
use
autom
analyz
manual
tube
method
evalu
stabil
antibodi
storag
compar
result
two
method
method
antibodi
identif
test
perform
use
biorad
cressier
fr
switzerland
manual
tube
method
fifti
sampl
show
posit
result
antibodi
screen
test
method
divid
three
test
immedi
week
storag
month
storag
specif
reactiv
antibodi
storag
state
record
compar
two
method
result
specif
antibodi
identifi
concord
manual
tube
method
irrespect
storag
state
result
follow
antieec
antil
antidi
antic
antim
antid
antic
antik
antijk
antixg
unidentifi
antibodi
autoantibodi
case
regard
chang
reactiv
owe
storag
sampl
antiec
antim
antidi
antid
antic
antil
antic
autoantibodi
unidentifi
antibodi
show
ident
reactiv
week
month
storag
tube
method
howev
sampl
compris
unidentifi
antibodi
antil
antic
anti
antiec
autoantibodi
show
decreas
reactiv
storag
method
three
sampl
compris
antidi
antiec
antik
antibodi
show
increas
reactiv
storag
one
sampl
antijk
show
increas
reactiv
month
storag
one
sampl
antixg
show
decreas
reactiv
month
storag
higher
reactiv
observ
sampl
detect
use
analyz
manual
tube
method
p
wilcoxon
rank
sum
test
summaryconclus
specif
unexpect
antibodi
detect
tube
method
storag
state
howev
reactiv
higher
tube
method
twentysix
sampl
show
ident
reactiv
week
refriger
month
freez
nineteen
sampl
show
decreas
reactiv
storag
howev
nonspecif
antibodi
unabl
identifi
use
commerci
id
panel
therefor
suggest
retest
evalu
transfus
reaction
qualiti
control
research
could
reliabl
perform
day
store
appropri
refriger
frozen
state
abstract
withdrawn
gleichnagel
hubermarcantonio
n
rufer
g
canellini
c
niederhaus
unit
transfus
medicin
interregion
blood
transfus
src
lausann
laboratori
diagnost
interregion
blood
transfus
src
bern
switzerland
background
posit
direct
antiglobulin
test
dat
mainli
found
patient
warmcold
autoantibodi
alloantibodi
direct
transfus
erythrocyt
identif
antibodi
fix
red
cell
import
clinician
allow
evalu
patient
clinic
situat
includ
current
medic
immunohematolog
elut
posit
dat
remain
tediou
expens
procedur
blood
transfus
servic
src
bt
src
deriv
flow
chart
indic
situat
elut
dat
posit
sampl
perform
order
follow
bt
src
guidelin
mandatori
obtain
addit
data
relat
patient
condit
haemolyt
paramet
recent
transfus
histori
current
laboratori
alway
abl
appli
recommend
flowchart
sinc
inform
often
unavail
aim
perform
compar
studi
algorithm
provid
bt
src
inhous
strategi
base
qualit
chang
posit
dat
without
need
addit
patient
biolog
inform
method
detail
dat
posit
patient
transfus
histori
taken
softwar
eprogesa
maksystem
analys
excel
analys
total
dat
evalu
posit
whether
elut
perform
whether
antibodi
detect
eluat
furthermor
perform
addit
analysi
sampl
deriv
recent
transfus
patient
day
result
posit
dat
found
igg
sampl
level
similar
previou
report
posit
dat
hospit
patient
among
posit
sampl
elut
qualit
chang
posit
accord
inhous
algorithm
identif
warm
autoantibodi
alloantibodi
occur
case
patient
transfus
within
last
day
posit
dat
elut
accord
inhous
algorithm
sampl
would
analys
swiss
transfus
guidelin
appli
howev
compar
studi
reveal
signific
discrep
regard
overal
sampl
number
elut
accord
two
algorithm
versu
sampl
mainli
due
fact
swiss
transfus
base
algorithm
recommend
elut
posit
dat
patient
receiv
transfus
within
last
except
signific
clinic
suspicion
eg
haemolysi
summaryconclus
compar
studi
indic
elutionbas
algorithm
perform
clinic
relev
sampl
recommend
bt
src
guidelin
qualit
chang
dat
posit
repres
main
paramet
select
sampl
eluat
besid
ensur
clinic
relev
sampl
miss
strategi
also
led
larg
number
unnecessari
elut
analys
conclus
signific
reduct
laboratori
workload
econom
save
aris
relev
clinic
inform
patient
histori
known
prior
laboratori
analysi
background
novel
monoclon
antibodi
daratumumab
dara
isatuximab
use
treatment
multipl
myeloma
interfer
routin
blood
bank
serolog
test
part
strategi
manag
patient
recommend
perform
extend
phenotyp
provid
match
unit
aabb
associ
bulletin
mani
investig
focus
interfer
iat
screen
identif
underli
alloantibodi
overcom
less
publish
potenti
interfer
extend
phenotyp
techniqu
aim
purpos
studi
compar
differ
technolog
type
import
antigen
myeloma
patient
treatment
therapeut
antibodi
vox
sanguini
suppl
method
edtaanticoagul
whole
blood
sampl
come
patient
differ
stage
treatment
daratumumab
isatuximab
type
parallel
dg
gel
microcolumn
grifol
mdmulticard
technolog
grifol
result
also
compar
genotyp
result
obtain
id
core
xt
grifol
direct
coomb
autocontrol
antibodi
screen
also
perform
complementari
test
result
studi
provid
four
patient
posit
dat
andor
ac
therapeut
antibodi
treatment
case
neg
antigen
fy
jk
andor
turn
posit
gel
technolog
mdmulticard
show
agreement
genotyp
id
core
xt
result
focus
data
obtain
treatment
neg
antigen
type
posit
gel
technolog
test
mdmulticard
agre
genotyp
analyz
antigen
complementari
data
patienttr
sampl
dat
ac
posit
show
panagglutin
summaryconclus
result
demonstr
mdmulticard
effect
method
type
cytolyt
antibodi
treat
sampl
addit
dat
autocontrol
posit
sampl
background
antibodi
titrat
semiquantit
method
estim
strength
concentr
antibodi
present
plasma
serum
sampl
titrat
methodolog
valid
togeth
clinic
data
evalu
relev
titer
valu
applic
titer
antibodi
depend
differ
paramet
antibodi
concentr
sampl
densiti
correspond
antigen
express
red
blood
cell
use
affin
constant
antibodyantigen
paramet
regard
techniqu
use
eg
gel
card
tube
test
gel
card
technolog
reduc
intra
interlaboratori
variat
titrat
studi
compar
tube
techniqu
aim
evalu
suitabl
dg
gel
coomb
dg
gel
antiigg
dg
gel
neutral
grifol
titrat
use
two
sampl
volum
method
twenti
frozen
plasma
sampl
contain
unexpect
antibodi
differ
specif
antijk
fy
k
e
c
titrat
dg
gel
coomb
dg
gel
antiigg
card
donor
fresh
plasma
natur
occur
antibodi
antia
b
titrat
dg
gel
coomb
dg
gel
neutral
salin
techniqu
titer
antibodi
determin
test
twofold
dilut
plasma
select
red
blood
cell
depend
antibodi
test
plasma
sampl
dilut
dg
gel
sol
select
red
blood
cell
serascan
diana
serigrup
diana
donor
blood
ad
card
sampl
dilut
dispens
card
subsequ
card
incub
min
coomb
techniqu
min
salin
techniqu
centrifug
dg
spin
result
read
agglutin
intens
grade
visual
accord
instruct
use
dg
gel
card
reciproc
highest
plasma
dilut
give
macroscop
agglutin
interpret
titer
result
titer
obtain
dg
gel
coomb
antiigg
n
titrat
titer
rang
compar
sampl
unexpect
antibodi
differ
found
gel
card
type
differ
titer
case
differ
dg
gel
coomb
neutral
salin
techniqu
n
titrat
titer
rang
observ
antia
b
antibodi
titrat
use
sampl
titer
similar
higher
coomb
comparison
salin
techniqu
coomb
titer
may
mix
igm
antibodi
react
igg
antibodi
differ
titer
comparison
titer
rest
case
compar
sampl
volum
card
n
titrat
higher
titer
observ
use
expect
differ
titer
comparison
titer
titer
case
background
autoimmun
haemolyt
anemia
aiha
character
product
antibodi
direct
red
blood
cell
destruct
mononuclear
phagocyt
system
complement
system
aiha
observ
paediatr
usual
selflimit
often
precipit
viral
infect
condit
secondari
autoimmun
diseas
drug
infect
underli
primari
immun
defici
appropri
immuno
hematolog
evalu
characteris
underli
autoantibodi
help
identifi
type
aiha
aid
diagnosi
treatment
case
aim
retrospect
analysi
immunehematolog
evalu
treatment
outcom
aiha
paediatr
method
patient
age
year
diagnos
aiha
april
month
includ
analysi
aiha
defin
posit
direct
coomb
test
dct
anemia
associ
corrobor
evid
haemolysi
form
rais
indirect
hyperbilirubinemia
rais
ldh
rais
reticulocyt
count
red
cell
agglutin
peripher
smear
monospecif
dct
evalu
specif
autoantibodi
done
patient
use
biorad
gel
card
panel
cell
steroid
given
first
line
second
line
agent
includ
cyclosporin
rituximab
red
cell
transfus
given
sever
anemia
cardiac
decompens
result
patient
diagnos
studi
period
autoimmun
haemolyt
anemia
haemoglobin
present
rang
gramsdl
initi
present
sever
anemia
children
mildmoder
anemia
thrombocytopenia
evan
syndrom
trigger
haemolysi
infect
children
rheumatolog
evalu
perform
children
diagnos
evolv
lupu
primari
immun
defici
evalu
advis
one
child
diagnos
suffer
combin
immunodefici
dat
posit
aiha
patient
one
infant
dat
neg
iga
mediat
aiha
secondari
viral
infect
two
dat
posit
case
igg
posit
monoclon
dat
test
wherea
rest
igg
coat
red
cell
dat
titrat
patient
patient
coat
rest
alloantibodi
screen
neg
specif
autoantibodi
found
one
case
rh
blood
group
antigen
anti
e
patient
receiv
prednisolon
primari
treatment
three
children
attain
remiss
follow
week
steroid
steroid
depend
cyclosporin
use
second
line
agent
rituximab
use
children
children
sustain
remiss
medic
wherea
rest
low
dose
steroid
cyclosporin
summaryconclus
aiha
uncommon
problem
children
vari
clinic
sever
proper
diagnosi
manag
involv
effici
immunohematolog
evalu
detail
character
autoantibodi
coat
red
cell
import
guid
clinician
manag
prognosi
abstract
withdrawn
background
druginduc
immun
hemolyt
anemia
diiha
rare
describ
dexchlorpheniramin
polaramin
tm
antihistamin
agent
wide
use
treatment
varieti
allerg
reaction
report
case
diiha
complic
acut
renal
failur
associ
antibodi
dexchlorpheniramin
woman
histori
transfus
treat
semimonthli
combin
chemotherapi
target
therapi
metastat
colorect
adenocarcinoma
chemotherapi
regimen
consist
oxaliplatin
leucovorin
rescu
folfox
panitumumab
monoclon
antibodi
antiegfr
use
target
therapi
premed
dexchlorpheniramin
iv
systemat
given
begin
cycl
treatment
reduc
risk
perfus
reaction
mainli
associ
panitumumab
patient
develop
chill
febril
agranulocytosi
first
second
infus
respect
third
infus
perform
due
pyrexia
chill
gener
discomfort
experienc
patient
begin
chemotherapi
probabilist
antibiotherapi
administ
patient
recov
rapidli
next
infus
day
follow
premed
dexchlorpheniramin
impress
reaction
includ
mention
symptom
occur
along
back
pain
dark
color
urin
infus
halt
chemotherapi
deliv
bacteri
infect
implant
port
first
thought
caus
advers
event
confirm
addit
laboratori
find
reveal
biolog
sign
inflamm
associ
iha
acut
renal
failur
patient
treat
hemodialysi
day
two
unit
rbc
day
discharg
one
week
later
stabl
condit
dexchlorpheniramin
suspect
sampl
collect
day
sent
diiha
laboratori
workup
aim
aim
studi
support
clinic
diagnosi
diiha
method
laboratori
workup
includ
direct
indirect
antiglobulin
test
dat
iat
drug
antibodi
investig
perform
incub
patient
serum
eluat
patient
rbc
presenc
drug
normal
donor
rbc
previous
treat
drug
ie
socal
immun
complex
method
control
test
perform
parallel
drug
dilut
pb
test
mgml
result
dat
posit
antiigg
unexpect
rbc
antibodi
detect
iat
patient
serum
eluat
without
vitro
addit
drug
antibodi
direct
untreat
titer
enzymetr
titer
normal
donor
rbc
demonstr
patient
serum
presenc
drug
test
mgml
gel
method
pool
normal
sera
react
presenc
drug
summaryconclus
multidrug
treat
patient
describ
studi
demonstr
dexchlorpheniramin
depend
antibodi
detect
immun
complex
method
key
diagnosi
observ
posit
dat
neg
eluat
test
prompt
reexamin
medic
administ
tempor
relationship
hemolyt
event
although
rare
case
report
alert
physician
need
investig
possibl
dexchlorpheniramin
induc
hemolyt
anemia
patient
develop
unexpect
anemia
hematolog
oncolog
procedur
singapor
singapor
singapor
background
daratumumab
monoclon
antibodi
use
treatment
multipl
myeloma
known
bind
rbc
interfer
indirect
antiglobulin
base
serolog
test
red
cell
antibodi
screen
crossmatch
compat
test
order
negat
interfer
daratumumab
refer
laboratori
follow
daratumumab
protocol
recommend
aabb
use
dithiothreitol
dtt
treat
reagent
red
cell
red
cell
antibodi
screen
identif
test
patient
known
receiv
daratumumab
aim
object
studi
determin
impact
daratumumab
turnaround
time
tat
red
cell
antibodi
screen
identif
method
retrospect
review
tat
red
cell
antibodi
screen
identif
sampl
patient
known
treat
daratumumab
octob
decemb
perform
turnaround
time
defin
time
sampl
receiv
time
result
report
tat
routin
red
cell
antibodi
screen
identif
also
review
period
compar
tat
sampl
patient
treat
daratumumab
result
total
patient
daratumumab
sampl
sent
refer
laboratori
red
cell
antibodi
screen
identif
studi
period
inform
daratumumab
treatment
provid
refer
lab
prior
start
test
patient
use
daratumumab
mention
serolog
request
form
patient
median
tat
red
cell
antibodi
screen
identif
min
rang
inform
daratumumab
provid
prior
start
test
min
rang
inform
provid
prior
test
median
tat
routin
test
min
rang
use
wilcoxon
ranksum
test
turnaround
time
antibodi
screen
identif
daratumumab
treat
patient
observ
statist
signific
compar
routin
sampl
p
valu
howev
tat
serolog
test
request
appropri
medic
histori
compar
test
request
without
relev
inform
also
observ
significantli
differ
p
valu
summaryconclus
signific
impact
tat
red
cell
antibodi
screen
identif
patient
known
receiv
daratumumab
compar
routin
test
howev
signific
differ
tat
inform
daratumumab
treatment
provid
prior
test
highlight
import
provid
relev
medic
inform
request
form
order
prevent
delay
test
provis
blood
patient
daratumumab
result
improv
organiz
effici
posit
impact
cost
resourc
save
background
daratumumab
monoclon
antibodi
shown
highli
efficaci
treatment
multipl
myeloma
mm
glycoprotein
highli
express
plasma
cell
less
extend
surfac
red
blood
cell
rbc
bound
rbc
daratumumab
interfer
pretransfus
test
posit
antibodi
screen
crossmatch
interfer
import
challeng
mani
mm
patient
requir
blood
transfus
treatment
dithiothreitol
reduc
reagent
multipl
applic
blood
bank
test
treatment
rbc
dithiothreitol
irrevers
remov
cell
surfac
tertiari
structur
avoid
bind
test
interfer
daratumumab
aim
demonstr
efficaci
safeti
celer
protocol
blood
bank
bb
haematooncolog
institut
use
crossmatch
method
retrospect
research
use
evalu
result
obtain
implement
protocol
comprehend
previou
contact
haematooncolog
lead
studi
patient
begin
daratumumab
treatment
consist
aborhd
group
rh
kell
phenotyp
clinic
signific
antigen
antibodi
screen
direct
antiglobulin
test
genotyp
may
requir
patient
receiv
previou
blood
transfus
begin
therapi
blood
sampl
patient
sent
bb
perform
laboratori
test
frozen
frozen
sampl
use
crossmatch
patient
alreadi
start
therapi
blood
transfus
posit
antibodi
screen
andor
crossmatch
transfus
case
posit
test
dithiothreitoltr
donor
rbc
appli
donor
rbc
antigen
alway
select
accordingli
patient
neg
clinic
signific
antigen
transfusion
support
need
laboratori
test
execut
gel
column
agglutin
techniqu
result
sinc
patient
studi
transfus
blood
unit
accord
protocol
immun
advers
reaction
transfus
regist
within
transfus
patient
neither
delay
avail
blood
unit
patient
blood
sampl
collect
frozen
prior
begin
treatment
shown
good
strategi
reduc
significantli
wait
time
blood
unit
first
transfus
summaryconclus
protocol
defin
commun
among
involv
profession
shown
secur
effect
way
reduc
interfer
caus
daratumumab
ensur
previou
studi
patient
transfus
rbc
respect
patient
neg
clinic
signific
antigen
adopt
mitig
measur
describ
protocol
delay
avail
rbc
request
alloimmun
may
possibl
occur
good
commun
bb
haematooncolog
crucial
good
time
manag
transfus
request
patient
three
method
use
resolv
dara
interfer
reagent
rbc
treat
dtt
know
denatur
test
patient
plasma
alloadsorpt
studi
perform
use
certain
ratio
red
cell
plasma
addit
select
phenotyp
cord
cell
use
antibodi
screen
panel
result
dtt
treatment
reagent
red
cell
success
elimin
dara
interfer
allow
presenc
underli
antibodi
identifi
case
underli
antibodi
detect
use
reagent
dtt
treat
red
cell
phenotyp
cord
cell
adsorpt
techniqu
ineffect
elimin
reactiv
summaryconclus
dara
first
commerci
fdaapprov
therapeut
monoclon
antibodi
use
treat
multipl
myeloma
patient
sinc
weakli
express
normal
red
blood
cell
dara
attach
red
blood
cell
interfer
pretransfus
iat
test
dtt
treatment
reagent
red
blood
cell
cord
cell
abolish
interfer
dara
test
presenc
underli
alloantibodi
prevent
delay
issu
red
blood
cell
unit
patient
hospit
send
patient
sampl
test
receiv
dara
treatment
ensur
clinic
signific
alloantibodi
mask
background
antibodi
screen
consid
superior
antihuman
globulin
ahg
cross
match
pretransfus
compat
test
spite
know
util
superior
adopt
uniformli
india
therefor
scarc
data
avail
subcontin
term
optimis
red
cell
antibodi
detect
pretransfus
test
form
type
screen
aim
main
object
studi
benefit
perform
simultan
antibodi
screen
along
blood
group
first
hospit
visit
hospit
object
studi
preval
clinic
signific
antibodi
among
indian
popul
follow
patient
transfus
antibodi
screen
neg
cross
match
incompat
blood
also
studi
relev
qualiti
indic
relat
effici
blood
transfus
servic
method
prospect
studi
carri
tertiari
healthcar
centr
india
juli
dec
month
studi
protocol
submit
institut
review
board
permiss
grant
blood
group
done
patient
first
hospit
visit
call
type
screen
patient
got
admit
hospit
requir
blood
transfus
blood
request
form
gener
user
sent
blood
bank
depend
upon
result
antibodi
detect
cours
action
chosen
patient
found
antibodi
immedi
spin
test
ist
cross
match
compat
blood
issu
transfus
case
procedur
ahg
crossmatch
test
continu
even
issu
blood
case
ahg
cross
match
test
found
neg
followup
patient
done
wherea
ahg
cross
match
found
posit
patient
follow
transfus
result
total
patient
type
screen
major
hematooncolog
bmt
liver
transplant
paediatr
cardiac
surgeri
medic
icu
unit
clinic
signific
alloantibodi
detect
patient
autoantibodi
detect
patient
alloantibodi
detect
mainli
rh
kell
blood
group
system
diagnos
aiha
case
major
form
warm
aiha
aiha
case
hidden
singl
multipl
alloantibodi
significantli
higher
proport
patient
posit
group
requir
blood
transfus
neg
group
vs
p
group
plan
case
time
blood
issu
immedi
within
defin
turnaround
time
except
either
transfus
delay
surgeri
postpon
happen
trauma
surgic
bleed
case
expiri
blood
decreas
significantli
due
usag
blood
vs
p
period
studi
obtain
case
ist
cross
match
compat
ahg
cross
match
incompat
follow
none
case
demonstr
sign
hemolysi
summaryconclus
develop
countri
like
us
optim
pretransfus
test
increas
oper
effici
significantli
decreas
expiri
blood
result
period
absc
perform
donat
sampl
test
found
absc
posit
antibodi
red
cell
identifi
donat
absc
posit
sampl
rest
irregular
antibodi
detect
preval
rate
atyp
antibodi
top
frequent
antibodi
specif
nonspecif
cold
antibodi
anti
antimi
antim
antil
total
donat
screen
atyp
antibodi
screen
posit
among
antir
cell
antibodi
identifi
sampl
significantli
higher
identifi
screen
posit
sampl
p
preval
rate
atyp
antibodi
screen
posit
confirm
red
cell
specif
also
significantli
higher
p
top
frequent
antibodi
specif
antimi
antim
antil
anti
nonspecif
cold
antibodi
antifi
b
detect
case
would
miss
detect
enzym
treat
reagent
cell
system
summaryconclus
perform
system
use
screen
panel
includ
one
cell
mi
express
column
agglutin
technolog
iat
phase
superior
comparison
context
higher
sensit
detect
true
posit
result
higher
specif
detect
true
neg
less
fals
posit
result
translat
advantag
reduct
workload
refer
laboratori
perform
less
antibodi
identif
fals
posit
sampl
well
enhanc
transfus
safeti
remov
irregular
red
cell
antibodi
posit
plasmacontain
compon
issuabl
inventori
may
potenti
lead
haemolyt
transfus
reaction
preval
irregular
red
cell
antibodi
healthi
blood
donor
hong
kong
reflect
true
statist
figur
background
chronic
red
blood
cell
rbc
transfus
upfront
therapi
thalassaemia
patient
howev
therapi
featur
sever
advers
event
includ
rbc
alloimmun
phenotyp
match
product
transfus
polici
prevent
alloantibodi
format
make
routin
transfus
difficult
donor
center
transfus
servic
recent
systemat
review
franchini
et
al
blood
transfu
report
rbcalloimmun
preval
higher
incid
rh
kell
system
thalassemia
intermedia
patient
aim
aim
retrospect
studi
evalu
rbc
alloimmun
preval
thalassemia
patient
transfus
singl
center
year
period
limit
phenotyp
match
rbc
rh
kell
system
antigen
unit
method
thalassaemia
patient
minimum
follow
year
transfus
rbc
unit
includ
studi
patient
studi
blood
group
rh
k
phenotyp
determin
direct
antiglobulin
test
dat
irregular
antibodi
research
abirr
crossmatch
detect
alloantibodi
perform
use
indirect
antiglobulin
test
column
agglutin
method
sixmonthli
dat
antibodi
screen
perform
use
indirect
antiglobulin
test
enzymat
papaintr
rbc
test
result
overal
patient
femal
male
includ
retrospect
analysi
patient
affect
thalassaemia
major
thalassaemia
intermedia
rbc
alloimmun
preval
patient
patient
found
posit
rbc
alloantibodi
four
alloantibodi
autoantibodi
eleven
alloantibodi
detect
antih
anticw
anti
kpa
antijka
antijkb
antim
antilua
alloimmun
patient
found
anti
antibodi
reactiv
enzymat
papaintr
rbc
test
third
alloimmun
patient
antikpa
antilua
antibodi
detect
remain
patient
auto
alloantibodi
detect
sever
autoimmun
hemolyt
anaemia
aea
requir
therapi
diagnos
case
appear
alloantibodi
concomit
presenc
autoantibodi
among
patient
posit
alloantibodi
affect
major
thalassemia
one
intermedia
thalassaemia
summaryconclus
experi
limit
phenotyp
match
rbc
transfus
polici
show
rbc
alloimmun
preval
similar
literatur
data
vs
nt
find
higher
alloimmun
preval
thalassemia
intermedia
patient
may
due
low
patient
number
believ
introduct
depart
extendedphenotyp
match
transfus
includ
antigen
main
group
system
fy
jk
mn
main
rare
antigen
cw
kp
lu
could
reduc
risk
red
blood
cell
alloimmun
thalassemia
patient
abstract
withdrawn
background
undoubtedli
prevent
alloimmun
advantag
overcom
consequ
howev
high
cost
technic
organiz
aspect
prevent
measur
requir
scientif
substanti
confirm
clinic
laboratori
data
select
donor
rhesu
c
kell
k
antigen
red
blood
cell
transfus
hematolog
patient
regul
russian
feder
sinc
recipi
phenotyp
cctransfus
red
blood
cell
antigen
combin
transfus
red
blood
cell
obtain
kneg
donor
use
compat
donor
recipi
antigen
c
e
e
c
w
rhesu
system
k
kell
system
addit
taken
account
april
transfus
red
blood
cell
contain
antigen
phenotyp
recipi
phenotyp
aim
evalu
effici
red
blood
cell
donor
select
use
antigen
rhesu
c
c
e
e
c
w
kell
k
k
system
prevent
recipi
alloimmun
method
immunohaematolog
studi
use
equip
reagent
biorad
usa
perform
patient
hematolog
clinic
nonhodgkin
lymphoma
diagnos
patient
acut
leukemia
multipl
myeloma
chronic
lymphat
leukemia
chronic
myeloid
leukemia
aplast
anemia
hemophilia
myelodysplast
syndrom
hematolog
diseas
frequenc
detect
antibodi
antigen
c
vs
antigen
e
vs
decreas
four
time
frequenc
detect
antibodi
c
w
antigen
chang
significantli
vs
respect
select
antigen
c
rhesu
k
kell
carri
clinic
sinc
therefor
immun
index
antigen
remain
unchang
amount
vs
antic
antibodi
vs
antik
antibodi
alloantibodi
antigen
e
rhesu
k
kell
detect
entir
observ
period
summaryconclus
research
verifi
effect
alloimmun
prevent
recipi
select
red
blood
cell
antigen
c
c
e
rhesu
system
k
kell
studi
conclud
select
red
blood
cell
antigen
c
w
e
rhesu
k
kell
affect
level
alloimmun
patient
clinic
justifi
background
russian
feder
order
accord
patient
requir
multipl
transfus
high
risk
immunolog
complic
type
red
blood
cell
antigen
abo
c
c
e
e
cw
k
k
select
erythrocytecontain
blood
compon
carri
take
account
donorrecipi
compat
accord
list
antigen
aim
analysi
result
immunolog
evalu
patient
hematolog
clinic
method
studi
includ
first
time
patient
hematolog
clinic
type
antigen
abo
rhesu
kell
system
screen
identif
antibodi
carri
use
equip
reagent
bio
rad
usa
result
interpret
result
immunohematolog
screen
complic
patient
total
number
complex
case
doubl
popul
red
blood
cell
often
determin
antigen
rhesu
system
total
number
patient
result
previou
transfus
therapi
chimera
antigen
e
detect
case
patient
chimera
rhesu
kell
antigen
cin
sin
e
cw
k
case
donor
red
blood
cell
chosen
carri
chimer
antigen
transfus
presenc
chimera
pair
antigensr
blood
cell
transfus
cc
phenotyp
ee
chimera
abo
antigen
detect
examin
individu
discrep
direct
revers
blood
group
abo
system
patient
due
decreas
product
antibodi
case
appear
extra
agglutinin
case
autoantibodi
detect
patient
includ
patient
caus
panagglutin
phenomenon
upon
detect
autoantibodi
complic
individu
select
donor
transfus
red
blood
cell
compat
antigen
abo
rhesu
kell
duffi
kidd
mn
system
alloantibodi
detect
patient
includ
specif
antidin
antidcin
antikin
antibodi
unidentifi
specificityin
polyspecificin
summaryconclus
complex
interpret
immunohematolog
test
hematolog
patient
due
intens
transfus
therapi
chang
red
blood
cell
antigen
appear
nonspecif
antibodi
due
underli
diseas
red
blood
cell
transfus
patient
select
take
account
expand
red
blood
cell
antigen
profil
abstract
withdrawn
background
blood
transfus
essenti
part
therapi
mani
patient
although
lifesav
mani
patient
blood
transfus
without
risk
main
goal
blood
transfus
servic
transfus
blood
compat
patient
clinic
serolog
evalu
allow
transfus
compat
least
incompat
blood
requir
joint
effort
clinician
transfus
medicin
physician
aim
root
caus
analysi
incompat
cross
match
patient
method
prospect
studi
total
crossmatch
perform
period
last
four
half
year
unit
found
incompat
column
agglutin
methodcat
polyspecif
antiigg
gel
media
root
caus
analysi
protocol
formul
resolv
incompat
ensur
safe
transfus
result
evalu
crossmatch
unit
found
incompat
major
caus
incompat
found
patient
aiha
caus
incompat
infect
multipl
transfus
trauma
evan
syndrom
rh
neg
mother
sca
incompat
due
dat
posit
pack
red
cell
common
antibodi
found
anti
c
anti
anti
summaryconclus
rca
protocol
involv
thorough
evalu
patient
clinic
condit
underli
patholog
identifi
caus
logic
stepwis
approach
enabl
provis
safe
transfus
patient
background
antibodi
highfrequ
antigen
hfa
transfus
hazard
compat
blood
often
difficult
obtain
clinic
signific
alloantibodi
repres
addit
transfus
risk
patient
treat
allogen
bone
marrow
transplant
bmt
recipi
red
cell
alloantibodi
may
caus
acut
delay
haemolysi
donor
red
blood
cell
rbc
contribut
morbid
mortal
aim
aim
present
case
patient
myelodysplast
syndrom
md
multipl
common
alloantibodi
addit
alloantibodi
highfrequ
antigen
treat
allogen
bmt
method
fortyoneyearold
caucasian
patient
md
admit
hospit
januari
unrel
allogen
bmt
previous
receiv
myeloabl
condit
therapi
accord
flu
atg
protocol
day
mg
iv
fludarabin
day
busulfan
mg
iv
day
mg
iv
antithymocyt
globulin
indirect
antiglobulin
test
iat
done
august
decemb
neg
accord
anamnest
data
patient
two
pregnanc
receiv
red
cell
transfus
childbirth
platelet
decemb
result
patient
blood
group
rhd
posit
iat
posit
donor
blood
group
rhd
posit
iat
neg
phenotyp
recipi
rbc
well
donor
rbc
also
determin
anti
c
w
found
patient
plasma
addit
alloantibodi
suspect
autocontrol
neg
column
agglutin
technolog
cat
tube
technolog
use
identifi
rbc
antibodi
plasma
test
phenomatch
rbc
papainand
dithiothreitoltr
rbc
well
cord
autolog
rbc
adsorpt
elut
test
done
exclud
usual
clinic
signific
alloantibodi
patient
receiv
three
incompat
xm
iat
cat
yt
e
c
w
kred
cell
unit
sampl
urgent
sent
antibodi
investig
intern
blood
group
refer
laboratori
bristol
uk
refer
laboratori
anti
c
w
alloantibodi
highfrequ
antigen
confirm
whose
specif
determin
antiyt
antijk
b
also
suspect
later
confirm
patient
discharg
hospit
receiv
eight
red
cell
unit
yt
e
c
w
jk
b
serolog
close
monitor
summaryconclus
result
antibodi
investig
case
studi
indic
presenc
multipl
alloantibodi
patient
previous
receiv
immunosuppress
myeloabl
condit
therapi
addit
common
alloantibodi
anti
c
w
jk
b
alloantibodi
highfrequ
antigen
antiyt
detect
patient
patient
transfus
incompat
red
cell
unit
yt
emerg
ill
effect
although
antiyt
rare
clinic
signific
antibodi
accord
literatur
caus
immedi
haemolyt
transfus
reaction
addit
risk
common
clinic
signific
alloantibodi
especi
antijk
b
case
extrem
difficult
detect
complic
select
blood
background
identif
antibodi
highincid
antigen
alway
introduc
challeng
due
difficulti
find
compat
unit
red
blood
cell
rbc
patient
need
surgeri
import
minim
transfusion
need
implement
patient
blood
manag
program
pbm
test
predict
clinic
signific
antibodi
monocyt
monolay
assay
mma
also
use
guid
clinic
decis
kell
blood
group
system
contain
highli
immunogen
antigen
antibodi
antigen
immunoglobulin
g
caus
sever
hemolyt
transfus
reaction
fetal
anemia
result
case
report
report
case
femal
nonhodgkin
lymphoma
chronic
anemia
scoliosi
sever
neurolog
compromis
propos
lumbar
spinal
stabil
surgeri
total
hip
replac
surgeri
unknown
transfus
histori
obstetr
histori
patient
histori
thromboembol
hemorrhag
event
pretransfusion
test
type
rr
posit
antibodi
screen
test
identif
studi
suggest
antibodi
highincid
antigen
surgeri
delay
clarif
result
also
refer
pbm
appoint
hemoglobin
improv
gdl
gdl
administr
ferric
carboxymaltos
iv
darbepoetin
sc
patient
phenotyp
kp
ab
antikpb
antibodi
highincid
antigen
preval
worldwid
rare
antibodi
variabl
reactiv
caus
none
moderatedelay
transfus
reaction
access
clinic
signific
antibodi
mma
perform
result
reactiv
suggest
clinic
relev
howev
could
alter
transfus
kpb
blood
order
find
compat
rbc
sever
famili
member
phenotyp
howev
posit
kpb
antigen
portug
rr
kp
b
blood
donor
extrem
rare
search
intern
rare
donor
panel
irdp
two
donor
found
spain
two
unit
compat
rbc
request
prior
surgeri
perform
success
four
month
later
without
transfusion
support
summaryconclus
antikpb
rare
antibodi
case
caus
hemolysi
transfus
kp
b
red
blood
cell
combin
kp
b
rr
extrem
rare
phenotyp
present
challeng
find
compat
rbc
case
illustr
complex
transfusion
logist
problem
antibodi
highincid
antigen
pose
also
import
effici
pbm
programm
mitig
transfusion
need
patient
background
blood
transfus
integr
part
support
care
patient
sickl
cell
diseas
scd
alloimmun
recogn
complic
red
blood
cell
transfus
rbc
patient
may
result
difficulti
provid
compat
blood
may
associ
risk
acut
delay
hemolyt
transfus
reaction
aim
describ
transfus
manag
patient
scd
multipl
alloantibodi
difficulti
obtain
compat
blood
order
highlight
import
clinic
consequ
complic
suggest
possibl
manag
approach
method
femal
patient
scd
present
hospit
hemoglobin
level
gdl
secondari
acut
splenic
sequestr
histori
multipl
previou
admiss
mani
previou
rbc
transfus
blood
group
pretransfus
compat
test
perform
addit
phenotyp
patient
red
cell
screen
done
use
column
agglutin
techniqu
autom
machin
ortho
usa
antibodi
identif
perform
manual
use
commerci
cell
identif
panel
phenotyp
patient
done
use
haemagglutin
techniqu
monospecif
anti
sera
biorad
switzerland
result
patient
group
rhd
posit
antibodi
screen
posit
antibodi
identif
reveal
probabl
anti
antifya
possibl
develop
antik
alloantibodi
addit
recent
develop
autoantibodi
give
panposit
reactiv
identif
panel
phenotyp
patient
rbc
found
kneg
mask
alloantibodi
undefin
specif
suspect
compat
blood
found
clinic
condit
warrant
blood
transfus
least
incompat
phenotyp
match
rbc
unit
releas
patient
develop
acut
hemolyt
transfus
reaction
drop
hb
level
gdl
despit
screen
hundr
rbc
unit
compat
unit
identifi
transfus
given
patient
manag
conserv
use
hydrat
analges
hydroxyurea
erythropoietin
intraven
immun
globulin
ivig
steroid
rituximab
hb
level
increas
gdl
week
patient
discharg
hospit
sampl
patient
sent
refer
lab
institut
fur
klinisch
chemi
und
laboratoriumsmedizinregensburg
germani
investig
clarif
advic
compat
transfus
case
need
report
refer
lab
reveal
develop
addit
antim
anti
confirm
presenc
antifya
antik
warm
autoantibodi
phenotyp
rbc
confirm
molecular
diagnost
test
done
refer
lab
kneg
summaryconclus
find
compat
blood
may
extrem
difficult
patient
scd
develop
multipl
alloantibodi
therefor
essenti
perform
initi
extend
red
cell
phenotyp
patient
diagnosi
shelf
readi
phenotyp
blood
unit
issu
patient
minim
alloimmun
transfus
may
occasion
avoid
alloimmun
patient
util
altern
option
treatment
reduc
risk
seriou
complic
hemolyt
transfus
reaction
background
red
blood
cell
rbc
antigen
present
less
popul
known
low
incid
antigen
present
known
high
incid
antigen
mn
blood
group
system
consist
antigen
carri
glycophorin
gpa
glycophorin
b
gpb
hybrid
glycophorin
low
incid
high
incid
antigen
mn
blood
group
system
individu
homozyg
gpmur
neg
high
incid
jenu
antigen
antijenu
first
describ
thai
patient
thalassemia
compat
unit
found
follow
screen
unit
jenu
neg
phenotyp
rare
phenotyp
estim
frequenc
male
patient
histori
previou
transfus
present
anti
weak
auto
antibodi
appar
specif
donor
unit
select
cross
match
group
rhd
posit
cece
k
incompat
reaction
grade
column
agglutin
technolog
patient
sampl
donor
unit
refer
red
cell
refer
laboratori
investig
possibl
antibodi
low
incid
antigen
aim
aim
character
phenotyp
incompat
donor
unit
method
standard
serolog
procedur
use
identifi
antibodi
specif
patient
sampl
blood
group
phenotyp
patient
donor
perform
standard
serolog
procedur
genotyp
zygos
test
perform
use
polymeras
chain
reaction
pcr
highresolut
melt
hrm
assay
gpmur
gp
bab
hybrid
glycophorin
result
gene
convers
event
gypa
gypb
disrupt
gpb
impact
express
donor
neg
anti
moab
albaclon
posit
anti
polyclon
immulab
neg
anti
monoclon
antibodi
immulab
phenotyp
consist
previous
report
exampl
gpmur
homozygot
jenu
neg
individu
molecular
test
consist
serolog
support
gpmur
homozygos
jenu
neg
phenotyp
summaryconclus
donor
ad
rare
donor
panel
red
cell
donat
cryopreserv
futur
use
rare
donor
frozen
inventori
limit
antijenu
antiserum
avail
confirm
jenu
neg
phenotyp
current
reli
serolog
profil
red
cell
present
gpmur
phenotyp
neg
discrep
phenotyp
identifi
jenu
neg
donor
case
highlight
import
follow
unexplain
serolog
incompat
develop
monoclon
antibodi
direct
jenu
antigen
would
provid
opportun
screen
suitabl
donor
rare
phenotyp
background
molecul
express
tumor
cell
target
interest
drug
develop
use
monoclon
antibodi
block
protein
howev
drug
potenti
interfer
pretransfus
test
target
molecul
also
express
red
blood
cell
rbc
recent
mani
drug
target
develop
appropri
mitig
strategi
approach
select
rbc
safe
transfus
still
obstacl
aim
describ
case
delay
hemolyt
transfus
reaction
dhtr
antijk
patient
treat
previous
target
high
affin
sirpa
fusion
protein
method
woman
diagnos
nasal
caviti
squamou
cell
carcinoma
enrol
clinic
trial
blood
type
group
ab
rhd
posit
antibodi
screen
test
neg
past
month
previou
transfus
histori
past
two
year
two
infus
two
unit
apheresi
platelet
request
transfus
blood
bank
notic
antibodi
screen
posit
investig
proceed
result
antibodi
screen
show
trace
posit
panel
cell
ii
room
temperatur
rt
albumin
phase
antihuman
globulin
ahg
phase
tube
method
auto
control
neg
rt
albumin
phase
ahg
phase
antibodi
screen
cell
identif
cell
show
ahg
phase
use
gel
card
direct
antiglobulin
test
antiigg
use
gel
card
two
unit
rbc
request
transfus
hemoglobin
decreas
gdl
rbc
genotyp
unavail
moment
previou
antibodi
screen
neg
antijk
detect
e
c
fy
b
rbc
given
second
best
option
consid
phenotyp
distribut
major
blood
group
korean
popul
hemoglobin
level
well
sustain
gdl
decreas
gdl
twenti
day
rbc
transfus
laboratori
investig
consist
dhtr
patient
longer
given
antibodi
screen
dat
decreas
reactiv
presum
antigen
type
result
would
reliabl
chloroquin
dissoci
cell
wash
use
antisera
requir
ahg
test
serolog
phenotyp
show
patient
cell
c
e
c
e
jk
jk
b
fy
fy
b
n
antibodi
identif
use
papain
panel
cell
reveal
antijk
antibodi
conclud
dhtr
due
antijk
jk
fy
b
srbc
issu
transfus
request
patient
hemoglobin
level
recov
g
dl
patient
genotyp
later
identifi
serolog
type
summaryconclus
commun
physician
blood
bank
perform
adequ
pretransfus
test
administr
drug
target
import
achiev
safe
transfus
patient
serolog
phenotyp
use
antisera
requir
ahg
test
use
second
option
genotyp
unavail
time
manner
background
transfus
still
key
treatment
sickl
cell
diseas
scd
patient
result
patient
much
expos
transfus
risk
fear
one
delay
hemolyt
transfus
reaction
dhtr
investig
femal
scd
pediatr
patient
known
antibodi
refer
us
suspicion
two
dhtr
three
transfus
episod
report
total
four
unit
collect
four
donor
last
transfus
premed
rituximab
done
patient
plan
undergo
bone
marrow
transplant
brother
donor
aim
describ
molecular
serolog
workup
need
investig
dhtr
scd
patient
method
antibodi
identif
crossmatch
perform
iat
gel
test
red
blood
cellspanel
use
raw
papaintr
trypsintr
rbc
phenotyp
determin
convent
techniqu
semiquantit
phenotyp
conduct
serial
dilut
monoclon
antijk
dna
extract
use
magna
pure
compact
instrument
roch
sequenc
jk
exon
carri
inhous
techniqu
result
antibodi
identif
show
weak
antijk
reactiv
papaintr
rbc
autolog
control
also
posit
techniqu
dat
eluat
neg
patient
recent
transfus
less
four
month
earlier
first
sampl
neither
abl
perform
autolog
adsorpt
verifi
jk
jk
b
phenotyp
order
rule
imput
antilfa
dhtr
outcom
crossmatch
donor
rbc
undertaken
three
four
donor
test
apart
antijk
reactiv
none
reactiv
patient
previous
phenotyp
jk
ab
jk
gene
sequenc
genotyp
determin
jk
jk
confirm
jk
variant
allel
famili
studi
conduct
sibl
found
harbor
genotyp
mother
father
genotyp
jk
jk
jk
respect
subsequ
autolog
adsorpt
perform
prove
antijk
autoantibodi
consid
weak
antibodi
intern
control
use
order
evalu
possibl
dilut
effect
techniqu
final
serial
dilut
antijk
reagent
show
weaken
jk
express
encod
jk
variant
allel
find
consist
fact
crossmatch
proband
serum
brother
rbc
weaker
perform
jkab
rbc
summaryconclus
third
dhtr
report
happen
patient
previou
histori
immun
perform
sensit
serolog
techniqu
order
identifi
antibodi
necessari
select
appropri
unit
molecular
work
extra
serolog
test
use
determin
whether
antibodi
allo
autoantibodi
even
though
case
antijk
antibodi
identifi
proven
autoantibodi
difficult
conclud
caus
dhtr
nevertheless
jk
ab
blood
issu
advers
event
report
luckili
patient
bone
marrow
donor
harbor
variant
allel
background
accord
aabb
pretransfus
sampl
must
obtain
within
day
transfus
patient
transfus
pregnant
preced
month
despit
safeguard
high
risk
patient
ie
recent
transfus
histori
pregnanc
transfus
may
develop
antibodi
day
window
avoid
issu
incompat
red
blood
cell
rbc
patient
new
antibodi
screen
ab
sampl
drawn
test
shortli
anticip
transfus
aim
report
case
yo
man
present
ed
hospit
day
postfal
intracrani
hemorrhag
multipl
fractur
anti
antijka
identifi
admiss
new
specimen
prior
current
specimen
expir
day
method
specimen
sent
type
ab
crossmatch
xm
rbc
ab
immedi
spin
xm
neg
patient
histori
neg
specimen
transfus
rbc
via
electron
xm
exm
hr
rbc
request
could
issu
via
exm
sinc
expir
midnight
howev
given
recent
transfus
bb
staff
first
call
patient
nurs
review
histori
patient
uncommun
scar
suggest
past
trauma
surgeri
request
receiv
hr
result
show
anti
antijk
plasma
eluat
hemoglobinhematocrit
hh
decreas
gdl
period
underw
sever
surgeri
without
unexpect
bleed
document
jaundic
dark
urin
two
ejk
rbc
transfus
toler
well
increas
hemoglobin
gdl
g
dl
well
post
transfus
stabl
hh
discharg
repeat
ab
neg
rbc
transfus
one
e
four
jk
famili
report
injur
year
prior
admit
hospit
unawar
transfus
hospit
report
admiss
year
ago
rbc
transfus
year
ago
ab
neg
admiss
year
ago
posit
ab
inconclus
workup
admiss
year
ago
show
neg
ab
summaryconclus
patient
develop
signific
antibodi
respons
less
day
specimen
collect
like
secondari
immun
respons
sensit
transfus
year
earlier
new
specimen
request
prior
transfus
even
though
exist
sampl
ab
neg
expir
approach
identifi
new
antibodi
prevent
transfus
incompat
rbc
potenti
seriou
hemolyt
transfus
reaction
case
suggest
highrisk
patient
ab
frequent
everi
day
may
benefici
import
increas
clinician
laboratorian
awar
issu
background
red
cell
partial
antigen
histor
classifi
base
fact
red
cell
type
posit
individu
make
antid
antibodi
expos
convent
antigen
definit
confirm
variant
antigen
obtain
rh
genotyp
aim
present
case
studi
patient
alloimmunis
present
partial
antigen
type
dnb
like
previous
receiv
transfus
method
patient
pretransfus
test
includ
determin
abo
blood
group
rhd
type
id
card
diaclon
abod
dv
dv
revers
group
monoclon
antibodi
gel
method
antiglobulin
crossmatch
addit
phenotyp
gel
tube
method
antibodi
screen
identif
specif
irregular
antierythrocyt
antibodi
commerci
avail
red
cell
panel
id
diapanel
bio
rad
gel
method
panocel
immucor
tube
method
indirect
antiglobulin
test
iat
enzym
routin
rhd
type
continu
characteris
rhd
antigen
serolog
assay
biorad
idparti
rhd
type
final
rhd
antigen
molecular
genotyp
fluogen
method
fluo
vista
machin
result
patient
year
old
woman
diagnosi
tu
mamma
prepar
total
mastectomi
surgeri
histori
blood
transfus
twenti
year
ago
also
two
birth
blood
group
type
ccdee
k
fy
ab
jk
ab
ss
mn
le
ab
agglutin
reaction
test
anti
serum
strong
compat
test
rhd
posit
donat
blood
unit
posit
presenc
antid
antifya
antibodi
serum
patient
determin
prepar
one
compat
blood
unit
rhd
neg
fya
neg
surgeri
interpret
idparti
rh
type
set
indic
diii
categori
partial
antigen
sampl
blood
patient
sent
blood
transfus
institut
serbia
molecular
type
antigen
perform
presenc
partial
form
antigen
dnb
type
found
summaryconclus
rhd
posit
patient
donor
antid
antibodi
present
serum
test
genotyp
recommend
transfus
patient
dnb
partial
alloimmunis
prepar
neg
fya
neg
erythrocyt
blood
compon
possibl
blood
donor
would
label
rh
posit
background
jr
blood
group
system
consist
jr
high
frequenc
antigen
express
gene
individu
jr
phenotyp
mainli
found
japanes
popul
may
develop
antijr
stimul
blood
transfus
pregnanc
antijr
danger
antibodi
pregnanc
also
could
caus
mild
moder
neonat
jaundic
aim
conduct
antibodi
specif
identif
high
frequenc
antibodi
pregnant
woman
histori
pregnanc
transfus
method
abo
rhd
special
blood
group
antigen
identifi
tube
method
salin
antibodi
screen
blood
group
specif
antibodi
identif
perform
indirect
antiglobulin
test
iat
gel
column
reagent
cell
treat
trypsin
chymotrypsin
papain
use
test
antiserum
obtain
characterist
antibodi
reaction
antibodi
titer
patient
serum
detect
dna
sampl
extract
exon
adjac
intron
sequenc
gene
sequenc
sampl
one
famili
member
collect
test
result
blood
group
patient
b
rhd
lu
b
kp
b
neg
reaction
serum
react
reagent
cell
test
salin
posit
iat
test
selfcontrol
neg
antiserum
react
strongli
iat
test
gel
card
papaintr
cell
kept
reaction
strength
trypsinand
chymotrypsintr
cell
indic
possibl
exist
antijr
titer
igg
antibodi
serum
cross
match
test
red
blood
cell
patient
brother
abo
rhd
blood
group
patient
success
match
serum
patient
sequenc
analysi
gene
patient
brother
reveal
one
homozyg
nonsens
mutat
exon
deliveri
pregnant
women
patholog
jaundic
seen
newborn
summaryconclus
condit
antijr
reagent
unavail
identif
jr
antigen
patient
indic
antijr
serolog
test
altern
genotyp
method
use
common
silenc
jr
allel
report
asian
popul
especi
japanes
popul
identifi
indic
jr
phenotyp
immunohemotherapi
centro
hospitalar
vila
nova
de
gaiaespinho
vila
nova
de
gaia
portug
background
investig
irregularunexpect
antibodi
reveal
pattern
screen
panel
cell
posit
reaction
phase
strength
along
neg
autocontrol
irregular
antibodi
highpreval
antigen
may
suspect
highpreval
antigen
present
almost
individu
fortun
antigen
occur
frequent
common
find
patient
antibodi
one
howev
happen
may
becom
troubl
situat
aim
clinic
case
report
panagglutin
assess
irregular
antibodi
method
collect
clinic
data
scl
siba
applic
result
woman
year
old
rhd
previous
transfus
red
blood
cell
concentr
propos
correct
surgeri
periprosthet
hip
fractur
pretransfus
serolog
test
request
irregular
antibodi
detect
screen
cell
order
identifi
specif
antibodi
panel
cell
test
result
consid
inconclus
due
posit
reaction
test
cell
lisscoomb
atyp
posit
drag
cell
enzymat
environ
autocontrol
direct
antiglobulin
test
neg
decid
send
two
blood
sampl
refer
laboratori
complet
immunohematolog
studi
compatibil
red
blood
cell
patient
also
request
wait
period
haematopoiesi
optim
although
patient
present
anaemia
admiss
analyt
studi
reveal
iron
defici
therefor
supplement
intraven
iron
perform
refer
laboratori
also
obtain
panreact
panel
cell
lisscoomb
weak
posit
papain
alloadsorpt
search
irregular
antibodi
neg
antiyt
appar
without
clinic
signific
neg
identifi
transfus
need
either
surgeri
good
recoveri
haemoglobin
valu
postop
period
summaryconclus
yt
belong
cartwright
system
highpreval
antigen
popul
antiyt
igg
antibodi
stimul
pregnanc
transfus
uncommon
may
think
suggest
reason
immunogen
antibodi
gener
consid
clinic
signific
report
case
acut
delay
haemolyt
transfus
reaction
antiyt
implic
therefor
although
describ
pattern
panagglutin
assess
irregular
antibodi
may
suggest
presenc
alloantibodi
direct
highfrequ
antigen
import
confirm
hypothesi
recur
refer
laboratori
necessari
identifi
antibodi
determin
clinic
relev
even
identifi
antibodi
associ
rare
haemolyt
transfus
reaction
crucial
optim
haematopoiesi
emerg
procedur
order
minim
transfus
associ
risk
emerg
elect
procedur
creation
nation
databas
patient
alreadi
identifi
irregular
antibodi
would
facilit
administr
red
cell
concentr
without
implic
antigen
aim
investig
frequenc
explor
genom
character
jk
ab
phenotyp
blood
donor
harbin
china
method
sampl
screen
jk
ab
phenotyp
use
direct
urea
lysi
test
result
confirm
iat
use
antijka
antijkb
standard
tube
test
addit
polymeras
chain
reaction
amplif
sequenc
analysi
jk
gene
perform
result
blood
sampl
four
donor
jk
ab
select
frequenc
among
four
sampl
avail
sequenc
jk
gene
total
two
genotyp
discov
heterozygot
combin
heterozygot
heterozygot
combin
heterozygot
summaryconclus
frequenc
jk
ab
phenotyp
blood
donor
harbin
area
lower
report
data
popul
area
china
finland
higher
japan
common
mutat
report
report
first
time
addit
effect
measur
establish
jk
ab
phenotyp
donor
region
solv
blood
transfus
problem
patient
background
blood
type
indic
type
blood
group
antigen
express
red
blood
cell
determin
type
allel
blood
group
gene
locu
therefor
allel
frequenc
blood
group
gene
determin
possibl
predict
frequenc
specif
blood
type
donor
homozyg
allel
also
possibl
estim
proport
donor
within
particular
blood
type
combin
specif
allel
ratio
blood
group
allel
differ
ethnic
race
use
basic
data
popul
genet
anthropolog
therefor
present
studi
examin
allel
frequenc
blood
group
system
korean
popul
blood
group
genotyp
aim
purpos
studi
determin
frequenc
blood
group
allel
korean
popul
predict
proport
homozyg
donor
obtain
basic
data
popul
genet
method
blood
donor
age
recruit
korean
red
cross
blood
center
locat
nationwid
acquir
sampl
examin
blood
group
genotyp
method
use
rbc
genotyp
system
id
core
xt
progenika
biopharma
donor
genotyp
blood
group
system
exclud
abo
rhd
identifi
calcul
frequenc
blood
group
allel
korean
popul
done
result
conduct
molecular
genotyp
rhce
kell
kidd
duffi
mnss
diego
dombrock
colton
cartwright
lutheran
blood
group
system
allel
frequenc
blood
group
system
korean
popul
estim
follow
rhce
ce
rhce
ce
rhce
ce
rhce
ce
kel
kkpbjsb
allel
jk
allel
jk
b
allel
jk
bnull
allel
fy
allel
fy
b
allel
gypa
allel
gypa
n
allel
gypb
allel
gypb
allel
gypb
mur
allel
di
allel
di
b
allel
allel
b
allel
co
allel
yt
allel
lu
b
allel
summaryconclus
signific
studi
accumul
data
allel
frequenc
blood
group
gene
highli
accur
genotyp
method
east
asia
region
enabl
predict
proport
donor
combin
specif
blood
group
allel
korean
popul
account
decent
percentag
popul
region
background
donor
arabian
countri
littl
known
blood
group
abo
rhesu
last
year
increas
migrat
central
europ
put
focu
question
guarante
blood
suppli
patient
countri
particularli
hemoglobinopathi
need
regular
blood
support
frequent
patient
region
aim
blood
group
allel
frequenc
determin
individu
syria
arabian
countri
iran
molecular
type
method
blood
group
defin
singl
nucleotid
polymorph
snp
introduc
malditof
ms
assay
detect
allel
encod
blood
group
includ
kk
fy
ab
fy
null
c
w
jk
ab
jo
aa
lu
ab
lu
ss
ab
co
ab
ab
js
ab
kp
ab
rhce
g
rhce
g
addit
blood
group
polymorph
like
yt
ab
ssu
vel
null
co
null
rhce
test
pcrssp
total
proband
includ
individu
syria
iran
arabian
peninsula
northern
african
countri
includ
result
donor
homozyg
fy
null
fy
c
fy
mutat
carri
heterozyg
mutat
syrian
proband
heterozyg
mutat
jo
virtual
unknown
caucasian
donor
syrian
donor
heterozyg
carri
kel
allel
code
js
phenotyp
js
b
rare
caucasian
howev
homozyg
kel
carrier
identifi
syrian
donor
neg
yt
definit
frequent
european
one
donor
northern
africa
homozyg
carri
gypb
g
intron
g
mutat
induc
su
w
phenotyp
northern
african
donor
heterozyg
rhce
g
substitut
syrian
donor
carri
rhce
g
heterozyg
donor
heterozyg
rhce
heterozygos
vel
defici
vel
detect
individu
syria
wherea
one
syrian
donor
carri
homozyg
mutat
none
donor
carri
co
mutat
induc
co
null
phenotyp
summaryconclus
studi
provid
first
overview
number
differ
blood
group
allel
blood
donor
arabian
countri
blood
group
allel
larg
lack
european
describ
african
individu
present
arabian
popul
somewhat
lower
frequenc
singl
case
could
challeng
provid
immun
arabian
patient
compat
blood
method
three
unrel
individu
blood
donor
one
pregnant
woman
polish
origin
type
ab
group
weak
antigen
normal
b
antigen
express
subject
extend
abo
type
one
case
famili
studi
perform
blood
sampl
donor
mother
father
sister
sequenc
analysi
donor
dna
perform
three
time
two
blood
sampl
buccal
swab
serolog
investig
perform
standard
method
card
diaclon
id
abod
antia
clone
antib
clone
antia
b
clone
birma
biorad
diaclon
id
abdconfirm
donor
antia
clone
biorad
techniqu
antia
birma
antib
genotyp
determin
rbc
fluogen
abo
basic
kit
innotrain
germani
sequenc
site
abo
gene
cover
sequenc
rang
end
intron
utr
abo
gene
addit
sequenc
exon
abo
gene
analyz
result
abo
type
show
normal
b
weak
antigen
rbc
three
individu
blood
donor
one
pregnant
woman
antigen
detect
tube
techniqu
use
antia
clone
birma
weak
neg
reaction
antigen
type
gel
card
observ
sera
individu
contain
antibodi
commerci
pcrssp
kit
reveal
three
heterozyg
ab
genotyp
absenc
typic
abo
allel
individu
abo
sequenc
fragment
confirm
heterozyg
genotyp
polymorph
characterist
abo
allel
g
g
c
detect
novel
abo
allel
sequenc
duplicationbas
insert
bp
posit
abo
gcaggacgtgtccatgcgccg
consequ
onlin
protein
translat
predict
infram
duplic
seven
amino
acid
codon
synonym
chang
repeat
codon
cgc
cgg
cgg
cgc
code
arginin
r
inherit
abo
allel
confirm
famili
studi
one
donor
father
sister
ab
genotyp
associ
normal
b
antigen
express
mother
normal
antigen
express
carri
abo
allel
abo
allel
son
summaryconclus
novel
weak
allel
abo
gene
detect
three
unrel
polish
individu
infram
insert
seven
amino
acid
wildtyp
glycosyltransferas
stabil
encod
protein
may
affect
caus
weak
phenotyp
inherit
mutat
confirm
famili
studi
background
sinc
clone
cdna
correspond
mrna
transcrib
blood
group
abo
locu
polymorph
phenotypegenotyp
correl
report
mani
investig
although
mani
subgroup
explain
genet
level
unresolv
sampl
still
encount
clinic
practic
report
result
abo
investig
sampl
swedish
blood
donor
show
weak
agglutin
rbc
antia
routin
forward
type
aim
elucid
genet
basi
appar
weak
subgroup
method
routin
abo
genotyp
pcrasp
pcrrflp
includ
pcrbase
analysi
upstream
cbfnfybind
enhanc
region
carri
genet
analysi
perform
dna
sequenc
abo
exon
includ
base
pair
adjac
intron
proxim
promot
flow
cytometr
test
rbc
perform
monoclon
antia
antib
antih
result
weak
agglutin
erythrocyt
antia
accompani
expect
lack
antia
plasma
abo
genotyp
gave
genotyp
abo
usual
consist
normal
express
antigen
enhanc
analysi
result
amplif
product
correspond
expect
singl
cbfnfi
bind
motif
flow
cytometr
test
sampl
show
antigen
express
almost
chimer
pattern
major
cell
approxim
express
antigen
low
level
margin
distinguish
group
control
remain
approxim
cell
display
antigen
level
rang
normal
weak
genom
abo
sequenc
show
abo
allel
except
novel
mutat
locat
intron
allel
addit
snp
consist
abo
allel
variant
summaryconclus
previous
unreport
variant
g
like
effect
donor
splice
site
intron
found
weak
sampl
type
mutat
expect
decreas
mrna
stabil
andor
caus
skip
preced
exon
mrna
howev
small
amount
fulllength
enzym
might
still
made
abl
give
rise
weak
antigen
express
seen
individu
interestingli
mutat
similar
genet
variant
underli
weak
subgroup
finn
case
howev
c
g
mutat
locat
end
intron
predict
caus
partial
skip
exon
strikingli
finn
phenotyp
also
result
pseudochimer
pattern
flow
cytometri
approxim
posit
stain
erythrocyt
due
well
document
lack
aallelederiv
mrna
peripher
blood
transcript
studi
could
undertaken
studi
need
investig
exact
mechan
underli
pseudochimer
pattern
observ
flow
cytometri
two
interest
genotypesphenotyp
abstract
withdrawn
background
abo
clinic
relev
blood
group
system
transfus
transplant
medicin
abo
genotyp
potenti
use
clarifi
serolog
blood
group
discrep
scenario
includ
inherit
subgroup
allel
temporari
acquir
variant
abo
phenotyp
diseas
pregnanc
chimer
due
exchang
progenitor
cell
earli
fetal
life
blood
progenitor
cell
transplant
aim
investig
molecular
basi
abo
discrep
detect
clinic
sampl
includ
donor
patient
sent
refer
laboratori
past
year
method
routin
abo
group
show
weak
agglutin
forward
vs
revers
type
discrep
abo
type
studi
perform
manual
adsorptionelut
test
also
perform
case
polyclon
antia
antib
confirm
whether
b
antigen
weakli
express
rbc
membran
pcr
approach
use
sequenc
specif
primer
b
allel
use
initi
genotyp
determin
full
abo
code
region
analys
previous
describ
select
sampl
abo
discrep
still
unexplain
allel
specif
fragment
span
exon
intron
exon
amplifi
use
forward
primer
target
nucleotid
exclud
allel
amplif
combin
either
b
gener
revers
primer
analysi
carri
sanger
sequenc
result
total
sampl
suspect
inherit
abo
subgroup
allel
select
molecular
studi
sequenc
analysi
subgroup
allel
sampl
suspect
subgroup
allel
insert
detect
correspond
abo
allel
abo
variant
hybrid
allel
found
case
case
found
c
chang
previous
report
associ
weak
antigen
express
final
novel
g
chang
detect
allel
b
cisab
suspect
allel
abo
b
variant
carri
g
chang
found
sampl
genotyp
weak
antigen
express
remain
case
consensu
b
allel
detect
thu
point
potenti
chimer
caus
result
observ
abo
group
final
identifi
abo
allel
carri
nucleotid
chang
g
context
abo
phenotyp
vs
genotyp
discrep
summaryconclus
sanger
sequenc
approach
appli
studi
prove
inform
help
determin
molecular
basi
abo
group
discrep
suspect
inherit
subgroup
found
mutat
within
exon
abo
gene
sampl
includ
novel
allel
chimer
suspect
case
antigen
express
sampl
genet
background
carri
appar
normal
b
allel
evalu
moment
deep
sequenc
approach
next
gener
sequenc
determin
presenc
small
amount
minor
allel
presenc
larg
surplu
two
allel
background
recent
multipl
pregnanc
rate
increas
due
advanc
artifici
fertil
includ
vitro
fertilizationembryo
transfer
dizygot
twin
dichorion
placenta
share
placenta
monochorion
dizygot
twin
blood
chimer
lead
doubl
rbc
popul
routin
abo
serolog
type
recent
sensit
object
column
agglutin
test
autom
system
wide
use
therefor
blood
chimer
dizygot
twin
detect
easili
routin
abo
blood
type
aim
report
congenit
blood
chimer
monochorion
dizygot
twin
triplet
found
incident
abo
serolog
test
confirm
abo
genotyp
str
marker
analysi
method
male
one
triplet
admit
hospit
medic
checkup
histori
transfus
bone
marrow
transplant
routin
abo
blood
group
test
perform
use
autom
blood
bank
system
howev
show
abo
discrep
red
blood
cell
show
doubl
cell
popul
gel
column
antia
antib
carri
abo
genotyp
blood
buccal
swab
evalu
perform
abo
serolog
test
abo
genotyp
str
marker
analysi
famili
member
result
among
triplet
blood
chimer
demonstr
patient
brother
show
b
phenotyp
serolog
test
triallel
abo
genotyp
blood
howev
buccal
swab
patient
show
brother
show
member
famili
father
mother
dizygot
sister
regular
abo
blood
type
serolog
test
perform
str
analysi
triplet
parent
eleven
loci
fga
reveal
one
addit
allel
blood
sampl
apart
buccal
swab
str
marker
analysi
show
brother
blood
chimer
summaryconclus
found
blood
chimer
monochorion
dizygot
twin
triplet
routin
abo
blood
type
confirm
str
analysi
applic
assist
reproduct
technolog
increas
incid
blood
chimer
also
increas
blood
chimer
often
creat
confus
abo
serolog
type
microchimer
overlook
routin
method
therefor
help
use
autom
blood
bank
system
improv
sensit
blood
chimer
consid
abo
blood
group
reveal
doubl
popul
background
express
abo
transferas
gene
affect
genet
variant
locat
within
code
sequenc
splice
junction
proxim
promot
intron
enhanc
describ
five
new
allel
singlenucleotid
substitut
found
sampl
discrep
unusu
abo
serolog
aim
resolv
serolog
discrep
unusu
serolog
find
abo
blood
group
system
molecular
method
particular
sanger
sequenc
method
forward
revers
abo
phenotyp
perform
gel
tube
method
genom
dna
extract
whole
blood
pcr
amplifi
cover
entir
abo
code
sequenc
splice
junction
proxim
promot
intron
enhanc
amplif
product
sanger
sequenc
directli
clone
bacteri
host
result
case
patient
unclear
abo
phenotyp
forward
type
b
revers
type
ab
sequenc
genom
dna
clone
abo
exon
detect
variant
g
heterozygos
otherwis
common
allel
tran
abo
allel
case
caucasian
donor
abo
discrep
forward
type
aweako
revers
type
sequenc
also
detect
variant
g
heterozygos
background
tran
abo
allel
given
variant
locat
near
intron
splice
acceptor
site
abo
transcript
postul
undergo
alter
splice
lead
aweak
phenotyp
case
prenat
sicklecel
diseas
patient
abo
discrep
forward
type
aweak
revers
type
dna
sequenc
detect
variant
heterozygos
otherwis
common
allel
abo
allel
tran
thu
data
establish
associ
allel
abo
aweaklik
phenotyp
case
donor
abo
type
discrep
forward
type
revers
type
sequenc
detect
variant
g
heterozygos
background
tran
abo
allel
interpret
data
variant
g
weaken
activ
transferas
allel
abo
encod
aweaklik
phenotyp
detect
serolog
case
yearold
patient
abo
discrep
forward
type
revers
type
ab
sequenc
genom
dna
clone
abo
exon
detect
variant
c
heterozygos
background
tran
abo
allel
serolog
molecular
result
suggest
allel
abo
encod
cisab
weak
phenotyp
case
caucasian
donor
abo
type
discrep
forward
type
weak
agglutin
antiab
revers
type
dna
sequenc
detect
variant
heterozygos
tran
background
variant
constitut
allel
abo
phenotyp
encod
abo
uncertain
summaryconclus
molecular
character
abo
allel
help
futur
identif
discrep
resolut
background
express
abo
transferas
gene
affect
genet
variant
locat
within
code
sequenc
splice
junction
proxim
promot
intron
enhanc
describ
five
new
allel
singlenucleotid
substitut
found
sampl
discrep
unusu
abo
serolog
aim
resolv
serolog
discrep
unusu
serolog
find
abo
blood
group
system
molecular
method
particular
sanger
sequenc
method
forward
revers
abo
phenotyp
perform
gel
tube
method
genom
dna
extract
whole
blood
pcr
amplifi
cover
entir
abo
code
sequenc
splice
junction
proxim
promot
intron
enhanc
amplif
product
sanger
sequenc
directli
clone
bacteri
plasmid
vector
result
case
yearold
pregnant
femal
abo
type
discrep
forward
type
revers
type
pcrrflp
predict
abo
sequenc
detect
variant
heterozygos
otherwis
common
allel
tran
abo
allel
unclear
earli
truncat
transferas
encod
allel
abo
still
allow
residu
enzym
activ
suggest
revers
type
case
recentlytransfus
yearold
black
patient
unresolv
abo
type
sequenc
detect
variant
g
silent
homozygos
variant
heterozygos
background
abo
allel
tran
although
variant
g
like
consequ
abo
phenotyp
patient
report
compon
new
abo
allel
case
yearold
prenat
femal
rhd
type
discrep
failur
yield
abo
genotyp
bloodchip
progenika
genotyp
microarray
interrog
polymorph
posit
rhd
abo
prompt
dna
sequenc
sequenc
genom
dna
clone
abo
exon
detect
variant
heterozygos
abo
b
allel
background
tran
abo
allel
phenotyp
encod
allel
abo
b
predict
b
evidenc
forward
type
immucor
neo
revers
manual
type
case
prenat
black
patient
abo
type
discrep
forward
type
gel
mix
field
mf
tube
revers
type
cell
gel
tube
sequenc
genom
dna
clone
pcr
product
cover
exon
detect
variant
c
heterozygos
tran
abo
allel
case
newborn
babi
case
forward
type
mf
gel
mf
tube
sequenc
babi
dna
detect
variant
c
heterozygos
tran
abo
allel
result
infer
phenotyp
encod
allel
abo
case
yearold
hispan
donor
abo
type
discrep
forward
type
revers
type
sequenc
genom
dna
abo
exon
detect
variant
heterozygos
tran
abo
allel
truncat
transferas
rel
late
posit
consist
retent
enzym
activ
explain
forward
type
encod
allel
abo
summaryconclus
molecular
character
abo
allel
help
futur
identif
discrep
resolut
background
express
abo
transferas
gene
affect
genet
variant
locat
within
code
sequenc
splice
junction
proxim
promot
intron
enhanc
variant
report
date
intron
enhanc
includ
larg
delet
small
delet
singlenucleotid
substitut
describ
four
new
allel
singlenucleotid
substitut
found
sampl
discrep
unusu
abo
serolog
aim
resolv
serolog
discrep
unusu
serolog
find
abo
blood
group
system
molecular
method
particular
sanger
sequenc
method
forward
revers
abo
phenotyp
perform
gel
tube
method
adsorptionelut
heat
elut
method
test
h
substanc
saliva
perform
follow
procedur
aabb
technic
manual
genom
dna
extract
whole
blood
pcr
amplifi
cover
entir
abo
code
sequenc
splice
junction
proxim
promot
intron
enhanc
amplif
product
sanger
sequenc
directli
clone
bacteri
plasmid
vector
background
inact
allel
could
decreas
abort
activ
fucosyltransferas
result
form
bombay
parabombay
phenotyp
weak
h
antigen
express
erythrocyt
mani
parabombay
individu
found
chines
popul
accord
name
h
blood
group
allel
red
cell
immunogenet
blood
group
terminolog
work
group
isbt
allel
identifi
bombay
parabombay
phenotyp
around
world
aim
studi
explor
distribut
allel
chines
individu
parabombay
phenotyp
method
sampl
come
blood
donor
patient
b
h
antigen
determin
use
convent
serolog
method
accord
manufactur
instruct
sequenc
full
code
region
amplifi
amplicon
purifi
enzym
digest
use
templat
sequenc
bidirect
nucleotid
sequenc
obtain
analyz
compar
standard
sequenc
result
nineteen
chines
individu
parabombay
phenotyp
identifi
ten
donor
nine
individu
come
hospit
rbc
weak
agglutin
reaction
antih
individu
homozyg
mutat
found
individu
heterozyg
chang
exist
individu
bidirect
sequenc
respect
individu
parabombay
phenotyp
accord
previous
report
fucosyltransferas
activ
abolish
vitro
assay
mrna
level
effect
compar
wild
type
summaryconclus
mutat
parabombay
individu
variou
common
allel
chines
individu
parabombay
phenotyp
background
regulatori
mechan
abo
gene
complic
investig
extensivelyvari
antigen
express
recogn
earli
twentieth
centuri
blood
group
divid
later
blood
group
subdivid
base
characterist
reactiv
human
polyclon
antisera
ie
strength
reactiv
presenc
mix
field
agglutin
presenc
whether
h
blood
group
substanc
present
saliva
secretor
subject
mutat
critic
abo
blood
group
phenotyp
predominantli
found
exon
abo
gene
encod
catalyt
domain
abo
glycosyltransferas
case
report
show
mutat
rang
singl
nucleotid
intron
enhanc
element
alter
efficaci
enzym
alter
antigen
express
aim
studi
aim
investig
molecular
basi
discrep
result
abo
forwardrevers
type
blood
donor
method
abo
type
perform
use
tube
techniqu
column
agglutin
test
biorad
grifol
standard
test
complet
adsorptionelut
studi
use
plasma
sourc
antia
saliva
test
presenc
h
substanc
perform
qualiti
control
method
abo
group
genotyp
perform
use
pcr
sequencespecif
primer
commerci
kit
abovari
bag
healthcar
lich
germani
pcramplifi
exon
intron
enhanc
subject
bidirect
dna
sequenc
analysi
use
standard
sanger
dideoxi
chemistri
seqscap
softwar
abi
use
analyz
sequenc
data
compar
obtain
sequenc
refer
sequenc
ncbi
result
standard
serolog
forward
test
identifi
blood
group
howev
antib
isoagglutinin
present
antia
adsorptionelut
studi
success
adsorb
elut
investig
cell
h
substanc
detect
saliva
abo
genotyp
use
pcrssp
indic
genotyp
dna
sequenc
analysi
show
result
abo
abo
specimen
reveal
subgroup
probabl
unusu
genet
variant
intron
region
abo
gene
enhanc
gene
express
summaryconclus
report
first
case
abo
mutat
locat
enhanc
region
gene
express
allel
caus
discrep
result
abo
forwardrevers
type
also
molecular
blood
group
test
base
serolog
find
subgroup
consid
background
chimera
singl
organ
compos
cell
distinct
phenotyp
andor
genotyp
sever
differ
type
chimera
describ
artifici
twin
disperm
artifici
chimer
seen
follow
hematopoiet
stem
cell
transplant
transient
follow
blood
transfus
second
type
may
also
inherit
commonli
blood
exchang
utero
twin
disperm
chimer
induc
fertil
two
matern
egg
two
spermatozoa
fusion
one
bodi
one
also
call
tetragamet
chimer
transfus
medicin
chimera
often
detect
mix
field
reactiv
observ
abod
type
less
commonli
phenotyp
blood
group
antigen
aim
investig
prompt
find
doubl
popul
erythrocyt
surgeri
patient
transfus
histori
aim
investig
chimera
determin
underli
abo
genotyp
patient
method
routin
blood
group
perform
column
agglutin
separ
doubl
cell
popul
perform
differenti
agglutin
igm
antid
immuclon
antid
fast
igm
clone
immucor
initi
abo
genotyp
perform
pcrssp
fluogen
innotrain
diagnostik
gmbh
resolut
perform
use
inhous
pcrasp
pcrrflp
method
next
gener
sequenc
monotyp
abo
omixon
use
illumina
sequenc
platform
sanger
sequenc
analysi
also
perform
identif
refer
allel
investig
fragment
analysi
short
tandem
repeat
str
polymorph
result
doubl
popul
found
column
agglutin
test
antia
antiab
subsequ
type
c
antigen
approxim
dc
cell
patient
genotyp
identifi
abo
cecertifi
pcrssp
kit
fluogen
routin
pcrasp
pcrrflp
could
resolv
patient
genotyp
possibl
abo
genotyp
detect
pcrrflp
pcrasp
analysi
gave
appar
abo
homozygot
result
sanger
sequenc
abo
exon
also
gave
anomal
reaction
abo
allel
detect
homozygos
observ
well
heterozygos
result
therefor
suggest
patient
genotyp
abo
next
gener
sequenc
omixon
reveal
result
howev
pcr
amplif
cbfnfi
enhanc
vntr
region
perform
possibl
heterozygos
observ
ie
weak
band
repres
singl
copi
one
repres
copi
enhanc
region
present
presenc
singl
copi
cbfnfi
enhanc
vntr
region
uniqu
background
del
weak
form
antigen
low
densiti
express
antigen
surfac
red
blood
cell
gener
type
dblood
group
could
nt
form
agglutin
routin
rhd
blood
group
test
could
detect
nonroutin
adsorptionelut
test
east
asian
southeast
asian
popul
individu
serolog
appar
dphenotyp
truli
dphenotyp
del
phenotyp
rare
caucasian
black
ethic
group
rhd
rhd
preval
del
peopl
region
del
carri
allel
commonli
known
asia
type
del
previou
studi
alloantid
observ
larg
cohort
chines
asia
type
del
pregnant
women
fetu
indic
occurr
alloantid
immun
red
cell
asia
type
del
individu
aim
conduct
genotyp
analysi
chines
patient
serolog
appar
dphenotyp
simultan
alloantid
confirm
exist
asia
type
individu
produc
alloantid
method
blood
sampl
patient
pregnant
women
identifi
alloantid
refer
lab
collect
antigen
confirm
use
blend
antid
reagent
clone
igmigg
tube
method
salin
indirect
antiglobulin
test
iat
gel
card
zygos
rhd
gene
detect
hybrid
rhesu
box
pcr
psti
digest
sampl
dd
genotyp
obtain
rhd
zygos
analysi
multiplex
ligationdepend
probe
amplif
mlpa
genotyp
conduct
rhd
genotyp
analysi
result
total
serolog
appar
dchines
patient
femal
n
male
n
alloantid
identifi
differ
titer
alloantid
n
n
detect
includ
case
mix
antibodi
antid
mix
antic
n
antid
mix
anti
n
serolog
rhd
type
confirm
serolog
appar
dphenotyp
rhd
homozyg
rhd
gene
delet
genotyp
identifi
major
rhd
zygos
analysi
rhd
genotyp
n
rhd
genotyp
n
carri
rhd
nonfunct
hybrid
allel
detect
mlpa
summaryconclus
compar
distribut
averag
frequenc
asia
type
del
serolog
appar
dpopul
guangzhou
china
one
case
asia
type
del
identifi
cohort
serolog
appar
dpatient
alloantid
studi
also
provid
evid
confirm
occurr
alloantid
immun
asia
type
del
individu
aim
serolog
rhdneg
donor
found
rhdposit
routin
rhd
screen
solv
discrep
serolog
molecular
screen
sampl
sequenc
dna
rna
level
method
phenotyp
idiatcard
biorad
done
use
commerci
antid
antibodi
adsorptionelut
analysi
perform
use
inhous
pool
polyclon
antid
antibodi
furthermor
antibodi
dscreen
perform
diagast
rhd
genotyp
rhtype
partial
dtype
assay
bag
health
care
carri
sampl
character
exon
sequenc
includ
flank
intron
region
rna
extract
whole
blood
revers
transcrib
cdna
sequenc
amplif
sequenc
publish
gassner
transfus
legler
tran
med
richard
transfus
inhous
primer
use
result
repeat
phenotyp
sampl
commerci
well
inhous
antid
antibodi
confirm
rhd
neg
addit
adsorptionelut
analysi
show
neg
result
howev
genotyp
use
commerci
avail
kit
yield
rhd
posit
result
variant
detect
investig
discrep
rhd
exon
sequenc
sequenc
data
reveal
mutat
splice
donor
site
exon
confirm
effect
splice
site
mutat
transcript
rna
fresh
whole
blood
sampl
analys
posit
control
gypb
amplifi
sequenc
cdna
wildtyp
gypb
found
rhd
specif
primer
product
could
amplifi
summaryconclus
present
serolog
rhd
neg
case
identifi
rhd
posit
standard
commerci
genotyp
kit
sequenc
reveal
new
splice
site
mutat
rna
sequenc
yield
detect
product
donor
classifi
rhd
neg
case
discrep
result
serolog
genet
show
import
profound
highli
sophist
genet
investig
conflict
laboratori
result
j
stettler
lejon
crottet
h
hustinx
c
von
arx
f
still
j
graber
c
niederhaus
c
henni
interregion
blood
transfus
src
bern
ltd
bern
switzerland
background
one
immunogen
clinic
signific
blood
group
antigen
transfus
medicin
rhd
antigen
variant
rhd
phenotyp
weaken
absent
antigen
express
pose
challeng
rhd
statu
assign
blood
donor
ensur
patient
safeti
necessari
fulli
character
variant
molecular
level
aim
sampl
two
donor
investig
laboratori
due
discrep
rhd
type
method
rh
blood
group
phenotyp
done
standard
serolog
column
agglutin
test
idsystem
biorad
rhd
character
perform
antid
antibodi
panel
contain
monoclon
antibodi
dscreen
diagast
adsorptionelut
test
use
inhous
pool
polyclon
antid
antibodi
molecular
investig
initi
perform
ssppcr
detect
common
rhd
variant
rbcreadi
gene
cde
innotrain
rhtype
bag
health
care
rhd
sequenc
done
either
dna
rna
use
publish
inhous
primer
amplif
sequenc
result
tube
test
rbc
donor
predict
rh
howev
ten
exon
rhd
gene
could
detect
routin
genotyp
sequenc
rhd
reveal
homozyg
mutat
c
g
posit
second
last
nucleotid
exon
thu
might
influenc
exon
splice
cdna
analysi
transcript
correctli
splice
exon
identifi
mutat
g
lead
amino
acid
substitut
locat
twelfth
transmembran
domain
rhd
use
model
flegel
transfu
apher
sci
refer
adsorptionelut
test
use
pool
polyclon
antid
show
weak
posit
reaction
reclassifi
donor
rhd
posit
novel
allel
rhd
could
thu
categor
del
allel
serolog
result
display
almost
normal
rhd
antigen
express
donor
serolog
determin
rhd
antigen
differ
antisera
howev
show
reaction
pattern
typic
observ
weak
variant
commerci
avail
kit
rhd
variant
could
detect
rhd
sequenc
reveal
novel
homozyg
mutat
c
exon
mutat
caus
exchang
sixth
membranespan
domain
rhd
base
serolog
data
donor
rhd
posit
case
transfus
patient
would
treat
rhd
neg
summaryconclus
report
two
novel
rhd
missens
mutat
g
c
harbour
amino
acid
substitut
within
transmembran
segment
g
variat
display
unusu
low
rhd
antigen
reactiv
would
mistyp
rhd
neg
without
extens
genotyp
test
molecular
analysi
variant
g
suggest
exchang
caus
del
phenotyp
rather
miss
splice
event
also
confirm
adsorptionelut
test
interestingli
variant
c
could
detect
due
comprehens
serolog
genet
investig
background
rh
blood
group
system
highli
polymorph
one
clinic
relev
system
transfus
actual
antigen
critic
import
due
involv
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
rhd
gene
variant
common
african
mostli
relat
partial
phenotyp
aim
rhd
gene
sequenc
investig
two
african
brazilian
sampl
attempt
take
advantag
combin
molecular
data
avail
silico
tool
function
interpret
variat
order
get
insight
clinic
phenotyp
may
predict
priori
genotyp
method
sampl
dneg
donor
selfdeclar
african
descent
sampl
patient
sickl
cell
diseas
scd
type
dposit
antid
serum
serolog
type
determin
manual
gel
test
micropl
autom
instrument
sampl
also
submit
adsorptionelut
test
genom
dna
extract
ten
rhd
exon
flank
intron
region
sampl
pcramplifi
rhdspecif
primer
analyz
sanger
sequenc
sampl
investig
nextgener
sequenc
miniseq
platform
illumina
use
previous
publish
custom
select
blood
group
gene
ampliseq
panel
report
threedimension
structur
model
rhdrhdrhag
heterotrim
use
visual
posit
variat
predict
put
functionalclin
effect
result
sampl
singl
nucleotid
missens
chang
ie
g
exon
identifi
transvers
thought
replac
threonin
arginin
residu
amino
acid
posit
rhd
protein
analysi
model
clearli
suggest
dramat
impact
substitut
occur
functionallycrit
conserv
motif
term
interhelix
interact
suppos
highli
deleteri
stabil
protein
potenti
impair
total
express
red
blood
cell
plasma
membran
predict
function
effect
definit
accord
dneg
phenotyp
report
sampl
sampl
singl
g
transit
found
exon
lead
threoninetoalanin
substitut
amino
acid
posit
amino
acid
locat
rhd
protein
extracellular
loop
thu
thought
alter
antigen
structur
result
partial
phenotyp
hypothesi
accord
antid
found
serum
sampl
summaryconclus
past
year
due
advent
nextgener
sequenc
subsequ
identif
numer
rare
variant
bioinformat
predict
model
tool
evolv
current
help
physician
diagnost
clinic
manag
genet
counsel
took
advantag
silico
method
predict
retrospect
effect
two
novel
variant
rhd
allel
includ
one
dneg
one
partial
allel
although
phenotyp
clinic
symptom
remain
definit
standard
determin
assess
effect
genet
variat
use
approach
may
soon
becom
valuabl
guid
subsequ
investig
immunohaematolog
abstract
withdrawn
allel
weak
type
diva
cluster
african
frequent
typic
associ
allel
weak
type
includ
dol
rhdpsi
diva
dau
cluster
occur
allel
addit
key
mutat
weak
type
dii
two
inactiv
mutat
report
rhb
among
first
polymorph
east
asian
rhd
frequent
follow
dfv
weak
type
key
mutat
diva
weak
type
cluster
well
rhcelik
substitut
mutat
weak
type
type
type
rhd
weak
rhd
weak
type
rhd
frequent
south
asia
elsewher
summaryconclus
data
tgp
gnomad
add
relevantli
knowledg
rhd
allel
tgd
disclos
link
intron
polymorph
gnomad
frequenc
data
bias
likelihood
serolog
detect
current
type
strategi
usual
start
serolog
later
complement
molecular
type
futur
molecular
method
gain
import
frequent
allel
current
distinguish
standard
rhd
may
need
ration
transfus
strategi
respect
high
frequenc
weak
type
type
european
surpris
might
warrant
confirm
altern
method
trigger
discuss
ration
transfus
strategi
allel
consist
r
haplotyp
probabl
dc
two
sibl
abo
compat
includ
dcsibl
incompat
iat
phase
reactiv
could
complet
adsorb
serum
use
r
r
r
r
rr
rbc
indic
antibodi
probabl
singl
specif
donor
return
continu
autolog
donat
aim
case
studi
examin
genet
framework
rhd
rhce
gene
character
rh
epitop
recogn
antibodi
aim
donor
return
continu
autolog
donat
aim
case
studi
examin
genet
framework
rhd
rhce
gene
character
rh
epitop
recogn
antibodi
method
serolog
test
perform
manual
tube
test
use
ahg
indirect
antiglobulin
phase
rbc
phenotyp
perform
standard
tube
hemagglutin
test
edta
anticoagul
blood
rhd
rhce
exon
sequenc
use
genom
dna
standard
sanger
dideoxi
method
bigdy
termin
cycl
sequenc
kit
sequenc
data
align
rhd
zygos
perform
use
pcrrflp
mspi
background
accord
recent
find
molecular
immunohematolog
rhd
genotyp
strongli
indic
rhc
rhe
donor
classifi
routin
dneg
among
one
could
find
nonneglig
share
entir
new
genet
alter
even
del
allel
often
identifi
routin
serolog
method
due
low
number
antigen
site
aim
present
studi
report
genotyp
data
rhd
rhc
rhe
caucasian
donor
classifi
serolog
dneg
enrol
singl
transfus
center
itali
method
rhd
serolog
type
carri
micropl
direct
agglutin
test
iri
immucor
use
differ
antid
igm
clone
clone
dvi
clone
dvi
differ
antid
igg
clone
clone
clone
donor
dneg
result
n
divid
subject
rhc
rhe
rhc
rhe
address
genotyp
analysi
rhd
beadchip
molecular
test
immucor
pcrssp
bagen
innotrain
andor
rbcfluogen
innotrain
discrep
result
serolog
dneg
molecular
biolog
wildtyp
fulllength
rhd
gene
investig
bidirect
sequenc
rhd
code
region
result
onehundr
donor
analyz
retrospect
part
pilot
studi
follow
data
obtain
first
phase
analysi
method
describ
implement
routin
allow
includ
donor
studi
prospect
donor
n
molecular
analys
show
complet
delet
rhd
locu
case
genet
statu
found
nondelet
rhd
bidirect
sequenc
donor
reveal
presenc
neg
weakd
variant
list
rhd
allel
identifi
molecular
level
follow
rhd
case
rhd
rhd
rhd
rhd
rhd
rhd
rhd
rhd
moreov
found
donor
lack
signal
encompass
exon
rhd
sequenc
bioarray
rhd
beadchip
addit
case
current
investig
summaryconclus
studi
confirm
nonneglig
number
caucasian
subject
classifi
serolog
dneg
present
rhd
gene
alter
differ
common
total
delet
line
literatur
data
also
found
frequenc
case
subject
donor
reclassif
dposit
weak
type
necessari
henc
wider
use
molecular
type
method
desir
order
achiev
correct
genet
character
appropri
phenotyp
classif
appar
dneg
donor
background
without
evid
abnorm
serolog
antigen
express
quest
weak
partial
variant
red
blood
cell
accord
blood
donor
registri
found
serolog
type
donor
dand
weak
aim
compar
differ
weak
serolog
reaction
antigen
rhd
genotyp
method
molecular
rhd
type
use
isol
dna
rbcreadi
gene
cde
rbcreadi
gene
weak
kit
perform
blood
donor
serolog
type
weak
use
monoclon
blend
igmigg
dviand
dvi
antid
reagent
slide
micropl
mp
techniqu
respect
well
antiglobulin
test
iat
gel
set
monoclon
partial
type
reagent
biorad
addit
rhccee
phenotyp
genotyp
also
perform
result
donor
serolog
weak
reaction
confirm
weak
variant
genotyp
except
one
donor
whose
iat
fals
posit
due
rbc
autoantibodi
frequenc
variant
genotyp
follow
weak
type
weak
type
one
donor
type
weak
type
anoth
one
weak
type
weak
type
associ
differ
degre
serolog
determin
weak
rang
neg
weak
posit
reaction
concern
slide
mp
gave
posit
reaction
rang
iat
except
weak
type
score
gave
neg
reaction
slide
mp
inconclus
result
set
monoclon
antid
reagent
partial
type
percentag
donor
serolog
type
found
posit
iat
one
weak
type
donor
neg
dviand
posit
dvi
reagent
mp
addit
rh
phenotyp
genotyp
ccee
donor
except
one
genotyp
weak
type
well
neg
donor
ccee
summaryconclus
rhd
genotyp
requir
estim
actual
frequenc
variant
blood
donor
practic
current
serolog
method
suffici
detect
almost
variant
phenotyp
consensu
routin
molecular
antigen
screen
neg
donor
order
detect
del
variant
ddccee
phenotyp
red
blood
cell
transfus
practic
neg
patient
seem
costeffect
background
rh
null
rh
mod
socal
rhdefici
phenotypesar
character
null
sever
reduc
rh
antigen
express
includ
cc
e
e
respect
molecular
genet
studi
show
phenotyp
transmit
autosom
recess
manner
rh
null
phenotyp
origin
two
differ
molecular
event
give
rise
amorph
type
regul
type
former
caus
homozygos
silent
gene
rhd
rhce
loci
caus
inactiv
mutat
rhce
delet
rhd
hand
regul
rh
null
type
well
rh
mod
phenotyp
attribut
mutat
rhag
gene
homozyg
state
heterozygos
anoth
rhag
allel
contain
inactiv
mutat
function
rhag
essenti
correct
rh
complex
assembl
rh
antigen
express
erythrocyt
membran
aim
aim
studi
investig
molecular
genet
basi
argentinean
proband
detect
c
c
e
e
antigen
standard
serolog
techniqu
method
blood
sampl
collect
proband
parent
sister
proband
yearold
young
woman
paramet
hemolyt
anemia
low
hemoglobin
level
gdl
reticulocytosi
hyperbilirubinemia
increas
ldh
mark
spherocytosi
c
c
e
e
statu
determin
standard
serolog
hemagglutin
techniqu
use
specif
monoclon
antibodi
genom
dna
isol
use
modifi
saltingout
method
dna
sampl
initi
screen
presenc
intron
untransl
region
rhd
gene
use
pcr
strategi
rhcc
rhee
allel
studi
allelespecif
pcr
determin
rhce
genotyp
rhd
zygos
analyz
pcrrflp
rhd
exon
polymorph
studi
rhd
exon
scan
procedur
base
pcrssp
rhag
gene
investig
exonspecif
pcr
amplif
sanger
sequenc
result
c
c
e
e
antigen
detect
proband
erythrocyt
father
sister
rh
phenotyp
c
c
e
e
wherea
mother
rh
phenotyp
c
c
e
e
rh
genotyp
confirm
rh
phenotyp
famili
member
except
proposita
genotyp
rhd
rhc
rhe
sampl
show
homozyg
statu
rhd
gene
rhd
exon
detect
exon
scan
sequenc
analysi
reveal
homozyg
mutat
rhag
exon
proband
wherea
rest
famili
show
heterozyg
state
nucleotid
posit
mutat
respons
amino
acid
substitut
predict
th
rhag
glycoprotein
transmembran
segment
summaryconclus
studi
describ
molecular
background
respons
rhdefici
phenotyp
argentinean
proband
identifi
novel
missens
mutat
rhag
gene
result
ser
phe
singl
amino
acid
substitut
show
critic
rh
antigen
complex
assembl
within
erythrocyt
membran
studi
perform
order
determin
whether
proband
rh
null
rh
mod
background
rh
blood
group
system
immunogenet
blood
group
system
blood
donor
type
account
express
antigen
order
prevent
antid
alloimmun
aim
object
prospect
studi
investig
rhd
allel
among
blood
donor
type
dbi
serolog
method
posit
c
andor
e
reason
develop
easytoperform
dnabas
screen
method
detect
rhd
gene
posit
sampl
character
two
commerci
pcrssp
kit
method
individu
blood
donor
within
month
period
type
dwith
standard
immunohematolog
method
includ
indirect
antiglobulin
test
iat
residu
edtaanticoagul
blood
sampl
use
isol
genom
dna
use
qiaamp
dna
blood
kit
qiagen
germani
ce
serolog
ddonor
dna
sampl
test
individu
presenc
rhdspecif
dna
sequenc
rhd
promot
intron
exon
exon
multiplex
pcrssp
method
reaction
conduct
final
volum
primer
appli
describ
f
wagner
et
al
bmc
genet
except
antisens
primer
exon
two
primer
amplifi
hgh
gene
fragment
intern
control
design
laboratori
pcr
product
visual
electrophoresi
agaros
gel
ethidium
bromid
stain
case
posit
reaction
sampl
analyz
pcrssp
weak
pcrssp
cde
innotrain
germani
result
dindividu
analyz
ddccee
ddccee
ddccee
one
ddccee
phenotyp
molecular
analysi
show
neg
four
rhd
dna
region
among
sampl
ddccee
phenotyp
three
found
posit
rhd
promot
intron
exon
exon
three
rhd
promot
exon
two
exon
alon
genotyp
reveal
five
hybrid
rhdced
allel
rhdce
rhdce
one
allel
repres
del
genotyp
remain
two
sampl
show
allel
could
determin
pcrssp
kit
summaryconclus
serotyp
standard
method
assign
transfus
strategi
alway
capabl
correctli
defin
sampl
show
weak
reaction
rhd
genotyp
strategi
need
confirm
dblood
donor
thu
avoid
antid
immun
reason
suggest
implement
easi
possibl
costeffect
method
background
weak
type
describ
date
transfus
recipi
weak
type
risk
form
allo
antid
expos
convent
rh
dposit
rbc
molecular
analysi
weak
offer
reliabl
basi
serotyp
determin
preval
weak
type
optim
transfus
strategi
background
antigen
consist
mosaic
epitop
determin
blood
donor
patient
peopl
either
rhdposit
rhdneg
certain
number
peopl
variat
antigen
call
weak
partial
del
phenotyp
aim
object
use
molecular
method
determin
whether
blood
donor
republika
srpska
serolog
weak
antigen
detect
realli
weak
antigen
addit
determin
whether
blood
donor
determin
person
rhdneg
phenotyp
c
e
rhd
gene
antigen
erythrocyt
membran
weak
could
determin
serolog
techniqu
method
blood
sampl
use
regular
blood
donor
determin
person
weaker
antigen
rhdneg
c
andor
e
posit
base
agglutin
strength
use
serolog
techniqu
test
tube
method
micropl
method
gel
method
gpmur
also
model
shown
close
resembl
tertiari
structur
glycophorin
predict
structur
antiparallel
b
sheet
arrang
b
barrel
also
refer
oblikefold
region
blood
group
antigen
identifi
predict
stabl
dimer
structur
summaryconclus
oblikefold
structur
typic
bind
oligonucleotid
oligosaccharid
associ
cold
shock
protein
model
progress
predict
structur
gpagpb
heterodim
basi
understand
present
blood
group
antigen
interest
find
consist
previou
report
show
gpa
bind
carbohydr
model
serv
foundat
futur
work
regard
properti
gpa
includ
identifi
locat
specif
interact
gpa
rbc
surfac
protein
gpb
band
well
identifi
structur
featur
antigen
region
gpa
even
though
signific
differ
found
among
group
studi
haplotyp
contain
mcc
b
polymorph
identifi
sampl
found
tb
l
group
summaryconclus
preliminari
data
obtain
suggest
polymorph
haplotyp
especi
contain
mcc
b
snp
could
involv
diseas
pathogenesi
tuberculosi
leprosi
entranc
mycobacteria
macrophag
mediat
complement
receptor
facilit
uptak
host
cell
combin
haplotyp
could
enhanc
parasit
phagocytosi
inflamm
studi
carri
establish
whether
polymorph
risk
protect
factor
whether
genet
variat
receptor
also
involv
abstract
withdrawn
background
dombrock
blood
group
system
consist
two
antithet
antigen
b
three
highpreval
antigen
gregori
gy
holley
hy
joseph
jo
rare
null
gy
phenotyp
lack
dombrock
antigen
null
allel
vari
background
report
molecular
basi
novel
null
allel
gy
brazilian
patient
antigi
aim
case
present
alloantibodi
highpreval
antigen
detect
serum
year
old
woman
northeast
brazil
histori
pregnanc
histori
previou
transfus
requir
transfus
schedul
total
thyroidectomi
surgeri
due
larg
compress
nodular
goiter
antibodi
react
autolog
rbc
react
indirect
antiglobulin
test
liss
panel
rbc
rbc
sampl
test
except
gy
phenotyp
correspond
antigen
resist
treatment
papain
sensit
dtt
trypsin
result
suggest
antibodi
recogn
antigen
dombrock
blood
group
system
purpos
studi
identifi
antibodi
specif
determin
molecular
basi
phenotyp
detect
method
red
cell
phenotyp
presenc
dombrock
relat
antibodi
serum
detect
standard
hemagglutin
techniqu
rbc
antibodi
inhous
collect
rare
sampl
genom
dna
prepar
peripher
blood
patient
dombrock
genotyp
perform
idcor
xt
platform
grifol
spain
exon
gene
amplifi
pcr
directli
sequenc
experiment
immunohematolog
diagnost
immunohematolog
diagnost
immunohematolog
experiment
immunohematolog
sanquin
amsterdam
netherland
background
type
blood
group
antigen
essenti
prevent
transfus
reaction
haemolyt
diseas
foetu
newborn
date
isbt
recognis
blood
group
antigen
antigen
belong
one
blood
group
system
sinc
genet
basi
system
known
genotyp
antigen
possibl
molecular
background
antigen
unknown
determin
serolog
one
antigen
sd
sid
first
report
popul
carri
sd
erythrocyt
frequenc
might
higher
sinc
identif
difficult
due
variabl
express
individu
sd
present
urin
cell
high
express
sd
cadsda
use
detect
antibodi
recent
antibodi
detect
panel
biorad
contain
sda
cell
mani
individu
antisd
detect
gene
implic
synthesi
sd
collect
individu
without
antisd
elucid
genet
background
antigen
aim
elucid
genet
basi
respons
loss
sd
antigen
red
blood
cell
method
routin
diagnost
identifi
antibodi
patient
perform
use
biorad
panel
contain
donor
high
express
sd
addit
pregnant
women
screen
antisd
dna
eight
sampl
antisd
eight
sampl
without
antisd
isol
analysi
sanger
sequenc
perform
exon
result
sequenc
reveal
two
homozyg
mutat
present
eight
individu
antisd
present
control
remain
two
control
heterozyg
mutat
first
mutat
within
exon
c
chang
cystein
arginin
posit
protein
second
mutat
exon
g
chang
amino
acid
snp
maf
therefor
expect
popul
homozyg
minor
allel
genotyp
larg
popul
pregnant
women
serolog
detect
antisd
women
homozyg
mutat
progress
summaryconclus
high
frequenc
antigen
sd
link
blood
group
system
molecular
basi
loss
antigen
elucid
gene
associ
sd
synthesi
therefor
analys
gene
mutat
individu
antibodi
sd
singl
homozyg
mutat
within
exon
caus
amino
acid
chang
found
individu
antisd
individu
without
antibodi
homozyg
snp
popul
studi
sd
neg
either
frequenc
overestim
difficulti
detect
low
express
antigen
mutat
gene
interf
sd
synthesi
larger
studi
individu
homozyg
mutat
linkag
sd
neg
presenc
antibodi
perform
sd
assign
new
blood
group
system
abstract
withdrawn
abstract
withdrawn
background
erythrocyt
duffi
blood
group
antigen
scaveng
chemokin
whole
blood
duffi
blood
group
gene
consist
two
major
allel
fy
fy
b
howev
littl
known
regard
associ
duffi
blood
group
polymorph
red
blood
cell
rbc
chemokin
scaveng
aim
aim
studi
determin
associ
duffi
blood
group
polymorph
rbc
chemokin
scaveng
method
duffi
blood
group
genotyp
assay
healthi
chines
han
individu
erythrocyt
chemokin
scaveng
function
duffi
antigen
express
sampl
measur
use
erythrocyt
chemokin
bind
assay
quantit
flow
cytometri
respect
result
rbc
chemokin
scaveng
significantli
lower
individu
fy
afi
genotyp
compar
fy
afi
b
genotyp
p
similar
result
also
observ
rbc
chemokin
scaveng
p
express
duffi
antigen
rbc
surfac
individu
fy
afi
genotyp
significantli
higher
compar
fy
fy
b
genotyp
p
summaryconclus
duffi
blood
group
polymorph
associ
differenti
rbc
chemokin
scaveng
probabl
chang
duffi
antigen
structur
caus
duffi
blood
group
polymorph
respons
differenti
rbc
chemokin
scaveng
background
individu
pphenotyp
develop
natur
occur
clinic
signific
caus
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
find
procur
blood
unit
pphenotyp
challeng
rariti
throughout
world
therefor
acut
normovolem
hemodilut
anh
hand
tool
periop
success
manag
patient
rare
blood
group
howev
approach
commonli
use
aim
na
method
na
result
korean
woman
refer
samsung
medic
center
surgic
manag
gallbladd
malign
blood
type
group
dposit
patient
known
histori
transfus
howev
antibodi
screen
identif
test
use
column
agglutin
method
biorad
cressier
switzerland
show
panagglutin
neg
reaction
autolog
red
blood
cell
indic
presenc
alloantibodi
high
frequenc
antigen
specimen
obtain
patient
sent
central
laboratori
swiss
red
cross
bern
switzerland
confirm
first
transfus
team
hospit
recommend
surgic
team
postpon
surgeri
howev
anh
plan
postpon
surgeri
prefer
patient
preoper
hemoglobin
gdl
ml
blood
withdrawn
radial
arteri
cathet
two
ml
blood
bag
contain
citratephosphatedextrosea
solut
anesthet
induct
equal
volum
hydroxyethyl
starch
solut
infus
procedur
patient
underw
radic
cholecystectomi
liver
wedg
resect
lymph
node
dissect
two
unit
autolog
blood
return
patient
surgeri
discharg
h
later
hemoglobin
level
gdl
later
famili
studi
perform
standard
serolog
method
use
proband
plasma
contain
sequenc
gene
conduct
accord
protocol
koda
et
al
transfus
proband
brother
homozyg
indic
rare
p
phenotyp
summaryconclus
experienc
autolog
blood
transfus
via
anh
altern
allogen
rbc
blood
transfus
patient
blood
avail
high
alloimmun
antibodi
rare
blood
group
third
sampl
gypb
sgyp
gypb
snull
predict
phenotyp
ss
mi
ssmi
respect
gypa
specif
primer
use
discrep
resolut
detect
nucleotid
substitut
gypaba
hybrid
associ
gphut
allel
thu
confirm
id
core
xt
result
express
mi
one
sampl
confirm
use
noncommerci
antisera
henc
three
sampl
gpmur
gphut
phenotyp
allel
codifi
express
mi
antigen
sinc
express
sever
hybrid
usual
form
glycophorin
b
two
three
gphut
sampl
africanamerican
donor
gphut
report
white
peopl
frequenc
thai
three
gphut
case
found
id
core
xt
studi
point
higher
frequenc
glycophorin
variant
also
presenc
african
american
popul
summaryconclus
id
core
xt
abl
detect
two
glycophorin
phenotyp
gpmur
gphut
codifi
express
mi
antigen
standard
molecular
method
implement
pretransfus
test
obstetr
care
routin
detect
clinic
relev
glycophorin
variant
mn
system
background
serf
high
preval
antigen
cromer
blood
group
system
encod
crom
allel
lack
serf
antigen
serf
red
cell
caus
singl
nucleotid
polymorph
exon
decayacceler
factor
daf
gene
alloantiserf
found
thai
pregnant
woman
serf
serf
individu
found
among
thai
blood
donor
antiserf
market
product
henc
molecular
techniqu
implement
genotyp
crom
allel
among
blood
donor
aim
studi
aim
identifi
crom
allel
among
thai
blood
donor
lead
predict
serf
serf
phenotyp
method
dna
sampl
obtain
central
thai
blood
donor
genotyp
serf
allel
detect
use
inhous
pcr
sequencespecif
primer
pcrssp
confirm
dna
sequenc
result
allel
frequenc
crom
crom
among
central
thai
respect
homozyg
crom
allel
found
studi
addit
pcrssp
techniqu
valid
dna
sequenc
use
randomli
chosen
sampl
togeth
heterozyg
crom
sampl
result
agreement
summaryconclus
result
confirm
high
frequenc
crom
allel
thai
popul
frequenc
similar
formerli
report
among
thai
blood
donor
studi
would
benefici
predict
serf
antigen
genotyp
result
due
unavail
commerci
antiserum
background
increas
interest
use
molecular
method
predict
abo
group
though
nextgen
sanger
sequenc
use
predict
abo
type
predict
abo
type
buccal
swabderiv
dna
deceas
donor
benefit
quick
reliabl
method
besid
pcrrflp
use
mani
lab
year
commerciallyavail
research
use
ruo
kit
interrog
nucleotid
associ
b
repres
ancestr
allel
aim
aim
report
compar
two
lowresolut
polymeras
chain
reaction
pcr
base
method
investig
sampl
submit
refer
molecular
immunohematolog
laboratori
abo
type
discrep
fiftysix
peripher
blood
sampl
test
patient
blood
donor
method
genom
dna
isol
peripher
blood
mononuclear
cell
background
del
weakest
known
posit
phenotyp
rh
blood
group
system
detect
adsorpt
elut
test
chang
import
marker
del
phenotyp
east
asian
rapid
effici
pcr
method
rhd
gene
g
genotyp
use
east
asian
countri
aim
aim
studi
develop
method
rhd
genotyp
use
singletub
pcr
melt
temperatur
shift
primer
method
two
allelespecif
primer
rhd
common
primer
design
synthes
two
gcrich
tail
differ
length
attach
end
allelespecif
pcr
primer
singletub
pcr
shift
primer
carri
three
primer
pcr
melt
curv
analysi
perform
rhd
could
genotyp
differ
pcr
product
genotyp
result
compar
obtain
convent
pcrssp
discord
result
rhd
exon
sequenc
perform
determin
rhd
genotyp
result
total
sampl
genotyp
rhd
pcr
mshift
primer
sampl
type
sampl
type
sampl
type
sampl
type
two
sampl
type
pcrssp
pcr
shift
primer
confirm
rhd
exon
sequenc
summaryconclus
singletub
pcr
shift
primer
rhd
genotyp
simpl
rapid
accur
superior
convent
pcrssp
abstract
withdrawn
background
rh
blood
group
system
numer
variant
allel
may
affect
rh
antigen
express
includ
rhdrhce
dce
hybrid
gene
variant
allel
frequent
found
peopl
african
descent
typic
result
either
dneg
phenotyp
partial
antigen
express
includ
silenc
highfrequ
antigen
andor
express
lowfrequ
antigen
patient
carri
allel
particularli
risk
alloimmun
suggest
identif
import
diagnost
quantit
multiplex
polymeras
chain
reaction
pcr
short
fluoresc
fragment
qmpsf
proven
success
genotyp
dna
sampl
carri
dce
hybrid
gene
assess
qualit
quantit
rhd
rhce
gene
exon
aim
aim
project
genotyp
rh
gene
cohort
brazilian
patient
sickl
cell
diseas
scd
known
african
descent
use
qmpsf
approach
report
hybrid
gene
variabl
popul
method
onehundr
fifteen
dna
sampl
select
studi
analyz
prospect
rhdqmpsf
rhceqmpsf
approach
investig
copi
number
exon
rh
gene
genotyp
confirm
investig
sanger
sequenc
convent
pcrrflp
assay
result
dna
sampl
exhibit
wildtyp
profil
qmpsf
analysi
hybrid
gene
involv
exon
function
relev
report
found
sampl
includ
sampl
carri
respect
rhdce
rhced
ce
two
homozyg
except
two
sampl
requir
addit
studi
rhd
zygos
resolv
success
n
rhd
gene
copi
clinic
relev
ie
partial
genotyp
identifi
four
hemizyg
sampl
carri
rhd
rhd
rhd
diiialik
allel
novel
rhd
dce
allel
confirm
sequenc
hybrid
allel
rhd
rhd
diiic
also
found
tran
normal
rhd
allel
rhce
cc
genotyp
could
resolv
rhce
rhce
ce
ce
allel
commonli
cisassoci
rhd
observ
four
sampl
howev
clinic
relev
polymorph
variant
rhce
allel
involv
cemo
cear
ceag
ceti
mostli
identifi
standard
method
summaryconclus
although
brazilian
patient
scd
investig
studi
carri
rhdrhce
hybrid
gene
qmpsf
analysi
shown
effici
tool
whole
genotyp
process
investig
rh
gene
variat
previous
report
conclus
character
rhd
zygos
identif
rare
well
novel
variant
allel
addit
result
show
larg
divers
hybrid
gene
among
brazilian
patient
scd
therefor
suggest
qmpsf
may
use
complementari
screen
approach
assess
rh
genotyp
select
patient
donor
vs
nonbleed
n
patient
platelet
pmp
cp
phenotyp
function
evalu
flow
cytometri
activ
granul
releas
examin
antibodi
granulphysin
pselectin
activ
gpiibiiia
phosphatidylserin
ps
lactadherin
unstimul
adp
trap
collagen
stimul
coat
platelet
identifi
highli
granul
independ
cell
popul
appear
follow
collagen
stimul
gate
side
scatter
gpiba
normal
healthi
refer
level
avail
result
platelet
count
bleed
l
nonbleed
l
patient
compar
p
bleed
patient
higher
bat
score
compar
nonbleed
patient
vs
p
proport
cp
normal
patient
howev
nonbleed
patient
proport
pscp
per
cell
ps
express
mfi
higher
compar
bleed
patient
p
proport
pscp
correl
neg
bat
score
r
p
cp
higher
nonbleed
compar
bleed
patient
significantli
higher
refer
level
p
final
proport
pspmp
normal
bleed
patient
pmp
express
higher
refer
ps
per
cell
unstimul
agonist
mfi
unstimul
vs
mfi
refer
p
summaryconclus
patient
exhibit
differ
bleed
tendenc
despit
compar
thrombocytopenia
nonbleed
patient
proport
per
cell
level
ps
higher
indic
gener
cp
high
ps
express
critic
factor
determin
bleed
phenotyp
find
high
pmp
ps
per
cell
level
bleed
patient
could
repres
inadequ
compens
lack
cp
function
indic
procoagul
pmp
may
less
import
cp
thrombocytopen
bleed
quantif
character
cp
may
use
tool
futur
assess
bleed
risk
well
therapeut
target
condit
bleed
diathesi
andor
thrombocytopenia
studi
investig
field
warrant
background
alloantibodi
human
platelet
antigen
hpa
human
leukocyt
antigen
hla
implic
sever
immunemedi
platelet
disord
detect
antibodi
crucial
diagnosi
manag
disord
aim
establish
method
detect
hla
antibodi
use
luminex
bead
technolog
method
monoclon
antibodi
specif
platelet
glycoprotein
hla
class
molecul
separ
coupl
luminex
microbead
posit
sampl
use
valid
specif
luminex
assay
standard
sampl
use
evalu
sensit
luminex
assay
serial
dilut
neat
result
sampl
collect
patient
isbt
platelet
workshop
test
luminex
assay
result
show
luminex
assay
could
detect
antibodi
success
known
sampl
sensit
luminex
assay
detect
respect
use
standard
sampl
crossreact
observ
sampl
contain
multiplatelet
antibodi
mixtur
antibodi
hpa
hla
result
sampl
platelet
disord
agreement
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
summaryconclus
luminex
bead
coupl
monoclon
antibodi
could
success
use
detect
hpa
hla
antibodi
high
sensit
background
platelet
transfus
import
clinic
treatment
express
abo
antigen
platelet
surfac
differenti
usual
need
ensur
consist
abo
antigen
clinic
transfus
mani
case
difficult
find
platelet
abo
blood
type
match
recipi
donor
aboincompat
platelet
infus
requir
case
data
express
abo
antigen
platelet
normal
blood
group
individu
rare
report
chines
popul
aim
understand
differenti
express
abo
antigen
platelet
surfac
popul
zhejiang
provinc
china
method
total
individu
normal
abo
group
group
group
b
group
ab
individu
group
neg
control
abo
antigen
platelet
analyz
express
abo
antigen
platelet
determin
flow
cytometri
use
monoclon
antibodi
fluorescein
isothiocyan
fitc
conjug
mous
antihuman
blood
group
peconjug
murin
antib
antibodi
flow
cytometr
paramet
statist
analyz
mannwhitney
test
kruskalw
test
observ
differ
two
group
use
graphpad
softwar
correl
regress
analysi
b
antigen
platelet
rbc
also
perform
softwar
popul
studi
report
mean
standard
deviat
sd
p
valu
less
consid
statist
signific
result
accord
mfi
valu
abo
antigen
express
platelet
sampl
divid
three
group
low
express
le
high
express
moder
express
accord
background
mfi
observ
group
sampl
found
individu
weak
express
abo
antigen
platelet
surfac
zhejiang
provinc
signific
differ
intens
antigen
express
three
differ
group
blood
group
blood
group
posit
correl
intens
abo
antigen
express
platelet
membran
red
blood
cell
individu
result
case
found
antibodi
posit
among
case
antihlai
posit
case
antihpa
posit
case
antihlai
antihpa
posit
case
found
without
antihlai
antihpa
among
case
antihpa
posit
distribut
antigpiibiiia
antigpiaiia
antigpibix
antigpiv
respect
hla
antibodi
posit
rate
femal
patient
higher
male
hpa
antibodi
posit
rate
femal
lower
male
signific
differ
p
summaryconclus
ptr
patient
platelet
antibodi
mainli
hlai
antibodi
combin
hpa
antibodi
background
human
neutrophil
antigen
hna
polymorph
structur
locat
surfac
membran
human
neutrophil
alloantibodi
hna
implic
number
clinic
condit
includ
immunemedi
neutropenia
transfus
reaction
genotyp
human
neutrophil
antigen
hna
system
import
diagnosi
disord
involv
alloimmun
hna
aim
aim
studi
investig
hna
allel
frequenc
among
blood
donor
hematolog
patient
undergo
blood
transfus
estim
possibl
hna
incompat
risk
hna
alloimmun
method
total
blood
donor
hematolog
patient
northwest
region
russian
feder
recruit
dna
sampl
obtain
type
system
use
polymeras
chain
reaction
sequencespecif
primer
pcrssp
specif
primer
hna
design
polymeras
chain
reaction
amplif
condit
optim
v
test
use
test
hardyweinberg
equilibrium
hna
system
probabl
incompat
potenti
risk
alloimmun
differ
hna
system
random
transfus
estim
base
hna
allel
genotyp
frequenc
result
blood
donor
frequenc
allel
allel
itgam
itgam
allel
itgal
itgal
allel
respect
hematolog
patient
gene
frequenc
respect
statist
signific
differ
genotyp
group
observ
sinc
allel
frequenc
hna
hematolog
patient
donor
statist
signific
differ
possibl
hna
incompat
risk
hna
alloimmun
estim
base
obtain
data
allel
genotyp
frequenc
hna
group
combin
donor
hematolog
patient
n
predict
risk
incompat
cohort
respect
possibl
risk
alloimmun
respect
alloimmun
alloimmun
alloimmun
respect
summaryconclus
inform
hna
gene
frequenc
use
blood
servic
detect
identif
hna
alloantibodi
donor
assess
alloimmun
risk
also
anthropolog
studi
background
noninvas
fetal
rhd
genotyp
perform
use
circul
cellfre
fetal
dna
matern
plasma
sampl
realtim
polymeras
chain
reaction
antenat
routin
dna
test
use
target
rhig
administr
prevent
hemolyt
diseas
newborn
aim
aim
studi
character
matern
rhd
variant
respons
indetermin
result
fetal
rhd
genotyp
due
earli
amplif
least
one
exon
rhd
gene
method
sampl
test
use
free
dna
fetal
kit
rhd
sampl
yield
prematur
signal
one
exon
rhd
gene
extract
matern
cellular
dna
matern
rhd
character
use
rhd
beadchip
assay
immucorbioarray
rhdiiiac
summaryconclus
greater
divers
observ
caucasian
popul
rather
afrocaribbean
identifi
variant
rhd
neg
allel
includ
allel
lead
partial
antigen
express
unexpect
allel
found
weak
type
data
underlin
benefit
matern
rhd
genotyp
abnorm
earli
signal
detect
noninvas
fetal
rhd
genotyp
background
consider
number
rhd
allel
respons
weak
phenotyp
identifi
serolog
determin
phenotyp
often
doubt
make
genet
analysi
rhd
gene
highli
desir
transfus
recipi
pregnant
women
dnabas
method
use
enhanc
immunohematolog
type
doubt
phenotyp
pregnant
women
aim
determin
rhd
gene
cohort
pregnant
women
doubt
phenotyp
method
determin
rhd
phenotyp
perform
microagglutin
techniqu
biorad
ortho
diagnost
simultan
rhd
genotyp
perform
case
type
serolog
discrep
readytous
innotrain
rbcreadi
gene
cde
rbcreadi
gene
weak
test
kit
base
polymeras
chain
reaction
sequencespecif
prime
pcrssp
unclear
serolog
find
result
molecular
analys
show
pregnant
women
rhd
weak
type
risk
antid
rhd
weak
type
type
case
case
rhd
weak
partial
potenti
risk
alloimmun
produc
antid
alloantibodi
summaryconclus
appropri
classif
rhd
phenotyp
recommend
correct
indic
rhig
pregnant
women
howev
serolog
differ
rhdneg
rhdposit
pregnant
women
real
problem
unnecessari
applic
rhig
prophylaxi
pregnant
women
variant
conclus
antenat
rhig
prophylaxi
use
rhd
neg
pregnant
women
genotyp
found
serolog
doubt
rhd
neg
women
variant
produc
anti
antibodi
case
rhig
prophylaxi
unnecessari
harm
product
human
origin
hand
save
stock
rhig
way
deficit
time
think
cost
benefit
rhig
prophylaxi
genotyp
pregnant
women
background
may
uk
neqa
btlp
creat
extern
qualiti
assess
eqa
sampl
design
mimic
fetomatern
haemorrhag
fmh
bleed
ml
materi
use
pass
preaccept
serolog
test
sampl
dispatch
particip
countri
postdispatch
test
flow
cytometri
fc
use
antid
marker
show
bleed
volum
ml
investig
initi
aim
determin
caus
unexpectedli
low
bleed
volum
lesson
could
learnt
method
product
methodolog
result
preaccept
test
review
fc
test
repeat
plot
examin
fmh
scientif
advisori
group
consult
advic
fc
test
perform
wb
use
altern
marker
materi
use
investig
ibgrl
particip
result
examin
determin
sampl
withdrawn
score
questionnair
result
manag
sent
particip
use
fc
antid
marker
result
materi
product
methodolog
review
show
obviou
caus
erron
inhous
result
review
preaccept
test
imag
show
issu
dtype
cord
show
reaction
vs
two
reagent
tube
cf
two
differ
reagent
column
agglutin
technolog
repeat
fc
test
use
antid
marker
gave
similar
result
howev
closer
examin
plot
show
left
shift
posit
peak
indic
reduc
fluorochrom
bind
possibl
due
reduc
antigen
densiti
cord
cell
fc
test
wb
demonstr
mark
reduct
fluoresc
intens
antid
marker
investig
use
antihbf
marker
show
bleed
volum
ml
indic
correct
proport
cord
materi
use
sampl
product
addit
serolog
ibgrl
cord
materi
show
reaction
weaker
control
antid
reagent
overal
investig
support
hypothesi
cord
materi
variant
review
result
submit
particip
mirror
fc
investig
sampl
withdrawn
score
fc
median
result
use
calcul
score
variant
cord
clearli
affect
test
antid
marker
questionnair
show
respond
examin
fc
plot
gate
use
act
report
result
backup
plan
antid
ig
dose
similar
situat
later
sequenc
gene
reveal
cord
donor
dvii
lower
normal
antigen
densiti
summaryconclus
use
variant
cord
eqa
sampl
plan
allow
uk
neqa
highlight
import
learn
point
thorough
examin
fc
plot
essenti
avoid
underestim
fmh
control
procedur
place
modif
gate
requir
access
cordneonat
blood
allow
serolog
investig
may
use
similar
clinic
situat
import
backup
plan
issu
antid
ig
event
uninterpret
fmh
result
background
alloantibodi
fetal
blood
group
platelet
antigen
produc
antigenneg
pregnant
women
caus
hemolyt
diseas
fetu
newborn
hdfn
fetal
neonat
alloimmun
thrombocytopenia
fnait
predict
fetu
antigen
statu
immun
women
import
make
decis
concern
manag
pregnanc
nipt
wide
use
determin
fetal
blood
group
determin
proper
specif
realtim
amplif
singl
nucleotid
polymorph
snp
k
requir
modifi
protocol
droplet
digit
pcr
ddpcr
permit
detect
lowgrad
fetal
chimer
matern
plasma
dna
higher
specif
use
allel
discrimin
pcr
protocol
aim
establish
ddpcr
protocol
noninvas
prenat
diagnost
nipd
clinic
import
blood
group
antigen
method
dna
isol
plasma
sampl
pregnant
women
donor
known
genotyp
easymag
biomerieux
allel
discrimin
protocol
determin
kk
n
ss
n
n
n
n
n
genotyp
perform
use
ddpcr
method
droplet
digit
tm
biorad
result
allel
discrimin
perform
use
ddpcr
concord
alreadi
known
phenotypegenotyp
donor
pregnant
women
ddpcr
enabl
detect
read
total
dna
plasma
test
sampl
fetal
result
agreement
antigen
posit
genotyp
neonat
fetal
chimer
one
case
advanc
pregnanc
week
gestat
test
sampl
fals
posit
result
detect
level
unspecif
read
summaryconclus
implement
allel
discrimin
protocol
ddpcr
allow
detect
fetalmatern
incompat
kk
ss
antigen
encod
snp
background
franc
pregnanc
complic
antid
antic
alloimmun
test
current
use
quantit
matern
antibodi
tube
method
titrat
continu
flow
analysi
determin
antibodi
concentr
recent
autom
assay
develop
use
column
agglutin
technolog
system
biorad
aim
want
evalu
score
calcul
agglutin
profil
antibodi
system
quantit
data
appreci
level
matern
antibodi
method
titer
sampl
contain
antid
contain
antic
establish
use
semiautom
tube
method
perform
sinc
decad
lab
fulli
autom
gel
method
system
score
calcul
manual
case
antibodi
concentr
also
determin
sampl
continu
flow
analysi
autoanalyz
devic
evolut
iii
am
allianc
look
possibl
correl
antid
antic
score
correspond
concentr
use
spearman
correl
test
result
antid
tube
gel
score
significantli
correl
antid
concentr
valu
p
r
p
r
respect
antic
score
also
significantli
correl
antic
concentr
valu
p
gel
score
better
correl
coeffici
tube
score
r
versu
easier
extrapol
gel
score
threshold
tube
score
threshold
autoanalyz
valu
aim
trigger
fetal
monitor
ultrasound
measur
peak
systol
veloc
middl
cerebr
arteri
risk
pregnanc
determin
gel
score
threshold
correspond
respect
uiml
uchpml
antid
uiml
uchpml
antic
conclus
calcul
score
hemagglutin
profil
display
system
provid
ad
valu
compar
sole
read
titer
antic
immun
gel
score
discrimin
tube
one
better
correl
concentr
valu
establish
continu
flow
analysi
propos
score
threshold
trigger
fetal
antenat
monitor
need
howev
confirm
sampl
clinic
document
background
hdnf
due
matern
igg
alloantibodi
direct
fetal
antigen
cross
placenta
pregnanc
caus
hemolysi
fetu
anemia
lead
edema
ascit
hydrop
case
death
diagnosi
manag
hdnf
base
matern
screen
middl
cerebr
arteri
mca
doppler
monitor
sever
hdnf
intrauterin
blood
transfus
iut
exchang
transfus
et
birth
necessari
correct
anemia
prevent
treat
fetal
hydrop
aim
report
eight
year
experi
immunohematolog
refer
laboratori
irl
highlight
import
red
cell
antibodi
detect
fundament
paramet
identifi
pregnanc
high
fetal
risk
drive
correct
treatment
method
report
laboratori
data
pregnant
women
posit
indirect
antiglobulin
test
iat
refer
irl
januari
decemb
perform
antibodi
screen
identif
indirect
antiglobulin
test
iat
microcolumn
method
biovu
system
orthoclin
diagnost
raritan
usa
titl
antibodi
iat
tube
method
without
addit
followup
test
also
perform
presenc
signific
red
cell
antibodi
order
check
antibodi
titl
begin
clinic
monitor
threshold
valu
anti
kell
antibodi
specif
result
women
display
clinic
signific
antibodi
clinic
insignific
antibodi
natur
antibodi
differ
specif
among
women
clinic
signific
antibodi
frequent
antid
also
combin
rh
antibodi
antik
account
anti
antibodi
highincid
antigen
antim
antil
antibodi
also
found
respect
clinic
signific
among
women
clinic
relev
antibodi
show
critic
antibodi
titl
underw
gynecolog
obstetr
monitor
fetus
result
affect
hdfn
display
antid
case
antikel
fetus
sever
hdfn
antid
antikel
requir
iut
treat
et
receiv
red
blood
cell
unit
birth
summaryconclus
mother
screen
program
led
import
improv
outcom
hdfn
identif
women
clinic
signific
antibodi
allow
appropri
monitor
program
therapi
background
hemolyt
diseas
fetu
newborn
hdfn
sever
diseas
result
matern
erythrocyt
alloantibodi
direct
fetal
erythrocyt
alloimmun
pregnant
women
found
rang
worldwid
erythrocyt
surfac
antigen
report
associ
hdfn
although
antirhesu
major
etiolog
hdfn
univers
introduct
antenat
postpartum
rh
immunoglobulin
result
mark
decreas
preval
alloimmun
rhd
antigen
pregnanc
consequ
alloantibodi
antid
emerg
import
caus
sever
hdnf
particular
antik
antic
howev
antigen
also
found
associ
hdfn
aim
retrospect
identif
erythrocyt
antibodi
pregnant
women
hospit
de
braga
method
studi
plan
assess
preval
erythrocyt
antibodi
respons
alloimmun
exclud
aboimmun
pregnant
women
attend
antenat
clinic
hospit
braga
year
januari
decemb
studi
retrospect
evalu
erythrocyt
antibodi
screen
result
pregnant
women
women
posit
erythrocyt
antibodi
screen
also
underw
identif
gel
card
system
follow
manufactur
instruct
diam
outcom
infant
whose
mother
indirect
antiglobulin
test
found
posit
examin
direct
antiglobulin
test
jaundic
phototherapi
histori
transfus
mortal
newborn
record
result
studi
period
pregnant
women
attend
hospit
de
braga
laboratori
regist
posit
erythrocyt
antibodi
screen
test
preval
posit
erythrocyt
antibodi
screen
antid
common
antibodi
found
antid
prophylaxi
given
pregnanc
respons
case
matern
antibodi
titer
level
exceed
among
case
preval
nonrhd
immun
anti
frequent
alloantibodi
antid
follow
antim
antic
multipl
matern
antibodi
found
pregnant
women
four
women
type
alloantibodi
antic
anti
antic
antid
antik
anticw
anti
nonidentifi
antibodi
one
pregnant
type
alloantibodi
antid
antic
anti
case
newborn
whose
mother
posit
antibodi
screen
test
icteru
occur
phototherapi
given
summaryconclus
preval
posit
erythrocyt
antibodi
screen
hospit
de
braga
erythrocyt
antibodi
screen
show
antid
common
antibodi
found
case
antid
prophylaxi
preval
nonrhd
immun
frequent
alloantibodi
anti
antim
antic
increas
preval
nonantid
alloimmun
found
current
prevent
strategi
contrast
rhd
alloimmun
main
risk
factor
nonantid
alloimmun
previou
transfus
therapi
thu
import
minim
exposur
women
incompat
erythrocyt
antigen
unnecessari
transfus
possibl
background
mn
blood
group
system
one
complex
blood
group
system
although
alloantim
common
antibodi
observ
pregnant
women
could
also
found
serum
individu
expos
posit
erythrocyt
rare
clinic
signific
regard
unimport
antibodi
caus
hemolyt
diseas
fetu
newborn
hdfn
especi
caucasian
black
ethnic
group
long
time
howev
increas
number
case
sever
hdfn
result
fetal
hydrop
recurr
abort
caus
alloantim
report
mainli
asian
popul
especi
japanes
chines
popul
aim
summar
charact
serolog
test
preterm
twin
newborn
suffer
sever
hdfn
method
blood
sampl
two
newborn
sever
hdfn
mother
histori
three
hydrop
fetu
collect
abo
rhd
rhce
mn
blood
group
type
twin
newborn
mother
perform
salin
tube
gel
card
direct
agglutin
test
dat
elut
test
antibodi
specif
identif
antibodi
titer
detect
conduct
iat
method
gel
card
result
rhd
ccee
blood
group
identifi
mother
twin
newborn
background
franc
sinc
may
legisl
promot
anymor
use
refer
tube
method
titrat
antir
blood
cell
antibodi
open
way
use
newli
develop
autom
antir
blood
cell
antibodi
quantit
column
agglutin
technolog
aim
want
assess
perform
titrat
score
idgel
test
system
compar
perform
establish
refer
tube
method
use
lab
sinc
decad
anoth
object
studi
determin
titer
threshold
gel
method
trigger
fetal
monitor
ultrasound
measur
peak
systol
veloc
middl
cerebr
arteri
method
homemad
intern
qualiti
control
iqc
prepar
calibr
use
intern
antid
standard
use
determin
intraassay
interassay
imprecis
regard
score
titer
result
patient
sampl
test
chosen
assay
period
regard
specif
antibodi
tube
titer
order
cover
wide
rang
lower
valu
highest
differ
dilut
higher
seen
antibodi
direct
rh
system
antigen
among
specif
antik
antim
antibodi
show
sampl
equal
lower
titer
compar
tube
method
conclus
autom
antir
blood
cell
antibodi
titrat
column
agglutin
technolog
system
show
better
intra
interassay
cv
compar
tube
method
explain
fulli
autom
process
includ
read
step
titer
result
almost
alway
higher
gel
technolog
thu
seem
possibl
safe
extrapol
titer
threshold
defin
antir
blood
cell
antibodi
tube
method
gel
method
howev
base
futur
clinic
studi
fetalneonat
outcom
would
probabl
necessari
increas
threshold
least
antirh
antibodi
order
avoid
heavi
expens
stress
useless
monitor
pregnanc
result
first
case
femal
infant
yellowish
skin
develop
next
day
birth
capillari
bilirubin
level
mgdl
evid
favor
neonat
hyperbilirubinemia
clinic
manifest
reveal
hemolysi
symptom
laboratori
find
show
elev
reticulocyt
ldh
iul
ughb
dat
iat
anemia
hb
gdl
hct
blood
smear
show
anisocytosi
spherocyt
polychromat
rbc
mother
blood
type
posit
blood
type
b
posit
antib
found
elut
rbc
due
rare
sever
anemia
abo
incompat
matern
plasma
analys
abo
igg
antibodi
show
high
antibodi
b
titr
femal
infant
receiv
one
unit
washedprbc
anemia
intens
phototherapi
hyperbilirubinemia
clinic
condit
improv
significantli
hb
rose
bilirubin
level
within
normal
rang
discharg
anoth
male
infant
second
case
third
day
birth
yellowish
skin
discolor
develop
bilirubin
level
mgdl
two
day
later
transcutan
bilirubin
tcb
measur
data
high
laboratori
find
also
show
rais
reticulocyt
dat
iat
hb
background
antiindian
b
rare
alloantibodi
high
frequenc
antigen
b
individu
phenotyp
ab
observ
frequenc
indian
popul
describ
caucasian
major
antiin
b
antibodi
report
individu
without
previou
transfus
indic
possibl
natur
occur
antibodi
antiin
b
consid
clinic
signific
haemolyt
reaction
b
incompat
transfus
report
haemolyt
diseas
foetu
newborn
hdfn
due
antiin
b
describ
howev
posit
direct
antihuman
globulin
test
dat
may
observ
aim
describ
challeng
manag
pregnanc
childbirth
woman
antiin
b
method
serolog
investig
perform
iat
tube
column
agglutin
papain
trypsin
treat
cell
also
utilis
solubl
recombin
blood
group
protein
inrbgp
innotrain
germani
use
neutral
test
clinic
signific
antiin
b
antibodi
determin
monocyt
monolay
assay
mma
genom
dna
isol
whole
blood
sampl
character
pcr
amplif
sanger
sequenc
exon
result
pregnant
para
woman
indian
origin
without
previou
transfus
alloantibodi
specif
antiin
b
titer
detect
iat
neg
papaintr
cell
gestat
week
gw
mma
perform
duplic
sampl
taken
date
show
mi
respect
mi
interpret
follow
relev
inconclus
clinic
signific
patient
parent
type
heterozyg
wherea
husband
homozyg
due
husband
phenotyp
fetu
predict
b
posit
doppler
flow
measur
peak
systol
veloc
middl
cerebr
arteri
foetu
normal
deliveri
took
place
gw
without
increas
bleed
neonat
present
clinic
manifest
hdfn
neither
mother
babi
requir
blood
transfus
summaryconclus
report
case
pregnant
woman
indian
origin
antiin
b
alloantibodi
first
mma
perform
gw
inconclus
wherea
second
mma
perform
gw
indic
antibodi
clinic
signific
miincreas
due
pregnanc
also
clinic
signific
state
b
neg
blood
compon
avail
patient
rel
b
posit
therefor
measur
avoid
transfus
includ
optimis
peripart
manag
haemostasi
utmost
import
case
publish
risk
hdfn
could
exclud
certainti
intrauterin
investig
doppler
perform
exclud
relev
anaemia
fetu
transfus
need
deliveri
haemorrhag
complic
neonat
present
clinic
sign
hdfn
background
hemolyt
diseas
fetu
newborn
hdfn
diseas
untreatedcan
caus
perinat
mortal
morbid
substanti
risk
longterm
sequela
albania
lack
studi
field
aim
aim
studi
determin
predict
valu
reliabl
critic
titr
evalu
red
cell
alloantibodi
abil
caus
hemolyt
diseas
fetu
newborn
method
conduct
descript
crosssect
studi
data
collect
univers
hospit
obstetr
gynecolog
albania
studi
includ
immun
pregnant
woman
antid
antibodi
newborn
affect
hemolyt
diseas
fetu
newborn
data
belong
period
result
critic
titr
studi
mean
minim
valu
titr
antibodi
could
caus
hemolyt
diseas
fetu
newborn
studi
conclud
newborn
born
without
hemolyt
diseas
fetu
newborn
titr
valu
less
moder
hemolyt
diseas
fetu
newborn
caus
titr
valu
summaryconclus
titr
valu
mother
predict
option
high
risk
give
birth
child
hemolyt
diseas
fetu
newborn
recommend
case
mother
follow
doppler
ultrasonographi
measur
blood
flow
middl
cerebr
arteri
also
doctor
recommend
pregnant
women
posit
coomb
test
identif
antid
antibodi
also
identif
antibodi
anti
antic
antik
background
rhdneg
pregnant
women
alloantid
risk
fetu
affect
haemolyt
diseas
fetu
newborn
hdfn
fetu
rhdposit
rhd
allel
highli
polymorph
mani
rhd
variant
give
rise
array
partial
phenotyp
clinic
signific
mani
partial
phenotyp
wellestablish
rhd
genotyp
noninvas
prenat
test
nipt
assess
fetal
rhd
statu
determin
whether
fetu
risk
hdfn
nipt
test
also
includ
strategi
detect
matern
rhd
variant
provid
accur
report
howev
presenc
patern
rhd
variant
potenti
confound
nipt
interpret
often
recognis
report
trio
famili
studi
trigger
request
nipt
rhdneg
pregnant
mother
week
gestat
present
alloantid
antijk
antibodi
subsequ
patern
fetal
rhd
genotyp
conduct
reveal
novel
variant
rhd
allel
aim
aim
characteris
patern
rhd
allel
review
clinic
case
featur
method
rh
phenotyp
perform
standard
serolog
procedur
nipt
test
fetal
rhd
exon
rhd
genotyp
whole
bloodcord
blood
dna
perform
immucor
bioarray
rhd
beadchip
kit
predict
rhd
phenotyp
variant
best
fit
dna
sequenc
perform
use
illumina
trusight
one
sequenc
panel
copi
number
variat
cnv
analysi
use
assess
rhd
exon
structur
zygos
result
patern
red
cell
type
group
rhdccee
ror
nipt
genotyp
detect
fetal
rhd
signal
exon
predict
rhdposit
matern
rhd
sequenc
detect
consist
homozygos
rhd
delet
haplotyp
patern
cord
genom
dna
gdna
beadchip
genotyp
predict
rhd
variant
diiiacehar
furthermor
signal
drop
observ
nucleotid
posit
locat
rhd
exon
suggest
exon
either
delet
rhcereplac
patern
cord
gdna
sequenc
detect
snp
c
g
associ
diiia
phenotyp
plu
addit
snp
c
rhd
gene
rhd
hemizygot
cnv
analysi
rhce
variant
detect
clinic
case
featur
matern
antid
quantit
increas
iuml
week
gestat
iuml
week
gestat
fetu
requir
intrauterin
transfus
pregnanc
manag
hdfn
summaryconclus
father
fetu
carri
rhd
allel
align
allel
encod
diii
phenotyp
put
novel
rhd
variant
allel
compris
snp
associ
diiia
possibl
exon
deletionrhcereplac
similar
allel
report
literatur
although
base
sequenc
analysi
phenotyp
data
variant
allel
encod
rhdposit
phenotyp
predict
may
loss
depitop
notwithstand
clinic
present
show
matern
antid
rhd
phenotyp
presum
partial
associ
sever
hdfn
rhd
blood
group
phenotyp
clinic
signific
alloimmunis
pregnanc
abstract
withdrawn
background
glycosylphosphatidylinositol
gpi
anchor
protein
appar
molecular
mass
kda
addit
express
human
plt
express
activ
tcell
endotheli
cell
hematopoiet
stem
cell
well
progenitor
cell
chines
popul
calcul
allel
frequenc
respect
base
data
risk
alloimmun
alloantibodi
due
incompat
plt
transfus
pregnanc
expect
occur
rel
high
frequenc
howev
today
report
alloimmun
chines
popul
studi
analyz
sera
hydrop
fetu
case
maipa
techniqu
icfa
aim
detect
antihpa
alloantibodi
maipa
icfa
method
mother
gravida
mother
first
pregnanc
diagnos
hydrop
fetu
pregnanc
week
ultrasound
second
pregnanc
fetal
hydrop
observ
ultrasound
pregnanc
week
mother
irregular
antibodi
test
neg
matern
platelet
specif
antibodi
hla
antibodi
neg
blood
routin
morpholog
examin
fetal
umbil
cord
blood
show
plt
count
drop
l
wbc
count
drop
l
includ
neutrophil
lymphocyt
mononuclear
eosinophil
basophil
red
blood
cell
normal
hb
gl
screen
hla
pltspecif
antibodi
perform
use
elisabas
plt
antibodi
kit
pakplu
gti
diagnost
recommend
manufactur
plt
antibodi
detect
icfa
maipahpa
genotyp
detect
cprssp
result
fetu
genotyp
naka
matern
naka
patern
genotyp
naka
incompat
antigen
compar
matern
hpa
sampl
test
use
fresh
plt
panel
consist
homozyg
donor
reactiv
neg
control
mother
sera
plt
donor
donor
donor
donor
maipa
mother
serum
show
reactiv
plt
weak
posit
reactiv
plt
od
valu
strong
reactiv
plt
od
valu
find
could
confirm
one
refer
plt
laboratori
japanes
red
cross
kantokoshinetsu
block
blood
center
japan
use
freshli
isol
plt
donor
averag
valu
summaryconclus
studi
found
case
fnait
patient
blood
group
use
maipa
techniqu
abl
detect
presenc
alloantibodi
one
case
nait
background
fetal
neonat
alloimmun
thrombocytopenia
fnait
occur
live
birth
caucasian
serolog
molecular
human
platelet
antigen
hpa
genotyp
test
perform
investig
conclud
fnait
diagnosi
howev
case
particularli
case
suspicion
privat
platelet
antigen
special
analyz
must
perform
laboratori
lab
analyz
rang
sanger
ng
sequenc
platelet
serolog
transfect
cell
aim
aim
studi
explor
frontier
research
care
take
place
field
platelet
immunolog
prism
fnait
investig
carri
platelet
immunolog
laboratori
method
twopart
electron
survey
sent
foreign
platelet
immunolog
expert
pie
platelet
immunobiolog
work
parti
piwp
member
espgi
board
member
n
first
part
focus
lab
practic
regulatori
environ
regard
accredit
contact
patient
inform
consent
patient
result
second
part
stress
investig
perform
discov
new
platelet
antigen
precis
perceiv
statu
analyz
background
haemolyt
diseas
fetu
newborn
hdfn
occur
matern
red
cell
antibodi
direct
red
cell
antigen
present
fetal
red
blood
cell
cross
placenta
enter
fetal
circul
tradit
conceiv
pregnanc
hdfn
occur
result
matern
antibodi
direct
fetal
red
cell
antigen
heterozyg
state
wherebi
antigen
inherit
father
advent
donor
oocyt
invitro
fertilis
ivf
addit
third
person
reproduct
equat
allow
possibl
sever
form
hdfn
fetal
red
cell
antigen
present
homozyg
state
one
copi
father
one
copi
donor
matern
antibodi
direct
antigen
express
homozyg
state
antigen
site
per
red
blood
cell
therefor
increas
risk
red
cell
destruct
matern
deriv
cognat
antibodi
aim
rais
awar
increas
sever
risk
hdfn
donor
oocyt
conceiv
pregnanc
method
describ
two
unusu
case
hdfn
institut
two
women
whose
pregnanc
induc
use
donor
oocyt
offspr
requir
transfus
support
postnat
period
treat
hdfn
result
first
case
previous
report
doyl
quigley
fitzgerald
et
al
transfus
medicin
protract
hdfn
due
antic
manag
phototherapi
initi
intervent
red
cell
topup
transfus
week
postdeliveri
second
unusu
case
sever
abo
hdfn
requir
exchang
transfus
therapi
prepubl
summaryconclus
given
increas
number
pregnanc
conceiv
use
recommend
antenat
guidelin
review
creat
awar
regard
potenti
increas
risk
hdfn
pregnanc
complic
alloimmunis
critic
antenat
test
guidelin
highlight
predict
outcom
associ
quantitationtitr
use
use
obtain
pregnanc
also
essenti
clinician
inform
blood
transfus
laboratori
use
abstract
withdrawn
deceas
due
organ
reject
patient
deceas
due
diseas
relat
reject
summaryconclus
use
therapeut
plasma
exchang
treatment
antibodi
mediat
reject
solid
organ
transplant
safe
effect
use
along
treatment
modal
studi
help
determin
whether
reproduc
larger
cohort
whether
effect
certain
organ
background
extracorpor
photopheresi
ecp
import
cellular
therapi
treatment
sever
auto
immun
diseas
graftversushost
diseas
intern
standard
ex
vivo
treatment
leukapheresi
product
applic
irradi
uva
light
howev
addit
illumin
bag
associ
potenti
risk
contamin
aim
basic
principl
ecp
induct
apoptosi
leukocyt
aim
find
altern
convent
apoptosi
induct
without
need
extern
substanc
applic
object
studi
investig
apoptosi
level
kinet
leukocyt
treatment
compar
uvc
treatment
without
addit
method
use
vitro
h
cell
cultur
approach
human
mononuclear
cell
healthi
blood
donor
untreat
control
cell
compar
lg
ml
plu
jcm
uva
treat
cell
jcm
effect
dose
uvc
treat
cell
apoptosi
sever
leukocyt
subpopul
detect
daili
annexin
v
flow
cytometri
stand
result
apoptosi
analysi
thelper
cell
cytotox
tcell
bcell
monocyt
neg
nkcell
nkt
cell
reveal
statist
differ
almost
cell
type
treatment
uvc
light
apoptosi
kinet
well
final
apoptosi
h
similar
treatment
group
summaryconclus
addit
photopheresi
irradi
bag
risk
potenti
infect
main
effect
treatment
probabl
induct
apoptosi
leukocyt
provid
inform
induct
apoptosi
also
achiev
uvc
irradi
without
need
addit
apoptosi
pattern
leukocyt
subpopul
similar
treatment
uvc
compar
treatment
futur
vivo
studi
need
prove
therapeut
effect
uvc
treat
cell
ecp
set
abstract
withdrawn
background
therapeut
plasma
exchang
tpe
perform
remov
implic
substanc
plasma
caus
diseas
period
apprais
tpe
data
import
get
insight
procedur
relat
effect
toxic
overal
outcom
order
guid
futur
approach
aim
purpos
studi
observ
overal
profil
outcom
patient
receiv
tpe
medicin
intens
care
unit
micu
tertiari
care
hospit
south
india
method
record
base
audit
conduct
patient
admit
tertiari
care
hospit
south
india
bed
micu
receiv
tpe
therapi
june
decemb
tpe
procedur
perform
use
haemonet
multicompon
system
mc
apheresi
system
base
intermitt
flow
centrifug
audit
tpe
number
treatment
clinic
indic
treatment
prescrib
administ
procedur
patient
complic
adher
current
best
practic
recommend
result
sixti
nine
patient
undergon
tpe
procedur
among
thirti
femal
patient
median
age
year
guillainbarr
syndrom
gb
common
indic
follow
case
thrombot
thrombocytopen
purpura
diffus
alveolar
hemorrhag
myasthenia
gravi
autoimmun
enceph
hypertriglyceridemia
respect
tpe
regimen
receiv
patient
icu
alway
prescrib
accord
current
best
practic
recommend
episod
patient
relat
complic
tpe
treatment
procedur
technic
error
machin
encount
summaryconclus
find
audit
identifi
differ
current
prescript
recommend
tpe
appli
infrequ
therapi
differ
indic
may
present
challeng
medicin
intens
care
clinician
provid
best
care
case
background
microangiopath
hemolyt
anaemia
maha
encompass
spectrum
disord
characteris
wide
dissemin
thrombosi
small
blood
vessel
result
format
schistocyt
concomit
thrombocytopenia
plasma
exchang
pe
need
consid
empir
urgent
life
save
therapi
disord
irrespect
wait
specif
test
like
adamt
level
thrombot
thrombocytopen
purpura
ttp
complement
level
factor
h
antibodi
atyp
hemolyt
urem
syndrom
ahu
aim
assess
efficaci
safeti
plasma
exchang
patient
diagnos
microangiopath
hemolyt
anaemia
method
retrospect
analysi
pe
procedur
perform
patient
diagnos
maha
done
period
year
procedur
done
apheret
devic
cobe
spectra
terumo
bct
lakewood
co
usa
patient
pre
post
procedur
hematolog
renal
paramet
analyz
appli
pair
test
advers
event
record
result
pe
perform
patient
diagnosi
maha
ttp
post
stem
cell
transplant
drug
induc
thrombot
microangiopathi
tma
post
thyroidectomi
tma
postpartum
tma
mean
age
patient
ae
year
f
number
procedur
per
patient
vari
post
pe
recoveri
observ
within
day
statist
signific
increas
mean
platelet
count
ae
ae
l
p
signific
declin
mean
lactat
dehydrogenas
level
ae
ae
lkatl
p
also
signific
declin
mean
percentag
schistocyt
peripher
smear
ae
ae
p
mean
serum
urea
chang
ae
ae
mmoll
creatinin
ae
ae
lmoll
p
respect
signific
increas
urin
output
ae
ae
mlkgh
p
advers
event
observ
patient
allerg
reaction
replac
fluid
n
commonest
follow
hypotens
n
rigor
chill
n
overal
surviv
rate
month
summaryconclus
pe
proven
safeti
use
lifesav
first
line
treatment
modal
maha
prompt
aggress
treatment
help
achiev
earli
complet
remiss
patient
background
neuromyel
optica
nmo
also
known
devic
diseas
devic
syndrom
rare
demyelin
diseas
central
nervou
system
often
result
select
involv
optic
nerv
optic
neuriti
spinal
cord
myeliti
femal
preponder
neuromyel
optica
nmo
attack
poorli
control
steroid
evolv
stepwis
neurolog
impair
assum
strong
humor
respons
underli
nmo
attack
therapeut
plasma
exchang
appropri
techniqu
sever
nmo
attack
aim
studi
effect
tpe
neuromyel
optica
method
year
old
femal
medicin
depart
civil
hospit
ahmedabad
admit
chief
complain
weak
numb
arm
leg
blur
vision
reduc
sensat
difficulti
control
bladder
bowel
uncontrol
vomit
hiccup
sinc
day
medicin
depart
civil
hospit
ahmedabad
attack
treat
short
cours
high
dose
intraven
corticosteroid
methylprednisolon
intraven
clinic
improv
result
clinician
advis
trial
tpe
patient
procedur
perform
autom
devic
continu
flow
centrifug
machin
freseniu
kabicomtec
use
doubl
lumen
femor
cathet
obtain
inform
consent
rel
patient
cycl
tpe
perform
daili
basi
cycl
subject
object
clinic
respons
tpe
estim
three
differ
sourc
patient
transfus
medicin
physician
treat
neurologist
motor
perform
patient
assess
disabl
scale
healthi
minor
symptom
abl
walk
meter
without
support
abl
walk
meter
support
confin
bed
wheelchair
requir
assist
ventil
dead
patient
motor
perform
increas
scale
upper
limb
lower
limb
scale
deep
tendon
reflex
normal
visual
function
began
improv
week
treatment
visual
acuiti
week
summaryconclus
assum
strong
humor
respons
underli
nmo
attack
therapeut
plasma
exchang
appropri
techniqu
sever
nmo
attack
suggest
tpe
benefici
nmo
patient
acut
attack
respons
corticosteroid
treatment
background
babesiosi
tick
born
infecti
diseas
caus
protozoa
babesia
infect
babesia
asymptomat
patient
present
symptomat
infect
rare
sever
life
threaten
ill
treatment
primarili
antibiot
red
cell
exchang
rce
use
sever
case
character
high
grade
parasitemia
evid
sever
hemolysi
multiorgan
failur
involv
kidney
lung
liver
threshold
parasit
level
arbitrarili
appli
indic
rce
howev
threshold
evid
base
aim
report
patient
babesiosi
high
grade
parasitemia
treat
antibiot
without
rce
method
data
collect
juli
juli
case
defin
patient
diagnos
babesiosi
rce
request
basi
parasitemia
clinic
evalu
consid
rce
could
withheld
patient
monitor
await
respons
antibiot
result
three
case
sever
babesiosi
use
rce
request
basi
parasit
level
greater
perform
rce
defer
account
good
clinic
state
patient
absenc
renal
failur
level
parasit
diagnosi
patient
follow
daili
discharg
two
patient
splenectom
receiv
singl
unit
red
blood
cell
hospit
third
patient
long
histori
refractori
lymphoma
pancytopen
requir
multipl
transfus
year
diagnosi
babesiosi
transfus
transmit
babesiosi
red
blood
cell
transfus
day
prior
diagnosi
three
patient
respond
well
antibiot
discharg
day
undetect
parasit
summaryconclus
small
case
seri
suggest
request
rce
sole
basi
arbitrari
level
parasitemia
question
clinic
state
evid
organ
failur
consid
decis
perform
rce
abstract
withdrawn
chronic
transfus
program
ctp
remain
gold
standard
therapi
stroke
prevent
patient
sever
diseas
inadequ
respons
hydroxyurea
treatment
aim
evalu
safeti
efficaci
cost
scd
patient
ctp
underw
aet
partial
manual
exchang
transfus
pmet
procedur
method
retrospect
observ
cohort
studi
patient
scd
ctp
switch
pmet
aet
studi
carri
hospit
portug
data
patient
histori
haematolog
valu
durat
procedur
interv
advers
event
well
cost
materi
work
hour
collect
compar
procedur
result
total
patient
met
inclus
criteria
describ
howev
patient
exclud
studi
lack
attend
ctp
studi
record
exchang
procedur
pmet
aet
peripher
venou
access
procedur
major
concern
poor
venou
access
reason
patient
return
pmet
major
complic
alloimmun
observ
indic
ctp
cerebr
vasculopathi
n
stroke
n
recurr
vasoocclus
crisi
multiorgan
failur
n
procedur
target
valu
obtain
preexchang
hb
level
stroke
cerebr
vasculopathi
indic
median
hb
level
pmet
aet
document
higher
hb
level
prior
next
procedur
patient
n
despit
patient
remain
stabl
without
major
scd
relat
event
procedur
well
toler
iron
overload
well
control
median
ferritin
level
pmet
vs
aet
ngml
durat
exchang
procedur
longer
interv
procedur
shorter
pmet
median
pmet
vs
aet
min
pmet
vs
aet
week
respect
annual
rbc
requir
per
procedur
superior
median
vs
unit
overal
cost
relat
aet
time
higher
aet
pmet
respect
estim
cost
per
session
aet
pmet
summaryconclus
studi
show
hb
level
procedur
perform
interv
similar
verifi
pmet
compar
efficaci
aet
term
prevent
develop
progress
chronic
complic
cost
per
procedur
significantli
higher
aet
howev
clinic
situat
import
rapidli
reduc
hb
level
andor
control
target
hb
stricter
patient
clinic
control
without
increas
hospit
visit
aet
prefer
conclud
aet
effect
rapid
reduct
hb
ferritin
level
well
less
time
consum
despit
reason
describ
costeffect
maintain
aet
pmet
procedur
background
erythrocytapheresisr
blood
cell
rbc
exchang
involv
remov
larg
number
rbc
patient
return
patient
plasma
platelet
along
compat
allogen
donor
rbc
typic
indic
rbc
exchang
sickl
cell
diseas
relat
complic
howev
one
miscellan
indic
rbc
exchang
patient
methemoglobinemia
refractori
treatment
methylen
blue
acquir
methemoglobinemia
common
genet
caus
acquir
methemoglobinemia
caus
toxin
oxid
heme
iron
notabl
nitrat
nitritecontain
compound
patient
fail
respond
standard
treatment
methylen
blue
use
contraind
hyperbar
oxygen
rbc
exchang
indic
aim
case
report
use
rbc
exchang
methemoglobinemia
indic
base
anecdot
report
method
exchang
perform
cell
separ
machin
com
tec
freseniu
kabi
result
report
case
acquir
methemoglobinemia
patient
admit
peripher
capillari
oxygen
satur
air
patient
show
improv
level
effect
emerg
treatment
methylen
blue
sinc
patient
refractori
treatment
methylen
blue
decis
made
clinician
proceed
rbc
exchang
patient
improv
significantli
two
cycl
one
rbc
volum
autom
rbc
exchang
discharg
air
summaryconclus
autom
rbc
exchang
use
patient
acquir
methemoglobinemia
success
methylen
blue
ineffect
may
superior
manual
one
background
therapeut
plasma
exchang
tpe
known
disturb
ph
electrolyt
statu
patient
compromis
liver
function
may
higher
risk
electrolyt
imbal
due
metabol
abnorm
aim
aim
studi
analyz
variat
ph
ioniz
calcium
sodium
potassium
bicarbon
liver
diseas
patient
undergo
tpe
method
patient
liver
diseas
undergo
tpe
period
juli
august
includ
studi
data
patient
demograph
detail
tpe
procedur
blood
ga
analysi
report
advers
effect
tpe
collect
analyz
result
one
hundr
seven
procedur
done
studi
period
done
mc
plu
haemonet
corpor
rest
done
spectra
optia
terumo
bct
percentag
chang
ioniz
calcium
sodium
potassium
due
procedur
found
statist
signific
p
systol
p
diastol
blood
pressur
also
chang
significantli
procedur
predictor
chang
ioniz
calcium
found
preprocedur
ioniz
calcium
p
age
patient
p
preprocedur
ph
p
procedurerel
complic
occur
procedur
complic
categor
featur
hypocalcemia
associ
found
hypocalcem
manifest
preprocedur
calcium
chang
calcium
age
gender
patient
summaryconclus
tpe
procedur
liver
diseas
patient
caus
remark
chang
ioniz
calcium
sodium
potassium
bicarbon
ion
decreas
ioniz
calcium
procedur
predict
preprocedur
ioniz
calcium
level
ph
age
patient
monitor
paramet
appropri
correct
measur
imper
patient
safeti
background
therapeut
plasma
exchang
tpe
pediatr
age
group
technic
demand
low
blood
volum
difficult
venou
access
poor
cooper
patient
procedur
present
experi
tpe
pediatr
patient
centr
aim
assess
challeng
tpe
pediatr
patient
formul
appropri
strategi
method
retrospect
analysi
tpe
procedur
perform
pediatr
patient
period
year
tpe
procedur
done
two
differ
apheret
devic
cs
plu
fenwal
usa
cobe
spectra
terumo
bct
lakewood
colorado
daili
altern
day
depend
clinic
condit
patient
procedur
kit
prime
compat
pack
red
cell
advers
event
procedur
note
analyz
result
total
tpe
rang
mean
procedur
perform
pediatr
patient
differ
indic
like
atyp
hu
categori
per
american
societi
apheresi
asfa
total
patient
neuromyel
optica
categori
ii
patient
rapid
prolif
glomerulonephr
categori
glomerulopathi
patient
one
patient
infect
hemophagocytosi
averag
age
patient
popul
yr
year
male
femal
ratio
averag
weight
kg
advers
event
observ
procedur
commonli
observ
advers
event
allerg
reaction
replac
fluid
follow
hypotens
line
occlus
vasovag
endotrach
tube
blockag
symptomat
hypocalcemia
observ
one
procedur
corel
observ
physic
paramet
patient
advers
event
advers
event
manag
per
department
standard
oper
procedur
sop
procedur
complet
success
except
one
procedur
abandon
mortal
observ
procedur
background
hemoglobin
hb
content
pack
red
blood
cell
prbc
unit
heterogen
patient
blood
volum
also
variabl
calcul
base
weight
height
bodi
surfac
area
bsa
patient
efficaci
transfus
episod
assess
hb
content
prbc
known
patient
posttransfus
hb
increment
determin
aim
prospect
studi
perform
compar
efficaci
transfus
prbc
base
hb
content
versu
standard
transfus
practic
thalassemia
major
patient
also
determin
correl
hb
increment
hb
content
prbc
unit
transfus
method
total
regist
thalassemia
major
patient
institut
includ
studi
exclud
patient
alloor
autoantibodi
studi
approv
institut
ethic
committe
enrol
patient
randomli
divid
two
group
group
n
receiv
aborhd
ident
prbc
suspend
addit
solut
salin
adenin
glucos
mannitol
sagmprbc
determin
hb
content
unit
hb
content
g
group
ii
n
receiv
randomli
select
aborhd
ident
sagmprbc
hb
estim
randomli
select
unit
group
ii
blind
follow
test
done
pretransfus
sampl
hb
estim
use
hematolog
analyz
orion
ocean
medic
technolog
india
blood
group
use
tube
techniqu
antihuman
globulin
ahg
crossmatch
direct
antiglobulin
test
dat
use
gel
techniqu
biorad
switzerland
antibodi
screen
ab
use
fulli
autom
immunohematolog
analyz
neo
immucor
usa
posttransfus
sampl
collect
h
transfus
hb
estim
dat
perform
result
signific
differ
among
patient
characterist
two
group
mean
hb
content
sagmprbc
unit
significantli
higher
p
group
mean
ae
standard
deviat
ae
g
rang
g
group
ii
ae
g
rang
g
mean
hb
increment
group
patient
ae
gdl
significantli
higher
p
group
ii
patient
ae
gdl
group
ii
signific
neg
correl
hb
increment
weight
p
group
ii
age
p
group
p
group
ii
bodi
surfac
area
bsa
p
group
p
group
ii
blood
volum
p
group
p
group
ii
group
ii
signific
posit
correl
hb
increment
hb
dose
adjust
bsa
hb
dose
adjust
blood
volum
p
group
ii
paramet
summaryconclus
efficaci
transfus
patient
transfus
sagmprbc
hb
content
g
compar
transfus
randomli
select
unit
optim
hb
increment
thalassemia
major
patient
transfus
strategi
base
hb
content
sagmprbc
background
male
transfus
recipi
year
age
receiv
red
blood
cell
rbc
everpregn
blood
donor
associ
increas
mortal
compar
receiv
product
male
donor
although
suggest
older
unit
rbc
could
associ
increas
mortal
signific
methodolog
challeng
studi
studi
indic
freshest
unit
rbc
could
associ
increas
mortal
among
transfus
recipi
hypothes
associ
everpregn
donor
fresh
unit
mortal
could
caus
passeng
leukocyt
transfus
rbc
unit
decay
storag
aim
quantifi
modif
effect
everpregn
donor
mortal
young
male
rbc
transfus
recipi
storag
time
method
data
transfus
recipi
receiv
firstev
rbc
transfus
one
six
major
dutch
hospit
collect
current
studi
male
transfus
recipi
year
receiv
transfus
one
donor
sex
exposur
categori
select
followup
censor
three
year
transfus
differ
storag
time
group
estim
linear
regress
adjust
total
number
transfus
patient
age
blood
group
transfus
year
month
singleunit
singletransfus
cohort
cumul
mortal
estim
separ
patient
receiv
transfus
everpregn
male
donor
fresh
day
storag
old
day
storag
rbc
result
recipi
blood
male
donor
storag
time
freshest
unit
day
shorter
compar
patient
die
patient
surviv
ci
recipi
blood
everpregn
donor
storag
time
freshest
unit
day
longer
compar
patient
die
patient
surviv
ci
singletransfus
cohort
patient
receiv
fresh
rbc
transfus
male
donor
die
patient
receiv
fresh
transfus
everpregn
femal
donor
die
patient
receiv
old
transfus
male
donor
die
patient
receiv
old
transfus
everpregn
femal
die
cumul
incid
death
among
young
male
recipi
confid
interv
ci
fresh
transfus
male
donor
ci
fresh
transfus
everpregn
femal
donor
cumul
incid
death
ci
old
transfus
male
donor
ci
old
transfus
everpregn
femal
donor
summaryconclus
prolong
storag
rbc
everpregn
donor
associ
decreas
mortal
year
contrari
expect
result
indic
older
unit
may
potenti
effect
everpregn
donor
howev
due
limit
sampl
size
observ
differ
statist
signific
background
accord
literatur
review
limit
impact
premed
antipyret
antihistamin
steroid
transfus
prevent
advers
transfus
reaction
atr
howev
necess
premed
remain
controversi
premed
transfus
still
common
clinic
practic
pacificasian
countri
along
premed
rate
rang
previou
investig
found
premed
rate
outpati
much
higher
report
rate
asia
aim
investig
incid
atr
decreas
premed
rate
without
increas
rate
atr
via
educ
evidencebas
clinic
practic
method
incid
atr
april
decemb
retrospect
survey
evidencebas
clinic
practic
initi
sinc
januari
clinic
data
outpati
receiv
transfus
therapi
request
analyz
januari
septemb
incid
atr
premed
rate
compar
use
chisquar
test
p
valu
less
statist
signific
besid
feedback
incid
atr
premed
rate
given
quarterli
clinician
investig
result
april
septemb
total
blood
unit
transfus
outpati
transfus
event
case
atr
includ
febril
nonhemolyt
transfus
reaction
fnhtr
minor
allerg
reaction
report
overal
premed
rate
outpati
significantli
decreas
p
report
incid
atr
per
unit
respect
remark
differ
incid
atr
p
summaryconclus
via
educ
evidencebas
clinic
practic
success
reduc
premed
rate
without
increas
rate
atr
outpati
furthermor
introduct
computer
provid
order
entri
cpoe
clinic
decis
support
system
cdss
could
consid
expect
prevent
unnecessari
premed
transfus
increas
complianc
optim
transfus
strategi
futur
method
retrospect
analysi
done
period
one
year
evalu
clinic
efficaci
granulocyt
transfus
hematooncolog
patient
febril
neutropenia
mobil
granulocyt
donor
done
per
standard
protocol
includ
subcutan
inject
granulocyt
coloni
stimul
factor
gcsf
lgkg
tablet
dexamethason
mg
h
prior
granulocyt
harvest
apheresi
granulocyt
product
gamma
irradi
transfus
patient
paramet
like
white
blood
count
wbc
absolut
neutrophil
count
anc
hemoglobin
platelet
count
record
preand
postgranulocyt
transfus
infect
relat
mortal
irm
within
day
granulocyt
transfus
also
record
result
minimum
adequ
granulocyt
yield
per
unit
fulfil
granulocyt
harvest
clinic
indic
granulocyt
transfus
fever
absolut
neutrophil
count
anc
evid
bacteri
andor
fungal
infect
ie
clinic
sign
infect
posit
cultur
radiolog
evid
unrespons
appropri
antimicrobi
therapi
least
h
effect
clinic
microbiolog
granulocyt
transfus
relat
variabl
infectionrel
mortal
investig
post
transfus
anc
within
h
increas
significantli
median
valu
compar
baselin
level
median
valu
p
infect
relat
mortal
observ
patient
patient
becam
afebril
within
day
cultur
neg
within
day
granulocyt
transfus
analysi
purpos
granulocyt
transfus
episod
group
accord
dose
granulocyt
transfus
base
european
guidelin
standard
dose
cellskg
high
dose
cellskg
background
hsa
blood
servic
group
bsg
singapor
nation
blood
servic
conduct
pilot
nation
pbm
audit
promot
pbm
practic
agre
audit
would
perform
annual
incorpor
new
indic
continu
promot
pbm
share
good
practic
aim
provid
updat
second
nation
pbm
audit
result
compar
pilot
audit
summar
method
collect
data
perform
indic
acut
public
care
hospit
week
march
august
pilot
audit
cover
week
perform
indic
percentag
complianc
document
red
blood
cell
transfus
indic
percentag
patient
screen
preoper
anaemia
day
surgeri
periop
transfus
rate
day
day
surgeri
commonli
perform
surgeri
coronari
arteri
bypass
graft
surgeri
cabg
total
knee
replac
tkr
total
hip
replac
thr
nephrectomi
colectomi
hysterectomi
first
two
indic
assess
pbm
effort
measur
pilot
audit
indic
ad
second
audit
assess
impact
pbm
practic
transfus
surgic
patient
appropri
time
incorpor
indic
hospit
would
familiar
pbm
sinc
introduct
result
recommend
share
senior
manag
hospit
transfus
committe
particip
hospit
result
indic
hospit
complianc
remain
complianc
hospit
incorpor
electron
blood
order
usag
compulsori
hospit
mandat
electron
order
perform
better
doctor
could
order
blood
product
enter
transfus
indic
saw
complianc
increas
hospit
newli
mandat
electron
order
indic
result
rang
hospit
made
notabl
improv
compar
achiev
respect
implement
preoper
workflow
screen
elect
surgic
case
anaemia
least
week
surgeri
one
hospit
also
start
outpati
intraven
iron
servic
reduc
preoper
anaemia
rate
indic
mean
number
transfus
unit
surgeri
rang
unit
per
patient
lowest
thr
highest
cabg
suggest
transfus
potenti
avoid
robust
pbm
practic
rate
periop
transfus
highest
cabg
lowest
tkr
summaryconclus
annual
nation
pbm
audit
increas
pbm
awar
allow
hospit
share
learn
good
practic
implement
measur
improv
base
audit
recommend
mandat
electron
order
blood
product
improv
adher
red
cell
transfus
indic
implement
preoper
workflow
consider
intraven
iron
support
made
audit
repres
pilot
longer
durat
data
collect
incorpor
indic
show
impact
pbm
practic
background
autoimmun
haemolyt
anaemia
aiha
decompens
acquir
haemolysi
caus
host
immun
system
act
red
cell
antigen
aiha
rare
disord
although
british
societi
haematolog
bsh
guidelin
diagnosi
treatment
publish
februari
littl
evid
clinic
practic
unit
kingdom
aim
investig
approach
diagnosi
investig
manag
patient
autoimmun
haemolyt
anaemia
aiha
english
nh
trust
method
design
distribut
survey
clinic
transfus
lead
english
nh
trust
novemb
march
survey
request
inform
detail
simul
clinic
scenario
first
simul
scenario
describ
young
patient
activ
aiha
month
allogen
stem
cell
transplant
receiv
multipl
transfus
last
week
hypotens
tachycard
fall
haemoglobin
hb
current
gl
second
scenario
describ
young
man
new
diagnosi
warm
aiha
initi
hb
gl
return
clinic
interv
symptom
fatigu
activ
haemolys
commenc
mgkg
prednisolon
result
respons
rate
trust
face
h
delay
alloadsorpt
studi
respond
would
instead
transfus
acut
abo
rh
k
match
red
cell
neg
previous
detect
alloantibodi
would
transfus
rh
neg
red
cell
would
wait
complet
alloadsorpt
studi
transfus
first
scenario
quarter
respond
appear
delay
potenti
lifesav
blood
transfus
british
societi
haematolog
guidelin
recommend
anaemia
lifethreaten
time
requir
full
compat
test
abo
rh
k
match
red
cell
transfus
seriou
hazard
transfus
shot
report
seriou
fatal
case
prevent
delay
transfus
patient
aiha
die
untransfus
hb
gl
await
alloadsorpt
studi
key
shot
messag
clinic
harm
patient
withhold
blood
outweigh
safeti
concern
possibl
delay
haemolyt
transfus
reaction
emerg
blood
essenti
offer
second
scenario
also
identifi
consider
variat
transfus
practic
take
sever
week
patient
aiha
respond
prednisolon
transfus
threshold
gl
hb
fall
least
gl
previou
week
perhap
overli
conserv
summaryconclus
overal
find
support
need
studi
explor
barrier
uptak
guidelin
identifi
area
audit
research
guid
safe
appropri
transfus
practic
aiha
background
balanc
suppli
demand
neg
red
cell
remain
challeng
almost
everi
blood
servic
reaudit
want
collect
object
comprehens
inform
regard
usag
neg
red
cell
suppli
nh
blood
transplant
nhsbt
privat
nh
hospit
england
aim
aim
understand
hospit
practic
actual
need
possibl
avoid
usag
neg
red
cell
possibl
comparison
made
two
previou
audit
method
particip
hospit
ask
determin
fate
group
neg
red
cell
receiv
th
th
may
exclud
substitut
complet
organis
survey
regard
activ
polici
stockhold
practic
respect
neg
blood
particip
hospit
ask
provid
avail
preval
percentag
neg
patient
popul
inform
conjunct
hospit
activ
use
estim
appropri
neg
stockhold
level
background
rhdneg
neg
red
blood
cell
rbc
preciou
resourc
often
short
suppli
transfus
unit
emerg
set
carri
potenti
risk
transfusionrel
advers
outcom
haemolyt
reaction
due
minor
blood
group
incompat
use
close
monitor
within
health
servic
recent
australian
guidelin
use
emerg
set
includ
premenopaus
femal
unknown
blood
group
mandatori
indic
blood
group
establish
use
limit
less
unit
possibl
switch
groupspecif
rbc
accept
indic
aim
audit
use
emerg
uncrossmatch
rhdneg
rbc
nation
guidelin
institut
australian
tertiari
metropolitan
public
hospit
provid
acut
medic
surgic
emerg
critic
care
servic
method
use
emerg
uncrossmatch
rhdneg
rbc
unit
sixyear
period
retrospect
review
collect
inform
rbc
transfus
discard
advers
outcom
patient
characterist
clinic
indic
whether
use
met
nation
guidelin
could
avoid
result
episod
emerg
uncrossmatch
rhdneg
rbc
identifi
encompass
transfus
rbc
unit
patient
discard
rbc
due
incorrect
transport
episod
episod
involv
eventu
switch
groupspecif
rbc
rang
emerg
unit
unit
main
request
emerg
depart
common
clinic
indic
transfus
acut
gastrointestin
bleed
episod
episod
meet
guidelin
emerg
use
unit
emerg
uncrossmatch
rhdneg
rbc
issu
episod
flag
potenti
inappropri
patient
clinic
stabl
accord
document
medic
record
episod
identifi
potenti
prevent
due
delay
pretransfus
sampl
collect
defin
h
elaps
patient
arriv
group
screen
sampl
collect
set
acut
bleed
receipt
unsuit
pretransfus
sampl
requir
sampl
recollect
delay
pretransfus
sampl
process
valid
pretransfus
sampl
avail
time
bleed
episod
despit
plan
elect
procedur
inpati
recent
clinic
bleed
one
patient
investig
potenti
transfusionrel
advers
outcom
thought
like
due
concurr
sepsi
summaryconclus
six
year
episod
utilis
emerg
uncrossmatch
rhdneg
rbc
identifi
rbc
issu
rbc
discard
signific
proport
episod
potenti
avoid
valid
pretransfus
sampl
avail
transfus
laboratori
time
episod
effort
minimis
use
preciou
resourc
ongo
includ
feedback
clinic
unit
regard
import
valid
pretransfus
sampl
prior
applic
invas
procedur
bleed
patient
ongo
educ
medic
nurs
staff
continu
audit
use
blood
compon
hospit
haemovigil
programm
abstract
withdrawn
abstract
withdrawn
background
platelet
transfus
often
given
prophylact
thrombocytopen
hematolog
patient
extent
platelet
function
improv
transfus
improv
correl
increas
platelet
count
well
studi
flow
cytometri
use
evalu
platelet
function
transfus
studi
perform
even
low
platelet
count
rotat
thromboelastometri
rotem
repres
physiolog
measur
platelet
function
whole
blood
extens
use
transfus
set
use
method
investig
platelet
transfus
improv
platelet
function
hematolog
patient
improv
correl
increas
platelet
count
aim
aim
evalu
relationship
respons
platelet
transfus
measur
correct
count
increment
cci
platelet
function
thrombocytopen
patient
hematolog
disord
method
blood
sampl
sodiumcitr
anticoagul
collect
unselect
hematolog
patient
receiv
prophylact
platelet
transfus
inform
consent
obtain
sampl
taken
three
timepoint
within
h
transfus
h
h
transfus
via
central
venou
cathet
subcutan
venou
port
timepoint
platelet
respons
adenosin
diphosph
adp
thrombin
receptoractiv
peptid
assess
flow
cytometri
measur
pselectin
express
singl
platelet
rotem
analysi
also
perform
sampl
use
intem
extem
reagent
result
interim
analysi
perform
inclus
patient
mean
platelet
count
transfus
l
rang
l
h
cci
l
h
cci
l
respons
highli
variabl
pselectin
express
stimul
adp
trap
significantli
higher
h
h
transfus
compar
transfus
p
express
stimul
adp
significantli
higher
h
transfus
p
h
transfus
rotem
clot
amplitud
min
well
maximum
clot
firm
mcf
improv
transfus
p
signific
correl
absolut
platelet
count
pselectin
express
trap
adp
stimul
found
r
respect
p
absolut
platelet
count
also
significantli
correl
mcf
r
p
patient
platelet
count
l
reach
mcf
valu
within
refer
interv
summaryconclus
platelet
function
gener
improv
transfus
patient
popul
correl
absolut
platelet
count
also
seen
singl
platelet
level
flow
cytometri
post
transfus
platelet
count
l
might
suffici
significantli
improv
coagul
heavili
thrombocytopen
patient
larger
studi
need
confirm
conclus
abstract
withdrawn
abstract
withdrawn
background
sickl
cell
diseas
scd
genet
disord
frequent
refer
hypercoagul
state
hydroxyurea
hu
known
decreas
frequenc
vasoocclus
complic
need
blood
transfus
sever
affect
individu
although
crosssect
studi
show
treatment
hu
associ
decreas
coagul
activ
prospect
studi
evalu
effect
hu
coagul
activ
aim
assess
effect
hu
marker
fibrinolysi
ddimer
endotheli
activ
solubl
vascular
cell
adhes
solubl
patient
scd
noncrisi
steadi
state
method
patient
least
year
age
document
hbss
hbsbthalassemia
elig
treatment
hu
studi
prospect
observ
studi
laboratori
investig
obtain
baselin
prior
commenc
therapi
hu
repeat
evalu
three
six
month
therapi
nonparametr
test
appli
observ
associ
hu
therapi
biomark
interest
result
twentyf
patient
scd
hbss
hbsb
thalassemia
enrol
femal
median
age
year
iqr
follow
month
hu
median
valu
wbc
count
l
vs
l
p
ddimer
ngml
vs
ngml
p
significantli
lower
baselin
valu
mean
corpuscular
volum
fl
vs
fl
p
significantli
higher
baselin
valu
signific
differ
baselin
observ
median
valu
hemoglobin
g
dl
vs
gdl
p
platelet
count
l
vs
l
p
lactat
dehydrogenas
ul
vs
ul
p
solubl
ng
ml
vs
ngml
p
follow
month
hu
therapi
summaryconclus
exploratori
studi
confirm
treatment
hu
associ
decreas
coagul
activ
patient
scd
although
effect
endotheli
activ
observ
decreas
coagul
activ
hu
may
decreas
risk
thrombot
complic
scd
abstract
withdrawn
abstract
withdrawn
transfus
medicin
apollo
gleneagl
hospit
kolkata
india
background
reduct
immun
respons
blood
transfus
document
previou
author
breast
cancer
consid
one
commonest
cancer
global
second
main
caus
death
femal
transfus
allogen
blood
breast
cancer
surgeri
variabl
differ
transfus
incid
observ
literatur
maximum
surgic
blood
order
schedul
msbo
dictat
cross
match
reserv
blood
surgeri
factor
decid
util
vari
numer
hospit
protocol
guid
everi
patient
plan
elect
breast
cancer
surgeri
routin
blood
sampl
sent
reserv
one
unit
compat
pack
red
blood
cell
prbc
blood
bank
aim
prospect
studi
aim
audit
blood
util
patient
undergo
elect
breast
surgeri
therebi
optim
blood
order
schedul
econom
burden
loss
clinic
resourc
method
studi
includ
confirm
breast
cancer
patient
plan
elect
breast
surgeri
januari
decemb
patient
diseas
detail
like
age
stage
tnm
statu
estrogen
receptor
er
progesteron
receptor
pr
statu
human
epiderm
growth
factor
receptor
express
tripl
neg
breast
cancer
tnbc
statu
reproduct
treatment
statu
document
patient
divid
younger
group
year
older
group
year
surgeri
blood
sampl
compat
test
sent
blood
bank
blood
reserv
detail
test
blood
issu
blood
transfus
document
blood
bank
approxim
loss
time
minut
wastag
resourc
term
money
inr
blood
bank
note
result
calcul
mean
ae
sd
p
valu
consid
statist
signific
result
total
patient
underw
wide
local
excis
breast
modifi
radic
mastectomi
total
patient
receiv
unit
blood
blood
compon
categori
surgeri
younger
women
year
mean
age
year
nontransfus
patient
significantli
transfus
one
p
frequenc
blood
transfus
young
patient
seven
total
stage
iv
patient
receiv
blood
transfus
frequenc
blood
transfus
patient
undergo
surgeri
chemotherapi
signific
loss
time
loss
revenu
observ
summaryconclus
conclud
routin
compat
test
justifi
patient
undergo
breast
surgeri
target
approach
need
reduc
blood
demand
associ
cost
patient
blood
transfus
servic
background
blood
transfus
guidelin
essenti
optim
use
blood
product
also
help
reduc
transfusionrel
advers
reaction
improv
patient
outcom
korean
nation
transfus
guidelin
develop
fulli
revis
korean
center
diseas
control
prevent
korean
societi
blood
transfus
hospit
univers
hospit
transfusionind
dataentri
program
base
nation
transfus
guidelin
develop
appli
electron
medic
record
system
transfus
order
except
emerg
perform
program
sinc
aim
plan
record
analyz
reason
transfus
order
monitor
blood
product
usag
provid
feedback
clinician
furthermor
intend
contribut
patient
safeti
appropri
use
blood
product
method
classifi
transfusionind
blood
product
request
creat
popup
window
list
indic
would
appear
regular
transfus
order
indic
transfus
blood
product
follow
red
blood
cell
rbc
acut
blood
loss
chronic
diseas
subclassifi
hb
gdl
cardiovascular
diseas
cerebrovascular
diseas
peripher
vascular
diseas
respiratori
diseas
age
year
age
month
chemotherapi
surgeri
procedur
transplant
platelet
plt
present
bleed
bleed
prevent
subclassifi
hematolog
diseas
solid
tumor
peripher
blood
stem
cell
transplant
dissemin
intravascular
coagulopathi
infant
surgeryprocedur
massiv
transfus
fresh
frozen
plasma
ffp
bleed
coagulopathi
bleed
prevent
coagulopathi
massiv
transfus
plasma
exchang
transfus
indic
enter
dataentri
program
sep
feb
analyz
result
number
transfusionind
analyz
rbc
plt
ffp
common
indic
transfus
chronic
diseas
rbc
bleed
prevent
plt
ffp
hb
gdl
frequent
subind
chronic
diseas
hematolog
diseas
frequent
subind
bleed
prevent
mani
clinician
enter
transfus
indic
rbc
plt
ffp
howev
freetext
suppli
clinician
select
often
correspond
indic
alreadi
categor
transfusionind
dataentri
program
rbc
plt
indic
enter
ffp
surgeryprocedurerel
summaryconclus
hospit
releas
blood
product
depend
dataentri
transfus
indic
except
emerg
sinc
sep
transfus
rbc
plt
common
chronic
diseas
bleed
prevent
respect
mani
case
enter
could
categor
exist
indic
dataentri
program
therefor
conclud
addit
train
need
clinician
regard
determin
transfusionind
correct
use
transfusionind
dataentri
program
order
use
blood
product
appropri
method
prospect
cohort
design
studi
subject
children
age
year
indic
platelet
transfus
sardjito
hospit
yogyakarta
indonesia
patient
sampl
collect
h
posttransfus
express
platelet
determin
flow
cytometri
method
result
subject
divid
two
group
fiftyon
subject
receiv
nonleukodeplet
pc
fiftyon
transfus
prestorag
leukodeplet
pc
mean
pretransfus
platelet
nonleukodeplet
leukodeplet
group
mean
increas
posttransfus
platelet
nonleukodeplet
mean
decreas
leukodeplet
group
shown
increas
posttransfus
platelet
nonleukodeplet
group
significantli
p
higher
leukodeplet
group
summaryconclus
increas
posttransfus
platelet
express
patient
receiv
nonleukodeplet
decreas
leukodeplet
pc
transfus
background
preoper
anaemia
common
find
patient
undergo
surgeri
often
neglect
countri
aim
object
studi
evalu
hb
valu
identif
cardiac
patient
enter
oper
anaemia
also
studi
correl
hb
valu
number
rbc
red
blood
cell
transfus
unit
method
retrospect
descript
analyt
studi
data
studi
collect
file
statist
servic
qsut
univers
hospit
center
mother
teresa
object
studi
file
patient
hospit
period
januari
may
cardiac
surgeri
ward
subject
cardiac
surgeri
file
collect
data
age
gender
primari
diagnosi
accompani
diseas
also
collect
hb
rbc
htc
hematocrit
mcv
mean
corpuscular
volum
mch
mean
corpuscular
hemoglobin
mchc
mean
corpuscular
hemoglobin
concentr
transfus
servic
qsut
file
pull
transfus
patient
number
transfus
unit
result
base
definit
anemia
femal
gdl
male
gdl
patient
includ
studi
anaem
male
studi
anaem
base
hb
lab
valu
wherea
women
studi
anaem
found
anaem
patient
studi
mild
anaemia
moder
anaemia
sever
anaemia
total
anaem
femal
overor
year
old
total
anaem
male
overor
year
old
notic
normochrom
normocyt
normocyt
hypochrom
anaemia
hyperchrom
microcyt
anaemia
macrocyt
normochrom
anaemia
macrocyt
hypochrom
anaemia
respect
microcyt
normochrom
anaemia
averag
valu
preoper
hb
decreas
gdl
surgeri
gdl
surgeri
decreas
approxim
gdl
hb
valu
patient
transfus
remain
transfus
transfus
patient
patient
anaem
correl
valu
hb
rbc
htc
number
transfus
show
decreas
valu
number
transfus
unit
increas
summaryconclus
diagnos
anaemia
underestim
surgic
intervent
countri
investig
hb
low
valu
take
proper
import
find
probabl
caus
correct
surgic
intervent
lower
hb
valu
greater
chanc
transfus
number
rbc
transfus
unit
failur
correct
hb
valu
surgeri
result
unnecessari
transfus
patient
could
avoid
elimin
also
risk
transfus
complic
background
alloimmun
red
blood
cell
transfus
affect
variou
factor
known
incid
alloimmun
increas
certain
diseas
extend
red
blood
cell
match
use
prevent
develop
alloimmun
diseas
rate
alloimmun
increas
asia
extend
red
blood
cell
match
activ
implement
aim
tri
investig
whether
differ
diseas
categori
unexpect
red
blood
cell
antibodi
posit
neg
group
method
januari
decemb
diseas
patient
undergon
unexpect
red
blood
cell
antibodi
identif
test
donga
univers
hospit
examin
medic
record
januari
decemb
diagnosi
made
patient
two
unexpect
antibodi
screen
test
analyz
frequenc
differ
diseas
categori
two
group
result
total
patient
perform
unexpect
antibodi
identif
test
patient
underw
screen
test
posit
consist
unexpect
antibodi
neg
patient
solid
tumor
n
hematolog
diseas
n
higher
incid
unexpect
antibodi
posit
group
patient
myeloid
malign
significantli
higher
frequenc
lymphoid
malign
p
frequenc
patient
liver
cirrhosi
significantli
higher
unexpect
antibodi
posit
group
neg
group
p
incid
nonhodgkin
lymphoma
significantli
higher
unexpect
antibodi
neg
group
posit
group
p
summaryconclus
differ
distribut
diseas
unexpect
antibodi
posit
group
neg
group
patient
liver
cirrhosi
frequent
unexpect
antibodi
posit
group
suggest
extend
red
blood
cell
match
would
consid
background
hematolog
patient
multipl
platelet
transfus
pc
often
develop
immun
respons
human
leukocyt
associ
antigen
hlai
human
plateletspecif
associ
antigen
hpa
besid
platelet
associ
immunoglobulin
paig
complement
compon
pac
found
platelet
lead
increas
platelet
destruct
develop
refractori
transfus
donor
platelet
transfus
therapi
use
individu
select
platelet
plasmapheresi
contribut
major
case
realiz
effici
transfus
pc
difficult
case
need
use
intraven
immunoglobulin
may
promot
effici
transfus
pc
aim
evalu
algorithm
use
complex
therapi
refractori
transfus
donor
platelet
addit
applic
intraven
immunoglobulin
ivig
method
three
femal
patient
clinic
centr
observ
age
year
ineffect
complex
therapi
overcom
refractori
transfus
donor
platelet
due
select
plasmapheresi
diagnos
follow
aplast
anaemia
aa
acut
myeloid
leukemia
aml
individu
select
platelet
carri
adhes
method
solid
phase
immucor
galileo
neo
paig
evalu
method
flow
cytometri
bd
facscanto
ii
method
doubl
stain
densiti
fix
paig
pac
author
vox
sanguini
intern
societi
blood
transfus
vox
sanguini
suppl
evalu
median
fluoresc
intens
mfi
two
patient
aa
receiv
ivigigg
therapi
standard
dose
gkg
per
day
day
one
patient
aml
receiv
ivigiggam
therapi
standard
dose
mlkgday
result
pressur
complex
therapi
use
ivig
standard
dose
decreas
mfi
time
case
two
patient
mfipaigg
reduc
patient
aml
paiga
reduc
paigm
patient
time
regardless
treatment
increas
mfi
effect
pc
transfus
achiev
pressur
complex
therapi
pressur
complex
therapi
patient
also
reduc
frequenc
reaction
alloantibodi
resort
individu
select
increas
frequenc
compat
coupl
donorrecipi
summaryconclus
deliveri
complex
therapi
addit
applic
ivig
enabl
adequ
transfus
therapi
pc
neutral
hemorrhag
syndrom
continu
treatment
main
diseas
detect
monitor
paigpac
develop
refractori
transfus
donor
platelet
addit
marker
prescript
ivig
therapi
anaesthesia
tan
tong
seng
hospit
singapor
singapor
background
blood
transfus
quit
preval
paediatr
cardiac
surgic
procedur
hypothes
routin
use
rotat
thromboelastographi
rotem
guid
transfus
decis
would
reduc
overal
proport
patient
receiv
transfus
paediatr
cardiac
surgeri
aim
aim
studi
find
use
blood
blood
product
pediatr
cardiac
surgic
case
singl
centr
affect
due
rotem
method
sixti
paediatr
cardiac
surgic
patient
undergo
cpb
includ
studi
thirti
patient
studi
group
prospect
includ
compar
thirti
procedur
agematch
control
patient
control
group
studi
group
rotem
perform
cpb
guid
intraop
transfus
periop
transfus
blood
blood
product
postop
blood
loss
hemoglobin
level
compar
two
group
result
patient
control
group
receiv
fewer
transfus
pack
cell
vs
fresh
frozen
plasma
vs
p
patient
studi
group
receiv
platelet
vs
cryoprecipit
vs
postop
blood
loss
lower
studi
group
compar
control
group
postop
hemoglobin
differ
two
group
summaryconclus
result
suggest
routin
use
rotem
paediatr
cardiac
surgeri
guid
transfus
associ
reduc
proport
patient
receiv
transfus
evid
base
practic
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
background
mycoplasma
pneumonia
mp
infect
often
implic
respiratori
tract
infect
although
agent
also
associ
nonrespiratori
diseas
hemolyt
anemia
common
hematolog
complic
mp
infect
episod
sudden
onset
sever
anemia
rare
seen
beta
thalassemia
report
femal
beta
thalassemia
major
diagnos
sever
anemia
secondari
autoimmun
hemolyt
anemia
induc
mp
infect
aim
report
case
patient
beta
thalassemia
major
diagnos
sever
anemia
secondari
autoimmun
hemolyt
anemia
induc
mp
infect
manag
minim
transfus
method
femal
case
beta
thalassemia
major
develop
autoimmun
hemolyt
anemia
follow
mycoplasma
infect
patient
monthli
blood
transfus
sinc
age
year
dubai
thalassemia
center
admit
hospit
day
histori
dizzi
sever
low
back
joint
pain
travel
histori
indic
fourweek
visit
pakistan
initi
investig
show
hemoglobin
level
gdl
direct
indirect
coomb
test
posit
patient
transfus
two
unit
leukodeplet
compat
prbc
rh
neg
e
kell
antigen
discharg
next
day
three
week
later
patient
still
lower
limb
pain
hemoglobin
gdl
posit
dat
patient
transfus
difficult
find
match
blood
therefor
given
one
week
follow
four
day
later
patient
report
center
fever
gener
bodi
pain
fatigu
signific
drop
hemoglobin
gdl
mcv
platelet
count
crp
retic
count
blood
cultur
growth
total
bilirubin
malaria
parasit
smear
neg
urin
cultur
microscopi
normal
mycoplasma
pneumonia
antibodi
show
posit
igg
igm
start
azithromycin
day
receiv
unit
prbc
least
incompat
leukodeplet
rh
neg
e
kell
antigen
hemoglobin
increas
gdl
show
improv
condit
follow
week
repeat
mycoplasma
pneumonia
antibodi
show
increas
titer
denot
resist
azithromycin
henc
start
second
line
treatment
levofloxacin
day
screen
collagen
diseas
neg
apart
high
esr
mmhr
patient
remain
afebril
transfus
least
incompat
avail
blood
post
transfus
hb
gdl
three
week
later
routin
follow
well
esr
drop
mmhr
hemoglobin
gdl
indic
gradual
settl
hemolysi
although
last
dat
remain
posit
subsequ
visit
show
hb
drop
gdlweek
accept
transfus
depend
thalassemia
result
conserv
manag
patient
condit
improv
summaryconclus
hemolyt
anemia
associ
mycoplasma
pneumonia
usual
selflimit
resolv
spontan
mycoplasma
infect
elimin
pack
red
cell
transfus
transfus
depend
patient
may
troublesom
aggrav
condit
therefor
util
limit
signific
symptomat
anaemia
background
earli
plasma
transfus
women
sever
postpartum
hemorrhag
often
institut
prevent
treat
coagulopathi
whether
matern
outcom
improv
treatment
unclear
aim
quantifi
associ
plasma
transfus
within
first
min
diagnos
persist
postpartum
hemorrhag
advers
matern
outcom
method
perform
retrospect
cohort
studi
women
persist
postpartum
hemorrhag
defin
postpartum
hemorrhag
refractori
firstlin
measur
control
bleed
women
enrol
januari
januari
dutch
hospit
timedepend
propens
scorematch
analysi
women
transfus
fresh
frozen
plasma
within
min
follow
diagnosi
persist
postpartum
hemorrhag
match
women
without
plasma
transfus
plasma
transfus
later
time
point
hemorrhag
plasma
transfus
guid
coagul
test
main
outcom
measur
advers
matern
outcom
defin
composit
mortal
hysterectomi
arteri
embol
control
bleed
perform
sensit
analys
initi
plasma
transfus
within
within
min
follow
diagnosi
persist
postpartum
hemorrhag
compar
plasma
transfus
strategi
result
result
cohort
consist
women
persist
postpartum
hemorrhag
uterin
atoni
caus
hemorrhag
women
cohort
seven
matern
death
hysterectomi
arteri
embol
observ
plasma
transfus
within
min
women
match
timedepend
propens
score
women
later
plasma
transfus
rate
advers
matern
outcom
similar
women
without
earli
plasma
transfus
versu
adjust
odd
ratio
confid
interv
result
sensit
analys
compar
primari
result
summaryconclus
among
women
persist
postpartum
hemorrhag
initi
plasma
transfus
within
min
follow
diagnosi
associ
improv
matern
outcom
compar
later
plasma
transfus
whether
transfus
strategi
identif
women
high
risk
coagulopathi
improv
matern
outcom
remain
studi
background
preoper
evalu
increas
risk
periop
bleed
essenti
cardiac
surgeri
patient
platelet
aggreg
laboratori
test
assess
platelet
function
effici
optim
antiplatelet
treatment
also
assess
increas
risk
postop
bleed
periop
applic
allogen
red
blood
cell
transfus
aim
aim
studi
establish
whether
preoper
platelet
function
test
presenc
residu
effect
acetylsalicyl
acid
asa
platelet
aggreg
correl
increas
risk
intraop
bleed
cardiac
intervent
method
retrospect
studi
includ
patient
underw
surgic
procedur
cabg
ii
cabg
iii
depart
cardiovascular
surgeri
clinic
center
ni
period
novemb
patient
previous
taken
asa
dose
mg
per
day
therapi
discontinu
day
surgeri
platelet
aggreg
measur
day
surgeri
use
imped
aggregomet
multipl
multipl
platelet
function
analyz
roch
use
trap
aspi
test
patient
divid
two
group
control
group
cg
includ
patient
preserv
function
platelet
aspi
au
min
examin
group
eg
includ
patient
inhibit
platelet
aggreg
aspi
test
au
min
background
hemophilia
b
xchromosomelink
inherit
bleed
disord
result
reduc
level
absenc
factor
ix
clinic
repres
recurr
prolong
bleed
mutat
inherit
acquir
de
novo
de
novo
mutat
aris
onethird
patient
haemophilia
diseas
affect
primarili
male
approxim
carrier
femal
factor
ix
clot
activ
lower
risk
bleed
aim
case
report
hemophilia
b
carrier
method
clinic
histori
patient
thoroughli
studi
analyz
medic
record
analyt
result
use
softwar
avail
health
institut
paper
record
result
year
old
woman
histori
abnorm
haemorrhag
healthi
dystoc
deliveri
present
subcutan
ocular
haemorrhag
dispers
bruis
basic
coagul
studi
perform
level
fix
found
genet
analysi
reveal
mutat
fix
gene
diagnos
carrier
hemophilia
b
except
son
direct
famili
member
carri
mutat
total
hysterectomi
bilater
adnexectomi
due
invas
carcinoma
uterin
cervix
patient
suffer
haemorrhag
shock
multipl
transfus
support
around
six
month
later
undergo
ureteronephrectomi
also
need
postsurgeri
transfus
support
patient
refer
immunohemotherapi
depart
regular
appoint
outpati
sinc
requir
surgeri
remov
thyrogloss
duct
cyst
perform
prophylact
treatment
iu
recombin
fix
rfix
daili
four
day
h
discharg
maintain
basal
level
fix
major
complic
report
patient
admit
er
haemodynam
shock
histori
black
stool
syncop
admitt
receiv
bolu
iu
rfix
requir
sever
transfus
support
due
activ
bleed
diagnos
colon
angiodysplasia
undergo
surgeri
daili
dose
iu
rfix
administ
day
maintain
fix
level
around
patient
oper
cover
iu
rfix
twice
per
day
surgeri
reach
fix
level
around
dose
diminish
iu
rfix
daili
discharg
rfix
replac
therapi
necessari
ambulatori
sinc
complic
new
occurr
report
patient
prophylact
administr
rfix
prior
minor
invas
procedur
nodul
biopsi
dental
extract
colonoscopi
summaryconclus
hemophilia
b
carrier
usual
requir
major
health
care
daili
routin
invas
procedur
howev
case
report
basal
fix
level
condit
minor
intervent
perform
thu
carrier
must
consid
moder
hemophilia
b
patient
mandatori
prophylaxi
rfix
must
perform
prior
invas
procedur
background
blood
transfus
life
save
procedur
transfus
associ
complic
equal
import
need
address
limit
resourc
blood
donat
screen
excess
transfus
must
avoid
prevent
risk
econom
burden
patient
hand
discuss
appropri
use
blood
product
matter
debat
medic
literatur
recommend
restrict
liber
use
transfus
aim
regard
aim
observ
frequenc
genuin
non
genuin
transfus
hospit
also
compar
outcom
liber
restrict
transfus
method
cross
section
studi
carri
nibd
bmt
pech
campu
karachi
pakistan
februari
januari
studi
approv
institut
review
board
pack
red
cell
prc
transfus
case
gdl
hemoglobin
hb
cardiac
histori
gdl
hb
symptomat
anemia
consid
genuin
platelet
transfus
case
sepsi
count
l
sepsi
bleed
l
patient
activ
chemotherapi
without
bleed
platelet
count
l
patient
present
bleed
consid
genuin
patient
present
bleed
derang
coagul
profil
sepsi
bleed
consid
genuin
fresh
frozen
plasma
ffp
transfus
spss
version
use
descript
inferenti
statist
result
total
transfus
evalu
genuin
non
genuin
transfus
male
predomin
high
data
prc
platelet
ffp
transfus
respect
platelet
platelet
apheresi
prc
platelet
non
genuin
transfus
per
criteria
describ
method
howev
ffp
platelet
apheresi
genuin
transfus
non
genuin
group
platelet
transfus
patient
receiv
unit
platelet
increment
platelet
count
post
transfus
found
statist
non
signific
p
thirti
six
transfus
done
unit
prc
non
genuin
group
mean
hb
level
patient
receiv
unit
unit
prc
statist
p
found
increment
hb
group
post
transfus
p
summaryconclus
conclud
although
blood
transfus
integr
procedur
save
life
yet
correct
use
blood
product
necessari
era
blood
donat
scarc
blood
transfus
potenti
associ
hazard
approach
toward
appropri
use
blood
product
minim
risk
transmiss
infecti
diseas
also
reduc
econom
burden
longitudin
studi
larg
sampl
size
need
valid
studi
uncertain
ovin
model
enabl
comparison
invas
noninvas
method
measur
oxygen
deliveri
utilis
tissu
level
b
efficaci
variou
resuscit
fluid
transfus
protocol
treat
haemorrhag
shock
aim
develop
ovin
model
haemorrhag
shock
method
sheep
n
anaesthetis
ventil
instrument
instrument
includ
blood
flow
perfus
microdialysi
probe
place
brain
kidney
liver
skelet
muscl
haemodynam
tissu
oxygen
tissu
flow
respiratori
data
record
continu
data
captur
softwar
noninvas
assess
includ
brain
muscl
oxygen
satur
nir
visualis
sublingu
microvascular
perfus
well
arteri
blood
ga
measur
plasmaserumurin
collect
made
specif
timepoint
baselin
period
h
sheep
estim
blood
volum
estim
mlkg
mean
arteri
blood
pressur
map
mmhg
sheep
resuscit
either
plasmalyt
mlkg
hr
n
transfus
sheep
red
cell
n
achiev
map
mmhg
sheep
euthanis
h
resuscit
data
present
mean
ae
standard
deviat
result
sheep
haemorrhag
averag
ae
ml
blood
combin
iatrogen
blood
loss
ml
correspond
averag
ae
blood
loss
two
four
sheep
met
clinic
criteria
haemorrhag
shock
map
mmhg
lactat
mm
svo
across
four
sheep
nadir
map
averag
ae
mmhg
lactat
peak
ae
mmol
l
nadir
svo
ae
sheep
surviv
end
experiment
protocol
summaryconclus
data
demonstr
success
induct
haemorrhag
shock
ovin
model
experi
plan
improv
protocol
achiev
incid
haemorrhag
shock
compar
invas
noninvas
measur
oxygen
deliveri
utilis
well
efficaci
differ
resuscit
fluid
red
cell
transfus
advers
event
includ
trali
bilirubin
record
within
period
clinic
paramet
compar
reaction
strength
antibodi
reaction
autom
strength
measur
solid
phase
manual
test
consist
incub
use
liss
ad
monospecif
igg
dat
perform
manual
ad
polyspecif
igg
test
monospecif
igg
rh
group
nonrh
group
case
perform
manual
result
weaker
indic
manual
strength
correl
clinic
hemolysi
likewis
dat
neg
show
correl
clinic
hemolysi
howev
ldh
bilirubin
measur
two
paramet
increas
autom
strength
antibodi
increas
summaryconclus
dshtr
investig
associ
overt
acceler
red
cell
destruct
strong
correl
observ
autom
immunohematolog
test
result
laboratori
marker
hemolysi
experi
direct
antiglobulin
test
manual
strength
show
correl
background
numer
transfus
patient
present
sever
sometim
critic
clinic
condit
occurr
advers
transfus
reaction
atr
may
induc
deterior
clinic
condit
worsen
clinic
cours
lifethreaten
fatal
outcom
case
nervou
system
impair
franc
notifi
atr
lifethreaten
death
respect
aim
aim
evalu
notifi
atr
neurolog
sign
occur
transfus
patient
period
six
year
six
month
hospit
auvergn
alp
area
studi
includ
patient
report
atr
hospit
area
januari
st
june
th
atr
regist
nation
haemovigil
databas
system
two
sign
observ
time
atr
analyz
unconsci
convuls
stroke
exclud
type
atr
sever
blood
product
involv
imput
studi
result
period
studi
atr
report
includ
unconsci
andor
convuls
patient
femal
male
unconsci
alon
frequent
observ
report
convuls
notifi
report
associ
unconsci
diagnosi
seizur
clinic
sign
establish
case
unconsci
andor
convuls
present
allerg
reaction
case
transfusionassoci
circul
overload
case
suspect
transfusiontransmit
bacteri
infect
hypertens
reaction
allerg
atr
unconsci
notifi
case
unconsci
associ
convuls
one
twelv
atr
sever
lifethreaten
case
result
death
recipi
allerg
atr
sever
lifethreaten
red
blood
cell
concentr
involv
atr
platelet
concentr
includ
case
apheresi
platelet
concentr
case
pool
platelet
concentr
fresh
frozen
plasma
involv
atr
nevertheless
imput
blood
product
exclud
unlik
atr
suspect
transfusiontransmit
bacteri
infect
imput
transfus
ultim
exclud
neg
result
obtain
bacteri
cultur
blood
product
imput
blood
product
probabl
possibl
atr
respect
certain
atr
summaryconclus
unconsci
andor
convuls
rare
observ
atr
notifi
transfus
patient
nevertheless
presenc
sign
highlight
serious
atr
ar
lastli
imput
blood
product
often
exclud
unlik
multivari
cox
model
effect
lpi
overal
surviv
adjust
age
ipssr
categori
elev
lpi
level
associ
inferior
overal
surviv
hr
ci
p
effect
pronounc
tdr
subgroup
hr
ci
p
similarli
elev
lpi
level
associ
inferior
pf
hr
ci
p
whole
studi
popul
tdr
subgroup
hr
ci
p
total
patient
receiv
iron
chelat
sampl
collect
period
patient
deferasirox
patient
desferrioxamin
lpi
level
normal
sampl
collect
deferasirox
treatment
sampl
collect
desferrioxamin
treatment
summaryconclus
transfus
depend
associ
presenc
toxic
iron
speci
inferior
overal
progressionfre
surviv
lowerrisk
md
patient
tdr
patient
effect
pronounc
indic
ineffect
erythropoiesi
lead
addit
iron
toxic
background
posttransfus
immunomodul
report
contribut
poor
patient
outcom
clinic
relev
transfus
model
need
improv
understand
underli
mechan
sheep
transfus
model
increas
import
blood
transfus
research
provid
sever
advantag
small
anim
includ
size
anatomi
physiolog
similar
blood
volum
compar
human
current
limit
sheep
transfus
model
lack
characteris
sheep
immun
system
understand
sheep
immunolog
necessari
advanc
sheep
transfus
model
identifi
mechan
contribut
posttransfus
immunomodul
facilit
translat
find
clinic
set
aim
characteris
sheep
leukocyt
inflammatori
respons
vitro
lipopolysaccharid
lp
challeng
edta
heparin
whole
blood
method
edta
heparin
sheep
whole
blood
n
cultur
rpmi
media
co
alon
addit
lp
lgml
deriv
escherichia
coli
inflammatori
respons
assess
h
h
h
h
h
h
h
supernat
harvest
time
point
store
inflammatori
cytokinechemokin
product
determin
use
sheep
specif
inhous
elisa
twoway
analysi
varianc
bonferroni
posttest
use
measur
effect
incub
time
concentr
compar
lp
match
sampl
result
edta
use
anticoagul
addit
lp
result
product
sheep
product
significantli
increas
follow
stimul
lgml
lp
h
p
declin
follow
h
incub
releas
signific
h
postlp
stimul
lgml
p
reach
maximum
h
use
heparin
blood
result
differ
immun
profil
inflammatori
marker
test
detect
follow
stimul
much
lower
concentr
lp
lgml
although
incub
time
differ
significantli
increas
follow
h
incub
p
increas
level
observ
h
postlp
stimul
product
evid
h
reach
signific
h
postlp
stimul
p
significantli
increas
follow
stimul
lgml
lp
hr
p
lower
concentr
lp
result
product
h
p
releas
signific
h
lgml
lp
stimul
p
lower
concentr
lp
result
product
h
p
heparin
whole
blood
lp
concentrationdepend
effect
evid
cytokin
summaryconclus
use
timeand
concentrationapproach
find
indic
sheep
toler
delay
respons
lp
stimul
compar
previou
research
use
similar
human
vitro
whole
blood
cultur
model
addit
data
suggest
sheep
greater
immun
respons
use
heparin
anticoagul
collect
blood
sampl
improv
understand
sheep
immunolog
develop
relev
sheep
transfus
model
provid
bridg
sheep
model
transfus
clinic
set
rhdig
inappropri
administ
unnecessari
exposur
n
administ
rhd
posit
woman
n
rhd
neg
mother
rhd
neg
neonat
n
woman
immun
anti
n
administ
error
instead
ig
n
delayedomittedwrong
dose
risk
sensitis
antigen
n
omit
n
delay
n
inadequ
dose
n
without
correct
patient
identif
n
handl
n
failur
check
matern
neonat
blood
group
prior
administr
identifi
sourc
error
misinterpret
blood
result
also
led
women
receiv
product
inappropri
eg
read
neg
antibodi
screen
mother
rhd
neg
patient
identif
rais
issu
rhdig
often
store
satellit
blood
fridg
easi
access
collect
area
alway
requir
confirm
patient
identifi
regist
women
receiv
product
link
batch
number
ensur
traceabl
two
incid
involv
administr
rhdig
prescript
immunoglobulin
product
clear
lead
child
babi
receiv
rhdig
instead
intend
immunoglobulin
summaryconclus
incid
indic
problem
process
appropri
identif
women
need
rhdig
use
interpret
patholog
test
requir
prescript
administr
result
omit
inappropri
dose
rhdig
blood
matter
made
number
recommend
regard
rhdig
administr
health
profession
involv
rhdig
administr
appropri
train
use
rhdig
confirm
matern
rhd
statu
essenti
prior
prescript
administr
posit
patient
identif
must
use
prior
administr
rhdig
health
servic
consid
regular
audit
identifi
area
improv
relat
rhdig
blood
matter
continu
work
matern
care
provid
improv
practic
centro
comunitario
de
sangr
tejido
de
asturia
oviedo
agencia
gallega
de
sangr
organo
tejido
galicia
banco
de
sangr
tejido
de
cantabria
cantabria
banco
de
sangr
de
la
rioja
la
rioja
banco
de
sangr
tejido
de
navarra
navarra
banco
de
sangr
tejido
de
arag
aragon
fundaci
de
hemoterapia
hemodonaci
de
castilla
le
castilla
leon
fundaci
banco
de
sangr
tejido
de
la
isla
balear
isla
balear
spain
terumo
bct
europ
nv
zaventem
belgium
background
hemovigil
longterm
monitor
process
made
mandatori
nation
supran
regul
begin
systemat
whole
blood
blood
compon
collect
end
examin
period
transfus
blood
compon
patient
spain
organ
autonom
region
hemovigil
system
structur
three
level
local
level
compris
transfus
center
hospit
base
transfus
servic
monitor
collect
transfus
relat
advers
event
ae
level
region
hemovigil
coordin
commun
region
data
spanish
ministri
health
issu
annual
report
correspond
european
institut
ensur
safer
blood
suppli
pathogen
reduct
technolog
prt
approv
implement
start
spain
mirasol
prt
system
platelet
plasma
introduc
current
use
spanish
region
aim
monitor
safeti
system
passiv
hemovigil
studi
mirasol
treat
product
initi
region
asturia
collabor
extend
region
balear
galicia
la
rioja
cantabria
navarra
castilla
leon
aragon
method
collect
data
includ
allerg
febril
reaction
trali
advers
event
observ
sever
event
level
imput
transfus
also
assess
use
grade
scale
hemovigil
data
mirasol
treat
product
platelet
mpc
plasma
mp
includ
blood
center
start
appli
technolog
routin
result
increas
adopt
mirasol
system
observ
mirasol
treat
blood
product
issu
hospit
mirasol
product
issu
due
low
number
transfus
mirasoltr
blood
compon
notif
rate
began
analyz
show
ae
rate
similar
report
nation
level
stabl
transfus
reaction
rate
observ
mpc
around
rate
ae
transfus
mp
fluctuant
fluctuat
could
due
inconsist
number
mp
transfus
one
year
transfus
reaction
around
grade
sever
grade
ii
level
imput
allerg
reaction
account
advers
event
g
reaction
respect
bacteri
viral
transfus
transmiss
record
mirasol
product
studi
period
nation
level
nine
case
bacteri
transfus
transmiss
g
report
transmiss
probabl
due
transfus
nonpathogen
reduc
product
summaryconclus
observ
notif
rate
ae
similar
nation
rate
allerg
reaction
g
inferior
mirasol
treat
product
also
found
report
transfus
transmiss
infect
case
transfus
associ
graftvshost
diseas
demonstr
safeti
mirasol
treat
product
attribut
human
error
lowest
frequenc
equip
failur
compar
respect
follow
three
year
root
caus
analysi
demonstr
failur
qualiti
manag
system
includ
failur
administr
inadequ
staf
blood
collect
well
distribut
process
failur
aris
institut
constraint
system
failur
hospit
manag
high
number
ae
distribut
whole
blood
collect
call
investig
indic
measur
necessari
prevent
correct
error
relat
incorrect
blood
compon
transfus
ibct
blood
unit
issu
transfus
result
seriou
reaction
fatal
lifethreaten
anoth
relat
ibct
caus
reaction
near
miss
compon
transfus
summaryconclus
data
demonstr
increas
complianc
report
requir
question
initi
factor
deviat
certain
activ
specifi
failur
equip
materi
due
system
well
human
error
highlight
need
specif
beyond
human
error
background
weakest
link
transfus
chain
current
handl
blood
compon
issu
bedsid
blood
administr
practic
aim
evalu
complianc
standard
procedur
bedsid
blood
transfus
practic
analysi
transfus
feedback
form
tertiari
care
multispecialti
hospit
set
method
studi
period
month
transfus
feedback
form
receiv
variou
clinic
area
hospit
studi
special
refer
transfus
time
data
categor
base
patient
locat
well
time
transfus
whether
done
routin
emerg
hour
result
blood
compon
issu
studi
period
transfus
feedback
form
compon
receiv
transfus
medicin
depart
delay
start
transfus
min
issu
observ
transfus
event
compon
transfus
time
exceed
permiss
limit
compon
overal
total
permiss
time
complet
compon
exceed
permiss
limit
transfus
event
pediatr
ward
icu
ot
complex
found
noncompli
delay
transfus
transfus
time
total
transfus
time
amongst
delay
transfus
issu
routin
hour
ie
pm
non
routin
hour
ie
pm
summaryconclus
audit
bedsid
blood
transfus
practic
given
us
good
insight
variou
area
noncompli
well
predomin
locat
hospit
practic
need
strengthen
focus
train
program
safe
blood
administr
practic
staff
involv
handl
transfus
blood
compon
plan
combat
issu
background
intern
surveil
transfus
advers
reaction
ar
event
ae
istar
intern
haemovigil
network
ihn
collect
aggreg
data
member
nation
haemovigil
system
hv
order
estim
morbid
mortal
blood
transfus
holist
approach
ultim
goal
contribut
improv
safeti
transfus
close
monitor
throughout
chain
vein
vein
aim
analys
recent
istar
data
suspect
transfus
transmit
infect
stti
comparison
previou
year
surveil
method
annual
aggreg
data
ihn
member
hv
transfus
associ
bacteri
viral
parasit
infect
collect
onlin
istar
analyz
incid
blood
compon
bc
issu
transfus
sever
imput
well
blood
compon
ar
definit
probabl
possibl
imput
includ
analysi
trend
analysi
perform
allow
comparison
collect
inform
establish
newli
emerg
infecti
threat
blood
transfus
result
set
annual
aggreg
data
countri
cover
bc
issu
analyz
ar
total
infecti
ar
amount
overal
incid
infecti
ar
unit
bc
issu
bacteri
infect
frequent
next
viral
parasit
seriou
fatal
incid
nine
death
attribut
sepsi
two
associ
nonmalari
parasit
pathogen
one
geotrichum
clavatum
fungal
infect
associ
apheresi
platelet
report
free
text
comment
rare
recogn
fungal
pathogen
caus
sever
infect
patient
rout
transmiss
inconclus
viral
stti
includ
hbv
hcv
hiv
record
includ
case
hev
one
case
parvoviru
one
cmv
one
ebv
case
ttmalaria
report
sttpi
two
fatal
prevail
bc
gener
rbc
follow
platelet
comparison
correspond
data
show
consist
overal
incid
total
stti
vs
howev
consider
differ
seen
separ
categori
bacteri
infect
significantli
increas
rate
p
almost
doubl
rate
parasit
infect
p
compar
earlier
period
mani
fewer
hbv
infect
vs
mani
hev
similar
reduct
rate
hcv
hiv
observ
comparison
previou
year
may
explain
fact
nat
test
hcvhivhbv
implement
mani
countri
last
decad
summaryconclus
infecti
risk
transfus
overal
remain
low
rate
bacteri
case
increas
among
viral
stti
frequenc
hev
increas
mortal
transfus
due
stti
lower
previou
period
surveil
abstract
withdrawn
background
one
main
aspect
haemovigil
system
hospit
follow
advers
event
reaction
relat
blood
transfus
aim
intend
analys
advers
reaction
relat
transfus
blood
compon
pediatr
patient
method
four
year
period
januari
haemovigil
record
patient
receiv
blood
transfus
procedur
review
transfus
reaction
analys
statist
analysi
data
perform
spss
softwar
version
spss
inc
chicago
il
usa
major
blood
compon
provid
region
blood
center
organ
nation
red
crescent
societi
granulocyt
collect
apheresi
donor
mobil
reconstitut
whole
blood
exchang
transfus
prepar
transfus
center
hospit
result
median
age
patient
develop
transfus
reaction
month
interquantil
rangeiqr
median
number
individu
transfus
children
year
iqr
median
number
blood
compon
individu
transfus
patient
iqr
patient
anaphylact
transfus
reaction
patient
transfusionrel
lung
injuri
trali
patient
overal
incid
transfus
reaction
estim
rate
per
unit
summaryconclus
report
advers
effect
relat
blood
transfus
especi
allerg
reaction
fnhtr
common
pediatr
patient
adult
multin
studi
concern
transfus
reaction
relat
red
cell
concentr
allerg
transfus
reaction
fnhtr
report
rate
unit
unit
respect
incid
transfus
reaction
children
found
studi
usa
overal
incid
transfus
reaction
studi
estim
rate
per
unit
repres
lower
rate
hospit
gran
canaria
dr
negr
gran
canaria
hospit
gener
universitario
ciudad
real
spain
hospit
nostra
senior
de
meritxel
andorra
andorra
banco
sangr
tejido
santand
banc
de
sang
teixit
barcelona
spain
fundaci
hematol
ogica
colombia
bogot
colombia
centro
region
de
transfusi
de
almer
almeria
complejo
hospitalario
de
navarra
pamplona
fundaci
banc
de
sang
teixit
ill
balear
palma
de
mallorca
hospit
de
gij
spain
background
root
analysi
caus
defin
caus
error
treat
elimin
repetit
error
aim
describ
type
human
latent
error
detect
work
group
root
analysi
caus
transfus
incid
analyz
concord
individu
respons
member
propos
recommend
order
improv
transfusion
safeti
method
fifteen
particip
nurs
hematologist
dedic
transfus
compon
prepar
studi
incid
administr
nonirradi
compon
tri
approach
root
caus
appli
classif
error
merstm
transfus
medicin
transfer
answer
questionnair
simpl
chain
error
initi
process
affect
human
latent
error
measur
deriv
analysi
correct
error
commun
made
mail
spanish
transfus
societi
web
forum
contain
consult
document
data
percentag
expos
type
error
answer
particip
tabul
result
case
correspond
patient
two
patient
year
age
diagnos
acut
myeloblast
leukemia
case
chronic
lymphat
leukemia
case
one
case
hematologist
transfus
servic
cancel
irradi
prescript
anoth
patient
fever
transfus
emerg
room
without
irradi
requir
later
discov
receiv
transplant
hemopoiet
progenitor
month
earlier
last
case
neither
request
doctor
laboratori
technician
follow
doctor
prescrib
detect
alert
locat
respect
comput
applic
case
stori
judg
suffici
analysi
major
review
diagnos
chain
error
agreement
respect
initi
process
affect
initi
error
commun
monitor
complianc
case
human
error
detect
per
case
averag
error
respect
latent
error
per
case
averag
respect
latent
error
punctuat
failur
qualiti
protocol
transfer
import
knowledg
avail
technolog
inform
patient
particip
contribut
feasibl
measur
improv
accord
root
caus
improv
qualiti
draft
work
procedur
complianc
includ
procedur
effect
commun
profession
train
staff
knowledg
import
safeti
commun
comput
applic
provid
improv
effect
visibl
alert
involv
patient
essenti
inform
ensur
transfus
safeti
measur
process
later
recommend
summaryconclus
root
analysi
show
agreement
particip
allow
elabor
use
recommend
increas
patient
safeti
strategi
contribut
comprehens
prevent
error
background
transfusionassoci
circulatori
overload
taco
pulmonari
oedema
develop
primarili
due
volum
excess
data
uk
haemovigil
scheme
seriou
hazard
transfus
shot
suggest
either
incid
taco
recognit
report
taco
increas
time
report
taco
increas
death
major
morbid
known
risk
factor
includ
preexist
cardiac
andor
renal
dysfunct
low
bodi
weight
extrem
age
eg
year
year
concomit
fluid
administr
posit
fluid
balanc
peripher
oedema
hypoalbuminemia
small
subset
case
report
shot
taco
develop
follow
transfus
sever
anaemia
absenc
risk
factor
may
underrecognis
independ
riskfactor
aim
rais
awar
sever
anaemia
underrecognis
risk
factor
taco
potenti
lifethreaten
transfus
method
case
taco
submit
shot
last
year
review
identifi
case
transfus
sever
anaemia
key
identifi
patient
risk
factor
result
follow
illustr
case
case
patient
weigh
kg
prescrib
six
unit
red
cell
iron
defici
anaemia
admit
hb
gl
patient
risk
factor
taco
except
profound
anaemia
transfus
fifth
unit
patient
becam
dyspnoeic
hypox
hypertens
patient
recov
diuret
therapi
posttransfus
hb
level
gl
case
patient
present
histori
weak
dizzi
felt
unwel
month
hb
gl
ferritin
lgl
ecg
show
cardiac
ischaemia
two
unit
red
cell
transfus
second
unit
oxygen
satur
fell
despit
supplement
oxygen
posttransfus
hb
gl
third
unit
transfus
min
hypoxia
worsen
dyspnoea
crackl
chest
auscult
chest
xray
show
enlarg
cardiac
silhouett
pulmonari
congest
patient
improv
diuret
case
patient
sever
megaloblast
anaemia
hb
gl
peripher
oedema
develop
taco
transfus
unit
recov
diuret
therapi
summaryconclus
chronic
acut
anaemia
associ
compensatori
cardiac
chang
irrespect
aetiolog
anaemia
compound
underli
caus
anaemia
particularli
haematin
defici
defici
independ
affect
myocardi
function
hyperdynam
circul
relat
anaemia
increas
load
heart
caus
myocardi
ischaemia
hypoxia
anaemia
correct
eventu
lead
heart
failur
clinician
need
make
accur
diagnosi
avoid
excess
transfus
patient
sever
anaemia
without
addit
risk
factor
patient
chronic
defici
without
haemodynam
instabl
given
appropri
haematin
replac
haematin
defici
respond
rapidli
appropri
vitaminminer
blood
transfus
given
clinic
indic
even
minimum
volum
need
symptomat
relief
transfus
consider
diuret
therapi
method
legal
form
report
transfus
reaction
use
retrospect
analysi
adjust
depart
qualiti
assur
qualiti
control
electron
form
distribut
clinic
use
blood
compon
clinician
train
report
transfus
reaction
hospit
transfus
board
servic
improv
qualiti
safeti
health
servic
clinic
center
sarajevo
analysi
report
reaction
institut
includ
immunohematolog
microbiolog
examin
base
guidelin
treatment
blood
compon
made
user
regist
servic
oblig
report
sinc
result
total
differ
blood
compon
appli
period
depart
qualiti
assur
control
receiv
seriou
advers
reaction
seriou
advers
event
report
transfus
reaction
inadequ
fill
period
transfus
reaction
erythrocyt
blood
compon
appli
platelet
compon
transfus
reaction
applic
fresh
frozen
plasma
analysi
shown
frequent
febril
nonhaemolysi
reaction
follow
allerg
reaction
two
transfus
reaction
character
circul
overload
summaryconclus
frequenc
seriou
advers
reaction
event
report
transfus
reaction
establish
hospit
transfus
board
increas
collabor
clinic
center
signific
progress
made
necessari
increas
awar
among
clinician
regard
safe
transfus
practic
report
transfus
reaction
mandatori
procedur
path
proper
select
blood
compon
monitor
advers
reaction
us
transfusiologist
guid
safest
effici
blood
compon
j
garc
e
martinezrevuelta
carog
omez
c
onfern
andez
fern
andezrodriguez
hospit
universitario
central
de
asturia
oviedo
spain
background
elderli
patient
main
group
transfus
recipi
countri
given
comorbid
risk
group
develop
complic
relat
transfus
aim
analyz
incid
advers
effect
relat
transfus
elderli
popul
assess
factor
may
influenc
appear
method
transfus
review
patient
year
old
variabl
analyz
sex
age
diagnosisreason
transfus
pretransfus
hemoglobin
hb
number
transfus
unit
infus
rate
transfus
side
effect
well
measur
use
prevent
treat
transfus
effect
circulatori
overload
result
total
patient
analyz
women
men
median
age
year
total
ch
transfus
patient
receiv
ch
patient
ch
patient
receiv
ch
patient
transfus
two
differ
time
median
hb
prior
transfus
gdl
patient
receiv
ch
gdl
receiv
ch
gdl
receiv
ch
gdl
infus
time
could
estim
patient
receiv
ch
min
min
receiv
ch
min
receiv
ch
patient
total
suffer
type
advers
effect
relat
transfus
patient
increas
posterior
ta
increas
hr
episod
hypotens
anoth
one
episod
acut
respiratori
failur
advers
effect
older
year
patient
aht
transfus
receiv
ch
remaind
ch
among
background
histori
ischem
heart
diseas
also
posit
balanc
averag
previou
bp
mmhg
subsequ
one
mmhg
patient
receiv
diuret
treatment
case
patient
acut
respiratori
failur
oligoanuria
posit
balanc
ch
transfus
total
treat
oxygen
therapi
intensif
diuret
treatment
recov
later
summaryconclus
patient
year
higher
risk
suffer
type
advers
effect
relat
transfus
preexist
risk
factor
ischem
heart
diseas
heart
failur
see
risk
suffer
type
advers
effect
elderli
popul
greater
transfus
appreci
patient
receiv
infus
rate
higher
studi
highlight
lack
method
prevent
develop
circulatori
overload
background
iron
defici
anemia
commonest
caus
anemia
worldwid
weak
fatigu
reduc
physic
activ
difficulti
concentr
symptom
associ
defici
forefront
treatment
avail
oral
iron
replac
therapi
conveni
cost
effect
substanti
outcom
anoth
option
intraven
iv
iron
oral
toler
despit
potenti
transfus
associ
hazard
limit
avail
blood
due
shortag
voluntari
blood
donat
insist
patient
prior
iron
therapi
aim
aim
conduct
studi
observ
impact
administr
oral
iron
iv
iron
transfus
hemoglobin
level
patient
present
iron
defici
anemia
method
observ
studi
carri
nibd
bmt
pech
campu
karachi
pakistan
februari
decemb
studi
approv
institut
review
board
diagnos
ida
patient
present
hospit
recruit
analysi
given
oral
iron
iv
iron
transfus
correct
anemia
inform
consent
taken
particip
descript
inferenti
statist
appli
use
spss
version
result
total
ida
patient
analyz
femal
male
common
symptom
femal
male
fatigu
follow
bodi
ach
femal
pallor
male
menorrhagia
present
femal
reproduct
age
surgic
histori
present
femal
surgic
histori
male
mean
hemoglobin
mch
mcv
femal
baselin
ae
ae
ae
male
ae
ae
ae
respect
sixti
two
femal
advis
oral
iv
iron
receiv
transfus
howev
male
receiv
transfus
advis
oral
iv
iron
therapi
observ
increment
hemoglobin
oraliv
iron
averag
month
follow
male
femal
transfus
p
summaryconclus
societi
blood
donat
scarc
especi
voluntari
blood
donat
consid
safest
type
blood
donat
would
like
draw
attent
toward
altern
correct
anemia
oral
iv
iron
replac
therapi
result
reveal
differ
increment
hemoglobin
two
group
need
educ
societi
especi
older
age
adult
young
women
vulner
get
ida
opt
oral
iv
iron
therapi
cost
effect
conveni
also
less
risk
transfus
cellular
therapi
stem
cell
tissu
bank
includ
cord
blood
background
differenti
megakaryocyt
play
import
role
product
platelet
howev
underli
mechan
regul
megakaryocyt
differenti
rare
studi
aim
identifi
candid
gene
involv
megakaryocyt
differenti
investig
potenti
regulatori
mechan
megakaryocyt
differenti
human
cord
blood
hematopoiet
stem
cell
vitro
method
cbderiv
cell
isol
use
densiti
gradient
centrifug
magnet
activ
cell
sort
mac
cultur
stimul
recombin
human
tpo
ngml
day
mk
fraction
select
immunomagnet
sort
nonmk
fraction
use
monoclon
antibodi
rnaseqderiv
gene
express
data
perform
uncultur
sampl
day
cultur
unselect
sampl
day
cultur
select
sampl
day
use
nextgener
sequenc
ng
platform
rqpcr
technolog
use
verifi
express
transcript
factor
result
comparison
transcriptom
profil
among
five
stage
show
massiv
gene
express
chang
occur
megakaryocyt
differenti
total
gene
detect
show
upregul
downregul
among
gene
differenti
express
gene
deg
fold
chang
fals
discoveri
rate
select
valid
rqpcr
includ
gabr
rqpcr
result
indic
mrna
express
level
increas
prolong
cultur
time
howev
mrna
express
level
highest
day
highest
day
summaryconclus
conclus
studi
identifi
seri
gene
may
particip
regul
megakaryocyt
differenti
result
serv
import
resourc
reveal
molecular
basi
megakaryocyt
differenti
thrombocytopoiesi
preoper
anemia
blood
transfus
requir
hip
knee
surgeri
rambam
health
care
campu
haifa
israel
background
blood
transfus
bt
independ
associ
increas
morbid
mortal
hospit
length
across
differ
patient
popul
due
btrelat
risk
concept
patient
blood
manag
pbm
introduc
clinic
practic
three
pbm
pillar
optim
red
cell
mass
minim
blood
loss
optim
physiolog
reserv
bt
indic
orthoped
surgeri
includ
excess
bleed
hemodynam
instabl
hemoglobin
hb
level
clinic
scenario
restrict
transfus
threshold
hb
level
gdl
appear
noninferior
liber
transfus
strategi
term
blood
use
morbid
mortal
similar
result
observ
highrisk
patient
hip
surgeri
hypothes
preoper
anemia
may
lead
blood
product
overus
complic
aim
evalu
potenti
correl
preoper
anemia
bt
requir
hip
knee
surgeri
method
review
medic
file
patient
underw
hip
knee
replac
surgeri
rambam
patient
hb
level
measur
within
day
presurgeri
includ
receiv
blood
unit
consid
surgeri
complic
patient
exclud
patient
demograph
clinic
data
includ
comorbid
surgeri
type
length
hospit
stay
collect
creat
synthet
data
cohort
use
mdclone
healthcar
data
sandbox
environ
enabl
fast
data
extract
produc
synthet
data
analysi
requir
irb
approv
result
evalu
period
patient
underw
hip
knee
surgeri
exclud
analysi
due
receiv
blood
unit
hb
measur
within
day
presurgeri
avail
patient
hip
knee
surgeri
perform
patient
respect
women
compris
n
patient
underw
hip
surgeri
hipsurgeri
group
patient
requir
bt
need
slightli
higher
among
women
vs
pvaluen
patient
transfus
knee
surgeri
cohort
analyz
patient
receiv
bt
significantli
lower
mean
hb
level
nt
requir
gdl
versu
gdl
women
gdl
vs
gdl
men
pvalu
hospit
longer
transfus
patient
compar
nontransfus
one
mean
vs
day
pvalu
patient
low
hb
level
femal
male
high
hb
level
irrespect
receiv
bt
pvalu
patient
least
one
follow
diagnos
diabet
renal
failur
ischem
heart
diseas
significantli
like
lower
preoper
hb
level
pvalu
factor
eg
patient
weight
rdw
valu
blood
pressur
predict
transfus
need
probabl
need
blood
unit
hb
gdl
group
hb
g
dl
group
reduct
summaryconclus
anemia
presenc
elect
hip
surgeri
risk
factor
bt
requir
longer
hospit
diagnosi
manag
anemia
use
time
presurgeri
consult
may
minim
intraop
bt
particularli
women
patient
comorbid
realpati
data
prospect
trial
warrant
abstract
withdrawn
abstract
withdrawn
background
known
platelet
glycoprotein
iv
belong
type
b
scaveng
receptor
relat
pathogenesi
mani
diseas
type
defici
express
platelet
monocyt
individu
type
defici
produc
homolog
antibodi
caus
relat
immun
diseas
recent
year
report
defici
individu
caus
fetal
immun
thrombocytopenia
fetal
edema
syndrom
asia
express
matur
rbc
exist
hematopoiet
stem
progenitor
cell
anemia
import
caus
edema
view
phenomena
clinic
anim
experi
hematopoiet
stem
progenitor
cell
cultur
vitro
observ
effect
monoclon
antibodi
hematopoiet
stem
progenitor
cell
aim
investig
effect
monoclon
antibodi
prolifer
differenti
human
hematopoiet
stem
progenitor
cell
vitro
method
choos
healthi
fullterm
matern
women
without
variou
obstetr
complic
take
cord
blood
ml
densiti
gradient
centrifug
ficol
cell
separ
solut
hematopoiet
stem
progenitor
cell
sort
flow
cytometri
cultur
gener
mtt
use
examin
effect
monoclon
antibodi
growth
hematopoiet
stem
progenitor
cell
flow
cytometri
analysi
use
detect
apoptosi
cell
cycl
hematopoiet
stem
progenitor
cell
effect
monoclon
antibodi
format
cfuebfu
hematopoiet
stem
progenitor
cell
analysi
cfuebfu
account
day
cultur
result
umbil
cord
blood
isol
ficol
obtain
mononuclear
cell
hematopoiet
stem
progenitor
cell
sort
flow
cytometri
hematopoiet
stem
progenitor
cell
isol
differ
concentr
monoclon
antibodi
hematopoiet
stem
progenitor
cell
cultur
vitro
od
valu
valu
ae
monoclon
antibodi
group
mgml
decreas
normal
group
ae
p
od
valu
ae
significantli
decreas
monoclon
antibodi
concentr
mgml
p
signific
differ
hematopoiet
stem
progenitor
cell
cultur
group
igg
control
group
p
annexin
v
flow
detect
apoptot
rate
monoclon
antibodi
group
mgml
statist
increas
normal
group
p
monoclon
antibodi
significantli
induc
hematopoiet
stem
progenitor
cell
undergo
phase
cell
reduct
phase
cell
increas
phase
cell
arrest
occur
number
cfuebfu
clone
normal
group
ae
number
cfuebfu
clone
control
group
ae
number
cfuebfu
clone
monoclon
antibodi
cultur
group
ae
number
coloni
form
hematopoiet
stem
progenitor
cell
monoclon
antibodi
cultur
group
significantli
lower
group
p
summaryconclus
monoclon
antibodi
reduc
prolifer
human
hematopoiet
stem
progenitor
cell
reduc
abil
erythroid
differenti
background
recent
new
modern
collect
techniqu
introduc
apheresi
procedur
cobe
spectra
system
replac
spectra
optia
necessari
verifi
effici
spectra
optia
pbpc
collect
aim
aim
studi
evalu
optim
new
cmnc
protocol
spectra
optia
v
terumo
pbpc
collect
patient
haematooncolog
malign
diseas
method
result
autolog
pbpc
collect
evalu
well
mobil
patient
precollect
cd
cell
concentr
blood
higher
b
first
collect
perform
either
use
cmnc
spectra
optia
v
cobe
spectra
v
v
terumo
c
collect
perform
standard
larg
volum
leukapheresi
regimen
lvl
engraft
data
transplant
patient
assess
result
standard
collect
perform
patient
yield
cd
cell
high
signific
differ
found
number
cd
cell
prepar
spectra
optia
cobe
spectra
kg
b
w
pval
depend
cd
cell
yield
precollect
concentr
cd
cell
blood
consid
linear
high
correl
coeffici
cmnc
spectra
optia
r
cobe
spectra
r
lvl
collect
perform
patient
signific
differ
number
cd
cell
prepar
cmnc
spectra
optia
cobe
spectra
kg
bw
pval
relat
precollect
cd
cell
concentr
blood
number
cd
cell
collect
also
consid
linear
correl
coeffici
cmnc
spectra
optia
r
cobe
spectra
r
respect
lvl
median
platelet
loss
significantli
lower
cmnc
spectra
optia
cobe
spectra
group
patient
transplant
mean
pbpc
prepar
standard
regimen
median
time
neutrophil
reconstitut
cmnc
spectra
optia
well
cobe
spectra
day
platelet
cmnc
day
cobe
spectra
day
respect
number
patient
obtain
pbpc
lvl
median
time
neutrophil
platelet
reconstitut
cmnc
spectra
optia
well
cobe
spectra
correspond
day
respect
summaryconclus
cmnc
protocol
spectra
optia
modern
effici
safe
system
use
standard
lvl
procedur
well
mobil
patient
suffici
dose
cd
cell
transplant
could
prepar
one
standard
one
lvl
procedur
seriou
advers
reaction
observ
background
peripher
hematopoiet
stem
cell
collect
patientsdonor
mobil
gscf
aim
collect
fix
number
cellskg
number
depend
preapheresi
number
blood
process
collect
effici
procedur
aim
collect
request
cell
day
whenev
possibl
order
reduc
dose
gcsf
given
donorpati
resourc
use
collect
centr
paramet
adjust
volum
blood
process
increas
likelihood
collect
request
amount
cell
increas
preapheresi
number
high
enough
therefor
need
know
feasibl
increas
volum
therebi
increas
time
procedur
intent
collect
request
cell
day
also
show
possibl
reduc
volum
blood
process
therebi
reduc
time
procedur
aim
develop
easi
tool
calcul
volum
blood
process
order
collect
request
cell
day
method
mean
collect
effici
ce
calcul
ce
calcul
cell
collect
preapheresi
number
process
volum
base
mean
ce
excel
sheet
gener
calcul
volum
blood
process
order
collect
request
cell
excel
sheet
design
user
enter
preapheresi
number
patient
weight
request
number
cell
ce
fix
accord
mean
ce
calcul
result
volum
blood
process
order
collect
request
yield
base
result
apheresi
machin
provid
time
procedur
therebi
possibl
evalu
collect
finish
day
eg
increas
volum
blood
process
spectra
optia
use
collect
cmnc
allogen
donor
mnc
autolog
patient
result
mean
ce
n
ce
chosen
cutoff
calcul
tool
use
calcul
tool
allogen
donor
n
mean
ce
mean
blood
volum
process
tbv
mean
time
min
donor
finish
day
collect
autolog
patient
n
mean
ce
mean
blood
volum
process
tbv
mean
time
min
patient
finish
day
calcul
fail
case
case
volum
blood
process
reduc
accord
calcul
unexpect
low
ce
request
number
cell
achiev
summaryconclus
calcul
tool
base
excel
sheet
shown
simpl
easi
use
order
person
stem
cell
collect
immunotherapi
product
blood
product
pharmaceut
new
categori
togeth
till
donor
hla
type
match
fulli
inform
donat
procedur
sign
inform
consent
donat
minimum
dose
requir
ensur
success
sustain
engraft
kg
cell
kg
mononucl
cell
mnc
pbsc
harvest
perform
continu
flow
cell
separ
baxter
cobe
spectra
spectra
optia
use
conventionalvolum
apheresi
process
total
blood
volum
per
apheresi
femor
cathet
use
harvest
acid
citrat
dextros
formula
use
anticoagul
recombin
human
granulocyt
colonystimul
factor
gcsf
use
mobil
pbpc
collect
harvest
pbsc
usual
perform
day
gcsf
subcutan
administr
dose
lgkg
bodi
weight
result
donor
sibl
patient
treat
univers
hematolog
hospit
apheresi
procedur
perform
healthi
sibl
donor
male
femal
age
one
two
apheresi
procedur
requir
collect
adequ
graft
singl
procedur
usual
took
h
volum
collect
stem
cell
ml
need
number
mnc
cell
success
collect
apheresi
abo
incompat
donor
procedur
mobil
collect
pbpc
healthi
donor
gener
well
toler
advers
effect
apheresi
procedur
bone
pain
reaction
gcsf
numb
extrem
reaction
acda
hypocalcemia
occur
rare
mild
collect
pbsc
use
allogen
stem
cell
transplant
patient
acut
myeloid
leukemia
patient
acut
lymphoblast
leukemia
patient
chronic
myeloid
leukemia
patient
myeloprolif
disord
patient
myelofibrosi
patient
sever
aplast
anemia
patient
nonhodgkin
lymphoma
patient
multipl
myeloma
patient
chronic
lymphoblast
leukemia
patient
hodgkin
diseas
patient
summaryconclus
apheresi
collect
pbsc
healthi
donor
effect
safe
procedur
develop
nation
stem
cell
donor
registri
part
bone
marrow
donor
worldwid
way
hope
help
widen
world
network
stem
cell
donor
enlarg
possibl
patient
find
right
match
background
leukocyteremov
filter
blood
use
wide
univers
leukocyt
reduct
polici
adopt
progress
throughout
world
filtrat
one
effect
method
prevent
variou
advers
transfus
effect
caus
leukocyt
includ
blood
compon
febril
reaction
alloimmun
transmiss
leukotrop
virus
aim
goal
evalu
whether
new
domest
blood
filter
finecel
develop
kolon
industri
gumi
korea
appropri
suit
intern
standard
reveal
efficaci
safeti
settlement
leukocyt
reduct
system
korea
method
thirtytwo
unit
pack
red
blood
cell
obtain
ml
whole
blood
collect
healthi
donor
use
done
analyz
filtrat
time
residu
leukocyt
count
rbc
recoveri
hemolysi
rate
storag
period
day
leukoreduct
result
standard
commonli
use
evalu
leukocyteremov
filter
set
food
drug
administr
usa
council
europ
result
studi
satisfi
intern
standard
summaryconclus
newli
develop
domest
leukoreduct
filter
thu
found
effici
contribut
improv
qualiti
isol
blood
compon
use
korea
faculti
scienc
human
educ
technic
univers
liberec
liberec
czech
republ
background
polymer
fibrou
scaffold
fabric
techniqu
strive
creat
structur
close
replic
tent
extracellular
matrix
form
function
need
increas
scaffold
bioactiv
becom
pronounc
fibrou
structur
made
biocompat
nontox
polym
ensur
mechan
stabil
howev
cell
prolifer
requir
stimul
plateletrich
plasma
shown
contain
bioactiv
molecul
potenti
deliv
combin
growth
factor
gf
cytokin
capabl
stimul
cellular
activ
aim
present
work
deal
prepar
nanofibr
materi
platelet
growth
factor
incorpor
intern
fiber
structur
polyvinyl
alcohol
pva
use
prepar
materi
provid
progress
releas
nativ
gf
without
need
subsequ
crosslink
method
materi
prepar
pva
mw
hydrolysi
use
electrospin
technolog
nanospid
tm
platelet
lysat
pl
prepar
thrombocyt
rich
solut
obtain
region
hospit
liberec
concentr
pltml
freezethaw
method
subsequ
centrifug
nanofib
electrospun
pva
solut
use
water
ethanol
solvent
system
materi
protein
electrospun
solut
contain
pva
pl
morpholog
analysi
perform
scan
electron
microscopi
protein
releas
monitor
use
spectrophotometri
bradford
method
chromatographi
result
prepar
fibrou
materi
consist
random
orient
endless
fiber
smooth
surfac
minim
defect
structur
morpholog
materi
alter
addit
protein
averag
fiber
diamet
ae
nm
pristin
pva
fiber
ae
nm
pva
incorpor
protein
pvapl
pvapl
layer
contain
mg
protein
per
gram
pva
protein
releas
first
day
burst
releas
follow
gradual
releas
week
summaryconclus
nanofibr
pvabas
nanofib
materi
prepar
nativ
growth
factor
process
use
prepar
solut
subsequ
spin
affect
activ
incorpor
protein
gradual
releas
therefor
believ
develop
materi
great
potenti
use
tissu
engin
eg
promot
heal
chronic
wound
acknowledg
support
czech
health
research
council
project
background
human
adefensin
small
cation
peptid
antimicrobi
anticanc
activ
till
six
adefensin
describ
human
includ
human
neutrophil
peptid
hnp
present
larg
amount
neutrophil
azurophil
granul
differ
first
amino
acid
fourth
defensin
term
compris
less
total
defensin
neutrophil
distinct
sequenc
two
human
defensin
synthes
mostli
intestin
paneth
cell
neutrophil
defensin
hnp
kda
peptid
character
three
disulfid
bridg
pattern
disulfid
bond
matur
form
crucial
function
properti
due
structur
featur
synthesi
defensin
use
chemic
recombin
approach
present
quit
challeng
moreov
purif
natur
sourc
difficult
larg
number
neutrophil
need
obtain
suffici
amount
protein
blood
bank
leukocyt
reduct
filter
use
remov
leukocyt
blood
compon
order
prevent
advers
transfus
reaction
leukofilt
contain
high
number
normal
human
cell
discard
use
aim
aim
studi
purifi
adefensin
neutrophil
trap
leukocyt
reduct
filter
method
blood
bag
healthi
blood
donor
collect
written
consent
donor
screen
infecti
diseas
hbv
hcv
hiv
neg
sampl
includ
studi
blood
bag
filter
leukoflex
filter
cell
extract
filter
backflush
cold
phosphat
buffer
salin
pb
ph
without
contain
mm
edta
sucros
pb
homogen
filter
content
collect
steril
tube
neutrophil
separ
mononuclear
cell
ficol
isol
neutrophil
resuspend
pb
concentr
cellsml
degranul
cell
stimul
nm
formylmethionylleucylphenylalanin
fmlp
min
follow
stimul
lm
cytochalasin
b
min
supernat
collect
centrifug
g
min
supernat
incub
mous
monoclon
antibodi
hnp
purif
hnp
perform
lmac
protein
g
microbead
system
presenc
protein
confirm
western
blot
result
presenc
kda
band
confirm
western
blot
correspond
size
adefensin
summaryconclus
develop
defensin
therapeut
product
requir
access
steadi
suppli
neutrophil
result
indic
filter
econom
sourc
purifi
adefensin
anatom
scienc
abadan
school
medic
scienc
abadan
iran
background
epigenet
reprogram
termin
differenti
cell
modifi
somat
cell
pluripotenti
state
sever
approach
induc
pluripot
somat
cell
exposur
cell
embryon
stem
cell
extract
easi
way
investig
done
fibroblast
cell
line
howev
effici
low
aim
purpos
studi
increas
number
reprogram
granulosa
cell
full
differenti
cell
pluripotenti
state
method
human
granulosa
cell
cultur
medium
contain
trichostatin
cell
expos
mous
esc
extract
cocultur
mous
embryon
fibroblast
presenc
leukemia
inhibitori
factor
lif
alkalin
phosphatas
test
also
immunohistochemistri
stain
nanog
perform
h
week
result
result
indic
h
granulosa
cell
reveal
round
expand
morpholog
cell
group
except
neg
control
show
alkalin
phosphatas
activ
cell
cultur
medium
contain
trichostatin
expos
extract
number
alkalin
phosphatas
posit
cell
immunocytochemistri
show
granulosa
cell
cultur
medium
contain
trichostatin
extract
express
weak
intens
h
express
nanog
observ
group
time
h
nanog
express
cell
treat
trichostatin
extract
furthermor
high
express
granulosa
cell
cultur
medium
contain
dmso
expos
extract
one
week
express
granulosa
cell
cultur
medium
contain
dmso
expos
extract
continu
express
ceas
group
express
nanog
ceas
group
one
week
summaryconclus
present
studi
reveal
inhibitor
methyl
transferas
histon
deacetylas
trichostatin
could
delet
epigenet
marker
improv
cell
reprogram
administr
extract
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
background
mesenchym
stem
cell
msc
adher
spindl
shape
cell
express
differ
surfac
marker
show
special
criteria
includ
paracrin
effect
differenti
sever
tissu
cell
migrat
immunomodulatori
regen
potenti
msc
isol
differ
sourc
employ
therapeut
tool
treat
sever
diseas
injuri
howev
msc
properti
includ
secret
growth
factor
migrat
abil
controversi
especi
remiss
presenc
tumor
interestingli
mscderiv
compart
could
use
practic
tool
term
diagnosi
follow
manag
monitor
diseas
instead
intact
msc
exosom
kind
extracellular
vesicl
ev
character
via
size
releas
mechan
usual
defin
less
nm
diamet
vesicl
secret
differ
cell
also
found
urin
blood
breast
milk
cerebrospin
fluid
bodi
fluid
exosom
contain
genet
materi
includ
dna
mrna
microrna
mirna
biomolecul
mirna
singl
strand
noncod
rna
transcrib
dna
immatur
mirna
subject
two
known
cleavag
modifi
matur
mirna
involv
either
mrna
degrad
gene
express
process
cellcel
interact
commun
via
secret
part
exosom
aim
studi
aim
discuss
aspect
exosom
microrna
deriv
msc
progress
diagnosi
treatment
diseas
method
differ
scientif
data
base
includ
pubm
googl
scholar
scopu
use
find
review
relat
articl
result
ev
play
import
role
either
intercellular
commun
relat
patholog
physiolog
situat
intracellular
commun
angiogenesi
immun
system
modul
metastasi
progress
mirna
could
regul
express
multipl
mrna
play
import
role
differ
biolog
process
contribut
cellcel
interact
well
influenc
progress
differ
diseas
exosom
mirnaderiv
msc
involv
cancer
process
tumor
growth
angiogenesi
metastasi
use
diagnosi
therapeut
tool
treat
differ
diseas
renal
failur
liver
fibrosi
myocardi
infarct
summaryconclus
due
controversi
aspect
use
intact
msc
especi
remiss
presenc
tumor
mscderiv
exosom
could
use
practic
tool
term
diagnosi
follow
manag
monitor
diseas
instead
intact
msc
